# Mishra_2012_Exercise interventions on health-related quality of life for people with cancer during active treatment.

Cochrane
Library

Cochrane Database of Systematic Reviews

Exercise interventions on health-related quality of life for people
with cancer during active treatment (Review)

Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O

Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O. 
Exercise interventions on health-related quality of life for people with cancer during active treatment. 
Cochrane Database of Systematic Reviews 2012, Issue 8. Art. No.: CD008465. 
DOI: 10.1002/14651858.CD008465.pub2.

www.cochranelibrary.com

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

T A B L E   O F   C O N T E N T S

HEADER.........................................................................................................................................................................................................
ABSTRACT.....................................................................................................................................................................................................
PLAIN LANGUAGE SUMMARY.......................................................................................................................................................................
SUMMARY OF FINDINGS..............................................................................................................................................................................
BACKGROUND..............................................................................................................................................................................................
OBJECTIVES..................................................................................................................................................................................................
METHODS.....................................................................................................................................................................................................
RESULTS........................................................................................................................................................................................................
Figure 1..................................................................................................................................................................................................
Figure 2..................................................................................................................................................................................................
Figure 3..................................................................................................................................................................................................
DISCUSSION..................................................................................................................................................................................................
Figure 4..................................................................................................................................................................................................
Figure 5..................................................................................................................................................................................................
Figure 6..................................................................................................................................................................................................
Figure 7..................................................................................................................................................................................................
Figure 8..................................................................................................................................................................................................
Figure 9..................................................................................................................................................................................................
AUTHORS' CONCLUSIONS...........................................................................................................................................................................
ACKNOWLEDGEMENTS................................................................................................................................................................................
REFERENCES................................................................................................................................................................................................
CHARACTERISTICS OF STUDIES..................................................................................................................................................................
DATA AND ANALYSES....................................................................................................................................................................................
Analysis 1.1. Comparison 1: Health-related quality of life, Outcome 1: Overall quality of life change score...................................
Analysis 1.2. Comparison 1: Health-related quality of life, Outcome 2: Overall quality of life follow-up values.............................
Analysis 1.3. Comparison 1: Health-related quality of life, Outcome 3: FACT-An change.................................................................
Analysis 1.4. Comparison 1: Health-related quality of life, Outcome 4: FACT-An follow-up values..................................................
Analysis 1.5. Comparison 1: Health-related quality of life, Outcome 5: FACT-B change...................................................................
Analysis 1.6. Comparison 1: Health-related quality of life, Outcome 6: FACT-B follow-up values....................................................
Analysis 1.7. Comparison 1: Health-related quality of life, Outcome 7: FACT-G change...................................................................
Analysis 1.8. Comparison 1: Health-related quality of life, Outcome 8: FACT-G follow-up values....................................................
Analysis 1.9. Comparison 1: Health-related quality of life, Outcome 9: FACT-P change...................................................................
Analysis 1.10. Comparison 1: Health-related quality of life, Outcome 10: FACT-P follow-up values................................................
Analysis 1.11. Comparison 1: Health-related quality of life, Outcome 11: FACIT-F change..............................................................
Analysis 1.12. Comparison 1: Health-related quality of life, Outcome 12: FACIT-F follow-up values...............................................
Analysis 1.13. Comparison 1: Health-related quality of life, Outcome 13: QLQ-C30 change............................................................
Analysis 1.14. Comparison 1: Health-related quality of life, Outcome 14: QLQ-C30 follow-up values.............................................
Analysis 1.15. Comparison 1: Health-related quality of life, Outcome 15: FLIC follow-up values....................................................
Analysis 1.16. Comparison 1: Health-related quality of life, Outcome 16: WHO BREF follow-up values..........................................
Analysis 1.17. Comparison 1: Health-related quality of life, Outcome 17: Ferrand and Powers follow-up values...........................
Analysis 1.18. Comparison 1: Health-related quality of life, Outcome 18: Spitzer QoL Uniscale follow-up values..........................
Analysis 1.19. Comparison 1: Health-related quality of life, Outcome 19: MDASI-T Symptom Interference change.......................
Analysis 1.20. Comparison 1: Health-related quality of life, Outcome 20: MDASI-T Symptom Interference follow-up values........
Analysis 1.21. Comparison 1: Health-related quality of life, Outcome 21: Quality of Life Systemic Inventory follow-up values......
Analysis 2.1. Comparison 2: Condition-specific quality of life, Outcome 1: Breast cancer change..................................................
Analysis 2.2. Comparison 2: Condition-specific quality of life, Outcome 2: Breast cancer follow-up values...................................
Analysis 2.3. Comparison 2: Condition-specific quality of life, Outcome 3: Overall prostate cancer change..................................
Analysis 2.4. Comparison 2: Condition-specific quality of life, Outcome 4: Overall prostate cancer follow-up values...................
Analysis 2.5. Comparison 2: Condition-specific quality of life, Outcome 5: FACT prostate cancer subscale change.......................
Analysis 2.6. Comparison 2: Condition-specific quality of life, Outcome 6: FACT prostate cancer subscale follow-up values........
Analysis 2.7. Comparison 2: Condition-specific quality of life, Outcome 7: Expanded Prostate Cancer Index Composite change....

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1
1
2
4
9
9
10
13
14
19
21
26
28
29
30
31
32
33
34
35
36
48
211
215
216
217
217
218
218
219
220
220
221
221
221
222
222
223
223
223
223
224
224
224
226
227
227
228
228
229
229

i

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.8. Comparison 2: Condition-specific quality of life, Outcome 8: Expanded Prostate Cancer Index Composite follow-
up values................................................................................................................................................................................................
Analysis 2.9. Comparison 2: Condition-specific quality of life, Outcome 9: QLSI cancer module subscale follow-up values.........
Analysis 3.1. Comparison 3: Anxiety, Outcome 1: Overall anxiety change........................................................................................
Analysis 3.2. Comparison 3: Anxiety, Outcome 2: Overall anxiety follow-up values.........................................................................
Analysis 3.3. Comparison 3: Anxiety, Outcome 3: Hospital Anxiety and Depression Scale anxiety subscale follow-up values.......
Analysis 3.4. Comparison 3: Anxiety, Outcome 4: State Trait Anxiety Inventory change..................................................................
Analysis 3.5. Comparison 3: Anxiety, Outcome 5: State Trait Anxiety Inventory follow-up values...................................................
Analysis 3.6. Comparison 3: Anxiety, Outcome 6: POMS anxiety subscale change...........................................................................
Analysis 3.7. Comparison 3: Anxiety, Outcome 7: POMS anxiety subscale follow-up values............................................................
Analysis 3.8. Comparison 3: Anxiety, Outcome 8: Symptom Checklist-90 Revised anxiety subscale follow-up values...................
Analysis 3.9. Comparison 3: Anxiety, Outcome 9: Symptom Checklist-90 Revised phobic anxiety subscale follow-up values.......
Analysis 3.10. Comparison 3: Anxiety, Outcome 10: General Health Questionnaire anxiety subscale follow-up values.................
Analysis 4.1. Comparison 4: Body image/self-esteem, Outcome 1: Overall body image/self-esteem change.................................
Analysis 4.2. Comparison 4: Body image/self-esteem, Outcome 2: Overall body image/self-esteem follow-up values..................
Analysis 4.3. Comparison 4: Body image/self-esteem, Outcome 3: Rosenberg self-esteem change................................................
Analysis 4.4. Comparison 4: Body image/self-esteem, Outcome 4: Rosenberg self-esteem follow-up values................................
Analysis 4.5. Comparison 4: Body image/self-esteem, Outcome 5: Body Image Visual Analog Scale follow-up values..................
Analysis 4.6. Comparison 4: Body image/self-esteem, Outcome 6: Tennessee Self concept subscale follow-up values................
Analysis 4.7. Comparison 4: Body image/self-esteem, Outcome 7: Tennessee physical subscale follow-up vales.........................
Analysis 5.1. Comparison 5: Cognitive functioning, Outcome 1: Overall cognitive functioning change..........................................
Analysis 5.2. Comparison 5: Cognitive functioning, Outcome 2: Overall cognitive functioning follow-up values...........................
Analysis 5.3. Comparison 5: Cognitive functioning, Outcome 3: QLQ-C30 cognitive subscale change............................................
Analysis 5.4. Comparison 5: Cognitive functioning, Outcome 4: QLQ-C30 cognitive subscale follow-up values.............................
Analysis 5.5. Comparison 5: Cognitive functioning, Outcome 5: FACT-Cog change..........................................................................
Analysis 5.6. Comparison 5: Cognitive functioning, Outcome 6: FACT-Cog follow-up values...........................................................
Analysis 5.7. Comparison 5: Cognitive functioning, Outcome 7: POMS confusion subscale change...............................................
Analysis 5.8. Comparison 5: Cognitive functioning, Outcome 8: POMS confusion subscale follow-up values................................
Analysis 5.9. Comparison 5: Cognitive functioning, Outcome 9: QLSI cognitive functioning subscale follow-up values................
Analysis 5.10. Comparison 5: Cognitive functioning, Outcome 10: MDASI-T problem remembering subscale change..................
Analysis 5.11. Comparison 5: Cognitive functioning, Outcome 11: MDASI-T problem remembering subscale follow-up values.....
Analysis 6.1. Comparison 6: Depression, Outcome 1: Overall depression change............................................................................
Analysis 6.2. Comparison 6: Depression, Outcome 2: Overall depression follow-up values............................................................
Analysis 6.3. Comparison 6: Depression, Outcome 3: Centers for Epidemiological Studies Depression change............................
Analysis 6.4. Comparison 6: Depression, Outcome 4: Centers for Epidemiological Studies Depression Scale follow-up values.....
Analysis  6.5.  Comparison  6:  Depression,  Outcome  5:  Hospital  Anxiety  and  Depression  Scale  depression  subscale  follow-up
values.....................................................................................................................................................................................................
Analysis 6.6. Comparison 6: Depression, Outcome 6: Beck Depression Inventory change..............................................................
Analysis 6.7. Comparison 6: Depression, Outcome 7: Beck Depression Inventory follow-up values...............................................
Analysis 6.8. Comparison 6: Depression, Outcome 8: POMS Depression subscale change..............................................................
Analysis 6.9. Comparison 6: Depression, Outcome 9: POMS depression subscale follow-up values...............................................
Analysis 6.10. Comparison 6: Depression, Outcome 10: Symptom Checklist 90 Revised Depression subscale follow-up values.....
Analysis 6.11. Comparison 6: Depression, Outcome 11: General Health Questionnaire Depression subscale follow-up values......
Analysis 7.1. Comparison 7: Emotional well-being/mental health functioning, Outcome 1: Overall emotional well-being/mental
health change........................................................................................................................................................................................
Analysis 7.2. Comparison 7: Emotional well-being/mental health functioning, Outcome 2: Overall emotional well-being/mental
health follow-up values........................................................................................................................................................................
Analysis 7.3. Comparison 7: Emotional well-being/mental health functioning, Outcome 3: FACT emotional subscale change......
Analysis 7.4. Comparison 7: Emotional well-being/mental health functioning, Outcome 4: FACT emotion subscale follow-up
values.....................................................................................................................................................................................................
Analysis 7.5. Comparison 7: Emotional well-being/mental health functioning, Outcome 5: QLQ-C30 change...............................
Analysis 7.6. Comparison 7: Emotional well-being/mental health functioning, Outcome 6: QLQ-C30 emotion subscale follow-
up values................................................................................................................................................................................................

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

229

230
232
233
234
234
235
235
236
236
236
236
238
239
239
240
240
241
241
243
244
244
245
245
246
246
246
247
247
247
250
251
252
252
253

253
253
254
254
254
255
261

262

263
263

264
264

ii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.7. Comparison 7: Emotional well-being/mental health functioning, Outcome 7: FACIT-E subscale change..................
Analysis 7.8. Comparison 7: Emotional well-being/mental health functioning, Outcome 8: POMS total mood change.................
Analysis 7.9. Comparison 7: Emotional well-being/mental health functioning, Outcome 9: POMS total mood follow-up values....
Analysis 7.10. Comparison 7: Emotional well-being/mental health functioning, Outcome 10: POMS anger subscale change.......
Analysis 7.11. Comparison 7: Emotional well-being/mental health functioning, Outcome 11: POMS anger subscale follow-up
values.....................................................................................................................................................................................................
Analysis 7.12. Comparison 7: Emotional well-being/mental health functioning, Outcome 12: MOS SF-36 Mental Component
Score follow-up values.........................................................................................................................................................................
Analysis 7.13. Comparison 7: Emotional well-being/mental health functioning, Outcome 13: MOS SF-36 mental health subscale
change....................................................................................................................................................................................................
Analysis 7.14. Comparison 7: Emotional well-being/mental health functioning, Outcome 14: MOS SF-36 mental health subscale
follow-up values....................................................................................................................................................................................
Analysis 7.15. Comparison 7: Emotional well-being/mental health functioning, Outcome 15: MOS SF-36 emotional role subscale
change....................................................................................................................................................................................................
Analysis 7.16. Comparison 7: Emotional well-being/mental health functioning, Outcome 16: MOS SF-36 emotional role subscale
follow-up values....................................................................................................................................................................................
Analysis  7.17.  Comparison  7:  Emotional  well-being/mental  health  functioning,  Outcome  17:  Positive  and  Negative  Affect
Schedule positivity subscale follow-up values...................................................................................................................................
Analysis  7.18.  Comparison  7:  Emotional  well-being/mental  health  functioning,  Outcome  18:  Positive  and  Negative  Affect
Schedule negativity subscale follow-up values..................................................................................................................................
Analysis 7.19. Comparison 7: Emotional well-being/mental health functioning, Outcome 19: Satisfaction with Life change.......
Analysis 7.20. Comparison 7: Emotional well-being/mental health functioning, Outcome 20: Satisfaction with Life follow-up
values.....................................................................................................................................................................................................
Analysis 7.21. Comparison 7: Emotional well-being/mental health functioning, Outcome 21: Perceived Stress follow-up values...
Analysis 7.22. Comparison 7: Emotional well-being/mental health functioning, Outcome 22: Psychosocial Adjustment to Illness
Scale follow-up values..........................................................................................................................................................................
Analysis 7.23. Comparison 7: Emotional well-being/mental health functioning, Outcome 23: Brief Symptom Inventory follow-
up values................................................................................................................................................................................................
Analysis 7.24. Comparison 7: Emotional well-being/mental health functioning, Outcome 24: Symptom Distress Scale follow-
up values................................................................................................................................................................................................
Analysis 7.25. Comparison 7: Emotional well-being/mental health functioning, Outcome 25: Symptom Checklist 90 R positive
symptom distress subscale follow-up values......................................................................................................................................
Analysis  7.26.  Comparison  7:  Emotional  well-being/mental  health  functioning,  Outcome  26:  Symptom  Checklist  90  R
somatization subscale follow-up values.............................................................................................................................................
Analysis 7.27. Comparison 7: Emotional well-being/mental health functioning, Outcome 27: Symptom Checklist 90 R obsessive
compulsive subscale follow-up values................................................................................................................................................
Analysis 7.28. Comparison 7: Emotional well-being/mental health functioning, Outcome 28: Symptom Checklist 90 R hostility
subscale follow-up values....................................................................................................................................................................
Analysis 7.29. Comparison 7: Emotional well-being/mental health functioning, Outcome 29: Fordyce Happiness Scale change...
Analysis 7.30. Comparison 7: Emotional well-being/mental health functioning, Outcome 30: Fordyce Happiness Scale follow-
up values................................................................................................................................................................................................
Analysis 7.31. Comparison 7: Emotional well-being/mental health functioning, Outcome 31: National Comprehensive Cancer
Network Distress thermometer follow-up values...............................................................................................................................
Analysis 7.32. Comparison 7: Emotional well-being/mental health functioning, Outcome 32: Cohen's Stress change.................
Analysis 7.33. Comparison 7: Emotional well-being/mental health functioning, Outcome 33: Cohen's Stress follow-up values....
Analysis  7.34.  Comparison  7:  Emotional  well-being/mental  health  functioning,  Outcome  34:  General  Health  Questionnaire
follow-up values....................................................................................................................................................................................
Analysis  7.35.  Comparison  7:  Emotional  well-being/mental  health  functioning,  Outcome  35:  General  Health  Questionnaire
somatization subscale follow-up values.............................................................................................................................................
Analysis 7.36. Comparison 7: Emotional well-being/mental health functioning, Outcome 36: WHO BREF psychological subscale
follow-up values....................................................................................................................................................................................
Analysis  7.37.  Comparison  7:  Emotional  well-being/mental  health  functioning,  Outcome  37:  MDASI-T  distress  subscale
change....................................................................................................................................................................................................
Analysis 7.38. Comparison 7: Emotional well-being/mental health functioning, Outcome 38: MDASI-T distress subscale follow-
up values................................................................................................................................................................................................
Analysis 7.39. Comparison 7: Emotional well-being/mental health functioning, Outcome 39: MDASI-T mood subscale change....

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

264
265
265
265
266

266

267

267

268

268

269

269

269
270

270
270

271

271

271

272

272

272

273
273

273

274
274
274

274

275

275

275

276

iii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.40. Comparison 7: Emotional well-being/mental health functioning, Outcome 40: MDASI-T mood subscale follow-
up values................................................................................................................................................................................................
Analysis  7.41.  Comparison  7:  Emotional  well-being/mental  health  functioning,  Outcome  41:  MDASI-T  feeling  sad  subscale
change....................................................................................................................................................................................................
Analysis  7.42.  Comparison  7:  Emotional  well-being/mental  health  functioning,  Outcome  42:  MDASI-T  feeling  sad  subscale
follow-up values....................................................................................................................................................................................
Analysis 7.43. Comparison 7: Emotional well-being/mental health functioning, Outcome 43: MDASI-T enjoyment of life subscale
change....................................................................................................................................................................................................
Analysis 7.44. Comparison 7: Emotional well-being/mental health functioning, Outcome 44: MDASI-T enjoyment of life subscale
follow-up values....................................................................................................................................................................................
Analysis 7.45. Comparison 7: Emotional well-being/mental health functioning, Outcome 45: QLSI affective functioning subscale
follow-up values....................................................................................................................................................................................
Analysis 8.1. Comparison 8: Fatigue, Outcome 1: Overall fatigue change.........................................................................................
Analysis 8.2. Comparison 8: Fatigue, Outcome 2: Overall fatigue follow-up values.........................................................................
Analysis 8.3. Comparison 8: Fatigue, Outcome 3: FACT-F subscale change......................................................................................
Analysis 8.4. Comparison 8: Fatigue, Outcome 4: FACT-F follow-up values......................................................................................
Analysis 8.5. Comparison 8: Fatigue, Outcome 5: FACIT-F subscale change.....................................................................................
Analysis 8.6. Comparison 8: Fatigue, Outcome 6: FACIT-F subscale follow-up values......................................................................
Analysis 8.7. Comparison 8: Fatigue, Outcome 7: QLQ-C30 change..................................................................................................
Analysis 8.8. Comparison 8: Fatigue, Outcome 8: QLQ-C30 fatigue subscale follow-up values.......................................................
Analysis 8.9. Comparison 8: Fatigue, Outcome 9: Brief Fatigue Inventory change...........................................................................
Analysis 8.10. Comparison 8: Fatigue, Outcome 10: Brief Fatigue Inventory follow-up values........................................................
Analysis 8.11. Comparison 8: Fatigue, Outcome 11: POMS fatigue subscale change.......................................................................
Analysis 8.12. Comparison 8: Fatigue, Outcome 12: POMS fatigue subscale follow-up values........................................................
Analysis 8.13. Comparison 8: Fatigue, Outcome 13: POMS vigor subscale change..........................................................................
Analysis 8.14. Comparison 8: Fatigue, Outcome 14: POMS vigor subscale follow-up values...........................................................
Analysis 8.15. Comparison 8: Fatigue, Outcome 15: Piper Fatigue Scale change.............................................................................
Analysis 8.16. Comparison 8: Fatigue, Outcome 16: Piper Fatigue Scale follow-up values..............................................................
Analysis 8.17. Comparison 8: Fatigue, Outcome 17: MOS SF-36 vitality subscale change................................................................
Analysis 8.18. Comparison 8: Fatigue, Outcome 18: MOS SF-36 vitality subscale follow-up values................................................
Analysis 8.19. Comparison 8: Fatigue, Outcome 19: Fatigue Severity Scale change........................................................................
Analysis 8.20. Comparison 8: Fatigue, Outcome 20: Fatigue Severity Scale follow-up values.........................................................
Analysis 8.21. Comparison 8: Fatigue, Outcome 21: Multidimensional Fatigue Inventory follow-up values...................................
Analysis 8.22. Comparison 8: Fatigue, Outcome 22: Multidimensional Fatigue Inventory physical fatigue subscale follow-up
values.....................................................................................................................................................................................................
Analysis 8.23. Comparison 8: Fatigue, Outcome 23: Multidimensional Fatigue Inventory reduced activation subscale follow-up
values.....................................................................................................................................................................................................
Analysis 8.24. Comparison 8: Fatigue, Outcome 24: Multidimensional Fatigue Inventory reduced motivation subscale follow-
up values................................................................................................................................................................................................
Analysis  8.25.  Comparison  8:  Fatigue,  Outcome  25:  Multidimensional  Fatigue  Inventory  mental  fatigue  subscale  follow-up
values.....................................................................................................................................................................................................
Analysis 8.26. Comparison 8: Fatigue, Outcome 26: Schwartz Fatigue follow-up values.................................................................
Analysis 8.27. Comparison 8: Fatigue, Outcome 27: LASA change....................................................................................................
Analysis 8.28. Comparison 8: Fatigue, Outcome 28: MDASI-T fatigue subscale change...................................................................
Analysis 8.29. Comparison 8: Fatigue, Outcome 29: MDASI-T fatigue subscale follow-up values....................................................
Analysis 9.1. Comparison 9: General health perspective, Outcome 1: Overall general health change............................................
Analysis 9.2. Comparison 9: General health perspective, Outcome 2: Overall general health perspective follow-up values..........
Analysis 9.3. Comparison 9: General health perspective, Outcome 3: MOS SF-36 general health change......................................
Analysis 9.4. Comparison 9: General health perspective, Outcome 4: MOS SF-36 general health subscale follow-up values........
Analysis 9.5. Comparison 9: General health perspective, Outcome 5: WHO BREF follow-up values................................................
Analysis 9.6. Comparison 9: General health perspective, Outcome 6: Ferrans and Powers health and functioning subscale follow-
up values................................................................................................................................................................................................
Analysis 9.7. Comparison 9: General health perspective, Outcome 7: Single question change.......................................................
Analysis 9.8. Comparison 9: General health perspective, Outcome 8: Single question follow-up values........................................

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

276

276

277

277

277

278

283
284
285
286
286
287
287
288
288
289
289
289
290
290
291
291
291
292
292
292
293
293

294

294

295

295
295
296
296
298
299
299
300
300
300

301
301

iv

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 9.9. Comparison 9: General health perspective, Outcome 9: MDASI-T general activity subscale change..........................
Analysis 9.10. Comparison 9: General health perspective, Outcome 10: MDASI-T general activity subscale follow-up values.......
Analysis 10.1. Comparison 10: Pain, Outcome 1: Overall pain change..............................................................................................
Analysis 10.2. Comparison 10: Pain, Outcome 2: Overall pain follow-up values...............................................................................
Analysis 10.3. Comparison 10: Pain, Outcome 3: QLQ-C30 change...................................................................................................
Analysis 10.4. Comparison 10: Pain, Outcome 4: QLQ-C30 pain follow-up values............................................................................
Analysis 10.5. Comparison 10: Pain, Outcome 5: MOS SF-36 bodily pain subscale change.............................................................
Analysis 10.6. Comparison 10: Pain, Outcome 6: MOS SF-36 bodily pain follow-up values.............................................................
Analysis 10.7. Comparison 10: Pain, Outcome 7: Visual Analog Scale follow-up values...................................................................
Analysis 10.8. Comparison 10: Pain, Outcome 8: MDASI-T pain subscale change............................................................................
Analysis 10.9. Comparison 10: Pain, Outcome 9: MDASI-T pain subscale follow-up values.............................................................
Analysis 11.1. Comparison 11: Physical functioning, Outcome 1: Overall physical function change...............................................
Analysis 11.2. Comparison 11: Physical functioning, Outcome 2: Overall physical function follow-up values................................
Analysis 11.3. Comparison 11: Physical functioning, Outcome 3: FACT-P subscale change.............................................................
Analysis 11.4. Comparison 11: Physical functioning, Outcome 4: FACT-P subscale follow-up values..............................................
Analysis 11.5. Comparison 11: Physical functioning, Outcome 5: FACIT-F change...........................................................................
Analysis 11.6. Comparison 11: Physical functioning, Outcome 6: QLQ-C30 Physical subscale change...........................................
Analysis 11.7. Comparison 11: Physical functioning, Outcome 7: QLQ-C30 Physical subscale follow-up values............................
Analysis 11.8. Comparison 11: Physical functioning, Outcome 8: MOS SF-36 Physical component score follow-up values...........
Analysis 11.9. Comparison 11: Physical functioning, Outcome 9: MOS SF-36 Physical Functioning subscale change....................
Analysis 11.10. Comparison 11: Physical functioning, Outcome 10: MOS SF-36 Physical Functioning subscale follow-up values....
Analysis 11.11. Comparison 11: Physical functioning, Outcome 11: MOS SF-36 role physical change............................................
Analysis 11.12. Comparison 11: Physical functioning, Outcome 12: MOS SF-36 role physical follow-up values.............................
Analysis 11.13. Comparison 11: Physical functioning, Outcome 13: LASA change...........................................................................
Analysis 11.14. Comparison 11: Physical functioning, Outcome 14: WHO BREF physical subscale follow-up values.....................
Analysis 11.15. Comparison 11: Physical functioning, Outcome 15: MDASI-T Symptom Severity change......................................
Analysis 11.16. Comparison 11: Physical functioning, Outcome 16: MDASI-T Symptom Severity follow-up values.......................
Analysis 11.17. Comparison 11: Physical functioning, Outcome 17: QLSI physical health subscale follow-up values....................
Analysis 12.1. Comparison 12: Role function, Outcome 1: Overall role function change.................................................................
Analysis 12.2. Comparison 12: Role function, Outcome 2: Overall role function follow-up values..................................................
Analysis 12.3. Comparison 12: Role function, Outcome 3: FACT role function subscale change.....................................................
Analysis 12.4. Comparison 12: Role function, Outcome 4: FACT role function subscale follow-up values......................................
Analysis 12.5. Comparison 12: Role function, Outcome 5: QLQ-C30 change....................................................................................
Analysis 12.6. Comparison 12: Role function, Outcome 6: QLQ-C30 function subscale follow-up values.......................................
Analysis 12.7. Comparison 12: Role function, Outcome 7: FACIT function subscale change............................................................
Analysis 12.8. Comparison 12: Role function, Outcome 8: WHO BREF environmental subscale follow-up values..........................
Analysis 12.9. Comparison 12: Role function, Outcome 9: Ferrans and Power family subscale follow-up values...........................
Analysis 12.10. Comparison 12: Role function, Outcome 10: Symptom Checklist 90 R interpersonal sensitivity subscale follow-
up values................................................................................................................................................................................................
Analysis 12.11. Comparison 12: Role function, Outcome 11: MDASI-T relations with other people subscale change....................
Analysis 12.12. Comparison 12: Role function, Outcome 12: MDASI-T relations with other people subscale follow-up values......
Analysis 12.13. Comparison 12: Role function, Outcome 13: MDASI-T work subscale change.........................................................
Analysis 12.14. Comparison 12: Role function, Outcome 14: MDASI-T work subscale follow-up values..........................................
Analysis 12.15. Comparison 12: Role function, Outcome 15: QLSI marital life subscale follow-up values......................................
Analysis 13.1. Comparison 13: Sleep, Outcome 1: Overall sleep change..........................................................................................
Analysis 13.2. Comparison 13: Sleep, Outcome 2: Overall sleep follow-up values...........................................................................
Analysis 13.3. Comparison 13: Sleep, Outcome 3: Pittsburgh Sleep Quality Index change..............................................................
Analysis 13.4. Comparison 13: Sleep, Outcome 4: Pittsburgh Sleep Quality Index follow-up values..............................................
Analysis 13.5. Comparison 13: Sleep, Outcome 5: QLQ-C30 insomnia subscale change..................................................................
Analysis 13.6. Comparison 13: Sleep, Outcome 6: QLQ-C30 insomnia subscale follow-up values...................................................
Analysis 13.7. Comparison 13: Sleep, Outcome 7: MDASI-T disturbed sleep subscale change........................................................
Analysis 13.8. Comparison 13: Sleep, Outcome 8: MDASI-T disturbed sleep subscale follow-up values.........................................

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

301
302
303
304
304
305
305
306
306
306
307
310
311
312
312
313
313
313
314
314
315
315
316
316
316
317
317
317
320
321
322
322
323
323
323
324
324
324

324
325
325
325
325
327
328
328
329
329
330
330
330

v

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.1. Comparison 14: Social functioning, Outcome 1: Overall social functioning change.................................................
Analysis 14.2. Comparison 14: Social functioning, Outcome 2: Overall social functioning follow-up values..................................
Analysis 14.3. Comparison 14: Social functioning, Outcome 3: FACT social subscale change.........................................................
Analysis 14.4. Comparison 14: Social functioning, Outcome 4: FACT social subscale follow-up values..........................................
Analysis 14.5. Comparison 14: Social functioning, Outcome 5: QLQ-C30 change.............................................................................
Analysis 14.6. Comparison 14: Social functioning, Outcome 6: QLQ-C30 social subscale follow-up values....................................
Analysis 14.7. Comparison 14: Social functioning, Outcome 7: FACIT social subscale change........................................................
Analysis 14.8. Comparison 14: Social functioning, Outcome 8: MOS SF-36 social function subscale change.................................
Analysis 14.9. Comparison 14: Social functioning, Outcome 9: MOS SF-36 social function subscale follow-up values..................
Analysis 14.10. Comparison 14: Social functioning, Outcome 10: WHO BREF social function subscale follow-up values..............
Analysis 14.11. Comparison 14: Social functioning, Outcome 11: Ferrans and Power social economic subscale follow-up values...
Analysis  14.12.  Comparison  14:  Social  functioning,  Outcome  12:  General  Health  Questionnaire  social  dysfunction  subscale
follow-up values....................................................................................................................................................................................
Analysis 14.13. Comparison 14: Social functioning, Outcome 13: QLSI social and familial functioning subscale follow-up values...
Analysis 15.1. Comparison 15: Spiritual functioning, Outcome 1: Overall spiritual function change..............................................
Analysis 15.2. Comparison 15: Spiritual functioning, Outcome 2: Overall spiritual function follow-up values...............................
Analysis 15.3. Comparison 15: Spiritual functioning, Outcome 3: FACT -Sp change........................................................................
Analysis 15.4. Comparison 15: Spiritual functioning, Outcome 4: FACIT-Sp follow-up values.........................................................
Analysis 15.5. Comparison 15: Spiritual functioning, Outcome 5: Ferrans and Power psychological/spiritual subscale follow-up
values.....................................................................................................................................................................................................
ADDITIONAL TABLES....................................................................................................................................................................................
APPENDICES.................................................................................................................................................................................................
WHAT'S NEW.................................................................................................................................................................................................
HISTORY........................................................................................................................................................................................................
CONTRIBUTIONS OF AUTHORS...................................................................................................................................................................
DECLARATIONS OF INTEREST.....................................................................................................................................................................
SOURCES OF SUPPORT...............................................................................................................................................................................
DIFFERENCES BETWEEN PROTOCOL AND REVIEW....................................................................................................................................
INDEX TERMS...............................................................................................................................................................................................

333
334
335
335
336
336
336
337
337
337
338
338

338
339
339
340
340
340

340
351
366
366
366
367
367
367
367

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

vi

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

[Intervention Review]

Cochrane Database of Systematic Reviews

Exercise interventions on health-related quality of life for people with
cancer during active treatment

Shiraz I Mishra1, Roberta W Scherer2, Claire Snyder3, Paula M Geigle4, Debra R Berlanstein5, Ozlem Topaloglu6

1University of New Mexico, Albuquerque, NM, USA. 2Department of Epidemiology, Johns Hopkins Bloomberg School of Public
Health, Baltimore, Maryland, USA. 3Division of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
4Rehabilitation Research Center; Department of Neurology, University of Maryland at Kernan Rehabilitation Hospital, Baltimore, MD,
USA. 5Hirsh Health Sciences Library, Tufts University, Boston, MA, USA. 6Department of Epidemiology, JHU Bloomberg School of Public
Health, Baltimore, MD, USA

Contact address: Shiraz I Mishra, smishra@salud.unm.edu.

Editorial group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group.
Publication status and date: Edited (no change to conclusions), published in Issue 5, 2020.

Citation: Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O. Exercise interventions on health-related quality of
life for people with cancer during active treatment. Cochrane Database of Systematic Reviews 2012, Issue 8. Art. No.: CD008465. DOI:
10.1002/14651858.CD008465.pub2.

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Background

A B S T R A C T

People  with  cancer  undergoing  active  treatment  experience  numerous  disease-  and  treatment-related  adverse  outcomes  and  poorer
health-related quality of life (HRQoL). Exercise interventions are hypothesized to alleviate these adverse outcomes. HRQoL and its domains
are important measures of cancer survivorship, both during and after the end of active treatment for cancer.

Objectives

To evaluate the effectiveness of exercise on overall HRQoL outcomes and specific HRQoL domains among adults with cancer during active
treatment.

Search methods

We searched the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed MEDLINE, EMBASE, CINAHL, PsycINFO, PEDRO, LILACS,
SIGLE, SportDiscus, OTSeeker, Sociological Abstracts from inception to November 2011 with no language or date restrictions. We also
searched citations through Web of Science and Scopus, PubMed's related article feature, and several websites. We reviewed reference lists
of included trials and other reviews in the field.

Selection criteria

We included all randomized controlled trials (RCTs) and quasi-randomized controlled clinical trials (CCTs) comparing exercise interventions
with usual care or other type of non-exercise comparison intervention to maintain or enhance, or both, overall HRQoL or at least one
distinct domain of HRQoL. Included trials tested exercise interventions that were initiated when adults with cancer were undergoing active
cancer treatment or were scheduled to initiate treatment.

Data collection and analysis

Five paired review authors independently extracted information on characteristics of included trials, data on effects of the intervention,
and assessed risk of bias based on predefined criteria. Where possible, we performed meta-analyses for HRQoL and HRQoL domains for
the reported difference between baseline values and follow-up values using standardized mean differences (SMDs) and a random-effects
model by length of follow-up. We also reported the SMD at follow-up between the exercise and control groups. Because investigators used

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

many different HRQoL and HRQoL domain instruments and often more than one for the same domain, we selected the more commonly
used instrument to include in the SMD meta-analyses. We also report the mean difference for each type of instrument separately.

Main results

We included 56 trials with 4826 participants randomized to an exercise (n = 2286) or comparison (n = 1985) group. Cancer diagnoses in
trial participants included breast, prostate, gynecologic, hematologic, and other. Thirty-six trials were conducted among participants who
were currently undergoing active treatment for their cancer, 10 trials were conducted among participants both during and post active
cancer treatment, and the remaining 10 trials were conducted among participants scheduled for active cancer treatment. Mode of exercise
intervention differed across trials and included walking by itself or in combination with cycling, resistance training, or strength training;
resistance training; strength training; cycling; yoga; or Qigong. HRQoL and its domains were assessed using a wide range of measures.

The results suggest that exercise interventions compared with control interventions have a positive impact on overall HRQoL and certain
HRQoL domains. Exercise interventions resulted in improvements in: HRQoL from baseline to 12 weeks' follow-up (SMD 0.33; 95% CI 0.12
to 0.55) or when comparing difference in follow-up scores at 12 weeks (SMD 0.47; 95% CI 0.16 to 0.79); physical functioning from baseline to
12 weeks' follow-up (SMD 0.69; 95% CI 0.16 to 1.22) or 6 months (SMD 0.28; 95% CI 0.00 to 0.55); or when comparing differences in follow-
up scores at 12 weeks (SMD 0.28; 95% CI 0.11 to 0.45) or 6 months (SMD 0.29; 95% CI 0.07 to 0.50); role function from baseline to 12 weeks'
follow-up (SMD 0.48; 95% CI 0.07 to 0.90) or when comparing differences in follow-up scores at 12 weeks (SMD 0.17; 95% CI 0.00 to 0.34) or 6
months (SMD 0.32; 95% CI 0.03 to 0.61); and, in social functioning at 12 weeks' follow-up (SMD 0.54; 95% CI 0.03 to 1.05) or when comparing
differences in follow-up scores at both 12 weeks (SMD 0.16; 95% CI 0.04 to 0.27) and 6 months (SMD 0.24; 95% CI 0.03 to 0.44). Further,
exercise interventions resulted in a decrease in fatigue from baseline to 12 weeks' follow-up (SMD -0.38; 95% CI -0.57 to -0.18) or when
comparing difference in follow-up scores at follow-up of 12 weeks (SMD -0.73; 95% CI -1.14 to -0.31). Since there is consistency of findings on
both types of measures (change scores and difference in follow-up scores) there is greater confidence in the robustness of these findings.

When  examining  exercise  effects  by  subgroups,  exercise  interventions  had  significantly  greater  reduction  in  anxiety  for  survivors  with
breast cancer than those with other types of cancer. Further, there was greater reduction in depression, fatigue, and sleep disturbances, and
improvement in HRQoL, emotional wellbeing (EWB), physical functioning, and role function for cancer survivors diagnosed with cancers
other than breast cancer but not for breast cancer. There were also greater improvements in HRQoL and physical functioning, and reduction
in anxiety, fatigue, and sleep disturbances when prescribed a moderate or vigorous versus a mild exercise program.

Results of the review need to be interpreted cautiously owing to the risk of bias. All the trials reviewed were at high risk for performance
bias. In addition, the majority of trials were at high risk for detection, attrition, and selection bias.

Authors' conclusions

This  systematic  review  indicates  that  exercise  may  have  beneficial  effects  at  varying  follow-up  periods  on  HRQoL  and  certain  HRQoL
domains including physical functioning, role function, social functioning, and fatigue. Positive effects of exercise interventions are more
pronounced  with  moderate-  or  vigorous-intensity  versus  mild-intensity  exercise  programs.  The  positive  results  must  be  interpreted
cautiously because of the heterogeneity of exercise programs tested and measures used to assess HRQoL and HRQoL domains, and the
risk of bias in many trials. Further research is required to investigate how to sustain positive effects of exercise over time and to determine
essential attributes of exercise (mode, intensity, frequency, duration, timing) by cancer type and cancer treatment for optimal effects on
HRQoL and its domains.

P L A I N   L A N G U A G E   S U M M A R Y

Can exercise interventions enhance health-related quality of life among people with cancer undergoing active treatment?

People  with  cancer  undergoing  treatment  often  have  many  psychological  and  physical  adverse  effects  as  a  result  of  their  cancer  and
the treatment for it. They also experience poorer quality of life because of the disease and its treatment. Some studies have suggested
that exercise may be helpful in reducing negative outcomes and improving the quality of life of people with cancer who are undergoing
treatment. Also, a better quality of life may predict longer life. This review looked at the effect of exercise on health-related quality of life
and areas of life that make up quality of life (e.g. tiredness, anxiety, emotional health) among people with cancer who are undergoing
treatment.

The review included 56 trials with a total of 4826 participants. The results suggest that exercise may improve overall quality of life right after
the exercise program is completed. Exercise may also improve the person's physical ability and the way the person can function in society.
Exercise also reduced tiredness at different times during and after the exercise program. The positive effects of exercise were greater when
the exercise was more intense. No effects of exercise was found in the way a person views his or her body, on the person's ability to think
clearly, the person's mood, feeling of pain, and on the way the person views his or her spiritual health.

However, these findings need to be viewed with caution because this review looked at many different types of exercise programs, which
varied by type of setting, length of the program, and how hard the trial participants had to exercise. Also, the investigators used a number
of different ways to measure quality of life.

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

2

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

There is a need for more research to understand how to maintain the positive effects of exercise over a longer period of time after the
exercise program is completed, and to determine which parts of the exercise program are necessary (i.e. when to start the program, type
of exercise, length of the program or exercise session, how hard to exercise). It is also important to find out if one type of exercise is better
for a specific cancer type than another for the maximum effect on quality of life.

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

3

 
 
S U M M A R Y   O F   F I N D I N G S

Summary of findings 1.   Summary of findings

Exercise compared with usual care on HRQoL and HRQoL domains for people with cancer during active treatment

Patient or population: people who are undergoing active treatment for cancer

Settings: varied

Intervention: exercise interventions (varied)

Comparison: usual care

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Comparison group

Overall QoL
change score
- up to 12
weeks' fol-
low-up

The standardized mean change from baseline
to up to 12 weeks' follow-up in overall QoL in
the control groups ranged from -0.65 to 0.70
standard deviation units

Overall QoL
follow-up val-
ues - up to 12
weeks' fol-
low-up

The standardized mean follow-up values at up
to 12 weeks' follow-up in anxiety in the control
groups ranged from -0.96 to 10.87 standard de-
viation units

Corresponding
risk

Exercise group

The standardized
mean change from
baseline to up to 12
weeks' follow-up
in overall QoL was
0.47 standard devi-
ation units higher
(0.16 to 0.79 stan-
dard deviation
units higher) in the
exercise groups

The SMD in fol-
low-up values at
up to 12 weeks'
follow-up in over-
all QoL was 0.33
standard deviation
units higher (0.12
to 0.55 standard
deviation units
higher) in the exer-
cise groups

Relative ef-
fect
(95% CI)

No of partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

806 (11 stud-
ies)

⊕⊝⊝⊝
very low1,2,5

(SMD 0.47; 95% CI 0.16 to
0.79)

A standard deviation unit
is equivalent to about a
14.8-point change using
the FACT-G HRQoL form

1166 (20 stud-
ies)

⊕⊝⊝⊝
very low1,2,5

(SMD 0.33; 95% CI 0.12 to
0.55)

C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

E
x
e
r
c
i
s
e
i

n
t
e
r
v
e
n
t
i
o
n
s
o
n
h
e
a
l
t
h
-
r
e
l
a
t
e
d
q
u
a
l
i
t
y
o
f

l
i
f
e
f
o
r
p
e
o
p
l
e
w

i
t
h
c
a
n
c
e
r
d
u
r
i
n
g
a
c
t
i
v
e
t
r
e
a
t
m
e
n
t

(
R
e
v
i
e
w

)

4

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Overall anxi-
ety follow-up
values - up to
12 weeks' fol-
low-up

The standardized mean follow-up values at up
to 12 weeks' follow-up in anxiety in the control
groups ranged from 0.70 to 12.2 standard devi-
ation units

Overall anxiety
follow-up val-
ues - 6 months'
follow-up

The standardized mean follow-up values at
6 months' follow-up in anxiety in the control
groups ranged from 0.10 to 0.40 standard devi-
ation units

Overall de-
pression fol-
low-up val-
ues - up to 12
weeks' fol-
low-up

The standardized mean follow-up values at up
to 12 weeks' follow-up in depression in the con-
trol groups ranged from 0.79 to 8.08 standard
deviation units

Overall de-
pression fol-
low-up values
- 6 months' fol-
low-up

The standardized mean follow-up values at up
to 12 weeks' follow-up in depression in the con-
trol groups ranged from 1.07 to 1.44 standard
deviation units.

The SMD in fol-
low-up values at
up to 12 weeks' fol-
low-up in anxiety
was -0.46 standard
deviation units
higher (-0.81 to
-0.11 standard de-
viation units high-
er) in the exercise
groups

The SMD in fol-
low-up values at 6
months' follow-up
in anxiety was -0.44
standard deviation
units higher (-0.71
to -0.17 standard
deviation units
higher) in the exer-
cise group

The SMD in fol-
low-up values at
up to 12 weeks'
follow-up in de-
pression was -0.55
standard deviation
units higher (-0.87
to -0.22 standard
deviation units
higher) in the exer-
cise groups

The SMD in fol-
low-up values at
up to 12 weeks'
follow-up in de-
pression was -0.29
standard deviation
units higher (-0.48
to -0.09 standard
deviation units

C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

E
x
e
r
c
i
s
e
i

n
t
e
r
v
e
n
t
i
o
n
s
o
n
h
e
a
l
t
h
-
r
e
l
a
t
e
d
q
u
a
l
i
t
y
o
f

l
i
f
e
f
o
r
p
e
o
p
l
e
w

i
t
h
c
a
n
c
e
r
d
u
r
i
n
g
a
c
t
i
v
e
t
r
e
a
t
m
e
n
t

(
R
e
v
i
e
w

)

5

1010 (12 stud-
ies)

⊕⊝⊝⊝
very low1,2,5

(SMD -0.46; 95% CI -0.81 to
-0.11)

A standard deviation unit
is equivalent to about a
2.7-point change using the
anxiety subscale of the
HADS form or about 11.8
points using the STAI form

286 (3 studies)

⊕⊕⊝⊝
low1,3

(SMD -0.44; 95% CI -0.71 to
-0.17)

1250 (15 stud-
ies)

⊕⊝⊝⊝
very low1,2,5

(SMD -0.55; 95% CI -0.87 to
-0.22)

A standard deviation unit
is equivalent to about an
8.86-point change using
the CES-D form or a 2.29-
point change using the de-
pression subscale of the
HADS form

452 (4 studies)

⊕⊕⊝⊝
low1,3

(SMD -0.29; 95% CI -0.48 to
-0.09)

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

E
x
e
r
c
i
s
e
i

n
t
e
r
v
e
n
t
i
o
n
s
o
n
h
e
a
l
t
h
-
r
e
l
a
t
e
d
q
u
a
l
i
t
y
o
f

l
i
f
e
f
o
r
p
e
o
p
l
e
w

i
t
h
c
a
n
c
e
r
d
u
r
i
n
g
a
c
t
i
v
e
t
r
e
a
t
m
e
n
t

(
R
e
v
i
e
w

)

6

Overall fa-
tigue change
score - up to
12 weeks' fol-
low-up

The standardized mean change from baseline
to up to 12 weeks' follow-up in fatigue in the
control groups ranged from -073 to 1.48 stan-
dard deviation units

Overall fatigue
follow-up val-
ues - up to 12
weeks' fol-
low-up

The standardized mean follow-up values at up
to 12 weeks' follow-up in fatigue in the control
groups ranged from -7.42 to 6.75 standard devi-
ation units

Overall phys-
ical func-
tion change
score - up to
12 weeks' fol-
low-up

The standardized mean change from baseline
to up to 12 weeks' follow-up in physical func-
tion in the control groups ranged from -26.3 to
0.33 standard deviation units

Overall phys-
ical function
change score -
6 months' fol-
low-up

The standardized mean change from baseline
to up to 12 weeks' follow-up in physical func-
tion in the control groups ranged from -0.26 to
0.24 standard deviation units

higher) in the exer-
cise groups

The standardized
mean change from
baseline to up to 12
weeks' follow-up
in fatigue was -0.73
standard deviation
units higher (-1.14
to -0.31 standard
deviation units
higher) in the exer-
cise groups

The SMD in fol-
low-up values at
up to 12 weeks'
follow-up in de-
pression was -0.38
standard deviation
units higher (-0.57
to -0.18 standard
deviation units
higher) in the exer-
cise groups

The standardized
mean change from
baseline to up to 12
weeks' follow-up in
physical function
was 0.69 standard
deviation units
higher (0.16 to 1.22
standard deviation
units higher) in the
exercise groups

The standard-
ized mean change
from baseline to 6
months' follow-up
in physical function
was 0.28 standard
deviation units

971 (12 stud-
ies)

⊕⊝⊝⊝
very low1,2,5

(SMD -0.73; 95% CI -1.14 to
-0.31)

A standard deviation unit
is equivalent to about an
11-point change using the
fatigue subscale of the
FACT form

1721 (23 stud-
ies)

⊕⊝⊝⊝
very low1,2,5

(SMD -0.38; 95% CI -0.57 to
-0.18)

540 (8 studies)

⊕⊝⊝⊝
very
low1,2,3,5

(SMD 0.69; 95% CI 0.16 to
1.22)

A standard deviation unit
is equivalent to about a
5.4-point change using the
PWB subscale of the FACT
form

305 (4 studies)

⊕⊝⊝⊝
very low1,2,5

(SMD 0.28; 95% CI -0.00 to
0.55)

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

E
x
e
r
c
i
s
e
i

n
t
e
r
v
e
n
t
i
o
n
s
o
n
h
e
a
l
t
h
-
r
e
l
a
t
e
d
q
u
a
l
i
t
y
o
f

l
i
f
e
f
o
r
p
e
o
p
l
e
w

i
t
h
c
a
n
c
e
r
d
u
r
i
n
g
a
c
t
i
v
e
t
r
e
a
t
m
e
n
t

(
R
e
v
i
e
w

)

7

Overall role
function
change score
- up to 12
weeks' fol-
low-up

Overall role
function fol-
low-up val-
ues - up to 12
weeks' fol-
low-up

Overall so-
cial func-
tion change
score - up to
12 weeks' fol-
low-up

The standardized mean change from baseline
to up to 12 weeks' follow-up in role function in
the control groups ranged from -2.11 to -0.26
standard deviation units

The standardized mean change from baseline
to up to 12 weeks' follow-up in role function in
the control groups ranged from -0.89 to 7.44
standard deviation units

The standardized mean change from baseline
to up to 12 weeks' follow-up in social function
in the control groups ranged from -0.71 to 0.11
standard deviation units

higher (-0.00 to
0.55 standard de-
viation units high-
er) in the exercise
groups

The standardized
mean change from
baseline to up to 12
weeks' follow-up in
role function was
0.48 standard de-
viation units high-
er (0.07 to 0.9 stan-
dard deviation
units higher) in the
exercise groups

The SMD in fol-
low-up values at
up to 12 weeks'
follow-up in role
function was 0.17
standard deviation
units higher (0.00
to 0.34 standard
deviation units
higher) in the exer-
cise groups

The standardized
mean change from
baseline to up to 12
weeks' follow-up
in social function
was 0.54 standard
deviation units
higher (0.03 to 1.05
standard deviation
units higher) in the
exercise groups

437 (7 studies)

⊕⊝⊝⊝
very
low1,2,3,5

(SMD 0.48; 95% CI 0.07 to
0.90)

A standard deviation unit
is equivalent to about a
5.5 point change using the
functional subscale of the
FACT form

1100 (15 stud-
ies)

⊕⊕⊝⊝
low1,5

(SMD 0.17; 95% CI 0.00 to
0.34)

378 (5 studies)

⊕⊝⊝⊝
very
low1,2,3,5

(SMD 0.54; 95% CI 0.03 to
1.05)

A standard deviation unit
is equivalent to about a
5.4 point change using the
social well-being subscale
of the FACT form

Overall social
function fol-
low-up val-
ues - up to 12

The standardized mean change from baseline
to up to 12 weeks' follow-up in social function
in the control groups ranged from -0.41 to 8.00
standard deviation units

The SMD in fol-
low-up values at
up to 12 weeks' fol-
low-up in social

1164 (16 stud-
ies)

⊕⊕⊝⊝
low1,5

(SMD 0.16; 95% CI 0.04 to
0.27)

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
weeks' fol-
low-up

function was 0.16
standard deviation
units higher (0.04
to 0.27 standard
deviation units
higher) in the exer-
cise groups

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the as-
sumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CES-D: Centers for Epidemiological Studies - Depression Scale; CI: confidence interval: FACT: Functional Assessment of Cancer Therapy; FACT-G; Functional Assessment of
Cancer Therapy - General; HADS: Hospital Anxiety and Depression Scale; HRQoL: health-related quality of life; PWB: physical well-being; QoL: quality of life; SMD: standard-
ized mean difference; STAI: State-Trait Anxiety Scale.

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 It was not possible to blind study participants or people administering treatment
2 Statistical heterogeneity was moderate to high
3 The small total population sample size (< 500) represents a small effect
4 Random sequence generation was unclear in half or more of the trials
5 Allocation concealment was unclear in half of more of the trials

C
o
p
y
r
i
g
h
t

©
2
0
1
2
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

E
x
e
r
c
i
s
e
i

n
t
e
r
v
e
n
t
i
o
n
s
o
n
h
e
a
l
t
h
-
r
e
l
a
t
e
d
q
u
a
l
i
t
y
o
f

l
i
f
e
f
o
r
p
e
o
p
l
e
w

i
t
h
c
a
n
c
e
r
d
u
r
i
n
g
a
c
t
i
v
e
t
r
e
a
t
m
e
n
t

(
R
e
v
i
e
w

)

8

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

B A C K G R O U N D

There  is  a  steady  increase  in  the  number  of  cancer  survivors,
that  is  people  diagnosed  with  cancer  (Aziz  2003),  worldwide.
This  is  because  of,  in  a  large  part,  the  dramatic  advances  in
cancer treatment and management (Aziz 2002; Aziz 2003), growing
attention  to  multidisciplinary  post-treatment  care  (Demark-
Wahnefried  2000;  Stull  2007),  and  healthier  lifestyles  (Demark-
Wahnefried 2005; Stull 2007). There are approximately 22 million
cancer survivors worldwide (Stewart 2003); 11.7 million of whom
are estimated to be present in the US alone (Rowland 2011).

Description of the condition

People  with  cancer  undergoing  active  treatment  experience
numerous disease- or treatment-related adverse outcomes, or both
(physiologic and psychosocial) (Aziz 2002; Aziz 2003; Aziz 2007; Aziz
2008; Cramp 2008) and poorer health-related quality of life (HRQoL)
(Ganz  2004;  Lee  2007b).  Some  of  the  adverse  outcomes  include
cardiotoxicity, neurotoxicity, lymphedema, premature menopause,
sexual dysfunction, infertility, and fatigue (Aziz 2002; Aziz 2003; Aziz
2007; Cramp 2008), all with a negative impact on HRQoL. Exercise
interventions are particularly relevant because they influence both
the  physiologic  and  psychosocial  adverse  outcomes,  including
HRQoL  (Courneya  2007b;  Ingram  2007;  Schmitz  2005;  Warburton
2006).  Further,  HRQoL  and  its  domains  are  important  measures
for  cancer  survivorship  as  they  provide  prognostic  (Gotay  2008)
and predictive (Efficace 2006; Osoba 1999; Osoba 2007) information
and  the  survivors''  subjective  experiences  (Bottomley  2002)  to
therapeutic and lifestyle interventions.

it 

is  broad  consensus 

Although  HRQoL  has  no  commonly  accepted  definition,
there 
is  a  patient-reported,
that 
multidimensional  construct.  Ferrans  provided  a  comprehensive
review of definitions of HRQoL and concluded that, "the literature
contains  a  bewildering  array  of  characterizations"  (Ferrans
2005).  Nonetheless,  the  review  indicated  that  there  is  broad
consensus among experts (Bottomley 2002; Gotay 1992; Lipscomb
2007;  Osoba  1994)  regarding  the  major  domains  of  HRQoL.
These  domains  comprise  subjective  assessments  of  physical,
psychological, economic, social, and spiritual wellbeing. Physical
function includes performance of self-care activities, mobility, and
physical  activities.  Psychological  functions  include  EWB,  anxiety,
body  image,  and  depression.  Social  and  economic  functions
include work or household responsibilities and social interactions.
Spiritual wellbeing includes perspectives on one's life as a whole.
HRQoL  also  encompasses  the  negative  aspects  of  the  disease  or
treatment  such  as  sexual  functioning,  neuropathy  or  cognitive
changes,  and  chronic  fatigue.  Lastly,  the  importance  of  also
assessing  positive  aspects  of  HRQoL  has  been  stressed  (Diener
2000). Our selection of the primary outcomes for this review reflects
these theoretical perspectives, in that we included both all the well-
agreed upon domains of HRQoL and positive aspects of wellbeing.

Description of the intervention

The  benefits  of  exercise  on  health  status,  length  of  survival,
promotion  of  HRQoL,  and  mitigating  premature  death  are
gaining wide attention (Warburton 2006). There is some evidence
suggesting  that  participation  in  exercise  by  people  with  cancer
undergoing  active  treatment 
increases  physical  functioning
(Courneya  2009;  Griffith  2009;  McNeely  2006;  Stevinson  2004),
reduces  fatigue  (Adamsen  2009;  Cramp  2008),  reduces  pain

Cochrane Database of Systematic Reviews

(Griffith 2009), reduces treatment-related toxicity (Kapur 2009), and
facilitates positive physiologic and psychological benefits (Galvao
2005;  Knols  2005;  Schmitz  2005).  In  addition,  evidence  suggests
that  exercise  enhances  HRQoL  during  active  treatment  in  people
with  breast  (McNeely  2006;  Mustian  2009;  Valenti  2008),  prostate
(Galvao  2010;  Mustian  2009;  Segal  2009;  Thorsen  2008),  head
and  neck  (Rogers  2006),  and  colorectal  (Courneya  2003b)  cancer,
and  multiple  myeloma  (Jones  2004).  Further,  exercise  leads  to
improvements  in  physical  functioning  and  a  reduction  in  fatigue
symptoms during active treatment in people with breast (McNeely
2006; Mustian 2009) and prostate (Galvao 2010; Mustian 2009; Segal
2009; Thorsen 2008) cancer. Despite the growing body of literature
documenting  the  beneficial  effects  of  exercise  (Courneya  2007b),
several studies have documented lower levels of exercise behavior
among  people  diagnosed  with  cancer  (Blanchard  2003;  Valenti
2008; Vallance 2005).

How the intervention might work

There is tremendous interest in the association between exercise
and  physiologic  and  psychological  wellbeing  in  general  and
HRQoL in particular. Systematic reviews on the effects of exercise
interventions on people with cancer during active treatment have
documented  improvements  in  cardiorespiratory  fitness  (McNeely
2006;  Schmitz  2005),  physical  function  (McNeely  2006;  Stevinson
2004; Thorsen 2008), psychological wellbeing (Galvao 2005; Knols
2005; Speck 2010), overall HRQoL (Knols 2005; Speck 2010), fatigue
(Cramp  2008;  McNeely  2006;  Mustian  2007;  Velthuis  2010a),  and
physiologic outcomes (Galvao 2005; Knols 2005; Schmitz 2005).

Why it is important to do this review

There  is  no  systematic  review  examining  the  effect  of  exercise
on:  (a)  overall  HRQoL  or  HRQoL  domains,  or  both  (e.g.  physical,
psychological,  economic,  social,  and  spiritual  wellbeing);  and  (b)
disease-  or  treatment-related  symptoms  (or  both)  (e.g.  sexual
functioning, neuropathy or cognitive changes, and chronic fatigue)
among  adults  with  cancer  during  active  treatment.  This  review
is  different  from  previous  systematic  reviews  in  the  number  of
databases  searched  (Galvao  2005;  Schmitz  2005)  and  on  the
inclusion  criteria  for  the  trials.  Several  of  the  previous  reviews
included  trials  with  non-randomized  controlled  trial  (non-RCT)
designs  (Galvao  2005;  Schmitz  2005;  Stevinson  2004;  Thorsen
2008),  people  with  cancer  during  active  treatment  and  in  the
immediate post-treatment phase (Cramp 2008; Galvao 2005; Knols
2005;  McNeely  2006;  Schmitz  2005;  Stevinson  2004),  and  site-
specific  cancers  (McNeely  2006;  Thorsen  2008).  This  lack  of
documentation  and  evidence  coupled  with  limitations  of  the
previous  reviews  necessitated  a  systematic  review  to  determine
the effectiveness of exercise on HRQoL among adults with cancer
during  active  treatment.  This  review  complements  a  previously
published protocol that described a systematic review determining
the effectiveness of exercise interventions on HRQoL among adult
cancer  survivors  who  were  beyond  the  active  treatment  period
(Mishra 2009).

O B J E C T I V E S

To  evaluate  the  effectiveness  of  exercise  on  overall  HRQoL
outcomes  and 
(e.g.  physical,
specific  HRQoL  domains 
psychological,  economic,  social,  and  spiritual  wellbeing,  and
key  disease  or  treatment  (or  both)  symptoms  such  as  sexual
functioning, neuropathy or cognitive changes, and chronic fatigue)

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

9

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

among  adults  with  cancer  who  are  undergoing  active  treatment
(excluding those who are terminally ill and receiving hospice care).

A  secondary  objective  examined,  where  data  were  available,  the
effectiveness  of  exercise  on  HRQoL  outcomes  among  adults  with
cancer  who  were  undergoing  active  treatment  stratified  by  the
following:

1. age at diagnosis (i.e. less than 65 years or greater than or equal

to 65 years);

2. Age at trial enrolment (i.e. less than 65 years or greater than or

equal to 65 years);

3. Sex;
4. Type  of  prescribed  exercise 

combination);

(i.e.  aerobic,  anaerobic,

5. Intensity of exercise (i.e. mild, moderate, vigorous);
6. Format of exercise (i.e. individual or group, professionally led or

not, home or group facility);

7. Type  of 

treatment 
chemotherapy, or combination); and

regimen 

(i.e. 

radiation, 

surgery,

Cochrane Database of Systematic Reviews

exercise  formats  of  aerobic,  anaerobic,  or  aerobic  and  anaerobic
combinations  focused  upon  cardiopulmonary,  musculoskeletal,
neuromuscular  conditioning,  or  a  combination:  active  or  active-
assisted  range  of  motion  (ROM),  stretching  exercises,  and
strengthening  or  resistance  exercises.  The  specific  prescribed,
active  exercise  included  but  was  not  limited  to  the  following
methods:  walking  programs,  aquatic  exercise,  running,  sports,
resistance training, yoga, tai chi, and pilates. The prescribed, active
exercise program was individual or group, professionally led or not,
and home or facility based. Exercise intensity was based on the rate
of perceived exertion (RPE) or heart rate (HR), or both, with mild
exercise defined as RPE of six to 11 or HR at 30% to 54% of maximum
HR, or both; moderate exercise was defined as RPE of 12 to 13 or
HR at 55% to 70% of maximal HR, or both; and vigorous exercise
was defined as RPE of 14 to 19 or HR at 71% to 95% of maximal HR,
or both (American College of Sports Medicine 1998). We classified
the intensity of the exercise based on RPE or HR, or both, or when
a quantitative measure of intensity of the exercise intervention was
not available, we used the authors' classification of an intervention
as mild, moderate, or vigorous.

8. Specific chemotherapeutic agents.

Types of outcome measures

M E T H O D S

The included trials measured self-reported participant measures of
HRQoL as primary or secondary end points.

Criteria for considering studies for this review

Primary outcomes

Types of studies

We  included  only  randomized  controlled  trials  (RCTs)  and  quasi-
randomized  controlled  clinical  trials  (CCTs).  The  included  trials
assessed  exercise  interventions  that  were  initiated  when  people
with cancer were undergoing active cancer treatment (i.e. surgery,
chemotherapy,  radiation  therapy,  or  hormone  therapy)  or  were
scheduled to initiate treatment.

Types of participants

Included  trials  evaluated  the  effect  of  exercise  on  HRQoL  among
people  with  cancer  undergoing  active  treatment  who  were
diagnosed  as  adults  (18  years  and  over)  regardless  of  age,  sex,
tumor  site,  tumor  type,  tumor  stage,  and  type  of  anticancer
treatment received. We excluded trials including participants who
were terminally ill or receiving hospice care, or both, and trials in
which fewer than one-third of participants were undergoing active
treatment for either the primary or a recurrent cancer.

Types of interventions

We  included  trials  that  evaluated  and  reported  the  effects  of
exercise,  excluding  dance,  on  HRQoL  outcomes.  We  excluded
trials  only  evaluating  dance  as  an  intervention  because  there  is
a  Cochrane  review  on  dance  movement  therapy  for  improving
psychological and physical outcomes in patients with cancer (Bradt
2011). Included trials compared exercise with no exercise, another
intervention, or usual care (e.g. with no specific exercise program
prescribed).

We  defined  exercise  as  any  physical  activity  causing  an  increase
in  energy  expenditure,  and  involving  a  planned  or  structured
movement  of  the  body  performed  in  a  systematic  manner  in
terms  of  frequency,  intensity,  and  duration,  and  designed  to
maintain or enhance health-related outcomes (American College of
Sports Medicine 1998; American College of Sports Medicine 2005).
The  primary  exercise  intervention  included  prescribed,  active

1. Overall HRQoL, at four follow-up intervals: up to 12 weeks; more
than 12 weeks but less than six months, six months, and more
than six months following the exercise intervention.

2. HRQoL  domains,  at  the  four  time  intervals  described  above

including, but not limited to:
a. physical  function  (e.g.  performance  of  self-care  activities,

mobility, physical activities);

b. psychological  function  (e.g.  EWB,  anxiety,  body  image,

depression, negative affect);

c. social and economic role function (e.g. performance of work

or household responsibilities, social interactions);

d. spiritual well-being;
e. pain;
f. vitality (e.g. energy and fatigue);
g. general health perceptions; and
h. positive  attributes  (e.g.  positive  affect,  sense  of  coherence,
interpersonal relationships, philosophy of life, spirituality).

3. Disease-  or  treatment-related  symptoms  (or  both)  (e.g.  sexual
functioning, neuropathy or cognitive changes, chronic fatigue).

The adverse outcomes of interest included:

1. any harm associated with the exercise intervention; and
2. decrease in overall HRQoL or HRQoL domain.

Search methods for identification of studies

Electronic searches

We used, at the minimum, the following databases and searches
to obtain relevant trials for this review. We searched all databases
from  inception  to  the  present.  There  were  no  language  or  date
restrictions in the electronic search for trials. We utilized the search
strategy for MEDLINE for the review using text and indexing terms
in  each  database,  combined  with  filters  for  RCT  and  CCT,  and

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

10

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

human studies (Glanville 2006). The MEDLINE search strategy was
developed for precision and sensitivity and was then appropriately
modified for the other databases.

any disagreement between review authors on classification of an
article, either between the two review authors or through use of a
third review author.

1. MEDLINE (Appendix 1)
2. The  Cochrane  Central  Register  of  Controlled  Trials  (CENTRAL)

(Appendix 2)

3. EMBASE (Appendix 3)
4. CINAHL (Appendix 4)
5. PsycINFO (Appendix 5)
6. PEDRO (Appendix 6)
7. LILACS (Appendix 6)
8. SIGLE (Appendix 6)
9. SportDiscus (Appendix 6)
10.OTSeeker (Appendix 6)
11.Sociological Abstracts (Appendix 6)

We also searched citations of key authors through Web of Science
and Scopus, and searched PubMed's related article feature.

The  review  author  team  developed  and  executed  the  search
strategies.

Searching other resources

We performed an expanded search in order to identify additional
trials for this review, including unpublished trials and references in
the "gray literature". This included the following:

1. review  of  the  reference  list  of  all  retrieved  articles  and  other

reviews on the topic;

2. contacting experts in the field of exercise and HRQoL in order to

identify unpublished research;
3. searching the following websites:

a. World Health Organization (WHO) International Clinical Trials

Registry Platform (www.who.int/ictrp/en)

b. Current Controlled Trials (www.controlled-trials.com)
c. CenterWatch (www.centerwatch.com)
d. ClinicalTrials.gov (www.clinicaltrials.gov)

4. We did not handsearch any journals specifically for this review.

Data collection and analysis

Selection of studies

Assessment of search results

Two  review  authors  (SM,  RS),  working  independently,  screened
all  the  titles  and  abstracts  resulting  from  the  searches  and
excluded articles that were clearly irrelevant. We retrieved full-text
copies  of  all  trials  if  either  review  author  determined  that  a  trial
possibly or definitely met the inclusion criteria. We translated into
English,  where  possible,  all  non-English  language  articles.  Paired
review  authors  (SM,  RS,  CS,  PG,  OT)  independently  reviewed  the
retrieved full-text articles and, using the defined eligibility criteria,
determined  their  eligibility  for  inclusion.  We  did  not  randomly
assign articles to review authors neither did we mask trial details
such  as  trial  authors,  journal  of  publication,  trial  location,  and
institutional  affiliations  of  the  trial  authors.  If  there  was  a  need
for  clarification  of  any  detail  of  a  trial,  we  contacted  the  trial
authors  to  obtain  such  clarification  for  a  complete  assessment
of  the  trial's  relevance  for  the  review.  We  resolved  by  consensus

Data extraction and management

Extraction of study characteristics

For each trial, we extracted:

1. Characteristics of the studies:

a. the study sponsors and the authors' affiliations;
b. trial methods: study design, method of sequence generation,
method  of  allocation  concealment,  masking  (participant,
researcher,  outcome),  exclusions  after  randomization,
follow-up  and
selective  outcome 
compliance.

reporting, 

loss 

to 

2. Characteristics of study population:

a. country where participants enrolled;
b. trial inclusion and exclusion criteria;
c. number randomized in each arm;
d. type of control group;
e. demographic  characteristics, 

including  age  at 

trial

f.

enrolment, sex, ethnicity, socioeconomic status;
type of cancer, including primary site, stage at diagnosis, and
hormone dependency;

g. age at diagnosis;
h. time since diagnosis;
i. primary or secondary cancer;
j.

type  of 
regimen 
treatment 
chemotherapy, or combination)
k. specific chemotherapeutic agents.

(i.e. 

radiation,  surgery,

3. Characteristics of the intervention:

a. type  of  exercise  intervention  in  each  intervention  group:

aerobic, anaerobic, combination;

b. description/details  of  the  exercise  intervention:  frequency,
duration,  intensity,  total  number  of  exercise  sessions,
duration  of  follow-up,  exercise  format  (i.e.  individual  or
group, professionally led or not, home or facility based);
c. description/details of control/comparison intervention;
d. adherence and contamination;
e. co-intervention (e.g. medication use).

4. Characteristics of the outcomes:

a. self-reported HRQoL measure  or HRQoL domain  measures,
or  both  (e.g.  physical,  psychological,  economic,  social,
and  spiritual  well-being,  pain,  vitality,  health  perceptions,
positive attributes);

b. disease  or  treatment  symptoms,  or  both  (e.g.  sexual
functioning,  neuropathy  or  cognitive  changes,  and  chronic
fatigue);
length  of  time  between  end  of  intervention  and  outcome
measurement;

c.

d. adverse 

(e.g. 
noncompliance with exercise program, trial attrition);

exercise-associated 

outcomes 

harm,

e. economic  data  on  cost  and  cost-benefit  of  the  exercise

intervention.

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

11

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Data extraction and entry

Measures of treatment effect

Paired review authors (SM, RS, CS, PG, OT) independently extracted
data, using a standardized form, from each article. Disagreements
between the review authors on the data abstracted were resolved
through consensus or, when necessary, there was a meeting with
a third review author not involved in the particular extraction (SM,
RS). In addition, we attempted to contact all trial authors (using e-
mail, letter, fax, or a combination) to search for additional articles,
seek clarity and additional information about trials, confirm data
extraction, and obtain missing data using a structured instrument
with standardized questions. If the trial authors could not provide
the  requested  information  or  were  unable  to  comply  with  the
request within two weeks, we proceeded with the review without
the  information.  If  available,  we  extracted  similar  data  for  each
outcome  from  each  trial  included  in  the  review.  For  the  primary
and  secondary  HRQoL  outcomes,  if  more  than  two  time  points
were reported during a single interval, the one closest to 12 weeks
(for  the  follow-up  time  point),  or  the  longest  time  interval  (for
the  other  follow-up  time  points)  was  selected  for  analyses.  We
also  collected  information  on  any  harm  reported  in  the  included
trials.  We  collected  data,  if  reported,  on  cost  and  cost-benefit  of
the  exercise  interventions.  The  unit  of  analysis  was  individuals,
people  with  cancer  undergoing  active  treatment  randomized  to
each arm of the trial. We entered and combined the trial data using
Review Manager, version 5.1 (RevMan 2011). One review author (RS)
entered the data into RevMan 5.1, and another review author (SM)
worked independently to verify the data entry.

Assessment of risk of bias in included studies

Two  review  authors  (SM,  RS)  assessed  the  risk  of  bias  of  all
the  included  trials  by  evaluating  the  parameters  listed  on  the
RevMan  5.1  'Risk  of  bias'  table  (RevMan  2011).  For  RCTs  and
CCTs this included assessment of sequence generation, allocation
concealment,  masking  or  blinding  (of  participants,  researchers/
healthcare  providers,  and  outcome  assessors),  methods  of
addressing  incomplete  outcome  data,  selective  reporting  of
outcomes,  and  other  possible  sources  of  bias  including  attrition
from, and adherence with, the exercise intervention. We assessed
and  graded  each  trial  quality  parameter  as  high  risk,  low  risk,  or
unclear  risk  based  on  recommendations  for  judging  risk  of  bias
provide  in  Chapter  8  of  the  Cochrane  Handbook  for  Systematic
Reviews of Interventions (Higgins 2011).

Comparability of treatment groups

Using  RCTs  and  CCTs,  by  definition,  ensures  comparability  of  the
treatment groups. However, it is likely that randomization (or quasi-
randomization) may not work as desired. We looked at the baseline
characteristics  (i.e.  demographic  characteristics  and  attributes  of
the  cancer  and  its  treatment)  of  the  treatment  groups  for  any
differences  between  the  groups  or  whether  the  differences  were
controlled for during the analyses. In particular, we recorded:

1. yes,  there  were  differences  between  the  treatment  groups  on
one or more baseline characteristic and the reported differences
were controlled for;

2. no,  there  were  differences  between  the  treatment  groups  on
one or more baseline characteristic and the reported differences
were not controlled for;

3. unclear,  differences  between  the  treatment  groups  were  not

reported and unclear whether they were controlled for.

Trials  reported  data  on  HRQoL  or  HRQoL  domains,  or  both  in
different  ways  or  used  different  instruments  to  measure  the
same construct, but all reported continuous (versus dichotomous)
outcomes.  If  necessary,  we  planned  to  transform  outcome  data
to  achieve  consistency  of  results,  but  did  not  need  to  do  so  for
this review. We combined data using a weighted mean difference
(WMD) and a random effect model when trials measured HRQoL or
HRQoL domains using the same measurement method or scale to
generate continuous data. We used a standardized mean difference
(SMD)  analysis  and  random-effects  model  to  combine  data  from
different  instruments  measuring  the  same  domain.  When  there
was significant clinical or statistical heterogeneity, we performed
subgroup analyses or provided a qualitative analysis rather than a
quantitative analysis of HRQoL or HRQoL domains.

Authors  did  not  report  any  dichotomous  data,  such  as  presence
or absence of an HRQoL outcome, but if they had, we would have
expressed the treatment effect as risk ratio (RR) together with 95%
confidence interval (CI).

Whenever possible, we conducted subgroup analysis of treatment
effect based on:

1. Grouping of the exercise intervention on:

a. type (i.e. aerobic, anaerobic, combination);
b. intensity (i.e. mild, moderate, vigorous); and
c. format  (i.e.  individual  or  group,  professionally  led  or  not,

home or facility based).

2. Grouping of people with cancer on:

a. sex;
b. cancer type;
c. age at trial enrolment (i.e. less than 65 years or greater than

or equal to 65 years);

d. age  at  diagnosis  (i.e.  less  than  65  years  or  greater  than  or

equal to 65 years);

e. type  of 

treatment 

regimen 

(i.e. 

radiation,  surgery,

chemotherapy, or combination); and

f. specific chemotherapeutic agents.

Assessment of heterogeneity

We evaluated clinical heterogeneity by examining diversity in the
people with cancer undergoing active treatment, and differences
in  cancers,  the  exercise  interventions,  and  overall  HRQoL  or
HRQoL  domains,  or  both  among  trials.  We  did  not  pool  clinically
heterogeneous trials. We also checked for statistical heterogeneity
by  visual  inspection  of  forest  plots  and  by  using  the  Chi  square
(Chi2) and the I2 tests.

Assessment of reporting biases

To  investigate  publication  bias,  we  prepared  funnel  plots  and
visually  examined  them  for  signs  of  asymmetry.  We  followed  the
recommendations  in  Chapter  10  of  the  Cochrane  Handbook  for
Systematic Reviews of Interventions (Sterne 2011) for any statistical
testing  for  funnel  plot  asymmetry.  If  there  was  statistically
significant  asymmetry,  we  considered  interpretations  other  than
publication bias.

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

12

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Data synthesis

Measurement of intervention intensity

We  reported  the  authors'  classification  of  the  intensity  of  the
exercise  based  on  RPE,  HR,  or  both,  or  on  authors'  classification
of the intensity of the exercise intervention as mild, moderate, or
vigorous.

We combined data from trials in a meta-analysis when appropriate
to pool for a meta-analysis, that is, those data showing no clinical
heterogeneity.  When  there  was  moderate  clinical  heterogeneity,
we conducted prespecified subgroup analyses (i.e. type of cancer,
intensity  of  exercise,  etc.  as  mentioned  above).  When  there
was  significant  heterogeneity  as  demonstrated  by  a  statistically
significant  Chi2  test  or  I2  above  50%,  we  investigated  source  of
heterogeneity  and  if  possible,  conducted  a  quantitative  meta-
analysis  by  subgroups  only.  We  pooled  all  studies  (or  all  similar
studies)  for  a  random-effects  meta-analysis  to  determine  the
pooled intervention effect estimate (odds ratio (OR) and 95% CI).

Sensitivity analysis

We  also  conducted  sensitivity  analysis  to  assess  the  effects  of
including trials with a high risk of bias.

R E S U L T S

Description of studies

Results of the search

See:  Characteristics  of 
included  studies;  Characteristics  of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies

Through  a  comprehensive  literature  search,  we  identified  and
screened  for  retrieval  1896  nonduplicate  potentially  relevant
references.  We  excluded  a  total  of  1703  references  based  on  the
title  and  abstract  and  retrieved  193  references  for  more  detailed
evaluation. From these, we excluded 102 trials as they did not meet
the inclusion criteria and 56 trials were appropriate for inclusion in
the current review. In addition, six trials (Christensen 2011; Galvao
2009; Haseen 2010; Newton 2009; van Waart 2010; Velthuis 2010)
were  ongoing  and  four  trials  (Courneya  2001;  Harandi  2010;  Sun
2009; Utz-Billing 2010) were awaiting classification and these trials
were  not  included  in  the  analysis  presented  below  but  will  be
considered  in  future  updates  of  this  review.  Twenty-five  eligible
trials  were  also  not  included  in  the  analysis  as  these  trials  were
classified  as  secondary  publications  for  some  of  the  56  trials
included  in  the  current  review.  All  searches  were  completed  in
November 2011. See Figure 1 for a flowchart of the search process
based on the PRISMA template (Moher 2009).

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

13

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 1.   Study flow diagram.

Cochrane Database of Systematic Reviews

Included studies

The final selection based on consensus resulted in 56 trials being
included  in  this  review  (Adamsen  2009;  Arbane  2009;  Banerjee
2007;  Battaglini  2008;  Bourke  2011;  Brown  2006;  Cadmus  2009;

Caldwell  2009;  Campbell  2005;  Chandwani  2010;  Chang  2008;
Cheville  2010;  Cohen  2004;  Courneya  2003a;  Courneya  2007a;
Courneya  2008;  Courneya  2009;  Crowley  2003;  Culos-Reed  2010;
Danhauer  2009;  de  Oliveira  2010;  Dimeo  1999;  DiSipio  2009;

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

14

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Donnelly  2011;  Galvao  2010;  Gomes  2011;  Griffith  2009;  Hacker
2011;  Haddad  2011;  Headley  2004;  Hwang  2008;  Jarden  2009;
Lanctot  2010;  Moadel  2007;  Mock  1994;  Mock  1997;  Mock  2001;
Mock  2005;  Monga  2007;  Moros  2010;  Mustian  2009;  Mutrie  2007;
Oh  2008;  Oh  2010;  Raghavendra  2007;  Rogers  2009;  Segal  2001;
Segal  2003;  Segal  2009;  Tang  2010;  Targ  2002;  Vadiraja  2009b;
Wang  2010;  Windsor  2004;  Wiskemann  2011;  Yang  2011).  We  also
reviewed  and  included  information  on  study  characteristics  and
outcomes related data from an additional 25 publications that were
secondary publications to several of the 56 trials. For seven trials,
there  were  limited  data  available  for  extraction  and  quantitative
analysis  (Brown  2006;  DiSipio  2009;  Gomes  2011;  Haddad  2011;
Headley 2004; Mock 1997; Oh 2008) and for two trials there were no
data available for extraction and use in the quantitative analyses
(Battaglini 2008; Mock 2001). We corresponded with, and requested
additional data from, these nine trial authors and an additional 13
trial authors (Arbane 2009; Campbell 2005; Cheville 2010; Crowley
2003;  Culos-Reed  2010;  Griffith  2009;  Jarden  2009;  Lanctot  2010;
Mock 1994; Raghavendra 2007; Segal 2001; Tang 2010; Yang 2011),
and  five  of  the  22  trial  authors  contacted  were  able  to  provide
additional data. Of the remaining 17 trials for which we requested
additional data, we were unable to contact the primary author for
seven trials, received no response from six trial authors, and four
trial authors either did not have access to their database or were
unable to provide additional information for some other reasons.
For  trial  characteristics  and  outcomes  see  the  Characteristics  of
included studies table.

Overall study characteristics

Of  the  56  included  trials,  54  were  RCTs,  although  one  trial
(Courneya  2003a)  used  a  variation  of  the  RCT  design  in  that  it
randomized clusters, where clusters were psychotherapy classes.
Two  trials  (Dimeo  1999;  Mock  1997)  used  a  quasi-randomized
design  to  allocate  participants  to  treatment.  All  trials,  except
for  four  (Courneya  2007a;  Haddad  2011;  Segal  2001;  Segal
2009),  randomized  eligible  participants  to  either  the  exercise  or
comparison  arm.  The  other  four  trials  included  more  than  two
study arms. The additional study arm comprised variations in the
exercise arm, such as aerobic exercise or resistance exercise group
(Courneya 2007a; Segal 2009), yoga exercise or stretching exercise
group  (Haddad  2011),  and  home-based  exercise  or  supervised
exercise  group  (Segal  2001).  In  all,  4826  (range  14  to  337)
participants  were  randomized  to  an  exercise  intervention  (n  =
2286;  range  9  to  135)  or  a  comparison  group  (n  =  1985;  range
5  to  134).  Six  trials  (Battaglini  2008;  DiSipio  2009;  Gomes  2011;
Headley 2004; Mock 2001; Monga 2007) did not report the number
of participants assigned to the exercise and control groups. In five
trials (Chandwani 2010; Hacker 2011; Hwang 2008; Mock 1997; Yang
2011), the number of participants randomized to the exercise and
comparison  arms  did  not  add  up  to  the  number  of  participants
randomized in the trial. For detailed information on overall study
characteristics see Characteristics of included studies table.

Participants

Participants  enrolled  in  the  trials  had  various  cancer  diagnoses
including  breast,  prostate,  gynecologic,  hematologic,  and  other.
Thirty  trials  investigated  participants  with  breast  cancer  only
(Banerjee  2007;  Battaglini  2008;  Cadmus  2009;  Caldwell  2009;
Campbell 2005; Chandwani 2010; Courneya 2007a; Crowley 2003;
Danhauer  2009;  de  Oliveira  2010;  DiSipio  2009;  Gomes  2011;
Haddad  2011;  Headley  2004;  Hwang  2008;  Lanctot  2010;  Moadel

Cochrane Database of Systematic Reviews

2007; Mock 1994; Mock 1997; Mock 2001; Mock 2005; Moros 2010;
Mutrie 2007; Raghavendra 2007; Rogers 2009; Segal 2001; Targ 2002;
Vadiraja  2009b;  Wang  2010;  Yang  2011)  and  an  additional  seven
trials  investigated  participants  with  prostate  cancer  only  (Bourke
2011; Culos-Reed 2010; Galvao 2010; Monga 2007; Segal 2003; Segal
2009; Windsor 2004). Twelve trials investigated participants with a
range  of  cancer  diagnoses  (Adamsen  2009;  Brown  2006;  Cheville
2010; Courneya 2003a; Courneya 2008; Dimeo 1999; Donnelly 2011;
Griffith 2009; Mustian 2009; Oh 2008; Oh 2010; Tang 2010).

Thirty-six  trials  were  conducted  among  participants  who  were
currently  undergoing  active  treatment  for  their  cancer  (Adamsen
2009;  Arbane  2009;  Banerjee  2007;  Bourke  2011;  Cadmus  2009;
Campbell  2005;  Chang  2008;  Cheville  2010;  Courneya  2007a;
Courneya 2008; Crowley 2003; de Oliveira 2010; Dimeo 1999; DiSipio
2009; Galvao 2010; Gomes 2011; Griffith 2009; Hacker 2011; Haddad
2011; Lanctot 2010; Mock 1994; Mock 1997; Mock 2001; Mock 2005;
Monga 2007; Moros 2010; Mustian 2009; Mutrie 2007; Raghavendra
2007;  Rogers  2009;  Segal  2001;  Segal  2009;  Vadiraja  2009b;  Wang
2010; Wiskemann 2011; Yang 2011), 10 trials were conducted among
participants both during and post active cancer treatment (Cohen
2004;  Courneya  2003a;  Courneya  2009;  Danhauer  2009;  Donnelly
2011;  Moadel  2007;  Oh  2008;  Oh  2010;  Tang  2010;  Targ  2002),
and  the  remaining  10  trials  were  conducted  among  participants
scheduled  for  active  cancer  treatment  (Battaglini  2008;  Brown
2006;  Caldwell  2009;  Chandwani  2010;  Culos-Reed  2010;  Headley
2004;  Hwang  2008;  Jarden  2009;  Segal  2003;  Windsor  2004).
One  of  the  trials  (Moadel  2007)  conducted  among  participants
both  during  and  post  active  treatment  reported  data  separately
on  participants  who  had  completed  treatment  and  those  who
were undergoing treatment, and we included only data on those
undergoing treatment in this review. Eleven trials reported the time
since cancer diagnosis and it ranged across the trials from about
a mean of 11 weeks to about a mean of 3.5 years (Adamsen 2009;
Cadmus  2009;  Courneya  2003a;  Courneya  2009;  Danhauer  2009;
Donnelly 2011; Moadel 2007; Mutrie 2007; Segal 2003; Tang 2010;
Targ  2002).  Twenty-nine  trials  were  conducted  among  females
(Banerjee  2007;  Battaglini  2008;  Cadmus  2009;  Campbell  2005;
Chandwani 2010; Courneya 2007a; Crowley 2003; Danhauer 2009;
de Oliveira 2010; DiSipio 2009; Donnelly 2011; Gomes 2011; Hacker
2011; Haddad 2011; Headley 2004; Hwang 2008; Moadel 2007; Mock
1994; Mock 1997; Mock 2001; Mock 2005; Moros 2010; Mutrie 2007;
Raghavendra  2007;  Rogers  2009;  Segal  2001;  Targ  2002;  Vadiraja
2009b; Wang 2010), nine trials among men (Arbane 2009; Bourke
2011; Caldwell 2009; Culos-Reed 2010; Galvao 2010; Monga 2007;
Segal 2003; Segal 2009; Windsor 2004), 17 trials included a mixed
sample of males and females (Adamsen 2009; Brown 2006; Chang
2008; Cheville 2010; Cohen 2004; Courneya 2003a; Courneya 2008;
Courneya  2009;  Dimeo  1999;  Griffith  2009;  Jarden  2009;  Mustian
2009; Oh 2008; Oh 2010; Tang 2010; Wiskemann 2011; Yang 2011),
with  one  trial  not  reporting  on  the  gender  of  the  participants
(Lanctot  2010).  The  mean  age  of  participants  ranged  between  40
and  71  years,  with  two  trials  reporting  an  age  range  rather  than
mean age of participants (Moros 2010; Oh 2008) and six trials not
reporting  on  the  age  of  the  participants  (Brown  2006;  Crowley
2003;  de  Oliveira  2010;  DiSipio  2009;  Lanctot  2010;  Raghavendra
2007). Twenty-one trials reported the ethnicity of the participants
and  33  trials  reported  the  education  level  of  the  participants.
Eleven  trials  reported  on  the  socio-demographic  status  of  the
participants  and  23  trials  reported  on  the  employment  status  of
the participants. Eighteen trials reported the past exercise history
of  the  participants  (Adamsen  2009;  Bourke  2011;  Campbell  2005;

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

15

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Chandwani  2010;  Cohen  2004;  Courneya  2003a;  Courneya  2007a;
Courneya  2008;  Courneya  2009;  Danhauer  2009;  Jarden  2009;
Mustian  2009;  Segal  2001;  Segal  2003;  Targ  2002;  Vadiraja  2009b;
Wang  2010;  Wiskemann  2011).  For  detailed  information  on  trial
characteristics see Characteristics of included studies table.

Interventions

Mode of exercise differed across trials. Twenty-two trials prescribed
walking by itself (Chang 2008; Courneya 2003a; Griffith 2009; Mock
1994; Mock 1997; Mock 2001; Mock 2005; Monga 2007; Rogers 2009;
Segal 2001; Tang 2010; Wang 2010; Windsor 2004; Yang 2011) or in
combination with cycling, resistance training, or strength training
(Courneya 2007a; Crowley 2003; Culos-Reed 2010; Donnelly 2011;
Galvao  2010;  Hwang  2008;  Mustian  2009;  Wiskemann  2011).  Ten
trials  prescribed  resistance  training  in  combination  with  cycling,
walking,  stretching,  strength  training,  or  various  other  exercise
modalities  (Adamsen  2009;  Battaglini  2008;  Bourke  2011;  Brown
2006; Courneya 2007a; Culos-Reed 2010; Galvao 2010; Jarden 2009;
Mustian  2009;  Segal  2009)  and  two  additional  trials  prescribed
resistance  training  by  itself  (Hacker  2011;  Segal  2003);  and  eight
trials prescribed cycling by itself (Courneya 2008; Courneya 2009;
Dimeo  1999)  or  in  combination  with  resistance  training,  walking,
stretching,  or  strength  training  (Courneya  2007a;  Galvao  2010;
Hwang 2008; Jarden 2009; Wiskemann 2011). Eight trials prescribed
yoga  by  itself  (Banerjee  2007;  Chandwani  2010;  Cohen  2004;
Danhauer  2009;  Lanctot  2010;  Moadel  2007;  Raghavendra  2007;
Vadiraja 2009b) and one trial prescribed yoga to one intervention
arm  and  stretching  exercise  to  the  second  intervention  arm
(Haddad 2011) and two trials incorporated practices of Qigong (Oh
2008; Oh 2010). Thirteen trials incorporated a range of modalities or
allowed participants to choose from a range of preferred modalities
(Adamsen 2009; Bourke 2011; Brown 2006; Caldwell 2009; Campbell
2005; Cheville 2010; Courneya 2003a; de Oliveira 2010; Griffith 2009;
Headley 2004; Mutrie 2007; Segal 2009; Targ 2002). Five trials did
not provide details of their exercise program (Arbane 2009; Cadmus
2009; DiSipio 2009; Gomes 2011; Moros 2010).

In the majority of trials (n = 46) the comparison arm did not receive
an exercise prescription (i.e. 'usual care' or 'no intervention') during
the course of the trial. For 15 of these trials (Cadmus 2009; Chang
2008;  Donnelly  2011;  Galvao  2010;  Griffith  2009;  Hacker  2011;
Headley  2004;  Hwang  2008;  Mock  1997;  Mock  2001;  Mock  2005;
Rogers 2009; Segal 2009; Windsor 2004; Yang 2011), participants in
the control arm were instructed to either continue their customary
physical  activity,  requested  not  to  exercise,  received  written
materials about physical activity, advised to rest, or received visits
or  telephone  call  from  trial  staff  for  attention  control;  and,  for
an  additional  ten  trials  (Chandwani  2010;  Cohen  2004;  Courneya
2007a; Courneya 2009; Culos-Reed 2010; Danhauer 2009; Haddad
2011;  Moadel  2007;  Segal  2003;  Tang  2010),  the  comparison  arm
was a 'waiting list' control where participants were offered either
a  portion  or  the  full  exercise  program  at  the  completion  of  the
trial. The comparison group in seven trials received an intervention
that  included  group  therapy  (Courneya  2003a);  brief  supportive
therapy  (Vadiraja  2009b);  psychodynamic  supportive-expressive
therapy  with  coping  preparation  (Raghavendra  2007);  psycho-
educational  support  group  (Targ  2002);  informed  that  moderate
physical  activity  was  beneficial  and  told  to  wear  a  pedometer
(Wiskemann 2011); and advised on the benefits of exercise (Segal
2001) coupled with suggestions to exercise (Banerjee 2007; Segal
2001).  Three  trials  did  not  either  provide  sufficient  information

Cochrane Database of Systematic Reviews

(Battaglini 2008; Lanctot 2010) or report on care received (DiSipio
2009) by the comparison arm.

Thirty-two  trials  implemented  an  aerobic  exercise  program  and
three trials implemented an anaerobic exercise program. Fourteen
trials  implemented  a  combined  (aerobic  and  anaerobic)  exercise
program and an additional three trials had two exercise arms which
implemented  either  an  aerobic  or  anaerobic  exercise  program
(Courneya  2007a;  Haddad  2011;  Segal  2009).  The  nature  of  the
exercise program for four trials was unclear (Arbane 2009; Cadmus
2009; DiSipio 2009; Lanctot 2010).

Length  of  the  exercise  intervention  varied  greatly  between  trials
with  a  range  from  three  weeks  (Chang  2008;  Cheville  2010)  to  26
weeks  (Segal  2001)  or  six  months  (Cadmus  2009),  with  a  modal
exercise  intervention  period  of  12  weeks  (n  =  14  trials).  For  11
trials  length  of  the  exercise  intervention  varied  with  duration  of
the  treatment  with  radiation,  chemotherapy,  or  a  combination
(Courneya  2007a;  de  Oliveira  2010;  Dimeo  1999;  Griffith  2009;
Jarden  2009;  Mock  1994;  Mock  2001;  Mock  2005;  Raghavendra
2007;  Windsor  2004;  Wiskemann  2011).  The  majority  of  trials  (n
=  33)  had  no  follow-up  period  between  the  end  of  the  exercise
intervention and the postexercise assessment. Among the 22 trials
with  a  follow-up  period,  this  period  ranged  from  one  to  two
weeks postintervention (Courneya 2008; Moros 2010) to 12 months
postintervention  (Culos-Reed  2010),  with  a  modal  length  of  six
months  from  the  end  of  the  intervention  (n  =  10).  Length  of  the
follow-up for one trial was unclear (DiSipio 2009).

The intensity of the exercise varied substantially between trials, as
did the methods used to measure and monitor intensity. Methods
used  to  measure  intensity  of  the  exercise  included  relatively
objective  measures  such  as  percentage  of  the  maximum  HR,
percentage of maximum oxygen consumption, HR, and ratings of
perceived  exertion,  and  perceived  effort  to  reach  a  value  on  the
Borg scale (Adamsen 2009; Battaglini 2008; Bourke 2011; Cadmus
2009;  Campbell  2005;  Chang  2008;  Courneya  2003a;  Courneya
2007a; Courneya 2008; Courneya 2009; Crowley 2003; Dimeo 1999;
Galvao 2010; Griffith 2009; Hwang 2008; Jarden 2009; Mock 2005;
Moros  2010;  Mutrie  2007;  Segal  2001;  Segal  2003;  Segal  2009;
Tang  2010;  Windsor  2004;  Wiskemann  2011).  Sixteen  trials  used
a  relatively  subjective  assessment  of  intensity  by  documenting  a
rating  of  mild,  low-  to  moderate,  mild-  to  moderate,  moderate,
or somewhat hard (Caldwell 2009; Chandwani 2010; Cohen 2004;
Culos-Reed  2010;  Danhauer  2009;  Donnelly  2011;  Hacker  2011;
Headley  2004;  Moadel  2007;  Mustian  2009;  Oh  2008;  Oh  2010;
Rogers 2009; Targ 2002; Wang 2010; Yang 2011). Fifteen trials did not
report intensity of the exercise program.

The  frequency  and  duration  of  individual  exercise  sessions,  and
the  total  number  of  exercise  sessions  varied  greatly  across  the
trials. Frequency of the exercise program ranged between once per
week  and  daily.  Duration  of  exercise  sessions  ranged  from  12  to
120  minutes,  with  a  modal  duration  of  90  minutes  (n  =  6;  and  3
additional trials provided duration as a range between 30 and 90
minutes or 60 and 90 minutes). In some trials the frequency of the
exercise program and duration of each exercise session increased
during the course of the trial. The total number of exercise sessions
varied greatly, ranging from a low of 7 sessions (Cohen 2004) to a
high of more than 275 sessions (Bourke 2011; Culos-Reed 2010).

The  exercise  program  was  implemented  at  a  facility  or  the
participant's  home  or  at  both  locations,  and  the  location  of

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

16

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

implementation determined in the most part the format (individual
or group) of the exercise program and whether it was professionally
led or not. Eighteen trials implemented the exercise program in a
facility such as a university or hospital facility, community center, or
yoga studio (Adamsen 2009; Battaglini 2008; Brown 2006; Campbell
2005; Chang 2008; Courneya 2007a; Courneya 2008; Courneya 2009;
Danhauer 2009; de Oliveira 2010; Dimeo 1999; Galvao 2010; Jarden
2009; Monga 2007; Moros 2010; Segal 2003; Segal 2009; Targ 2002),
18 trials implemented the exercise program at both a facility and
the  participant's  home  (Banerjee  2007;  Bourke  2011;  Chandwani
2010;  Cheville  2010;  Cohen  2004;  Culos-Reed  2010;  Hacker  2011;
Lanctot  2010;  Moadel  2007;  Mustian  2009;  Mutrie  2007;  Oh  2008;
Oh  2010;  Raghavendra  2007;  Rogers  2009;  Segal  2001;  Vadiraja
2009b; Wiskemann 2011), and 16 trials implemented the exercise
program  only  at  the  participant's  home  (Cadmus  2009;  Caldwell
2009; Courneya 2003a; Crowley 2003; Donnelly 2011; Gomes 2011;
Griffith  2009;  Headley  2004;  Mock  1994;  Mock  1997;  Mock  2001;
Mock 2005; Tang 2010; Wang 2010; Windsor 2004; Yang 2011), and
four trials either did not report the location of implementation of
the exercise program (DiSipio 2009; Hwang 2008) or the description
of the location was not clear (Arbane 2009; Haddad 2011). In terms
of the format of implementing the exercise program, 32 trials used
an  individual  format  (Bourke  2011;  Cadmus  2009;  Caldwell  2009;
Chang  2008;  Courneya  2003a;  Courneya  2007a;  Courneya  2008;
Crowley 2003; de Oliveira 2010; Dimeo 1999; Donnelly 2011; Gomes
2011; Griffith 2009; Hacker 2011; Headley 2004; Jarden 2009; Mock
1994;  Mock  1997;  Mock  2001;  Mock  2005;  Moros  2010;  Mustian
2009; Raghavendra 2007; Segal 2001; Segal 2003; Segal 2009; Tang
2010; Vadiraja 2009b; Wang 2010; Windsor 2004; Wiskemann 2011;
Yang 2011), 12 trials used a group format (Adamsen 2009; Banerjee
2007; Battaglini 2008; Brown 2006; Campbell 2005; Cheville 2010;
Courneya 2009; Danhauer 2009; Galvao 2010; Moadel 2007; Rogers
2009;  Targ  2002),  six  trials  used  both  an  individual  and  group
format  (Chandwani  2010;  Cohen  2004;  Culos-Reed  2010;  Mutrie
2007; Oh 2008; Oh 2010), and for six trials the format was either not
reported (DiSipio 2009; Haddad 2011; Hwang 2008; Lanctot 2010)
or not clearly described (Arbane 2009; Monga 2007). The majority of
exercise programs (n = 37) were either supervised or professionally
led  by  yoga  instructors,  sports  trainers,  exercise  physiologists,  or
other professionals.

For  detailed  information  on  interventions  see  Characteristics  of
included studies table.

Outcome measures

See  Table  1  for  a  summary  of  instruments,  the  HRQoL  domains
assessed, and trials using each scale.

HRQoL assessment included a wide range of measures including,
for  example,  the  European  Organization  for  Research  and
Treatment  of  Cancer  Quality  of  Life  Questionnaire-C30  (EORTC
QLQ),  Functional  Assessment  of  Cancer  Therapy  (FACT),  and
Medical  Outcomes  Study  Short  Form  (MOS-SF).  In  addition
to  measuring  overall  HRQoL,  trials  measured  HRQoL  domains
including  anxiety,  body  image/self-esteem,  cognitive  function,
depression,  emotional  function/mental  health,  fatigue,  general
health perspective, pain, physical well-being (PWB), role function,
sleep,  social  functioning,  and  spiritual  function.  Similar  to  the
assessment of overall HRQoL, HRQoL domains were assessed using
a plethora of measures. Table 1 provides a summary of instruments,
the HRQoL domains assessed, and trials using each scale.

Cochrane Database of Systematic Reviews

Twenty-two trials measured only HRQoL outcomes (Adamsen 2009;
Brown  2006;  Cadmus  2009;  Campbell  2005;  Chandwani  2010;
Cheville  2010;  Cohen  2004;  Courneya  2003a;  Courneya  2007a;
Courneya 2009; Danhauer 2009; Dimeo 1999; DiSipio 2009; Donnelly
2011;  Gomes  2011;  Haddad  2011;  Headley  2004;  Lanctot  2010;
Moadel  2007;  Mock  1994;  Tang  2010;  Targ  2002)  and  34  trials
measured  both  HRQoL  and  non-HRQoL  outcomes  (Arbane  2009;
Banerjee 2007; Battaglini 2008; Bourke 2011; Caldwell 2009; Chang
2008; Courneya 2008; Crowley 2003; Culos-Reed 2010; de Oliveira
2010; Galvao 2010; Griffith 2009; Hacker 2011; Hwang 2008; Jarden
2009;  Mock  1997;  Mock  2001;  Mock  2005;  Monga  2007;  Moros
2010; Mustian 2009; Mutrie 2007; Oh 2008; Oh 2010; Raghavendra
2007;  Rogers  2009;  Segal  2001;  Segal  2003;  Segal  2009;  Vadiraja
2009b; Wang 2010; Windsor 2004; Wiskemann 2011; Yang 2011). The
most frequently measured non-HRQoL outcomes included physical
function  or  activity  (n  =  15),  strength  training  (n  =  9),  and  fitness
(n = 7). Other non-HRQoL outcomes assessed included flexibility,
exercise  level,  physiologic  measures,  anthropometric  measures,
functional  capacity,  ROM,  micronutrient  intake,  caloric  intake,
biomarkers, nausea and vomiting, and treatment toxicity. Among
the 34 trials that measured both HRQoL and non-HRQoL outcomes,
nine  trials  each  identified  HRQoL  outcome(s)  (Caldwell  2009;
Courneya 2008; Mock 2005; Mutrie 2007; Oh 2008; Oh 2010; Segal
2003;  Segal  2009;  Wiskemann  2011)  and  non-HRQoL  outcome(s)
(Battaglini 2008; Crowley 2003; Culos-Reed 2010; de Oliveira 2010;
Galvao 2010; Griffith 2009; Jarden 2009; Raghavendra 2007; Segal
2001) as primary outcome measure(s), and the remaining 16 trials
did  not  identify  any  primary  outcome  measure(s)  (Arbane  2009;
Banerjee  2007;  Bourke  2011;  Chang  2008;  Hacker  2011;  Hwang
2008;  Mock  1997;  Mock  2001;  Monga  2007;  Moros  2010;  Mustian
2009; Rogers 2009; Vadiraja 2009b; Wang 2010; Windsor 2004; Yang
2011).

For  detailed 
Characteristics of included studies table.

information  on  outcome  measures  see 

the

Excluded studies

The 102 trials retrieved and subsequently excluded did not meet
the  inclusion  criteria  for  the  following  reasons:  26  trials  included
only  participants  who  had  completed  active  cancer  treatment
for  either  their  primary  or  recurrent  cancer  and  the  exercise
intervention  was  initiated  after  completion  of  active  treatment
(Banasik  2011;  Bourke  2011a;  Cho  2006;  Daley  2004;  Daley  2007;
Daley  2007a;  Daubenmier  2006;  Dimeo  2004;  Frattaroli  2008;
Galantino 2003; Hayes 2011; Heim 2007; Heim 2011; Houborg 2006;
Jones  2010;  Kampshoff  2010;  Knols  2011;  Latka  2009;  Mehnert
2011; Penttinen 2009; Persoon 2010; Pinto 2003; Pinto 2005; Sekse
2011; Thorsen 2005; Vardy 2010); 20 trials did not compare exercise
with  no  exercise,  another  intervention,  or  usual  care  (Baumann
2011; Carmack Taylor 2004; Carmack Taylor 2006; Carmack Taylor
2007;  Demark-Wahnefried  2008;  Haines  2010;  Hartmann  2007;
Henderson 2012; John 2007; Koller 2006; Korstjens 2008; Lau 2010;
Le Vu 1997; Manassero 2007; McClure 2010; Mina 2010; Patel 2005;
Roscoe  2005;  Stephenson  2000;  von  Gruenigen  2009);  12  trials
focused  on  complications  owing  to  treatment  (e.g.  menopause,
lymphedema,  shoulder  dysfunction)  rather  than  on  improving
whole  body  function  or  HRQoL  (Aaronson  2011;  Beurskens  2007;
Bloom  2011;  Duijts  2009;  Duijts  2009a;  Duijts  2010;  Duijts  2010a;
Kilbreath 2006a; Lee 2007a; McKenzie 2003; Todd 2008; Xie 2010);
four trials were not RCTs or CCTs (Aghili 2007; Baumann 2008; Cho
2004; Park 2006); four trials did not measure overall HRQoL or an
HRQoL  domain  as  a  study  outcome  (Dimeo  1997;  MacVicar  1989;

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

17

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Pickett  2002;  Schwartz  2009);  and  one  trial  included  participants
below 18 years of age (Marchese 2004). The remaining 35 trials were
excluded for meeting more than one of the reasons for exclusion.
For  detailed  information  on  reasons  for  exclusion  of  retrieved
studies see Characteristics of excluded studies table.

Risk of bias in included studies

The  included  studies  were  assessed  for  risk  of  bias  using  the
'Risk  of  Bias'  assessment  tool  and  recommendations  for  judging

Cochrane Database of Systematic Reviews

risk  of  bias  provided  in  Chapter  8  of  the  Cochrane  Handbook  for
Systematic  Reviews  of  Interventions  (Higgins  2011).  For  each  trial
the  risk  of  bias  is  detailed  in  the  'Risk  of  bias'  tables  included
with the Characteristics of included studies and the 'Risk of bias'
summary  (Figure  2).  In  addition,  an  overall  assessment  of  risk  of
bias is presented in Figure 3.

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

18

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 2.

Cochrane Database of Systematic Reviews

s
e
m
o
c
t
u
o
l
l

A

:
)
s
a
i
b

e
c
n
a
m
r
o
f
r
e
p
(

l
e
n
n
o
s
r
e
p

d
n
a

s
t
n
a
p
i
c
i
t
r
a
p
f
o

g
n
i
d
n
i
l

B

s
e
m
o
c
t
u
o
l
l

A

:
)
s
a
i
b

n
o
i
t
c
e
t
e
d
(

t
n
e
m
s
s
e
s
s
a

e
m
o
c
t
u
o
f
o

g
n
i
d
n
i
l

B

s
e
m
o
c
t
u
o
l
l

A

:
)
s
a
i
b

n
o
i
t
i
r
t
t
a
(

a
t
a
d

e
m
o
c
t
u
o

e
t
e
l
p
m
o
c
n
I

)
s
a
i
b

n
o
i
t
c
e
l
e
s
(
n
o
i
t
a
r
e
n
e
g

e
c
n
e
u
q
e
s

m
o
d
n
a
R

)
s
a
i
b

n
o
i
t
c
e
l
e
s
(

t
n
e
m
l
a
e
c
n
o
c

n
o
i
t
a
c
o
l
l

A

)
s
a
i
b

g
n
i
t
r
o
p
e
r
(

g
n
i
t
r
o
p
e
r

e
v
i
t
c
e
l
e
S

s
a
i
b
r
e
h
t
O

Adamsen 2009
Arbane 2009
Banerjee 2007
Battaglini 2008
Bourke 2011
Brown 2006
Cadmus 2009
Caldwell 2009
Campbell 2005
Chandwani 2010
Chang 2008
Cheville 2010
Cohen 2004
Courneya 2003a
Courneya 2007a
Courneya 2008
Courneya 2009
Crowley 2003
Culos-Reed 2010
Danhauer 2009
de Oliveira 2010
Dimeo 1999
DiSipio 2009

+ + -
-
? ?
+ + -
-
? ?
+ + -
-
? ?
+ + -
-
+ ?
-
? ?
-
+ ?
-
? ?
-
+ ?
+ + -
+ -
-
+ + -
+ + -
+ + -
+ + -
-
? ?
-
? ?
-
+ ?
-
-
?
-
? ?

- + + -
-
-
? ?
- + +
-
-
? ? +
- + +
-
- +
-
-
- + + +
- + +
-
- + +
-
- + + +
- + +
-
-
- +
?
- + +
-
-
- + +
- + + +
- + + +
- + +
-
-
- + +
- + + +
-
- + +
-
? + +
- + +
-
-
? ? +

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

19

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 2.   (Continued)

Cochrane Database of Systematic Reviews

Dimeo 1999
DiSipio 2009
Donnelly 2011
Galvao 2010
Gomes 2011
Griffith 2009
Hacker 2011
Haddad 2011
Headley 2004
Hwang 2008
Jarden 2009
Lanctot 2010
Moadel 2007
Mock 1994
Mock 1997
Mock 2001
Mock 2005
Monga 2007
Moros 2010
Mustian 2009
Mutrie 2007
Oh 2008
Oh 2010
Raghavendra 2007
Rogers 2009
Segal 2001
Segal 2003
Segal 2009
Tang 2010
Targ 2002
Vadiraja 2009b
Wang 2010
Windsor 2004
Wiskemann 2011
Yang 2011

-

-
?
-
? ?
+ + -
+ + -
-
? ?
-
? ?
-
? ?
-
? ?
-
+ ?
-
? ?
-
+ ?
-
? ?
-
? ?
-
? ?
-
-
-
-
+ ?
+ + -
-
? ?
-
? ?
-
+ ?
+ + -
-
+ ?
-
+ ?
+ + -
-
+ ?
-
+ ?
+ + -
+ + -
-
+ ?
-
? ?
+ + -
-
? ?
? + -
-
+ ?
-
+ ?

- + +
-
-
? ? +
- + + +
- + + +
-
? ? +
- + +
-
- + +
-
-
? ? +
- + +
-
-
- + +
- + + +
-
? ? +
-
- + +
- + - +
- + +
-
- + +
-
- + +
-
- + +
-
-
- + +
- + + +
- + +
?
- + -
-
- + + +
- + -
-
-
- + +
- + + +
- + +
?
- + + +
- + + +
- + +
-
- + + +
? + -
-
- + -
-
- + +
-
- + +
-

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

20

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 3.   Risk of bias graph: review authors' judgments about each 'Risk of bias' item presented as percentages
across all included studies.

Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): All outcomes
Blinding of outcome assessment (detection bias): All outcomes
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
Other bias

Low risk of bias

Unclear risk of bias

High risk of bias

0%

25%

50%

75% 100%

Allocation

Incomplete outcome data

Thirty-three  trials  were  at  a  low  risk  of  selection  bias  owing  to
adequate generation of the randomized sequence as the trials used
a random component to generate their sequence. Two trials had a
high risk of selection bias as they used a nonrandom component
to generate their sequence (Dimeo 1999; Mock 1997). Twenty-one
trials  were  considered  to  have  an  unclear  risk  of  selection  bias,
largely  because  the  generation  of  the  random  sequence  was  not
described  (Arbane  2009;  Battaglini  2008;  Brown  2006;  Campbell
2005; Chang 2008; Culos-Reed 2010; Danhauer 2009; DiSipio 2009;
Gomes 2011; Griffith 2009; Hacker 2011; Haddad 2011; Hwang 2008;
Lanctot 2010; Moadel 2007; Mock 1994; Monga 2007; Moros 2010;
Targ 2002; Wang 2010; Windsor 2004).

Eighteen trials were at a low risk of selection bias owing to adequate
concealment  of  allocation  to  the  intervention  as  the  participants
and investigators could not foresee assignment to the study groups.
Two  trials  had  a  high  risk  of  selection  bias  as  the  participants
or  investigators  might  foresee  assignment  to  the  study  groups
(Courneya  2003a;  Mock  1997).  Thirty-six  trials  were  considered
to  have  an  unclear  risk  of  selection  bias  owing  to  allocation
concealment,  largely  because  the  method  of  concealment  either
was  not  described  or  not  described  in  detail  to  allow  a  definite
judgment  (Arbane  2009;  Battaglini  2008;  Brown  2006;  Caldwell
2009; Campbell 2005; Chandwani 2010; Chang 2008; Cheville 2010;
Culos-Reed  2010;  Danhauer  2009;  de  Oliveira  2010;  Dimeo  1999;
DiSipio 2009; Gomes 2011; Griffith 2009; Hacker 2011; Haddad 2011;
Headley  2004;  Hwang  2008;  Jarden  2009;  Lanctot  2010;  Moadel
2007;  Mock  1994;  Mock  2001;  Monga  2007;  Moros  2010;  Mustian
2009; Oh 2008; Oh 2010; Rogers 2009; Segal 2001; Tang 2010; Targ
2002; Wang 2010; Wiskemann 2011; Yang 2011).

Blinding

All trials included in this review were at high risk for performance
bias because, owing to the nature of the intervention (exercise), it
was not possible to blind the study personnel and participants.

With  the  exception  of  two  trials  that  were  considered  to  have
unclear  risk  for  detection  bias  (Mutrie  2007;  Segal  2003),  the
remaining 54 trials were at high risk for detection bias.

Sixteen  trials  were  at  a  low  risk  of  attrition  bias  owing  to
the  amount,  nature,  or  handling  of  incomplete  outcome  data
(Adamsen 2009; Cadmus 2009; Chandwani 2010; Courneya 2007a;
Courneya  2008;  Culos-Reed  2010;  Donnelly  2011;  Galvao  2010;
Jarden 2009; Mock 1994; Mustian 2009; Oh 2010; Segal 2001; Segal
2009; Tang 2010; Vadiraja 2009b) and nine trials were considered to
have an unclear risk for attrition bias (Arbane 2009; Battaglini 2008;
Cheville 2010; de Oliveira 2010; DiSipio 2009; Gomes 2011; Haddad
2011; Lanctot 2010; Wang 2010). Thirty-one trials were at high risk
for attrition bias.

Selective reporting

Forty-seven  trials  were  at  a  low  risk  of  reporting  bias  as,  based
on  the  information  provided  by  the  trial  authors,  there  was  no
reason to believe that there was selective reporting of the primary
and  secondary  outcomes.  Three  trials  were  considered  at  high
risk  (Brown  2006;  Cheville  2010;  Mock  1994)  and  six  trials  were
considered  as  unclear  risk  (Arbane  2009;  Battaglini  2008;  DiSipio
2009; Gomes 2011; Haddad 2011; Lanctot 2010) for reporting bias.

Other potential sources of bias

Fifty trials were at a low risk for other biases such as description
of  the  sample,  generalizability  of  findings,  and  sample  size  and
six  trials  were  considered  to  be  at  high  risk  for  other  biases
(Adamsen 2009; Arbane 2009; Oh 2008; Raghavendra 2007; Wang
2010; Windsor 2004).

Effects of interventions

See: Summary of findings 1 Summary of findings

Authors  reported  trial  results  either  as  change  in  score  from
baseline  to  follow-up  or  follow-up  values.  We  completed  meta-
analyses for both types of outcomes and for each follow-up time
period,  categorizing  follow-up  as:  up  to  12  weeks,  more  than
12  weeks  to  less  than  6  months,  6  months,  and  more  than  6
months.  If  authors  reported  results  in  another  manner  (e.g.  to
end  of  chemotherapy  treatment)  where  the  length  of  follow-up
differed for each trial participant, we classified the follow-up time
by the average follow-up time, if reported. If not, we determined
the  mid-point  of  the  extremes  for  follow-up  and  used  that  as
an  “average”.  In  cases  where  authors  included  more  than  one
measurement within a time period (e.g. 6 week and 12 weeks) we

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

21

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

included measures from the longer time point. Because the change
in  scores  from  baseline  to  follow-up  takes  into  account  baseline
variability,  we  preferentially  pooled  results  for  change  scores.
However, authors frequently only reported follow-up values, and so
we also pooled results of follow-up values. We combined data using
a WMD and a random-effects model when trials measured HRQoL
or  HRQoL  domains  using  either  the  same  measurement  method
or scale to generate continuous data. We used a SMD analysis and
random-effects model to combine data from different instruments
measuring  the  same  domain.  If  we  found  heterogeneity  in  an
analysis,  we  investigated  subgroups  by  cancer  type,  intensity  of
the exercise intervention, or by inclusion of participants who had
completed all therapy. All trials showed a relatively high risk of bias,
so we conducted sensitivity analysis of trials where the allocation
concealment scored as low risk of bias versus unclear or with a high
risk of bias. We did not complete subgroup analyses when there was
only one trial in a subgroup.

For detailed information on HRQoL and HRQoL domain outcomes,
number  of  trials  reporting  the  outcomes,  number  of  participants
on whom the outcomes were reported, statistical methods used for
analysis, and effect estimates see the Data and analyses table.

Overall health-related quality of life

Change in HRQoL from baseline following an exercise intervention
showed  a  significant  improvement  compared  with  control  in  806
study participants at 12 weeks (SMD 0.47; 95% CI 0.16 to 0.79), no
difference  at  follow-up  between  12  weeks  and  6  months  in  442
participants (SMD 1.25; 95% CI -0.03 to 2.53), and no difference in
282 participants at 6 months' follow-up (SMD 0.14; 95% CI -0.11 to
0.39)  (Analysis  1.1).  At  12  weeks'  follow-up,  subgroups  by  cancer
type resulted in breast cancer (SMD 0.40; 95% CI -0.11 to 0.92) not
showing a significant effect of exercise in contrast to all other types
of cancer (SMD 0.55; 95% CI 0.19 to 0.92). At follow-up time of more
than 12 weeks to less than 6 months, we observed no significant
effect by cancer type (breast cancer, SMD 0.25; 95% CI -0.01 to 0.50)
versus  all  other  types  of  cancer  (SMD  2.95;  95%  CI  -2.21  to  8.12).
At 12 weeks' follow-up, trials in which the investigators described
the exercise as moderate or vigorous showed a positive effect (SMD
0.51; 95% CI 0.13 to 0.89) compared with those described as mild
(SMD 0.45; 95% CI -0.30 to 1.19); this effect was also observed at
follow-up  from  12  weeks  to  6  months  (SMD  1.57;  95%  CI  0.01  to
3.12), but not at 6 months' follow-up. The effect of exercise was still
significant when we excluded trials that included participants who
had completed treatment at 12 weeks' follow-up (SMD 0.52; 95% CI
0.16 to 0.88) but not at longer follow-up time periods.

All  trials  showed  a  relatively  high  risk  of  bias,  so  we  conducted
a  sensitivity  analysis  of  trials  where  the  allocation  concealment
scored as low risk of bias versus unclear or with a high risk of bias.
We found that the effect of exercise on the change from baseline to
12 weeks' follow-up resulted in a nonsignificant effect at 12 weeks
(SMD 0.33; 95% CI -0.02 to 0.68) when we included only trials scoring
as low risk of bias for allocation concealment.

Because there was significant clinical and statistical heterogeneity
when  combining  all  trials  in  an  SMD  model,  we  also  examined
the  treatment  effect  by  individual  HRQoL  instrument.  The  most
commonly  used  instruments  included  those  in  the  FACT  series;
including  FACT-An  (anemia),  FACT-B  (breast),  FACT-G  (general),
FACT-P  (prostate),  and  Functional  Assessment  of  Chronic  Illness
Therapy  (FACIT);  and  the  QLQ-C30.  A  significant  change  in  the

Cochrane Database of Systematic Reviews

HRQoL score from baseline to 12 weeks compared with change in
the control group was seen at 12 weeks' follow-up with the FACT-G
(MD 5.70; 95% CI 2.30 to 9.09) and FACT-P (MD 8.55; 95% CI 0.45 to
16.65), but not the FACT-An (MD -6.90; 95% CI -21.73 to 7.93), FACT-
B  (MD  6.81;  95%  CI  -5.81  to  19.43),  FACIT  (MD  1.55;  95%  CI  -6.37
to 9.48), or QLQ-C30 (MD -5.14; 95% CI -15.97 to 5.69). Additional
instruments  were  used  in  only  a  single  trial  or  only  a  few  trials.
Similar results were seen at longer follow-up periods.

We found similar results when we looked at the follow-up values
reported rather than the differences between baseline and follow-
up (Analysis 1.2). Again, we found a significant effect at 12 weeks
(SMD  0.33;  95%  CI  0.12  to  0.55),  and  follow-up  at  more  than  12
weeks to less than 6 months (SMD 0.25; 95% CI 0.07 to 0.43), but
not at 6 months (SMD 0.13; 95% CI -0.09 to 0.35). Subgroup analyses
at 12 weeks' follow-up did not show a significant effect for breast
cancer (SMD 0.31; 95% CI -0.03 to 0.65), but did for other types of
cancer  (SMD  0.34;  95%  CI  0.15  to  0.53).  Including  only  studies  in
which authors reported that the exercise was moderate to vigorous
did not show a significant effect (SMD 0.16; 95% CI -0.07 to 0.40).
Limiting the analyses to trials with a low risk of bias for allocation
concealment continued to show a significant effect of exercise at 12
weeks (SMD 0.29; 95% CI 0.03 to 0.55).

Looking  at  the  treatment  effect  by  the  individual  instrument
administered,  we  found  significant  effects  with  FACT-G  (MD  6.89;
95% CI 0.44 to 13.35), FACT-P (MD 7.36; 95% CI -1.59 to 16.31), and
QLQ-C30 (MD 7.31; 95% CI 1.99 to 12.63), but not with the FACT-An
(MD 4.50; 95% CI -4.31 to 13.32), FACT-B (MD 0.73; 95% CI -8.23 to
9.69), or FACIT (MD 13.30; 95% CI -3.16 to 29.76). Again, few trials
contributed  to  each  analysis  and  there  were  insufficient  trials  to
complete subgroup analyses or look at longer times of follow-up.

Trials for which we were unable to extract data and that measured
HRQoL included Brown 2006, DiSipio 2009, Gomes 2011, Headley
2004,  and  Oh  2008.  All  but  one  trial  reported  a  higher  HRQoL  in
the exercise group compared with the control group, although this
difference was typically manifested as less of a decrease in HRQoL
during  active  treatment  (Brown  2006;  DiSipio  2009;  Gomes  2011;
Headley 2004).

Cancer-specific health-related quality of life

Although we observed a significant effect of exercise compared to
control in change in scores from baseline to 12 weeks' follow-up for
prostate cancer concerns (SMD 0.41; 95% CI 0.15 to 0.67), we did
not  observe  a  significant  improvement  at  longer  follow-up  times
for either breast cancer or prostate cancer concerns (Analysis 2.1).
Similar  findings  were  obtained  when  we  examined  differences  in
follow-up scores rather than the difference between baseline and
follow-up,  with  a  single  significant  observation  at  6  months  for
breast cancer (MD 1.45; 95% CI 0.08 to 2.81).

Anxiety

We  did  not  observe  a  significant  reduction  in  change  scores  in
instruments  assessing  anxiety  in  the  group  exposed  to  exercise
compared  with  the  control  group  at  12  weeks  (SMD  -0.17;  95%
CI  -0.41  to  0.06)  or  at  longer  time  periods  such  as  more  than  12
weeks to less than 6 months (SMD -0.16; 95% CI -0.44 to 0.12), and
at 6 months' follow-up (SMD -0.18; 95% CI -0.49 to 0.12) (Analysis
3.1). There were insufficient trials to examine subgroups within the
comparison of change scores.

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

22

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

A larger number of authors reported follow-up values rather than
looking at the change from baseline to follow-up, and we observed
a  significant  effect  of  exercise  on  anxiety  when  we  looked  at  the
difference  in  follow-up  scores  after  12  weeks  (SMD  -0.46;  95%  CI
-0.81  to  -0.11)  or  6  months'  follow-up  (SMD  -0.44;  95%  CI  -0.71
to  -0.17),  but  not  when  follow-up  was  between  12  weeks  and  6
months  (SMD  -0.20;  95%  CI  -0.57  to  0.17).  There  was  statistical
heterogeneity across studies, however, and examining subgroups,
we  found  a  significant  effect  at  follow-up  for  breast  cancer  at  all
time points (12 weeks: SMD -0.90; 95% CI -1.68 to -0.11; more than
12 weeks to less than 6 months: SMD -0.27; 95% CI -0.52 to -0.02; 6
months: SMD -0.40; 95% CI -0.70 to -0.10), but not for other types
of  cancer.  When  we  compared  subgroup  by  the  intensity  of  the
exercise intervention, we found a modest effect of exercise reported
as moderate to vigorous on anxiety at 12 weeks (SMD -0.18; 95% CI
-0.32 to -0.03) but not at longer times of follow-up. Examining the
effect of exercise compared with control on anxiety in trials with a
low risk of bias for allocation concealment resulted in these results
becoming significant at all time points (12 weeks: SMD -0.72; 95% CI
-1.41 to -0.03; more than 12 weeks to less than 6 months: SMD -0.27;
95% CI -0.52 to -0.02; 6 months: SMD -0.40; 95% CI -0.70 to -0.10).

Examination  by  individual  instruments  assessing  anxiety  showed
a significant effect at six months' follow-up only when the anxiety
subscale of the Hospital Anxiety and Depression Scale (HADS; MD
-2.50; 95% CI -4.89 to -0.11) or the State-Trait Anxiety Scale (STAI)
(MD -2.12; 95% CI -3.44 to -0.81) were used to assess anxiety at six
months' follow-up, but not shorter times of follow-up.

In  addition  to  these  results,  a  single  trial  (Mock  1997)  reported
a  significant  difference  between  exercise  and  control  groups  at  6
weeks on anxiety assessed using the Symptom Assessment Scale.

Body image

No significant effect of exercise was observed on body image when
comparing an exercise with a control intervention and looking at
differences in scores except for a single trial of 223 breast cancer
participants that reported change at approximately 3 months in the
Rosenberg Self-esteem Instrument (MD 1.30; 95% CI 0.51 to 2.09)
(Analysis  4.1).  This  significant  effect  was  not  maintained  through
six  months  in  this  trial  and  no  other  significant  differences  were
observed in body image or self-esteem.

Mock  1997  also  assessed  dissatisfaction  with  body  using  the
Symptom Assessment Scale and reported a significant difference
between scores at 6 weeks as reported by the exercise and control
groups.

Cognitive function

We  observed  no  significant  effect  of  exercise  on  any  measure  of
cognitive function, except for a modest effect when looking at the
follow-up scores in cognitive functioning at 12 weeks (SMD -0.16;
95% CI -0.31 to -0.01) (Analysis 5.1). When we examined this effect
by subgroup, the effect was not significant by type of cancer (breast
(SMD -0.22; 95% CI -0.47 to 0.02) or other (SMD -0.15; 95% CI -0.45
to 0.14)) or by level of exercise intensity (moderate to intense (SMD
-0.20; 95% CI -0.41 to 0.02)).

One trial whose data were not extracted reported a significant effect
on cognitive function with exercise without a corresponding effect
in the control group (Oh 2008).

Cochrane Database of Systematic Reviews

Depression

We observed no significant effect of exercise on depression in 418
participants  looking  at  the  change  in  score  across  instruments
from  baseline  to  follow-up  (Analysis  6.1).  Because  there  was
heterogeneity, we examined results by subgroup including cancer
type (breast versus other) and observed a significant effect for other
types  of  cancer  (SMD  -0.45;  95%  CI  -0.70  to  -0.20)  but  not  in  the
single trial that looked at breast cancer (Targ 2002). No differences
were  noted  when  we  looked  at  trials  by  reported  intensity  of
exercise (vigorous to moderate versus mild to moderate), but we
did see a significant effect of exercise after excluding two trials that
included patients who had completed therapy (Oh 2010; Targ 2002)
(SMD -0.55; 95% CI -0.87 to -0.22).

When  we  looked  at  follow-up  values  (Analysis  6.2),  we  observed
a significant effect of the exercise intervention at 12 weeks (SMD
-0.55; 95% CI -0.87 to -0.22) and 6 months' follow-up (SMD -0.29;
95%  CI  -0.48  to  -0.09),  but  not  at  follow-up  between  these  two
time points (SMD -0.21; 95% CI -0.43 to 0.01). This effect was still
significant at both 12 weeks (SMD -0.67; 95% CI -1.13 to -0.22) and
6  months  (SMD  -0.26;  95%  CI  -0.51  to  -0.01)  after  excluding  trials
that included individuals who had completed treatment. Subgroup
analysis by cancer type continued to be significant at both 12 weeks
(SMD  -0.98;  95%  CI  -1.64  to  -0.32)  and  6  months'  follow-up  (SMD
-0.27; 95% CI -0.47 to -0.07) for trials of breast cancer, as it was for
other types of cancer for 12 weeks' follow-up (SMD -0.28; 95% CI
-0.44 to -0.11) and more than 12 weeks but less than 6 months (SMD
-0.58; 95% CI -1.10 to -0.06). There was only a single trial of cancer
other  than  breast  at  six  months'  follow-up  and  it  did  not  show  a
significant  effect  of  exercise  on  depression  (Jarden  2009).  There
was  improvement  in  depression  when  the  exercise  intervention
was noted to be moderate to vigorous at 12 weeks' follow-up (SMD
-0.26;  95%  CI  -0.39  to  -0.13),  but  not  when  it  was  reported  to  be
mild (SMD -0.31; 95% CI -0.91 to 0.28), although this latter subgroup
included only two trials (Chandwani 2010; Danhauer 2009). When
we performed a sensitivity analysis including only trials with a low
risk of bias for allocation concealment, there was a significant effect
of exercise on depression at 12 weeks' follow-up (SMD -0.76; 95% CI
-1.24 to -0.28) and at 6 months' follow-up (SMD -0.27; 95% CI -0.47
to -0.07), but not when follow-up was more than 12 weeks to less
than 6 months (SMD -0.08; 95% CI -0.32 to 0.17).

We  also  looked  at  the  effect  of  the  exercise  intervention  by
individual instrument, and observed a significant treatment effect
looking at change at 12 weeks in the Centers for Epidemiological
Studies - Depression Scale (CES-D; MD -2.40; 95% CI -4.05 to -0.75)
and follow-up values in the Beck Depression Inventory at 12 weeks
(MD  -3.36;  95%  CI  -5.87  to  -0.85)  and  at  6  months'  follow-up  (MD
-2.40; 95% CI -4.57 to -0.23).

We  were  unable  to  extract  data  from  two  trials  that  reported
on  depression,  with  one  trial  reporting  a  significant  difference  in
depression between treatment groups (Mock 1997) and the second
showing no difference (Haddad 2011).

Emotional well-being

Meta-analyses  of  the  change  in  score  from  baseline  to  follow-up
and  comparing  exercise  with  control  intervention  did  not  show
a  significant  improvement  in  EWB  at  any  follow-up  time  point
(Analysis  7.1).  When  we  looked  at  the  effect  of  exercise  by  type
of  cancer  or  by  excluding  studies  that  included  participants  who
had completed treatment, we found no significant effect of exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

23

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

on change in emotional status. Similarly, there was no significant
difference  when  we  looked  at  subgroups  by  reported  exercise
intensity.

By  comparing  the  differences  in  follow-up  values,  we  observed  a
significant  effect  of  exercise  compared  with  control  at  follow-up
of more than 12 weeks but less than 6 months (SMD 0.59; 95% CI
0.12  to  1.07)  but  not  at  either  12  weeks  (SMD  0.05;  95%  CI  -0.18
to  0.28)  or  6  months'  follow-up  (SMD  0.25;  95%  CI  -0.08  to  0.57).
However,  when  we  looked  at  trials  by  type  of  cancer,  we  found
a  significant  effect  for  types  of  cancer  other  than  breast  cancer
(between  12  weeks'  and  6  months'  follow-up:  SMD  0.86;  95%  CI
0.28 to 1.44; 6 months' follow-up: SMD 1.16; 95% CI 0.36 to 1.95),
but  no  effect  for  breast  cancer  trials.  Including  only  trials  where
all trial participants were undergoing active treatment resulted in
a nonsignificant effect of exercise on emotional state at all follow-
up times. A sensitivity analysis including only trials with a low risk
of bias for allocation concealment also did not show a significant
effect at 12 weeks' follow-up (SMD -0.31; 95% CI -0.86 to 0.25).

Looking  at  each  type  of  instrument  separately,  we  found  a
significant  difference  between  the  exercise  and  the  control
interventions  in  QLQ-C30  follow-up  values  at  longer  follow-up
periods  (more  than  12  weeks  to  less  than  6  months:  MD  13.33;
95%  CI  5.19  to  21.47;  6  months:  MD  19.10;  95%  CI  6.39  to
31.81),  change  in  the  Profile  of  Mood  Scale  (POMS)  total  mood
disturbance score from baseline to 12 weeks' follow-up (MD -8.92;
95% CI -10.81 to -7.03), follow-up scores in the POMS total mood
(MD  -7.16;  95%  CI  -12.64  to  -1.69),  and  the  positivity  subscale
of  the  Positive  and  Negative  Affect  Scale  (PANAS)  at  6  months'
follow-up  (MD  3.80;  95%  CI  0.98  to  6.62).  We  did  see  significant
results in some additional individual instruments (Brief Symptom
Inventory,  Symptom  Checklist  (SCL),  National  Comprehensive
Cancer Network Distress Scale, M.D. Anderson Symptom Inventory
(MDASI)  subscales),  but  these  included  only  a  single  trial  in  each
case.

Two trials without extractable data reported no change over time in
EWB in either the exercise or control group (Headley 2004; Oh 2008).

Fatigue

We observed a significant effect of exercise on change in fatigue at
follow-up of 12 weeks (SMD -0.73; 95% CI -1.14 to -0.31), although
this effect was not present at follow-up between 12 weeks and 6
months (SMD -0.11; 95% CI -0.37 to 0.14) (Analysis 8.1). Although
we observed no treatment difference within a subgroup of breast
cancer trial participants, we found that a positive effect of exercise
was present in participants with other types of cancer at 12 weeks
(SMD -0.72; 95% CI -1.23 to -0.20). A subgroup analysis looking at
trials  where  the  exercise  intervention  was  reported  as  moderate
to vigorous provided an effect at 12 weeks' follow-up (SMD -0.93;
95%  CI  -1.60  to  -0.26)  but  not  at  longer  time  periods.  Only  two
trials reported that the exercise was mild (Oh 2010; Targ 2002) and
in  these  two  trials  the  exercise  intervention  showed  a  significant
effect  compared  with  control  on  change  in  fatigue  at  12  weeks
(SMD -0.82; 95% CI -1.16 to -0.48). The effect of exercise remained
significant  when  we  excluded  trials  with  participants  who  had
completed treatment (SMD -0.78; 95% CI -1.29 to -0.27). A sensitivity
analysis including only trials with a low risk of bias for allocation
concealment  resulted  in  a  nonsignificant  effect  of  exercise  on
fatigue compared with control at all time points.

Cochrane Database of Systematic Reviews

We  continued  to  observe  a  positive  effect  of  exercise  on  fatigue
compared with a control intervention when we completed meta-
analyses looking at differences in follow-up scores at all follow-up
time points (12 weeks' follow-up: SMD -0.38; 95% CI -0.57 to -0.18;
more than 12 weeks to less than 6 months' follow-up: SMD -0.19;
95% CI -0.33 to -0.05; 6 months' follow-up: SMD -0.18; 95% CI -0.35
to -0.00) (Analysis 8.2). This effect was present in trial participants
with breast cancer at 12 weeks (SMD -0.32; 95% CI -0.57 to -0.07), but
not at longer time points. We continued to find a significant effect at
all three follow-up time points for trials that enrolled participants
with  other  types  of  cancer  (12  weeks'  follow-up;  SMD  -0.43;  95%
CI  -0.75  to  -0.12;  more  than  12  weeks'  to  less  than  6  months'
follow-up:  SMD  -0.25;  95%  CI  -0.45  to  -0.04;  6  months'  follow-up:
SMD  -0.49;  95%  CI  -0.93  to  -0.05).  We  also  continued  to  see  a
significant effect of exercise compared with a control intervention
after excluding trials that included participants who had completed
treatment. Including only trials with a low risk of bias for allocation
concealment showed a positive effect of exercise at 12 weeks (SMD
-0.35; 95% CI -0.67 to -0.03), but not at longer follow-up times.

Comparing results by individual instruments showed mixed effects
in that analyses for some instruments showed a significant effect of
exercise at some follow-up times, while others did not. We observed
a  significant  improvement  in  fatigue  from  baseline  to  follow-up
when we combined trials at 12 weeks for the FACT-F subscale and
the  Piper  Fatigue  Scale  (PFS).  We  observed  a  significant  effect  of
exercise on differences between follow-up scores at 12 weeks when
pooling results from trials using the FACT fatigue subscale, FACIT,
the POMS fatigue scale or vitality subscales, the PFS, the MOS SF-36
vitality subscale, and the Multidimensional Fatigue Inventory (MFI)
at various times of follow-up.

We were unable to extract data from a number of trials reporting on
the differences in fatigue between exercise and control groups. Four
of these trials reported a significant difference between the exercise
and control groups (Brown 2006; Gomes 2011; Haddad 2011; Mock
1997) and two reported no difference (Headley 2004; Oh 2008).

General health perspective

We only observed a single significant effect of exercise on general
health perspective by looking at the difference in follow-up scores
at 12 weeks (SMD 0.33; 95% CI 0.01 to 0.64) (Analysis 9.1). Neither
change  from  baseline  to  follow-up  nor  any  other  measure  of
difference in scores at any time point or for any single instrument
showed an effect of exercise on general health perspective.

A  single  trial  without  extractable  data  reported  a  significant
difference in general health as measured by the MOS SF-36 between
a yoga exercise group with either a waiting list control or stretching
control group (Haddad 2011).

Pain

Few trials reported on pain or change in pain related to the exercise
intervention. No significant effect was obtained when pooling trials
that reported change in pain from baseline to follow-up (Analysis
10.1).  We  did  not  observe  a  significant  effect  when  looking  at
follow-up scores either, although a single trial reported a significant
reduction  in  pain  at  six  months  (Jarden  2009).  When  we  looked
at  the  comparison  of  exercise  with  control  on  pain  by  individual
instrument, although we sometimes observed a significant effect,
but only when a single trial was included in the analysis.

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

24

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

One small trial for which we could not extract data also reported on
pain (Oh 2008), finding a significant difference between the exercise
and control groups.

Physical functioning

A significant effect of an exercise intervention on physical function
appeared relatively consistently at 12 weeks across most measures
(Analysis 11.1). We observed a significant difference from baseline
to  12  weeks'  follow-up  (SMD  0.69;  95%  CI  0.16  to  1.22)  and  at  6
months  follow-up  (SMD  0.28;  95%  CI  -0.00  to  0.55)  but  not  when
follow-up  was  between  12  weeks  and  6  months  (SMD  -0.18;  95%
CI  -0.53  to  0.17)  (Analysis  11.1).  Trials  that  included  only  breast
cancer participants did not show a significant effect of exercise on
physical functioning (SMD 0.96; 95% CI -0.26 to 2.17) at 12 weeks;
neither  did  trials  that  only  included  other  types  of  cancer  (SMD
0.46;  95%  CI  -0.04  to  0.97)  or  trials  where  the  author  reported
moderate to vigorous-intensity exercise (SMD 0.96; 95% CI -0.26 to
2.17). However, a significant effect at 12 weeks was observed when
we only looked at trials that had all participants undergoing active
treatment (i.e. when we excluded trials that included participants
who had completed treatment) (SMD 1.00; 95% CI 0.26 to 1.74).

A similar pattern emerged when we looked at difference in follow-
up  scores,  with  significant  effects  seen  at  12  weeks  (SMD  0.28;
95%  CI  0.11  to  0.45),  and  6  months'  follow-up  (SMD  0.29;  95%  CI
0.07  to  0.50),  but  not  at  follow-up  of  more  than  12  weeks  to  less
than  6  months  (SMD  0.33;  95%  CI  -0.17  to  0.82)  (Analysis  11.2).
Subgroup analyses by type of cancer showed no effect at 12 weeks
for  trials  of  breast  cancer  participants,  but  a  significant  effect  for
trials examining participants with other types of cancer (SMD 0.37;
95% CI 0.19 to 0.55), as did including only trials that did not include
any participants who had completed treatment (SMD 0.38; 95% CI
0.17 to 0.58). Looking at trials that reported moderate to vigorous
intensity of exercise also showed a significant effect of exercise at
12 weeks' follow-up (SMD 0.41; 95% CI 0.17 to 0.64). A sensitivity
analysis that included only trials at a low risk of bias for allocation
concealment also showed a positive effect at 12 weeks (SMD 0.24;
95% CI 0.07 to 0.40). We could not perform sensitivity analyses for
longer times of follow-up because there were too few trials at a low
risk of bias for allocation concealment.

Looking  at  individual  instruments,  a  significant  effect  of  exercise
compared  with  control  was  observed  in  change  from  baseline  to
12 weeks' follow-up in the FACT physical well-being subscale (MD
2.31;  95%  CI  0.65  to  3.98).  Difference  in  scores  at  follow-up  was
observed  at  6  months  in  the  FACT  physical  well-being  subscale
(6  months:  MD  1.17;  95%  CI  0.14  to  2.19);  the  QLQ-C30  physical
functioning subscale (12 weeks' follow-up: MD 3.72; 95% CI 0.61 to
6.84;  more  than  12  weeks'  to  less  than  6  months'  follow-up:  MD
3.72; 95% CI 0.61 to 6.84); and the MOS-SF 36 physical component
scale  (PCS)  (12  weeks'  follow-up:  MD  3.96;  95%  CI  0.99  to  6.94),
physical functioning subscale (12 weeks' follow-up: MD 4.04; 95%
CI  0.63  to  7.46),  and  physical  role  subscale  (12  weeks'  follow-up:
MD 11.24; 95% CI 3.10 to 19.39). In addition, single trials reported
a significant effect on physical functioning using a variety of other
instruments, including the WHO QOL BREF, MDASI, and the Quality
of Life Symptom Inventory.

There  were  four  trials  whose  investigators  measured  physical
functioning  in  trial  participants  assigned  to  exercise  and  control
groups.  Of  these,  three  found  a  significant  difference  between

Cochrane Database of Systematic Reviews

treatment  groups  (Haddad  2011;  Mock  1997;  Oh  2008)  and  one
reported no difference (Headley 2004).

Role function

Results for role function showed a significant effect of exercise on
role  function  compared  with  control  when  we  pooled  results  for
change from baseline to follow-up at 12 weeks (SMD 0.48; 95% CI
0.07  to  0.90)  or  differences  in  follow-up  scores  at  12  weeks  (SMD
0.17;  95%  CI  0.00  to  0.34)  and  6  months  (SMD  0.32;  95%  CI  0.03
to  0.61),  but  not  at  other  time  points  (Analysis  12.1).  Subgroup
analyses  of  the  change  from  baseline  to  follow-up  at  12  weeks
in  role  function  showed  a  significant  effect  for  trials  examining
types of cancer other than breast (SMD 0.58; 95% CI 0.04 to 1.12),
and  when  excluding  trials  that  included  participants  who  had
completed  treatment  (SMD  0.75;  95%  CI  0.14  to  1.36),  but  not
when the investigators reported that the exercise was moderate to
vigorous in intensity (SMD 0.61; 95% CI -0.40 to 1.62). In contrast,
there  was  no  significant  effect  for  any  subgroup  when  observing
differences in follow-up scores of the exercise compared with the
control  groups  at  12  weeks.  Results  using  individual  instruments
infrequently  showed  significant  effects,  including  only  the  FACT
functional well-being (FWB) subscale at 12 weeks' and 6 months'
follow-up,  the  QLQ-C30  role  function  at  6  months,  and  three
different subscales on the MDASI.

Role  function  was  reported  by  two  trial  investigators  who  found
no change in role function in either the exercise or control group
(Headley 2004; Oh 2008).

Sleep disturbance

We  observed  no  significant  effect  of  exercise  on  any  reported
measure  of  sleep  problems  when  we  looked  at  the  change  from
baseline to follow-up scores, but did see a significant effect showing
improvement  when  comparing  follow-up  values  by  comparison
group  at  12  weeks  (SMD  -0.40;  95%  CI  -0.67  to  -0.14),  but  not
at  longer  follow-up  time  points  (Analysis  13.1).  We  observed  a
significant  effect  when  the  analyses  included  only  trials  with
participants  who  had  cancers  other  than  breast  cancer  (SMD
-0.43;  95%  CI  -0.79  to  -0.07)  or  included  only  participants  who
were all undergoing active treatment (SMD -0.42; 95% CI -0.75 to
-0.09).  Including  only  trials  where  the  investigators  reported  that
the  exercise  was  moderate  to  vigorous  in  intensity  approached
significance  (SMD  -0.36;  95%  CI  -0.72  to  0.00).  We  also  observed
an improvement in sleep disturbance when follow-up values were
reported using the Pittsburgh Sleep Quality Index (PSQI) (MD -1.67;
95% CI -2.88 to -0.46), but only at 12 weeks, In addition, a single trial
reported a significant effect on the MDASI disturbed sleep subscale
(Yang 2011).

Two  additional  trials  reported  on  sleep  disturbances,  finding  a
significant  difference  between  the  exercise  and  control  groups
(Mock 1997; Oh 2008).

Social functioning

Pooling  results  of  trials  evaluating  change  from  baseline  to
follow-up  in  HRQoL  instruments  assessing  social  functioning
showed significant improvement following an exercise intervention
compared  with  a  control  intervention  in  378  trial  participants  at
12  weeks  (SMD  0.54;  95%  CI  0.03  to  1.05),  but  no  effect  was
observed at 6 months' follow-up (Analysis 14.1). We also observed
a  significant  effect  of  exercise  when  comparing  follow-up  scores

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

25

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

obtained  with  those  from  the  control  group  at  both  12  weeks'
follow-up (SMD 0.16; 95% CI 0.04 to 0.27) and 6 months' follow-up
(SMD 0.24; 95% CI 0.03 to 0.44). A positive treatment effect was still
present after excluding results from trials that included participants
who  had  completed  treatment  when  comparing  differences  in
scores  at  follow-up  between  the  exercise  and  control  groups  at
12  weeks  (SMD  0.16;  95%  CI  0.01  to  0.31)  and  whether  the  trial
participants only included individuals with breast cancer or other
types  of  cancer.  No  effect  of  exercise  was  present  at  12  weeks
when we included only trials with a low risk of bias for allocation
concealment (SMD 0.10; 95% CI -0.06 to 0.27).

Results obtained when pooling by individual instruments showed
mixed results with positive findings observed only when the FACT
instrument was used to measure social function.

From  trials  whose  data  were  not  extracted,  one  reported  no
difference on social functioning between the exercise and control
groups (Headley 2004) and a second reported a significant effect on
social functioning with exercise without a corresponding effect in
the control group (Oh 2008).

Spirituality

Few  trials  evaluated  spirituality  as  a  HRQoL  domain  while
comparing  an  exercise  with  a  control  intervention.  A  significant
effect  was  seen  in  172  trial  participants  enrolled  in  3  trials  at  12
weeks' follow-up (SMD 0.46; 95% CI 0.14 to 0.77) (Analysis 15.1).

A single trial without extractable data also reported no difference in
spirituality between exercise and control groups (Haddad 2011).

D I S C U S S I O N

Summary of main results

We  included  56  trials  with  4826  participants  randomized  to
an  exercise  (n  =  2286)  or  comparison  (n  =  1985)  group.
Cancer  diagnoses  in  trial  participants  included  breast,  prostate,
gynecologic,  hematologic,  and  other.  Thirty-six  trials  were
conducted  among  participants  who  were  currently  undergoing
active treatment for their cancer, 10 trials were conducted among
participants both during and post active cancer treatment, and the
remaining 10 trials were conducted among participants scheduled
for active cancer treatment. Mode of exercise interventions differed
across trials and included walking by itself or in combination with
cycling, resistance training, or strength training; resistance training;
strength training; cycling; yoga; or Qigong. HRQoL and its domains
were assessed using a wide range of measures.

The  results  suggest  that  exercise  interventions  compared  with
control  interventions  have  a  positive  impact  on  overall  HRQoL
and  certain  HRQoL  domains.    Exercise  interventions  resulted  in
improvements  in:  HRQoL  from  baseline  to  12  weeks'  follow-up
or  when  comparing  difference  in  follow-up  scores  at  12  weeks'
follow-up; physical functioning from baseline to 12 weeks' follow-
up  and  6  months'  follow-up  or  when  comparing  differences  in
follow-up scores at 12 weeks' follow-up or 6 months' follow-up; role
function from baseline to 12 weeks' follow-up or when comparing
differences  in  follow-up  scores  at  12  weeks  and  6  months;  and
in  social  functioning  at  12  weeks'  follow-up  or  when  comparing
differences  in  follow-up  scores  at  both  12  weeks'  follow-up  and
6  months'  follow-up.  Further,  exercise  interventions  resulted  in
a  decrease  in  fatigue  from  baseline  to  12  weeks'  follow-up  or

Cochrane Database of Systematic Reviews

when comparing difference in follow-up scores at follow-up of 12
weeks.  Since  there  is  consistency  of  findings  on  both  types  of
measures (change scores and difference in follow-up scores) there
is greater confidence in the robustness of these findings.

Exercise interventions also resulted in improvements in: prostate
cancer  concerns  at  12  weeks'  follow-up;  breast  cancer  concerns
when examining differences in follow-up scores at 6 months; EWB
at follow-up more than 12 weeks but less than 6 months; and, in
general health perspective when comparing differences in follow-
up  scores  at  12  weeks'  follow-up.  Further,  exercise  interventions
resulted  in  a  decrease  in  anxiety  at  12  weeks'  follow-up  and  at
6  months'  follow-up;  depression  at  12  weeks'  follow-up  and  at  6
months' follow-up; and, in sleep disturbances at 12 weeks' follow-
up. These findings, however, need to be interpreted cautiously as
their robustness is uncertain given the fact that the positive effects
were  observed  not  on  the  change  scores  but  in  the  difference  in
follow-up scores. These findings could be because of the different
number (or type) of trials reporting results in this manner or it could
be that there really is not a difference because trial authors did not
account for differences in baseline values.

When  examining  exercise  effects  by  subgroups,  exercise
interventions  had  significantly  greater  reduction  in  anxiety  for
survivors  with  breast  cancer  than  those  with  other  types  of
cancer. Further, there was greater reduction in depression, fatigue,
and sleep disturbances, and improvement in HRQoL, EWB, physical
functioning, and role function for cancer survivors diagnosed with
cancers other than breast cancer but not for breast cancer.  There
were also greater improvement in HRQoL and physical functioning,
and  reduction  in  anxiety,  fatigue,  and  sleep  disturbances  when
prescribed a moderate or vigorous versus a mild exercise program.

There  were  positive  trends  and  impact  of  exercise  interventions
for body image and self-esteem, cognitive functioning, depression
based  on  exercise  program  intensity,  fatigue  based  on  exercise
program intensity, general health perspective, pain, and spiritual
well-being.  No  conclusions  can  be  drawn  based  on  these  trends
since  few  trials  measured  these  outcomes  or  reported  on  the
intensity of the exercise program.

The  positive  results  must  be  interpreted  cautiously  owing  to  the
heterogeneity of exercise programs tested, measures used to assess
HRQoL  and  HRQoL  domains,  and  the  risk  of  bias  in  many  trials.
Further research is required to investigate how to sustain positive
effects of exercise over time and to determine essential attributes
of exercise (mode, intensity, frequency, duration, timing) by cancer
type  and  cancer  treatment  for  optimal  effects  on  HRQoL  and  its
domains.

The Summary of findings 1 provides a summary of the main results
with associated risks.

Overall completeness and applicability of evidence

This  systematic  review  included  56  trials,  54  of  which  were
RCTs  and  two  trials  used  a  quasi-randomized  design  to  allocate
participants to treatment. These trials allocated 4826 participants
to either the exercise or comparison groups. Participants enrolled
in  the  trials  had  various  cancer  diagnoses  including  breast,
prostate,  gynecologic,  hematologic,  and  other.  All  trials  included
participants  who  were  undergoing  active  cancer  treatment;
however, 10 trials also included participants who had completed

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

26

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

active cancer treatment. Exercise interventions tested in the trials
greatly  varied  and  included  walking  by  itself  or  in  combination
with  cycling,  resistance  training,  or  strength  training;  resistance
training;  strength  training;  cycling;  yoga;  or  Qigong.  HRQoL  and
HRQoL  domains  were  assessed  using  a  wide  range  of  measures.
The  Characteristics  of  included  studies  table  provides  detailed
information on the trial attributes.

it is unclear if this finding is because of lack of effect of the exercise
intervention  at  later  times,  or  because  there  were  so  few  trials
measuring outcomes at longer times of follow-up.

The trials provided no data on cost or cost-effectiveness of exercise
program on HRQoL and HRQoL domains among cancer survivors
undergoing treatment for their cancer.

The  review  draws  upon  studies  from  across  the  globe.  The
comprehensive search strategy obtained information from several
electronic databases, citations through Web of Science and Scopus,
PubMed's related article feature, and several websites; and review
of reference list of other reviews in the field and reference list of all
included trials. There were no language or date restrictions in the
search strategy. See Search methods for identification of studies for
details on the search strategy.

In  terms  of  applicability  of  evidence,  the  majority  of  trials  were
conducted  among  women.  Further,  many  trials  did  not  provide
sociodemographic  information  of  participants  (race/ethnicity,
education  level,  employment  status,  annual  income,  social  and
health  benefits)  that  would  enable  comparisons  between  trials
and assess generalizability of findings. Based on sociodemographic
data presented in trials, participants were generally white and with
more  than  'high  school'  level  of  education.  These  characteristics
would limit applicability of evidence to a broader cancer survivor
population. Further, the majority of trials measured effects of the
intervention at the end of the intervention. Thus it is unclear about
how sustainable the positive effects of the intervention would be.

The  exercise  programs  varied  greatly  in  their  mode  and  in
their  frequency,  duration,  and  intensity.  These  variations  and
the  lack  of  understanding  about  important  elements  of  exercise
programs  (mode,  frequency,  duration  of  sessions  and  programs,
and intensity) for optimal effects on HRQoL and HRQoL domains
would preclude informed decision-making in clinical settings and
limit applicability of findings.

The  HRQoL  and  HRQoL  domains  were  assessed  using  a  diverse
range  of  instruments  with  varying  psychometric  properties.
Further,  reliance  on  self-report  measures,  without  triangulation
of  findings  with  objectively  measured  outcomes,  can  open
interpretation of findings to bias.

Because of the variability across interventions, outcome measures,
and  follow-up  times,  we  looked  for  treatment  effects  that  were
consistent  across  time  and  different  instruments  used  to  assess
a  specific  domain.  Although  we  found  some  significant  effects,
they  tended  to  be  in  subgroups  or  only  at  one  time  point,
undermining  our  confidence  in  the  observed  effect.  When  we
observed a significant effect, it was usually at the 12-week follow-
up period, which typically equates to the end of the intervention.
We  frequently  found  that  a  positive  effect  at  12  weeks  was  not
observed at later time periods (i.e. improvement in global HRQoL,
improvements in physical function, reduction in fatigue, etc.), but

Quality of the evidence

Results  of  the  review  need  to  be  interpreted  cautiously  owing
to  the  risk  of  bias.  All  the  trials  reviewed  were  at  high  risk
for  performance  bias  because  blinding  of  participants  is  not
possible in exercise intervention unless more rigorously controlled
comparative  designs  are  utilized  to  test  the  effects  of  exercise
interventions.  Performance  bias  becomes  accentuated  in  trials
where participants are asked to provide subjective assessments of
outcomes  such  as  HRQoL  and  HRQoL  domains.  In  addition,  the
majority of trials were at high risk for detection bias as the outcome
assessors were not blinded, were at high risk for attrition bias owing
to  inadequate  handling  of  incomplete  data,  and  were  at  high  or
unclear risk for selection bias because of inadequate concealment
of allocation to the intervention.

The  Summary  of  findings  1,  Figure  2,  and  Figure  3  provide  a
summary on the quality of evidence.

Potential biases in the review process

The  strength  of  this  review  is  the  comprehensive  search  strategy
that included a search of 11 electronic databases, citations through
Web  of  Science  and  Scopus,  PubMed's  related  article  feature,
and  several  websites;  and,  review  of  reference  lists  of  other
reviews  in  the  field  and  reference  lists  of  all  included  trials.  The
comprehensive search strategy was designed and implemented to
ensure the identification and retrieval of the maximum number of
available published trials and trials in the gray literature. The search
strategy also ensured no language restrictions. Trials published in
non-English language were assessed for eligibility and, if eligible,
had data abstracted by native speakers of the language in which
the trial was published. In spite of such a comprehensive search,
it  is  still  possible  that  this  review  may  have  a  publication  bias.
We  prepared  funnel  plots  to  assess  publication  bias  for  change
from baseline to follow-up and for follow-up values for outcomes
such as global QoL (Figure 4; Figure 5), fatigue (Figure 6; Figure 7),
and physical functioning (Figure 8; Figure 9). Visually these figures
showed  some  slight  asymmetry  indicating  that  there  is  some
publication bias in this area of research. We did not complete funnel
plots for the other outcomes because too few studies contributed
to  the  outcome  measures.  It  is  possible  this  review  missed  some
potentially eligible trials in the gray literature, but given the study
results, it is unclear whether the addition of trials only in the gray
literature would have a significant impact on results of the review
if, as has been suggested, trials reported only in the gray literature
includes trials that have small sample sizes and inconclusive results
(McAuley 2000).

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

27

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 4.   Funnel plot of comparison: 1 Health-related quality of life, outcome: 1.1 Overall quality of life change
score.

0

SE(SMD)

0.1

0.2

0.3

0.4

0.5

-10

-5

0

5

SMD

10

Subgroups
Up to 12 weeks' follow-up
More than 12 weeks' to less than 6 months' follow-up
6 months' follow-up

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

28

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 5.   Funnel plot of comparison: 1 Health-related quality of life, outcome: 1.2 Overall quality of life follow-up
values.

0

SE(SMD)

0.2

0.4

0.6

0.8

1
-10

-5

0

5

SMD

10

Subgroups
Up to 12 weeks' follow-up
More than 12 weeks' to less than 6 months' follow-up
6 months' follow-up

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

29

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 6.   Funnel plot of comparison: 8 Fatigue, outcome: 8.1 Overall fatigue change.

0

SE(SMD)

0.2

0.4

0.6

0.8

1
-10

-5

0

5

SMD

10

Subgroups
Up to 12 weeks' follow-up
More than 12 weeks' to less than 6 months' follow-up
6 months' follow-up

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

30

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 7.   Funnel plot of comparison: 8 Fatigue, outcome: 8.2 Overall fatigue follow-up values.

0

SE(SMD)

0.2

0.4

0.6

0.8

1
-10

-5

0

5

SMD

10

Subgroups
Up to 12 weeks' follow-up
More than 12 weeks' to less than 6 months' follow-up
6 months' follow-up

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

31

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 8.   Funnel plot of comparison: 11 Physical functioning, outcome: 11.1 Overall physical function change.

0

SE(SMD)

0.2

0.4

0.6

0.8

1
-10

-5

0

5

SMD

10

Subgroups
Up to 12 weeks' follow-up
More than 12 weeks' to less than 6 months' follow-up
6 months' follow-up

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

32

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 9.   Funnel plot of comparison: 11 Physical functioning, outcome: 11.2 Overall physical function follow-up
values.

0

SE(SMD)

0.1

0.2

0.3

0.4

0.5

-10

-5

0

5

SMD

10

Subgroups
Up to 12 weeks' follow-up
More than 12 weeks' to less than 6 months' follow-up
6 months' follow-up

We  corresponded  with  and  requested  additional  data  from  22
trial authors (Arbane 2009; Battaglini 2008; Brown 2006; Campbell
2005; Cheville 2010; Crowley 2003; Culos-Reed 2010; DiSipio 2009;
Gomes  2011;  Griffith  2009;  Haddad  2011;  Headley  2004;  Jarden
2009;  Lanctot  2010;  Mock  1994;  Mock  1997;  Mock  2001;  Oh  2008;
Raghavendra 2007; Segal 2001; Tang 2010; Yang 2011), and five of
these trial authors (Arbane 2009; Griffith 2009; Lanctot 2010; Segal
2001; Yang 2011) contacted were able to provide additional data. Of
the remaining 17 trials for which we requested additional data, we
were unable to contact the primary author for seven trials, received
no  response  from  six  trial  authors,  and  four  trial  authors  either
did  not  have  access  to  their  database  or  were  unable  to  provide
additional information for some other reason. Obtaining additional
data  allowed  inclusion  of  these  trials  in  the  quantitative  meta-
analyses, which made the analyses and findings more robust and
complete.

Agreements and disagreements with other studies or
reviews

Several systematic reviews (Craft 2011; Cramp 2008; Cramp 2010;
Duijts 2011; Ferrer 2011; Speck 2010a) evaluated the effectiveness
of exercise interventions on HRQoL or HRQoL domains. All of these
reviews  included  people  both  during  and  after  active  cancer  and
only  one  review  (Speck  2010a)  presented  findings  by  treatment
status.  Cramp  2008  examined  the  effect  of  exercise  on  cancer-
related  fatigue  and  reported  that  overall  exercise  was  beneficial
in  the  management  of  cancer-related  fatigue  and  that  exercise
was beneficial in the management of cancer-related fatigue among
breast cancer survivors during and after active cancer treatment,
a  finding  that  is  similar  to  what  we  report  here.  In  a  more
recent  review,  Cramp  2010,  based  on  a  review  of  the  effect  of
resistance  (strength)  training  on  HRQoL,  reported  no  significant
benefit of resistance training on global HRQoL and on anxiety and
depression.  In  contrast,  we  found  an  effect  of  exercise  on  global
HRQoL, but not a consistent effect on depression. Two of the four
trials reviewed by Cramp 2010 reported a significant improvement

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

33

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

in  fatigue.  Duijts  2011  evaluated  the  effects  of  exercise  (and
behavioral)  interventions  on  fatigue,  depression,  body-image,
stress, and HRQoL in breast cancer survivors both during and after
cancer  treatment.  Physical  exercise  interventions  had  moderate
statistically significant effects for fatigue, depression, body-image,
and  HRQoL  but  the  effect  on  anxiety,  although  in  the  expected
direction,  was  not  statistically  significant.  Again,  these  findings
are  generally  consistent  with  those  presented  here  although  we
did  not  find  a  consistent  effect  on  depression  and  anxiety,  and
no  effect  on  body  image.  Ferrer  2011,  based  on  a  meta-analysis
of  the  efficacy  of  exercise  interventions  in  improving  HRQoL  in
cancer  survivors  during  and  after  cancer  treatment,  documented
increased  HRQoL  scores  but  the  effect  was  more  pronounced
for  interventions  that  had  intense  aerobic  exercises  and  which
targeted  women.  Speck  2010a  evaluated  the  effects  of  physical
activity  across  the  cancer  control  continuum  (including  during
and after cancer treatment). Physical activity interventions among
people who had completed active treatment for their cancer had
moderate  effects  on  fatigue  and  breast  cancer-specific  concerns
and  had  small  to  moderate  effects  on  overall  HRQoL.  Craft  2011
reviewed  the  effects  of  exercise  on  depression  and  documented
that exercise had a modest positive effect on depressive symptoms.
Our review did not find a consistent effect on depression in contrast
to  these  reviews,  but  our  findings  are  congruent  with  respect  to
global  HRQoL  and  fatigue  observed  by  other  reviewers.  These
differences  may  be  because  of  differences  in  the  trial  population
in that our review only included individuals who were undergoing
active cancer treatment, although some of the trials included in this
review also included participants who had completed active cancer
treatment.

A U T H O R S '   C O N C L U S I O N S

Implications for practice

This systematic review finds that exercise interventions may have
beneficial  effects  at  varying  follow-up  periods  on  overall  HRQoL
and  certain  HRQoL  domains  including  physical  functioning,  role
function,  social  functioning,  and  fatigue  among  cancer  survivors
undergoing active cancer treatment for their primary or recurrent
cancer.  Since  there  is  consistency  of  findings  on  both  types
of  measures  (change  scores  and  difference  in  follow-up  scores)
there  is  greater  confidence  in  the  robustness  of  these  findings.
Positive  effects  of  exercise  interventions  are  more  pronounced
with moderate or vigorous-intensity versus mild-intensity exercise
programs.  Exercise  programs  could  be  considered  as  an  integral
component for the management of HRQoL among cancer survivors
undergoing active cancer treatment.

Exercise  interventions  also  resulted  in  improvements  at  varying
follow-up  periods  in  prostate  cancer  concerns,  breast  cancer
concerns,  EWB,  general  health  perspective,  anxiety,  depression,
and  sleep  disturbances.    These  findings,  however,  need  to  be
interpreted cautiously as their robustness is uncertain given the fact
that the positive effects were observed not on the change scores
but in the difference in follow-up scores.  These findings could be
because of the different number (or type) of trials reporting results
in  this  manner  or  it  could  be  that  there  really  is  not  a  difference
because  trial  authors  did  not  account  for  differences  in  baseline
values.

There  were  positive  trends  and  impact  of  exercise  interventions
for body image and self-esteem, cognitive functioning, depression

Cochrane Database of Systematic Reviews

based  on  exercise  program  intensity,  fatigue  based  on  exercise
program intensity, general health perspective, pain, and spiritual
well-being.  No  conclusions  can  be  drawn  based  on  these  trends
since  few  trials  measured  these  outcomes  or  reported  on  the
intensity of the exercise program.

The  positive  results  must  be  interpreted  cautiously  owing  to  the
heterogeneity  of  exercise  programs  tested  and  measures  used  to
assess  HRQoL  and  HRQoL  domains,  and  the  risk  of  bias  in  may
trials. Further, a lack of understanding about important elements
of  exercise  programs  (mode,  frequency,  duration  of  sessions  and
programs, and intensity) for optimal effects on HRQoL and HRQoL
domains  would  preclude  informed  decision-making  in  clinical
settings and limit practical applicability of findings.

From a practice perspective, it would be important to understand
whether  certain  exercise  attributes  have  more  or  less  optimal
effects  on  HRQoL  and  HRQoL  domains  among  survivors  of
certain  types  of  cancers  undergoing  active  treatment  for  their
cancer.  Further,  it  would  be  important  to  understand  which
mode of exercise program (e.g. strength, resistance, Tai Chi, yoga,
aerobic, anaerobic) coupled with what levels of essential attributes
(frequency  of  program,  duration  of  program  and  each  session)  is
optimal for which cancer type and cancer treatment.

Implications for research

This systematic review and meta-analysis of 56 trials on the effects
of  exercise  on  HRQoL  and  HRQoL  domains  for  cancer  survivors
undergoing  active  treatment  for  their  cancer  provides  evidence
that exercise interventions may have beneficial effects at varying
follow-up periods on overall HRQoL and certain HRQoL domains,
including  physical  functioning,  role  function,  social  functioning,
and  fatigue,  among  cancer  survivor  undergoing  active  cancer
treatment  for  their  primary  or  recurrent  cancer.  Positive  effects
of  exercise  interventions  are  more  pronounced  with  moderate-
or  vigorous-intensity  versus  mild-intensity  exercise  programs.
Further, findings of this review suggests that exercise interventions
may have minimal or no effects on HRQoL domains such as body
image  and  self-esteem,  cognitive  functioning,  depression  based
on exercise program intensity, fatigue based on exercise program
intensity, general health perspective, pain, and spiritual well-being
among  cancer  survivors  undergoing  active  treatment  for  their
cancer.

Further  research  is  required  to  investigate  whether  the  effect
of  an  exercise  intervention  can  be  maintained  beyond  the
active  intervention  period,  and  if  so,  how  to  sustain  changes  in
exercise behaviors and positive effects of exercise on HRQoL and
HRQoL domains. Empirical evidence is also needed to determine
the  optimal  follow-up  period  from  end  of  the  intervention.  To
further this understanding, rigorous RCTs could include qualitative
research components in trials to benefit from the contextually rich
insights gained from engaging participants about their experiences
in exercise interventions.

More  research  is  needed  to  determine  essential  attributes  of
exercise  (mode,  intensity,  frequency,  duration,  timing)  by  cancer
type  and  cancer  treatment  for  optimal  effects  on  HRQoL  and  its
domains.

HRQoL  and  HRQoL  domains  are  important  measures  of  cancer
survivorship.  However,  the  heterogeneous  range  of  measures

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

34

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

used  to  assess  HRQoL  and  HRQoL  domains,  make  comparisons
of  findings  between  trials  extremely  difficult.  Efforts  such  as
the Patient-Reported Outcomes Measurement Information System
(PROMIS)  may  help  address  these  issues  (Cella  2010;  National
Cancer Institute 2012).

A C K N O W L E D G E M E N T S

The  authors  would  like  to  thank  and  acknowledge  Clare  Jess
(Managing Editor) and Editorial Base of the Cochrane Gynecological
Cancer  Review  Group  for  their  help  and  editorial  advice  during
the  preparation  of  the  review.  Moreover,  the  authors  would  like

to  thank  the  peer  reviewers  and  consumer  reviewer  for  their
invaluable  feedback  during  the  peer  review  process,  and  the
authors  of  primary  trials  for  additional  information  about  their
trials. The authors also gratefully acknowledge the contributions of
Dr. Carolyn Gotay who assisted in identifying trials for inclusion in
the review and Nadia Bennett who assisted in extracting data for
trials meeting the eligibility criteria. This research was supported
in  part  by  the  National  Institute  for  Health  Research  (NIHR)
Health Technology Assessment program. The views and opinions
expressed therein are those of the authors and do not necessarily
reflect those of the funding agency.

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

35

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

R E F E R E N C E S

References to studies included in this review

Adamsen 2009 {published data only}

*  Adamsen L, Quist M, Andersen C, Moller T, Herrstedt J,
Kronborg D, et al. Effect of a multimodal high intensity exercise
intervention in cancer patients undergoing chemotherapy:
randomised controlled trial. BMJ 2009; 339:b3410.

Andersen C, Bloomquist K, Adamsen L, Moeller T, Quist M,
Roerth M. Reduced fatigue through a six week structured
group exercise intervention in cancer in patients undergoing
chemotherapy - a randomized clinical controlled trial.
Supportive Care in Cancer 2009; 17(7):888-9.

Midtgaard J, Stage M, Møller T, Andersen C, Quist M, Rørth M,
et al. Exercise may reduce depression but not anxiety in self-
referred cancer patients undergoing chemotherapy. Post-hoc
analysis of data from the 'Body & Cancer' trial. Acta Oncologica
2011; 50(5):660-9.

Arbane 2009 {published data only}

*  Arbane G, Jackson D, Tropman D, Garrod R. An early exercise
intervention prevents quadriceps weakness after thoracotomy
for non-small cell lung cancer: randomized controlled trial.
Thorax 2009; 64(Suppl IV):A20-1.

Banerjee 2007 {published data only}

*  Banerjee B, Vadiraj HS, Ram A, Rao R, Jayapal M, Gopinath KS,
et al. Effects of an integrated yoga program in modulating
psychological stress and radiation-induced genotoxic stress
in breast cancer patients undergoing radiotherapy. Integrative
Cancer Therapies 2007; 6(3):242-50.

Battaglini 2008 {published data only}

*  Battaglini CL, Mihalik JP, Bottaro M, Dennehy C,
Petschauer MA, Hairston LS, et al. Effect of exercise on the
caloric intake of breast cancer patients undergoing treatment.
Brazilian Journal of Medical and Biological Research 2008;
41(8):709-15.

Bourke 2011 {published data only}

*  Bourke L, Doll H, Crank H, Daley A, Rosario D, Saxton JM.
Lifestyle intervention in men with advanced prostate cancer
receiving androgen suppression therapy: a feasibility
study. Cancer Epidemiology, Biomarkers & Prevention 2011;
20(4):647-57.

Brown 2006 {published data only}

*  Brown P, Clark MM, Atherton P, Huschka M, Sloan JA,
Gamble G, et al. Will improvement in quality of life (QOL) impact
fatigue in patients receiving radiation therapy for advanced
cancer? American Journal of Clinical Oncology 2006; 29(1):52-8.

Cadmus 2009 {published data only}

*  Cadmus LA, Salovey P, Yu H, Chung G, Kasl S, Irwin ML.
Exercise and quality of life during and after treatment for
breast cancer: results of two randomized controlled trials.
Psychooncology 2009; 18(4):343-52.

Cadmus LA. Exercise and quality of life during and after
treatment for breast cancer. Dissertation Abstracts
International: Section B: The Sciences and Engineering 2008;
68(12-B).

Caldwell 2009 {published data only}

*  Caldwell MG. The Effects of an Endurance Exercise Regimen
on Cancer-related Fatigue and Physical Performance in Women
with Breast Cancer [Doctoral dissertation]. Louisiana, US:
Louisiana State University Health Sciences Center School of
Nursing, 2009.

Campbell 2005 {published data only}

*  Campbell A, Mutrie N, White F, McGuire F, Kearney N. A
pilot study of a supervised group exercise programme as a
rehabilitation treatment for women with breast cancer receiving
adjuvant treatment. European Journal of Oncology Nursing
2005; 9(1):56-63.

Chandwani 2010 {published data only}

*  Chandwani KD, Thornton B, Perkins GH, Arun B,
Raghuram NV, Nagendra HR, et al. Yoga improves quality of
life and benefit finding in women undergoing radiotherapy for
breast cancer. Journal of the Society for Integrative Oncology
2010; 8(2):43-55.

Chang 2008 {published data only}

*  Chang PH, Lai YH, Shun SC, Lin LY, Chen ML, Yang Y, et al.
Effects of a walking intervention on fatigue-related experiences
of hospitalized acute myelogenous leukemia patients
undergoing chemotherapy: a randomized controlled trial.
Journal of Pain and Symptom Management 2008; 35(5):524-34.

Cheville 2010 {published data only}

*  Cheville AL, Girardi J, Clark M, Rummans TA, Pittelkow T,
Brown P, et al. Therapeutic exercise during outpatient radiation
therapy for advanced cancer: feasibility and impact on
physical well-being. American Journal of Physical Medicine and
Rehabilitation 2010; 89(8):611-9.

Lapid MI, Rummans TA, Brown PD, Frost MH, Johnson ME,
Huschka MM, et al. Improving the quality of life of geriatric
cancer patients with a structured multidisciplinary intervention:
a randomized controlled trial. Palliative and Supportive Care
2007; 5:107-14.

Rummans TA, Clark MM, Sloan JA, Frost MH, Bostwick JM,
Atherton PJ, et al. Impacting quality of life for patients
with advanced cancer with a structured multidisciplinary
intervention: a randomized controlled trial. Journal of Clinical
Oncology 2006; 24(4):635-42.

Cohen 2004 {published data only}

*  Cohen L, Warneke C, Fouladi RT, Rodriguez MA, Chaoul-
Reich A. Psychological adjustment and sleep quality in a
randomized trial of the effects of a Tibetan yoga intervention in
patients with lymphoma. Cancer 2004; 100(10):2253-60.

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

36

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Courneya 2003a {published data only}

*  Courneya KS, Friedenreich CM, Sela RA, Quinney HA,
Rhodes RE, Handman M. The group psychotherapy and home-
based physical exercise (group-hope) trial in cancer survivors:
physical fitness and quality of life outcomes. Psychooncology
2003; 12(4):357-74.

Courneya KS, Friedenreich CM, Sela RA, Quinney HA, Rhodes RE.
Correlates of adherence and contamination in a randomized
controlled trial of exercise in cancer survivors: an application
of the theory of planned behavior and the five factor model of
personality. Annals of Behavioral Medicine 2002; 24(4):257-68.

Courneya 2007a {published data only}

Courneya KS, McKenzie DC, Mackey JR, Gelmon K, Reid RD,
Friedenreich CM, et al. Moderators of the effects of exercise
training in breast cancer patients receiving chemotherapy: a
randomized controlled trial. Cancer 2008; 112(8):1845-53.

Courneya KS, McKenzie DC, Reid RD, Mackey JR, Gelmon K,
Friedenreich CM, et al. Barriers to supervised exercise training
in a randomized controlled trial of breast cancer patients
receiving chemotherapy. Annals of Behavioral Medicine 2008;
35(1):116-22.

Courneya KS, Reid RD, Friedenreich CM, Gelmon K, Proulx C,
Vallance JK, et al. Understanding breast cancer patients'
preference for two types of exercise training during
chemotherapy in an unblinded randomized controlled trial.
International Journal of Behavioral Nutrition and Physical
Activity 2008; 5:52.

Courneya KS, Segal RJ, Gelmon K, Reid RD, Mackey JR,
Friedenreich CM, et al. Predictors of supervised exercise
adherence during breast cancer chemotherapy. Medicine and
Science in Sports and Exercise 2008; 40(6):1180-7.

Courneya KS, Segal RJ, Gelmon K, Reid RD, Mackey JR,
Friedenreich CM, et al. Six-month follow-up of patient-rated
outcomes in a randomized controlled trial of exercise training
during breast cancer chemotherapy. Cancer Epidemiology,
Biomarkers & Prevention 2007; 16(12):2572-8.

*  Courneya KS, Segal RJ, Mackey JR, Gelmon K, Reid RD,
Friedenreich CM, et al. Effects of aerobic and resistance exercise
in breast cancer patients receiving adjuvant chemotherapy:
a multicenter randomized controlled trial. Journal of Clinical
Oncology 2007; 25(28):4396-04.

Courneya 2008 {published data only}

*  Courneya KS, Jones LW, Peddle CJ, Sellar CM, Reiman T,
Joy AA, et al. Effects of aerobic exercise training in anemic
cancer patients receiving darbepoetin alfa: a randomized
controlled trial. Oncologist 2008; 13(9):1012-20.

Courneya 2009 {published data only}

Courneya KS, Sellar CM, Stevinson C, McNeely ML,
Friedenreich CM, Peddle CJ, et al. Moderator effects in a
randomized controlled trial of exercise training in lymphoma
patients. Cancer Epidemiology, Biomarkers & Prevention 2009;
18(10):2600-7.

*  Courneya KS, Sellar CM, Stevinson C, McNeely ML, Peddle CJ,
Friedenreich CM, et al. Randomized controlled trial of the
effects of aerobic exercise on physical functioning and quality
of life in lymphoma patients. Journal of Clinical Oncology 2009;
27(27):4605-12.

Courneya KS, Stevinson C, McNeely ML, Sellar CM,
Friedenreich CM, Peddle-McIntyre CJ, et al. Predictors of
follow-up exercise behavior 6 months after a randomized
trial of supervised exercise training in lymphoma patients.
Psychooncology 2011; Jul 18:.

Courneya KS, Stevinson C, McNeely ML, Sellar CM, Peddle CJ,
Friedenreich CM, et al. Predictors of adherence to supervised
exercise in lymphoma patients participating in a randomized
controlled trial. Annals of Behavioral Medicine 2010; 40(1):30-9.

Crowley 2003 {published data only}

*  Crowley SA. The Effect of a Structured Exercise Program
on Fatigue, Strength, Endurance, Physical Self-efficacy, and
Functional Wellness in Women with Early Stage Breast Cancer
[doctoral dissertation]. Michigan, US: University of Michigan,
2003.

Culos-Reed 2010 {published data only}

*  Culos-Reed SN, Robinson JW, Lau H, Stephenson L, Keats M,
Norris S, et al. Physical activity for men receiving androgen
deprivation therapy for prostate cancer: benefits from a 16-
week intervention. Supportive Care in Cancer 2010; 18(5):591-9.

Danhauer 2009 {published data only}

*  Danhauer SC, Mihalko SL, Russell GB, Campbell CR, Felder L,
Daley K, et al. Restorative yoga for women with breast cancer:
findings from a randomized pilot study. Psychooncology 2009;
18(4):360-8.

de Oliveira 2010 {published data only}

*  Oliveira MM, Souza GA, , Okubo MA, Amaral MT, Silva MP,
et al. Upper limbs exercises during radiotherapy for breast
cancer and quality of life [Exercicios para membros superiores
durante radioterapia para cancer de mama e qualidade de
vida]. Rervista Brasileira de Ginecologia e Obstetricia 2010;
32(3):133-8.

Dimeo 1999 {published data only}

*  Dimeo FC, Stieglitz RD, Novelli-Fischer U, Fetscher S, Keul J.
Effects of physical activity on the fatigue and psychologic
status of cancer patients during chemotherapy. Cancer 1999;
85(10):2273-7.

DiSipio 2009 {published data only}

*  DiSipio T, Rye S, Newton M, Guy L, Spathonis K, Eakin E, et al.
Exercise for health: a breast cancer recovery program - quality
of life benefits. Asia-Pacific Journal of Clinical Oncology 2009;
5(Suppl 2):A232.

Donnelly 2011 {published data only}

*  Donnelly CM, Blaney JM, Lowe-Strong A, Rankin J P,
Campbell A, McCrum-Gardner E, et al. A randomised controlled
trial testing the feasibility and efficacy of a physical activity
behavioural change intervention in managing fatigue with

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

37

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

gynaecological cancer survivors. Gynecological Oncology 2011;
122(3):618-24.

Galvao 2010 {published data only}

Galvao DA, Taaffe DR, Spry N, Joseph D, Levin G, Newton RU.
Resistance and aerobic training improves quality of life in
men undergoing androgen suppression therapy for prostate
cancer: a randomized controlled trial. British Journal of Urology
International 2010; 105:18.

*  Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU.
Combined resistance and aerobic exercise program reverses
muscle loss in men undergoing androgen suppression therapy
for prostate cancer without bone metastases: a randomized
controlled trial. Journal of Clinical Oncology 2010; 28(2):340-7.

Gomes 2011 {published data only}

*  Gomes A, Fernandes EL, Carvalho MP, Fabricio VC.
Effectiveness of brief exercise orientation program on breast
cancer induced fatigue. European Journal of Cancer 2011;
47(Suppl. 1):S238-9.

Griffith 2009 {published data only}

*  Griffith K, Wenzel J, Shang J, Thompson C, Stewart K, Mock V.
Impact of a walking intervention on cardiorespiratory fitness,
self-reported physical function, and pain in patients undergoing
treatment for solid tumors. Cancer 2009; 115(20):4874-84.

Mock V, Krumm S, Belcher A, Stewart K, DeWeese T, Shang J,
et al. Exercise during prostate cancer treatment: effects on
functional status and symptoms. Oncology Nursing Forum 2007;
34(1):189-90.

Mock V, , Hall S, Bositis A, Tillery M, Belcher A, et al. Using a
conceptual model in nursing research--mitigating fatigue
in cancer patients. Journal of Advanced Nursing 2007;
58(5):503-12.

Hacker 2011 {published data only}

*  Hacker ED, Larson J, Kujath A, Peace D, Rondelli D,
Gaston L. Strength training following hematopoietic stem cell
transplantation. Cancer Nursing 2011; 34(3):238-49.

Haddad 2011 {published data only}

*  Haddad R, Chandwani K, Perkins G, Spelman A, Johnson K,
Fortier A, et al. Randomized controlled trial of yoga for women
with breast cancer undergoing radiotherapy. Psychosomatic
Medicine 2011; 73(3):A119-20.

Headley 2004 {published data only}

*  Headley JA, Ownby KK, John LD. The effect of seated exercise
on fatigue and quality of life in women with advanced breast
cancer. Oncology Nursing Forum 2004; 31(5):977-83.

Hwang 2008 {published data only}

*  Hwang JH, Chang HJ, Shim YH, Park WH, Park W, Huh SJ, et
al. Effects of supervised exercise therapy in patients receiving
radiotherapy for breast cancer. Yonsei Medical Journal 2008;
49(3):443-50.

Cochrane Database of Systematic Reviews

Jarden 2009 {published data only}

*  Jarden M, Baadsgaard MT, Hovgaard D, Boesen E, Adamsen L.
A randomized trial on the effect of a multimodal intervention
on physical capacity, functional performance and quality of
life in adult patients undergoing allogenic SCT. Bone Marrow
Transplantation 2009; 43:725-37.

Jarden M, Hovgaard D, Boesen E, Quist M, Adamsen L. Pilot
study of a multimodal intervention: mixed-type exercise and
psychoeducation in patients undergoing allogeneic stem
cell transplantation. Bone Marrow Transplantation 2007;
40(8):793-800.

Lanctot 2010 {published data only}

*  Dominique L, Gilles D, Annelie A, Madan B, Pierre D, Ginette M.
Impact of the yoga Bali method on quality of life and depressive
symptoms among women diagnosed with breast cancer
undergoing chemotherapy. Psychooncology 2010; 19(Suppl.
2):S136-40.

Moadel 2007 {published data only}

*  Moadel AB, Shah C, Wylie-Rosett J, Harris MS, Patel SR,
Hall CB, et al. Randomized controlled trial of yoga among a
multiethnic sample of breast cancer patients: effects on quality
of life. Journal of Clinical Oncology 2007; 25(28):4387-95.

Mock 1994 {published data only}

*  Mock V, Burke MB, Sheehan P, Creaton EM, Winningham ML,
McKenney-Tedder S, et al. A nursing rehabilitation program for
women with breast cancer receiving adjuvant chemotherapy.
Oncology Nursing Forum 1994; 21(5):899-907; discussion 908.

Mock 1997 {published data only}

*  Mock V, Dow KH, Meares CJ, Grimm PM, Dienemann JA,
Haisfield-Wolfe ME, et al. Effects of exercise on fatigue, physical
functioning, and emotional distress during radiation therapy for
breast cancer. Oncology Nursing Forum 1997; 24(6):991-1000.

Mock 2001 {published data only}

*  Mock V, Pickett M, Ropka ME, Muscari Lin E, Stewart KJ,
Rhodes VA, et al. Fatigue and quality of life outcomes of exercise
during cancer treatment. Cancer Practice 2001; 9(3):119-27.

Mock 2005 {published data only}

*  Mock V, Frangakis C, Davidson NE, Ropka ME, Pickett M,
Poniatowski B, et al. Exercise manages fatigue during
breast cancer treatment: a randomized controlled trial.
Psychooncology 2005; 14(6):464-77.

Monga 2007 {published data only}

*  Monga U, Garber SL, Thornby J, Vallbona C, Kerrigan AJ,
Monga TN, et al. Exercise prevents fatigue and improves quality
of life in prostate cancer patients undergoing radiotherapy.
Archives of Physical Medicine and Rehabilitation 2007;
88(11):1416-22.

Moros 2010 {published data only}

*  Moros MT, Ruidiaz M, Caballero A, Serrano E, Martinez V,
Tres A. [Effects of an exercise training program on the quality
of life of women with breast cancer on chemotherapy]. Revista
Medica de Chile 2010; 138(6):715-22.

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

38

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Mustian 2009 {published data only}

Segal 2003 {published data only}

*  Mustian KM, Peppone L, Darling TV, Palesh O, Heckler CE,
Morrow GR. A 4-week home-based aerobic and resistance
exercise program during radiation therapy: a pilot randomized
clinical trial. Journal of Supportive Oncology 2009; 7(5):158-67.

*  Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB,
Scott CG, et al. Resistance exercise in men receiving androgen
deprivation therapy for prostate cancer. Journal of Clinical
Oncology 2003; 21(9):1653-9.

Mutrie 2007 {published data only}

Segal 2009 {published data only}

*  Mutrie N, Campbell AM, Whyte F, McConnachie A,
Emslie C, Lee L, et al. Benefits of supervised group exercise
programme for women being treated for early stage breast
cancer: pragmatic randomised controlled trial. BMJ 2007;
334(7592):517.

*  Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP,
Prud'Homme DG, et al. Randomized controlled trial of
resistance or aerobic exercise in men receiving radiation
therapy for prostate cancer. Journal of Clinical Oncology 2009;
27(3):344-51.

Oh 2008 {published data only}

Tang 2010 {published data only}

*  Oh B, Butow P, Mullan B, Clarke S. Medical Qigong for cancer
patients: pilot study of impact on quality of life, side effects
of treatment and inflammation. American Journal of Chinese
Medicine 2008; 36(3):459-72.

Oh B, Butow PN, Clarke SJ, Beale PJ, Pavlakis N. Impact of
medical Qigong on quality of life, fatigue, symptoms, mood and
inflammation in cancer patient: a randomized controlled trial.
Asia-Pacific Journal of Clinical Oncology 2009; 5(Suppl 2):A237.

Oh 2010 {published data only}

*  Oh B, Butow P, Mullan B, Clarke S, Beale P, Pavlakis N, et al.
Impact of medical Qigong on quality of life, fatigue, mood and
inflammation in cancer patients: a randomized controlled trial.
Annals of Oncology 2010; 21(3):608-14.

Oh B, Butow P, Mullan B, Clarke S, Beale P, Pavlakis N, et al.
Randomized clinical trial of medical Qigong on quality of life,
fatigue, side effects, mood, status, and inflammation of cancer
patients. Journal of Clinical Oncology 2009; 27(15):Suppl. 1.

Oh B, Butow PN, Mullan BA, Clarke SJ, Beale PJ, Pavlakis N,
et al. Effect of medical Qigong on cognitive function, quality
of life, and a biomarker of inflammation in cancer patients: a
randomized controlled trial. Supportive Care in Cancer 2012;
20(6):1235-42.

*  Tang MF, Liou TH, Lin CC. Improving sleep quality for cancer
patients: benefits of a home-based exercise intervention.
Supportive Care in Cancer 2010; 18(10):1329-39.

Targ 2002 {published data only}

*  Targ EF, Levine EG. The efficacy of a mind-body-spirit group
for women with breast cancer: a randomized controlled trial.
General Hospital Psychiatry 2002; 24(4):238-48.

Vadiraja 2009b {published data only}

Vadiraja HS, Raghavendra RM, Nagarathna R, Nagendra HR,
Rekha M, Vanitha N, et al. Effects of a yoga program on cortisol
rhythm and mood states in early breast cancer patients
undergoing adjuvant radiotherapy: a randomized controlled
trial. Integrative Cancer Therapies 2009; 8(1):37-46.

Vadiraja HS, Rao MR, Nagarathna R, Nagendra HR, Rekha M,
Vanitha N, et al. Effects of yoga program on quality of life and
affect in early breast cancer patients undergoing adjuvant
radiotherapy: a randomized controlled trial. Complementary
Therapies in Medicine 2009; 17(5-6):274-80.

*  Vadiraja HS, Rao RM, Hongasandra NR, Nagarathna R,
Rekha M, Vanitha N, et al. Effects of yoga on symptom
management in breast cancer patients: a randomized
controlled trial. International Journal of Yoga 2009; 2(2):73-9.

Raghavendra 2007 {published data only}

Wang 2010 {published data only}

*  Raghavendra RM, Nagarathna R, Nagendra HR, Gopinath KS,
Srinath BS, Ravi BD, et al. Effects of an integrated yoga
programme on chemotherapy-induced nausea and emesis in
breast cancer patients. European Journal of Cancer Care 2007;
16(6):462-74.

Rogers 2009 {published data only}

*  Rogers LQ, Hopkins-Price P, Vicari S, Markwell S, Pamenter R,
Courneya KS, et al. Physical activity and health outcomes
three months after completing a physical activity behavior
change intervention: persistent and delayed effects. Cancer
Epidemiology, Biomarkers & Prevention 2009; 18(5):1410-8.

Segal 2001 {published data only}

*  Segal R, Evans W, Johnson D, Smith J, Colletta S, Gayton J, et
al. Structured exercise improves physical functioning in women
with stages I and II breast cancer: results of a randomized
controlled trial. Journal of Clinical Oncology 2001; 19(3):657-65.

Wang YJ, Boehmke M, Wu YW, Dickerson SS, Fisher N. Effects
of a 6-week walking program on Taiwanese women newly
diagnosed with early-stage breast cancer. Cancer Nursing 2011;
34(2):E1-13.

*  Wang YJ. Effects of a Six-week Home-based Walking Program
on Taiwanese Women Newly Diagnosed with Early Stage Breast
Cancer [Doctoral dissertation]. New York, US: State University of
New York at Buffalo, 2010.

Windsor 2004 {published data only}

*  Windsor PM, Nicol KF, Potter J. A randomized, controlled
trial of aerobic exercise for treatment-related fatigue in men
receiving radical external beam radiotherapy for localized
prostate carcinoma. Cancer 2004; 101(3):550-7.

Wiskemann 2011 {published data only}

*  Wiskemann J, Dreger P, Schwerdtfeger R, Bondong A,
Huber G, Kleindienst N, et al. Effects of a partly self-
administered exercise program before, during, and

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

39

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

after allogeneic stem cell transplantation. Blood 2011;
117(9):2604-13.

life (QOL) and body mass index (BMI) in a multi-ethnic sample.
Psychooncology 2011; 20(Suppl 2):91.

Yang 2011 {published data only}

Bourke 2011a {published data only}

*  Yang CY, Tsai JC, Huang YC, Lin CC. Effects of a home-based
walking program on perceived symptom and mood status
in postoperative breast cancer women receiving adjuvant
chemotherapy. Journal of Advanced Nursing 2011; 67(1):158-68.

Bourke L, Thompson G, Gibson D J, Daley A, Crank H, Adam I, et
al. Pragmatic lifestyle intervention in patients recovering from
colon cancer: a randomized controlled pilot study. Archives of
Physical Medicine and Rehabilitation 2011; 92(5):749-55.

References to studies excluded from this review

Aaronson 2011 {published data only}

Aaronson N, Duijts S, van Beurden M, Hunter M, Oldenburg H.
Cognitive behavioral therapy and physical exercise for
climacteric symptoms in breast cancer patients experiencing
treatment induced menopause: final results of a multicenter
randomized controlled trial. Psychooncology 2011; 20(Suppl
2):94-5.

Adamsen 2006 {published data only}

Adamsen L, Quist M, Midtgaard J, Andersen C, Moller T,
Knutsen L, et al. The effect of a multidimensional exercise
intervention on physical capacity, well-being and quality of life
in cancer patients undergoing chemotherapy. Supportive Care in
Cancer 2006; 14(2):116-27.

Aghili 2007 {published data only}

Aghili M, Farhan F, Rade M. A pilot study of the effects of
programmed aerobic exercise on the severity of fatigue in
cancer patients during external radiotherapy. European Journal
of Oncology Nursing 2007; 11(2):179-82.

Banasik 2011 {published data only}

Banasik J, Williams H, Haberman M, Blank SE, Bendel R.
Effect of Iyengar yoga practice on fatigue and diurnal salivary
cortisol concentration in breast cancer survivors. Journal of the
American Academy of Nurse Practitioners 2011; 23(3):135-42.

Baumann 2008 {published data only}

Baumann FT, Müller S, Krakowski-Roosen H, Knicker A,
Schneider J. Effects of resistance training during the
chemotherapy of breast cancer patients. Isokinetics and Exercise
Science 2008; 16(3):173.

Baumann 2011 {published data only}

Baumann FT, Zopf EM, Nykamp E, Kraut L, Schule K, Elter T,
et al. Physical activity for patients undergoing an allogeneic
hematopoietic stem cell transplantation: benefits of a moderate
exercise intervention. European Journal of Haematology 2011;
87(2):148-56.

Beurskens 2007 {published data only}

Beurskens CH, van Uden CJ, Strobbe LJ, Oostendorp RA,
Wobbes T. The efficacy of physiotherapy upon shoulder function
following axillary dissection in breast cancer, a randomized
controlled study. BMC Cancer 2007; 7:166.

Bloom 2011 {published data only}

Bloom J, Stewart S, Sellmeyer D, Oakley-Girvan I, Luce J. Early
results of the exercise for bone health in younger women with
breast cancer study: the effects of exercise on physical quality of

Box 2002 {published data only}

Box RC, Reul-Hirche HM, Bullock-Saxton JE, Furnival CM.
Shoulder movement after breast cancer surgery: results of a
randomised controlled study of postoperative physiotherapy.
Breast Cancer Research and Treatment 2002; 75(1):35-50.

Box 2009 {published data only}

Box R. Restriction of the range of arm elevation exercises for one
week after surgery for breast cancer can reduce the incidence
of lymphoedema. Australian Journal of Physiotherapy 2009;
55(1):64.

Carmack Taylor 2004 {published data only}

Carmack Taylor CL, Smith MA, de Moor C, Dunn AL, Pettaway C,
Sellin R, et al. Quality of life intervention for prostate cancer
patients: design and baseline characteristics of the active for life
after cancer trial. Controlled Clinical Trials 2004; 25(3):265-85.

Carmack Taylor 2006 {published data only}

Carmack Taylor CL, Demoor C, Smith MA, Dunn AL, Basen-
Engquist K, Nielsen I, et al. Active for Life After Cancer: a
randomized trial examining a lifestyle physical activity
program for prostate cancer patients. Psychooncology 2006;
15(10):847-62.

Carmack Taylor 2007 {published data only}

Carmack Taylor CL, de Moor C, Basen-Engquist K, Smith MA,
Dunn AL, Badr H, et al. Moderator analyses of participants in the
Active for Life after cancer trial: implications for physical activity
group intervention studies. Annals of Behavioral Medicine 2007;
33(1):99-104.

Chen 2010 {published data only}

Chen J, Luo A, He Y. Influence of postoperative rehabilitation
exercises on functional recovery of ill limb of breast cancer
patients. Chinese Nursing Research 2010; 24(4A):875-7.

Cho 2004 {published data only}

Cho OH. [Effects of a comprehensive rehabilitation program
for mastectomy patients]. Taehan Kanho Hakhoe Chi 2004;
34(5):809-19.

Cho 2006 {published data only}

Cho OH, Yoo YS, Kim NC. Efficacy of comprehensive group
rehabilitation for women with early breast cancer in South
Korea. Nursing and Health Sciences 2006; 8(3):140-6.

Crevenna 2003 {published data only}

Crevenna R, Zoch C, Keilani M, Quittan M, Fialka-Moser V.
Implementation of a physical rehabilitation group for post-
prostatectomy urinary incontinence patients and its effects

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

40

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

on quality of life. Physikalische Medizin Rehabilitationsmedizin
Kurortmedizin 2003; 13(6):339-44.

breast cancer. Chinese Journal of Clinical Rehabilitation 2006;
10(42):28-30.

Culos-Reed 2007 {published data only}

Duijts 2009 {published data only}

Culos-Reed SN, Robinson JL, Lau H, O'Connor K, Keats MR.
Benefits of a physical activity intervention for men with
prostate cancer. Journal of Sport and Exercise Psychology 2007;
29(1):118-27.

Daley 2004 {published data only}

Daley AJ, Mutrie N, Crank H, Coleman R, Saxton J. Exercise
therapy in women who have had breast cancer: design of the
Sheffield women's exercise and well-being project. Health
Education Research 2004; 19(6):686-97.

Daley 2007 {published data only}

Daley AJ, Crank H, Mutrie N, Saxton JM, Coleman R.
Determinants of adherence to exercise in women treated for
breast cancer. European Journal of Oncology Nursing 2007;
11(5):392-9.

Daley 2007a {published data only}

Daley AJ, Crank H, Saxton JM, Mutrie N, Coleman R, Roalfe A.
Randomized trial of exercise therapy in women treated for
breast cancer. Journal of Clinical Oncology 2007; 25(13):1713-21.

Daubenmier 2006 {published data only}

Daubenmier JJ, Weidner G, Marlin R, Crutchfield L, Dunn-
Emke S, Chi C, et al. Lifestyle and health-related quality of life
of men with prostate cancer managed with active surveillance.
Urology 2006; 67(1):125-30.

Demark-Wahnefried 2008 {published data only}

Demark-Wahnefried W, Case LD, Blackwell K, Marcom PK,
Kraus W, Aziz N, et al. Results of a diet/exercise feasibility trial
to prevent adverse body composition change in breast cancer
patients on adjuvant chemotherapy. Clinical Breast Cancer
2008; 8(1):70-9.

Dhillon 2011 {published data only}

Dhillon H, Parkes A, Boyers M, Horvath L, Clarke SJ, Vardy JL.
The impact of physical activity on fatigue and quality of life in
lung cancer patients (PAL study): one year screening results.
Journal of Thoracic Oncology 2011; 6(3, Suppl 1):S22.

Dimeo 1997 {published data only}

Dimeo F, Fetscher S, Lange W, Mertelsmann R, Keul J. Effects of
aerobic exercise on the physical performance and incidence of
treatment-related complications after high-dose chemotherapy.
Blood 1997; 90(9):3390-4.

Dimeo 2004 {published data only}

Dimeo FC, Thomas F, Raabe-Menssen C, Propper F, Mathias M.
Effect of aerobic exercise and relaxation training on fatigue
and physical performance of cancer patients after surgery. A
randomised controlled trial. Supportive Care in Cancer 2004;
12(11):774-9.

Dong 2006 {published data only}

, , Cai L. Correlation between quality of life and rehabilitative
guidance education in the postoperative patients with

Duijts SF, Oldenburg HS, van Beurden M, Aaronson NK.
Cognitive behavioral therapy and physical exercise for
climacteric symptoms in breast cancer patients experiencing
treatment-induced menopause: design of a multicenter trial.
BMC Women's Health 2009; 9:15.

Duijts 2009a {published data only}

Duijts S, Oldenburg H, van Beurden M, Gerritsma M, Nagtegaal T,
Aaronson N. Cognitive behavioral therapy (CBT) and physical
exercise for climacteric symptoms in breast cancer patients
experiencing treatment-induced menopause. Psychooncology
2009; 18(Suppl. 2):S72-3.

Duijts 2010 {published data only}

Duijts S, Oldenburg H, van Beurden M, Aaronson N. Cognitive
behavioral therapy and physical exercise for climacteric
symptoms in breast cancer patients experiencing treatment
induced menopause: first results of a multicenter trial.
Psychooncology 2010; 19(Suppl 2):S58-9.

Duijts 2010a {published data only}

Duijts S, Oldenburg H, van Beurden M, Aaronson N. Cognitive
behavioral therapy and physical exercise for climacteric
symptoms in breast cancer patients experiencing treatment-
induced menopause. European Journal of Cancer 2010; 8(3,
Suppl.):210.

Eyigor 2010 {published data only}

Eyigor S, Karapolat H, Yesil H, Uslu R, Durmaz B. Effects of
pilates exercises on functional capacity, flexibility, fatigue,
depression and quality of life in female breast cancer patients: a
randomized controlled study. European Journal of Physical and
Rehabilitation Medicine 2010; 46(4):481-7.

Frattaroli 2008 {published data only}

Frattaroli J, Weidner G, Dnistrian AM, Kemp C, Daubenmier JJ,
Marlin RO, et al. Clinical events in prostate cancer lifestyle
trial: results from two years of follow-up. Urology 2008;
72(6):1319-23.

Galantino 2003 {published data only}

Galantino ML, Capito L, Kane RJ, Ottey N, Switzer S, Packel L.
The effects of Tai Chi and walking on fatigue and body mass
index in women living with breast cancer: a pilot study.
Rehabilitation Oncology 2003; 21(1):17-22.

Galvao 2006 {published data only}

Galvao DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ,
McGuigan MR, et al. Resistance training and reduction of
treatment side effects in prostate cancer patients. Medicine and
Science in Sports and Exercise 2006; 38(12):2045-52.

Greenfield 2010 {published data only}

Greenfield RH. "Qigong Show" - MQ for Cancer Patients.
Alternative Medicine Alert 2010; 13(1):11.

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

41

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Guo 2004 {published data only}

Herold 2010 {published data only}

. Effects of moderate strength and endurance exercise on
emotion and quality of sleep in patients with malignant tumor.
Chinese Journal of Clinical Rehabilitation 2004; 8(35):7896-7.

Haines 2010 {published data only}

Haines TP, Sinnamon P, Wetzig NG, Lehman M, Walpole E,
Pratt T, et al. Multimodal exercise improves quality of life of
women being treated for breast cancer, but at what cost?
Randomized trial with economic evaluation. Breast Cancer
Research and Treatment 2010; 124(1):163-75.

Hartmann 2007 {published data only}

Hartmann U, Muche R, Reuss-Borst M. Effects of a step-by-step
inpatient rehabilitation programme on quality of life in breast
cancer patients. A prospective randomised study. Onkologie
2007; 30(4):177-82.

Hayes 2004 {published data only}

Hayes SC, Davies PS, Parker TW, Bashford J, Green A. Role of
a mixed type, moderate intensity exercise programme after
peripheral blood stem cell transplantation. British Journal of
Sports Medicine 2004; 38(3):304-9; discussion 309.

Herold J, Leskaroski A, Bloch W, Knicker A, Krakowski-Roosen H,
Warm M, et al. Results of a three months strength training of
breast cancer patients during chemotherapy on the symptom of
fatigue. Archives of Gynecology and Obstetrics 2010; 282(Suppl
1):S115.

Houborg 2006 {published data only}

Houborg KB, Jensen MB, Rasmussen P, Gandrup P, Schroll M,
Laurberg S. Postoperative physical training following colorectal
surgery: a randomised, placebo-controlled study. Scandinavian
Journal of Surgery 2006; 95(1):17-22.

Irwin 2008 {published data only}

Irwin ML, Cadmus L, Alvarez-Reeves M, O'Neil M, Mierzejewski E,
Latka R, et al. Recruiting and retaining breast cancer survivors
into a randomized controlled exercise trial: the Yale Exercise and
Survivorship Study. Cancer 2008; 112(11 Suppl):2593-606.

John 2007 {published data only}

John LD. Pilot study of a seated exercise intervention for lung
cancer patients: clinical significance. Oncology Nursing Forum
2007; 34(1):190.

Hayes 2011 {published data only}

Jones 2008 {published data only}

Hayes S, Rye S, Battistutta D, Yates P, Pyke C, Bashford J, et al.
Design and implementation of the Exercise for Health trial - a
pragmatic exercise intervention for women with breast cancer.
Contemporary Clinical Trials 2011; 32(4):577-85.

Jones LW, Eves ND, Peterson BL, Garst J, Crawford J, West MJ, et
al. Safety and feasibility of aerobic training on cardiopulmonary
function and quality of life in postsurgical nonsmall cell lung
cancer patients: a pilot study. Cancer 2008; 113(12):3430-9.

Heim 2007 {published data only}

Jones 2010 {published data only}

Heim ME, v d Malsburg ML, Niklas A. Randomized controlled
trial of a structured training program in breast cancer
patients with tumor-related chronic fatigue. Onkologie 2007;
30(8-9):429-34.

Heim 2011 {published data only}

Heim ME, Heim M, Nicklas A. Resistance training for cancer-
related fatigue: a controlled, randomized study. Onkologie 2011;
34(Suppl. 6):224.

Heislein 2009 {published data only}

Heislein DM, Bonanno AM. Effect of exercise on quality of life
and functional performance for patients undergoing treatment
for gastrointestinal cancer. Rehabilitation Oncology 2009;
27(1):3-8.

Henderson 2012 {published data only}

Henderson VP, Clemow L, Massion AO, Hurley TG, Druker S,
Hebert JR. The effects of mindfulness-based stress reduction on
psychosocial outcomes and quality of life in early-stage breast
cancer patients: a randomized trial. Breast Cancer Research and
Treatment 2012; 131(1):99-109.

Herdman 1995 {published data only}

Herdman SJ, Clendaniel RA, Mattox DE, Holliday MJ, Niparko JK.
Vestibular adaptation exercises and recovery: acute stage after
acoustic neuroma resection. Otolaryngology - Head and Neck
Surgery 1995; 113(1):77-87.

Jones LW, Eves ND, Kraus WE, Potti A, Crawford J,
Blumenthal JA, et al. The lung cancer exercise training study: a
randomized trial of aerobic training, resistance training, or both
in postsurgical lung cancer patients: rationale and design. BMC
Cancer 2010; 10:155.

Kampshoff 2010 {published data only}

Kampshoff CS, Buffart LM, Schep G, van Mechelen W, Brug J,
Chinapaw MJ. Design of the Resistance and Endurance exercise
After ChemoTherapy (REACT) study: a randomized controlled
trial to evaluate the effectiveness and cost-effectiveness of
exercise interventions after chemotherapy on physical fitness
and fatigue. BMC Cancer 2010; 10:658.

Kilbreath 2006 {published data only}

Kilbreath S, Refshauge K, Beith J, Lee MJ. Resistance and
stretching shoulder exercises early following axillary surgery for
breast cancer. Rehabilitation Oncology 2006; 24(2):9-14.

Kilbreath 2006a {published data only}

Kilbreath SL, Refshauge KM, Beith JM, Ward LC, Simpson JM,
Hansen RD. Progressive resistance training and stretching
following surgery for breast cancer: study protocol for a
randomised controlled trial. BMC Cancer 2006; 6:273.

Knols 2011 {published data only}

Knols RH, de Bruin ED, Uebelhart D, Aufdemkampe G, Schanz U,
Stenner-Liewen F, et al. Effects of an outpatient physical
exercise program on hematopoietic stem-cell transplantation

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

42

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

recipients: a randomized clinical trial. Bone Marrow Transplant
2011; 46(9):1245-55.

Koller 2006 {published data only}

Koller M, Klinkhammer-Schalke M, Ehret C, Steinger B,
Ernst B, Hofstadter F, et al. [Diagnosis and therapy of illness-
related quality of life in breast cancer patients. Protocol of a
randomized clinical trial at the Regensburg Tumour Centre].
Zeitschrift fur Arztliche Fortbildung und Qualitatssicherung 2006;
100(3):175-82.

Mathewson-Chapman 1997 {published data only}

Mathewson-Chapman M. Pelvic muscle exercise/biofeedback
for urinary incontinence after prostatectomy: an education
program. Journal of Cancer Education 1997; 12(4):218-23.

McClure 2010 {published data only}

McClure MK, McClure RJ, Day R, Brufsky AM. Randomized
controlled trial of the Breast Cancer Recovery Program for
women with breast cancer-related lymphedema. American
Journal of Occupational Therapy 2010; 64(1):59-72.

Korstjens 2008 {published data only}

McKenzie 2003 {published data only}

Korstjens I, May AM, van Weert E, Mesters I, Tan F, Ros WJ, et al.
Quality of life after self-management cancer rehabilitation: a
randomized controlled trial comparing physical and cognitive-
behavioral training versus physical training. Psychosomatic
Medicine 2008; 70(4):422-9.

Latka 2009 {published data only}

Latka RN, Alvarez-Reeves M, Cadmus L, Irwin ML. Adherence to a
randomized controlled trial of aerobic exercise in breast cancer
survivors: the Yale exercise and survivorship study. Journal of
Cancer Survivorship 2009; 3(3):148-57.

Lau 2010 {published data only}

Lau Y, Czaykowski P, Gingerich JR, Sathya J, Drachenberg D,
Kriellaars D, et al. The effect of a home-based walking exercise
program among men with prostate cancer receiving androgen
deprivation therapy: a feasibility trial. Journal of Clinical
Oncology 2010; 28(15):Suppl 1.

Lee 2007a {published data only}

Lee TS, Kilbreath SL, Refshauge KM, Pendlebury SC, Beith JM,
Lee MJ. Pectoral stretching program for women undergoing
radiotherapy for breast cancer. Breast Cancer Research and
Treatment 2007; 102(3):313-21.

Le Vu 1997 {published data only}

Le Vu B, Dumortier A, Guillaume MV, Mouriesse H, Barreau-
Pouhaer L. [Efficacy of massage and mobilization of the upper
limb after surgical treatment of breast cancer]. Bulletin du
Cancer 1997; 80(10):957-61.

MacVicar 1989 {published data only}

MacVicar MG, Winningham ML, Nickel JL. Effects of aerobic
interval training on cancer patients' functional capacity. Nursing
Research 1989; 38(6):348-51.

McKenzie DC, Kalda AL. Effect of upper extremity exercise on
secondary lymphedema in breast cancer patients: a pilot study.
Journal of Clinical Oncology 2003; 21(3):463-6.

Mehnert 2011 {published data only}

Mehnert A, Veers S, Howaldt D, Braumann KM, Koch U,
Schulz KH. Effects of a physical exercise rehabilitation group
program on anxiety, depression, body image, and health-
related quality of life among breast cancer patients. Onkologie
2011; 34(5):248-53.

Midtgaard 2005 {published data only}

Midtgaard J, Rorth M, Stelter R, Tveteras A, Andersen C, Quist M,
et al. The impact of a multidimensional exercise program
on self-reported anxiety and depression in cancer patients
undergoing chemotherapy: a phase II study. Palliative and
Supportive Care 2005; 3(3):197-208.

Mina 2010 {published data only}

Mina DS, Alibhai S, Pirbaglou M, Matthew A, Trachtenberg J,
Fleshner N, et al. Aerobic versus resistance exercise training
for prostate cancer patients on ADT. Psychooncology 2010;
19(Suppl. 2):S196.

Newton 2011 {published data only}

Newton MJ, Hayes SC, Janda M, Webb PM, Obermair A,
Eakin EG, et al. Safety, feasibility and effects of an individualised
walking intervention for women undergoing chemotherapy for
ovarian cancer: a pilot study. BMC Cancer 2011; 11:389.

O'Brien 2003 {published data only}

O'Brien AR. The impact of physical activity on quality of life,
depression, and anxiety in breast cancer patients undergoing
treatment. Dissertation Abstracts International: Section B: The
Sciences and Engineering 2003; 64(5-B):2397.

Manassero 2007 {published data only}

Park 2006 {published data only}

Manassero F, Traversi C, Ales V, Pistolesi D, Panicucci E,
Valent F, et al. Contribution of early intensive prolonged pelvic
floor exercises on urinary continence recovery after bladder
neck-sparing radical prostatectomy: results of a prospective
controlled randomized trial. Neurourology Urodynamics 2007;
26(7):985-9.

Marchese 2004 {published data only}

Marchese VG, Chiarello LA, Lange BJ. Effects of physical therapy
intervention for children with acute lymphoblastic leukemia.
Pediatric Blood and Cancer 2004; 42(2):127-33.

Park HS, Cho GY, Park KY. [The effects of a rehabilitation
program on physical health, physiological indicator and quality
of life in breast cancer mastectomy patients]. Taehan Kanho
Hakhoe Chi 2006; 36(2):310-20.

Patel 2005 {published data only}

Patel SR. The effects of yoga on mood disturbance and pain
in an underserved breast cancer population. Dissertation
Abstracts International: Section B: The Sciences and
Engineering 2005; 66(2-B):1181.

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

43

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Peddle 2009 {published data only}

Schwartz 2000 {published data only}

Peddle CJ, Jones LW, Eves ND, Reiman T, Sellar CM, Winton T,
et al. Effects of presurgical exercise training on quality of life in
patients undergoing lung resection for suspected malignancy: a
pilot study. Cancer Nursing 2009; 32(2):158-65.

Penttinen 2009 {published data only}

Penttinen H, Nikander R, Blomqvist C, Luoto R, Saarto T.
Recruitment of breast cancer survivors into a 12-month
supervised exercise intervention is feasible. Contemporary
Clinical Trials 2009; 30(5):457-63.

Persoon 2010 {published data only}

Persoon S, Kersten MJ, Chinapaw MJ, Buffart LM, Burghout H,
Schep G, et al. Design of the EXercise Intervention after Stem
cell Transplantation (EXIST) study: a randomized controlled
trial to evaluate the effectiveness and cost-effectiveness of
an individualized high intensity physical exercise program on
fitness and fatigue in patients with multiple myeloma or (non-)
Hodgkin's lymphoma treated with high dose chemotherapy and
autologous stem cell transplantation. BMC Cancer 2010; 10:671.

Pickett 2002 {published data only}

Pickett M, Mock V, Ropka ME, Cameron L, Coleman M,
Podewils L. Adherence to moderate-intensity exercise during
breast cancer therapy. Cancer Practice 2002; 10(6):284-92.

Pinto 2003 {published data only}

Pinto BM, Clark MM, Maruyama NC, Feder SI. Psychological and
fitness changes associated with exercise participation among
women with breast cancer. Psychooncology 2003; 12(2):118-26.

Pinto 2005 {published data only}

Pinto BM, Frierson GM, Rabin C, Trunzo JJ, Marcus BH. Home-
based physical activity intervention for breast cancer patients.
Journal of Clinical Oncology 2005; 23(15):3577-87.

Roscoe 2005 {published data only}

Roscoe JA, Matteson SE, Mustian KM, Padmanaban D,
Morrow GR. Treatment of radiotherapy-induced fatigue through
a nonpharmacological approach. Integrative Cancer Therapies
2005; 4(1):8-13.

San Juan 2008 {published data only}

San Juan AF, Chamorro-Vina C, Moral S, Fernandez del
Valle M, Madero L, Ramirez M, et al. Benefits of intrahospital
exercise training after pediatric bone marrow transplantation.
International Journal of Sports Medicine 2008; 29(5):439-46.

Scheier 2005 {published data only}

Scheier MF, Helgeson VS, Schulz R, Colvin S, Berga S,
Bridges MW, et al. Interventions to enhance physical and
psychological functioning among younger women who are
ending nonhormonal adjuvant treatment for early-stage breast
cancer. Journal of Clinical Oncology 2005; 23(19):4298-311.

Schwartz 1999 {published data only}

Schwartz AL. Daily fatigue patterns and effect of exercise in
women with breast cancer. Cancer Practice 2000; 8(1):16-24.

Schwartz 2009 {published data only}

Schwartz AL, Winters-Stone K. Effects of a 12-month
randomized controlled trial of aerobic or resistance exercise
during and following cancer treatment in women. Physician and
Sportsmedicine 2009; 37(3):62-7.

Sekse 2011 {published data only}

Sekse RJT, Hausmann F, Iversen V, Ncsheim-Bjørkvik G,
Tengesdal E, Bjerke A, et al. Rehabilitation of women following
treatment for gynaecological cancer: a randomized, controlled
study - a description of a multicenter study and experiences so
far. Psychooncology 2011; 20(Suppl 2):236-7.

Shelton 2009 {published data only}

Shelton ML, Lee JQ, Morris GS, Massey PR, Kendall DG,
Munsell MF, et al. A randomized control trial of a supervised
versus a self-directed exercise program for allogeneic stem cell
transplant patients. Psychooncology 2009; 18(4):353-9.

Stephenson 2000 {published data only}

Stephenson NL, Weinrich SP, Tavakoli AS. The effects of foot
reflexology on anxiety and pain in patients with breast and lung
cancer. Oncology Nursing Forum 2000; 27(1):67-72.

Thorsen 2005 {published data only}

Thorsen L, Skovlund E, Stromme SB, Hornslien K, Dahl AA,
Fossa SD. Effectiveness of physical activity on cardiorespiratory
fitness and health-related quality of life in young and middle-
aged cancer patients shortly after chemotherapy. Journal of
Clinical Oncology 2005; 23(10):2378-88.

Todd 2008 {published data only}

Todd J, Scally A, Dodwell D, Horgan K, Topping A. A randomised
controlled trial of two programmes of shoulder exercise
following axillary node dissection for invasive breast cancer.
Physiotherapy 2008; 94(4):265-72.

Turner 2004 {published data only}

Turner J, Hayes S, Reul-Hirche H. Improving the physical status
and quality of life of women treated for breast cancer: a pilot
study of a structured exercise intervention. Journal of Surgical
Oncology 2004; 86(3):141-6.

Ulger 2010 {published data only}

Ulger O, Yagli NV. Effects of yoga on the quality of life in cancer
patients. Complementary Therapies in Clinical Practice 2010;
16(2):60-3.

Vallance 2008 {published data only}

Vallance JK, Courneya KS, Plotnikoff RC, Dinu I, Mackey JR.
Maintenance of physical activity in breast cancer survivors after
a randomized trial. Medicine and Science in Sports and Exercise
2008; 40(1):173-80.

Schwartz AL. Fatigue mediates the effects of exercise on quality
of life. Quality of Life Research 1999; 8(6):529-38.

Vardy 2010 {published data only}

Vardy J, Dhillon H, Van Der Ploeg H, Goddard E, Clarke S,
Spencer L, et al. CHALLENGE: a phase III study of a physical

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

44

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

activity program on disease-free survival in patients with high
risk stage II/III colon cancer. Asia-Pacific Journal of Clinical
Oncology 2010; 6(Suppl 3):186.

References to ongoing studies

Christensen 2011 {published data only}

von Gruenigen 2009 {published data only}

von Gruenigen VE, Gibbons HE, Kavanagh MB, Janata JW,
Lerner E, Courneya KS. A randomized trial of a lifestyle
intervention in obese endometrial cancer survivors: quality of
life outcomes and mediators of behavior change. Health and
Quality of Life Outcomes 2009; 7:17.

von Gruenigen 2011 {published data only}

von Gruenigen VE, Frasure HE, Kavanagh MB, Lerner E,
Waggoner SE, Courneya KS. Feasibility of a lifestyle intervention
for ovarian cancer patients receiving adjuvant chemotherapy.
Gynecologic Oncology 2011; 122(2):328-33.

Wang 2005 {published data only}

Wang Y, , . (Effect of rehabilitation exercises on the recovery
outcomes of lung function in postoperative patients with
lung cancer) [Chinese - simplified characters]. Zhongguo
Linchuang Kangfu [Chinese Journal of Clinical Rehabilitation]
2005; 9(24):66-8.

Xie 2010 {published data only}

Xie X, Liu Z, Qu S, Guo F, Zheng Z, Liu Y, et al. 169 patients with
postoperative breast cancer on exercising the function of limbs
and investigating quality of life: a clinical study. Chinese-German
Journal of Clinical Oncology 2010; 9(10):590-3.

Zhang 2006 {published data only}

Zhang AY, Strauss GJ, Siminoff LA. Intervention of urinary
incontinence and quality of life outcome in prostate cancer
patients. Journal of Psychosocial Oncology 2006; 24(2):17-30.

References to studies awaiting assessment

Courneya 2001 {published data only}

Courneya KS, Friedenreich HA, Quinney HA, Fields ALA.
Baseline relationships between exercise and quality of life
in colorectal cancer patients participating in a randomized
exercise trial. Journal of Sport and Exercise Psychology 2001;
23(2 Supplement):S40.

Harandi 2010 {published data only}

Harandi TF, Ghofranipour F, Anoosheh M, Montazeri A. A home-
based exercise therapy and quality of life in breast cancer
patients: an experimental study. Supportive Care in Cancer 2010;
18(Suppl 3):S208.

Sun 2009 {published data only}

*  Sun H, Zhu Y, Xu X. A study on exercise interventions for
postoperative breast cancer patients with fatigue [Chinese].
Chinese Nursing Research 2009; 23(10B):2655-6.

Utz-Billing 2010 {published data only}

Utz-Billing I, Rosemeyer M. Yoga supports physical and mental
well-being after breast cancer surgery. Journal of Psychosomatic
Obstetrics and Gynecology 2010; 31(Suppl. 1):125.

*  Christensen JF, Andersen JL, Adamsen L, Lindegaard B,
Mackey AL, Nielsen RH, et al. Progressive resistance training
and cancer testis (PROTRACT) - efficacy of resistance training
on muscle function, morphology and inflammatory profile in
testicular cancer patients undergoing chemotherapy: design of
a randomized controlled trial. BMC Cancer 2011; 11:326.

Galvao 2009 {published data only}

Galvao DA, Spry N, Taaffe DR, Denham J, Joseph D, Lamb DS,
et al. A randomized controlled trial of an exercise intervention
targeting cardiovascular and metabolic risk factors for prostate
cancer patients from the RADAR trial. BMC Cancer 2009; 9:419.

Haseen 2010 {published data only}

*  Haseen F, Murray LJ, O'Neill RF, O'Sullivan JM, Cantwell MM.
A randomised controlled trial to evaluate the efficacy of a 6
month dietary and physical activity intervention for prostate
cancer patients receiving androgen deprivation therapy. Trials
2010; 11:86.

Newton 2009 {published data only}

Newton RU, Taaffe DR, Spry N, Galvao DA. Initiating exercise
therapy and LHRHa simultaneously to reduce toxicity induced
declines in structure and function in men with prostate cancer.
BJU International 2010; 105:31.

*  Newton RU, Taaffe DR, Spry N, Gardiner RA, Levin G, Wall B, et
al. A phase III clinical trial of exercise modalities on treatment
side-effects in men receiving therapy for prostate cancer. BMC
Cancer 2009; 9:210.

van Waart 2010 {published data only}

*  van Waart H, Stuiver MM, van Harten WH, Sonke GS,
Aaronson NK. Design of the Physical exercise during Adjuvant
Chemotherapy Effectiveness Study (PACES): a randomized
controlled trial to evaluate effectiveness and cost-effectiveness
of physical exercise in improving physical fitness and reducing
fatigue. BMC Cancer 2010; 10:673.

Velthuis 2010 {published data only}

*  Velthuis MJ, May AM, Koppejan-Rensenbrink RA, Gijsen BC,
van Breda E, de Wit GA, et al. Physical Activity during Cancer
Treatment (PACT) study: design of a randomised clinical trial.
BMC Cancer 2010; 10:272.

Additional references

American College of Sports Medicine 1998

American College of Sports Medicine. Position stand: the
recommended quantity and quality of exercise for developing
and maintaining cardiorespiratory and muscular fitness, and
flexibility in health adults. Medicine and Science in Sports and
Exercise 1998; 30(6):975-91.

American College of Sports Medicine 2005

American College of Sports Medicine. ACSM's Guidelines for
Exercise Testing and Prescription. 7th edition. Philadelphia:
Lippincott Williams & Wilkins, 2005.

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

45

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Aziz 2002

Cramp 2008

Aziz NM. Cancer survivorship research: challenge
and opportunity. Journal of Nutrition 2002; 132(11
Suppl):3494S-503S.

Cramp F, Daniel J. Exercise for the management of cancer-
related fatigue in adults. Cochrane Database of Systematic
Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD006145.pub2]

Aziz 2003

Cramp 2010

Aziz NM, Rowland JH. Trends and advances in cancer
survivorship research: challenge and opportunity. Seminars in
Radiation Oncology 2003; 13(3):248-66.

Cramp F, James A, Lambert J. The effects of resistance training
on quality of life in cancer: a systematic literature review and
meta-analysis. Supportive Care in Cancer 2010; 18:1367-76.

Aziz 2007

Demark-Wahnefried 2000

Aziz NM. Cancer survivorship research: state of knowledge,
challenges and opportunities. Acta Oncologica 2007;
46(4):417-32.

Aziz 2008

Aziz NM, Bellizzi K. Older survivors and cancer care. Journal of
the National Cancer Institute 2008; 100(1):4-5.

Blanchard 2003

Blanchard CM, Denniston MM, Baker F, Ainsworth SR,
Courneya KS, Hann DM, et al. Do adults change their lifestyle
behaviors after a cancer diagnosis? American Journal of Health
Behavior 2003; 27(3):246-56.

Bottomley 2002

Demark-Wahnefried W, Peterson B, McBride C, Lipkus I, Clipp E.
Current health behaviors and readiness to pursue life-style
changes among men and women diagnosed with early stage
prostate and breast carcinomas. Cancer 2000; 88(3):674-84.

Demark-Wahnefried 2005

Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM. Riding
the crest of the teachable moment: promoting long-term health
after the diagnosis of cancer. Journal of Clinical Oncology 2005;
23(24):5814-30.

Diener 2000

Diener E. Subjective well-being. The science of happiness and
a proposal for a national index. American Psychologist 2000;
55(1):34-43.

Bottomley A. The cancer patient and quality of life. Oncologist
2002; 7(2):120-5.

Duijts 2011

Bradt 2011

Bradt J, Dileo C. Dance/movement therapy for improving
psychological and physical outcomes in cancer patients.
Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI:
10.1002/14651858.CD007103]

Cella 2010

Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, et al.
The Patient-Reported Outcomes Measurement Information
System (PROMIS) developed and tested its first wave of adult
self-reported health outcome item banks: 2005-2008. Journal of
Clinical Epidemiology 2010; 63(11):1179-94.

Courneya 2003b

Courneya KS, Friedenreich CM, Quinney HA, Fields AL, Jones LW,
Fairey AS. A randomized trial of exercise and quality of life in
colorectal cancer survivors. European Journal of Cancer Care
(English Language Edition) 2003; 12(4):347-57.

Courneya 2007b

Courneya KS, Friedenreich CM. Physical activity and cancer
control. Seminars in Oncology Nursing 2007; 23(4):242-52.

Craft 2011

Duijts SFA, Faber MM, Oldenburg HSA, van Beurden M.
Effectiveness of behavioral techniques and physical exercise
on psychosocial functioning and health-related quality of
life in breast cancer patients and survivors - a meta-analysis.
Psychooncology 2011 2011; 20:115-26.

Efficace 2006

Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T,
Schoffski P, et al. Does a patient's self-reported health-related
quality of life predict survival beyond key biomedical data in
advanced colorectal cancer? European Journal of Cancer 2006;
42(1):42-9.

Ferrans 2005

Ferrans CE. Definitions and conceptual models of quality of
life. In: Lipscomb J, Gotay CC, Snyder C, editors(s). Outcomes
Assessment in Cancer: Measures, Methods, and Applications.
New York, NY: Cambridge University Press, 2005:14-30.

Ferrer 2011

Ferrer RA, Huedo-Medina TB, Johnson BT, Ryan S, Pescatello LS.
Exercise interventions for cancer survivors: a meta-analysis of
quality of life outcomes. Annals of Behavioral Medicine 2011;
41:32-47.

Craft LL, Vanlterson EH, Helenowski IB, Rademaker AW,
Courneya KS. Exercise effects on depressive symptoms in
cancer survivors: a systematic review and meta-analysis. Cancer
Epidemiology, Biomarkers & Prevention 2011; 21(1):3-19.

Galvao 2005

Galvao DA, Newton RU. Review of exercise intervention
studies in cancer patients. Journal of Clinical Oncology 2005;
23(4):899-909.

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

46

Ganz 2004

Ganz PA, Kwan L, Stanton AL, Krupnick JL, Rowland JH,
Meyerowitz BE, et al. Quality of life at the end of primary

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

treatment of breast cancer: first results from the moving beyond
cancer randomized trial. Journal of the National Cancer Institute
2004; 96(5):376-87.

Glanville 2006

Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to
identify randomized controlled trials in MEDLINE: ten years on.
Journal of the Medical Library Association 2006; 94(2):130-6.

Gotay 1992

Gotay CC, Korn EL, McCabe MS, Moore TD, Cheson BD. Quality-
of-life assessment in cancer treatment protocols: research
issues in protocol development. Journal of the National Cancer
Institute 1992; 84(8):575-9.

Gotay 2008

Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic
significance of patient-reported outcomes in cancer clinical
trials. Journal of Clinical Oncology 2008; 26(8):1355-63.

Higgins 2011

Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing
risk of bias in included studies. In: Higgins JPT, Green S
(editors). Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0 [updated March 2011]. The
Cochrane Collaboration, 2011. Available from: www.cochrane-
handbook.org.

Ingram 2007

Ingram C, Visovsky C. Exercise intervention to modify
physiologic risk factors in cancer survivors. Seminars in
Oncology Nursing 2007; 23(4):275-84.

Jones 2004

McAuley 2000

McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of
grey literature influence estimates of intervention effectiveness
reported in meta-analyses? Lancet 2000; 356:1228-31.

McNeely 2006

McNeely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR,
Courneya KS. Effects of exercise on breast cancer patients and
survivors: a systematic review and meta-analysis. Canadian
Medical Association Journal 2006; 175(1):34-41.

Mishra 2009

Mishra SI, Aziz NM, Scherer RW, Baquet CR, Berlanstein DR,
Geigle PM. Exercise interventions on health related quality
of life for cancer survivors. Cochrane Database of Systematic
Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD007566]

Moher 2009

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting
Items for Systematic Reviews and Meta-Analyses: the PRISMA
statement. PLoS Medicine 2009; 6:e1000097. [DOI: 10.1371/
journal.pmed1000097]

Mustian 2007

Mustian KM, Morrow GR, Carroll JK, Figuero-Moseley CD, Jean-
Pierre P, Williams GC. Integrative nonpharmacologic behavioral
interventions for the management of cancer-related fatigue.
The Oncologist 2007; 12(suppl 1):52-67.

National Cancer Institute 2012

National Cancer Institute. Patient Reported Outcomes
Measurement Information System (PROMIS). Available at:
www.nihpromis.org.

Jones LW, Courneya KS, Vallance JK, Ladha AB, Mant MJ,
Belch AR, et al. Association between exercise and quality of life
in multiple myeloma cancer survivors. Supportive Care in Cancer
2004; 12(11):780-8.

Osoba 1994

Osoba D. Lessons learned from measuring health-related
quality of life in oncology. Journal of Clinical Oncology 1994;
12(3):608-16.

Kapur 2009

Osoba 1999

Kapur G, Windsor PM, McCowan C. The effect of aerobic exercise
on treatment-related acute toxicity in men receiving radical
external beam radiotherapy for localized prostate cancer.
European Journal of Cancer Care 2010; 19(5):643-7.

Knols 2005

Knols R, Aaronson NK, Uebelhart D, Fransen J, Aufdemkampe G.
Physical exercise in cancer patients during and after medical
treatment: a systematic review of randomized and controlled
clinical trials. Journal of Clinical Oncology 2005; 23(16):3830-42.

Lee 2007b

Lee MK, Son BH, Hwang SY, Han W, , Lee S, et al. Factors
affecting health-related quality of life in women with recurrent
breast cancer in Korea. Quality of Life Research 2007; 16:559-69.

Lipscomb 2007

Lipscomb J, Gotay CC, Snyder CF. Patient-reported outcomes in
cancer: a review of recent research and policy initiatives. CA: A
Cancer Journal for Clinicians 2007; 57(5):278-300.

Osoba D. What has been learned from measuring health-related
quality of life in clinical oncology. European Journal of Cancer
1999; 35(11):1565-70.

Osoba 2007

Osoba D. Health-related quality of life and predicting survival
in cancer: not a simple matter. Supportive Care in Cancer 2007;
15(4):353-5.

RevMan 2011 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration
Review Manager (RevMan). Version 5.1. Copenhagen: The
Nordic Cochrane Centre, The Cochrane Collaboration, 2011.

Rogers 2006

Rogers LQ, Courneya KS, Robbins KT, Malone J, Seiz A, Koch L, et
al. Physical activity and quality of life in head and neck cancer
survivors. Supportive Care in Cancer 2006; 14(10):1012-9.

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

47

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Rowland 2011

Stull 2007

Rowland JH, Mariotto A, Alfano CM, Pollack LA, Weir HK,
White A. Cancer survivors - United States, 2007. Morbidity and
Mortality Weekly Report (MMWR) 2011; 60(9):269-72.

Schmitz 2005

Schmitz KH, Holtzman J, Courneya KS, Masse LC, Duval S,
Kane R. Controlled physical activity trials in cancer survivors:
a systematic review and meta-analysis. Cancer Epidemiology,
Biomarkers and Prevention 2005; 14(7):1588-95.

Speck 2010

Stull VB, Snyder DC, Demark-Wahnefried W. Lifestyle
interventions in cancer survivors: designing programs that meet
the needs of this vulnerable and growing population. Journal of
Nutrition 2007; 137(1 Suppl):243S-8S.

Thorsen 2008

Thorsen L, Courneya KS, Stevinson C, Fossa SD. A systematic
review of physical activity in prostate cancer survivors:
outcomes, prevalence, and determinants. Supportive Care in
Cancer 2008; 16(9):987-97.

Speck RM, Courneya KS, Masse LC, Duval S, Schmitz KH. An
update of controlled physical activity trials in cancer survivors:
a systematic review and meta-analysis. Journal of Cancer
Survivorship 2010; 4(2):87-100.

Valenti 2008

Valenti M, Porzio G, Aielli F, Verna L, Cannita K, Manno R, et al.
Physical exercise and quality of life in breast cancer survivors.
International Journal of Medical Sciences 2008; 5(1):24-8.

Speck 2010a

Vallance 2005

Speck RM, Courneya KS, Masse LC, Duval S, Schmitz KH. An
update of controlled physical activity trials in cancer survivors:
a systematic review and meta-analysis. Journal of Cancer
Survivorship 2010; 4:87-100.

Vallance JK, Courneya KS, Jones LW, Reiman T. Differences in
quality of life between non-Hodgkin's lymphoma survivors
meeting and not meeting public health exercise guidelines.
Psycho-Oncology 2005; 14(11):979-91.

Sterne 2011

Velthuis 2010a

Sterne JAC, Matthias E, . Chapter 10: Addressing reporting bias.
In: Higgins JPT, Green S, editors(s). Cochrane Handbook for
Systematic Reviews of Interventions, Version 5.1.0 (updated
March 2011). The Cochrane Collaboration, 2011 Available at:
www.cochrane-handbook.org.

Stevinson 2004

Stevinson C, Lawlor DA, Fox KR. Exercise interventions for
cancer patients: systematic review of controlled trials. Cancer
Causes and Control 2004; 15(10):1035-56.

Velthuis MJ, Agasi-Idenburg SC, Aufdemkampe G, Wittink HM.
The effect of physical exercise on cancer-related fatigue during
cancer treatment: a meta-analysis of randomized controlled
trials. Clinical Oncology 2010; 22(3):208-21.

Warburton 2006

Warburton DE, Nicol CW, Bredin SS. Health benefits of physical
activity: the evidence. Canadian Medical Association Journal
2006; 174(6):801-9.

Stewart 2003

* Indicates the major publication for the study

Stewart BW, Kleihues P, . World Cancer Report. Lyon, France:
World Health Organization, International Agency for Research
on Cancer, 2003.

C H A R A C T E R I S T I C S   O F   S T U D I E S

Characteristics of included studies [ordered by study ID]

Adamsen 2009 

Study characteristics

Methods

Study design: RCT

Number randomized: 269; 135 to the exercise group and 134 to the control group

Study start and stop dates: participants recruited from March 2004 to March 2007

Length of intervention: 6 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: various

Participants had 21 different cancer diagnoses, including 17 solid tumors (i.e. cancer of the breast,
bowel, ovaries, testes, esophagus, brain, cervix, pharynx, pancreas, stomach, and other), and 4 hema-

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

48

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Adamsen 2009  (Continued)

Cochrane Database of Systematic Reviews

tologic malignancies (i.e. Hodgkin lymphoma, NHL(Non-Hodgkin’s lymphoma), acute leukemia, and
chronic leukemia)

Time since cancer diagnosis, median (range) days:

• exercise group: 83 (34 to 280) days
• control group: 89.5 (31 to 271) days

Time beyond active treatment: not reported

Inclusion criteria:

• had received at least 1 cycle of chemotherapy for advance disease or as adjuvant disease
• 18 to 65 years old

Eligibility criteria related to interest, ability to exercise, or both:

• had a WHO performance status of 0 or 1

Exclusion criteria:

• people with brain or bone metastases, thrombocytopenia (< 50 x 109/L), myocardial infraction within

the past 3 months, or uncontrolled hypertension (diastolic pressure > 95 mm Hg)

Gender, n (%):

• exercise group: male, 34 (25.2%); female, 101 (74.8%)
• control group: male, 39 (29.1%); female, 95 (70.9%)

Current age, mean (SD) years

• exercise group: 47.2 (10.7) years
• control group: 47.2 (10.6) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level; completed secondary school or higher, n (%)

• exercise group: 104 (77.0)
• control group: 106 (79.7)

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history; physical activity level pre-illness, n (%)

• exercise group: sedentary, 10 (7.5%); walking or cycling for pleasure, 40 (30.1%); regular physical ex-

ercise (at least 3 hours/week), 74 (55.6%); intense physical activity (> 4 hours/week), 9 (6.8%)

• control group: sedentary, 5 (4.0%); walking or cycling for pleasure, 34 (27.0%); regular physical exer-

cise, 75 (59.5%); intense physical activity 12 (9.5%)

On hormone therapy: not reported

Interventions

135 participants assigned to the exercise intervention, including:

• high- and low-intensity activities, including:

* high intensity: Mondays, Wednesdays, and Fridays in high-intensity physical training for 90 minutes
followed by 30 minutes relaxation training. The program included 90 minutes of body awareness

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

49

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Adamsen 2009  (Continued)

Cochrane Database of Systematic Reviews

*

followed by 30 minutes of relaxation training on Tuesdays. The participants received 30 minutes
of massage on Mondays and Fridays
low-intensity physical training comprised 3 psychosocial components: relaxation (30 minutes 4
times per week), body awareness and restorative training (90 minutes once per week), and mas-
sage (30 minutes twice per week).

Type exercise (aerobic/anaerobic): aerobic and anaerobic

Intensity of the exercise intervention: the intervention activities were equivalent to a total of 43 meta-
bolic equivalent of task (MET) hours per week

Frequency: 9 hours per week

Duration of individual sessions: 90 minutes for high intensity, 30 minutes for low-intensity exercise

Duration of exercise program: 6 weeks

Total number of exercise sessions: 24 sessions (3 sessions per week for 6 weeks)

Format: group

Facility: facility based

Professionally led: professionally led by trained nurse specialists and physical therapists

Adherence: 70.8%

134 participants assigned to control group, including:

• usual care

Contamination of control group: not reported

Outcomes

Primary outcome included:

• fatigue, assessed using the EORTC QLQ-C30

Other outcomes included subscales of the QLQ C-30, including:

• global health status/QoL
• physical functioning
• role functioning
• emotional functioning
• cognitive functioning
• social functioning
• pain

Additional HRQoL outcomes included subscales from the MOS SF-36, including:

• physical functioning
• role physical
• bodily pain
• vitality
• social functioning
• role emotional
• mental health
• physical component scale
• mental component scale

Outcomes were measured at baseline and at 6 weeks:

• exercise group: n = 135 at baseline, n = 118 at 6 weeks

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

50

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Adamsen 2009  (Continued)

• control group: n = 134 at baseline, n = 117 at 6 weeks

Subgroup analysis: none conducted or specified

Adverse events: not reported

Notes

Country: Denmark

Cochrane Database of Systematic Reviews

Funding: The Lundbeck Foundation, The Novo Nordic Foundation, The Egmont Foundation, The Dan-
ish Cancer Society, The Svend Andersen Foundation, The Aase and Ejnar Danielsen Foundation, The
Beckett Foundation, The Wedell-Wedellsborg Foundation, The Hede Nielsen Family Foundation, The
Gangsted Foundation, Copenhagen University Hospital

Authors' judgement

Support for judgement

Low risk

Randomization was done by computer (CITMAS)

Low risk

The allocation sequence was executed by the clinical research unit

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

Allocation to the intervention was not concealed from the study personnel

Low risk

Missing outcome data were assumed to be missing at random

Low risk

There appears to be no selective reporting of outcomes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Other bias

High risk

Since the control group was allowed to engage in or increase levels of physical
activity, this could bias the effect of the overall intervention. Further, it is un-
clear whether there was a possibility of contamination of the control group

Arbane 2009 

Study characteristics

Methods

Study design: RCT

Number randomized: 51; 25 to the exercise group and 26 to the control group

Study start and stop dates: not reported

Length of intervention: 12 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: lung cancer

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

51

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Arbane 2009  (Continued)

Cochrane Database of Systematic Reviews

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Inclusion criteria:

• attending thoracotomy for lung cancer

Eligibility criteria related to interest or ability, or both, to exercise:

• none reported

Exclusion criteria:

• none reported

Gender: male

Current age, mean (range) years: 64 (32 to 82) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level: not reported

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Interventions

Number of participants assigned to the exercise intervention: not reported. The intervention included:

• twice daily training plus usual care during hospital stay. After discharge monthly home visits and week-

ly telephone calls

Type exercise (aerobic/anaerobic): unclear

Intensity of the experimental exercise intervention: not reported

Frequency: twice per day at the clinic and monthly home visits

Duration of individual sessions: not reported

Duration of exercise program: 12 weeks

Total number of exercise sessions: not reported

Format: unclear, appears to be individual

Facility: unclear

Professionally led: not reported

Adherence: not reported

Number of participants assigned to control group: not reported. The control included:

• usual care

Contamination of control group: not reported

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

52

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Arbane 2009  (Continued)

Outcomes

No primary outcome was identified.

QoL outcomes included:

• global HRQoL, assessed using QLQ-C30

Other outcomes included:

• quadriceps strength, assessed using magnetic stimulation
• 6-minute walking distance

Outcomes were measured at baseline 5 days and 12 weeks. The number of participants in groups at
time points was not reported

Subgroup analysis: none

Adverse events: not reported

Notes

Country: UK

Funding: none reported

Published as abstract

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

The generation of the random sequence was not described

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

Allocation to the intervention was not concealed from the study personnel

Unclear risk

Insufficient details provided to determine whether there was any attrition

Selective reporting (re-
porting bias)

Unclear risk

Insufficient details provided to assess whether there was selective outcome re-
porting

Other bias

High risk

The small sample size, lack of description of the recruitment and selection of
study participants, lack of identification of a primary outcome could give rise
to additional biases

Banerjee 2007 

Study characteristics

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

53

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Banerjee 2007  (Continued)

Methods

Study design: RCT

Cochrane Database of Systematic Reviews

Number randomized: 68; 35 to the exercise group and 33 to the control group

Study start and stop dates: not reported

Length of intervention: 6 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: breast cancer

Stage, n (%)

• exercise group: Stage II, 16 (46%); Stage III, 19 (54%)
• control group: Stage II, 10 (43%); Stage III, 13 (57%)

Time since cancer diagnosis: not reported

Time in active treatment: all patients received 6 weeks of radiation therapy for a total dosage of 50.4
Gy. Some patients apparently received concurrent chemotherapy but how many is not stated since
previous chemotherapy and current concomitant chemotherapy are not distinguished

Inclusion criteria:

• "recently operated breast cancer" (not further specified)
• 30 to 70 years old
• Zubrod performance status 0 to 2 (ambulatory > 50% of time)
• 'high school' education
• treatment plan of radiation therapy or both adjuvant radiation therapy and chemotherapy
• consent to participate

Eligibility criteria related to interest or ability, or both, to exercise:

• none

Exclusion criteria:

• concurrent medical condition likely to interfere with the treatment
• major psychiatric disorder, neurologic illness, or autoimmune disorder
• cardiovascular illness
• known metastases
• exposure to other mutagens, smoking, or alcohol within 3 months of pre-radiation blood donation

Gender: female

Current age, mean (SD) years:

• exercise group: 47 (1.1) years
• control group: 43 (1.5) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level: all required to have completed 'high school'

SES: not reported

Employment status: not reported

Comorbidities: not reported

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

54

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Banerjee 2007  (Continued)

Past exercise history: not reported

On hormone therapy: not reported

Interventions

35 participants assigned to the exercise intervention, including:

• integrated yoga program
• special  techniques  for  cancer  patients,  including  guided  imagery  of  cancer  cells,  positive  thought

provocations, and chanting of various sounds

Type exercise (aerobic/anaerobic): aerobic and anaerobic

Intensity of the experimental exercise intervention: not reported

Frequency: not reported

Duration of individual sessions: 90 minutes

Duration of exercise program: 6 weeks

Total number of exercise sessions: not reported

Format: group

Facility: facility and home practice

Professionally led: professionally led by yoga instructors and trainers

Adherence: not reported

33 participants assigned to control group, including:

• supportive counseling and advised to "take light exercise" - described as going on for 6 weeks but no

further information provided

Contamination of control group: not reported

Outcomes

No primary outcome identified. Outcomes included:

• anxiety, assessed using the HADS
• depression, using the HADS
• psychological stress, assessed using the Perceived Stress Scale
• DNA damage assessed through blood alkaline single-cell gel electrophoresis

Outcomes were measured at baseline and at 6 weeks:

• exercise group: n = 35 at baseline, n = 35 at 6 weeks
• control group: n = 23 at baseline, n = 23 at 6 weeks

Subgroup analysis: none

Adverse events: not reported

Notes

Country: India

Funding: Atomic Energy Radiation Board of India; SVYASA University Bangalore, India; National Medical
Research Council, Singapore

Risk of bias

Bias

Authors' judgement

Support for judgement

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

55

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Banerjee 2007  (Continued)

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Computer-generated random number table

Low risk

Group assignments sent to clinics of the recruiting hospitals

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

Allocation to the intervention was not concealed from the study personnel

Incomplete outcome data
(attrition bias)
All outcomes

High risk

All 10 attritions experienced in the study were from the control group. The at-
trition occurred either immediately after random assignment or during the
course of the study

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Battaglini 2008 

Study characteristics

Methods

Study design: RCT

Number randomized: 20, but the numbers assigned to the exercise and control groups not reported

Study start and stop dates: not reported

Length of intervention: 16 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: breast cancer

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Inclusion criteria:

• recently diagnosed women with breast cancer
• designated to undergo any type of surgery and required to receive either chemotherapy or radiation
• 35 to 70 years old during the course of the study

Eligibility criteria related to interest or ability, or both, to exercise:

• cardiovascular disease; acute or chronic respiratory disease; acute or chronic bone, joint, or muscular

abnormalities that could prevent engagement in regular exercise was exclusionary

Exclusion criteria:

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

56

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Battaglini 2008  (Continued)

Cochrane Database of Systematic Reviews

• none

Gender: female

Current age, mean (SD) years:

• exercise group: 57.5 (23) years
• control group: 56.6 (16) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level: not reported

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Interventions

The number of participants assigned to the exercise intervention: not reported. The exercise interven-
tion included:

• an individualized exercise program included cardiovascular, resistance, and flexibility training

Type exercise (aerobic/anaerobic): aerobic and anaerobic

Intensity of the experimental exercise intervention: 40% to 60% of predicted maximum exercise capac-
ity

Frequency: twice per week

Duration of individual sessions: 60 minutes

Duration of exercise program: 16 weeks

Total number of exercise sessions: 32 sessions

Format: group

Facility: facility based

Professionally led by an undergraduate or graduate cancer exercise specialist

Adherence: not reported

The number of participants assigned to the control intervention was not reported and the control inter-
vention was not described

Contamination of control group: not reported

Outcomes

Primary outcome:

• total caloric intake, assessed using 3-day food diary

Other outcomes included:

• fatigue, assessed using the Revised PFS
• body composition analysis, assessed using skinfold measurement for the determination of percent

body fat

• fitness assessments included cardiovascular endurance and dynamic muscular endurance

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

57

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Battaglini 2008  (Continued)

Cochrane Database of Systematic Reviews

Outcomes were measured at baseline; postsurgery; at treatments 1, 2, and 3; and at end of study, but
the number of participants at each time point by treatment group was not reported

Subgroup analysis: none reported

Adverse events: none reported

Notes

Country: US

Funding: none reported

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

The generation of the random sequence was not described

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

Allocation to the intervention was not concealed from the study personnel

Unclear risk

There was no description of missing outcome data or attrition from the trial

Selective reporting (re-
porting bias)

Unclear risk

Owing to a lack of sufficient description of the outcomes, it is unclear whether
there is selective reporting of the outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Bourke 2011 

Study characteristics

Methods

Study design: RCT

Number randomized: 50; 25 to the exercise group and 25 to the control group

Study start and stop dates: not reported

Length of intervention: 12 weeks

Length of follow-up: 6 months

Participants

Type cancer: prostate cancer, nonlocalized, with metastatic disease

• exercise group, n = 7
• control group, n = 7

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

58

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bourke 2011  (Continued)

Cochrane Database of Systematic Reviews

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Inclusion criteria:

• ≥ 6 months and currently on androgen suppression therapy
• Histologically confirmed, nonlocalized prostate cancer

Eligibility criteria related to interest or ability, or both, to exercise:

• sedentary
• not undertaking regular physical activity, defined as exercise or physical activity at moderate intensity

for 30 minutes or more 3 times per week

Exclusion criteria:

• unstable angina
• uncontrolled hypertension
• recent myocardial infarction
• pacemakers
• painful or unstable bon metastasis

Gender: male

Current age, mean (SD) years:

• exercise group: 71.3 (6.4) years
• control group: 72.2 (7.7) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level: not reported

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history, exercise behavior (Godin LSI), mean (SD):

• exercise group: 13 (9)
• control group: 15 (10)

On hormone therapy: all on androgen suppression therapy

Interventions

25 participants assigned to the exercise intervention, including:

• anaerobic: supervised exercise sessions comprising 2 and 4 sets of resistance exercises (body weight

resistance and free weights) targeting large skeletal muscle groups

• aerobic: self-directed exercise (e.g. brisk walking, cycling, or gym exercise) using a log book (23) to

record activity

• small group healthy eating seminars lasting 15 to 20 minutes fortnightly for 12 weeks

Type exercise (aerobic/anaerobic): aerobic and anaerobic

Intensity of the experimental exercise intervention:

• aerobic: 55% to 85% age predicted maximum HR, or ratings of perceived exertion 11 to 15/fairly light

to hard on the Borg RPE scale, or both

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

59

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bourke 2011  (Continued)

• anaerobic: not reported

Frequency:

Cochrane Database of Systematic Reviews

• aerobic: once time per week during the initial 6 weeks and twice per week for the final 6 weeks
• anaerobic: twice per week for the initial 6 weeks and once per week for the following 6 weeks

Duration of individual sessions: 30 minutes each

Duration of exercise program: 12 weeks

Total number of exercise sessions: 278 sessions

Format: individual; unclear if group "dedicated suite"

Facility: facility and home based

Professionally led by an exercise physiologist

Adherence:

• aerobic: 329/378 sessions completed (87%)
• anaerobic: 360/378 sessions completed (95%)

25 participants assigned to control group, including:

• usual care

Contamination of control group: control group showed activity of 17.4 Godin LSI points at end of inter-
vention (12 weeks)

Outcomes

No primary outcome was identified. Outcomes included:

• total exercise behavior, assessed using the Godin LSI
• dietary macronutrient intake, assessed with 3-day diet diaries
• fatigue, assessed using the FACT-F
• global HRQoL, assessed using the FACT-P and FACT-G
• physiologic/functional fitness, assessed by a trained blinded technician
• anthopometric variables, assessed by BMI and weight
• aerobic exercise tolerance, assessed by treadmill and Borg RPE scale
• muscle strength assessed by MVT by isometric dynamometry of the quadriceps
• functional fitness, assessed by maximum number of repetitions in 30 seconds in a standardized chair

sit-to-stand test

• circulating biomarker

Outcomes were measured at baseline, 12 weeks, and 6 months:

• exercise group: n = 25 at baseline, n = 21 at 12 weeks, n = 15 at 6 months
• control group: n = 25 at baseline, n = 22 at 12 weeks, n = 13 at 6 months

Subgroup analysis: none reported

Adverse events: drop-outs owing to health problems were noted in 4 men in the exercise group (2 be-
cause of cardiac issues) and 5 men in the control group

Notes

Country: US

Funding: none reported

Risk of bias

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

60

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Bourke 2011  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"Randomization was carried out remotely using nQuery statistical software"

Allocation concealment
(selection bias)

Low risk

" … without disclosure of the sequence to the researcher responsible for the
running of the trial until after completion of the baseline assessments"

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

"Physiologic and functional fitness outcomes were assessed by a trained tech-
nician blinded to group allocation but blinding was not possible for those com-
pleting the HRQoL questionnaires"

Incomplete outcome data
(attrition bias)
All outcomes

High risk

In the exercise group, 4 participants at 12 weeks and 6 at 6 months were lost
to follow-up. In the control group, 3 at 12 weeks and 9 at 6 months were lost to
follow-up. However, the investigators used the SPSS Expectation Maximization
procedure to impute missing values so ITT analyses could be done

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Brown 2006 

Study characteristics

Methods

Study design: RCT

Number randomized: 115; 57 to the exercise group and 58 to the control group

Study start and stop dates: not reported

Length of intervention: 4 weeks

Length of follow-up: 4, 7, and 27 weeks after baseline

Participants

Type cancer, n (%): various

• exercise group: brain, 6 (12.7%); head and neck, 7 (14.3%); lung, 9 (18.4%); ovarian, 1 (2.0%); gastroin-

testinal, 18 (36.7%); other, 8 (16.3%)

• control group: brain, 6 (11.1%); head and neck, 11 (20.4%); lung, 6 (11.1%); ovarian, 0 (0.0%); gastroin-

testinal, 21 (38.9%); other, 10 (18.5%)

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Inclusion criteria:

• adults
• scheduled to undergo radiation therapy for at least 2 weeks
• cancer diagnosis within the past 12 months

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

61

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Brown 2006  (Continued)

Cochrane Database of Systematic Reviews

• expected survival of at least 6 months, but a 5-year survival probability of no more than 50%

Eligibility criteria related to interest or ability, or both, to exercise:

• none, but participants were screened preceding the exercise intervention to assure ability to partici-

pate

Exclusion criteria:

• MMSE score < 20
• ECOG performance score of ≥ 3
• active alcohol or substance dependence (except nicotine)
• active thought disorder
• suicidal plans
• participation in a psychosocial research trial

Gender, n (%):

• exercise group: male, 29 (59.2%); female, 20 (40.8%)
• control group: male, 37 (58.5%); female, 17 (31.5%)

Current age, n (%):

• exercise group: < 50 years, 7 (14.3%); ≥ 50 years, 42 (85.7%)
• control group: < 50 years, 12 (22.2%); ≥ 50 years, 42 (77.8%)

Age at cancer diagnosis: not reported

Ethnicity/race: all patients were white or of unknown ethnicity

Education level: not reported

SES: not reported

Employment status, currently employed, n (%):

• exercise group: 10 (35.7%)
• control group: 29 (53.7%)

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Interventions

57 participants assigned to the exercise intervention, including:

• a structured multidisciplinary intervention focused on specific strategies designed to improve partic-

ipants' overall QoL. Sessions included 20 minutes of exercises, including:
*

seated active ROM exercises of upper and lower extremities, progressing to resistive exercises with
an elastic band
stretching exercises
functional lower extremity exercises (e.g. marching in place) stressing increasing endurance

*
*

• Educational sessions coinciding with exercise sessions

Type exercise (aerobic/anaerobic): aerobic and anaerobic

Intensity of the experimental exercise intervention: not reported

Frequency: twice per week

Duration of individual sessions: 90 minutes

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

62

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Brown 2006  (Continued)

Duration of exercise program: 4 weeks

Total number of exercise sessions: 8 sessions

Format: group

Facility: facility

Professionally led by a physical therapist

Cochrane Database of Systematic Reviews

Adherence: 78% of participants attended all sessions, 92% attended all but 1 session. No subject
missed more than 2 sessions

58 participants assigned to control group, including:

• usual care

Contamination of control group: not reported

Outcomes

Primary outcome:

• global HRQoL, but how assessed was not reported

Other outcomes included:

• fatigue, assessed using:

• Linear Analogue Self Assessment fatigue
• Profile of Moods State fatigue-inertia and vigor-activity subscales
• Speilberger's STAI fatigue question
• Symptom Distress Scale fatigue question

Outcomes were measured at baseline, 4 weeks, 7 weeks, and 27 weeks:

• exercise group: n = 55 at baseline, n = 46 at 4 weeks, number of participants completing longer fol-

low-up visits not reported

• control group: n = 57 at baseline, n = 54 at 4 weeks, number of participants completing longer fol-

low-up visits not reported

Subgroup analysis: none reported

Adverse events: not reported

Notes

Country: US

Funding: Linse Bock Foundation, Saint Mary's Hospital Sponsorship Board

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

The generation of the random sequence was not described

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

63

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Brown 2006  (Continued)

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Allocation to the intervention was not concealed from the study personnel

Incomplete outcome data
(attrition bias)
All outcomes

High risk

The number of participants who withdrew from the study was not reported be-
yond the 4-week period. An ITT analysis was not completed

Selective reporting (re-
porting bias)

High risk

The authors describe some QoL measures in the methods for which no results
are presented

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Cadmus 2009 

Study characteristics

Methods

Study design: RCT

Number randomized: 75; 37 to the exercise group and 38 to the control group

Study start and stop dates: March 2004 to July 2006

Length of intervention: 6 months

Length of follow-up: to end of the intervention

Participants

Type cancer: breast cancer, Stage 0 to IIIA

Time since cancer diagnosis, mean (SD) weeks:

• exercise group: 11.1 (4.5) weeks
• control group: 11.0 (5.2) weeks

Time in active treatment: scheduled for chemotherapy or radiation therapy or within first 2 weeks of
starting chemotherapy or radiation therapy

Inclusion criteria:

• pre- or postmenopausal
• 35 to 75 years old

Eligibility criteria related to interest or ability, or both, to exercise:

• physically able to exercise
• physician consent to begin an exercise program

Exclusion criteria:

• diagnosis of recurrent or other primary cancer event
• current smoker

Gender: female

Current age, mean (SD) years:

• exercise group: 54.5 (8.2) years
• control group: 54.0 (10.9) years

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

64

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cadmus 2009  (Continued)

Cochrane Database of Systematic Reviews

Age at cancer diagnosis: not reported

Ethnicity/race, %:

• exercise group: non-Hispanic white, 96%
• control group: non-Hispanic white, 92%

Education level, %:

• exercise group: college degree or higher, 68%
• control group: college degree or higher, 72%

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy:

• exercise group, 56%
• control group, 68%

BMI, mean (SD):

• exercise group: 27.9 (5.3)
• control group: 27.5 (5.4)

Body fat, mean (SD):

• exercise group: 36.7% (5.9%)
• control group: 38.0% (6.1%)

Interventions

25 participants assigned to the exercise intervention, including:

• home-based supervised exercise program with weekly telephone calls, information, heart monitor,

activity logs

Type exercise (aerobic/anaerobic): unclear, up to the women's choice

Intensity of the experimental exercise intervention: 60% to 80% of predicted maximal HR

Frequency: 5 days per week

Duration of individual sessions: 30 minutes

Duration of exercise program: 6 months

Total number of exercise sessions: 120 sessions

Format: individual

Facility: home

Professionally led by "staff"

Adherence, mean (SD) minutes of activity per week:

• 144 (75) minutes compared with target of 150 minutes with 64% meeting goal

25 participants assigned to control group, including:

• usual exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

65

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Cadmus 2009  (Continued)

Contamination of control group: not reported

Outcomes

No primary outcome was identified. QoL outcomes included:

• happiness, assessed using the 2-item Fordyce Happiness Measure
• self-esteem, assessed using the Rosenberg Self-Esteem Scale
• depression, assessed using the CES-D scale
• anxiety, assessed using the STAI
• stress, assessed using the Cohen's 10-item Perceived Stress Scale
• QoL, assessed using FACT-B
• QoL, assessed using the MOS SF-36

Outcomes were measured at baseline and 6 months:

• exercise group: n = 25 at baseline, n = 22 at 6 months
• control group: n = 25 at baseline, n = 23 at 6 months

Subgroups: HRQoL level at baseline, by weight loss, or body fat, or both

Adverse events: none reported

Notes

Country: US

Funding: Lance Armstrong Foundation, American Cancer Society, Susan G. Komen. National Institutes
of Health

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Computer-generated randomization code

Allocation concealment
(selection bias)

Low risk

"The randomization code was obtained by the principal investigator (who was
not involved in recruitment or data collection) only after baseline measures for
that individual had been completed and staff conducting clinic visits did not
have access to the randomization program"

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

ITT analysis performed and baseline values were carried forward for the 5
women who had missing 6-month data

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

66

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Caldwell 2009 

Study characteristics

Methods

Study design: RCT

Cochrane Database of Systematic Reviews

Number randomized: 25; 13 to the exercise group and 12 to the control group

Study start and stop dates: not reported

Length of intervention: 12 weeks

Length of follow-up: 6 months

Participants

Type cancer: breast cancer

Stage, n (%):

• exercise group: Stage I, 5 (38.5%); Stage II, 4 (30.8%); Stage III, 4 (30.8%)
• control group: Stage I, 2 (16.7%); Stage II, 7 (58.3%); Stage III, 3 (25.0%)

Time since cancer diagnosis: not reported

Time in active treatment: completed surgery, and scheduled to receive chemotherapy

Inclusion criteria:

• had a clinical diagnosis of breast cancer (Stage I to III)
• 21 to 60 years old
• had undergone a definitive surgical procedure (lumpectomy or mastectomy)
• scheduled to receive any chemotherapy regimen/hormone blocker deemed as an appropriate treat-
ment for breast cancer administered prior to (neoadjuvant) and after (adjuvant) surgical intervention
• approved to participate in the study by an oncologist who would oversee the participant's cancer

treatment

Eligibility criteria related to interest or ability, or both, to exercise:

• presence of concomitant major health problems in which an exercise regimen is contraindicated
• currently participating in a structured exercise program

Exclusion criteria:

• male

Gender: female

Current age, mean (SD) years:

• exercise group: 47.15 (9.20) years
• control group: 46.33 (10.8) years

Age at cancer diagnosis: not reported

Ethnicity/race, n (%):

• exercise group: Asian, 1 (7.7%); African American, 2 (15.4%); Hispanic/Latino, 1 (7.7%); Caucasian, 9

(69.2%)

• control group: Asian, 0 (0.0%); African American, 1 (8.3%); Hispanic/Latino, 5 (41.7%); Caucasian, 6

(50.0%)

Education level, n (%):

• exercise group: high school, 2 (15.4%); vocational, 1 (7.7%); some college, 2 (15.4%); college graduate,

8 (61.5%)

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

67

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Caldwell 2009  (Continued)

Cochrane Database of Systematic Reviews

• control group: high school, 3 (25.0%); vocational, 1 (8.3%); some college, 2 (16.7%); college graduate,

6 (50.0%)

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Interventions

13 participants assigned to the exercise intervention, including:

• home-based low-intensity level strength training/functional endurance regimen including:

* biceps curl
* arm raises
* chair stands
* 1 foot stands
side leg raises
*
* walking

Type exercise (aerobic/anaerobic): aerobic and anaerobic

Intensity of the experimental exercise intervention: mild

Frequency: 3 to 5 times per week

Duration of individual sessions: as per participant ability and endurance

Duration of exercise program: 12 weeks

Total number of exercise sessions: 72 to 100 sessions

Format: individual

Facility: home

Professionally led by a physical therapist

Adherence: not reported

12 participants assigned to control group, including:

• usual care

Contamination of control group: not reported

Outcomes

Primary outcome:

• fatigue, assessed using the SCFS

Other outcomes included:

• Karnofsky's Performance Scale
• International Physical Activity Questionnaire
• timed Get Up and Go Test
• 6-MWT

Outcomes were measured at baseline and 6 months. 3 participants were not able to start the study ow-
ing to changes in treatment plan and were not included in any analysis:

• exercise group: n = 13 at baseline, n = 8 at 6 months

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

68

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Caldwell 2009  (Continued)

• control group: n = 12 at baseline, n = 9 at 6 months

Subgroup analysis: not reported

Adverse events: not reported

Notes

Country: US

Funding: none reported

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"...computerized randomization program..."

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

Allocation to the intervention was not concealed from the study personnel

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Analyses were not conducted on an ITT basis and the treatment of missing da-
ta was not described. There was substantial attrition from the trial, especially
in the intervention arm

The number of participants who withdrew from the study was not reported be-
yond the 4-week period

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Campbell 2005 

Study characteristics

Methods

Study design: RCT

Number randomized: 22; 12 to the exercise group and 10 to the control group

Study start and stop dates: not reported

Length of intervention: 12 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: breast cancer

Time since cancer diagnosis: not reported

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

69

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Campbell 2005  (Continued)

Cochrane Database of Systematic Reviews

Time in active treatment: not reported

Inclusion criteria:

• had surgery
• undergoing adjuvant therapy

Eligibility criteria related to interest or ability, or both, to exercise:

• already exercising vigorously 3 times per week for 20 minutes or more

Exclusion criteria:

• uncontrolled cardiac or hypertensive disease
• respiratory disease
• cognitive dysfunction

Gender: female

Current age, mean (SD) years:

• exercise group: 48 (10) years
• control group: 47 (5) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level: not reported

SES, Carstairs Deprivation Index:

• exercise group: 3.0
• control group: 3.8

Employment status: not reported

Comorbidities: not reported

Past exercise history, mean minutes of physical activity per week (SD):

• exercise group: 330 (71) minutes
• control group: 421 (191) minutes

On hormone therapy: not reported

Interventions

12 participants assigned to the exercise intervention, including:

• supervised exercise program consisting of:

* warm-up
* 10 to 20 minutes' exercise including walking, cycling, low-level aerobics, muscle-strengthening ex-

ercises, circuits, etc.

* cool down
*

relaxation period

• discussion targeting different motivational factors, 6 different themes discussed twice during the 12-

week intervention

Type exercise (aerobic/anaerobic): aerobic

Intensity of the experimental exercise intervention: moderate, 60% to 75% age-adjusted HR maximum

Frequency: twice per week

Duration of individual sessions: not reported

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

70

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Campbell 2005  (Continued)

Duration of exercise program: 12 weeks

Total number of exercise sessions: 24 sessions

Format: group

Facility: facility

Professionally led: unclear

Cochrane Database of Systematic Reviews

Adherence: 10 of 12 women completed that 12-week intervention. Participants completed an average
of 70% of the total number of sessions

10 participants assigned to control group, including:

• usual care

Contamination of control group: not reported

Outcomes

Primary outcome:

• change in HRQoL between baseline and 12 weeks, as assessed by FACT-G

Other HRQoL outcomes included:

• fatigue, assessed using the PFS
• HRQoL, assessed using FACT-B
• functional well-being, assessed using the FACT-B subscale
• PWB, assessed using the FACT-B subscale
• breast cancer concerns, assessed using the FACT-B subscale
• satisfaction, assessed using the SWLS

Other outcomes included:

• 12-MWT
• perceived expectation of treatment, assessed using the Perceived Expectations and Benefits of Total

Care

Outcomes were measured at baseline and 12 weeks:

• exercise group: n = 12 at baseline, n = 10 at 12 weeks
• control group: n = 10 at baseline, n = 9 at 12 weeks

Subgroup analysis: none reported

Adverse events: none reported

Notes

Country: UK/Scotland

Funding: Greater Glasgow NHS Trust

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

The generation of the random sequence was not described

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

71

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Campbell 2005  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

Allocation to the intervention was not concealed from the study personnel

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Analyses were not conducted on an ITT basis and the treatment of missing da-
ta was not described

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Chandwani 2010 

Study characteristics

Methods

Study design: RCT

Number randomized: 71, but 10 withdrew leaving 61; 30 to the exercise group and 31 to the control
group

Study start and stop dates: not reported

Length of intervention: 6 weeks

Length of follow-up: 3 months

Participants

Type cancer: breast cancer

Stage, n (%):

• exercise group: Stage 0, 2 (7%); Stage I, 6 (20%); Stage II, 12 (40%); Stage III, 10 (33%)
• control group: Stage 0, 0 (0%); Stage I, 10 (32%); Stage II, 15 (48%); Stage III, 6 (19%)

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Inclusion criteria:

• ≥ 18 years old
• able to read, write, and speak English
• scheduled to undergo radiation therapy
• written informed consent

Eligibility criteria related to interest or ability, or both, to exercise:

• physical limitations that would prohibit participation in the yoga program (e.g. lymphedema or unre-

solved surgical issues)

Exclusion criteria:

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

72

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Chandwani 2010  (Continued)

• major psychiatric diagnosis (e.g. a mood or thought disorder)

Gender: female

Current age, mean (SD, range):

• exercise group: 51.39 (7.97, 37.1 to 67.6) years
• control group: 4.02 [typographical error in table], (9.96, 31.8 to 67.9) years

Age at cancer diagnosis: not reported

Ethnicity/race, n (%):

• exercise group: black/African American, 1 (3%); white/Caucasian, 24 (80%); Latino/Hispanic, 3 (10%);

Asian/Pacific Islander, 1 (3%); other, 1 (3%)

• control group: black/African American, 2 (7%); white/Caucasian, 23 (79%); Latino/Hispanic, 2 (7%);

Asian/Pacific Islander, 0 (0%); other, 2 (7%)

Education level, n (%):

• exercise group: completed high school or technical school, 6 (20%); some college, 6 (20%); higher

education, 18 (60%)

• control group: completed high school or technical school, 4 (13%); some college, 5 (17%); higher ed-

ucation, 21 (70%)

SES: not reported

Employment status, n (%):

• exercise group: employed full-time, 5 (17%); employed part-time, 4 (13%); not employed, 21 (70%)
• control group: employed full-time, 8 (27%); employed part-time, 2 (7%); not employed, 20 (67%)

Comorbidities: not reported

Past exercise history: 4 patients in the exercise and 2 in the control group reported practicing yoga
"currently" and 7 in the exercise and 9 in the control group practiced in the past

On hormone therapy: not reported

Interventions

The number of participants assigned to the exercise intervention was unclear because 10 participants
withdrew and their assignment was not reported. Of the remaining participants 30 were assigned to
the exercise intervention, including:

• yoga, as defined by the VYASA yoga research foundation and university in Bengaluru, India. The mul-

tidimensional module of yoga included:
* preparatory warm-up movements synchronized with breathing (10 minutes)
* maintenance in selected postures (forward-, backward-, and side-bending asanas in sitting and
standing positions, cobra posture, crocodile, and half-shoulder stand with support) (25 minutes)

* deep relaxation technique (in corpse posture, 10 minutes)
* alternate-nostril breathing (pranayama) (5 minutes)
* meditation (10 minutes)

Type exercise (aerobic/anaerobic): aerobic and anaerobic

Intensity of the experimental exercise intervention: mild

Frequency: twice per week plus encouragement to practice daily at home

Duration of individual sessions: 60 minutes

Duration of exercise program: 6 weeks

Total number of exercise sessions: 12 sessions

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

73

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Chandwani 2010  (Continued)

Cochrane Database of Systematic Reviews

Format: although designed to be group, the program ended up with most women having 1-on-1 ses-
sions

Facility: facility with encouragement to practice at home

Professionally led by VYASA trained teachers

Adherence: 15 participants (50%) attended all 12 classes; 8 (28%) attended 11 classes; and 1 (3%) at-
tended 10 classes. 8 participants (28%) reported practicing yoga outside of class every day, 12 (40%) re-
ported practicing more than twice per week, 8 (28%) reported practicing twice per week, and 1 (3%) re-
ported not practicing outside the classes

The number of participants assigned to the control intervention was unclear because 10 participants
withdrew and their assignment was not reported. Of the remaining participants 31 were assigned to
the control intervention, including:

• waiting list

Contamination of control group: not reported

Outcomes

Primary outcome included:

• physical function, assessed using the Physical component scale of the MOS-SF-36
• emotional state, assessed using the Mental component scale of the MOS-SF-36

Other outcomes were other subscales of the MOS SF-36, including:

• general health
• physical function
• body pain
• role-physical
• role emotional
• mental health
• social function
• vitality
• fatigue, measured using the BFI
• sleep, measured using the PSQI
• depression, measured using the CES-D
• anxiety, measured using the STAI
• intrusiveness, measured using a subscale of the Impact of Events Scale
• avoidant, measured using a subscale of the Impact of events Scale
• benefit finding, measured using the Benefit Finding Scale

Outcomes were measured at baseline, 1 week, 1 month, and 3 months:

• exercise group: n = 30 at baseline, n = 27 at 1 week, n = 26 at 1 month, n = 27 at 3 months
• control group: n = 31 at baseline, n = 31 at 1 week, n = 27 at 1 month, n = 29 at 3 months

Subgroup analysis: a number of subgroup analyses are reported for different times and different mea-
sures

Adverse events: not reported

Notes

Country: US

Funding: National Cancer Institute, Philanthropic support from the Integrative Medicine Program, The
University of Texas M.D. Anderson Cancer Center

Risk of bias

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

74

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Chandwani 2010  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"Participants were then randomly assigned… by use of minimization, a form
of adaptive randomization"

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

Allocation to the intervention was not concealed from the study personnel

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

 "An intent-to-treat approach was used to analyze the data." The authors used
2 different methods to impute missing data: simple mean imputation and mul-
tiple imputation

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Chang 2008 

Study characteristics

Methods

Study design: RCT

Number randomized: 24; 12 to the exercise group and 12 to the control group

Study start and stop dates: not reported

Length of intervention: 3 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: AML

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Inclusion criteria:

• Aware of diagnosis
• Prescribed chemotherapy: specifically, induction therapy with cytarabine 100 mg/m2/day by contin-
uous intravenous infusion for 7 days and idarubicin 12 mg/m2/day by intravenous push on days 1, 2,
and 3

• Performance status 0 to 3 on ECOG

Eligibility criteria related to interest or ability, or both, to exercise:

• none

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

75

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Chang 2008  (Continued)

Exclusion criteria:

• none

Gender, n (%):

Cochrane Database of Systematic Reviews

• exercise group: male, 8 (72.7%); female, 3 (27.3%)
• control group: male, 4 (36.4%); female, 7 (63.6%)

Current age, mean (SD) years:

• exercise group: 49.4 (15.3) years
• control group: 53.3 (13.6) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level: not reported

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Interventions

12 participants assigned to the exercise intervention, including:

• walking exercise program consisted of 12 minutes' supervised walking in the hospital hallway on 5

days per week

Type exercise (aerobic/anaerobic): aerobic

Intensity of the experimental exercise intervention: target HR = resting + 30

Frequency: 5 days per week

Duration of individual sessions: 12 minutes

Duration of exercise program: 3 weeks

Total number of exercise sessions: 15 sessions

Format: individual

Facility: hospital

Professionally led by an Masters-prepared nurse research assistant, who accompanied patient on walk

Adherence: not reported

12 participants assigned to control group, including:

• visit by trained research assistant to maintain same patient contact

Contamination of control group: not reported

Outcomes

No primary outcome was identified. QoL outcomes included:

• fatigue, measured using the BFI, and subscales:

*
*

fatigue intensity
fatigue interference

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

76

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Chang 2008  (Continued)

Cochrane Database of Systematic Reviews

• 12-MWT
• overall symptom distress, assessed using the Symptom Distress Scale Modified Form
• mood disturbance, assessed using the Profile of Moods State short-form

Outcomes were measured at baseline, 1 week, 2 weeks, and 3 weeks:

• exercise group: n = 11 at baseline and all subsequent time points
• control group: n = 11 at baseline and at all subsequent time points

Subgroup analysis: none

Adverse events: not reported

Notes

Country: Taiwan

Funding: none reported

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

The generation of the random sequence was not described

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

Allocation to the intervention was not concealed from the study personnel

Incomplete outcome data
(attrition bias)
All outcomes

High risk

1 participant from the exercise group and 1 from the control group were not in-
cluded in any analyses

Selective reporting (re-
porting bias)

Low risk

There is no evidence of selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Cheville 2010 

Study characteristics

Methods

Study design: RCT

Number randomized: 103; 49 to the exercise group and 54 to the control group

Study start and stop dates: not reported

Length of intervention: 3 weeks

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

77

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cheville 2010  (Continued)

Length of follow-up: 6 months

Participants

Type cancer, n (%): various:

Cochrane Database of Systematic Reviews

• exercise group: gastrointestinal, 18 (36.7%); head and neck, 7 (14.3%); lung, 9 (18.4%); brain, 6 (12.2%);

other, 9 (18.3%)

• control group: gastrointestinal, 21(38.9%); head and neck, 11 (20.4%); lung, 6 (11.1%); brain, 6 (11.1%);

other, 10 (18.5%)

Time since cancer diagnosis: not reported

Time in active treatment, mean (SD) days from surgery to enrolment:

• exercise group: 49.1 (7.1) days
• control group: 42.5 (6.9) days

Time in active treatment, currently receiving chemotherapy, n (%):

• exercise group: 29 (59.2%)
• control group: 34 (63.0%)

Inclusion criteria:

• diagnosis of cancer within the last 12 months
• expected survival time of at least 6 months
• 5-year survival probability of no more than 50% (as routinely determined by the primary radiation

oncologist)

• treatment recommendation of radiation therapy of at least 2 weeks

Eligibility criteria related to interest or ability, or both, to exercise:

• evaluated by a physiatrist to ensure the capacity for safe participation

Exclusion criteria:

• previous radiation therapy
• recurrent disease after a disease-free period > 6 months
• previous cancer diagnosis within 5 years
• MMSE score < 20
• ECOG performance score ≥ 3
• active alcohol or substance dependence (except nicotine)
• active thought disorder, or suicidal plans
• participating in another psychosocial research trial

Gender, n (%):

• exercise group: female, 20 (40.8%); male, 29 (59.2%)
• control group: female, 17 (31.5%); male, 37 (68.5%)

Current age, mean (SD, range) years:

• exercise group: 59.7 (11.49, 31.0 to 85.0) years
• control group: 59.4 (10.62, 36.0 to 82.0) years

Age at cancer diagnosis: not reported

Ethnicity/race: 100% white

Education level: not reported

SES: not reported

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

78

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Cheville 2010  (Continued)

Employment status, currently employed, n (%):

• exercise group: 28 (57.1%)
• control group: 29 (53.7%)

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Interventions

57 participants assigned to the exercise intervention, including:

• structured, multidisciplinary intervention including

* physical therapy
* conditioning exercises (flexibility and strengthening activities)
* cognitive, emotional, social, and spiritual components centered around specific topics
* coping strategies

Type exercise (aerobic/anaerobic): anaerobic

Intensity of the experimental exercise intervention: not reported

Frequency: 3 times per week

Duration of individual sessions: 90 minutes, with 30 minutes devoted to physical therapy conditioning
exercises

Duration of exercise program: 3 weeks

Total number of exercise sessions: 8 sessions

Format: group

Facility: facility and home

Professionally supervised and led by a physical therapist

Adherence: 6 participants (10.9%) missed ≥ 4 sessions. Attended session rate for the entire cohort was
89.3%

58 participants assigned to control group, including:

• usual care

Contamination of control group: not reported

Outcomes

Primary outcome:

• global HRQoL, measured using the Spitzer QOL Uniscale

Other outcomes included:

• HRQoL and HRQoL domains, assessed using the LASAs of QoL, including subscales for:

* cognitive
* physical functioning
* EWB
*
*
* physical symptoms (fatigue, pain frequency, and pain severity)

social (overall SWB, social support, financial well-being, and legal concerns)
spiritual well-being

• distress, assessed using the Symptom Distress Scale
• Vigor-Activity and Fatigue-Inertia, assessed using the POMS–Short Form

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

79

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cheville 2010  (Continued)

Cochrane Database of Systematic Reviews

• Spiritual well-being, assessed using the Functional Assessment of Chronic Illness Therapy–Spiritual

Well-Being

Outcomes were measured at baseline and at 4 weeks, 8 weeks, and 27 weeks:

• exercise group: n = 49 at baseline, n = 46 at 4 weeks, n = 47 at 8 weeks, n = 39 at 27 weeks
• control group: n = 54 at baseline, n = 54 at 4 weeks, n = 49 at 8 weeks, n = 43 at 27 weeks

Subgroup analysis: cancer type and age group

Adverse events: not reported

Notes

Country: US

Funding: Linse Bock Foundation and the Saint Marys Hospital Sponsorship Board

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"...randomly assigned...using a minimization procedure that balances the mar-
ginal distribution"

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

Allocation to the intervention was not concealed from the study personnel

Unclear risk

Analyses were not conducted on an ITT basis and there was substantial attri-
tion from the trial, especially in the intervention arm. However, "...Missing da-
ta were dealt with in a number of ways. Simple imputations of missing data for
the primary QOL-related secondary endpoints was undertaken as a sensitivity
analysis."

Selective reporting (re-
porting bias)

High risk

Data on several secondary outcomes were not reported. There were subgroup
analyses which were not prespecified

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Cohen 2004 

Study characteristics

Methods

Study design: RCT

Number randomized: 39; 20 to the exercise group and 19 to the control group

Study start and stop dates: not reported

Length of intervention: 7 weeks

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

80

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Cohen 2004  (Continued)

Length of follow-up: 1 week, 1 month, and 3 months after the last session

Participants

Type cancer: lymphoma

Stage, %:

• exercise group: Stage I, 22%; Stage II, 39%; Stage III, 17%; Stage IV, 22%
• control group: Stage I, 22%; Stage II, 33%; Stage III, 12%; Stage IV, 33%

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Inclusion criteria:

• lymphoma
• receiving chemotherapy or had received it within the past 12 month
• age ≥ 18 years
• able to read and speak English

Eligibility criterion related to interest or ability, or both, to exercise:

• none reported

Exclusion criteria:

• major psychotic illnesses

Gender, n: female, 12; male, 32

Current age, mean years: 51 years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level: not reported

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history, n:

• exercise group: 4
• control group: 8

On hormone therapy, n:

• exercise group: 1
• control group: 2

Interventions

19 participants assigned to the Tibetan yoga exercise intervention, including:

• controlled breathing and visualization
• mindfulness
• postures from the Tsa lung
• preliminary set of postures from the Trul khor (sngon 'gro)

The exercises are simple motions done with specific breathing patterns

Type exercise (aerobic/anaerobic): aerobic

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

81

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Cohen 2004  (Continued)

Intensity of experimental exercise intervention: mild

Frequency: once per week, with recommendation to practice techniques at home at least daily

Duration of individual session: not reported

Duration of exercise program: 7 weeks

Total number of exercise sessions: 7 sessions

Format: group and individual

Facility: tertiary care hospital and home

Professionally led: Tibetan yoga instructor

Adherence: all participants attended at least 1 yoga session; 6 (32%) attended all 7 sessions; 5 (26%) at-
tended 5 or 6 sessions; 6 (32%) attended 2 or 3 sessions; and 2 (10%) attended only 1 session

Co-intervention: none

Control group: 19 assigned to control group, consisting of

• waiting list

Contamination of control group: not reported

Outcomes

Outcomes: QoL outcomes, including:

• psychological distress, assessed using the Impact of Events Scale
• anxiety, assessed using the Spielberger State Anxiety Inventory
• depression, assessed using the Center for Epidemiologic Studies - Depression scale
• fatigue, assessed using the BFI
• sleep, assessed using the PSQI

Outcomes were measured at baseline and at 1 week, 1 month, and 3 months after the last yoga session:

• exercise group: n = 20 at baseline, n = 19 at follow-up (time of measure not reported)
• control group: n = 19 at baseline, n = 19 at follow-up (time of measure not reported)

Adverse events: not reported

Notes

Country: US

Funding: Bruce S. Gelb Foundation

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Low risk

"Group assignment was conducted sequentially using minimization"

Allocation concealment
(selection bias)

Low risk

"The allocation process was concealed from all investigators because all the
relevant information was entered into a computer program and group assign-
ment was determined by the program"

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

82

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Cohen 2004  (Continued)

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Although it was stated that only 1 study participant dropped out before the
end of the study, data were presented only for 30 study participants, not the 38
who completed the study

Selective reporting (re-
porting bias)

Low risk

There is no evidence of selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Courneya 2003a 

Study characteristics

Methods

Study design: Cluster randomized controlled trial, where clusters were psychotherapy classes

Number randomized: 108; 60 (in 11 classes) to the exercise group and 48 (in 11 classes) to the control
group

Study start and stop dates: group psychotherapy classes were conducted between September 1998
and April 2001

Length of intervention: 10 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: various

Breast cancer, 40.6%; colon cancer, 9.4%; ovarian cancer, 5.2%; stomach cancer, 4.2%, melanoma,
4.2%; HD, 3.1%; NHL, 3.1%; brain, 3.1%; lung cancer, 3.1%; other, 15.6%; missing, 8.3%

Time since cancer diagnosis, mean (SD) months:

• exercise group: 16.79 (18.45) months
• control group: 15.71 (16.70) months

Time in active treatment: not reported, although 43.5% of participants in exercise group and 45.2% of
participants in control group were still receiving treatment

 Inclusion criteria:

• diagnosis of cancer
• voluntary participation in a group psychotherapy class offered at the cancer institute
• ability to answer questions written in English

Eligibility criterion related to interest or ability, or both, to exercise:

• passing the rPAR-Q, a screening tool to determine the need to consult a physician before increasing

exercise levels

• no contraindications to moderate-intensity exercise based on a submaximal fitness assessment were

inclusionary

Exclusion criteria:

• none

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

83

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Courneya 2003a  (Continued)

Gender, %:

Cochrane Database of Systematic Reviews

• exercise group: female, 84.4%
• control group: female, 86.7%

Current age, mean (SD) years:

• exercise group: 52.51 (10.21) years
• control group: 50.53 (10.08) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level, % completing university:

• exercise group: 57.1%
• control group: 60.5%

SES, % with family income > USD40,000:

• exercise group: 63.0%
• control group: 71.1%

Employment status, % currently employed:

• exercise group: 64.61%
• control group: 47.7%

Comorbidities: not reported

Past exercise history, mean (SD) minutes participants engaged in mild, moderate, or strenuous exer-
cise:

• exercise group: 192.53 (227.43) minutes
• control group: 137.68 (117.76) minutes

On hormone therapy: not reported

Interventions

60 participants assigned to the personalized exercise intervention, including:

• prescription for walking although participants were allowed to choose alternate mode of exercise (e.g.

swimming, cycling)
• group psychotherapy

Type exercise (aerobic/anaerobic): aerobic

Intensity of experimental exercise intervention: goal was to achieve 65% to 75% of estimated HR maxi-
mum as soon as safely possible

Frequency: 3 to 5 times per week

Duration of individual sessions: 20 to 30 minutes

Duration of exercise program: 10 weeks

Total number of exercise sessions: variable, but maximum would be 50 sessions

Format: individual

Facility: home, with group psychotherapy classes offered in facility (Cross Cancer Institute)

Not professionally led

48 participants assigned to the control group, including:

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

84

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Courneya 2003a  (Continued)

• group psychotherapy

Cochrane Database of Systematic Reviews

Adherence: 51/60 participants completed the 10-week intervention; 43/51 (84.3%) achieved the min-
imum exercise prescription of 60 minutes of moderate to strenuous exercise per week and 16/51
(31.4%) achieved the optimum exercise prescription of 150 minutes of moderate to strenuous exercise
per week. Total minutes of exercise, mean (SD) = 196.65 (149.56) minutes

Contamination of control group: mean (SD) minutes when participants in the control group participat-
ed in exercise = 100.91 (104.24) minutes

Outcomes

No primary outcome was identified. QoL outcomes included:

• QoL, assessed using FACT-G and subscales for physical, functional, emotional, social/family, and spir-

itual well-being

• satisfaction with life, measured using the SWLS
• depression, assessed by the CES-D scale
• anxiety, assessed by the STAI
• fatigue, assessed using the 13-item FS of the FACT measurement system

Outcomes were measured at baseline and 10 weeks:

• exercise group: n = 60 at baseline, n = 51 at 10 weeks
• control group: n = 48 at baseline, n = 45 at 10 weeks

Subgroup analysis: several subgroup analyses were prespecified and conducted

Adverse events: none reported

Notes

Country: Canada

Funding: National Institutes of Health, Canadian Institutes of Health Research, National Cancer Insti-
tute of Canada (NCIC), CCS, CCS/NCIC Sociobehavioral Cancer Research Network

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Low risk

Allocation sequence was generated using a random numbers table

Allocation concealment
(selection bias)

High risk

Allocation was not completely concealed. It was concealed from the fitness
appraiser but not from other study personnel

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Although stated that analyses were conducted on an ITT basis, the treatment
of missing data was not described. There was substantial attrition from the
study in both study groups

Selective reporting (re-
porting bias)

Low risk

There is no evidence of selective reporting of outcomes

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

85

 
 
Cochrane Database of Systematic Reviews

The trial appears to be free of other problems that could put it at a high risk of
bias

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Courneya 2003a  (Continued)

Other bias

Low risk

Courneya 2007a 

Study characteristics

Methods

Study design: RCT

Number randomized: 242; 78 to an aerobic exercise group, 82 to a resistance exercise group, and 82 to
the control group

Study start and stop dates: February 2003 to July 2005

Length of intervention: length of the chemotherapy session (median 17 weeks; 95% CI 9 to 24 weeks)

Length of follow-up: 6 months

Participants

Type cancer: breast cancer

Stage, n (%)

• aerobic exercise group: Stage I, 18 (23.1%); Stage IIa, 33 (42.3%); Stage IIb, 17 (21.8%); Stage IIIa, 10

(12.8%)

• resistance exercise group: Stage I, 22 (26.8%); Stage IIa, 36 (43.9%); Stage IIb, 9 (11.0%); Stage IIIa, 15

(18.3%)

• control group: Stage I, 20 (24.4%); Stage IIa, 30 (36.6%); Stage IIb, 22 (26.8%); Stage IIIa, 10 (12.2%)

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Inclusion criteria:

• English- or French-speaking
• ≥ 18 years old
• Stage I to IIIA breast cancer 
• beginning first-line adjuvant chemotherapy
• approval by treating oncologist

Eligibility criteria related to interest or ability, or both, to exercise:

• none

Exclusion criteria:

• pregnancy
• incomplete axillary surgery
• transabdominal rectus abdominus muscle reconstructive surgery
• uncontrolled hypertension
• cardiac illness
• psychiatric illness

Gender: female

Current age, mean (range) years:

• aerobic exercise group: 49.0 (30 to 75) years
• resistance exercise group: 49.5 (25 to 76) years

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

86

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Courneya 2007a  (Continued)

Cochrane Database of Systematic Reviews

• control group: 49.0 (26 to 78) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level, completed university, n (%):

• aerobic exercise group: 51 (65.4%)
• resistance exercise group: 51 (62.2%)
• control group: 53 (64.6%)

SES, income > USD60,000 per year, n (%):

• aerobic exercise group: 28 (38.4%)
• resistance exercise group: 41 (53.9%)
• control group: 34 (42.5%)

Employment status, full time employed, n (%):

• aerobic exercise group: 20 (25.6%)
• resistance exercise group: 29 (35.4%)
• control group: 23 (28.0%)

Comorbidities, hypertension, n (%):

• aerobic exercise group: 5 (6.4%)
• resistance exercise group: 8 (9.8%)
• control group: 4 (4.9%)

Past exercise history, n (%)

• aerobic exercise group: current exerciser, 15 (19.2%); current weight trainer, 4 (5.1%)
• resistance exercise group: current exerciser, 22 (26.8%); current weight trainer, 6 (7.3%)
• control group: current exerciser, 27 (32.9%); current weight trainer, 9 (11.3%)

On hormone therapy: not reported

Obese, n (%):

• aerobic exercise group, 17 (21.8%)
• resistance exercise group, 14 (17.1%)
• control group, 19 (23.2%)

BMI, n (%):

• aerobic exercise group, 26.7 (5.6%)
• resistance exercise group, 26.1 (5.5%)
• control group, 27.1 (5.4%)

Current smoker, n (%):

• aerobic exercise group, 6 (7.7%)
• resistance exercise group, 9 (11.0%)
• control group, 5 (6.1%)

Interventions

78 participants assigned to the aerobic exercise intervention, including:

• cycle ergometer, treadmill, or elliptical

82 participants assigned to the resistance exercise intervention, including:

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

87

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Courneya 2007a  (Continued)

Cochrane Database of Systematic Reviews

• performing 2 sets of 8 to 12 repetitions of 9 different exercises: leg extension, leg curl, leg press, calf

raises, chest press, seated row, triceps extension, biceps curls, and modified curl-ups

Type exercise (aerobic/anaerobic): aerobic or anaerobic

Intensity of the experimental exercise intervention:

• aerobic: beginning at 60% of their maximal oxygen consumption, or VO2max, for weeks 1 to 6 and

progressing to 70% during weeks 7 to 12 and 80% beyond week 12

• resistance: 60% to 70% of their estimated 1 repetition maximum, resistance was increased by 10%

when participants completed > 12 repetitions

Frequency: 3 times per week

Duration of individual sessions:

• aerobic: 15 minutes for weeks 1 to 3 and increased by 5 minutes every 3 weeks until the duration

reached 45 minutes at week 18

• resistance: not reported

Duration of exercise program: length of chemotherapy (~ 17 weeks)

Total number of exercise sessions: ~ 51 sessions

Format: individual

Facility: facility

Professionally led by exercise trainers

Adherence:

• aerobic: 72.0% adherence rate
• resistance: 68.2% adherence rate

82 participants assigned to control group, including:

• request not to initiate an exercise program
• offer of a 1-month exercise program after postintervention assessments

Contamination of control group: not reported

Outcomes

No primary outcome was identified. QoL outcomes included:

• global HRQoL, assessed using the FACT-An

Other outcomes included:

• psychosocial functioning, assessed by the Rosenberg Self-Esteem Scale
• depression, assessed using the Center for Epidemiological Studies Depression Scale
• anxiety, assessed using the Spielberger State Anxiety Inventory

Outcomes were measured at baseline, at mid-point, at end of the intervention, and at 6-month fol-
low-up:

• aerobic exercise group: n = 78 at baseline, n = 73 at mid-point, n = 74 at the end of intervention, n =

68 at the 6-month follow-up

• resistance exercise group: n = 82 at baseline, n = 75 at mid-point, n = 76 at the end of intervention, n

= 73 at the 6-month follow-up

• control group: n = 82 at baseline, n = 75 at mid-point, n = 73 at the end of intervention, n = 60 at the

6-month follow-up

Subgroup analysis: subgroups included patient preference, marital status, age, disease stage,
chemotherapy protocol

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

88

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Courneya 2007a  (Continued)

Cochrane Database of Systematic Reviews

Adverse events: 2 participants experienced an adverse event related to exercise after baseline maximal
treadmill testing: 1 became lightheaded, hypotensive, and moderately nauseous and 1 experienced
dizziness, weakness, and mild diarrhea

Notes

Country: Canada

Funding: Canadian Breast Cancer Research Alliance, Canada Research Chairs Program, NCIC with funds
from the CCS and the NCIC/CCS Sociobehavioral Cancer Research Network, Heart and Stroke Founda-
tion of Canada, Canadian Institutes of Health Research, Alberta Heritage Foundation for Medical Re-
search

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Computer generated

Allocation concealment
(selection bias)

Low risk

The allocation sequence was generated in Edmonton and concealed from the
project directors at each site who assigned participants to groups

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

Used all available data in ITT analyses, using the missing at random assump-
tion for mixed models

Selective reporting (re-
porting bias)

Low risk

There is no evidence of selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Courneya 2008 

Study characteristics

Methods

Study design: RCT

Number randomized: 55; 26 to the exercise group and 29 to the control group

Study start and stop dates: July 2003 to September 2006

Length of intervention: 12 weeks

Length of follow-up: 1 to 2 weeks after intervention

Participants

Type cancer, n (%): breast cancer (primary) or metastatic disease

• exercise group: primary breast cancer, 15 (57.7%); metastatic disease, 15 (57.7%)
• control group: primary breast cancer, 18 (62.1%); metastatic disease, 11 (37.9%)

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

89

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Courneya 2008  (Continued)

Cochrane Database of Systematic Reviews

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Inclusion criteria:

• ≥ 18 years of age
• histologically confirmed nonmyeloid cancer diagnosis
• hemoglobin level 80 to 110 g/L
• ECOG performance status score of 0 to 2
• completed definitive surgery
• expected survival duration of ≥ 3 months
• English speaking

Eligibility criteria related to interest or ability, or both, to exercise:

• contraindications to maximal exercise testing

Exclusion criteria:

• iron deficiency (ferritin, 12 μg/L)
• received an erythropoiesis-stimulating agent within 4 weeks of randomization
• uncontrolled hypertension
• cardiac abnormalities
• psychiatric illness
• known hematologic disorder causing anemia
• substantial lung, pleural, or pericardial disease
• preexisting bone metastases at high risk for fractures

Gender, female, n (%):

• exercise group: 20 (76.9%)
• control group: 25 (86.2%)

Current age, mean (range) years:

• exercise group: 58 (40 to 77) years
• control group: 54 (25 to 77) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level, completed university, n (%):

• exercise group: 16 (61.5%)
• control group: 13 (44.8%)

SES, income > USD60,000 per year, n (%)

• exercise group: 10 (38.5%)
• control group: 14 (48.3%)

Employment status, employed full or part-time, n (%):

• exercise group: 8 (30.8%)
• control group: 6 (20.7%)

Comorbidities, n (%):

• exercise group: lung disease, 6 (23.1%); current heart disease, 4 (15.3%)
• control group: lung disease, 5 (17.2%); current heart disease, 5 (17.2%)

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

90

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Courneya 2008  (Continued)

Past exercise history, current exerciser, n (%):

• exercise group: 3 (11.5%)
• control group: 3 (10.3%)

On hormone therapy: not reported

Interventions

26 participants assigned to the exercise intervention, including:

• individually tailored exercise program consisting of 3 cycle ergometry per week, aimed at improving

cardiorespiratory fitness

• darbepoetin alfa treatment at a dose of 4.5 μg/kg on weeks 1, 2, 3, 4, 5, 8, and 11

Type exercise (aerobic/anaerobic): aerobic

Intensity of the experimental exercise intervention: 60% to 100% of baseline peak power output

Frequency: 3 times per week

Duration of individual sessions: not reported

Duration of exercise program: 12 weeks

Total number of exercise sessions: 36 sessions

Format: individual

Facility: facility

Professionally led by an exercise physiologist

Adherence: participants attended 84.2% (30.3/36) of scheduled exercise sessions and achieved the pre-
scribed exercise duration and intensity in 94.7% (28.7/30.3) and 94.1% (28.5/30.3) of the sessions

29 participants assigned to control group, including:

• darbepoetin alfa treatment at a dose of 4.5 μg/kg on weeks 1, 2, 3, 4, 5, 8, and 11

Contamination of control group: mean (SD) 32 (80) minutes of nonprotocol-related moderate to strenu-
ous exercise per week

Outcomes

Primary outcome:

• global HRQoL, assessed using the FACT-An

Other outcomes included:

• fatigue, assessed using the FACT-An
• physiologic outcomes, including:

* cardiorespiratory fitness, assessed by peak VO2
* hemoglobin

Outcomes were measured at baseline, 12 weeks, and 13 to 14 weeks:

• exercise group: n = 29 at baseline, n = 29 at 12 weeks, n = 29 at 13 to 14 weeks
• control group: n = 26 at baseline, n = 25 at 12 weeks, n = 26 at 13 to 14 weeks

Subgroup analysis: none reported

Adverse events: not reported

Notes

Country: Canada

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

91

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Courneya 2008  (Continued)

Cochrane Database of Systematic Reviews

Funding: Canada Research Chairs Program, Research Team Grant from the National Cancer Institute of
Canada, CCS, NCIC/CCS Sociobehavioral Cancer Research Network, Health Research Studentships from
the Alberta Heritage Foundation for Medical Research

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"computer-generated program"

Allocation concealment
(selection bias)

Low risk

"The allocation sequence was concealed from the project director who as-
signed participants to groups"

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

Allocation to the intervention was not concealed from the study personnel

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

"...according to intention-to-treat principles using the last observation car-
ried-forward method"

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Courneya 2009 

Study characteristics

Methods

Study design: RCT

Number randomized: 122; 60 to an exercise group and 62 to the control group

Study start and stop dates: 2005 to 2008

Length of intervention: 12 weeks

Length of follow-up: 6 months

Participants

Type cancer, n (%): lymphoma

• exercise group: NHL indolent, 25 (41.7%); NHL aggressive, 24 (40.0%); HL, 11 (18.3%)
• control group: NHL indolent, 27 (43.5%); NHL aggressive, 24 (38.7%); HL, 11 (17.7%)

Stage, n (%):

• exercise group: Stage I, 11 (18.3%); Stage II, 8 (13.3%); Stage III, 9 (15.0%); Stage IV, 15 (25.0%)
• control group: Stage I, 7 (11.3%); Stage II, 15 (24.2%); Stage III, 8 (12.9%); Stage IV, 13 (21.0%)

Time since cancer diagnosis, mean (SD) months since diagnosis:

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

92

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Courneya 2009  (Continued)

• exercise group: 25.3 (31.5) months
• control group: 33.0 (39.0) months

Time in active treatment: not reported, but some participants still being actively treated.

Inclusion criteria:

• English speaking
• ≥ 18 years old
• histologically confirmed HL or NHL
• receiving chemotherapy or no treatment. Patients receiving chemotherapy may have started treat-

ment before enrolment but needed to have at least 8 weeks of planned treatment remaining

Eligibility criterion related to interest or ability, or both, to exercise:

• none

Exclusion criteria:

• uncontrolled hypertension
• cardiac illness
• residence > 80 km from facility
• not approved by their oncologist

Gender, n (%):

• exercise group: male, 37 (61.7%)
• control group: male, 35 (56.5%)

Current age, mean (range) years:

• exercise group: 52.8 (18 to 77) years
• control group: 53.5 (18 to 80) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level, completed university, n (%):

• exercise group: 31 (51.7%)
• control group: 32 (51.6%)

SES, income > USD60,000 per year, n (%):

• exercise group: 34 (63.0%)
• control group: 39 (62.9%)

Employment status, employed, n (%):

• exercise group: 22 (36.7%)
• control group: 32 (51.6%)

Comorbidities, n (%):

• exercise group: arthritis, 24 (40.0%); hypercholesteremia, 18 (30.0%); hypertension, 14 (23.3%)
• control group: arthritis, 14 (22.6%); hypercholesteremia, 18 (29.0%); hypertension, 21 (33.9%)

Past exercise history, baseline exerciser, n (%):

• exercise group: 12 (20.0%)
• control group: 23 (37.1%)

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

93

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Courneya 2009  (Continued)

On hormone therapy: not reported

Current chemotherapy, n (%):

• exercise group: 28 (46.7%)
• control group: 26 (41.9%)

Other characteristics, n (%):

Cochrane Database of Systematic Reviews

• exercise group: overweight, 27 (45.0%); obese, 16 (26.7%); current smoker, 4 (6.7%)
• control group: overweight, 20 (32.3%); obese, 17 (27.4%); current smoker, 9 (14.5%)

Other characteristics, mean (SD):

• exercise group: BMI, 27.4 (4.5) kg/m2; weight (SD), 81.8 (14.8) kg
• control group: BMI, 26.7 (5.4) kg/m2; weight (SD), 78.5 (17.1) kg

Interventions

60 participants assigned to the exercise group, including:

• exercise on an upright or recumbent cycle ergometer (Life Fitness, Schiller Park, IL) for 12 weeks
• 1 session per week of interval training above the ventilatory threshold in week 7
• 1 session of VO2 peak interval training in week 9

Type exercise (aerobic/anaerobic): aerobic

Intensity of experimental exercise intervention: started at 60% of peak power output (VO2 peak) and in-
creased by 5% each week to 75% by the fourth week

Frequency: 3 times per week

Duration of individual sessions: 15 to 20 minutes for first 4 weeks, increased by 5 minutes per week to
40 to 45 minutes in the ninth week

Duration of exercise program: 12 weeks

Total number of exercise sessions: 36 sessions

Format: group

Facility: facility

Professionally led by an exercise physiologist

62 participants assigned to the control group, including:

• request not to increase exercise above baseline levels
• offer of 4 weeks supervised exercise at end of the study

Adherence: attended a mean of 28/36 (77.8%) and a median of 33/36 (91.7%) supervised sessions. Du-
ration and intensity were met during 27.8/28 (99.0%) and 25.4/28 (90.7%) supervised sessions, respec-
tively.

• 45/60 (75%) participants attended ≥ 66% of sessions
• 3/60 (65%) participants attended ≥ 80% of sessions
• 21/60 (35%) participants attended 100% of sessions

Contamination of control group: the mean change in vigorous exercise from baseline: -4 minutes

• 49/62 (79%) participants reported no regular vigorous exercise during intervention
• 13/62 (21%) participants reported regular vigorous exercise during intervention

Outcomes

Primary outcome: patient-rated physical functioning, assessed using the TOI-An from the FACT-An scale

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

94

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Courneya 2009  (Continued)

Secondary QoL outcomes included:

• total FACT-An
• FACT-Fatigue subscale
• happiness, assessed by the Happiness scale
• depression, assessed by the CES-D
• anxiety, assessed by the SF STAI
• lymphoma symptoms, assessed by the lymphoma scale of the FACT
• general health by the single item on the MOS SF-12

Outcomes were measured at baseline, 12 weeks, and 6 months:

• exercise group: n = 60 at baseline, n = 57 at 12 weeks, n = 55 at 6 months
• control group: n = 62 at baseline, n = 60 at 12 weeks, n = 55 at 6 months

Subgroup analyses: major disease type, current treatment status (on chemotherapy versus not), pa-
tient preference, age, sex, marital status, disease stage at entry, general health, BMI

Adverse events: 3 adverse events related to exercise (back, hip, knee)

Notes

Country: Canada

Funding: Lance Armstrong Foundation; Canada Research Chairs Program; Alberta Heritage Foundation
for Medical Research; NCIC; and by the CCS and the NCIC/CCS Sociobehavioral Cancer Research Net-
work

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"computer-generated sequence"

Allocation concealment
(selection bias)

Low risk

 "The allocation sequence was generated independently and concealed in
opaque envelopes from the study coordinator who assigned participants to
groups."

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

"Outcomes assessors were not always blinded to group assignment but were
trained in standardizing testing procedures."

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Although stated ITT analyses, missing data were not accounted for. In exercise
group, 3 participants did not complete QoL measures postintervention and 3
at 6 months

In control group, 2 participants did not complete QoL measures postinterven-
tion, and 5 at 6 months

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

95

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Crowley 2003 

Study characteristics

Methods

Study design: RCT

Number randomized: 22; 13 to the exercise group and 9 to the control group

Study start and stop dates: not reported

Length of intervention: 13 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: breast cancer

Cancer stage, n (%): Stage I, 13 (59.1%); Stage II, 9 (40.9%)

Time since cancer diagnosis: not reported

Time in active treatment: completed surgery, initiating adjuvant chemotherapy of four 3-week cycles of
adriamycin and cytoxan

Inclusion criteria:

• ages 35 to 60 years
• complete primary surgery
• receiving adjuvant chemotherapy, specifically adriamycin and cytotoxan

Eligibility criteria related to interest or ability, or both, to exercise:

• medical condition that did not allow participation in a structured exercise program
• commitment to not initiating participation in a formal exercise program during the study period
• continuation of an ongoing exercise regimen was acceptable

Exclusion criteria:

• previous history of cancer treated with cytotoxic drugs or radiation therapy
• breast reconstruction at the time of primary surgery
• treatment regimen that required radiation therapy either before or concurrent with chemotherapy
• pre-existing cardiac or pulmonary disease
• current pregnancy or active lactation
• inability to give informed consent

Gender: female

Current age, range: 36 to 58 years

Age at cancer diagnosis: not reported

Ethnicity/race, n (%): Caucasian, 21 (95.5%); African American, 1 (4.5%)

Education level, n (%): high school, 1 (4.5%); vocational school, 1 (4.5%); some years of college, 6
(27.3%); college graduate, 14 (63.6%)

SES: not reported

Employment status, n (%): unemployed, 3 (13.6%); full-time, 14 (63.6%); part-time, 5 (22.7%)

Comorbidities: not reported

Past exercise history: not reported

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

96

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Crowley 2003  (Continued)

On hormone therapy: not reported

Menopausal status, n (%): premenopausal, 12 (54.5%); postmenopausal, 10 (45.5%)

Interventions

13 participants assigned to the exercise intervention, including:

• 13-week home-based structured endurance and strength training exercise program

* endurance component consisted of a home-based walking program
*

strength training component consisted of the performance of progressive resistance training using
exercise tubing

Type exercise (aerobic/anaerobic): aerobic and anaerobic

Intensity of the experimental exercise intervention:

• endurance component: 60% of the target HR
• strength training: not reported

Frequency: 3 to 5 times per week

Duration of individual sessions: not reported

Duration of exercise program: 13 weeks

Total number of exercise sessions: 39 to 65 sessions over 13 weeks

Format: individual

Facility: home

Professionally led in that education provided by an exercise physiologist twice during the program,
once at the beginning and once during week 8

Adherence: average days walked per week was 3.66 days or 113 minutes per week

9 participants assigned to control group, including:

• usual care

Contamination of control group: average days walked per week was 1.79 days or 53 minutes per week

Outcomes

Primary outcomes: non-HRQoL and HRQoL outcomes including:

• non-HRQoL outcomes:

• physical performance/endurance, assessed using a symptom limited graded exercise test with the

Cornell Treadmill Protocol to measure functional capacity (VO2max/kg)

• physical self-efficacy, assessed using the Self-Efficacy to Perform Self-Management Behaviors and

the Self-Efficacy to Achieve Outcomes scales

• strength, assessed using a 1-repetition maximal chest press and leg press

• HRQoL outcomes were:

*

fatigue,  assessed  using  the  Revised  PFS  to  measure  overall  fatigue  and  4  subscales,  behav-
ioral/severity, sensory, affective/meaning, and cognitive/mood; and subject report of fatigue as-
sessed using the AFI

* attention performance, assessed using the AFI as a measure of cognitive function
*

functional wellness, assessed using the MOS SF-36 Health Survey measuring subscales of physical
functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional,
and mental health

* health transitions, assessed using a single-item question included on the SF-36
* belief of current state of health, assessed using the Functional Wellness Questionnaire

Outcomes were measured at baseline, 7 weeks, and 13 weeks:

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

97

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Crowley 2003  (Continued)

Cochrane Database of Systematic Reviews

• exercise group: n = 13 at baseline (for all outcomes), n = 13 at 7 weeks (all outcomes, except physical

performance/endurance), n = 13 at 13 weeks (all outcomes)

• control group: n = 9 at baseline (for all outcomes), n = 9 at 7 weeks (all outcomes, except physical

performance/endurance), n = 9 at 13 weeks (all outcomes)

Subgroup analysis: none reported

Adverse events: not reported

Notes

Country: US

Funding: Sigma Theta, Rho Chapter, Oncology Nursing Society Foundation, Pharmacia & Upjohn

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Random numbers table used, with consecutive numbers on the table used
with those numbers ending in an even integer assigned to the exercise group,
and numbers ending in an odd integer assigned to the control group

Allocation concealment
(selection bias)

Low risk

Each random number placed in an envelope that was sealed and consecutive-
ly numbered on the outside

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

Allocation to the intervention was not concealed from the study personnel

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Analyses were not conducted on an ITT basis and the treatment of missing da-
ta was not described.  It is unclear how much attrition occurred in the trial

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Culos-Reed 2010 

Study characteristics

Methods

Study design: RCT

Number randomized: 100; 53 to the exercise group and 47 to the control group

Study start and stop dates: recruitment occurred between 2004 and 2006

Length of intervention: 16 weeks

Length of follow-up: 12 months

Participants

Type cancer: prostate cancer

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

98

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Culos-Reed 2010  (Continued)

Cochrane Database of Systematic Reviews

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Inclusion criteria:

• diagnosis of prostate cancer (any stage)
• may or may not have had previous treatment
• expected to receive androgen deprivation therapy for at least 6 months

Eligibility criteria related to interest or ability, or both, to exercise:

• physician's clearance to participate in a hybrid exercise program consisting of aerobic, strength, and

flexibility components

Exclusion criteria:

• any comorbid condition that would restrict the participant's ability to enter the program (e.g. heart

disease, emphysema, and arthritis)

• high risk of osteoporotic fracture because of long-term steroid use or T-score < −2.5 on screening bone

mineral densitometry DXA scan

Gender: male

Current age, mean (SD, range) years:

• exercise group: 67.2 (8.8, 46 to 82) years
• control group: 68.0 (8.4, 49 to 86) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level, n (%):

• exercise group: some high school, 12 (23.1%); completed high school, 10 (19.2%); some university/col-
lege, 8 (15.4%); completed university/college, 17 (32.7%); some/completed graduate school, 5 (9.6%)
• control group: some high school, 7 (14.9%); completed high school, 6 (12.8%); some university/col-
lege,  12  (25.5%);  completed  university/college,  11  (23.4%);  some/completed  graduate  school,  11
(23.4%)

SES, annual income, n (%):

• exercise group: < USD20,000, 4 (8.3%); USD20,000 to USD39,999, 13 (27.1%); USD40,000 to USD59,999,

7 (14.6%); USD60,000 to USD79,000, 9 (18.8%); > USD80,000, 15 (31.3%)

• control group: < USD20,000, 3 (6.8%); USD20,000 to USD39,999, 14 (31.8%); USD40,000 to USD59,999,

14 (31.8%); USD60,000 USD79,000, 6 (13.6%); > USD80,000, 7 (15.9%)

Employment status, n (%):

• exercise group: full-time, 16 (30.2%); retired, 30 (56.6%); disability/sick leave, 3 (5.7%); other, 4 (7.6%)
• control group: full-time, 5 (10.6%); retired, 31 (66.0%); disability/sick leave, 1 (2.1%); other, 10 (21.2%)

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Interventions

53 participants assigned to the individualized physical activity exercise intervention, including:

• home-based component primarily consisting of walking, stretching, and light resistance (i.e. thera-

band)

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

99

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Culos-Reed 2010  (Continued)

Cochrane Database of Systematic Reviews

• group-based component in a fitness center consisting of an activity component (walking, stretching,

light resistance) and education/discussion

Type exercise (aerobic/anaerobic): aerobic

Intensity of the experimental exercise intervention: moderate

Frequency:

• home-based component: 3 to 5 times per week
• group-based component: once per week during the 16-week intervention and once per month until

completion of the follow-up assessments

Duration of individual sessions:

• home-based component: 60 minutes
• group-based component: 90 minutes

Duration of exercise program: 16 weeks

Total number of exercise sessions:

• home-based component: 156 to 260 sessions
• group-based component: 24 sessions

Format: individual and group

Facility: home and facility (fitness center)

Group-based component professionally led by certified fitness professional

Adherence: not reported

47 participants assigned to control group, including:

• waiting list control

Contamination of control group: not reported

Outcomes

Primary outcome:

• physical activity behavior, assessed using the Godin LSI of the Godin Leisure Time Exercise question-

naire

Other outcomes included:

• HRQoL, assessed using the European Organization for the Research and Treatment of Cancer, Quality

of Life Study Group (QLQ-C30)

• organ-specific function and bother, assessed using the EPIC
• fatigue, assessed using the Fatigue Severity Scale
• depression, assessed using the CES-D scale

Outcomes were measured at baseline, 16 weeks, 6 months, and 12 months:

• exercise group: n = 53 at baseline, n = 53 at 16 weeks, n = 53 at 6 months, n = 53 at 12 months
• control group: n = 47 at baseline, n = 47 at 16 weeks, n = 47 at 6 months, n = 47 at 12 months

Subgroup analysis: not reported

Adverse events: not reported

Notes

Country: Canada

Funding: none reported

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

100

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Culos-Reed 2010  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

The generation of the random sequence was not described

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assigned was concealed from study personnel and par-
ticipants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

Allocation to the intervention was not concealed from the study personnel

Low risk

Analyses were conducted on an ITT basis

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Danhauer 2009 

Study characteristics

Methods

Study design: RCT

Number randomized: 44; 22 to the exercise group and 22 to the control group

Study start and stop dates: recruitment from August 2005 to October 2006

Length of intervention: 10 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: breast cancer, DCIS or Stages I to IV

Cancer stage, n (%):

• exercise group: DCIS, 3 (13.6%); Stage I, 5 (22.7%); Stage II, 10 (45.5%); Stage III, 3 (13.6%); Stage IV,

1 (4.6%)

• control group: DCIS, 5 (22.7%); Stage I, 9 (40.9%); Stage II, 3 (13.6%); Stage III, 2 (9.1%); Stage IV, 3

(13.6%)

Time since cancer diagnosis, mean (SD) months:

• exercise group: 24.4 (39.5) months
• control group: 22.8 (35.6) months

Time in active treatment: 2 to 24 months post primary treatment (surgery); 34% still in active treatment

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

101

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Danhauer 2009  (Continued)

Inclusion criteria:

Cochrane Database of Systematic Reviews

• ≥ 18 years old
• 2 to 24 months post primary treatment (surgery) following initial diagnosis
• recurrence of breast cancer within the past 24 months (regardless of treatment status)
• able to understand English

Eligibility criterion related to interest or ability, or both, to exercise:

• physically able to attend restorative yoga classes

Exclusion criteria:

•  medical contraindications as reported by physician

Gender: female

Current age, mean (SD) years:

• exercise group: 54.3 (9.6) years
• control group: 57.2 (10.2) years

Age at cancer diagnosis: not reported

Ethnicity/race, n (%):

• exercise group: non-Hispanic White, 19 (86.4%); African American, 2 (9.1%); Asian/Pacific Islander, 1

(4.6%)

• control group: non-Hispanic White, 20 (90.9%); African American, 1 (4.6%); Asian/Pacific Islander, 1

(4.6%)

Education level, n (%):

• exercise group: high school diploma/GED, 0 (0.0%); some college or vocational school, 6 (27.3%); col-

lege graduate, 5 (22.7%); graduate study or degree, 1 (50.0%)

• control group: high school diploma/GED, 3 (13.6%; some college or vocational school, 8 (36.4%); col-

lege graduate, 3 (13.6%); graduate study or degree, 8 (36.4%)

SES, n (%):

• exercise group: < USD35,000, 6 (30.0%); USD35,000 to USD49,999, 3 (15.0%); USD50,000 to USD99,999,

8 (40.0%); USD100,000+, 3 (15.0%)

• control group: < USD35,000, 5 (27.8%); USD35,000 to USD49,999, 1 (5.6%); USD50,000 to USD99,999,

5 (27.8%); USD100,000+, 6 (33.3%)

Employment status: not reported

Comorbidities: not reported

Past exercise history, n (%):

• exercise group: never had done yoga, 20 (90.9%); no yoga experience in the past year, 20 (90.9%)
• control group: never had done yoga, 15 (68.2%); no yoga experience in the past year, 18 (81.8%)

On hormone therapy: not reported

Ongoing treatment, n (%):

• exercise group: receiving chemotherapy, 8 (36.4%); receiving radiation therapy, 6 (27.3%)
• control group: receiving chemotherapy, 3 (13.6%); receiving radiation therapy, 3 (13.6%)

Interventions

22 participants assigned to the exercise intervention, including:

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

102

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Danhauer 2009  (Continued)

Cochrane Database of Systematic Reviews

• restorative yoga which combined physical postures (asanas), breathing (pranayama), and deep relax-
ation (savasana). Yoga poses were modified based on participant needs. Poses included: mountain
pose; arm and shoulder stretch; supported forward fold; seated sun salutation; and reclining twist
with a bolster

Type exercise (aerobic/anaerobic): aerobic/anaerobic

Intensity of experimental exercise intervention: mild

Frequency: once per week

Duration of individual sessions: 75 minutes

Duration of exercise program: 10 weeks

Total number of exercise sessions: 10 sessions

Format: group

Facility: Wake Forest University Health Sciences and local studio

Professionally led by yoga instructor with cancer-specific yoga training who was registered by the Na-
tional Yoga Alliance

22 participants assigned to control group, including:

• waiting list for yoga

Adherence: 11 women attended 7 or more sessions; 6 women attended 3 to 6 sessions; and 5 women
attended ≤ 2 sessions

Contamination of control group: not reported

Outcomes

No primary outcomes were identified. Outcomes included:

• physical health status (PCS and MCS), measured using the MOS's SF-12
• HRQoL, measured using the FACT-B, which consists of the subPWB subscale, SWB subscale, EWB sub-

scale, FWB subscale, and breast cancer specific concerns

• fatigue, measured using the FACT-F scale
• spirituality, measured using the FACT-Sp, which has 2 domains, sense of meaning/peace and role of

faith. Only the sense of meaning/peace subscale was included in this study

• depression, measured using the CES-D
• sleep dysfunction, measured using the PSQI
• positive and negative affect, measured using the PANAS

Outcomes were measured at baseline and at 10 weeks (end of the intervention):

• exercise group: n = 22 at baseline, n = 13 at 10 weeks
• control group: n = 22 at baseline, n = 14 at 10 weeks

Adverse events: cancer recurrence was reported for 4 women in the exercise group and 6 women in the
control group. No adverse events were reported

Notes

Country: US

Funding: Wake Forest University Comprehensive Cancer Center

Risk of bias

Bias

Authors' judgement

Support for judgement

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

103

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Danhauer 2009  (Continued)

Random sequence genera-
tion (selection bias)

Unclear risk

The generation of the random sequence was not described

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

Data were analyzed on an ITT basis. Participants who failed to return the study
questionnaire were excluded from the analyses - 9 participants in the exercise
group and 7 participants in the control group did not return the study ques-
tionnaire. 1 participant in the control group withdrew from the study

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

de Oliveira 2010 

Study characteristics

Methods

Study design: RCT

Number randomized: 55; 28 to the exercise group and 27 to the control group

Study start and stop dates: June 2005 to September 2006

Length of intervention: length of radiation

Length of follow-up: 6 months

Participants

Type cancer: breast cancer

Time in cancer diagnosis: not reported

Time in active treatment: not reported

Inclusion criteria:

• invasive breast cancer
• indication of radiation therapy
• postsurgery

Eligibility criteria related to interest or ability, or both, to exercise:

• medical contraindication

Exclusion criteria:

• inability to complete questionnaires

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

104

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

de Oliveira 2010  (Continued)

Gender: female

Current age, range: 40 to 60 years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level, %: primary, 60%; middle, 20%; secondary, 20%

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: about 50% were on hormone therapy

Interventions

28 participants assigned to the exercise intervention, including:

• kinesotherapy of the upper limb, including 19 different exercises

Type exercise (aerobic/anaerobic): aerobic

Intensity of the experimental exercise intervention: not reported

Frequency: not reported

Duration of individual sessions: 45 minutes

Duration of exercise program: length of radiation therapy

Total number of exercise sessions: about 18 sessions

Format: individual

Facility: facility

Professionally led: not reported

Adherence: not reported

27 participants assigned to control group, including:

• usual care

Contamination of control group: not reported

Outcomes

Primary outcome:

• amplitude of movement, assessed using Gosselnik

Other outcomes included:

• global HRQoL, assessed using FACT-B and subscales:

social/family well-being

* PWB
*
* FWB
* breast subscale
* EWB

Outcomes were measured at baseline, end of treatment (~ 3 months), and 6 months:

• exercise group: n = 28 at baseline, n = 28 at 3 months, n = 24 at 6 months

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

105

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

de Oliveira 2010  (Continued)

• control group: n = 27 at baseline, n = 27 at 3 months, n = 25 at 6 months

Subgroup analysis: none reported

Adverse events: not reported

Notes

Country: Brazil

Funding: FAEPEX UNICAMP, pelo financiamento e Bolsa CAPES

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"greada por computador"

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

The outcome assessor was blinded to the study allocation

Unclear risk

Insufficient details provided to determine whether there was any attrition

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Dimeo 1999 

Study characteristics

Methods

Study design: quasi-randomized controlled trial

Number randomized: 62; 29 to the exercise group and 33 to the control group

Study start and stop dates: not reported

Length of intervention: length of hospitalization

Length of follow-up: to end of the intervention

Participants

Type cancer, n: various

• exercise group: breast carcinoma, 13; metastatic breast carcinoma, 3; seminoma, 3; sarcoma/adeno-

carcinoma, 2; small cell lung carcinoma, 0; HD, 2; NHL, 4

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

106

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Dimeo 1999  (Continued)

Cochrane Database of Systematic Reviews

• control group: breast carcinoma, 12; metastatic breast carcinoma, 3; seminoma, 3; sarcoma/adeno-

carcinoma, 0; small cell lung carcinoma, 4; HD, 5; NHL, 5

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Inclusion criteria:

• undergoing HDC followed by peripheral stem cell transplantation
• ages 18 to 60 years
• active malignancy confirmed histologically
• ability to understand written German

Eligibility criteria related to interest or ability, or both, to exercise:

• none reported

Exclusion criteria:

• associated psychiatric, muscular, cardiovascular, or pulmonary disease

Gender, n:

• exercise group: male, 9; female, 18
• control group: male, 13; female, 19

Current age, mean (SD, range) years:

• exercise group: 40 (11, 21 to 59) years
• control group: 40 (10, 20 to 56) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level: not reported

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

BMI, mean (SD, range):

• exercise group: 24.5 (3.8, 18 to 32)
• control group: 23.6 (2.9, 19 to 32)

Interventions

29 participants assigned to the exercise intervention, including:

• biking on a ergometer in the supine position following an interval training pattern of 1 minute biking

followed by 1-minute rest

Type exercise (aerobic/anaerobic): aerobic

Intensity of the experimental exercise intervention: participants "biked" for 1 minute with an intensity
sufficient to reach a HR equivalent to at least 50% of the cardiac reserve, calculated as 220 - age - rest-
ing HR

Frequency: daily

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

107

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Dimeo 1999  (Continued)

Cochrane Database of Systematic Reviews

Duration of individual sessions: 30 minutes

Duration of exercise program: length of hospitalization

Total number of exercise sessions: varied

Format: individual

Facility: facility

Professionally supervised and instructed by study personnel

Adherence: 82% (SD, 16%) of the hospitalization days

33 participants assigned to control group, including:

• usual care

Contamination of control group: not reported

Outcomes

No primary outcome was identified. QoL outcomes included:

• Total mood disturbance, as assessed by the POMS, and subscales:

* depression
fatigue
*
* vigor
* anger/hostility

• Psychological stress, as assessed by the SCL-90 and subscales, including:

somatization

*
* obsessive-compulsive traits
interpersonal sensitivity
*
* depression
* anxiety
* hostility
* phobic anxiety
* global psychological distress

Outcomes were measured at baseline and discharge from hospital (~ 3 months):

• exercise group: n = 29 at baseline, n = 27 at end of intervention
• control group: n = 33 at baseline, n = 32 at end of intervention

Subgroup analysis: none reported

Adverse events: not reported

Notes

Country: Germany

Funding: Nenad Keul Foundation, Freiburg, and Daimler-Benz AG

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

High risk

Quasi-randomized

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

108

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Dimeo 1999  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

The outcome assessor was blinded to the study allocation

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Analyses were conducted on an ITT basis; However, the treatment of missing
data was not described. There was substantial attrition from the trial, especial-
ly in the intervention arm

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

DiSipio 2009 

Study characteristics

Methods

Study design: RCT

Number randomized: 337; numbers assigned to the exercise or control group not reported

Study start and stop dates: started 2006, but end date not reported

Length of intervention: unclear

Length of follow-up: unclear

Participants

Type cancer: breast cancer

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Inclusion criteria:

• resident of Queensland
• diagnosed with unilateral breast cancer in 2006 or 2007

Eligibility criteria related to interest or ability, or both, to exercise:

• none reported

Exclusion criteria:

• none reported

Gender: female

Current age: not reported

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

109

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

DiSipio 2009  (Continued)

Education level: not reported

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Cochrane Database of Systematic Reviews

Interventions

Neither the exercise nor control interventions were described, nor the number of participants assigned
to either group

Outcomes

No primary outcome was identified. QoL outcomes included:

• Global HRQoL, assessed using FACT-B

Outcomes were measured at baseline, mid-intervention (6 months), and 3 months postintervention (12
months)

Subgroup analysis: none reported

Adverse events: not reported

Notes

Country: Australia

Funding: none reported

Published conference abstract

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

The generation of the random sequence was not described

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

The outcome assessor was blinded to the study allocation

Unclear risk

Insufficient details provided to determine whether there was any attrition

Selective reporting (re-
porting bias)

Unclear risk

Insufficient details provided to assess whether there was selective outcome re-
porting

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

110

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Donnelly 2011 

Study characteristics

Methods

Study design: RCT

Number randomized: 33; 16 to the exercise group and 17 to the control group

Study start and stop dates: recruitment form June 2008 to March 2009

Length of intervention: 12 weeks

Length of follow-up: 6 months

Participants

Type cancer, n (%): gynecologic cancers (ovarian, endometrial, uterine, cervical, or mixed)

• exercise group: ovarian, 6 (37.5%); endometrial, 6 (37.5%); cervical, 2 (12.5%); mixed, 1 (12.5%)
• control group: ovarian, 6 (35.3%); endometrial, 5 (29.4%); cervical, 3 (17.6%); mixed, 2 (11.8%)

Cancer stage, stage I to III, n (%):

• exercise group: Stage I, 7 (43.8%); Stage II, 7 (43.8%); Stage III, 2 (12.5%)
• control group: Stage I, 9 (52.9%); Stage II, 3 (17.6%); Stage III, 5 (29.4%)

Time since cancer diagnosis, mean (SD) months:

• exercise group: 8.7 (9.6) months
• control group: 8.6 (8.9) months

Time in active treatment: some women still receiving treatment

 Inclusion criteria:

• women
• ≥ 18 years old
• diagnosis of gynecologic cancer (Stage I to III)
• completed surgery and either undergoing or completed anticancer treatment
• within 3 years of diagnosis
• report of mild to severe fatigue

Eligibility criterion related to interest or ability, or both, to exercise:

• currently sedentary (i.e. vigorous physical activity < 20 minutes/week or moderate physical activity <

60 minutes/week for the past 6 months) was inclusionary

Exclusion criteria:

• current medical or psychiatric illness (i.e. unstable cardiovascular disease, uncontrolled hyperten-
sion, diabetes or respiratory disease, severe mental illness, cognitive dysfunction or orthopedic prob-
lems)

• participation in other intervention trials
• previous diagnosis of cancer
• another  fatigue-related  comorbidity  (fibromyalgia,  chronic  fatigue  syndrome,  multiple  sclerosis,

myalgic encephalopathy, lupus, or arthritis)

Gender: female

Current age, mean (SD) years:

• exercise group: 53.5 (8.7) years
• control group: 52.1 (11.8) years

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

111

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Donnelly 2011  (Continued)

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level: not reported

SES: not reported

Employment status, n (%):

• exercise group: full/part-time, 1 (6.3%); sick leave, 9 (56.3%); housewife, 2 (12.5%); retired, 4 (25.0%)
• control group: full/part-time, 3 (17.6%); sick leave, 8 (47.1%); housewife, 2 (11.8%); retired, 4 (23.5%)

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Interventions

16 participants assigned to the exercise intervention, including:

• physical activity, including walking and strengthening exercises, implemented by an initial, individ-
ual face to face consultation with a physical therapist and physical activity consultations guidelines
followed by weekly telephone calls for 10 weeks, a final face-to-face consultation at week 12, and 2
monthly follow-up calls

Type exercise (aerobic/anaerobic): aerobic

Intensity of experimental exercise intervention: moderate

Frequency: aim to meet physical activity guidelines (30 minutes of physical activity on at least 5 days
per week)

Duration of individual sessions: 30 minutes

Duration of exercise program: 12 weeks

Total number of exercise sessions: maximum of 60 sessions

Format: individual

Facility: home

Professionally led with initial consultation with a professional physical therapist

17 participants assigned to control group, including:

• usual care
• telephone calls at same time and length as exercise group

Adherence: 44% of all participants, or 58% of all individuals who remained medically unfit to take part

Contamination of control group: unclear

Outcomes

Primary outcome:

• fatigue, assessed using the MFSI-SF and the FACIT-F subscale

Secondary outcomes:

• QoL, assessed using the FACT-G scale
• depression, assessed using the BDI-II
• positive and negative affect, assessed using the PANAS
• sleep dysfunction, assessed using the PSQI

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

112

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Donnelly 2011  (Continued)

Cochrane Database of Systematic Reviews

Outcomes were measured at baseline, 12 weeks (end of intervention), and 6-month follow-up (9
months after baseline):

• exercise group: n = 16 at baseline, n = 15 at 12 weeks, n = 12 at 6-month follow-up
• control group: n = 17 at baseline, n = 17 at 12 weeks, n = 17 at 6-month follow-up

Subgroup analysis: none reported

Adverse events:

• exercise group: lung metastasis (n = 1), pulmonary embolism (n = 1), heart palpitations (n = 1)
• control group: none reported

Notes

Country: UK

Funding: Department of Employment and Learning, Northern Ireland

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Computer-generated random numbers table was used to generate the alloca-
tion sequence

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Low risk

Allocation was concealed in sequentially numbered opaque envelopes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

The outcome assessor was blinded to the study allocation

Low risk

The study used ITT analyses

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Galvao 2010 

Study characteristics

Methods

Study design: RCT

Number randomized: 57; 29 to the exercise group and 28 to the control group

Study start and stop dates: July 2007 to September 2008

Length of intervention: 12 weeks

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

113

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Galvao 2010  (Continued)

Length of follow-up: to end of the intervention

Participants

Type cancer: prostate cancer

Stage, n (%)

• exercise group: localized, 27 (93.1%); nodal metastases, 2 (6.9%); bone metastases, 0 (0%)
• control group: localized, 25 (89.3%); nodal metastases, 3 (10.7%); bone metastases, 0 (0%)

Time since cancer diagnosis: not reported

Time in active treatment: 6 months after enrolling

Inclusion criteria:

• minimum prior exposure to androgen suppression therapy > 2 months
• anticipated to remain hypogonadal for the subsequent 6 months

Eligibility criteria related to interest or ability, or both, to exercise:

• musculoskeletal, cardiovascular, or neurologic disorders that could inhibit them from exercising
• inability to walk 400 m or undertake upper and lower limb exercise, and resistance training in the

previous 3 months

Exclusion criteria:

• prostate specific antigen evidence of disease activity
• bone metastatic disease

Gender: male

Current age, mean (SD) years

• exercise group: 69.5 (7.3) years
• control group: 70.1 (7.3) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level, postsecondary education, n (%):

• exercise group: 15 (51.7%)
• control group: 20 (71.4%)

SES: not reported

Employment status, full-time, n (%):

• exercise group: 4 (13.8%)
• control group: 2 (7.1%)

Comorbidities, number of comorbidities (cardiovascular, hypertension, diabetes, osteoporosis, dyslipi-
demia), mean (SD):

• exercise group: 1.0 (1.3)
• control group: 1.0 (1.1)

Past exercise history: not reported

On hormone therapy, LHRHa antiandrogen, n (%):

• exercise group: 6 (20.7)
• control group: 11 (39.3)

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

114

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Galvao 2010  (Continued)

Previous androgen suppression therapy, n (%):

• exercise group: 5 (17.2)
• control group: 4 (14.3)

Time on androgen suppression therapy, mean (SD) months:

• exercise group: 18.2 (38.5) months
• control group: 10.1 (26.8) months

Interventions

29 participants assigned to the exercise intervention, including:

• combined progressive resistance and aerobic training. The resistance exercises included chest press,
seated row, shoulder press, triceps extension, leg press, leg extension and leg curl, with abdominal
crunches  also  performed.  Aerobic  component  included  cycling  or  walking/jogging.  Sessions  com-
menced and concluded with general flexibility exercises.

Type exercise (aerobic/anaerobic): aerobic and anaerobic

Intensity of the experimental exercise intervention: moderate, at 65% to 80% maximum HR and per-
ceived exertion at 11 to 13 (6 to 20 point, Borg scale)

Frequency: twice per week

Duration of individual sessions: aerobic session was 15 to 20 minutes

Duration of exercise program: 12 weeks

Total number of exercise sessions: 24 sessions

Format: group

Facility: facility

Professionally led by an exercise physiologist

Adherence: not reported

28 participants assigned to control group, including:

• encouragement to maintain customary activity and dietary patterns

Contamination of control group: not reported

Outcomes

Primary outcome:

• whole body and regional lean mass, fat mass, and percent fat, assessed using DXA

Other outcomes included:

• dynamic muscle strength and function, assessed by using the maximal number of repetitions per-

formed at 70% of 1-RM for the chest press and leg press exercises

• functional performance, assessed by repeated chair rise to standing (5 times) and the 6-musual and

fast walk using electronic timing gates

• cardiorespiratory capacity, assessed by the 400-m walk. Tests were performed in triplicate
• blood biomarkers, including testosterone, PSA, insulin, glucose, CRP, and lipid profile levels
• HRQoL, assessed using the MOS SF-36 and subscales
• balance,  assessed  using  the  sensory  organization  test  using  the  Neurocom  Smart  Balance  Master
and dynamic balance by the 6-m backward walk. Falls self-efficacy was determined using the Activi-
ties-Specific Balance Confidence scale

Outcomes were measured at baseline and end of intervention (12 weeks):

• exercise group: n = 29 at baseline, n = 29 at 12 weeks

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

115

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Galvao 2010  (Continued)

• control group: n = 28 at baseline, n = 28 at 12 weeks

Subgroup analysis: none reported

Adverse events: not reported

Notes

Country: Australia

Funding: Cancer Council of Western Australia

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Computer random assignment program

Low risk

Concealed from project coordinator and exercise physiologist

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

Allocation to the intervention was not concealed from the study personnel

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

ITT analyses was completed with missing values imputed as change across
time to be zero

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Gomes 2011 

Study characteristics

Methods

Study design: RCT

Number randomized: 54; number assigned to exercise and control groups not reported

Study start and stop dates: not reported

Length of intervention: not reported

Length of follow-up: to end of the intervention

Participants

Type cancer: non-metastatic breast cancer

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

116

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gomes 2011  (Continued)

Inclusion criteria:

• none reported

Eligibility criteria related to interest or ability, or both, to exercise:

Cochrane Database of Systematic Reviews

• none reported

Exclusion criteria:

• none reported

Gender: female

Current age, median years:

• exercise group: 52.5 years
• control group: 48.5 years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level: not reported

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

BMI, median:

• exercise group: 27.61
• control group: 26.49

Premenopausal, %:

• exercise group: 39.3%
• control group: 57.7%

Interventions

The number of participants assigned to the exercise intervention was not reported. The exercise inter-
vention included:

• brief home-based exercise orientation program

Type exercise (aerobic/anaerobic): aerobic

Intensity of the experimental exercise intervention: not reported

Frequency: not reported

Duration of individual sessions: not reported

Duration of exercise program: not reported

Total number of exercise sessions: not reported

Format: individual

Facility: home

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

117

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gomes 2011  (Continued)

Professionally led: unclear

Adherence: not reported

Cochrane Database of Systematic Reviews

The number of participants assigned to the control intervention was not reported. The control inter-
vention included:

• usual care

Contamination of control group: not reported

Outcomes

No primary outcome was identified. QoL outcomes included:

• global HRQoL, assessed using the

* QLQ-C30
* QLQ-BR23

• fatigue, assessed using the Chalder Fatigue Questionnaire

Outcomes were measured at baseline and end of intervention, but the number of individuals by treat-
ment group at each time point was not reported

Subgroup analysis: none reported

Adverse events: not reported

Notes

Country: Brazil

Funding: none reported

Published as conference abstract

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

The generation of the random sequence was not described

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

Allocation to the intervention was not concealed from the study personnel

Unclear risk

Insufficient details provided to determine whether there was any attrition

Selective reporting (re-
porting bias)

Unclear risk

Insufficient details provided to assess whether there was selective outcome re-
porting

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

118

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Griffith 2009 

Study characteristics

Methods

Study design: RCT

Number randomized: 138; 73 to the exercise group and 65 to the control group

Study start and stop dates: not reported

Length of intervention: varied by duration of cancer treatment. For the entire sample, the mean (SD)
number of cancer treatment weeks was 12.83 (5.15) with a range of 5 to 35 weeks. The mean (SD) total
weeks of cancer treatment was 15.8 (5.89) for nonprostate and 10.44 (2.73) for prostate cancer patients

Length of follow-up: to end of the intervention

Participants

Type cancer, n (%): various

• exercise group: breast, 23 (33.8%); colorectal, 2 (2.9%); prostate, 38 (55.9%); other, 5 (7.4%)
• control group: breast, 18 (31.0%); colorectal, 5 (8.6%); prostate, 32 (55.2%); other, 3 (5.2%)

Cancer stage, n (%): Stage I, 12 (10%); Stage II, 89 (70%); Stage III, 25 (20%)

Time since cancer diagnosis: not reported

Time in active treatment: currently undergoing treatment

Inclusion criteria:

• ≥ 21 years old
• diagnoses of Stage I to III cancer
• scheduled to receive chemotherapy, radiation therapy, or both

Eligibility criteria related to interest or ability, or both, to exercise:

• were already exercising more than 120 minutes per week
• conditions that could preclude the advisability or safety of a moderate-intensity walking program

Exclusion criteria:

• comorbidities such as cardiovascular disease, cognitive dysfunction, metastatic cancer, hematologic

malignancies

Gender, n (%):

• exercise group: male, 27 (39.7%), female, 41 (60.3%)
• control group: male, 22 (37.9%), female 36 (62.1%)

Current age, mean (SD) years:

• exercise group: 59.8 (10.8) years
• control group: 60.6 (10.8) years

Age at cancer diagnosis: not reported

Ethnicity/race, n (%):

• exercise group: American Indian, 0 (0%); Asian/Pacific Islander, 0 (0%): black non-Hispanic, 9 (13.2%);

white non-Hispanic, 57 (83.8%); Hispanic, 1 (1.5%); other, 1 (1.5%)

• control  group:  American  Indian,  1  (1.7%);  Asian/Pacific  Islander,    2  (3.4%);  black  non-Hispanic  11

(19.0%); white non-Hispanic, 42 (72.5%); Hispanic, 2 (3.4%); other, 0 (0%)

Education level, n (%):

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

119

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Griffith 2009  (Continued)

Cochrane Database of Systematic Reviews

• exercise group: high school, 7 (10.3%); college, 35 (51.5%); graduate school, 26 (38.2%)
• control group: high school, 8 (13.8%); college, 17 (29.3%); graduate school, 33 (56.9%)

SES: not reported

Employment status, n (%):

• exercise group: full-time, 31 (54.4%); part-time, 5 (8.8%); resigned, 15 (26.3%); disabled, 6 (10.5%);

leave of absence, 1 (1.7%); other, 8 (11.8%)

• control group: full-time, 29 (55.8%); part-time, 6 (11.5%); resigned, 15 (28.9%); disabled, 2 (3.9%); leave

of absence, 3 (4.4%); other, 5 (8.6%)

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported\

Interventions

73 participants assigned to the exercise intervention, including:

• brisk 20- to 30-minute walk followed by 5 minutes of slower walking (cool down)
• other aerobic activities such as cycling could substitute or supplement walking
• biweekly telephone calls from study nurse

Type exercise (aerobic/anaerobic): aerobic

Intensity of the experimental exercise intervention: moderate, corresponding to approximately 50% to
70% of the maximum HR

Frequency: 5 times per week

Duration of individual sessions: 25 to 35 minutes

Duration of exercise program: varied by duration of cancer treatment. For the entire sample, the mean
(SD) number of cancer treatment weeks was 12.83 (5.15); range (5 to 35 weeks)

Total number of exercise sessions: varied

Format: individual

Facility: home

Not professionally led

Adherence, defined as walking at least 60 minutes weekly for more than 2/3 of the total program: 67.6%
with an average walking time of 117 (SD = 105) minutes per week

65 participants assigned to control group, including:

• encouragement to maintain current activity levels
• biweekly telephone calls

Contamination of control group: non-adherence defined as walking more than 60 minutes for more
than 2/3 of treatment weeks. Adherence = 77.6%, and contamination = 22.4%

Outcomes

Primary outcome included:

• cardiorespiratory fitness, expressed as peak oxygen uptake (VO2), either directly measured by tread-

mill testing or estimated from the 12-MWT

Other outcomes included:

• physical functioning subscale, assessed using the Medical Outcomes Survey Short Form-36

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

120

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Griffith 2009  (Continued)

Cochrane Database of Systematic Reviews

• role limitations owing to physical health subscale, assessed using the Medical Outcomes Survey Short

Form-36

• pain level, assessed using the pain subscale of the Medical Outcomes Survey Short Form-36

Outcomes were measured at baseline and end of intervention:

• exercise group: n = 68 at baseline, n = 68 at end of intervention
• control group: n = 58 at baseline, n = 58 at end of intervention

Subgroup analysis: examined outcomes by cancer type (prostate versus other cancer) and performed
secondary dose-response analysis, which evaluated outcomes based on the actual amount of exercise
performed according to the Physical Activity Questionnaire, regardless of group assignment. This sec-
ondary analysis was necessitated by the finding that, contrary to study instructions, 22.4% of the con-
trol group participants performed exercise at a level at least equivalent to what was assigned for the ex-
ercise group. The subgroup analysis and the secondary analysis were not prespecified

Adverse events: not reported

Notes

Country: US

Funding: none reported

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

The generation of the random sequence was not described

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

Allocation to the intervention was not concealed from the study personnel

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Although analyses were conducted on an ITT basis, 5 participants from the in-
tervention arm and 7 from the control arm were not included in the analyses

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Hacker 2011 

Study characteristics

Methods

Study design: RCT

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

121

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Hacker 2011  (Continued)

Cochrane Database of Systematic Reviews

Number randomized: 22, but 2 did not have a transplant and 1 did not have baseline data. The author
reported that 19 individuals were randomized, 9 to the exercise group and 10 to the control group

Study start and stop dates: not reported

Length of intervention: 6 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: hematologic malignancies

Time since cancer diagnosis: not reported

Time in active treatment: all receiving an HSCT

Inclusion criteria:

• patients scheduled to receive an HSCT
• ability to speak English
• ability to comprehend the purpose of the study
• no history of psychiatric illness
• treating physicians provided approval for participants to participate in the trial

Eligibility criteria related to interest or ability, or both, to exercise:

• none reported

Exclusion criteria:

• none reported

Gender, n: male, 14; female, 5

Current age, mean (SD, range) years: 46.26 (16.23, 20 to 67) years

Age at cancer diagnosis: not reported

Ethnicity/race, n: African Americans, 11; white, 7; Hispanic, 1

Education level, n: completed some college as their highest level of education, 10

SES, n: income level < USD40,000, 10

Employment status: not reported

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Interventions

9 participants assigned to the exercise intervention, including:

• progressive strength-training intervention, including a comprehensive program of progressive resis-
tance  to  strengthen  the  upper  body,  lower  body,  and  abdominal  muscles  using  elastic  resistance
bands (Thera-Bands; Hygenic Corp) if able, and body weight for resistance. Progression of the exer-
cise prescription was structured to first increase the number of sets from 1 to 2 sets of 8 to 10 repeti-
tions and then to increase the resistance level of elastic bands. Preselected exercises with concentric
and eccentric muscle contractions included:
• 8 exercises using elastic resistance bands (chest fly, biceps curl, triceps extension, shoulder shrug,

shoulder upright row, shoulder lateral raise, knee flexion, and knee extension)

• 3 exercises that used body weight as resistance (wall push-ups, squats, and bed sit-ups)

Type exercise (aerobic/anaerobic): anaerobic

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

122

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Hacker 2011  (Continued)

Cochrane Database of Systematic Reviews

Intensity of the experimental exercise intervention: Borg RPE scale of somewhat hard (Borg scale 13)

Frequency: 3 times per week, once or twice at the clinic and once or twice at home

Duration of individual sessions: varied

Duration of exercise program: 6 weeks

Total number of exercise sessions: 18 sessions

Format: individual

Facility: facility and home

Professionally led: unsupervised and supervised by the principal investigator or a trained member of
the research team

Adherence: by week 2, all participants in the strength-training group exercised at least once or twice
per week, and most met the strength-training prescription of exercising 3 times per week by week 3. All
of the participants exercised at least once or twiceper week for at least 5 of the 6 weeks

10 participants assigned to control group, including:

• usual activities
• recommendations regarding rest, physical activity, and exercise from their attending HSCT physician
• request not to exercise

Contamination of control group: not reported

Outcomes

No primary outcome was identified. QoL outcomes included:

• fatigue, assessed using a 1-item fatigue intensity scale and the fatigue subscale of the QLQ-C30
• Health Status Perceptions, assessed using the QLQ-C30 and including:

* global HRQoL
* physical
* emotional
role
*
* cognitive
social
*
symptoms (fatigue, pain, nausea/vomiting)
*
*
single-item questions (appetite loss, constipation, dyspnea, diarrhea, financial stress, and sleep
disturbances)

• Life Satisfaction, assessed using the Ferrans and Powers QLI and subscales, including:

• global HRQoL
• health and functioning
• psychological/spiritual
• social and economic
• family

Other outcomes included:

• physical activity, measured using a wrist-worn accelerometer, the Actiwatch-Score (Phillips Respiron-

ics)

• muscle strength consisting of timed stair climb, handgrip strength, 30-s chair-stand, time needed to

stand up from bed rest examination

Outcomes were measured at baseline, 8 days after transplant (second baseline), and 6 weeks after dis-
charge from the hospital:

• exercise group: n = 9 at baseline, n = 8 at 8 days, n = 8 at 6 weeks
• control group: n = 10 at baseline, n = 9 at 8 days, n = 7 at 6 weeks

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

123

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Hacker 2011  (Continued)

Subgroup analysis: none

Cochrane Database of Systematic Reviews

Adverse events: 2 participants, 1 each from the exercise and control groups died during the course of
the trial as a result of their underlying medical condition

Notes

Country: US

Funding: National Institutes of Health/National Institute of Nursing Research

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

The generation of the random sequence was not described

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

Allocation to the intervention was not concealed from the study personnel

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Analyses were not conducted on an ITT basis and the treatment of missing da-
ta was not described. There was substantial attrition from the trial, especially
in the intervention arm

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Haddad 2011 

Study characteristics

Methods

Study design: RCT

Number randomized: 163; 53 to the yoga exercise group, 56 to the stretching exercise group, and 54 to
the control group

Study start and stop dates: not reported

Length of intervention: 6 weeks

Length of follow-up: 1, 3, and 6 months

Participants

Type cancer: breast cancer, Stages 0 to III

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

124

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Haddad 2011  (Continued)

Cochrane Database of Systematic Reviews

Inclusion criteria:

• breast cancer Stage 0 to III
• undergoing radiation therapy

Eligibility criteria related to interest or ability, or both, to exercise:

• none reported

Exclusion criteria:

• none reported

Gender: female

Current age, mean years: 51.9 years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level: not reported

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Interventions

53 participants assigned to the yoga exercise intervention

56 participants assigned to the stretching exercise intervention

Type exercise (aerobic/anaerobic): aerobic or anaerobic

• yoga: aerobic
• stretching: anaerobic

Intensity of the experimental exercise intervention: not reported

Frequency: 3 times per week for either yoga or stretching

Duration of individual sessions: not reported

Duration of exercise program: 6 weeks

Total number of exercise sessions: 18 sessions for either yoga or stretching

Format: not reported

Facility: unclear

Professionally led: not reported

Adherence: not reported

54 participants assigned to control group, including:

• waiting list

Contamination of control group: not reported

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

125

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Haddad 2011  (Continued)

Outcomes

No primary outcome was identified. QoL outcomes included:

• fatigue, assessed using the BFI
• depression, assessed using the CES-D
• global QoL, assessed using the MOS SF-36 and subscales
• benefit finding, assessed using the Benefit Finding
• spiritualty, assessed using the FACT-Sp

Outcomes were measured at baseline, end of treatment (6 weeks), 1, 3, and 6 months following end of
treatment:

• yoga exercise group: n = 53 at baseline and all follow-up visits
• stretching exercise group: n = 56 at baseline and all follow-up visits
• control group: n = 54 at baseline and all follow-up visits

Subgroup analysis: not reported

Adverse events: not reported

Notes

Country: unclear, investigators from US, India and Germany

Funding: none reported

Published conference abstract

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

Generation of allocation sequence was not described

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Insufficient details provided to determine whether there was any attrition

Selective reporting (re-
porting bias)

Unclear risk

Insufficient details provided to assess whether there was selective outcome re-
porting

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

126

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Headley 2004 

Study characteristics

Methods

Study design: RCT

Cochrane Database of Systematic Reviews

Number randomized: 38; the number of participants originally assigned to the exercise or control
group not reported

Study start and stop dates: not reported

Length of intervention: 12 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: breast cancer, Stage IV

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Inclusion criteria:

• scheduled to initiate outpatient chemotherapy
• would be receiving HDC for the purpose of bone marrow or stem cell transplantation or would be

receiving hormonal therapy as a single treatment

• English-literate
• ≥ 18 years of age

Eligibility criteria related to interest or ability, or both, to exercise:

• having performance status of ≤ 2 on the Zubrod scale
• being able to sit in a straight back chair for at least 30 minutes
• having access to a television and video cassette player

Exclusion criteria:

• received radiation therapy during the prior 2 months
• serum hemoglobin level ≤ 8.0 g/dL
• resting pain level of > 2 on a 0 to 10 pain scale
• symptomatic bone metastases

Gender: female

Current age, mean (SD) years:

• exercise group: 52.25 (11.43) years
• control group: 50.00 (7.10) years

Age at cancer diagnosis: not reported

Ethnicity/race, n:

• exercise group: Caucasian, 15; African American, 1
• control group: Caucasian, 12; African American, 4

Education level, years of education, mean (SD):

• exercise group: 12.60 (2.5) years
• control group: 14.4 (3.12) years

SES: not reported

Employment status, n:

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

127

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Headley 2004  (Continued)

Cochrane Database of Systematic Reviews

• exercise group: not employed, 10; employed full-time, 6; employed part-time, 0
• control group: not employed, 7; employed full-time, 8; employed part-time, 1

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Interventions

The number of study participants originally assigned to the exercise intervention not reported. Data
available for 16 participants assigned to the exercise intervention, including:

• 30-minute seated exercise program in which participants sit in a straight backed chair while perform-
ing stretching and repeated flexion and extension of the arms, head, upper torso, and legs with the
assistance of a video

• The program includes: a 5-minute warm-up, 20 minutes of moderate-intensity repetitive motion ex-

ercises, and a 5-minute cool-down

Type exercise (aerobic/anaerobic): aerobic

Intensity of the experimental exercise intervention: moderate

Frequency: 3 times per week

Duration of individual sessions: 30 minutes

Duration of exercise program: 12 weeks

Total number of exercise sessions: 36 sessions

Format: individual

Facility: home

Not professionally led

Adherence: not reported

The number of study participants originally assigned to the control intervention not reported. Data
available for 16 participants assigned to the control group, including:

• permission to continue any usual physical activity

Contamination of control group: not reported

Outcomes

No primary outcome was identified. QoL outcomes included:

• fatigue, assessed using the FACIT-F Version IV
• global QoL, using the FACIT-F

Outcomes were measured at baseline and at the beginning of each course of chemotherapy for 12
weeks for a total of 4 measurements. The numbers by treatment group not reported. The total number
of participants at each time point included:

baseline, n = 32; cycle 2, n = 28; cycle 3, n = 30; cycle 4, n = 24

Subgroup analysis: none

Adverse events: not reported

Notes

Country: US

Funding: ONS Foundation and the University of Texas Health Sciences Center in the Houston School of
Nursing

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

128

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Headley 2004  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Low risk

Computer used to generate the random sequence

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

Incomplete outcome data
(attrition bias)
All outcomes

High risk

There was no discussion on how missing data were addressed. In addition,
there were no ITT analyses as data on women who did not complete the study
were excluded from the analyses

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Hwang 2008 

Study characteristics

Methods

Study design: RCT

Number randomized: 40; 17 to the exercise group and 20 to the control group

Study start and stop dates: not reported

Length of intervention: 5 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: breast cancer

Time since cancer diagnosis: not reported

Time in active treatment: women approached at first planned radiation therapy treatment visit

Inclusion criteria:

• outpatient waiting list for radiation therapy for breast cancer

Eligibility criteria related to interest or ability, or both, to exercise:

• concurrent major health problems that could affect participation in an exercise program including
uncontrolled hypertension, cardiovascular disease, acute or chronic respiratory disease, and cogni-
tive dysfunction

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

129

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Hwang 2008  (Continued)

Cochrane Database of Systematic Reviews

Exclusion criteria:

• none

Gender: female

Current age, mean (SD) years:

• exercise group: 46.3 (9.5) years
• control group: 46.3 (7.5) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level: not reported

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Interventions

17 participants assigned to the exercise intervention, including:

• supervised exercise program, including stretching exercises focused on the shoulders, aerobic exer-

cise such as treadmill walking and bicycling, and strengthening exercise

Type exercise (aerobic/anaerobic): aerobic and anaerobic

Intensity of the experimental exercise intervention: target HR of 50% to 70% of the age-adjusted HR
maximum

Frequency: 3 times per week

Duration of individual sessions: 50 minutes

Duration of exercise program: 5 weeks

Total number of exercise sessions: 15 sessions

Format: not reported

Facility: not reported

Professionally led: not reported

Adherence: all 17 patients completed the program

23 participants assigned to control group, including:

• demonstration of shoulder ROM exercises and encouragement to continue with normal activities

Contamination of control group: not reported

Outcomes

No primary outcome was identified. Outcomes included:

• global QoL, assessed using the WHO QOL-BREF
• fatigue, assessed using the BFI
• ROM, assessed by a physical therapist
• pain, assessed using a single-item VAS

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

130

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Hwang 2008  (Continued)

Cochrane Database of Systematic Reviews

Outcomes were measured at baseline and 5 weeks:

• exercise group: n = 17 at baseline, n = 5 weeks
• control group: n = 20 at baseline, n = 5 weeks

Subgroup analysis: none

Adverse events: "No significant exercise-related adverse events such as lymphedema were reported"

Notes

Country: Korea

Funding: none reported

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

Generation of allocation sequence was not described

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

High risk

3 in control group lost to follow-up

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Jarden 2009 

Study characteristics

Methods

Study design: RCT

Number randomized: 42; 21 to the exercise group and 21 to the control group

Study start and stop dates: April 2005 to November 2007

Length of intervention: length of hospitalization

Length of follow-up: 6 months

Participants

Type cancer, n: hematologic malignancies

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

131

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Jarden 2009  (Continued)

Cochrane Database of Systematic Reviews

• exercise  group:  CML,  4;  AML  9;  acute  lymphocytic  (lymphoblastic)  leukemia;  3;  aplastic  anemia,  3;
myelodysplasia,  2;  Waldenstrom  macroglobulinemia,  0;  paroxysmal  nocturnal  hemoglobinuria,  0;
myelofibrosis, 1

• control  group:  CML,  5;  AML  7;  acute  lymphocytic  (lymphoblastic)  leukemia;  5;  aplastic  anemia,  1;
myelodysplasia,  1;  Waldenstrom  macroglobulinemia,  1;  paroxysmal  nocturnal  hemoglobinuria,  1;
myelofibrosis, 0

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Inclusion criteria:

• 18 to 65 years old
• scheduled for a myeloablative allo-HSCT

Eligibility criteria related to interest or ability, or both, to exercise:

• none reported

Exclusion criteria:

• prior HSCT
• recent cardiovascular or pulmonary disease
• abnormal electrocardiogram
• psychiatric disorder
• motor, musculoskeletal, or neurologic dysfunction requiring walking aides
• bony metastasis

Gender, n (%):

• exercise group: male, 13 (61.9%); female, 8 (38.1%)
• control group: male, 13 (61.9%); female, 8 (38.1%)

Current age, mean (SD) years:

• exercise group: 40.9 (13.3) years
• control group: 37.4 (11.1) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level, university or secondary school, n (%):

• exercise group: 10 (47.6%)
• control group: 13 (61.9%)

SES: not reported

Employment status, full-time, employed, n (%):

• exercise group: 16 (76.2%)
• control group: 19 (90.5%)

Comorbidities: not reported

Past exercise history, baseline physical activity level I + II, n (%)

• exercise group: 15 (71.4%)
• control group: 14 (66.7%)

On hormone therapy: not reported

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

132

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Jarden 2009  (Continued)

BMI, mean (SD)

• exercise group: 27.5 (5.5)
• control group: 24.73 (5.2)

Cochrane Database of Systematic Reviews

Interventions

21 participants assigned to the exercise intervention, including:

• multimodal exercise program, including:

• stationary cycling, 15 to 30 minutes for 5 days per week
• dynamic and stretching exercises, 5 days per week
• resistance training, 3 days per week
• progressive relaxation on 2 days per week
• psychoeducation

Type exercise (aerobic/anaerobic): aerobic and anaerobic

Intensity of the experimental exercise intervention: not to exceed 75% of maximal HR

Frequency: 5 days per week

Duration of individual sessions: 1 hour ± 10 minutes

Duration of exercise program: length of hospitalization

Total number of exercise sessions: varied

Format: individual

Facility: hospital

Professionally led by a research investigator

Adherence: not reported

21 participants assigned to control group, including:

• usual care

Contamination of control group: not reported

Outcomes

Primary outcome:

• physical capacity, assessed by measuring the VO2 max

Other outcomes included:

• physiologic outcomes included:

• muscle strength
• functional performance
• HRQoL outcomes included:

• global HRQoL measured using the EORTC QLQ-C30
• cancer–specific QoL and fatigue, assessed using the FACT-An
• anxiety, assessed using the HADS
• depression, assessed using the HADS

Outcomes were measured at baseline, postintervention, 3 months, and 6 months:

• exercise group: n = 21 at baseline, n = 17 post-intervention, n = 17 at 3 months, n = 13 at 6 months
• control group: n = 21 at baseline, n = 17 at end of hospitalization, n = 13 at 3 months, n = 13 at 6 months

Subgroup analysis: none

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

133

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Jarden 2009  (Continued)

Adverse events:

Cochrane Database of Systematic Reviews

• exercise group: 1 participant developed complications and 2 died
• control group: 1 participant developed complications and 1 died

Notes

Country: Denmark

Funding: The Lundbeck Foundation, The Novo Nordic Foundation, The Danish Cancer Society, The
Copenhagen Hospital Corporation, The Danish Nursing Society

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Low risk

"...using the computerized Clinical International Trial Management System"

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Low risk

Used ITT with assumption that data were missing at random

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Lanctot 2010 

Study characteristics

Methods

Study design: RCT

Number randomized: 101; 58 to the exercise group and 43 to the control group

Study start and stop dates: not reported

Length of intervention: 8 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: breast cancer, Stages I to III

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

134

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lanctot 2010  (Continued)

Inclusion criteria:

• undergoing chemotherapy

Eligibility criteria related to interest or ability, or both, to exercise:

Cochrane Database of Systematic Reviews

• none reported

Exclusion criteria:

• none reported

Gender: not reported

Current age: not reported

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level: not reported

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Interventions

58 participants assigned to the exercise intervention, including:

• yoga postures, visualization, relaxation, meditation, breathing exercises. A video was given for daily

home practice

Type exercise (aerobic/anaerobic): unclear

Intensity of the experimental exercise intervention: not reported

Frequency: once per week

Duration of individual sessions: 90 minutes

Duration of exercise program: 8 weeks

Total number of exercise sessions: 8 sessions

Format: not reported

Facility: facility and home

Professionally led by yoga instructors accredited with the Bali method

Adherence: not reported

43 participants assigned to control group, which was not described

Contamination of control group: not reported

Outcomes

No primary outcome was identified. QoL outcomes included:

• global QoL, assessed using the Quality of Life Systematic Inventory and subscales:

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

135

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lanctot 2010  (Continued)

Cochrane Database of Systematic Reviews

• physical health
• cognitive functioning
• affective functioning
• leisure
• cancer module
• familial functioning
• marital life

• depression, assessed using the BDI

Outcomes were measured at baseline and at 8 weeks:

• exercise group: n = 41 at baseline and at 8 weeks
• control group: n = 32 at baseline and at 8 weeks

Subgroup analysis: none reported

Adverse events: not reported

Notes

Country: Canada

Funding: none reported

Published conference abstract

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

Generation of allocation sequence was not described

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Insufficient details provided to determine whether there was any attrition

Selective reporting (re-
porting bias)

Unclear risk

Insufficient details provided to assess whether there was selective outcome re-
porting

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Moadel 2007 

Study characteristics

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

136

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Moadel 2007  (Continued)

Methods

Study design: RCT

Cochrane Database of Systematic Reviews

Number randomized: 164; 108 to a yoga exercise group and 56 to the control group

Study start and stop dates: 2001 to 2005

Length of intervention: 12 weeks

Length of follow-up: 1, 3, and 6 months

Participants

Type cancer: breast cancer, stage of disease:

• exercise group: Stage I, 42%; Stage II, 36%; Stage III, 17%; Stage IV, 5%
• control group: Stage I, 50%; Stage II, 38%; Stage III, 12%; Stage IV, 0%

Time since cancer diagnosis, mean (SD, range) years:

• exercise group: 1.15 (1.14, 0.06 to 4.06) years
• control group: 0.98 (1.13, 0.03 to 4.70) years

Time in active treatment: receiving chemotherapy, %:

• exercise group: at baseline, 30%; at 3 months, 36%
• control group: at baseline, 23%; at 3 months, 27%

Randomization was stratified by treatment status

Inclusion criteria:

• ≥ 18 years old
• new/recurrent breast cancer (Stages I to III) diagnosis within previous 5 years
• high performance status (ECOG performance status of < 3)
• ability to speak English or Spanish

Eligibility criterion related to interest or ability, or both, to exercise:

• not actively practicing yoga

Exclusion criteria: none reported

Gender: female

Current age, mean (SD, range) years:

• exercise group: 55.11 (10.07, 32 to 75) years
• control group: 54.23 (9.81, 28 to 71) years

Age at cancer diagnosis: not reported

Ethnicity/race, %:

• exercise group: African-American, 42%; Hispanic, 30%; non-Hispanic white, 22%; other, 6%
• control group: African-American, 43%; Hispanic, 34%; non-Hispanic white, 23%; other, 0%

Education level:

• exercise group: high school, 69%; college/graduate, 31%
• control group: high school, 89%; college/graduate, 11%

SES: not reported

Employment status: not reported

Comorbidities: not reported

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

137

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Moadel 2007  (Continued)

Past exercise history: not reported

On hormone therapy, %:

• exercise group: at baseline, 24%; at 3 months, 36%
• control group: at baseline, 41%; at 3 months, 50%

Cochrane Database of Systematic Reviews

Interventions

108 participants assigned to exercise group, consisting of yoga with each session including:

• physical stretches and poses
• breathing exercises
• meditation

All exercises were done in a seated or reclined position

Type exercise (aerobic/anaerobic): aerobic

Intensity of experimental exercise intervention: mild

Frequency: once per week, but participants were allowed to attend more than 1 session per week and
asked to practice yoga at home

Duration of sessions: 90 minutes

Duration of program: 12 weeks

Total number of exercise sessions: 12 sessions

Facility: facility and home

Professionally led: not reported

56 participants assigned to control group, including:

• waiting list

Adherence: 26 (31%) participants did not attend any classes, but 8 reported practicing yoga at home at
least a few times per week. The mean number of classes attended by active class participants was 7.00
(SD 3.80) classes. Of 59 participants reporting data, 61% practiced yoga at home at least a few times
per week

Contamination of control group: not reported

Outcomes

No primary outcome was identified. QoL outcomes included:

• global QoL, measured using the FACT-G and subscales of

functional well-being

* PWB
*
* EWB
* SWB

• fatigue, assessed using the FACIT-F
• spiritual well-being, assessed using the FACIT-Sp
• mood, assessed using subscales of the POMS

Outcomes were measured at baseline and 12 weeks:

• exercise group: n = 84 at baseline, n = 84 at 12 weeks
• control group: n = 44 at baseline, n = 44 at 12 weeks

Subgroup analysis: by treatment status

Adverse events: none reported

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

138

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Moadel 2007  (Continued)

Notes

Country: US

Cochrane Database of Systematic Reviews

Funding: National Cancer Institute, Langeloth Foundation

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

Generation of allocation sequence was not described

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Investigators stated that they used an "intention-to-treat approach" but it is
unclear how the 24 drop-outs in the exercise arm and the 12 drop-outs in the
control arm were handled

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Mock 1994 

Study characteristics

Methods

Study design: RCT

Number randomized: 14; 9 to the exercise group and 5 to the control group

Study start and stop dates: not reported

Length of intervention: duration of chemotherapy (4 to 6 months)

Length of follow-up: 1 month postchemotherapy

Participants

Type cancer: breast cancer

Time since cancer diagnosis: not reported

Time in active treatment: enrolled prior to beginning chemotherapy

Inclusion criteria:

• age 30 to 69 years
• able to understand English
• accepted into a program of adjuvant cytotoxic chemotherapy

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

139

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mock 1994  (Continued)

• Stage I or II breast cancer

Cochrane Database of Systematic Reviews

Eligibility criteria related to interest or ability, or both, to exercise:

• "Before entering the program, subjects were questioned about whether they engaged in a regular
exercise program and were screened for health problems that would contraindicate beginning such
a program"

Exclusion criteria:

• history of previous breast cancer
• concurrent  major  health  problems  (e.g.  gross  obesity,  cardiovascular  disease,  respiratory  disease,

cognitive dysfunction)

Gender: female

Current age: mean (range), 44 (34 to 61) years

Age at cancer diagnosis: not reported

Ethnicity/race: 93% Caucasian, 7% Other

Education level: mean years of education, 16 years

SES: not reported

Employment status: 78% employed

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Interventions

9 participants assigned to the exercise intervention, including:

• progressive, regular program composed of a brisk, incremental 10- to 45-minute walk followed by 5

minutes of slow walking (cool down)

• support group led by an oncology clinical nurse specialist: 90 minutes every 2 weeks for the duration

of the chemotherapy treatments

Type exercise (aerobic/anaerobic): aerobic

Intensity of the experimental exercise intervention: not reported

Frequency: 4 or 5 times per week

Duration of individual sessions: 10 to 45 minutes and 5 minutes cool-down

Duration of exercise program: 4 to 6 months

Total number of exercise sessions: varied

Format: individual

Facility: home

Not professionally led

Adherence: "...not all equally successful in maintaining an active exercise program, but all exercised for
a minimum of 30 minutes three or more times per week throughout the program"

5 participants assigned to control group, including:

• usual care

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

140

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mock 1994  (Continued)

Cochrane Database of Systematic Reviews

Contamination of control group: "two did not exercise at all, and three exercised less than 30 minutes
twice per week"

Outcomes

No primary outcome was identified. QoL outcomes included:

• physical functioning, assessed using the Karnofsky Performance Status scale
• psychosocial adjustment, assessed using

• Psychosocial Adjustment to Illness Scale
• Brief Symptom Inventory

• self concept, assessed using the total score of the Tennessee Self-Concept Scale
• body image, using
• Body Image VAS
• Physical Self Subscale of the Tennessee Self-Concept Scale
• symptom intensity, assessed using Symptoms Assessment Scales

Outcomes were measured at baseline, mid-treatment (about 3 months), and end of the intervention
(about 6 months):

• exercise group: n = 9 at baseline, n = 9 at 3 months, n = 9 at 6 months
• control group: n = 5 at baseline n = 5 at 3 months, n = 5 at 6 months

Subgroup analysis: none

Adverse events: "No walkers suffered any known physical injury or bleeding episode related to the
walking program"

Notes

Country: US

Funding: American Cancer Society—Massachusetts Division, American Nurses Foundation, Massachu-
setts Nurses Foundation, Boston College

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

The generation of the random sequence was not described

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

All study participants were included in the analyses in the originally assigned
treatment group

Selective reporting (re-
porting bias)

High risk

Only some of the symptoms from the SAS were included in the table; others
were summarized only using generalities in the text "infrequently"

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

141

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mock 1994  (Continued)

Other bias

Low risk

Mock 1997 

Study characteristics

Cochrane Database of Systematic Reviews

The trial appears to be free of other problems that could put it at a high risk of
bias

Methods

Study design: quasi-randomized controlled trial

Number randomized: 50, numbers originally assigned to treatment groups not reported, but 22 report-
ed assigned to the exercise group and 24 to the control group

Study start and stop dates: not reported

Length of intervention: about 6 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: breast cancer, Stage I or II

Time since cancer diagnosis: not reported

Time in active treatment: received breast-conserving surgery; undergoing radiation therapy

Inclusion criteria:

• newly diagnosed Stage I or II breast cancer
• received breast conserving surgery
• undergoing radiation therapy
• age 35 to 65 years

Eligibility criteria related to interest or ability, or both, to exercise:

• participating in a structured exercise program

Exclusion criteria:

• concurrent major health problems such as cardiovascular disease, acute or chronic respiratory dis-

ease

• cognitive dysfunction

Gender: female

Current age, mean (SD) years:

• exercise group: 48.09 (5.42) years
• control group: 50.29 (8.47) years

Age at cancer diagnosis: not reported

Ethnicity/race, n (%):

• exercise group: Caucasian, 18 (82%), African American, 4 (18%)
• control group: Caucasian, 22 (92%), African American, 1 (4%), Hispanic, 1 (4%)

Education level, mean (SD) years:

• exercise group: 15.36 (2.72) years
• control group: 14.96 (2.46) years

SES: not reported

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

142

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mock 1997  (Continued)

Employment status, n (%):

Cochrane Database of Systematic Reviews

• exercise group: full-time, 9 (41%), part-time, 9 (41%), unemployed, 4 (18%)
• control group: full-time, 9 (38%), part-time, 6 (25%), unemployed, 9 (38%)

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Interventions

22 participants reported to be assigned to the exercise intervention, including:

• self-paced progressive program "...a brisk incremental 20- to 30-minute walk, followed by 5 minutes

of slow walking (cool down)" 4 or 5 times per week

Type exercise (aerobic/anaerobic): aerobic

Intensity of the experimental exercise intervention: not reported

Frequency: 4 or 5 times per week

Duration of individual sessions: 25 to 35 minutes

Duration of exercise program: about 6 weeks

Total number of exercise sessions: 24 to 30 sessions

Format: individual

Facility: home

Not professionally led

Adherence: 19/22 (86%) reported exercising ≥ 3 times per week for at least 30 minutes

24 participants reported to be assigned to control group, including:

• usual care, with regular contact from study staff to inquire about health and general response to treat-

ment

Contamination of control group: "several control subjects were regular walkers at the time of study en-
try"

Outcomes

No primary outcome was identified. Outcomes included:

• physical function, assessed using the 12-MWT
• exercise level, assessed using the Exercise Rating Scale (frequency and length of time spent exercising)
• symptom experience (pain, skin changes, nausea, vomiting, fatigue, diarrhea, difficulty sleeping, irri-
tability, depression, mouth sores, anxiety, constipation, and satisfaction with body), assessed using
the Symptom Assessment Scales

• fatigue, assessed using PFS

Outcomes were measured at baseline and end of intervention at 6 weeks. Symptom experience and fa-
tigue were also assessed at 3 weeks. Numbers of participants with data at each time point not reported
by treatment group, but implied to be 22 in exercise group and 24 in control group

Subgroup analysis: none

Adverse events: not reported

Notes

Country: US

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

143

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Mock 1997  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Funding: Commonwealth of Massachusetts Department of Public Health Breast Cancer Researcher's
Award; National Institute for Nursing Research Exploratory Center Award

Authors' judgement

Support for judgement

High risk

Random assignment of first participant and then alternating assignment

High risk

Alternation of treatment assignment

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

No ITT analyses were performed and no accounting of study participants who
withdrew from study

Selective reporting (re-
porting bias)

Low risk

There is no evidence of selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Mock 2001 

Study characteristics

Methods

Study design: RCT

Number randomized: 52, numbers assigned to exercise or control group not reported

Study start and stop dates: not reported

Length of intervention: duration of treatment; 6 weeks for radiation therapy and 4 to 6 months for
chemotherapy

Length of follow-up: to end of the intervention

Participants

Type cancer: breast cancer

Stage, %: Stage I, 54%; Stage II, 40%; Stage IIIa, 6%

Time since cancer diagnosis: not reported

Time in active treatment: In treatment

Inclusion criteria:

• recently treated for Stage I to IIIa breast cancer by definitive surgery
• scheduled to receive outpatients adjuvant radiation (64%) or chemotherapy (36%)

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

144

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mock 2001  (Continued)

Cochrane Database of Systematic Reviews

Eligibility criteria related to interest or ability, or both, to exercise:

• concurrent major health problem that would contraindicate an exercise program

Exclusion criteria:

• none reported

Gender: female

Current age: mean (range) years: 47.98 (28 to 75) years

Age at cancer diagnosis: not reported

Ethnicity/race, n (%): white, 43 (86%); African American, 6 (12%); Hispanic, 1 (2%)

Education level, mean (range) years of education: 14.76 (8 to 20) years

SES: not reported

Employment status, n (%): full-time, 24 (48%); part-time, 9 (18%; unemployed, 17 (34%)

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Interventions

Number of participants assigned to the exercise intervention not reported. The exercise intervention
included:

• individualized  walking  program,  with  contact  from  clinic  staff  every  2  weeks  to  check  on  progress

based on Levine conservation model

Type exercise (aerobic/anaerobic): aerobic

Intensity of the experimental exercise intervention: not reported

Frequency: 5 or 6 sessions per week

Duration of individual sessions: 10 to 15 minutes to start, advancing to 30 minutes

Duration of exercise program: to end of therapy

Total number of exercise sessions: varied

Format: individual

Facility: home

Not professionally led

Adherence: 33% did not maintain a minimum of 90 minutes/week in ≥ 3 daily sessions

Number of participants assigned to control group not reported. The control intervention included:

• usual care, with contact from study staff every 2 weeks for attention control

Contamination of control group: 50% were actively exercising during the study period

Outcomes

No primary outcome was identified. QoL outcomes included:

• fatigue, assessed using Modified PFS, including

* overall fatigue and 4 fatigue dimensions: temporal, severity, affective, and sensory

• physical function, assessed using

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

145

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mock 2001  (Continued)

Cochrane Database of Systematic Reviews

• 12-MWT
• activity level rating scale
• MOS SF-36 physical function

• emotional distress, assessed using the Profile of Moods State questionnaire
• global HRQoL and QoL domains, assessed using the MOS SF-36 and following subscales

• physical functioning
• social functioning
• role functioning physical limitations
• role functioning-emotional limitations
• bodily pain
• general mental health
• vitality
• general health perceptions

Outcomes were measured at baseline and end of the intervention, but numbers by treatment group
with data at each time point were not reported

Subgroup analysis: owing to poor adherence in the experimental group and high contamination in the
control group, the analyses reported were not based on randomization but based on high-walkers ver-
sus low-walkers

Adverse events: none reported

Cost: Described as "low cost" but no data reported

Notes

Country: US

Funding: Fatigue Initiative in Research, Education Grant from the Oncology Nursing Society Foundation
through a donation from Ortho Biotech

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

 Computer generated

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Unclear risk

 Sealed envelopes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

High risk

No ITT analyses were performed

Low risk

There is no evidence of selective reporting of outcomes

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

146

 
 
 
 
Cochrane Database of Systematic Reviews

The trial appears to be free of other problems that could put it at a high risk of
bias

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mock 2001  (Continued)

Other bias

Low risk

Mock 2005 

Study characteristics

Methods

Study design: RCT

Number randomized: 119; 60 to the exercise group and 59 to the control group

Study start and stop dates: recruitment between 1998 and 2001

Length of intervention: for the duration of treatment, 6 weeks if radiation therapy or 3 to 6 months if
chemotherapy

Length of follow-up: to end of the intervention

Participants

Type cancer: breast cancer

Stage, %

• exercise group: Stage 0, 20%; Stage I, 45%; Stage II, 35%; Stage IIIa, 0%
• control group: Stage 0, 27.2%; Stage I, 40.7%; Stage II, 25.4%; Stage IIIa, 6.7%

Time since cancer diagnosis: not reported

Time in active treatment: initiating adjuvant therapy

Inclusion criteria:

• 18 to 70 years old

Eligibility criteria related to interest or ability, or both, to exercise:

• concurrent major health problems that could affect participation in an exercise program, including
obesity (BMI > 35 kg/m2), cardiovascular disease, acute or chronic respiratory disease, cognitive dys-
function

• engaged in active exercise (> 45 minutes per week)

Exclusion criteria:

• no additional exclusions

Gender: female

Current age, mean (SD) years:

• exercise group: 51.3 (8.9) years
• control group: 51.6 (9.7) years

Age at cancer diagnosis: not reported

Ethnicity/race, % Caucasian:

• exercise group: 85.0%
• control group: 79.3%

Education level, years of education, mean (SD) years:

• exercise group: 15.1 (2.8) years

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

147

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mock 2005  (Continued)

• control group: 14.9 (2.7) years

SES: not reported

Employment status: 73% employed

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Adjuvant treatment: radiation therapy, 58%; chemotherapy, 42%

Interventions

60 participants assigned to the exercise intervention, including:

• walking briskly for 15 minutes and increasing to 30 minutes as training progressed

Type exercise (aerobic/anaerobic): aerobic

Intensity of the experimental exercise intervention: target HR range of ~ 50% to 70% of maximum HR

Frequency: 5 or 6 times per week

Duration of individual sessions: 45 minutes

Duration of exercise program: 6 weeks for radiation or 3 to 6 months for chemotherapy

Total number of exercise sessions: varied

Format: individual

Facility: home

Not professionally led

Adherence: defined as engaging in ≥ 60 minutes of aerobic activity for at least 67% of the duration of
the trial: 39/54 (72%) adhered

59 participants assigned to control group, including:

• usual care, with contact from the research team every 2 weeks for attention control

Contamination of control group: defined as exceeding 45 minutes of aerobic activity weekly for 67% of
the duration of the trial: 33/54 (61%) were not contaminated; 39% were contaminated

Outcomes

Primary outcome:

• fatigue, assessed using the PFS

Other outcomes included

• physical function, assessed using

• 12-MWT
• SF-36 Physical Function Scale
• Physical Activity Questionnaire

Outcomes were measured at baseline and end of the intervention:

• exercise group: n = 54 at baseline, n = 54 at end of the intervention
• control group: n = 54 at baseline n = 54 at end of the intervention

Subgroup analysis: high walkers (>60 minutes per week in ≥ 3 sessions) versus low walkers (< 60 min-
utes per week or not at all)

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

148

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mock 2005  (Continued)

Adverse events: not reported

Notes

Country: US

Cochrane Database of Systematic Reviews

Funding: Fatigue Initiative in Research and Education multi-institutional award from the Oncology
Nursing Society Foundation

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Computer generated

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Low risk

Number sealed opaque envelopes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

No ITT analyses were performed and 6 participants withdrew from the exercise
group and 5 form the control group

Selective reporting (re-
porting bias)

Low risk

There is no evidence of selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Monga 2007 

Study characteristics

Methods

Study design: RCT

Number randomized: 30; not clear how many originally randomized to the exercise or control groups

Study start and stop dates: not reported

Length of intervention: 8 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: prostate cancer

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Inclusion criteria:

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

149

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Monga 2007  (Continued)

Cochrane Database of Systematic Reviews

• first time cancer diagnosis
• ambulatory
• able to complete self-report measures,

Eligibility criteria related to interest or ability, or both, to exercise:

• inability to exercise

Exclusion criteria:

• concurrently receiving chemotherapy
• major health problems (uncontrolled hypertension, i.e. seated systolic blood pressure > 160 mmHg or
seated diastolic blood pressure > 90 mmHg, uncontrolled insulin-dependent diabetes mellitus, severe
arthritis, and obvious cognitive dysfunction)

• recent  history  of  sudden  onset  of  shortness  of  breath  on  exertion  or  a  recent  history  of  dizziness,

blurred vision, or fainting spells

• recent history of unstable angina, coronary artery disease, myocardial infarction, or cardiac failure
• bone, back, or neck pain of recent origin

Gender: male

Current age, mean (SD, range) years:

• exercise group: 68.0 (4.2, 62 to 77) years
• control group: 70.6 (5.3, 64 to 80) years

Age at cancer diagnosis: not reported

Ethnicity/race: n, (%)

• exercise group: white, 3 (27%); black, 7 (64%); Hispanic, 1(9%)
• control group: white, 4 (40%); black, 5 (50%); Hispanic, 1 (10%)

Education level, years education, mean (SD) years:

• exercise group: 12.4 (3.3) years
• control group: 11.6 (2.8) years

SES: not reported

Employment status: not reported

Comorbidities, n (%):

• exercise group: hypertension, 5 (45%); diabetes mellitus, 3 (27%); cardiovascular disease, 2 (18%);

chronic obstructive pulmonary disease, 2 (11%)

• control  group:  hypertension,  3  (30%);  diabetes  mellitus,  3  (30%);  cardiovascular  disease,  2  (20%);

chronic obstructive pulmonary disease, 1 (10%)

Past exercise history: not reported

On hormone therapy: not reported

Weight, mean (SD) lb:

• exercise group: 177.3 (29.1) lb
• control group: 80.1 (28.8) lb

Interventions

11 participants assigned to the exercise intervention had data (unclear how many originally assigned to
exercise group), including:

• 10-minute warm-up, a 30-minute aerobic segment consisting of walking on a treadmill, and a 5-to 10-

minute cool down period

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

150

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Monga 2007  (Continued)

Type exercise (aerobic/anaerobic): aerobic

Intensity of the experimental exercise intervention: not reported, instructed to maintain target HR

Frequency: 3 times per week

Duration of individual sessions: 50 minutes

Duration of exercise program: 8 weeks

Total number of exercise sessions: 24 sessions

Format: unclear

Facility: facility

Professionally led by a staff kinesiotherapist and supervised by a physician

Adherence: not reported

10 participants assigned to control group with data (unclear how many originally assigned to control
group), including:

• standard care

Contamination of control group: not reported

Outcomes

No primary outcome was identified. Outcomes included:

• cardiovascular fitness assessed using the modified Bruce treadmill test
• flexibility, assessed using the modified sit-and-reach test
• strength, assessed by measuring the time it takes to stand up and sit down 5 times from an armless

chair

• fatigue, assessed using the PFS
• global HRQoL, assessed by using the FACT-P and the FACT-G questionnaire
• depression, assessed using the BDI

Outcomes were measured at baseline and end of the intervention at 8 weeks:

• exercise group: n = 11 at baseline, n = 11 at 8 weeks
• control group: n = 10 at baseline n = 10 at 8 weeks

Subgroup analysis: none

Adverse events: none reported

Notes

Country: US

Funding: none reported

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

The generation of the random sequence was not described

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

151

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Monga 2007  (Continued)

All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Cochrane Database of Systematic Reviews

Study personnel and outcome assessors were not masked or blinded to the
study interventions

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

High risk

9 participants withdrew, but data not provided on these 9 participants 

Low risk

There is no evidence of selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Moros 2010 

Study characteristics

Methods

Study design: RCT

Number randomized: 22; 11 to the exercise group and 11 to the control group

Study start and stop dates: not reported

Length of intervention: 18 to 22 weeks

Length of follow-up: 10 to 15 days after end of the intervention

Participants

Type cancer: breast cancer, Stages I to III

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Inclusion criteria:

• postsurgery
• scheduled to receive chemotherapy

Eligibility criteria related to interest or ability, or both, to exercise:

• did not regularly exercise
• could not exercise

Exclusion criteria:

• < 65 years old
• presence of comorbidities, including diabetes, cardiovascular disease, osteoarticular disease

Gender: female

Current age: age range 38 to 64 years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level: not reported

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

152

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Moros 2010  (Continued)

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Cochrane Database of Systematic Reviews

Interventions

11 participants assigned to the exercise intervention, including:

• "dynamic aerobic exercise" adapted individually

Type exercise (aerobic/anaerobic): aerobic

Intensity of the experimental exercise intervention: 60% to 70% of determined cardiac HR

Frequency: 3 times per week

Duration of individual sessions: 60 minutes

Duration of exercise program: 18 to 22 weeks

Total number of exercise sessions: maximum of 66 sessions

Format: individual

Facility: facility

Professionally led by investigators

Adherence: 10 participants adhered > 80%

11 participants assigned to control group, including:

• usual care

Contamination of control group: not reported

Outcomes

Outcomes included:

• functional capacity, assessed using the Karnofsky Scale
• psychological status, assessed using the General Health Questionnaire
• global HRQoL, measured using the QLQ-C30

Outcomes were measured at baseline and postintervention (about 3 months):

• exercise group: n = 10 at baseline, n = 10 at postintervention
• control group: n = 7 at baseline n = 7 at postintervention

Subgroup analysis: none

Adverse events: not reported

Notes

Country: Spain

Funding: none reported

Risk of bias

Bias

Authors' judgement

Support for judgement

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

153

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Moros 2010  (Continued)

Random sequence genera-
tion (selection bias)

Unclear risk

The generation of the random sequence was not described

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

1 participant withdrew from the exercise group and 4 from the control group
and were not included in the analyses

Selective reporting (re-
porting bias)

Low risk

There is no evidence of selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Mustian 2009 

Study characteristics

Methods

Study design: RCT

Number randomized: 40; 20 to the exercise group and 20 to the control group

Study start and stop dates: August 2004 to December 2006

Length of intervention: 4 weeks

Length of follow-up: 3 months

Participants

Type cancer: breast cancer and prostate cancer

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Inclusion criteria:

• primary diagnosis of breast or prostate cancer
• completion of enrolment and baseline assessments before the end of the first calendar week of radi-

ation treatments

• at least 30 scheduled radiation treatments (6 weeks)

Eligibility criteria related to interest or ability, or both, to exercise:

• sedentary lifestyle
• no contraindications prohibiting participation in a low- to moderate-intensity walking or resistance
exercise program or physical fitness testing, as assessed by patients' radiation oncologist (or physi-
cian designee)

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

154

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mustian 2009  (Continued)

Exclusion criteria:

• distant metastases
• recurrent disease

Gender, n (%):

Cochrane Database of Systematic Reviews

• exercise group: male, 6 (32%), female, 13 (68%)
• control group: male, 5 (26%), female, 14 (74%)

Current age, mean (SD, range) years:

• exercise group: 56.6 (13.7, 36 to 82) years
• control group: 63.3 (9.4, 48 to 78) years

Age at cancer diagnosis: not reported

Ethnicity/race, n (%):

• exercise group: white, 16 (84%); Asian, 2 (11%); black, 1 (5%)
• control group: white, 18 (95%); Asian, 0 (0%); black, 1 (5%)

Education level; partial college education or greater, n (%):

• exercise group: 16 (84%)
• control group: 12 (63%)

SES: not reported

Employment status, currently employed, n (%):

• exercise group: 17 (90%)
• control group: 12 (63%)

Comorbidities: not reported

Past exercise history: all were "sedentary"

On hormone therapy, n (%):

• exercise group: 1 (5%)
• control group: 2 (10%)

Weight, mean (SD, range) lbs:

• exercise group: 173.7 (46.8, 109 to 256) lb
• control group: 188.3 (43.9, 130 to 264) lb

BMI, mean (SD, range)

• exercise group: 28.7 (5.4, 21 to 39)
• control group: 31.3 (6.8, 20 to 42)

Interventions

20 participants assigned to the exercise intervention, including:

• aerobic and anaerobic program provided as a single, 45-minute, instructional session and a prepack-
aged individual "exercise kit" with written instructions and materials necessary for the patient to com-
plete the home-based walking and resistance band exercise intervention
• the individually tailored aerobic component included a walking program
• the individually tailored resistance band exercise prescription included individually determined num-
ber of sets (1 set = 8 to 15 repetitions) for each of the 11 exercises (i.e. bicep curl, tricep extension,
overhead press, rows, chest press, internal and external rotation, lateral and front raises, horizontal

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

155

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mustian 2009  (Continued)

Cochrane Database of Systematic Reviews

adduction, and abduction) with instructions to increase resistance to a maximum of 4 sets of 15 rep-
etitions for each exercise daily

Type exercise (aerobic/anaerobic): aerobic and anaerobic

Intensity of the experimental exercise intervention:

• aerobic: moderately intense aerobic exercise (60% to 70% of HR reserve, 3 to 5 exercise rating of per-

ceived exertion on the AC SM revised rating scale)

• anaerobic: low to moderately intense progressive resistance exercise (3 to 5 exercise rating of per-

ceived exertion on the AC SM revised rating scale)

Frequency: 7 times per week

Duration of individual sessions: not reported

Duration of exercise program: 4 weeks

Total number of exercise sessions: 28 sessions

Format: individual

Facility: facility and home

Professionally led by a certified exercise scientist

Adherence: 15/19 reported increased daily steps walked; 12/19 reported doing resistance training at
the end of the intervention; 8/19 maintained resistance training through 3-month follow-up. Change in
number of steps from baseline to 4 weeks, 3997 (5959) and at 3 months, 5792 (7094.6); change in min-
utes daily resistance at 4 weeks, 9.43 (11.44), at 6 weeks and at 3 months 6.81 (9.94); change in days/
week resistance at 4 weeks, 3.05 (2.99) and at 3 months, 1.33 (2.52)

20 participants assigned to control group, including:

• usual care

Contamination of control group: 1/19 reported resistance training at 3-month follow-up. Change in
number of steps from baseline to 4 weeks, -572.3 (2139.1) and at 3 months, -64.4 (2756.4); change in
minutes daily resistance at 4 weeks, -1.57 (4.73), at 6 weeks and at 3 months, -1.03 (6.06); change in
days/week resistance at  4 weeks, -0.21 (0.63) and 3 months, -0.12 (0.86)

Outcomes

No primary outcome was identified. QoL outcomes included:

• fatigue, assessed using the BFI
• global QoL and fatigue, assessed using the FACIT-F

Non-HRQoL outcomes included:

• 6-MWT
• handgrip dynamometry
• bioelectrical impedance

Outcomes were measured at baseline, 4 weeks, and 3 months:

• exercise group: n = 19 at baseline, n = 19 at 4 weeks, n = 19 at 3 months
• control group: n = 19 at baseline, n = 19 at 4 weeks, n = 19 at 3 months

Subgroup analysis: none

Adverse events: none reported

Notes

Country: US

Funding: National Cancer Institute

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

156

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Mustian 2009  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Low risk

"using a randomization scheme with blocks of four"

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

The study appears to have been blinded at baseline, but it is not clear if it was
at follow-up, "A clinical research coordinator obtained patient consent and
collected all the self-report assessments (e.g. BFI) while a second coordina-
tor with a Master's in Exercise Science performed the objective tests (e.g. 6-
minute walk, handgrip dynamometer) and explained the home-based exercise
program to participants." The study statistician and data managers remained
blinded at all times

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

"Data were analyzed on an "intent-to-treat" basis, with patients being ana-
lyzed in the group to which they were assigned." 1 participant from each group
withdrew before any measures were made

Selective reporting (re-
porting bias)

Low risk

There is no evidence of selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Mutrie 2007 

Study characteristics

Methods

Study design: RCT

Number randomized: 203; 101 to the exercise group and 102 to the control group

Study start and stop dates: January 2004 to January 2005

Length of intervention: 12 weeks

Length of follow-up: 6 months

Participants

Type cancer: breast cancer

Stage, n (%):

• exercise group: Stage I, 17 (17.2%); Stage II, 74 (74.7%); Stage III, 8 (8.1%)
• control group: Stage I, 16 (15.7%); Stage II, 77 (75.5%); Stage III, 9 (8.8%)

Time since cancer diagnosis, mean (SD) days:

• exercise group: 162.2 (78.0) days
• control group: 161.9 (69.8) days

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

157

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mutrie 2007  (Continued)

Cochrane Database of Systematic Reviews

Time in active treatment: not reported

Inclusion criteria:

• Stage 0 to III breast cancer

Eligibility criteria related to interest or ability, or both, to exercise:

• regular exercise

Exclusion criteria:

• concurrent unstable cardiac, hypertensive, or respiratory disease
• cognitive dysfunction

Gender: female

Current age, mean (SD) years:

• exercise group: 51.3 (10.3) years
• control group: 51.8 (8.7) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level: not reported

SES: not reported

Employment status; n (%):

• exercise group: employed full/part time, 16 (16.2%); sick, 49 (49.5%); housewife, 14 (14.1%); retired,

20 (20.2%)

• control group: employed full/part time, 13 (12.7%); sick, 62 (60.8%); housewife, 12 (11.8%); retired,

15 (14.7%)

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Weight, mean (SD) kg:

• exercise group: 70.2 (12.5) kg
• control group: 71.5 (16.4) kg

BMI, mean (SD)

• exercise group: 27.3 (5.2)
• control group: 27.5 (6.0)

Interventions

101 participants assigned to the exercise intervention, including:

• program based on guidelines for prescription of exercise for cancer patients and survivors. The classes
consisted of a warm-up of 5 to 10 minutes, 20 minutes of exercise (e.g. walking, cycling, low level aer-
obics, muscle strengthening exercises, or circuits of specifically tailored exercises), and a cool-down
and relaxation period

• usual care from the healthcare team
• support in form of group discussions following exercise session in which a specific theme was covered

Type exercise (aerobic/anaerobic): aerobic

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

158

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mutrie 2007  (Continued)

Cochrane Database of Systematic Reviews

Intensity of the experimental exercise intervention: moderate; 50% to 75% of age adjusted maximum
HR

Frequency: 3 times per week

Duration of individual sessions: 45 minutes

Duration of exercise program: 12 weeks

Total number of exercise sessions: 36 sessions

Format: 2 group and 1 individual session per week

Facility: group session were facility based and individual session home based

Professionally led by trained exercise specialists

Adherence: not reported

102 participants assigned to control group, including:

• usual care from the healthcare team

Contamination of control group: not reported

Outcomes

Primary outcomes included:

• QoL as assessed by the FACT-G questionnaire

Other outcomes included:

• depression, assessed using the BDI
• emotional state, assessed using the PANAS
• BMI
• 7-day recall of physical activity, measured using the SPAQ
• performance in a 12-MWT
• score on a shoulder mobility test

Outcomes were measured at baseline, at end of the intervention (12 weeks), and 6 months:

• exercise group: n = 99 at baseline, n = 82 at 12 weeks, n = 82 at 6 months
• control group: n = 102 at baseline, n = 92 at 12 weeks, n = 95 at 6 months

Subgroup analysis: none

Adverse events: none reported

Notes

Country: UK

Funding: Cancer Research UK, UK Medical Research Council

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"The randomisation was stratified by hospital and treatment at baseline
(chemotherapy, radiotherapy, or combination) and used randomised permut-
ed blocks of length four and six (that is, for sequences of four or six women
in each hospital-treatment combination, exactly half were allocated to each
group)"

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

159

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mutrie 2007  (Continued)

Cochrane Database of Systematic Reviews

Allocation concealment
(selection bias)

Low risk

"Randomisation was done by telephone to an interactive voice response sys-
tem"

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

"We took steps to blind the evaluation of outcomes by having questionnaire
responses in sealed envelopes and ensuring that outcome measures were tak-
en by researchers who were not involved in exercise classes"

Incomplete outcome data
(attrition bias)
All outcomes

High risk

"We did the analysis on an intention-to-treat basis, in the sense that we took
no account of adherence to the intervention. We used all available data."

However, 19 participants were not included in the analyses at the 12 weeks, in-
cluding 12 lost to follow-up (including 2 excluded from the analyses since they
were taking tamoxifen) and 7 not assessed. In the control group, 3 participants
were lost to follow-up and 7 not assessed. At the 6-month time period, 7 were
not assessed in the exercise group and 4 in the control group

Selective reporting (re-
porting bias)

Low risk

There is no evidence of selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Oh 2008 

Study characteristics

Methods

Study design: RCT

Number randomized: 30; 15 to the exercise group and 15 to the control group

Study start and stop dates: recruitment took place from July 2006 to August 2006

Length of intervention: 8 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer, n:

• exercise group: breast, 6; ovary, 4; lymphoma, 1; lung, 1; colon, 0; others, 3
• control group: breast, 6; ovary, 2; lymphoma, 1; lung, 1; colon, 3; others, 2

Time since cancer diagnosis: not reported

Time in active treatment: some patients still undergoing chemotherapy; randomization stratified by
whether still being treated or completed therapy

 Inclusion criteria:

• confirmed diagnosis of cancer at any stage
• ≥ 18 years old
• ECOG performance status of 0 to 3
• expected survival length of > 12 months
• ability to complete all study questionnaires and sign the consent form

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

160

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Oh 2008  (Continued)

Eligibility criterion related to interest or ability, or both, to exercise:

• medical contraindication for exercise (e.g. significant orthopedic problem or cardiovascular disease)
• already practicing Qigong

Exclusion criteria:

• diagnosis of other major medical or psychiatric disorder
• history of epilepsy, brain metastasis, delirium, or dementia

Gender, n:·        

• exercise group: male, 3; female, 12
• control group: male, 3; female, 12

Age group, n:

• exercise group: 36 to 45 years, 2; 46 to 55 years, 4; 56 to 65 years, 3; 66 to 75 years, 6
• control group: 36 to 45 years, 2; 46 to 55 years, 3; 56 to 65 years, 9; 66 to 75 years, 1

Age at cancer diagnosis: not reported

Ethnicity, n:

• exercise group: Caucasian, 11; Asian, 3; Indigenous Australian, 1
• control group: Caucasian, 14; Asian, 0; Indigenous Australian, 1

Education level, n:

• exercise group: primary, 1; secondary, 5; tertiary, 9
• control group: primary, 1; secondary, 4; tertiary, 10

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history: limited by eligibility criteria

On hormone therapy: not reported

Interventions

15 participants assigned to exercise group, consisting of medical Qigong, with each session including:

• 15 minutes of general discussion
• 30 minutes of gentle stretching and body movement in standing postures
• 15 minutes movement in seated posture, and
• 30 minutes of breathing exercise

Type exercise (aerobic/anaerobic): aerobic

Intensity of experimental exercise intervention: mild

Frequency: once or twice per week for 8 weeks and recommendation to practice at home daily

Duration of sessions: 90 minutes, 1 hour for home sessions

Duration of program: 8 weeks

Total number of exercise sessions: maximum of 16 facility-based and 56 home-based sessions

Facility: facility

Professionally led: experienced medical Qigong instructor who was a Chinese medicine practitioner

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

161

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Oh 2008  (Continued)

15 participants assigned to control group, including:

• usual care

Adherence: not reported

Contamination of control group: not reported

Outcomes

Primary outcomes, QoL and symptom experience, included:

• global QoL, measured using EORTC Core QLQ-C30, and subscales of

* physical function
role function
*
* emotional function
* cognition function
social function
*
fatigue
*
* nausea
* pain
* dyspnea
insomnia
*
* appetite
* constipation
* diarrhea
* perceived financial impact of the disease

Physiologic outcomes included:

• CRP

Outcomes were measured at baseline and 8 weeks:

• exercise group: n = 15 at baseline, n = 8 at 8 weeks
• control group: n = 15 at baseline, n = 10 at 8 weeks

Subgroup analysis: none reported

Adverse events: none reported

Notes

Country: Australia

Funding: University of Sydney Cancer Research Fund

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Low risk

"Randomization was done by a computer program"

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

162

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Oh 2008  (Continued)

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Cochrane Database of Systematic Reviews

Study personnel and outcome assessors were not masked or blinded to the
study interventions

ITT analysis not completed. Of 15 randomized participants in each treatment
group, 7 withdrew from the exercise group and 5 from the control group...

Selective reporting (re-
porting bias)

Low risk

There is no evidence of selective reporting of outcomes

Other bias

High risk

Small sample size can put study at risk of bias

Oh 2010 

Study characteristics

Methods

Study design: RCT

Number randomized: 162; 79 to the exercise group and 83 to the control group

Study start and stop dates: first recruitment phase was between July 2006 and August 2007 and the
second recruitment phase was from August 2007 to May 2008

Length of intervention: 10 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer, n (%):

• exercise group: breast, 26 (37.7%); lung, 6 (8.7%); prostate, 8 (11.6%); colorectal/bowel, 8 (11.6%);

others, 23 (33.3%)

• control group: breast, 21 (30.9%); lung, 3 (4.4%); prostate, 4 (5.9%); colorectal/bowel, 8 (11.8%); oth-

ers, 32 (47.1%)

Time since cancer diagnosis: not reported

Time in active treatment: 36 (47.4%) of patients in the intervention group still undergoing cancer treat-
ment and 34 (45.9%) in the control group; randomization stratified by whether still being treated or
completed therapy

 Inclusion criteria:

• confirmed diagnosis of malignancy at any stage
• ≥ 18 years old
• expected survival length of > 12 months

Eligibility criterion related to interest or ability, or both, to exercise:

• medical contraindication for exercise (e.g. significant orthopedic problem or cardiovascular disease)
• already practicing Qigong

Exclusion criteria:

• diagnosis of other major medical or psychiatric disorder
• history of epilepsy, brain metastasis, delirium, or dementia

Gender, n (%):·        

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

163

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Oh 2010  (Continued)

• exercise group: male, 31 (39.2%); female, 48 (60.8%)
• control group: male, 38 (45.8); female, 45 (54.2%)

Age, mean (SD) years:

• exercise group: 60.1 (11.7) years
• control group: 59.9 (11.3) years

Age at cancer diagnosis: not reported

Ethnicity, n (%):

• exercise  group:  Caucasian,  57  (77.0%);  Asian,  10  (13.5%);  Indigenous  Australian,  1  (1.4%);  other,  6

(8.1%)

• control  group:  Caucasian,  49  (64.5%);  Asian,  17  (22.4%);  Indigenous  Australian,  1  (1.3%);  other,  9

(11.8%)

Education level, n (%):

• exercise group: primary, 1 (1.3%); secondary, 35 (45.5%); undergraduate, 19 (24.7%); postgraduate,

22 (28.6%)

• control group: primary, 7 (9.2%); secondary, 34 (44.7%); undergraduate, 19 (25.0%); postgraduate, 16

(21.1%)

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history: limited by eligibility criteria

On hormone therapy: not reported

Interventions

79 participants assigned to exercise group, consisting of medical Qigong, with each session including:

• 15 minutes of general discussion
• 30 minutes of gentle stretching and body movement in standing postures
• 15 minutes movement in seated posture, and
• 30 minutes meditation and including breathing exercises

Type exercise (aerobic/anaerobic): aerobic

Intensity of experimental exercise intervention: mild

Frequency: twice per week for 10 weeks and recommendation to practice at home daily

Duration of sessions: 90 minutes for supervised sessions, 30 minutes for home sessions

Duration of program: 10 weeks

Total number of exercise sessions: maximum of 20 facility-based and 70 home-based sessions

Facility: facility

Professionally led: experienced medical Qigong instructor who was a Chinese medicine practitioner

83 participants assigned to control group, including:

• usual care

Adherence: not reported

Contamination of control group: not reported

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

164

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Oh 2010  (Continued)

Outcomes

Primary outcome of QoL included:

• QoL, measured using the FACT-G, and subscales of:

* PWB
* SWB
* EWB
*

functional well-being

Secondary outcomes included:

• fatigue, measured using the FACT-F scale
• mood, measured using the Profile of Mood State and subscales of:

tension and anxiety

*
* depression
* anger and hostility
lack of vigor
*
fatigue
*
* confusion

Physiologic outcomes included:

• CRP

Outcomes were measured at baseline and 10 weeks:

• exercise group: n = 79 at baseline, n = 54 at 10 weeks
• control group: n = 83 at baseline, n = 54 at 10 weeks

Subset: cognitive function outcomes were reported for a subset of patients enrolled after October
2007, including:

• EORTC QLQ-C30 cognitive subscale
• FACT-Cog subscales of:

* perceived cognitive impairment
* perceived cognitive abilities
*

impact of cognitive impairments on QoL

For this group, outcomes were measured at baseline and 10 weeks:

• exercise group: n = 37 at baseline, n = 23 at 10 weeks
• control group: n = 44 at baseline, n = 31 at 10 weeks

Subgroup analysis: none reported

Adverse events: none reported

Notes

Country: Australia

Funding: University of Sydney Cancer Research Fund

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"Randomization, by computer..."

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

165

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Oh 2010  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

ITT analysis completed. There were 25 drop-outs in the exercise group and 29
drop-outs in the control group, and missing values were "dealt with by multi-
ple imputation..."

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Raghavendra 2007 

Study characteristics

Methods

Study design: RCT

Number randomized: 98; 45 to the exercise group and 53 to the control group, but this substudy on-
ly included 65 participants who began chemotherapy, 31 to the exercise group, and 34 to the control
group

Study start and stop dates: participants were recruited between January 2000 and June 2002

Length of intervention: varied, based on the number (4 to 8) of adjuvant chemotherapy cycles pre-
scribed following surgery

Length of follow-up: to end of the intervention

Participants

Type cancer: breast cancer

Stage, n (%):

• exercise group: Stage II, 16 (57.1%); Stage III, 12 (42.9%)
• control group: Stage II, 14 (41.1%); Stage III, 20 (58.8%)

Time since cancer diagnosis: not reported

Time in active treatment; number of chemotherapy cycles, n (%):

• exercise group: 6 cycles, 22 (78.6%); 8 cycles, 3 (10.7%); 4 cycles, 3 (10.7%)
• control group: 6 cycles, 27 (79.4%); 8 cycles, 4 (11.8%); 4 cycles, 3 (8.8%)

Inclusion criteria:

• recently diagnosed operable breast cancer
• 30 to 70 years old
• Zubrod's performance status 0 to 2 (ambulatory > 50% of time)
• high-school education
• having a treatment plan with surgery followed by adjuvant chemotherapy or by both adjuvant radia-

tion therapy and chemotherapy

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

166

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Raghavendra 2007  (Continued)

• consenting to participate in the trial

Eligibility criteria related to interest or ability, or both, to exercise:

• none

Exclusion criteria:

• any concurrent medical condition that was likely to interfere with the treatment
• major psychiatric, neurologic illness, or autoimmune disorders
• any known metastases
• history of intestinal obstruction
• sensitivity to any class of antiemetics (such as 5HT3 receptor antagonists or dopamine antagonists)

and corticosteroids (such as dexamethasone)

Gender: female

Current age: not reported

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level, mean (SD) years of education:

• exercise group: 10.4 (5) years
• control group: 13.5 (3) years

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Interventions

28 participants assigned to the exercise intervention, including:

• an integrated yoga program tailored to the participant's need during chemotherapy, consisting of a
set of asanas (postures done with awareness) breathing exercises, meditation, and yogic relaxation
techniques
• during chemotherapy infusion, the exercise program consisted of yogic relaxation, meditation us-
ing  breath  awareness,  and  impulses  of  touch  emanating  from  palms  and  fingers,  or  chanting  a
mantra

• the home sessions consisted of yoga postures, breathing exercises and pranayama, and yogic re-

laxation

Type exercise (aerobic/anaerobic): aerobic

Intensity of the experimental exercise intervention: not reported

Frequency: 6 days per week at home

Duration of individual sessions: 1 hour per day at home

Duration of exercise program: varied

Total number of exercise sessions: unclear

Format: individual

Facility: clinic and home based

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

167

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Raghavendra 2007  (Continued)

Cochrane Database of Systematic Reviews

Professionally led by a yoga expert in the clinic

Adherence: not reported

34 participants assigned to control group, including:

• psychodynamic supportive-expressive therapy with coping preparation

Originally 53 participants assigned, but only 34 were eligible for this substudy

Contamination of control group: not reported

Outcomes

Primary outcomes included:

• nausea and vomiting, assessed as frequency and intensity of both postchemotherapy and anticipato-

ry nausea and vomiting using the MANE questionnaire

Other outcomes included:

• anxiety state and trait, assessed using the STAI
• depression, assessed using the BDI
• global HRQoL, assessed using the FLIC
• subjective symptoms, assessed using a subjective symptom checklist to measure treatment-related
side effects, problems with sexuality and image, and relevant psychological and somatic symptoms
• treatment-related  toxicity  and  side  effects,  assessed  using  the  WHO  Toxicity  Criteria  during

chemotherapy

Outcomes were measured at baseline (before starting chemotherapy), mid-cycle, and at the end of
chemotherapy:

• exercise group: n = 28 before starting the first chemotherapy infusion cycle, n = 28 during the mid-

chemotherapy infusion cycle, n = 28 after completion of the chemotherapy infusion cycle

• control group: n = 34 before starting the first chemotherapy infusion cycle, n = 34 during the mid-

chemotherapy infusion cycle, n = 34 after completion of the chemotherapy infusion cycle

Subgroup analysis: none

Adverse events: not reported

Notes

Country: India

Funding: Central Council for Research in Yoga and Naturopathy, Ministry of Health and Family Welfare,
Government of India

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Allocation sequence was generated using random numbers generated by a
random number table

Allocation concealment
(selection bias)

Low risk

Treatment assigned was concealed from study personnel using opaque en-
velopes, which were opened sequentially in the order of assignment during re-
cruitment, with the names and registration numbers of the participants writ-
ten on the covers 

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

168

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Raghavendra 2007  (Continued)

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Cochrane Database of Systematic Reviews

Study personnel and outcome assessors were not masked or blinded to the
study interventions

Analyses were not conducted on an ITT basis and the treatment of missing da-
ta was not described

Although no study participants were excluded after the substudy began, it is
unclear whether additional study participants could have been included in the
substudy

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

High risk

The study was completed on a subgroup of the originally randomized study
participants. Because a significant proportion of the originally randomized
study participants were not included in the substudy, it is unclear if the selec-
tion bias prevented by randomization was maintained

Rogers 2009 

Study characteristics

Methods

Study design: RCT

Number randomized: 41; 21 to the exercise group and 20 to the control group

Study start and stop dates: recruitment from April 2006 to May 2007

Length of intervention: 12 weeks

Length of follow-up: 3 months after end of the intervention

Participants

Type cancer: breast cancer

Cancer stage, Stage I to III, n (%):

• exercise group: Stage I, 6 (29%); Stage II, 11 (52%); Stage III, 4 (19%)
• control group: Stage I, 6 (30%); Stage II, 10 (50%); Stage III, 4 (20%)

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Inclusion criteria:

• female
• 18 to 70 year old
• history of Stage I, II, or IIIA breast cancer
• English speaking
• currently taking an aromatase inhibitor or estrogen receptor modulator
• medical clearance provided by physician
• At least 8 weeks postsurgery

Eligibility criterion related to interest or ability, or both, to exercise:

• engaging in ≥ 60 minutes of vigorous physical activity or ≥ 150 minutes of moderate plus vigorous

activity per week during the past month based on self-report

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

169

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rogers 2009  (Continued)

Exclusion criteria:

Cochrane Database of Systematic Reviews

• dementia or organic brain syndrome
• medical, psychological, or social characteristic that would interfere with the ability to fully participate

in program activities and assessments

• contraindication to participate in a regular physical activity program (e.g. unstable angina, debilitat-

ing arthritis pain)
• inability to ambulate
• plans to relocate outside the study area during the study period
• breast cancer recurrence or metastasis.

Gender: female

Current age, mean (SD) years:

• exercise group: 52 (15) years
• control group: 54 (8) years

Age at cancer diagnosis: not reported

Ethnicity/race, n (%):

• exercise group: white, 19 (90%); other, 2 (10%)
• control group: white, 19 (95%); other, 1 (5%)

Education level, mean (SD) years:

• exercise group: 15 (2) years
• control group: 15 (2) years

SES household income, n (%):

• exercise group: < USD10,000, 1 (5%); USD10,000 to USD35,000, 7 (33%); USD35,000 to USD50,000, 3

(14%); > USD50,000, 10 (48%)

• control  group:  <  USD10,000,  1  (5%);  USD10,000  to  USD35,000,  0  (0%);  USD35,000  to  USD50,000,  5

(25%); > USD50,000, 14 (70%)

Employment status: not reported

Comorbidities:

• exercise group: comorbidity score on a scale from 0 to 5: 2 (1.4)
• control group: comorbidity score on a scale from 0 to 5: 2 (1.6)

Past exercise history: not reported

On hormone therapy:

• exercise group: months on hormonal therapy, mean (SD) months, 15 (15) months; estrogen receptor

modulator, n (%), 7 (33%); aromatase inhibitor, n (%), 14 (67%)

• control group: months on hormonal therapy, mean (SD) months, 22 (18) months; estrogen receptor

modulator, n (%), 4 (20%); aromatase inhibitor, n (%), 16 (80%)

Interventions

21 participants assigned to the exercise group, including:

• 6 discussion group sessions with a clinical psychologist at baseline, and weeks 1, 2, 4, 6, and 8
• 6 supervised exercise programs (walking), 3 per week during weeks 1 and 2, 2 per week during weeks

3 and 4, and 1 per week during weeks 5 and 6

• 40 home-based exercise (walking), 2 per week during weeks 3 and 4, 3 per week during weeks 5 and

6, 5 per week during weeks 7 through 12

• 3 individual update counseling sessions with an exercise specialist during week 8, 10, and 12

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

170

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Rogers 2009  (Continued)

Type exercise (aerobic/anaerobic): aerobic

Intensity of experimental exercise intervention: transition from baseline to week 12 to 150 minutes of
moderate-intensity activity

Frequency: gradually increased from 3 times per week to 5 times per week

Duration of sessions: not reported

Duration of program: 12 weeks

Total number of exercise sessions: 52 sessions

Format: individual exercise; group peer support

Facility: facility and home

Professionally led: exercise specialists certified (or certification-eligible) by the American College of
Sports Medicine

Adherence: participants completed 100% (252/252) of the individual exercise sessions, 95% (60/63) of
the individual update sessions, and 98% (123/126) of the group session for overall 99% (435/441) ad-
herence. 6% (4/63) of update sessions were completed by telephone.

20 participants were assigned to the control group, including:

• usual care, including written materials about physical activity available through the American Cancer

Society

Contamination of control group: not reported

Outcomes

Outcomes: QoL outcomes and physiologic outcomes, including:

• FACT-B, including subscales of physical functioning, SWB, EWB, FWB, and additional concerns
• FACT-G, the sum of the physical functioning, SWB, EWB, and FWB
• FACT-F, a 13-item instrument
• FACT-Cog, a 42-item instrument
• FACT-ES, a 19-item instrument
• sleep dysfunction, assessed using the PSQI
• joint pain, stiffness, and physical function, using a 5-point Likert scale version (1 = none to 5 = extreme)

of the 24-item WOMAC

• objective activity monitoring, measured using a GT1M accelerometer
• self-reported leisure time physical activity, assessed using the Godin Leisure-Time Exercise Question-

naire

• stage of motivational readiness for physical activity, classified as precomtemplation, contemplation,

preparation, action, and maintenance

• fitness, assessed using a submaximal treadmill test and Naughton protocol to estimate oxygen con-

sumption at 85% of predicated maximal HR

• muscle strength, assessed using back/leg extensor dynamometers (Takei Back-A model #Tkk5002 - i.e.

best of 3 attempts) and handgrip dynamometer (Lafeyette Model No. 78010)

• BMI
• waist to hip ratio, using a nonstretching tape measure to measure the waist and hip circumferences

over undergarments with 3 measurements averaged

• percent body fat and BMD, assessed by DXA
• caloric intake, assessed with a 3-day diet record (i.e. 1 weekend and 2 weekdays) and analyzed with

Diet Analysis Plus software, version 7.0.1 (Thomson)
• perceived health, assessed using a 5-point Likert scale

Outcomes were measured at baseline, 12 weeks, and 3 months after intervention (6 months after ran-
domization):

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

171

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rogers 2009  (Continued)

Cochrane Database of Systematic Reviews

• exercise group: n = 21 at baseline, n = 20 at 12 weeks, n = 19 at 6 months
• control group: n = 20 at baseline, n = 19 at 12 weeks n = 17 at 6 months

Adverse events: None reported

Notes

Country: US

Funding: Southern Illinois University School of Medicine Excellence in Academic Medicine Award,
Brooks Medical Research Fund, Memorial Medical Center Foundation and Regional Cancer Center

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"computer-generated"

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Unclear risk

"sealed envelopes"

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

The investigators stated that they conducted an ITT analyses, but 2 partici-
pants withdrew from the exercise group and 3 from the control group. The au-
thors also reported that the rate of missing data for the FACT-ES and the FACT-
Cog exceeded the prespecified amount for imputation of values and they ana-
lyzed

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Segal 2001 

Study characteristics

Methods

Study design: RCT

Number randomized: 123; 40 to the home-based exercise group, 42 to the supervised exercise group,
and 41 to the control group

Study start and stop dates: not reported

Length of intervention: 26 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: breast cancer, Stages I and II

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

172

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Segal 2001  (Continued)

Time since cancer diagnosis: not reported

Time in active treatment: within 2 weeks

Inclusion criteria:

Cochrane Database of Systematic Reviews

• Stages I and II breast cancer
• within 2 weeks of the initiation of prescribed adjuvant therapy (radiation therapy, hormonal therapy,

or chemotherapy)

Eligibility criteria related to interest or ability, or both, to exercise:

• treating oncologist believed that exercise was not indicated

Exclusion criteria:

• receiving only alternative or dose-intensive chemotherapy regimens
• severe cardiac disease
• uncontrolled hypertension (160/95 mmHg blood pressure)

Gender: female

Current age, mean (SD) years:

• home-based exercise group: 51.0 (8.7) years
• supervised exercise group: 51.4 (8.7) years
• control group: 50.3 (8.7) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level: not reported

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history; "physically active", %:

• home-based exercise group: 60%
• supervised exercise group: 50%
• control group: 47.6%

Interventions

40 participants assigned to the home-based exercise intervention and 40 to the supervised exercise in-
tervention. Both groups included:

• instructions for monitoring exercise intensity and completing an exercise diary, along with a standard-

ized series of warm-up and cool-down exercises and a progressive walking program

The home-based (self-directed) exercise group also included:

• home exercise prescription
• contact by telephone every 2 weeks during the 26-week training period to check on progress and  iden-

tify barriers to exercise

The supervised exercise group also included:

• a supervised exercise program with a 7- to 10-minute warm-up, walking at prescribed pace, and stan-

dard cool-down.

Type exercise (aerobic/anaerobic): aerobic

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

173

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Segal 2001  (Continued)

Cochrane Database of Systematic Reviews

Intensity of the experimental exercise intervention: 50% to 60% of the predicted maximal oxygen up-
take

Frequency:

• home-based: 5 times per week
• supervised: 3 times per week in the facility and asked to exercise at home 2 days per week

Duration of individual sessions: not reported

Duration of exercise program: 26 weeks

Total number of exercise sessions: 130 sessions

Format: individual

Facility: both home and facility

Professionally led by an exercise specialist

Adherence: not reported

41 participants assigned to control group, including:

• general advice from the oncologist about the benefits of exercise and a suggestion to participants to

exercise if they felt well enough

Outcomes

Primary outcome included:

• change in physical functioning, assessed by measuring change in the physical functioning subscale

of  the MOS SF-36

Other outcomes included:

• global HRQoL, assessed using the other subscales of MOS SF-36, FACT-G, and FACT-B
• aerobic capacity
• body weight

Outcomes were measured at baseline, 13 weeks, and 26 weeks:

• home-based exercise group: n = 40 at baseline, n = 40 at 13 weeks, n = 40 at 26 weeks (imputed values

carried forward, so even though withdrawals, analyses included all participants)

• supervised exercise group: n = 40 at baseline, n = 40 at 13 weeks, n = 40 at 26 weeks (imputed values

carried forward, so even though withdrawals, analyses included all participants)

• control group: n = 41 at baseline, n = 41 at 13 weeks, n = 41 at 26 weeks (imputed values carried forward,

so even though withdrawals, analyses included all participants)

Subgroup analysis: treated with chemotherapy versus other treatment

Adverse events: none reported

Notes

Country: Canada

Funding: National Cancer Institute of Canada, CCS

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Random numbers table

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

174

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Segal 2001  (Continued)

Cochrane Database of Systematic Reviews

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

Values carried forward for withdrawals, and withdrawals balanced across
groups: home-based exercise, 7; supervised, 8; control, 7

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Segal 2003 

Study characteristics

Methods

Study design: RCT

Number randomized: 155; 82 to the exercise group and 73 to the control group

Study start and stop dates: September 1999 to August 2001

Length of intervention: 12 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: prostate cancer

Stage, n (%):

• exercise group: Stage I, 0 (0%); Stage II, 40 (48.8%); Stage III, 11 (13.4%); Stage IV, 17 (20.7%); unassign-

able, 14 (17.1%)

• control group: Stage I, 0 (0%); Stage II, 35 (47.9%); Stage III, 13 (18.1%); Stage IV, 10 (13.9%); unassign-

able, 15 (20.8%)

Time since cancer diagnosis, mean (SD) days:

• exercise group: 980.1 (1115.4) days
• control group: 762.9 (1292.6) days

Time in active treatment: "scheduled to receive androgen deprivation therapy"

Inclusion criteria:

• histologically documented prostate cancer
• scheduled to receive androgen deprivation therapy for at least 3 months after recruitment
• treating oncologist provided consent

Eligibility criteria related to interest or ability, or both, to exercise:

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

175

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Segal 2003  (Continued)

• none

Exclusion criteria:

Cochrane Database of Systematic Reviews

• severe cardiac disease (NYHA class III or greater)
• uncontrolled hypertension (blood pressure > 160/95 mmHg)
• uncontrolled pain
• unstable bone lesions
• residence > 1 hour from the study center

Gender: male

Current age, mean (SD) years

• exercise group: 68.2 (7.9) years
• control group: 67.7 (7.5) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level: not reported

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history; prior activity level, n (%):

• exercise group: < twice per week, 31 (37.8%); ≥ 3 times per week, 51 (62.2%); prior resistance training

at < twice per week, 64 (78.0%); ≥ 3 times per week, 16 (22.0%)

• control group: < twice per week, 26 (35.6%); ≥ 3 times per week, 47 (64.4%); prior resistance training

at < twice per week, 56 (76.7%); ≥ 3 times per week, 17 (23.3%)

On hormone therapy: not reported

Interventions

82 participants assigned to the exercise intervention, including:

• personalized resistance exercise program  consisting of  a standardized series of warm-up and cool-
down exercises to be performed under supervision with 2 sets of 8 to 12 repetitions of the following 9
exercises were  performed: leg extension, calf raises, leg curl, chest press, latissimus pull-down, over-
head press, triceps extension, biceps curls, and modified curl-ups

Type exercise (aerobic/anaerobic): anaerobic

Intensity of the experimental exercise intervention: at 60% to 70% of 1-repetition maximum, increasing
resistance by 5 lb when > 12 repetitions

Frequency: 3 times per week

Duration of individual sessions: as needed to complete program

Duration of exercise program: 12 weeks

Total number of exercise sessions: 36 sessions

Format: individual

Facility: fitness center

Professionally led by a certified fitness consultant

Adherence: attendance averaged 79% (28 of 36 sessions)

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

176

 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Segal 2003  (Continued)

73 participants assigned to control group, including:

• waiting list

Contamination of control group: not reported

Outcomes

Primary outcomes included:

• fatigue, assessed using the FACT-F
• global HRQoL, assessed using the FACT-P

Other outcomes included:

• muscular fitness, assessed using a standard load test
• body composition, including BMI, weight, waist circumference, subcutaneous skin-folds

Outcomes were measured at baseline and end of the intervention:

• exercise group: n = 82 at baseline, n = 74 at postintervention
• control group: n = 73 at baseline, n = 61 at postintervention

Subgroup analysis:

• curative versus palliative treatment goal
• receiving androgen deprivation therapy for < 1 year versus longer

Adverse events: none reported

Notes

Country: Canada

Funding: NCIC. CCS; Heart and Stroke Foundation of Canada; Canadian Institutes of Health Research
CCS/NCIC Sociobehavioral Cancer Research Network.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Table of random numbers

Allocation concealment
(selection bias)

Low risk

"The treatment allocation was concealed from the study coordinator until
completion of baseline testing and stratification"

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Study personnel and outcome assessors for the HRQoL outcomes were not
masked or blinded to the study interventions. However, blinding was used for
physical outcomes "A research assistant with no knowledge of group assign-
ment collected muscular fitness and anthropometric data and scored ques-
tionnaire responses"

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

High risk

8 men in the exercise group and 12 in the control group withdrew

Low risk

There appears to be no selective reporting of outcomes

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

177

 
 
Cochrane Database of Systematic Reviews

The trial appears to be free of other problems that could put it at a high risk of
bias

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Segal 2003  (Continued)

Other bias

Low risk

Segal 2009 

Study characteristics

Methods

Study design: RCT

Number randomized: 121; 40 to the aerobic exercise group, 40 to the resistance training exercise group,
and 41 to the control group

Study start and stop dates: February 2003 to April 2006

Length of intervention: 24 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: prostate cancer

Stage, n (%):

• aerobic exercise group: Stage I, 1 (2.5%); Stage II, 29 (72.5%); Stage III, 9 (22.5%); Stage IV, 0 (0%); unas-

signable, 1 (2.5%)

• resistance exercise group: Stage I, 0 (0%); Stage II, 31 (77.5%); Stage III, 8 (20.0%); Stage IV, 8 (20.0%);

unassignable, 1 (2.5%)

• control group: Stage I, 0 (%); Stage II, 35 (85.4%); Stage III, 4 (9.8%); Stage IV, 1 (2.4%); unassignable,

1 (2.4%)

Time since cancer diagnosis: not reported

Time in active treatment: not reported

Inclusion criteria:

• histologically documented prostate cancer
• scheduled to receive radiation therapy with or without androgen deprivation therapy
• treating oncologist approved

Eligibility criteria related to interest or ability, or both, to exercise:

• none

Exclusion criteria:

• severe cardiac disease (NYHA functional class III or IV)
• uncontrolled hypertension
• uncontrolled pain
• psychiatric illness
• lives > 1 hour away

Gender: male

Current age, mean (SD) years:

• aerobic exercise group: 66.2 (6.8) years
• resistance exercise group: 66.4 (7.6) years
• control group: 65.3 (7.6) years

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

178

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Segal 2009  (Continued)

Cochrane Database of Systematic Reviews

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level; completed university or college, n (%):

• aerobic exercise group: 22 (55%)
• resistance exercise group: 19 (47.5%) 
• control group: 21 (51.2%)

SES: not reported

Employment status; employed full-time, n (%):

• aerobic exercise group: 9 (22.5%)
• resistance exercise group: 6 (15.0%)
• control group: 14 (34.1%)

Comorbidities: no reported

Past exercise history: not reported

On hormone therapy: not reported

Weight, mean (SD) kg:

• aerobic exercise group: 88.1 (10.9) kg
• resistance exercise group: 84.3 (9.9) kg
• control group: 86.5 (15.2) kg

BMI, mean (SD):

• aerobic exercise group: 28.9 (3.4)
• resistance exercise group: 28.1 (3.5)
• control group: 29.0 (4.2)

Interventions

40 participants assigned to the aerobic exercise intervention, including:

• exercise on a cycle ergometer, treadmill, or elliptical trainer

40 participants assigned to the resistance exercise intervention, including:

• 2 sets of 8 to 12 repetitions of 10 different exercises (leg extension, leg curl, seated chest fly, latissimus
pull-down, overhead press, triceps extension, biceps curls, calf raises, low back extension, and mod-
ified curl-ups)

Type exercise (aerobic/anaerobic): aerobic or anaerobic

Intensity of the aerobic exercise intervention: beginning at 50% to 60% of their predetermined peak
oxygen consumption (VO2peak) for weeks 1 to 4 and progressing to 70% to 75% for weeks 5 to 24

Intensity of anaerobic exercise intervention: 60% to 70% of estimated 1-repetition maximum, increased
by 5 lb when more than 12 repetitions

Frequency: 3 times per week

Duration of individual sessions: initially 15 minutes, increasing by 5 minutes every 3 weeks up to 45
minutes

Duration of exercise program: 24 weeks

Total number of exercise sessions: 72 sessions

Format: individual

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

179

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Segal 2009  (Continued)

Facility: facility

Cochrane Database of Systematic Reviews

Professionally led: professionally led by an exercise specialist

Adherence: resistance and aerobic participants completed a median of 88% (63 of 72 sessions) and
83% (60 of 72 sessions) of scheduled sessions, respectively

41 participants assigned to control group, including:

• request not to initiate exercise
• offer of a program postintervention assessments and radiation therapy

Contamination of control group: 6 control participants reported aerobic exercise ≥ 3 times per week

Outcomes

Outcome included HRQoL outcomes of:

• fatigue, assessed using the FACT-F
• prostate-specific QoL, assessed using the FACT-P
• general cancer-specific QoL were assessed using the FACT-G

Physical outcomes, including:

• aerobic fitness,
• strength
• body weight
• body fat percentage,
• serum lipids
• PSA
• testosterone
• hemoglobin

Outcomes were measured at baseline, 12 weeks, and 24 weeks:

• aerobic exercise group: n = 40 at baseline, n = 35 for fatigue at 12 weeks, n = 34 at 24 weeks
• resistance exercise group: n = 40 at baseline, n = 39 for fatigue at 12 weeks, n = 38 at 24 weeks
• control group: n = 41 at baseline, n = 38 at 12 weeks, n = 39 at 24 weeks

Adverse events: 1 myocardial infarction, 1 syncope in aerobic group, 1 chest pain in resistance group

Notes

Country: Canada

Funding: Canadian Prostate Cancer Research Fund

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Computer generated

Allocation concealment
(selection bias)

Low risk

"Central random assignment was used, with allocation concealment before
assignment"

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)

High risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

180

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Segal 2009  (Continued)

All outcomes

Cochrane Database of Systematic Reviews

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Used mixed model, analyzing data from all participants, 7 withdrew in aero-
bic exercise group, 3 withdrew in resistance group, and 1 withdrew in control
group

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Tang 2010 

Study characteristics

Methods

Study design: RCT

Number randomized: 72; 37 to the exercise group and 35 to the control group

Study start and stop dates: not reported

Length of intervention: 8 weeks

Length of follow-up: 1 and 2 months

Participants

Type cancer, n (%):

• exercise group: breast, 23 (63.9%); gastrointestinal, 6 (16.7%); nasopharyngeal, 4 (11.1%); lung, 0 (0%);

other, 3 (8.3%)

• control  group:  breast,  16  (45.7%);  gastrointestinal,  5  (14.3%);  nasopharyngeal,  3  (8.6%);  lung,  4

(11.4%); other, 7 (20%)

Time since cancer diagnosis, mean (SD) years:

• exercise group: 3.56 (3.92) years
• control group: 4.13 (4.06) years

Time in active treatment, undergoing cancer treatment, n (%):

• exercise group: 7 (19.4%)
• control group: 14 (40.0%)

 Inclusion criteria:

• ≥ 18 years old
• diagnosed with cancer
• complaint of sleep disturbance with a PSQI score > 5
• approved for participation by their oncologist
• able to communicate in Mandarin or Taiwanese

Eligibility criterion related to interest or ability, or both, to exercise:

• neuromuscular deficits that would contraindicate a walking exercise intervention
• have not regularly undertaken more than 1 session of moderate-intensity exercise each week over the

past 6 months

Exclusion criteria:

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

181

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Tang 2010  (Continued)

Cochrane Database of Systematic Reviews

• uncontrolled hypertension, cardiac, or psychiatric illness
• blood pressure > 140/90 mmHg

Gender, n (%):

• exercise group: male, 5 (13.9%); female, 31 (86.1%)
• control group: male, 12 (34.3%); female, 23 (65.7%)

Current age, mean (SD) years:

• exercise group: 47.36 (10.14) years
• control group: 56.37 (12.43) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level, mean (SD) years:

• exercise group: 9.97 (3.67) years
• control group: 8.26 (4.66) years

SES: not reported

Employment status, n (%):

• exercise group: working, 13 (36.1%); not working, 23 (63.9%)
• control group: working, 10 (28.6%); not working, 25 (71.4%)

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy: not reported

Interventions

37 participants assigned to a walking exercise intervention, including:

• instructions to walk briskly (at a pace that was faster than normal), starting with a 5-minute warm-up

(walking slowly) and finishing with a 5-minute cool-down after completing the 30-minute walk

• exercise booklet - written material for home use focusing on safety and proper technique

Type exercise (aerobic/anaerobic): aerobic

Intensity of experimental exercise intervention: rating of perceived exertion between 11 and 13, with a
rating of 6 = resting and 20 = very, very hard

Frequency: 3 times per week

Duration of individual sessions: 30 minutes plus 5 minutes warm-up and 5 minutes cool-down

Duration of exercise program: 8 weeks

Total number of exercise sessions: 24 sessions

Format: individual

Facility: home

Not professionally led

35 participants assigned to the control group, including:

• instructions to maintain current lifestyle for 8 weeks
• instructions to record in a diary provided by the researchers any exercise taken beyond what they

normally do

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

182

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Tang 2010  (Continued)

Cochrane Database of Systematic Reviews

• invited to begin their own walking program following study completion at 8 weeks

Adherence: 32/36 (89%) reached an adherence rate of at least 50%. The mean (SD) number of complete
exercise sessions was 20.03 (6.60)

Contamination of control group: not reported

Outcomes

Primary outcome:

•  sleep quality, assessed using the PSQI

Secondary outcomes included:

• QoL, measured using the PCS and MCS subscales of the MOS SF-36

Outcomes were measured at baseline, 1 month, and 2 months:

• exercise group: n = 37 at baseline, n = 35 at 1 month, n = 36 at 2 months
• control group: n = 35 at baseline, n = 35 at 1 month, n = 35 at 2 months

Subgroup analysis: none specified

Adverse events: none reported

Notes

Country: Taiwan

Funding: not reported

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Low risk

Allocation sequence was generated using a table of random numbers

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

The study was analyzed on an ITT basis. Missing observations, including those
incurred by participant drop-outs, were imputed by the "last observation car-
ried forward" method. The disproportionate attrition from the intervention
group places the study at a high risk of bias

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

183

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Targ 2002 

Study characteristics

Methods

Study design: RCT

Cochrane Database of Systematic Reviews

Number randomized: 181; 93 to the exercise group and 88 to the control group

Study start and stop dates: not reported

Length of intervention: 12 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: breast cancer

Stage, n (%):

• exercise group: Stage I, 31 (39%); Stage II, 35 (43%); Stage III, 5 (6%); Stage IV, 5 (6%); missing, 3 (4%)
• control group: Stage I, 16 (32%); Stage II, 26 (52%); Stage III, 7 (14%); Stage IV, 2 (4%); missing, 5 (10%)

Time since cancer diagnosis: within 18 months of diagnosis

Time in active treatment: not reported, but some women were on chemotherapy, n (%):

• exercise group: 42 (54%)
• control group: 24 (48%)

 Inclusion criteria:

• 26 to 78 years old
• within 18 months of initial diagnosis of primary breast cancer or metastatic breast cancer

Eligibility criterion related to interest or ability, or both, to exercise: none reported

Exclusion criteria: none reported

Gender: female

Current age, mean (SD) years:

• exercise group: 49 (8.6) years
• control group: 47 (8.8) years

Age at cancer diagnosis: not reported

Ethnicity/race, n (%):

• exercise group: Asian, 8 (11%); Hispanic, 1 (1%); African American, 4 (5%); Caucasian, 62 (83%)
• control group: Asian, 2 (4%); Hispanic, 1 (2%); African American, 4 (8%); Caucasian, 41 (85%)

Education level, n (%):

• exercise group: < 8th grade, 1 (1%); some high school, 1 (1%); high school graduate, 0 (0%); some

college, 13 (16%); college graduate, 22 (28%); postdoctorate study, 42 (53%)

• control group: < 8th grade, 0 (0%); some high school, 0 (0%); high school graduate, 0 (0%); some col-

lege, 7 (14%); college graduate, 9 (18%); postdoctorate study, 34 (68%)

SES, income, n (%):

• exercise group: < USD15,000, 6 (8%); USD15,000 to USD29,000, 9 (12%); USD30,000 to USD44,000, 10

(13%); USD45,000 to USD49,000, 17 (22%); > USD50,000, 36 (46%)

• control group: < USD15,000, 2 (4%); USD15,000 to USD29,000, 5 (10%); USD30,000 to USD44,000, 9

(18%); USD45,000 to USD49,000, 5 (10%); > USD50,000, 28 (57%)

Employment status: not reported

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

184

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Targ 2002  (Continued)

Comorbidities: not reported

Cochrane Database of Systematic Reviews

Past exercise history, number of days spent exercising and minutes of exercise, mean (SD) days and
minutes:

• exercise group: 4.16 (1.82) days, 49.58 (23.09) minutes
• control group: 4.22 (1.62) days, 51.5 (25.64) minutes

On hormone therapy, n (%):

• exercise group: 28 (53%)
• control group: 11 (48%)

Post-menopausal status, n (%):

• exercise group: 17 (29%)
• control group: 4 (14%)

Interventions

93 participants assigned to an intensive lifestyle change and group support program that included:

• weekly health series discussion group, followed by a 90-minutes dance/movement program
• weekly session consisting of silent meditation and guided imagery

Type exercise (aerobic/anaerobic): aerobic

Intensity of experimental exercise intervention: mild to moderate

Frequency: once per week

Duration of individual sessions: 90 minutes

Duration of exercise program: 12 weeks

Total number of exercise sessions: 12 sessions

Format: group

Facility: facility

Professionally led: nurse

88 participants assigned to the control group, including:

• unstructured psycho-educational support group

Adherence: 6 women did not attend any session, but no other adherence was noted

Contamination of control group: not reported

Outcomes

Outcomes: QoL outcomes, including:

• change in overall QoL, measured using FACIT and subscales

* PWB
* SWB
* EWB
* FWB
* additional concerns

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

185

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Targ 2002  (Continued)

• change in mood as measured by POMS and subscales

* anxiety
* depression
* anger
* vigor
fatigue
*
* confusion

• change in spiritual function, measured using the FACIT-Sp and the Principle of Living Survey

Outcomes were measured at baseline and at 12 weeks:

• exercise groups: n = 93 at baseline, n = 79 at 12 weeks
• control group: n = 88 at baseline, n = 88 at 12 weeks

Adverse events: none reported

Notes

Country: US

Funding: United States Department of Defense Material Command

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

The generation of the random sequence was not described

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assignment was concealed from study personnel and
participants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to the
study interventions

Although it was stated that an ITT analysis was performed, there were 7
women who dropped out in the intervention group and 24 in the control group
and an additional 27 who did not attend any session and were not included in
the analyses

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Vadiraja 2009b 

Study characteristics

Methods

Study design: RCT

Number randomized: 88; 44 to the exercise group and to 44 the control group

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

186

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Vadiraja 2009b  (Continued)

Cochrane Database of Systematic Reviews

Study start and stop dates: participants were recruited over a 2-year period from January 2004 to June
2006

Length of intervention: 6 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: breast cancer

Cancer stage, n (%):

• exercise group: Stage I, 2 (4.5%); Stage II, 11 (25.0%); Stage III, 31 (70.5%)
• control group: Stage I, 3 (6.8%); Stage II, 7 (15.9%); Stage III, 34 (77.3%)

Time since cancer diagnosis: not reported

Time in active treatment: prescribed adjuvant radiation therapy with a cumulative dose of 50.4 Gy with
fractionations spread over 6 weeks

Inclusion criteria:

• women with recently diagnosed operable breast cancer
• 30 to 70 years old
• Zubrod's performance status 0 to 2 (ambulatory > 50% of time)
• had high-school education
• provided written consent to participate in the study

Eligibility criteria related to interest or ability, or both, to exercise:

• none

Exclusion criteria:

• had any concurrent medical condition that was likely to interfere with the treatment
• had major psychiatric, neurologic illness, or autoimmune disorder
• had any known metastases

Gender: female

Current age, mean (SD) years

• exercise group: 46.7 (9.3) years
• control group: 48.5 (10.2) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level: not reported

SES: 94.2% of participants were in "middle class" and remainder were in "upper middle class"

Employment status: not reported

Comorbidities: not reported

Past exercise history: 9% of population had previous exposure to yoga

On hormone therapy: not reported

Interventions

44 participants assigned to the exercise intervention, including:

• a set of asanas (postures done with awareness)
• breathing exercises

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

187

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Vadiraja 2009b  (Continued)

Cochrane Database of Systematic Reviews

• pranayama (voluntarily regulated nostril breathing)
• meditation
• yogic relaxation techniques with imagery (mind-sound resonance technique and cyclic meditation)

Type exercise (aerobic/anaerobic): aerobic

Intensity of the experimental exercise intervention: not reported

Frequency: at last 3 sessions 1 hour per week  and asked to practice daily at home

Duration of individual sessions: 60 minutes

Duration of exercise program: 6 weeks

Total number of exercise sessions: at least 18 sessions

Format: individual

Facility: facility and home

Professionally led: professionally led by a trained yoga therapist

Adherence: adherence to intervention was: 29.7% attended 10 to 20 supervised sessions, 56.7% attend-
ed 20 to 25 supervised sessions, and 13.7% attended > 25 supervised sessions over a 6-week period

44 participants assigned to control group, including:

• brief supportive therapy with education as a component

Contamination of control group: not reported

Outcomes

No primary outcome was identified. Outcomes included:

• positive and negative affect, assessed using the PANAS
• global HRQoL, assessed using the EORTC Quality of Life C30 and subscales

• physical function
• role function
• emotional function
• cognitive function
• social function
• fatigue
• pain
• insomnia

• Psychological distress, assessed using the Rotterdam Symptom Checklist and subscales

• psychological distress
• physical distress
• impairment in activities of daily living

• depression, measured using the HADS
• anxiety, measured using the HADS
• perceived stress, measured using the Perceived Stress scale
• physical outcomes included cortisol levels

Outcomes were measured at baseline and 6 weeks:

• exercise group: n = 44 at baseline, n = 42 at 6 weeks
• control group: n = 44 at baseline, n = 33 at 6 weeks

Subgroup analysis: none

Adverse events: not reported

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

188

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Vadiraja 2009b  (Continued)

Notes

Country: India

Cochrane Database of Systematic Reviews

Funding: Central Council for Research in Yoga and Naturopathy, Ministry of Health and Family Welfare,
Government of India

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Allocation sequence was generated using computer-generated computer
numbers

Allocation concealment
(selection bias)

Low risk

Randomization was performed using opaque sequentially numbered en-
velopes

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

Allocation to the intervention was not concealed from the study personnel

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Analyses were conducted on an ITT basis, which accounted for the substantial
attrition from the trial, especially in the control arm

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Wang 2010 

Study characteristics

Methods

Study design: RCT

Number randomized: 72; 35 to the exercise group and 37 to the control group

Study start and stop dates: participants were recruited between December 2008 and June 2009

Length of intervention: 6 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: breast cancer

 Stage, n (%):

• exercise group: Stage I, 9 (25.7%); Stage II, 26 (74.3%)
• control group: Stage I, 7 (18.9%); Stage II, 30 (81.1%)

Time since cancer diagnosis: not reported

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

189

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Wang 2010  (Continued)

Cochrane Database of Systematic Reviews

Time in active treatment: followed participants from 24 hours before surgery to end of the chemothera-
py cycle (6 weeks)

Inclusion criteria:

• 18 to 72 years old
• newly diagnosed with Stage I or Stage II breast cancer
• expecting chemotherapy following recovery from surgery
• able to read or write Chinese

Eligibility criteria related to interest or ability, or both, to exercise:

• adverse effects or inability to exercise as recommended by their physicians - for example, women with

leukopenia, anemia, thrombocytopenia, and high fever up to 102°F

• unsafe conditions to exercise
• contraindications to exercise

Exclusion criteria:

• obesity (BMI ≥30 kg/m2; excluded to avoid bone and joint problems)
• degenerative arthritis
• limiting dyspnea with exertion
• bone pain
• severe nausea
• psychiatric problems
• recurrent breast cancer
• reported history of other types of cancer

Gender: female

Current age, mean (SD) years:

• exercise group: 48.40 (10.15) years
• control group: 52.30 (8.84) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level, n (%):

• exercise  group:  able  to  read,  2  (5.7%);  elementary,  3  (8.6%);  high  school,  12  (34.3%);  college,  12

(34.4%); graduate, 6 (17.1%)

• control  group:  able  to  read,  2  (5.4%);  elementary,  7  (18.9%);  high  school,  13  (35.1%);  college,  14

(37.8%); graduate, 1 (2.7%)

SES: not reported

Employment status, n (%):

• exercise group: not employed, 8 (22.9%); full-time, 20 (57.1%); part-time, 1 (2.9%); retired, 4 (11.4%);

leave no pay, 2 (5.7%)

• control group: not employed, 10 (27.0%); full-time, 17 (45.9%); part-time, 1 (2.7%); retired, 9 (24.3%);

leave no pay, 0 (0.0%)

Comorbidities: not reported

Past exercise history, mean (SD):

• exercise group: exercise time (before), 77.00 (138.00) minutes; exercise time (current), 67.71 (127.35)

minutes

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

190

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Wang 2010  (Continued)

Cochrane Database of Systematic Reviews

• control group: exercise time (before), 94.46 (126.41) minutes; exercise time (current), 66.89 (109.60)

minutes

Exercise type performed at baseline, n (%):

• exercise group: none, 11 (31.4%); walk, 15 (42.9%); fast walk, 5 (14.3%); mountain climbing, 1 (2.9%);

yoga, 0 (0.0%); tai-chi, 0 (0.0%); others, 3 (8.6%)

• control group: none, 12 (32.4%); walk, 12 (32.4%); fast walk, 3 (8.1%); mountain climbing, 3 (8.1%);

yoga, 2 (5.4%); tai-chi, 2 (5.4%); others, 3 (8.1%)

Interventions

35 participants assigned to the exercise group, including a 6-week home-based walking program and
strategies to boost women's exercise self-efficacy. The exercise program included the use of:

• HR ring monitor (functioning as a HR monitor (Unilife Corporation, Taipei, Taiwan); pedometer
• weekly phone call
• weekly exercise diary
• weekly meeting
• a role model story to advance participants' exercise self-efficacy

Type exercise (aerobic/anaerobic): aerobic

Intensity of the experimental exercise intervention: low- to moderate-intensity measured by a maximal
HR from 40% to 60% or the modified Borg Scale between 0.5 and 2

Frequency: 3 to 5 sessions per week

Duration of individual sessions: 30 minutes

Duration of exercise program: 6 weeks

Total number of exercise sessions: 18 to 30 sessions

Format: individual

Facility: home

Professionally led: not professionally led

Adherence: poor compliance (exercise not of low to moderate intensity, < 3 exercise sessions per week,
or < 30 minutes per session) were 1 (3.3%), 2 (6.7%), and 2 (6.7%), respectively

37 participants assigned to control group, including:

• usual care

Contamination of control group: 30.4% (n = 10) participants exercised more than 3 times per week and
30 minutes per session

Outcomes

No primary outcome was identified. QoL outcomes included:

• HRQoL, assessed using the FACT-G
• fatigue, assessed using the FACIT-F
• sleep disturbances, assessed using the PSQI

Other outcomes included:

• exercise self-efficacy, assessed using the ESES
• exercise behavior during the past week, assessed using the GLTEQ
• exercise capacity, assessed by 6MWD

Outcomes were measured at baseline, 2 to 3 weeks after surgery (second baseline), 4 weeks, and 6
weeks:

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

191

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Wang 2010  (Continued)

Cochrane Database of Systematic Reviews

• exercise group: n = 35 at baseline, n = 35 at 2 to 3 weeks, n = 4 weeks, n = 35 at 6 weeks
• control group: n = 35 at baseline, n = 35 at 2 to 3 weeks, n = 4 weeks, n = 35 at 6 weeks

Subgroup analysis: none

Adverse events: 2 participants (2.8%) had adverse effects of anemia and dizziness with dyspnea during
the program, and both dropped out from the study at weeks 2 and 3, respectively. 3 adverse events in
control group: 1 discomfort with exercise, 1 dizziness, 1 dyspnea

Notes

Country: Taiwan

Funding: Hebei Department of Hygiene

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

The generation of the random sequence was not described

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assigned was concealed from study personnel and par-
ticipants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

Allocation to the intervention was not concealed from the study personnel

Unclear risk

Although there was attrition, the author completed a longitudinal repeated
measure, which typically would incorporate data for missing values. However,
it was not stated whether this was done

Low risk

There appears to be no selective reporting of outcomes

Other bias

High risk

Substantial number of control group participants engaging in exercise could
place the trial at a high risk of additional biases

Windsor 2004 

Study characteristics

Methods

Study design: RCT

Number randomized: 66; 33 to the exercise group and 33 to the control group

Study start and stop dates: December 2001 to December 2002

Length of intervention: to end of radiation therapy

Length of follow-up: 4 weeks' post-treatment

Participants

Type cancer: prostate cancer; 51 of 65 patients had tumors classified as T1 to T2

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

192

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Windsor 2004  (Continued)

Time since cancer diagnosis: not reported

Time in active treatment: not begun

Inclusion criteria:

Cochrane Database of Systematic Reviews

• on outpatient waiting list for radical conformal radiation therapy for localized prostate carcinoma

Eligibility criteria related to interest or ability, or both, to exercise:

• none

Exclusion criteria:

• physical frailty owing to age
• comorbidity, such as unstable or severe angina, recent myocardial infarction, or dementia cardiac

pacemaker

Gender: male

Current age, mean (SD) years:

• exercise group: 68.3 (0.9, 52 to 82) years
• control group: 69.3 (1.3, 52 to 82) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level: not reported

SES: not reported

Employment status: not reported

Comorbidities: not reported

Past exercise history: not reported

On hormone therapy, receiving adjuvant hormone therapy for high-risk tumors, n (%):

• exercise group: 9 (27%)
• control group: 10 (30%)

Interventions

33 participants assigned to the exercise intervention, including:

• home-based continuous walking

Type exercise (aerobic/anaerobic): aerobic

Intensity of the experimental exercise intervention: target HR of 60% to 70% calculated maximum HR

Frequency: 3 days per week

Duration of individual sessions: 30 minutes

Duration of exercise program: to end of therapy

Total number of exercise sessions: varied

Format: individual

Facility: home

Professionally led: unclear

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

193

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Windsor 2004  (Continued)

Cochrane Database of Systematic Reviews

Adherence: all patients in the exercise group recorded at least 1.5 hours of aerobic exercise at the rec-
ommended percentage maximum HR per week throughout radiation therapy

33 participants assigned to control group, including:

• discouraged from performing normal activities and were advised to rest and take things easy if they

became fatigued

Contamination of control group: none, the control group showed a small, nonsignificant decline in
hours of reported aerobic activity per week during radiation therapy

Outcomes

No primary outcome was identified. Outcomes included:

• fatigue, assessed using the BFI
• resting HR
• exercise HR, assessed using the shuttle test
• physical activity, assessed using the SPAQ

Outcomes were measured at baseline; after 5, 10, 15, and 20 fractions of radiation therapy; and at fol-
low-up 4 weeks after the completion of treatment:

• exercise group: n = 32 at all time points
• control group: n = 33 at all time points

Subgroup analysis: none

Adverse events: none reported

Notes

Country: UK

Funding: none reported

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

The generation of the random sequence was not described

Allocation concealment
(selection bias)

Low risk

"Patients were randomized to trial group by telephone call to the Scottish Can-
cer Therapy Network randomization line…" 

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

Allocation to the intervention was not concealed from the study personnel

Incomplete outcome data
(attrition bias)
All outcomes

High risk

1 participant in the exercise group withdrew and was not included in the
analysis

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

High risk

Baseline tests performed after randomization

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

194

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Wiskemann 2011 

Study characteristics

Methods

Study design: Multicenter RCT

Number randomized: 112; 57 to the exercise group and 55 to the control group

Study start and stop dates: recruitment took place starting in May 2007 and the last participant com-
pleted the trial in February 2009

Length of intervention: at least 7 to 12 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer, n:

• exercise group: AML, 12; ALL, 6; CML, 2; chronic lymphocytic leukemia, 2; myelodysplastic syndrome, 7;
secondary AML, 6; myeloproliferative syndrome, 7; multiple myeloma, 2; other lymphomas, 7; aplastic
anemia, 1

• control group: AML, 10; ALL, 8; CML, 2; chronic lymphocytic leukemia, 2; myelodysplastic syndrome, 5;
secondary AML, 5; myeloproliferative syndrome, 6; multiple myeloma, 1; other lymphomas, 13; aplas-
tic anemia, 1

Time since cancer diagnosis: not reported

Time in active treatment, median (range) days:

• exercise group: outpatient before HSCT, 21 (5 to 112) days; duration of hospitalization, 45 (24 to 92)

days; outpatient after HSCT, 49 (39 to 63) days

• control group: outpatient before HSCT, 15 (5 to 90) days; duration of hospitalization, 43 (22 to 120)

days; outpatient after HSCT, 52 (40 to 83) days

Inclusion criteria:

• scheduled for allogenic stem cell transplant

Eligibility criteria related to interest or ability, or both, to exercise: not reported

Exclusion criteria: not reported

Gender, n (%):

• exercise group: male, 32 (45%); female, 21 (62%)
• control group: male, 39 (55%); female, 13 (38%)

Current age, mean (range) years:

• exercise group: 47.6 (18 to 70) years
• control group: 50 (20 to 71) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level: not reported

SES: not reported

Employment status: not reported

Comorbidities: none reported

Past exercise history, sedentary (< once per week physically active) at baseline, n (%):

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

195

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Wiskemann 2011  (Continued)

• exercise group: 38 (48%)
• control group: 41 (52%)

Interventions

57 participants assigned to the exercise intervention, including:

Cochrane Database of Systematic Reviews

• endurance training, recommended primarily as (brisk) walking in the outpatient setting; bicycling and
treadmill walking during hospitalization. If patients had experience in Nordic walking (walking with
specially designed poles imitating the motion of cross-country skiing) or jogging, these techniques
were also recommended

• strength training included exercises for the upper and lower extremities with and without a set of
color-coded stretch bands with different levels of resistance. 3 different strength-training protocols
were used: (1) focused on extremities, (2) the entire body, or (3) bed exercises (limited to inpatient
period)

Type exercise (aerobic/anaerobic): aerobic and anaerobic

Intensity of the experimental exercise intervention: Borg scale target scores of 12 to 14 for endurance
and 14 to 16 for resistance exercises

Frequency: 3 endurance (up to 5 during hospitalization) and 2 resistance training sessions per week

Duration of individual sessions:

• endurance training, brisk walking for 20 to 40 minutes
• strength training, 8 to 20 repetitions, 2 or 3 sets

Duration of exercise program: length of treatment

Total number of exercise sessions: 21 to 36 endurance sessions and 14 to 24 resistance training ses-
sions

Format: individual

Facility: home and facility based

Professionally supervised during the inpatient period and unsupervised during the outpatient period

Adherence: from baseline (medical check-up) until admission = 87.5%; during hospitalization, 83.0%;
outpatient period from discharge until study end (6 to 8 weeks later), 91.3%

55 participants assigned to control group, including:

• pedometer wearing and told that moderate physical activity is favorable during the treatment period

Contamination of control group: not reported

Outcomes

Primary outcome was fatigue, assessed using:

• MFI
• fatigue subscale of the POMS
• fatigue subscale of the EORTC QLQ-C30

Secondary outcomes included:

• global HRQoL, assessed using the EORTC QLC-C30 and subscales of:

• physical functioning
• role function
• cognitive functioning
• social functioning
• pain
• insomnia

• anxiety assessed using the HADS

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

196

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Wiskemann 2011  (Continued)

• depression assessed using

• HADS
• POMS depression scale

• emotional functioning, assessed using

• QLQ-C30 emotional functioning subscale
• POMS anger/hostility subscale

Cochrane Database of Systematic Reviews

• stress, assessed using the National Comprehensive Cancer Network Distress thermometer
• physical outcomes, including

• endurance performance assessed using the 6MWT
• maximal isometric voluntary muscle strength assessed with a hand-held dynameter

Outcomes were measured at baseline, at admission to hospital (second baseline), at discharge from
hospital, and at 6 to 8 weeks after discharge:

• exercise group: n = 57 at baseline (T0), n = 52 at admission to the hospital (second baseline) (T1), n =

40 at discharge from hospital (T2), n = 40 at 6 to 8 weeks after discharge (T3)

• control group: n = 55 at baseline (T0), n = 53 at admission to the hospital (second baseline) (T1), n = 41

at discharge from hospital (T2), n = 40 at 6 to 8 weeks after discharge (T3)

Subgroup analysis: none reported

Adverse events: 24 participants (11 in the exercise and 13 in the control group) died

Notes

Country: Germany

Funding: German Jose Carreras Leukemia Foundation

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Low risk

Allocation sequence was generated using the minimization procedure

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assigned was concealed from study personnel and par-
ticipants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

Allocation to the intervention was not concealed from the study personnel

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Analyses were not conducted on an ITT basis and the treatment of missing
data was not described. Although the authors used last observation carried
forward for the participants who did not complete the last study visit, they
excluded randomized individuals who were considered ineligible after ran-
domization (missing donor, revised diagnosis, contraindications in check-up,
dropped out)

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

197

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Yang 2011 

Study characteristics

Methods

Study design: RCT

Number randomized: 44; 19 to the exercise group and 21 to the control group

Study start and stop dates: recruitment of participants took place between 2008 and 2009

Length of intervention: 12 weeks

Length of follow-up: to end of the intervention

Participants

Type cancer: breast cancer

Cancer stage, n (%):

• exercise group: Stage I, 9 (47.4%); Stage II, 10 (52.6%); Stage IIIa, 0 (0%)
• control group: Stage I, 6 (28.6%); Stage II, 12 (57.1%); Stage IIIa, 3 (14.3%)

Time since cancer diagnosis: not reported

Time in active treatment: receiving 12 weeks of adjuvant chemotherapy postoperatively

Inclusion criteria:

• women with postoperative Stage I to IIIA breast cancer
• receiving adjuvant chemotherapy during the study period
• ≥ 18 years old

Eligibility criteria related to interest or ability, or both, to exercise:

• skeletomuscular deficits that would contraindicate a walking exercise program
• regularly engaged in > 1 session of moderate-intensity exercise per week over the past 6 months

Exclusion criteria:

• uncontrolled hypertension, diabetes mellitus, cardiac, or psychiatric illness

Gender: female

Current age, mean (SD) years:

• exercise group: 50.79 (7.05) years
• control group: 52.71 (8.11) years

Age at cancer diagnosis: not reported

Ethnicity/race: not reported

Education level: not reported

SES: not reported

Employment status, employed, n (%):

• exercise group: 3 (15.8%)
• control group: 8 (38.1%)

BMI, mean (SD)

• exercise group: 23.09 (3.32)
• control group: 24.37 (3.23)

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

198

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Yang 2011  (Continued)

Comorbidities: none reported

Past exercise history: not reported

Interventions

19 participants assigned to the exercise intervention, including:

• 12-week  home-based  walking  program,  developed  using  the  American  College  of  Sports  Medicine
Guidelines, and included walking starting 2 to 3 days after each chemotherapy session. The interven-
tion included:
• 5 minutes' warm-up
• 30 minutes' brisk walking
• 5 minutes' cool down

Type exercise: (aerobic/anaerobic): aerobic

Intensity of the experimental exercise intervention: moderate-intensity brisk walking (60% to 80% of
age-adjusted maximal HR)

Frequency: 3 times per week

Duration of individual sessions: about 40 minutes

Duration of exercise program: 12 weeks

Total number of exercise sessions: 36 sessions

Format: individual

Facility: home

Professionally led: not professionally led

Adherence: adherence to the exercise intervention was about 77% (31.2 of 36) of the prescribed exer-
cise sessions and 100% of the prescribed exercise intensity

21 participants assigned to control group, including:

• maintenance of their previous lifestyle for 12 weeks

Contamination of control group: not reported

Outcomes

No primary outcome was identified. QoL outcomes included:

• symptom severity, assessed using the MDASI-Taiwanese Version (MDASI-T)
• symptoms interference with daily life, assessed using the MDASI-T
• emotional distress, assessed using the POMS-SF

Other outcomes included:

• self-reported physical activity level, assessed using the Seven-Day Physical Activity Recall (7-Day PAR)

Outcomes were measured at baseline, 6 weeks, and 12 weeks:

• exercise group: n = 19 at baseline, n = 19 at 6 weeks, n = 19 at 12 weeks
• control group: n = 21 at baseline, n = 21 at 6 weeks, n = 21 at 12 weeks

Subgroup analysis: none reported

Adverse events: no participants experienced any adverse events related to home-based exercise during
the 12-week study period

Notes

Country: Taiwan

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

199

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Yang 2011  (Continued)

Risk of bias

Bias

Funding: Taipei Medical University Hospital

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

The random location sequence was generated using a table of random num-
bers

Allocation concealment
(selection bias)

Unclear risk

Whether the treatment assigned was concealed from study personnel and par-
ticipants was not described

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from the participants

High risk

Allocation to the intervention was not concealed from the study personnel

Incomplete outcome data
(attrition bias)
All outcomes

High risk

44 women were randomly assigned to exercise or control groups and 40
women completed the trial. No information is provided on the 4 women who
did not complete the trial

Selective reporting (re-
porting bias)

Low risk

There appears to be no selective reporting of outcomes

Other bias

Low risk

The trial appears to be free of other problems that could put it at a high risk of
bias

6MWD: 6-minute walk distance; 7-Day PAR: Seven-Day Physical Activity Recall; HR: heart rate; AFI: Attentional Functional Index; ALL: acute
lymphoblastic leukemia; AML: acute myelogenous leukemia; BDI: Beck's Depression Inventory; BFI: Brief Fatigue Inventory; BMD: bone
mineral density; BMI: body mass index; Borg RPE: Borg Rating of Perceived Exertion; CCS: Canadian Cancer Society; CES-D: Center for
Epidemiological Studies Depression scale; CML: chronic myeloid leukemia; CRP: C-reactive protein; DXA: dual energy X-ray absorptiometry;
ECOG:  Eastern  Cooperative  Oncology  Group;  EORTC:  European  Organization  for  Research  and  Treatment  of  Cancer;  EPIC:  Expanded
Prostate Cancer Index Composite; ESES: Exercise Self-efficacy Scale; EWB: emotional well-being; FACIT-F: Functional Assessment of Chronic
Illness Therapy - Fatigue; FACIT-Sp: Functional Assessment of Chronic Illness Therapy - Spiritual; FACT-An: Functional Assessment of Cancer
Therapy  -  Anemia;  FACT-B:  Functional  Assessment  of  Cancer  Therapy  -  Breast;  FACT-Cog:  Functional  assessment  of  Cancer  Therapy  -
Cognitive Function; FACT-ES: Functional Assessment of Cancer Therapy - Endocrine symptoms; FACT-F: Functional Assessment of Cancer
Therapy  -  Fatigue;  FACT-G:  Functional  Assessment  of  Cancer  Therapy  -  General;  FACT-P:  Functional  Assessment  of  Cancer  Therapy  -
Physical; FACT-P: Functional Assessment of Cancer Therapy - Prostate; FACT-Sp: Functional Assessment of Cancer Therapy - Spirituality;
FAEPEX : Ao Fundo de Apoio ao Ensino, Pesquisa e Entenxao; FLIC: Functional Living Index for Cancer; FWB: functional well-being; GLTEQ:
Goldin Leisure Time Exercise Questionnaire; HADS: Hospital Anxiety and Depression Scale; HDC: high-dose chemotherapy; HL: Hodgkin
lymphoma; HR: heart rate; HRQoL: health-related quality of life; HSCT: hematopoietic stem cell transplantation; ITT: intention-to-treat;
LASA:  Linear  Analog  Scales  of  Assessment;  LHRHa:  luteinizing  hormone-releasing  hormone  analogue;  LOCF:  last  observation  carried
forward;  LSI:  Leisure  Score  Index;  MANE:  Morrow  Assessment  of  Nausea  and  Emesis;  MCS:  mental  component  status;  MDASI-T:  M.D.
Anderson Symptom Inventory-Taiwanese Version; MFI: Multidimensional Fatigue Inventory; MFSI-SF: Multidimensional Fatigue Symptom
Inventory Short Form; MMSE: Mini Mental Status Examination; MOS SF-36: Medical Outcomes 36-Item Short Form Health Survey; MVT:
maximum voluntary torque; MWT: minute walk test; NCIC: National Cancer Institute of Canada; NHL: non-Hodgkin lymphoma; NYHA: New
York Heart Association; PANAS: Positive and Negative Affect Schedule; PCS: physical component status; PFS: Piper Fatigue Scale; POMS:
Profile of Mood States; POMS-SF; Profile of Mood State-Short Form; PSA: prostate specific antigen; PSQI: Pittsburgh Sleep Quality Inventory;
PWB: physical well-being; QLQ: Quality of Life Questionnaire; QoL: quality of life; ROM: range of motion; rPAR-Q: revised Physical Activity
Readiness Questionnaire; SCFS: Schwartz Cancer Fatigue Scale; SCL: Symptom Check List; SPAQ: Scottish Physical Activity Questionnaire;
SPSS  Expectation Maximization; STAI: State-Trait Anxiety Index; SWB: social/family well-being; SWLS: Satisfaction with Life Scale; TOI-
An: Trial Outcome Index - Anemia; UNICAMP: da Universidade Estadual de Campinas; VAS: visual analog scale; VO2max: maximal oxygen
uptake; VYASA: Vivekananda Yoga Anusandhana Samsthana; WHO: World Health Organization; WOMAC: Western Ontario and McMaster
Universities Osteoarthritis Index.

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

200

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Aaronson 2011

Adamsen 2006

Aghili 2007

Banasik 2011

This study was excluded as the exercise was aimed toward reduction in treatment-induced
menopause rather than for improvement in whole body function or QoL

This study was excluded as it was not an RCT or a CCT and it did not compare an exercise with no
exercise, another intervention, or usual care

This study was excluded as it was not an RCT or a CCT

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

Baumann 2008

This study was excluded as it was not an RCT or a CCT

Baumann 2011

Beurskens 2007

Bloom 2011

Bourke 2011a

Box 2002

Box 2009

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care

This study was excluded as the exercise was aimed toward reduction in shoulder dysfunction
rather than for improvement in whole body function or QoL

This study was excluded as the exercise was aimed toward reduction in treatment-related bone
loss rather than for improvement in whole body function or QoL

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care and it did not measure overall HRQoL or an HRQoL domain as a study outcome

This study was excluded as it was not an RCT or a CCT; it did not compare an exercise with no ex-
ercise, another intervention, or usual care; and it did not measure overall HRQoL or an HRQoL do-
main as a study outcome

Carmack Taylor 2004

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care

Carmack Taylor 2006

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care

Carmack Taylor 2007

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care

Chen 2010

Cho 2004

Cho 2006

This study was excluded as the exercise was aimed toward reduction in treatment-related ill limb
rather than for improvement in whole body function or QoL, it only included people who had com-
pleted active cancer treatment for either the primary or recurrent cancer, and the exercise inter-
vention was initiated after completion of active treatment

This study was excluded as it was not an RCT or a CCT

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

201

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Reason for exclusion

Crevenna 2003

Culos-Reed 2007

Daley 2004

Daley 2007

Daley 2007a

Daubenmier 2006

This study was excluded as it was not an RCT or a CCT, and it only included people who had com-
pleted active cancer treatment for either the primary or recurrent cancer

This study was excluded as it was not an RCT or a CCT, and it did not compare an exercise with no
exercise, another intervention, or usual care

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

Demark-Wahnefried 2008

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care

Dhillon 2011

Dimeo 1997

Dimeo 2004

Dong 2006

Duijts 2009

Duijts 2009a

Duijts 2010

Duijts 2010a

Eyigor 2010

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care; it only included people who had completed active cancer treatment for either the
primary or recurrent cancer; and the exercise intervention was initiated after completion of active
treatment

This study was excluded as it did not measure overall HRQoL or an HRQoL domain as a study out-
come

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

This study was excluded as it only included people who had completed active cancer treatment
for either the primary or recurrent cancer; it did not compare an exercise with no exercise, anoth-
er intervention, or usual care; and the exercise intervention was initiated after completion of active
treatment

This study was excluded as the exercise was aimed toward reduction in treatment-induced
menopause rather than for improvement in whole body function or QoL

This study was excluded as the exercise was aimed toward reduction in treatment-induced
menopause rather than for improvement in whole body function or QoL

This study was excluded as the exercise was aimed toward reduction in treatment-induced
menopause rather than for improvement in whole body function or QoL

This study was excluded as the exercise was aimed toward reduction in treatment-induced
menopause rather than for improvement in whole body function or QoL

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care; it only included people who had completed active cancer treatment for either the

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

202

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Reason for exclusion

Frattaroli 2008

Galantino 2003

Galvao 2006

Greenfield 2010

Guo 2004

Haines 2010

Hartmann 2007

Hayes 2004

Hayes 2011

Heim 2007

Heim 2011

Heislein 2009

Henderson 2012

Herdman 1995

primary or recurrent cancer; and the exercise intervention was initiated after completion of active
treatment

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

This study was excluded as it was not an RCT or a CCT; it did not compare an exercise with no ex-
ercise, another intervention, or usual care; and it did not measure overall HRQoL or an HRQoL do-
main as a study outcome

This study was excluded as it was not an RCT or a CCT; it did not compare an exercise with no ex-
ercise, another intervention, or usual care; it only included people who had completed active can-
cer treatment for either the primary or recurrent cancer; the exercise intervention was initiated af-
ter completion of active treatment; and it did not measure overall HRQoL or an HRQoL domain as a
study outcome

This study was excluded as it was not an RCT or a CCT, and it did not compare an exercise with no
exercise, another intervention, or usual care

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, it did not exclude people below the age of 18 years, and the
exercise intervention was initiated after completion of active treatment

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

This study was excluded as it was not an RCT or a CCT, and it did not compare an exercise with no
exercise, another intervention, or usual care

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer; the exercise intervention was initiated after completion of
active treatment; and it did not measure overall HRQoL or an HRQoL domain as a study outcome

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

203

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Herold 2010

Houborg 2006

Irwin 2008

John 2007

Jones 2008

Jones 2010

Kampshoff 2010

Kilbreath 2006

Kilbreath 2006a

Knols 2011

Koller 2006

Korstjens 2008

Latka 2009

Lau 2010

Le Vu 1997

Lee 2007a

Reason for exclusion

This study was excluded as it was not an RCT or a CCT, and it did not compare an exercise with no
exercise, another intervention, or usual care

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer; the exercise intervention was initiated after completion of
active treatment; and it did not measure overall HRQoL or an HRQoL domain as a study outcome

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care

This study was excluded as it was not an RCT or a CCT, and it did not compare an exercise with no
exercise, another intervention, or usual care

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer; the exercise intervention was initiated after completion of
active treatment; and the exercise was aimed toward reduction in lymphedema rather than for im-
provement in whole body function or QoL

This study was excluded as the exercise was aimed toward reduction in shoulder dysfunction
rather than for improvement in whole body function or QoL

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care

This study was excluded as the exercise was aimed toward reduction in shoulder dysfunction
rather than for improvement in whole body function or QoL

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

204

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Reason for exclusion

MacVicar 1989

Manassero 2007

This study was excluded as it did not measure overall HRQoL or an HRQoL domain as a study out-
come

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care

Marchese 2004

This study was excluded as it did not exclude people below the age of 18 years

Mathewson-Chapman 1997

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care, and it did not measure overall HRQoL or an HRQoL domain as a study outcome

McClure 2010

McKenzie 2003

Mehnert 2011

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care

This study was excluded as the exercise was aimed toward reduction in lymphedema rather than
for improvement in whole body function or QoL

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

Midtgaard 2005

This study was excluded as it was not an RCT or a CCT, and it did not compare an exercise with no
exercise, another intervention, or usual care

Mina 2010

Newton 2011

O'Brien 2003

Park 2006

Patel 2005

Peddle 2009

Penttinen 2009

Persoon 2010

Pickett 2002

Pinto 2003

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care

This study was excluded as it was not an RCT or a CCT, and it did not compare an exercise with no
exercise, another intervention, or usual care

This study was excluded as it was not an RCT or a CCT, and it did not compare an exercise with no
exercise, another intervention, or usual care

This study was excluded as it was not an RCT or a CCT

This study was excluded as there was no exercise intervention, the exercise included 10 to 15 min-
utes of gentle stretching

This study was excluded as it was not an RCT or a CCT, and it did not compare an exercise with no
exercise, another intervention, or usual care

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

This study was excluded as it did not measure overall HRQoL or an HRQoL domain as a study out-
come

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

205

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Pinto 2005

Roscoe 2005

San Juan 2008

Scheier 2005

Schwartz 1999

Schwartz 2000

Schwartz 2009

Sekse 2011

Shelton 2009

Stephenson 2000

Thorsen 2005

Todd 2008

Turner 2004

Ulger 2010

Vallance 2008

Reason for exclusion

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care; it did not exclude people below the age of 18 years; it only included people who had
completed active cancer treatment for either the primary or recurrent cancer; and the exercise in-
tervention was initiated after completion of active treatment

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care; it only included people who had completed active cancer treatment for either the
primary or recurrent cancer; and the exercise intervention was initiated after completion of active
treatment

This study was excluded as it was not an RCT or a CCT, and it did not compare an exercise with no
exercise, another intervention, or usual care

This study was excluded as it was not an RCT or a CCT, and it did not compare an exercise with no
exercise, another intervention, or usual care

This study was excluded as it did not measure overall HRQoL or an HRQoL domain as a study out-
come

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer; the exercise intervention was initiated after completion of
active treatment; and it did not compare an exercise with no exercise, another intervention, or usu-
al care

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

This study was excluded as the exercise was aimed toward reduction in lymphedema rather than
for improvement in whole body function or QoL

This study was excluded as it was not an RCT or a CCT; it did not compare an exercise with no exer-
cise, another intervention, or usual care; it only included people who had completed active cancer
treatment for either the primary or recurrent cancer; and the exercise intervention was initiated af-
ter completion of active treatment

This study was excluded as it was not an RCT or a CCT, and it did not compare an exercise with no
exercise, another intervention, or usual care

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care; it only included people who had completed active cancer treatment for either the
primary or recurrent cancer; and the exercise intervention was initiated after completion of active
treatment

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

206

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Vardy 2010

von Gruenigen 2009

von Gruenigen 2011

Wang 2005

Xie 2010

Zhang 2006

Reason for exclusion

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer, and the exercise intervention was initiated after completion
of active treatment

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care

This study was excluded as it was not an RCT or a CCT, and it did not compare an exercise with no
exercise, another intervention, or usual care

This study was excluded as it only included people who had completed active cancer treatment for
either the primary or recurrent cancer; the exercise intervention was initiated after completion of
active treatment; and it did not measure overall HRQoL or an HRQoL domain as a study outcome

This study was excluded as the exercise was aimed toward upper limb function rather than for im-
provement in whole body function or QoL

This study was excluded as it did not compare an exercise with no exercise, another intervention,
or usual care; it only included people who had completed active cancer treatment for either the
primary or recurrent cancer; and the exercise intervention was initiated after completion of active
treatment

CCT: controlled clinical; HRQoL: health-related quality of life; QoL: quality of life; RCT: randomized controlled trial.

Characteristics of studies awaiting classification [ordered by study ID]

Courneya 2001 

Methods

RCT

Participants

96 participants with colorectal cancer (treatment status unknown)

Interventions

Fitness/exercise, details not provided on the intervention and comparison arm

Outcomes

HRQoL outcomes included psychological distress (anxiety, depression, fatigue) and well-being
(physical, functional, emotional)

Notes

Published abstract

Harandi 2010 

Methods

RCT

Participants

63 women with breast cancer (treatment status unknown)

Interventions

Home-based exercise therapy compared with control group

Outcomes

Notes

QoL assessed using the QLQ-C30 and QLQ-BR23

Published abstract

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

207

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Sun 2009 

Methods

Participants

Interventions

Outcomes

Notes

RCT

240 women with breast cancer receiving chemotherapy

Exercise intervention (specifics not provided)

Fatigue

Published report

Utz-Billing 2010 

Methods

RCT

Participants

93 women who had breast cancer surgery (breast-sparing therapy or mastectomy)

Interventions

Yoga classes compared with waiting list control

Outcomes

QoL assessed by QLQ-C23, physical function assessed by FACT-B (Version 4), and disabilities of up-
per limbs (DASH)

Notes

Published abstract

DASH: ; FACT-B: Functional Assessment of Cancer Therapy - Breast; HRQoL: health-related quality of life; QLQ-C23; QLQ-C30: QLQ-BR23;
QoL: quality of life; RCT: randomized controlled trials

Characteristics of ongoing studies [ordered by study ID]

Christensen 2011 

Study name

Methods

Participants

PROTRACT

RCT

Men with testicular cancer undergoing 3 cycles of combination chemotherapy with bleomycin,
etoposide, and cisplatin (BEP)

Interventions

HIPRT compared to standard care

Outcomes

Primary outcomes include mean fiber area and fiber type composition measured by histochemi-
cal analyses, satellite cells and levels of protein and mRNA expression of intracellular mediators
of protein turnover. Secondary outcomes include maximum muscle strength and muscle power
measured by maximum voluntary contraction and leg-extensor-power tests, body composition
assessed by DXA scan, and systemic inflammation analyzed by circulating inflammatory markers,
lipid and glucose metabolism in blood samples. HRQoL outcomes assessed using the QLQ-C30 and
SF-36

Starting date

Not reported

Contact information

Jesper F Christensen, University Hospital Centre for Nursing and Care Research, Copenhagen Uni-
versity Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark

Notes

Published protocol. Trial Registration: Current Controlled Trials ISRCTN32132990

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

208

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Galvao 2009 

Study name

Methods

Participants

RADAR

RCT

Cohort undergoing or previously treated for prostate cancer involving androgen deprivation thera-
py

Interventions

Supervised resistance/aerobic exercise compared to standard physical activity recommendation

Outcomes

Outcomes include aerobic walking capacity, anthropometric measures (abdominal obesity), var-
ious blood markers, self-reported physical activity, HRQoL assessed using the QLQ-C30, falls self-
efficacy assessed using the activities-specific balance, psychological distress assessed using the
BSI, nutrition, and lower body physical function. In addition, at 1 of the study sites, additional out-
comes assessed include body composition, muscle strength, balance, and risk of falling

Starting date

Not reported

Contact information

Daniel A. Galvao, Vario Health Institute, School of Exercise, Biomedical and Health Sciences, Edith
Cowan University, Joondalup, WA, Australia

Notes

Published protocol. Trial Registration: ACTRN 12609000729224

Haseen 2010 

Study name

Dietary and physical activity intervention for prostate cancer patients

Methods

RCT

Participants

Prostate cancer survivors receiving ADT

Interventions

Dietary modification and physical activity compared to standard care

Outcomes

Primary outcomes include body composition, fatigue assessed using the FSS, and QoL assessed us-
ing the FACT-P. Secondary outcomes include nutrient intake, physical activity and perceived stress
assessed using the PSS-10

Starting date

Not reported

Contact information

Farhana Haseen, Centre for Public Health, Queen's University Belfast, Northern Ireland, UK

Notes

Published protocol. Trial registration: ISRCTN trial number ISCRTN75282423

Newton 2009 

Study name

Exercise modalities on treatment side-effects in men receiving therapy for prostate cancer

Methods

RCT

Participants

Men undergoing treatment for prostate cancer involving ADT

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

209

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Newton 2009  (Continued)

Interventions

Outcomes

(1) Resistance/impact loading exercise, (2) resistance/cardiovascular exercise groups, or (3) usual
care/delayed exercise

Primary outcomes include whole body and hip and spine BMD, body composition, cardiorespira-
tory capacity, blood pressure and arterial stiffness, and blood markers. Secondary outcomes in-
clude muscle strength and endurance, physical function, balance and risk of falling, physical ac-
tivity, QoL, and psychological distress. QoL assessed using the QLQ-C30 and QLQ-PR25 as well as
a health history questionnaire, and psychological distress (anxiety, depression, and somatization)
assessed using the BSI-18

Starting date

Not reported

Contact information

Robert U Newton, Vario Health Institute, Edith Cowan University, Joondalup, WA, Australia

Notes

Published protocol. Clinical Trial Registry: ACTRN12609000200280

van Waart 2010 

Study name

Methods

PACES

RCT

Participants

Participants with breast or colon cancer receiving adjuvant chemotherapy

Interventions

Outcomes

(1) Onco-Move, a relatively low-intensity, home-based, individualized, self-managed physical activ-
ity program, (2) OnTrack, a relatively high-intensity exercise program that is supervised by a physi-
cal therapist in an outpatient or general physical therapy practice setting, or (3) usual care

Primary outcomes include cardiorespiratory fitness, muscle strength, and fatigue assessed using
the MFI and the FQL. Secondary outcomes include mood disturbance assessed using the HADS,
quality of sleep assessed using the PSQI, HRQoL assessed using the QLQ-C30, functioning in daily
life, measured physical activity level, self-reported physical activity level, and anthropometric mea-
sures

Starting date

Not reported

Contact information

Hanna van Waart, The Netherlands Cancer Institute, Division of Psychosocial Research and Epi-
demiology, Amsterdam, The Netherlands

Notes

Published protocol. Trial registration: The Netherlands Trial Register (NTR 2159)

Velthuis 2010 

Study name

Methods

PACT

RCT

Participants

Participants with breast or colon cancer undergoing cancer treatment

Interventions

An 18-week supervised group or control group asked to maintain their habitual physical activity
pattern

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

210

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Velthuis 2010  (Continued)

Outcomes

Primary outcome is fatigue assessed using the MFI and the FQL. Secondary outcomes include
HRQoL assessed using the EORTC QLQ-C30 (Version 3) and the SF-36, perceived impact of the dis-
ease on participation and autonomy assessed using the IPA questionnaire, anxiety and depression
assessed using the Dutch language version of the HADS, physical fitness, BMI, body fat distribution,
self efficacy about the performance of physical activity, and physical activity level

Starting date

Not reported

Contact information

Miranda J Velthuis, Comprehensive Cancer Center Middle Netherlands, Utrecht, the Netherlands

Notes

Published protocol. Trial registration: Current Controlled trials ISRCTN43801571, Dutch Trial Regis-
ter NTR2138

ADT: androgen deprivation therapy; BMD: bone mineral density; BMI: body mass index; BSI-18: Brief Symptom Inventory-18; DXA: dual
energy X-ray absorptiometry; DCIS: ductal carcinoma in situ; EORTC: European Organization for Research and Treatment of Cancer: FACT-
P: Functional Assessment of Cancer Therapy - prostate; Functional Assessment of Cancer Therapy - Prostate; FQL: Fatigue Quality List;
FSS: Fatigue Severity Scale; GED: general educational development; HADS: Hospital Anxiety and Depression Scale; HIPRT: high-intensity
progressive resistance training; HRQoL: health-related quality of life; IPA: Impact on Participation and Autonomy; MFI: Multidimensional
Fatigue  Inventory;  PSQI:  Pittsburgh  Sleep  Quality  Index;  PSS-10:  Perceived  Stress  Scale;  EORTC  QLQ-C30:  European  Organization  for
Research and Treatment of Cancer: Quality of Life Questionnaire-C30; QoL: quality of life; RCT: randomized controlled Trial; SF-36: Short
Form-36.

D A T A   A N D   A N A L Y S E S

Comparison 1.   Health-related quality of life

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

1.1 Overall quality of life change score

1.1.1 Up to 12 weeks' follow-up

1.1.2 More than 12 weeks' to less than 6 months'
follow-up

1.1.3 6 months' follow-up

1.2 Overall quality of life follow-up values

1.2.1 Up to 12 weeks' follow-up

1.2.2 More than 12 weeks' to less than 6 months'
follow-up

1.2.3 6 months' follow-up

14

11

4

3

26

20

6

8

Std. Mean Difference (IV,
Random, 95% CI)

Subtotals only

Std. Mean Difference (IV,
Random, 95% CI)

0.47 [0.16, 0.79]

Std. Mean Difference (IV,
Random, 95% CI)

1.25 [-0.03, 2.53]

Std. Mean Difference (IV,
Random, 95% CI)

0.14 [-0.11, 0.39]

Std. Mean Difference (IV,
Random, 95% CI)

Subtotals only

Std. Mean Difference (IV,
Random, 95% CI)

0.33 [0.12, 0.55]

Std. Mean Difference (IV,
Random, 95% CI)

0.25 [0.07, 0.43]

Std. Mean Difference (IV,
Random, 95% CI)

0.13 [-0.09, 0.35]

806

442

282

1166

529

686

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

211

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

1.3 FACT-An change

1.3.1 Up to 12 weeks' follow-up

1.3.2 More than 12 weeks' to less than 6 months'
follow-up

1.3.3 6 months' follow-up

1.4 FACT-An follow-up values

1.4.1 Up to 12 weeks' follow-up

1.4.2 More than 12 weeks' to less than 6 months'
follow-up

1.4.3 6 months' follow-up

1.5 FACT-B change

1.5.1 Up to 12 weeks' follow-up

1.5.2 6 months' follow-up

1.6 FACT-B follow-up values

1.6.1 Up to 12 weeks' follow-up

1.6.2 6 months' follow-up

1.7 FACT-G change

1.7.1 Up to 12 weeks' follow-up

1.7.2 More than 12 weeks' to less than 6 months'
follow-up

1.7.3 6 months' follow-up

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

2

1

1

1

3

3

2

2

2

2

1

4

3

2

5

4

1

2

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

-6.90 [-21.73, 7.93]

Mean Difference (IV, Ran-
dom, 95% CI)

6.33 [1.31, 11.34]

Mean Difference (IV, Ran-
dom, 95% CI)

2.10 [-5.77, 9.97]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

4.50 [-4.31, 13.32]

Mean Difference (IV, Ran-
dom, 95% CI)

8.31 [-3.36, 19.98]

Mean Difference (IV, Ran-
dom, 95% CI)

5.16 [-4.15, 14.46]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

6.81 [-5.81, 19.43]

Mean Difference (IV, Ran-
dom, 95% CI)

8.20 [-0.29, 16.69]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

0.73 [-8.23, 9.69]

Mean Difference (IV, Ran-
dom, 95% CI)

-0.55 [-3.65, 2.55]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

5.70 [2.30, 9.09]

Mean Difference (IV, Ran-
dom, 95% CI)

2.52 [-0.75, 5.79]

Mean Difference (IV, Ran-
dom, 95% CI)

3.52 [-2.94, 9.99]

55

223

201

312

253

230

57

36

120

170

286

81

81

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

212

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

1.8 FACT-G follow-up values

10

1.8.1 Up to 12 weeks' follow-up

1.8.2 More than 12 weeks' to less than 6 months'
follow-up

1.8.3 6 months' follow-up

1.9 FACT-P change

1.9.1 Up to 12 weeks' follow-up

1.10 FACT-P follow-up values

1.10.1 Up to 12 weeks' follow-up

1.11 FACIT-F change

1.11.1 Up to 12 weeks' follow-up

1.11.2 More than 12 weeks' to less than 6
months' follow-up

1.12 FACIT-F follow-up values

1.12.1 Up to 12 weeks' follow-up

1.12.2 More than 12 weeks' to less than 6
months' follow-up

1.13 QLQ-C30 change

1.13.1 Up to 12 weeks' follow-up

1.13.2 More than 12 weeks' to less than 6
months' follow-up

1.14 QLQ-C30 follow-up values

6

2

7

2

2

2

2

2

2

1

1

1

1

2

1

1

7

318

151

485

176

64

205

38

38

38

44

100

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

6.89 [0.44, 13.35]

Mean Difference (IV, Ran-
dom, 95% CI)

6.25 [-0.75, 13.26]

Mean Difference (IV, Ran-
dom, 95% CI)

1.89 [-2.38, 6.17]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

8.55 [0.45, 16.65]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

7.36 [-1.59, 16.31]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

1.55 [-6.37, 9.48]

Mean Difference (IV, Ran-
dom, 95% CI)

0.21 [-8.78, 9.20]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

13.30 [-3.16, 29.76]

Mean Difference (IV, Ran-
dom, 95% CI)

6.83 [-9.26, 22.92]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

-5.14 [-15.97, 5.69]

Mean Difference (IV, Ran-
dom, 95% CI)

5.03 [4.68, 5.38]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

213

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

1.14.1 Up to 12 weeks' follow-up

1.14.2 More than 12 weeks' to less than 6
months' follow-up

1.14.3 6 months' follow-up

1.15 FLIC follow-up values

1.15.1 Up to 12 weeks' follow-up

1.16 WHO BREF follow-up values

1.16.1 Up to 12 weeks' follow-up

1.17 Ferrand and Powers follow-up values

1.17.1 Up to 12 weeks' follow-up

1.18 Spitzer QoL Uniscale follow-up values

1.18.1 Up to 12 weeks' follow-up

1.19 MDASI-T Symptom Interference change

1.19.1 Up to 12 months' follow-up

1.20 MDASI-T Symptom Interference follow-up
values

1.20.1 Up to 12 weeks' follow-up

1.21 Quality of Life Systemic Inventory follow-up
values

1.21.1 Up to 12 months' follow-up

5

3

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

210

147

29

62

37

17

96

40

40

73

Mean Difference (IV, Ran-
dom, 95% CI)

7.31 [1.99, 12.63]

Mean Difference (IV, Ran-
dom, 95% CI)

6.00 [0.69, 11.31]

Mean Difference (IV, Ran-
dom, 95% CI)

14.50 [-0.75, 29.75]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

30.40 [21.03, 39.77]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

0.17 [-0.05, 0.39]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

1.00 [-3.33, 5.33]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

3.50 [-5.10, 12.10]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

-1.64 [-2.29, -0.99]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

-1.50 [-2.36, -0.64]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

-0.75 [-3.32, 1.82]

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

214

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.1.   Comparison 1: Health-related quality of life, Outcome 1: Overall quality of life change score

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.1.1 Up to 12 weeks' follow-up
Arbane 2009
Campbell 2005
Courneya 2008
Monga 2007
Mustian 2009
Oh 2010
Rogers 2009
Segal 2003
Segal 2009
Segal 2009
Targ 2002
Yang 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.22; Chi² = 46.31, df = 11 (P < 0.00001); I² = 76%
Test for overall effect: Z = 2.97 (P = 0.003)

14.65
13.8
27
10.4
18.3
9
8.4
9.1
8.4
8.8
16.1
1.4

-0.79
11.9
13.4
7.4
6
8.86
4.5
2
0.75
2.27
4.98
1.41

4.35
-2.9
20.3
-6.4
-0.67
-0.13
2.9
-3.3
-2.48
-2.48
6.62
-0.23

21
10
26
11
19
54
20
82
40
40
79
19
421

21.6
16.1
29.1
9.8
11.51
8.6
12
10.2
8.5
8.5
21.7
0.36

1.1.2 More than 12 weeks' to less than 6 months' follow-up
Courneya 2007a
Courneya 2007a
Culos-Reed 2010
Mustian 2009
Segal 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 2.05; Chi² = 132.26, df = 4 (P < 0.00001); I² = 97%
Test for overall effect: Z = 1.92 (P = 0.06)

25.6
23.3
0.9
16.51
7.5

-1
-1
-2.33
8.55
-0.17

76
74
53
19
40
262

5.9
4.8
2.7
8.76
2.35

13.7
13.7
0.88
11.28
7.5

23
9
29
10
19
54
18
73
21
20
88
21
385

8.3%
5.6%
8.8%
5.6%
7.9%
9.9%
7.9%
10.5%
8.8%
8.7%
10.6%
7.3%
100.0%

-0.27 [-0.87 , 0.32]
0.95 [-0.01 , 1.91]
-0.24 [-0.77 , 0.29]
1.31 [0.35 , 2.27]
0.43 [-0.22 , 1.07]
1.01 [0.61 , 1.42]
0.15 [-0.49 , 0.79]
0.55 [0.23 , 0.87]
0.38 [-0.15 , 0.91]
0.54 [-0.01 , 1.08]
-0.08 [-0.39 , 0.22]
1.61 [0.89 , 2.33]
0.47 [0.16 , 0.79]

37
36
47
19
41
180

20.4%
20.4%
19.0%
19.8%
20.3%
100.0%

0.31 [-0.09 , 0.70]
0.28 [-0.12 , 0.68]
5.60 [4.72 , 6.49]
0.01 [-0.62 , 0.65]
0.33 [-0.11 , 0.77]
1.25 [-0.03 , 2.53]

1.1.3 6 months' follow-up
Courneya 2007a
Courneya 2007a
Donnelly 2011
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.26, df = 3 (P = 0.52); I² = 0%
Test for overall effect: Z = 1.13 (P = 0.26)

68
73
22
19
182

26.8
27
7.3
11

20.1
20.5
3.7
3.4

18.2
18.2
3.4
-3.5

25.69
25.69
15
10.8

30
30
23
17
100

33.7%
34.4%
18.2%
13.8%
100.0%

0.07 [-0.36 , 0.50]
0.09 [-0.34 , 0.51]
0.02 [-0.56 , 0.61]
0.62 [-0.05 , 1.29]
0.14 [-0.11 , 0.39]

Test for subgroup differences: Chi² = 4.83, df = 2 (P = 0.09), I² = 58.6%

-10
Favours control

-5

0

5

10
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

215

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.2.   Comparison 1: Health-related quality of life, Outcome 2: Overall quality of life follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.2.1 Up to 12 weeks' follow-up
Adamsen 2009
Arbane 2009
Bourke 2011
Cheville 2010
Courneya 2007a
Courneya 2007a
Courneya 2008
Danhauer 2009
Donnelly 2011
Hacker 2011
Hwang 2008
Jarden 2009
Lanctot 2010
Monga 2007
Mustian 2009
Raghavendra 2007
Segal 2009
Wang 2010
Wiskemann 2011
Yang 2011
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.16; Chi² = 62.32, df = 20 (P < 0.00001); I² = 68%
Test for overall effect: Z = 3.03 (P = 0.002)

67.2
71.03
91
71.9
135.5
132.6
138.4
114.8
80.19
76
3.19
81.6
-5.63
145.9
130.2
142.1
90.2
84.28
61.7
0.75
81.6

63.3
63.78
86
68.4
131.1
131.1
143.7
98.4
78.71
58.3
3.02
69
-6.38
138.1
116.9
111.7
87.5
66.06
57.1
2.25
81.6

20.3
14.1
10
19.41
27.2
2.4
29.4
19.1
16.93
12.2
0.33
14.5
3.77
18.3
20.13
10.2
13.1
13.05
22.2
0.79
12.4

18
21
21
47
73
75
26
13
16
8
17
17
41
11
19
28
40
35
40
19
28
613

22.4
30.42
18
23.48
29.5
29.5
25.8
31.8
19.1
19.5
0.36
11.5
6.64
12.7
30.58
25.5
13.2
13.6
17.3
1.84
13

1.2.2 More than 12 weeks' to less than 6 months' follow-up
Courneya 2007a
Courneya 2007a
Culos-Reed 2010
Jarden 2009
Moros 2010
Mustian 2009
Segal 2009
Segal 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 6.93, df = 7 (P = 0.44); I² = 0%
Test for overall effect: Z = 2.73 (P = 0.006)

132.6
135.5
73.12
85.6
70
132.96
91.8
92.4

2.4
27.2
16
9.9
18.9
16.41
13.1
13.4

131.1
131.1
69
71.3
60.7
126.13
89.3
89.3

75
73
53
17
10
19
40
40
327

1.2.3 6 months' follow-up
Bourke 2011
Cadmus 2009
Courneya 2007a
Courneya 2007a
Jarden 2009
Mutrie 2007
Rogers 2009
Segal 2001
Segal 2001
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.06; Chi² = 16.46, df = 9 (P = 0.06); I² = 45%
Test for overall effect: Z = 1.16 (P = 0.25)

13
11.1
26
24
11.9
12.8
13.6
14.48
11.3
10

90
89.3
152.9
156.3
90.1
83.2
86.1
89.19
95.04
84.1

87
89.5
152.4
152.4
78.1
77.1
85.4
96.79
96.79
77.1

15
22
73
68
16
82
19
40
40
24
399

29.5
29.5
15.12
13
19
31.81
13.1
13.1

17
11.8
26.4
26.4
18
17
18.4
9.08
9.08
13.3

17
23
22
49
38
37
29
14
17
9
20
17
32
10
19
34
41
37
40
21
27
553

37
38
47
13
7
19
21
20
202

13
23
30
30
13
95
17
20
21
25
287

4.3%
4.7%
4.7%
5.9%
5.9%
5.9%
5.1%
3.8%
4.2%
2.8%
4.4%
4.1%
5.5%
3.4%
4.4%
4.9%
5.7%
5.2%
5.6%
4.3%
5.1%
100.0%

20.5%
20.6%
20.4%
5.0%
3.3%
7.8%
11.4%
11.0%
100.0%

6.5%
9.0%
12.6%
12.5%
6.2%
16.5%
7.8%
9.7%
10.1%
9.2%
100.0%

0.18 [-0.49 , 0.84]
0.30 [-0.30 , 0.89]
0.33 [-0.27 , 0.94]
0.16 [-0.24 , 0.56]
0.16 [-0.24 , 0.55]
0.09 [-0.31 , 0.48]
-0.19 [-0.72 , 0.34]
0.60 [-0.17 , 1.38]
0.08 [-0.60 , 0.76]
1.02 [-0.01 , 2.05]
0.48 [-0.18 , 1.14]
0.94 [0.23 , 1.65]
0.14 [-0.32 , 0.61]
0.47 [-0.40 , 1.34]
0.50 [-0.14 , 1.15]
1.49 [0.92 , 2.06]
0.20 [-0.23 , 0.64]
1.35 [0.84 , 1.87]
0.23 [-0.21 , 0.67]
-1.02 [-1.68 , -0.36]
0.00 [-0.53 , 0.53]
0.33 [0.12 , 0.55]

0.09 [-0.31 , 0.48]
0.16 [-0.24 , 0.55]
0.26 [-0.13 , 0.66]
1.23 [0.43 , 2.02]
0.47 [-0.52 , 1.45]
0.26 [-0.37 , 0.90]
0.19 [-0.34 , 0.72]
0.23 [-0.31 , 0.77]
0.25 [0.07 , 0.43]

0.19 [-0.55 , 0.94]
-0.02 [-0.60 , 0.57]
0.02 [-0.41 , 0.44]
0.16 [-0.27 , 0.59]
0.78 [0.02 , 1.54]
0.40 [0.10 , 0.70]
0.04 [-0.61 , 0.70]
-0.58 [-1.13 , -0.03]
-0.16 [-0.69 , 0.37]
0.58 [0.01 , 1.16]
0.13 [-0.09 , 0.35]

Test for subgroup differences: Chi² = 1.64, df = 2 (P = 0.44), I² = 0%

-10
Favours control

-5

0

5

10
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

216

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.3.   Comparison 1: Health-related quality of life, Outcome 3: FACT-An change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.3.1 Up to 12 weeks' follow-up
Courneya 2008
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.91 (P = 0.36)

13.4

27

20.3

29.1

26
26

29
29

100.0%
100.0%

-6.90 [-21.73 , 7.93]
-6.90 [-21.73 , 7.93]

1.3.2 More than 12 weeks' to less than 6 months' follow-up
Courneya 2007a
Courneya 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.05, df = 1 (P = 0.83); I² = 0%
Test for overall effect: Z = 2.47 (P = 0.01)

76
74
150

25.6
23.3

5.9
4.8

-1
-1

1.3.3 6 months' follow-up
Courneya 2007a
Courneya 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.96); I² = 0%
Test for overall effect: Z = 0.52 (P = 0.60)

68
73
141

26.8
27

20.1
20.5

18.2
18.2

13.7
13.7

37
36
73

47.8%
52.2%
100.0%

6.90 [-0.35 , 14.15]
5.80 [-1.14 , 12.74]
6.33 [1.31 , 11.34]

25.69
25.69

30
30
60

49.6%
50.4%
100.0%

1.90 [-9.28 , 13.08]
2.30 [-8.78 , 13.38]
2.10 [-5.77 , 9.97]

Test for subgroup differences: Chi² = 3.12, df = 2 (P = 0.21), I² = 35.8%

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 1.4.   Comparison 1: Health-related quality of life, Outcome 4: FACT-An follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.4.1 Up to 12 weeks' follow-up
Courneya 2007a
Courneya 2007a
Courneya 2008
Jarden 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 39.49; Chi² = 5.94, df = 3 (P = 0.11); I² = 49%
Test for overall effect: Z = 1.00 (P = 0.32)

132.6
135.5
138.4
136.5

131.1
131.1
143.7
115.8

75
73
26
17
191

2.4
27.2
29.4
26.1

1.4.2 More than 12 weeks' to less than 6 months' follow-up
Courneya 2007a
Courneya 2007a
Jarden 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 65.39; Chi² = 5.29, df = 2 (P = 0.07); I² = 62%
Test for overall effect: Z = 1.40 (P = 0.16)

140.9
144.7
145.6

139.9
139.9
121.7

76
74
17
167

24.8
25.2
19.9

1.4.3 6 months' follow-up
Courneya 2007a
Courneya 2007a
Jarden 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 20.79; Chi² = 2.86, df = 2 (P = 0.24); I² = 30%
Test for overall effect: Z = 1.09 (P = 0.28)

156.3
152.9
153.8

152.4
152.4
131.7

68
73
16
157

24
26
25.1

29.5
29.5
25.8
21.6

28.2
28.2
25.2

26.4
26.4
34.6

37
38
29
17
121

32.1%
27.9%
21.1%
18.9%
100.0%

1.50 [-8.02 , 11.02]
4.40 [-6.87 , 15.67]
-5.30 [-19.99 , 9.39]
20.70 [4.60 , 36.80]
4.50 [-4.31 , 13.32]

36
37
13
86

37.1%
37.1%
25.8%
100.0%

1.00 [-9.77 , 11.77]
4.80 [-5.95 , 15.55]
23.90 [7.25 , 40.55]
8.31 [-3.36 , 19.98]

30
30
13
73

42.9%
42.3%
14.8%
100.0%

3.90 [-7.14 , 14.94]
0.50 [-10.67 , 11.67]
22.10 [-0.37 , 44.57]
5.16 [-4.15 , 14.46]

Test for subgroup differences: Chi² = 0.28, df = 2 (P = 0.87), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

217

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.5.   Comparison 1: Health-related quality of life, Outcome 5: FACT-B change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.5.1 Up to 12 weeks' follow-up
Campbell 2005
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 44.90; Chi² = 1.92, df = 1 (P = 0.17); I² = 48%
Test for overall effect: Z = 1.06 (P = 0.29)

14.3
5.4

19.8
10.8

10
20
30

-1.7
3.1

19.4
14.1

9
18
27

32.9%
67.1%
100.0%

16.00 [-1.64 , 33.64]
2.30 [-5.75 , 10.35]
6.81 [-5.81 , 19.43]

1.5.2 6 months' follow-up
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.89 (P = 0.06)

4.1

12

-4.1

13.8

19
19

17
17

100.0%
100.0%

8.20 [-0.29 , 16.69]
8.20 [-0.29 , 16.69]

Test for subgroup differences: Chi² = 0.03, df = 1 (P = 0.86), I² = 0%

-100

-50

0

50

100

Favours control

Favours exrcise

Analysis 1.6.   Comparison 1: Health-related quality of life, Outcome 6: FACT-B follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.6.1 Up to 12 weeks' follow-up
Danhauer 2009
Rogers 2009
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 26.05; Chi² = 3.43, df = 2 (P = 0.18); I² = 42%
Test for overall effect: Z = 0.16 (P = 0.87)

98.4
118.7
106.7

114.8
114.4
106.2

19.1
16.2
18

13
20
28
61

1.6.2 6 months' follow-up
Segal 2001
Segal 2001
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 3.86; Chi² = 4.58, df = 2 (P = 0.10); I² = 56%
Test for overall effect: Z = 0.35 (P = 0.73)

21.3
23.54
108.5

23.78
23.78
101.4

40
40
24
104

4.82
4.73
14.8

31.8
14.4
17.9

4.73
4.73
18.2

14
18
27
59

16.5%
41.2%
42.2%
100.0%

16.40 [-3.23 , 36.03]
-4.30 [-14.03 , 5.43]
-0.50 [-9.99 , 8.99]
0.73 [-8.23 , 9.69]

20
21
25
66

44.9%
45.5%
9.5%
100.0%

-2.48 [-5.04 , 0.08]
-0.24 [-2.74 , 2.26]
7.10 [-2.17 , 16.37]
-0.55 [-3.65 , 2.55]

Test for subgroup differences: Chi² = 0.07, df = 1 (P = 0.79), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

218

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.7.   Comparison 1: Health-related quality of life, Outcome 7: FACT-G change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.7.1 Up to 12 weeks' follow-up
Campbell 2005
Oh 2010
Rogers 2009
Segal 2009
Segal 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 7.07; Chi² = 8.16, df = 4 (P = 0.09); I² = 51%
Test for overall effect: Z = 3.29 (P = 0.001)

-2.9
-0.13
2.9
-2.48
-2.48

10
54
20
40
40
164

11.9
8.86
4.5
0.75
2.27

13.8
9
8.4
8.4
8.8

16.1
8.6
12
8.5
8.5

9
54
18
21
20
122

5.5%
30.2%
16.1%
24.4%
23.8%
100.0%

14.80 [1.24 , 28.36]
8.99 [5.67 , 12.31]
1.60 [-5.05 , 8.25]
3.23 [-1.24 , 7.70]
4.75 [0.13 , 9.37]
5.70 [2.30 , 9.09]

1.7.2 More than 12 weeks' to less than 6 months' follow-up
Segal 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.51 (P = 0.13)

40
40

2.35

7.5

-0.17

7.5

41
41

100.0%
100.0%

2.52 [-0.75 , 5.79]
2.52 [-0.75 , 5.79]

1.7.3 6 months' follow-up
Donnelly 2011
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 9.06; Chi² = 1.71, df = 1 (P = 0.19); I² = 42%
Test for overall effect: Z = 1.07 (P = 0.29)

22
19
41

3.4
-3.5

7.3
11

3.7
3.4

15
10.8

23
17
40

51.2%
48.8%
100.0%

0.30 [-6.55 , 7.15]
6.90 [-0.23 , 14.03]
3.52 [-2.94 , 9.99]

Test for subgroup differences: Chi² = 1.77, df = 2 (P = 0.41), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

219

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.8.   Comparison 1: Health-related quality of life, Outcome 8: FACT-G follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.8.1 Up to 12 weeks' follow-up
Bourke 2011
Donnelly 2011
Jarden 2009
Segal 2009
Wang 2010
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 48.33; Chi² = 21.62, df = 5 (P = 0.0006); I² = 77%
Test for overall effect: Z = 2.09 (P = 0.04)

91
80.19
81.6
90.2
84.28
81.6

10
16.93
14.5
13.1
13.05
12.4

86
78.71
69
87.5
66.06
81.6

21
16
17
40
35
28
157

1.8.2 More than 12 weeks' to less than 6 months' follow-up
Jarden 2009
Segal 2009
Segal 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 23.77; Chi² = 5.28, df = 2 (P = 0.07); I² = 62%
Test for overall effect: Z = 1.75 (P = 0.08)

9.9
13.1
13.4

85.6
91.8
92.4

71.3
89.3
89.3

17
40
40
97

1.8.3 6 months' follow-up
Bourke 2011
Cadmus 2009
Jarden 2009
Mutrie 2007
Rogers 2009
Segal 2001
Segal 2001
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 23.39; Chi² = 20.78, df = 7 (P = 0.004); I² = 66%
Test for overall effect: Z = 0.87 (P = 0.39)

90
89.3
90.1
83.2
86.1
89.19
95.04
84.1

13
11.1
11.9
12.8
13.6
14.48
11.3
10

87
89.5
78.1
77.1
85.4
96.79
96.79
77.1

15
22
16
82
19
40
40
24
258

18
19.1
11.5
13.2
13.6
13

13
13.1
13.1

17
11.8
18
17
18.4
9.08
9.08
13.3

22
17
17
41
37
27
161

16.0%
12.4%
15.8%
19.1%
18.6%
18.1%
100.0%

5.00 [-3.65 , 13.65]
1.48 [-10.82 , 13.78]
12.60 [3.80 , 21.40]
2.70 [-3.03 , 8.43]
18.22 [12.06 , 24.38]
0.00 [-6.72 , 6.72]
6.89 [0.44 , 13.35]

13
21
20
54

30.0%
35.3%
34.7%
100.0%

14.30 [5.81 , 22.79]
2.50 [-4.42 , 9.42]
3.10 [-3.99 , 10.19]
6.25 [-0.75 , 13.26]

13
23
13
95
17
20
21
25
227

8.4%
13.6%
8.3%
16.8%
9.0%
14.6%
15.6%
13.8%
100.0%

3.00 [-8.34 , 14.34]
-0.20 [-6.89 , 6.49]
12.00 [0.61 , 23.39]
6.10 [1.70 , 10.50]
0.70 [-9.97 , 11.37]
-7.60 [-13.60 , -1.60]
-1.75 [-6.98 , 3.48]
7.00 [0.43 , 13.57]
1.89 [-2.38 , 6.17]

Test for subgroup differences: Chi² = 2.10, df = 2 (P = 0.35), I² = 4.7%

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 1.9.   Comparison 1: Health-related quality of life, Outcome 9: FACT-P change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.9.1 Up to 12 weeks' follow-up
Monga 2007
Segal 2003
Subtotal (95% CI)
Heterogeneity: Tau² = 25.19; Chi² = 3.30, df = 1 (P = 0.07); I² = 70%
Test for overall effect: Z = 2.07 (P = 0.04)

10.4
9.1

11
82
93

-6.4
-3.3

7.4
2

9.8
10.2

10
73
83

38.2%
61.8%
100.0%

13.80 [5.16 , 22.44]
5.30 [2.24 , 8.36]
8.55 [0.45 , 16.65]

Test for subgroup differences: Not applicable

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

220

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.10.   Comparison 1: Health-related quality of life, Outcome 10: FACT-P follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.10.1 Up to 12 weeks' follow-up
128
Bourke 2011
145.9
Monga 2007
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.93); I² = 0%
Test for overall effect: Z = 1.61 (P = 0.11)

14
18.3

21
11
32

121
138.1

25
12.7

22
10
32

55.2%
44.8%
100.0%

7.00 [-5.04 , 19.04]
7.80 [-5.58 , 21.18]
7.36 [-1.59 , 16.31]

Test for subgroup differences: Not applicable

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 1.11.   Comparison 1: Health-related quality of life, Outcome 11: FACIT-F change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.11.1 Up to 12 weeks' follow-up
6
Mustian 2009
4.98
Targ 2002
Subtotal (95% CI)
Heterogeneity: Tau² = 17.91; Chi² = 2.08, df = 1 (P = 0.15); I² = 52%
Test for overall effect: Z = 0.38 (P = 0.70)

-0.67
6.62

18.3
16.1

19
79
98

1.11.2 More than 12 weeks' to less than 6 months' follow-up
Mustian 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.05 (P = 0.96)

19
19

16.51

8.76

8.55

11.51
21.7

19
88
107

38.4%
61.6%
100.0%

6.67 [-3.05 , 16.39]
-1.64 [-7.40 , 4.12]
1.55 [-6.37 , 9.48]

11.28

19
19

100.0%
100.0%

0.21 [-8.78 , 9.20]
0.21 [-8.78 , 9.20]

Test for subgroup differences: Chi² = 0.05, df = 1 (P = 0.83), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 1.12.   Comparison 1: Health-related quality of life, Outcome 12: FACIT-F follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.12.1 Up to 12 weeks' follow-up
130.2
Mustian 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.58 (P = 0.11)

20.13

116.9

30.58

19
19

19
19

100.0%
100.0%

13.30 [-3.16 , 29.76]
13.30 [-3.16 , 29.76]

1.12.2 More than 12 weeks' to less than 6 months' follow-up
132.96
Mustian 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.83 (P = 0.41)

19
19

16.41

126.13

31.81

19
19

100.0%
100.0%

6.83 [-9.26 , 22.92]
6.83 [-9.26 , 22.92]

Test for subgroup differences: Chi² = 0.30, df = 1 (P = 0.58), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

221

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.13.   Comparison 1: Health-related quality of life, Outcome 13: QLQ-C30 change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.13.1 Up to 12 weeks' follow-up
-0.79
Arbane 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.93 (P = 0.35)

14.65

4.35

21.6

21
21

23
23

100.0%
100.0%

-5.14 [-15.97 , 5.69]
-5.14 [-15.97 , 5.69]

1.13.2 More than 12 weeks' to less than 6 months' follow-up
Culos-Reed 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 28.22 (P < 0.00001)

53
53

2.7

0.9

-2.33

0.88

47
47

100.0%
100.0%

5.03 [4.68 , 5.38]
5.03 [4.68 , 5.38]

Test for subgroup differences: Chi² = 3.39, df = 1 (P = 0.07), I² = 70.5%

-50
Favours control

-25

0

25

50
Favours exercise

Analysis 1.14.   Comparison 1: Health-related quality of life, Outcome 14: QLQ-C30 follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.14.1 Up to 12 weeks' follow-up
67.2
Adamsen 2009
71.03
Arbane 2009
76
Hacker 2011
61.3
Jarden 2009
61.7
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.40, df = 4 (P = 0.66); I² = 0%
Test for overall effect: Z = 2.69 (P = 0.007)

18
21
8
17
40
104

20.3
14.1
12.2
17.2
22.2

63.3
63.78
58.3
52.9
57.1

1.14.2 More than 12 weeks' to less than 6 months' follow-up
73.12
Culos-Reed 2010
65.1
Jarden 2009
70
Moros 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.61, df = 2 (P = 0.45); I² = 0%
Test for overall effect: Z = 2.21 (P = 0.03)

16
15.9
18.9

53
17
10
80

69
51.9
60.7

22.4
30.42
19.5
16.7
17.3

15.12
20.2
19

17
23
9
17
40
106

14.1%
14.8%
12.1%
21.8%
37.2%
100.0%

3.90 [-10.29 , 18.09]
7.25 [-6.57 , 21.07]
17.70 [2.41 , 32.99]
8.40 [-3.00 , 19.80]
4.60 [-4.12 , 13.32]
7.31 [1.99 , 12.63]

47
13
7
67

75.7%
15.9%
8.4%
100.0%

4.12 [-1.98 , 10.22]
13.20 [-0.13 , 26.53]
9.30 [-9.01 , 27.61]
6.00 [0.69 , 11.31]

1.14.3 6 months' follow-up
Jarden 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.86 (P = 0.06)

72.8

20

58.3

21.5

16
16

13
13

100.0%
100.0%

14.50 [-0.75 , 29.75]
14.50 [-0.75 , 29.75]

Test for subgroup differences: Chi² = 1.08, df = 2 (P = 0.58), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

222

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.15.   Comparison 1: Health-related quality of life, Outcome 15: FLIC follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.15.1 Up to 12 weeks' follow-up
142.1
Raghavendra 2007
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 6.36 (P < 0.00001)

10.2

Test for subgroup differences: Not applicable

111.7

25.5

28
28

34
34

100.0%
100.0%

30.40 [21.03 , 39.77]
30.40 [21.03 , 39.77]

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 1.16.   Comparison 1: Health-related quality of life, Outcome 16: WHO BREF follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.16.1 Up to 12 weeks' follow-up
3.19
Hwang 2008
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.50 (P = 0.13)

0.33

Test for subgroup differences: Not applicable

3.02

0.36

17
17

20
20

100.0%
100.0%

0.17 [-0.05 , 0.39]
0.17 [-0.05 , 0.39]

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 1.17.   Comparison 1: Health-related quality of life, Outcome 17: Ferrand and Powers follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.17.1 Up to 12 weeks' follow-up
23.3
Hacker 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.45 (P = 0.65)

4.2

Test for subgroup differences: Not applicable

22.3

4.9

8
8

9
9

100.0%
100.0%

1.00 [-3.33 , 5.33]
1.00 [-3.33 , 5.33]

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 1.18.   Comparison 1: Health-related quality of life, Outcome 18: Spitzer QoL Uniscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.18.1 Up to 12 weeks' follow-up
71.9
Cheville 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.80 (P = 0.43)

19.41

Test for subgroup differences: Not applicable

68.4

23.48

47
47

49
49

100.0%
100.0%

3.50 [-5.10 , 12.10]
3.50 [-5.10 , 12.10]

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

223

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.19.   Comparison 1: Health-related quality of life, Outcome 19: MDASI-T Symptom Interference change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.19.1 Up to 12 months' follow-up
-1.41
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 4.96 (P < 0.00001)

1.4

Test for subgroup differences: Not applicable

0.23

0.36

19
19

21
21

100.0%
100.0%

-1.64 [-2.29 , -0.99]
-1.64 [-2.29 , -0.99]

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 1.20.   Comparison 1: Health-related quality of life,
Outcome 20: MDASI-T Symptom Interference follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.20.1 Up to 12 weeks' follow-up
0.75
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.40 (P = 0.0007)

0.79

Test for subgroup differences: Not applicable

2.25

1.84

19
19

21
21

100.0%
100.0%

-1.50 [-2.36 , -0.64]
-1.50 [-2.36 , -0.64]

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 1.21.   Comparison 1: Health-related quality of life,
Outcome 21: Quality of Life Systemic Inventory follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.21.1 Up to 12 months' follow-up
5.63
Lanctot 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.57 (P = 0.57)

3.77

Test for subgroup differences: Not applicable

6.38

6.64

41
41

32
32

100.0%
100.0%

-0.75 [-3.32 , 1.82]
-0.75 [-3.32 , 1.82]

-50
Favours exercise

-25

0

25

50
Favours control

Comparison 2.   Condition-specific quality of life

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

2.1 Breast cancer change

2.1.1 Up to 12 weeks' fol-
low-up

2.1.2 6 months' follow-up

4

3

2

Mean Difference (IV, Random, 95% CI)

Subtotals only

224

Mean Difference (IV, Random, 95% CI)

-0.37 [-1.93, 1.20]

81

Mean Difference (IV, Random, 95% CI)

0.24 [-1.60, 2.08]

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

224

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

2.2 Breast cancer follow-up
values

2.2.1 Up to 12 weeks' fol-
low-up

2.2.2 6 months' follow-up

2.3 Overall prostate cancer
change

2.3.1 Up to 12 weeks' fol-
low-up

2.3.2 More than 12 weeks' to
less than 6 months' follow-up

2.4 Overall prostate cancer fol-
low-up values

2.4.1 Up to 12 weeks' fol-
low-up

2.4.2 More than 12 weeks' to
less than 6 months' follow-up

2.5 FACT prostate cancer sub-
scale change

2.5.1 Up to 12 weeks' fol-
low-up

2.5.2 More than 12 weeks' to
less than 6 months' follow-up

2.6 FACT prostate cancer sub-
scale follow-up values

2.6.1 Up to 12 weeks' fol-
low-up

2.6.2 More than 12 weeks' to
less than 6 months' follow-up

2.7 Expanded Prostate Cancer
Index Composite change

2.7.1 Up to 12 weeks' fol-
low-up

2.8 Expanded Prostate Can-
cer Index Composite follow-up
values

5

4

4

3

3

1

3

3

1

2

2

1

2

2

1

1

1

1

331

307

242

121

242

162

142

121

142

162

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

1.21 [-0.65, 3.07]

Mean Difference (IV, Random, 95% CI)

1.45 [0.08, 2.81]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

0.41 [0.15, 0.67]

Std. Mean Difference (IV, Random, 95% CI)

0.28 [-0.10, 0.65]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

0.22 [-0.04, 0.48]

Std. Mean Difference (IV, Random, 95% CI)

0.27 [-0.04, 0.58]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

2.02 [0.12, 3.93]

Mean Difference (IV, Random, 95% CI)

1.42 [-0.48, 3.32]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

1.91 [-0.21, 4.03]

Mean Difference (IV, Random, 95% CI)

1.75 [-0.25, 3.75]

Mean Difference (IV, Random, 95% CI)

Subtotals only

100

Mean Difference (IV, Random, 95% CI)

6.75 [1.44, 12.06]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

225

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

2.8.1 Up to 12 weeks' fol-
low-up

2.9 QLSI cancer module sub-
scale follow-up values

2.9.1 Up to 12 weeks' fol-
low-up

1

1

1

100

Mean Difference (IV, Random, 95% CI)

1.73 [-4.19, 7.65]

Mean Difference (IV, Random, 95% CI)

Subtotals only

64

Mean Difference (IV, Random, 95% CI)

-0.52 [-2.24, 1.20]

Analysis 2.1.   Comparison 2: Condition-specific quality of life, Outcome 1: Breast cancer change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

2.1.1 Up to 12 weeks' follow-up
Campbell 2005
Rogers 2009
Targ 2002
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.06, df = 2 (P = 0.59); I² = 0%
Test for overall effect: Z = 0.46 (P = 0.65)

2.44
1
-0.29

10
20
79
109

6.9
5.3
5.8

1.2
0.3
0.62

2.1.2 6 months' follow-up
Cadmus 2009
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.89, df = 1 (P = 0.35); I² = 0%
Test for overall effect: Z = 0.26 (P = 0.79)

22
19
41

3.7
3.7

0.6
0.7

1.1
-0.6

5.14
5
6.6

9
18
88
115

8.3%
22.7%
69.0%
100.0%

1.24 [-4.20 , 6.68]
0.70 [-2.58 , 3.98]
-0.91 [-2.79 , 0.97]
-0.37 [-1.93 , 1.20]

4.5
4.9

23
17
40

58.7%
41.3%
100.0%

-0.50 [-2.90 , 1.90]
1.30 [-1.56 , 4.16]
0.24 [-1.60 , 2.08]

Test for subgroup differences: Chi² = 0.25, df = 1 (P = 0.62), I² = 0%

-50
Favours exercise

-25

0

25

50
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

226

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.2.   Comparison 2: Condition-specific quality of life, Outcome 2: Breast cancer follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

2.2.1 Up to 12 weeks' follow-up
Lanctot 2010
Mutrie 2007
Rogers 2009
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 1.84; Chi² = 6.47, df = 3 (P = 0.09); I² = 54%
Test for overall effect: Z = 1.28 (P = 0.20)

-2.83
25.8
27
24.6

-3.35
22.4
26.7
25.1

35
82
20
28
165

2.22
6
5.5
6.7

2.2.2 6 months' follow-up
Cadmus 2009
Mutrie 2007
Rogers 2009
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.05, df = 3 (P = 0.79); I² = 0%
Test for overall effect: Z = 2.08 (P = 0.04)

22
82
19
24
147

27.1
26.1
26.5
24.2

6.2
5.6
6
5.9

25.7
24.2
25.3
24.3

4.27
7.2
6.4
6.4

6.8
6.3
6.7
6.4

29
92
18
27
166

34.4%
31.6%
15.9%
18.1%
100.0%

0.52 [-1.20 , 2.24]
3.40 [1.44 , 5.36]
0.30 [-3.51 , 4.11]
-0.50 [-3.96 , 2.96]
1.21 [-0.65 , 3.07]

23
95
17
25
160

12.9%
60.7%
10.7%
15.7%
100.0%

1.40 [-2.40 , 5.20]
1.90 [0.15 , 3.65]
1.20 [-2.97 , 5.37]
-0.10 [-3.54 , 3.34]
1.45 [0.08 , 2.81]

Test for subgroup differences: Chi² = 0.04, df = 1 (P = 0.84), I² = 0%

-50
Favours control

-25

0

25

50
Favours exercise

Analysis 2.3.   Comparison 2: Condition-specific quality of life, Outcome 3: Overall prostate cancer change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

2.3.1 Up to 12 weeks' follow-up
Culos-Reed 2010
Monga 2007
Segal 2009
Segal 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.24, df = 3 (P = 0.74); I² = 0%
Test for overall effect: Z = 3.05 (P = 0.002)

3.65
1.8
-3.17
-1.91

53
11
40
40
144

14
5.8
5.6
5.9

-3.1
-1.8
-4.2
-4.2

2.3.2 More than 12 weeks' to less than 6 months' follow-up
Segal 2009
Segal 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.96); I² = 0%
Test for overall effect: Z = 1.43 (P = 0.15)

0.27
0.31

40
40
80

5.3
5

-1.13
-1.13

13.1
4.2
5.6
5.6

47
10
21
20
98

43.2%
8.8%
24.6%
23.4%
100.0%

0.49 [0.09 , 0.89]
0.68 [-0.21 , 1.56]
0.18 [-0.35 , 0.71]
0.39 [-0.15 , 0.93]
0.41 [0.15 , 0.67]

5
5

20
21
41

49.2%
50.8%
100.0%

0.27 [-0.27 , 0.80]
0.28 [-0.25 , 0.82]
0.28 [-0.10 , 0.65]

Test for subgroup differences: Chi² = 0.32, df = 1 (P = 0.57), I² = 0%

-20
Favours control

-10

0

10

20
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

227

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.4.   Comparison 2: Condition-specific quality of life, Outcome 4: Overall prostate cancer follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

2.4.1 Up to 12 weeks' follow-up
Culos-Reed 2010
Monga 2007
Segal 2009
Segal 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.72, df = 3 (P = 0.87); I² = 0%
Test for overall effect: Z = 1.66 (P = 0.10)

65.87
39.9
34.3
35.5

53
11
40
40
144

15.9
4.9
6.5
6.7

64.14
38.2
32.9
32.9

2.4.2 More than 12 weeks' to less than 6 months' follow-up
Segal 2009
Segal 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.95); I² = 0%
Test for overall effect: Z = 1.69 (P = 0.09)

37.7
37.8

40
40
80

6.7
6.5

36
36

14.3
4.8
6.5
6.5

47
10
21
20
98

43.8%
9.1%
24.1%
23.1%
100.0%

0.11 [-0.28 , 0.51]
0.34 [-0.53 , 1.20]
0.21 [-0.32 , 0.74]
0.39 [-0.15 , 0.93]
0.22 [-0.04 , 0.48]

6.4
6.4

41
41
82

50.0%
50.0%
100.0%

0.26 [-0.18 , 0.69]
0.28 [-0.16 , 0.71]
0.27 [-0.04 , 0.58]

Test for subgroup differences: Chi² = 0.05, df = 1 (P = 0.82), I² = 0%

-10
Favours exercise

-5

0

5

10
Favours control

Analysis 2.5.   Comparison 2: Condition-specific quality of life, Outcome 5: FACT prostate cancer subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

2.5.1 Up to 12 weeks' follow-up
Monga 2007
Segal 2009
Segal 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.98, df = 2 (P = 0.61); I² = 0%
Test for overall effect: Z = 2.08 (P = 0.04)

1.8
-3.17
-1.91

11
40
40
91

5.8
5.6
5.9

-1.8
-4.2
-4.2

2.5.2 More than 12 weeks' to less than 6 months' follow-up
Segal 2009
Segal 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.98); I² = 0%
Test for overall effect: Z = 1.46 (P = 0.14)

0.27
0.31

40
40
80

5.3
5

-1.13
-1.13

4.2
5.6
5.6

5
5

10
21
20
51

19.6%
41.6%
38.8%
100.0%

3.60 [-0.70 , 7.90]
1.03 [-1.93 , 3.99]
2.29 [-0.77 , 5.35]
2.02 [0.12 , 3.93]

20
21
41

48.2%
51.8%
100.0%

1.40 [-1.34 , 4.14]
1.44 [-1.20 , 4.08]
1.42 [-0.48 , 3.32]

Test for subgroup differences: Chi² = 0.19, df = 1 (P = 0.66), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

228

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.6.   Comparison 2: Condition-specific quality of life,
Outcome 6: FACT prostate cancer subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

2.6.1 Up to 12 weeks' follow-up
Monga 2007
Segal 2009
Segal 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.24, df = 2 (P = 0.89); I² = 0%
Test for overall effect: Z = 1.77 (P = 0.08)

39.9
35.5
34.3

11
40
40
91

4.9
6.7
6.5

38.2
32.9
32.9

2.6.2 More than 12 weeks' to less than 6 months' follow-up
Segal 2009
Segal 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.96); I² = 0%
Test for overall effect: Z = 1.71 (P = 0.09)

37.7
37.8

40
40
80

6.7
6.5

36
36

4.8
6.5
6.5

6.4
6.4

10
20
21
51

26.0%
36.0%
38.0%
100.0%

1.70 [-2.45 , 5.85]
2.60 [-0.93 , 6.13]
1.40 [-2.03 , 4.83]
1.91 [-0.21 , 4.03]

41
41
82

49.2%
50.8%
100.0%

1.70 [-1.15 , 4.55]
1.80 [-1.01 , 4.61]
1.75 [-0.25 , 3.75]

Test for subgroup differences: Chi² = 0.01, df = 1 (P = 0.91), I² = 0%

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 2.7.   Comparison 2: Condition-specific quality of life,
Outcome 7: Expanded Prostate Cancer Index Composite change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

2.7.1 Up to 12 weeks' follow-up
Culos-Reed 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.49 (P = 0.01)

3.65

14

Test for subgroup differences: Not applicable

-3.1

13.1

53
53

47
47

100.0%
100.0%

6.75 [1.44 , 12.06]
6.75 [1.44 , 12.06]

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 2.8.   Comparison 2: Condition-specific quality of life, Outcome
8: Expanded Prostate Cancer Index Composite follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

2.8.1 Up to 12 weeks' follow-up
Culos-Reed 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.57 (P = 0.57)

65.87

15.9

64.14

14.3

53
53

47
47

100.0%
100.0%

1.73 [-4.19 , 7.65]
1.73 [-4.19 , 7.65]

Test for subgroup differences: Not applicable

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

229

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.9.   Comparison 2: Condition-specific quality of life,
Outcome 9: QLSI cancer module subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

2.9.1 Up to 12 weeks' follow-up
Lanctot 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.59 (P = 0.55)

2.83

2.22

3.35

4.27

35
35

29
29

100.0%
100.0%

-0.52 [-2.24 , 1.20]
-0.52 [-2.24 , 1.20]

Test for subgroup differences: Not applicable

-50
Favours exercise

-25

0

25

50
Favours control

Comparison 3.   Anxiety

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

3.1 Overall anxiety change

3.1.1 Up to 12 weeks' fol-
low-up

3.1.2 More than 12 weeks' to
less than 6 months' follow-up

3.1.3 6 months' follow-up

3.2 Overall anxiety follow-up
values

3.2.1 Up to 12 weeks' fol-
low-up

3.2.2 More than 12 weeks' to
less than 6 months' follow-up

3.2.3 6 months' follow-up

3.3 Hospital Anxiety and De-
pression Scale anxiety sub-
scale follow-up values

3.3.1 Up to 12 weeks' fol-
low-up

3.3.2 More than 12 weeks' to
less than 6 months' follow-up

3.3.3 6 months' follow-up

3.4 State Trait Anxiety Invento-
ry change

3

2

1

1

13

12

5

3

4

4

2

1

1

275

223

201

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

-0.17 [-0.41, 0.06]

Std. Mean Difference (IV, Random, 95% CI)

-0.16 [-0.44, 0.12]

Std. Mean Difference (IV, Random, 95% CI)

-0.18 [-0.49, 0.12]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

1010

Std. Mean Difference (IV, Random, 95% CI)

-0.46 [-0.81, -0.11]

440

286

Std. Mean Difference (IV, Random, 95% CI)

-0.20 [-0.57, 0.17]

Std. Mean Difference (IV, Random, 95% CI)

-0.44 [-0.71, -0.17]

Mean Difference (IV, Random, 95% CI)

Totals not selected

Mean Difference (IV, Random, 95% CI)

Totals not selected

Mean Difference (IV, Random, 95% CI)

Totals not selected

Mean Difference (IV, Random, 95% CI)

Totals not selected

Mean Difference (IV, Random, 95% CI)

Subtotals only

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

230

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

3.4.1 More than 12 weeks' to
less than 6 months' follow-up

3.4.2 6 months' follow-up

3.5 State Trait Anxiety Invento-
ry follow-up values

3.5.1 Up to 12 weeks' fol-
low-up

3.5.2 More than 12 weeks' to
less than 6 months' follow-up

3.5.3 6 months' follow-up

3.6 POMS anxiety subscale
change

3.6.1 Up to 12 weeks' fol-
low-up

3.7 POMS anxiety subscale fol-
low-up values

3.7.1 Up to 12 weeks' fol-
low-up

3.8 Symptom Checklist-90
Revised anxiety subscale fol-
low-up values

3.8.1 Up to 12 weeks' fol-
low-up

3.9 Symptom Checklist-90 Re-
vised phobic anxiety subscale
follow-up values

3.9.1 Up to 12 weeks' fol-
low-up

3.10 General Health Question-
naire anxiety subscale fol-
low-up values

3.10.1 Up to 12 weeks' fol-
low-up

1

1

5

5

3

2

2

2

2

2

1

1

1

1

1

1

223

201

464

332

257

Mean Difference (IV, Random, 95% CI)

-1.60 [-4.40, 1.20]

Mean Difference (IV, Random, 95% CI)

-2.45 [-6.38, 1.48]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-2.96 [-6.16, 0.24]

Mean Difference (IV, Random, 95% CI)

-1.11 [-2.30, 0.08]

Mean Difference (IV, Random, 95% CI)

-2.12 [-3.44, -0.81]

Mean Difference (IV, Random, 95% CI)

Subtotals only

275

Mean Difference (IV, Random, 95% CI)

-1.24 [-2.82, 0.33]

Mean Difference (IV, Random, 95% CI)

Subtotals only

150

Mean Difference (IV, Random, 95% CI)

-0.80 [-1.98, 0.39]

Mean Difference (IV, Random, 95% CI)

Subtotals only

59

Mean Difference (IV, Random, 95% CI)

-1.00 [-2.76, 0.76]

Mean Difference (IV, Random, 95% CI)

Subtotals only

59

Mean Difference (IV, Random, 95% CI)

0.29 [-0.38, 0.96]

Mean Difference (IV, Random, 95% CI)

Subtotals only

17

Mean Difference (IV, Random, 95% CI)

-1.70 [-4.19, 0.79]

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

231

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.1.   Comparison 3: Anxiety, Outcome 1: Overall anxiety change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

3.1.1 Up to 12 weeks' follow-up
Oh 2010
Targ 2002
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.31, df = 1 (P = 0.58); I² = 0%
Test for overall effect: Z = 1.44 (P = 0.15)

54
79
133

-1.71
-3.08

4.5
13.1

-0.47
-1.82

3.1.2 More than 12 weeks' to less than 6 months' follow-up
Courneya 2007a
Courneya 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.95); I² = 0%
Test for overall effect: Z = 1.10 (P = 0.27)

76
74
150

10.1
10.4

-5.7
-5.9

-4.2
-4.2

3.1.3 6 months' follow-up
Courneya 2007a
Courneya 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.39, df = 1 (P = 0.53); I² = 0%
Test for overall effect: Z = 1.19 (P = 0.24)

73
68
141

13.7
13.2

-6.5
-9

-5.3
-5.3

5
7.3

9.9
9.9

54
88
142

39.2%
60.8%
100.0%

-0.26 [-0.64 , 0.12]
-0.12 [-0.42 , 0.18]
-0.17 [-0.41 , 0.06]

36
37
73

49.8%
50.2%
100.0%

-0.15 [-0.55 , 0.25]
-0.16 [-0.56 , 0.23]
-0.16 [-0.44 , 0.12]

12.8
12.8

30
30
60

50.7%
49.3%
100.0%

-0.09 [-0.51 , 0.34]
-0.28 [-0.71 , 0.15]
-0.18 [-0.49 , 0.12]

Test for subgroup differences: Chi² = 0.02, df = 2 (P = 0.99), I² = 0%

-10
Favours exercise

-5

0

5

10
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

232

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.2.   Comparison 3: Anxiety, Outcome 2: Overall anxiety follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

3.2.1 Up to 12 weeks' follow-up
Adamsen 2009
Banerjee 2007
Chandwani 2010
Chang 2008
Cohen 2004
Courneya 2003a
Courneya 2007a
Courneya 2007a
Dimeo 1999
Jarden 2009
Moadel 2007
Moros 2010
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.33; Chi² = 78.77, df = 12 (P < 0.00001); I² = 85%
Test for overall effect: Z = 2.56 (P = 0.01)

4.47
4.1
32.1
1.15
34.1
43.81
37
35.3
2
5.1
8.1
2.3
19.6

4.79
10.5
33.1
1.68
33.8
44.34
39
39
3
7.7
10.26
4
19.5

3.43
1
11.7
1.27
8.4
12
12
11.9
2.5
2.7
7.64
2.58
2.4

106
35
26
11
16
51
75
73
27
17
84
10
40
571

3.42
1.8
13
1.65
8.5
8.98
11.9
11.9
4.3
3.8
8.08
2.58
1.6

3.2.2 More than 12 weeks' to less than 6 months' follow-up
Chandwani 2010
Courneya 2007a
Courneya 2007a
Jarden 2009
Raghavendra 2007
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.15; Chi² = 16.84, df = 5 (P = 0.005); I² = 70%
Test for overall effect: Z = 1.07 (P = 0.29)

27
73
75
17
26
40
258

30.2
35.3
37
4.1
32.1
20.3

13.5
11.9
12
2.6
2.3
2

32.1
39
39
7.9
33.1
19

3.2.3 6 months' follow-up
Courneya 2007a
Courneya 2007a
Jarden 2009
Raghavendra 2007
Subtotal (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 3.34, df = 3 (P = 0.34); I² = 10%
Test for overall effect: Z = 3.22 (P = 0.001)

68
73
16
27
184

32.2
35.5
4.4
30.2

11.2
13
2.8
2.6

37.4
37.4
6.9
32.1

15.1
11.9
11.9
4.3
2.5
2.5

12
12
3.6
2.8

103
23
27
11
14
45
37
38
32
17
44
7
41
439

29
37
36
13
27
40
182

9.3%
5.4%
8.0%
6.3%
7.0%
8.7%
8.7%
8.7%
8.1%
7.1%
8.9%
5.5%
8.5%
100.0%

16.3%
19.0%
19.0%
11.7%
15.9%
18.0%
100.0%

-0.09 [-0.36 , 0.18]
-4.60 [-5.62 , -3.59]
-0.08 [-0.62 , 0.46]
-0.35 [-1.19 , 0.50]
0.03 [-0.68 , 0.75]
-0.05 [-0.45 , 0.35]
-0.17 [-0.56 , 0.23]
-0.31 [-0.70 , 0.09]
-0.27 [-0.79 , 0.24]
-0.77 [-1.47 , -0.07]
-0.28 [-0.64 , 0.09]
-0.63 [-1.62 , 0.37]
0.05 [-0.39 , 0.48]
-0.46 [-0.81 , -0.11]

-0.13 [-0.66 , 0.39]
-0.31 [-0.71 , 0.09]
-0.17 [-0.56 , 0.23]
-1.08 [-1.86 , -0.30]
-0.41 [-0.95 , 0.13]
0.57 [0.12 , 1.02]
-0.20 [-0.57 , 0.17]

30
30
13
29
102

32.6%
33.7%
11.6%
22.1%
100.0%

-0.45 [-0.89 , -0.02]
-0.15 [-0.57 , 0.28]
-0.76 [-1.53 , -0.00]
-0.69 [-1.23 , -0.15]
-0.44 [-0.71 , -0.17]

Test for subgroup differences: Chi² = 1.29, df = 2 (P = 0.53), I² = 0%

-10
Favours exercise

-5

0

5

10
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

233

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.3.   Comparison 3: Anxiety, Outcome 3: Hospital
Anxiety and Depression Scale anxiety subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

3.3.1 Up to 12 weeks' follow-up
Adamsen 2009
Banerjee 2007
Jarden 2009
Wiskemann 2011

4.47
4.1
5.1
19.6

3.43
1
2.7
2.4

106
35
17
40

3.3.2 More than 12 weeks' to less than 6 months' follow-up
Jarden 2009
Wiskemann 2011

4.1
20.3

2.6
2

17
40

4.79
10.5
7.7
19.5

7.9
19

3.42
1.8
3.8
1.6

4.3
2.5

103
23
17
41

-0.32 [-1.25 , 0.61]
-6.40 [-7.21 , -5.59]
-2.60 [-4.82 , -0.38]
0.10 [-0.79 , 0.99]

13
40

-3.80 [-6.44 , -1.16]
1.30 [0.31 , 2.29]

3.3.3 6 months' follow-up
Jarden 2009

4.4

2.8

16

6.9

3.6

13

-2.50 [-4.89 , -0.11]

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 3.4.   Comparison 3: Anxiety, Outcome 4: State Trait Anxiety Inventory change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

3.4.1 More than 12 weeks' to less than 6 months' follow-up
Courneya 2007a
Courneya 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.94); I² = 0%
Test for overall effect: Z = 1.12 (P = 0.26)

74
76
150

10.4
10.1

-5.9
-5.7

-4.2
-4.2

3.4.2 6 months' follow-up
Courneya 2007a
Courneya 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.39, df = 1 (P = 0.53); I² = 0%
Test for overall effect: Z = 1.22 (P = 0.22)

73
68
141

13.7
13.2

-6.5
-9

-5.3
-5.3

9.9
9.9

37
36
73

49.7%
50.3%
100.0%

-1.70 [-5.67 , 2.27]
-1.50 [-5.45 , 2.45]
-1.60 [-4.40 , 1.20]

12.8
12.8

30
30
60

50.0%
50.0%
100.0%

-1.20 [-6.75 , 4.35]
-3.70 [-9.25 , 1.85]
-2.45 [-6.38 , 1.48]

Test for subgroup differences: Chi² = 0.12, df = 1 (P = 0.73), I² = 0%

-100
Favours exercise

-50

0

50

100

Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

234

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.5.   Comparison 3: Anxiety, Outcome 5: State Trait Anxiety Inventory follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

3.5.1 Up to 12 weeks' follow-up
Chandwani 2010
Cohen 2004
Courneya 2003a
Courneya 2007a
Courneya 2007a
Raghavendra 2007
Subtotal (95% CI)
Heterogeneity: Tau² = 10.01; Chi² = 14.38, df = 5 (P = 0.01); I² = 65%
Test for overall effect: Z = 1.81 (P = 0.07)

33.1
33.8
44.34
39
39
37.5

32.1
34.1
43.81
35.3
37
29.2

26
16
51
73
75
28
269

11.7
8.4
12
11.9
12
3.8

3.5.2 More than 12 weeks' to less than 6 months' follow-up
Chandwani 2010
Courneya 2007a
Courneya 2007a
Raghavendra 2007
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.36, df = 3 (P = 0.95); I² = 0%
Test for overall effect: Z = 1.83 (P = 0.07)

27
76
74
26
203

13.5
12.7
11.7
2.3

30.2
36.4
35
32.1

32.1
37.4
37.4
33.1

3.5.3 6 months' follow-up
Courneya 2007a
Courneya 2007a
Raghavendra 2007
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.53, df = 2 (P = 0.47); I² = 0%
Test for overall effect: Z = 3.16 (P = 0.002)

73
68
27
168

13
11.2
2.6

35.5
32.2
30.2

37.4
37.4
32.1

13
8.5
8.98
11.9
11.9
7.6

15.1
12
12
2.5

12
12
2.8

27
14
45
38
37
34
195

12.4%
13.6%
18.2%
17.0%
16.9%
21.8%
100.0%

-1.00 [-7.65 , 5.65]
0.30 [-5.76 , 6.36]
-0.53 [-4.74 , 3.68]
-3.70 [-8.37 , 0.97]
-2.00 [-6.70 , 2.70]
-8.30 [-11.22 , -5.38]
-2.96 [-6.16 , 0.24]

29
37
36
27
129

2.5%
6.1%
6.3%
85.0%
100.0%

-1.90 [-9.39 , 5.59]
-1.00 [-5.81 , 3.81]
-2.40 [-7.14 , 2.34]
-1.00 [-2.29 , 0.29]
-1.11 [-2.30 , 0.08]

30
30
29
89

6.4%
6.8%
86.8%
100.0%

-1.90 [-7.13 , 3.33]
-5.20 [-10.25 , -0.15]
-1.90 [-3.31 , -0.49]
-2.12 [-3.44 , -0.81]

Test for subgroup differences: Chi² = 1.92, df = 2 (P = 0.38), I² = 0%

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 3.6.   Comparison 3: Anxiety, Outcome 6: POMS anxiety subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

3.6.1 Up to 12 weeks' follow-up
Oh 2010
Targ 2002
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.99); I² = 0%
Test for overall effect: Z = 1.55 (P = 0.12)

54
79
133

-1.71
-3.08

4.5
13.1

-0.47
-1.82

5
7.3

54
88
142

76.8%
23.2%
100.0%

-1.24 [-3.03 , 0.55]
-1.26 [-4.53 , 2.01]
-1.24 [-2.82 , 0.33]

Test for subgroup differences: Not applicable

-100
Favours exercise

-50

0

50

100

Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

235

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.7.   Comparison 3: Anxiety, Outcome 7: POMS anxiety subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

3.7.1 Up to 12 weeks' follow-up
Chang 2008
Moadel 2007
Subtotal (95% CI)
Heterogeneity: Tau² = 0.04; Chi² = 1.03, df = 1 (P = 0.31); I² = 3%
Test for overall effect: Z = 1.32 (P = 0.19)

1.27
7.64

1.15
8.1

11
84
95

1.68
10.26

1.65
8.08

11
44
55

83.6%
16.4%
100.0%

-0.53 [-1.76 , 0.70]
-2.16 [-5.05 , 0.73]
-0.80 [-1.98 , 0.39]

Test for subgroup differences: Not applicable

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 3.8.   Comparison 3: Anxiety, Outcome 8: Symptom Checklist-90 Revised anxiety subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

3.8.1 Up to 12 weeks' follow-up
Dimeo 1999
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.11 (P = 0.27)

2

2.5

Test for subgroup differences: Not applicable

27
27

3

4.3

32
32

100.0%
100.0%

-1.00 [-2.76 , 0.76]
-1.00 [-2.76 , 0.76]

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 3.9.   Comparison 3: Anxiety, Outcome 9: Symptom
Checklist-90 Revised phobic anxiety subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

3.9.1 Up to 12 weeks' follow-up
Dimeo 1999
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.85 (P = 0.39)

0.89

1.3

Test for subgroup differences: Not applicable

0.6

1.3

27
27

32
32

100.0%
100.0%

0.29 [-0.38 , 0.96]
0.29 [-0.38 , 0.96]

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 3.10.   Comparison 3: Anxiety, Outcome 10: General Health Questionnaire anxiety subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

3.10.1 Up to 12 weeks' follow-up
2.3
Moros 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.34 (P = 0.18)

2.58

Test for subgroup differences: Not applicable

10
10

4

2.58

7
7

100.0%
100.0%

-1.70 [-4.19 , 0.79]
-1.70 [-4.19 , 0.79]

-100
Favours exercise

-50

0

50

100

Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

236

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Comparison 4.   Body image/self-esteem

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Cochrane Database of Systematic Reviews

Statistical method

Effect size

4.1 Overall body image/self-
esteem change

4.1.1 More than 12 weeks'
to less than 6 months' fol-
low-up

4.1.2 6 months' follow-up

4.2 Overall body image/self-
esteem follow-up values

4.2.1 Up to 12 weeks' fol-
low-up

4.2.2 More than 12 weeks'
to less than 6 months' fol-
low-up

4.2.3 6 months' follow-up

4.3 Rosenberg self-esteem
change

4.3.1 More than 12 weeks'
to less than 6 months' fol-
low-up

4.3.2 6 months' follow-up

4.4 Rosenberg self-esteem
follow-up values

4.4.1 Up to 12 weeks' fol-
low-up

4.4.2 More than 12 weeks'
to less than 6 months' fol-
low-up

4.4.3 6 months' follow-up

4.5 Body Image Visual Ana-
log Scale follow-up values

4.5.1 Up to 12 weeks' fol-
low-up

4.5.2 6 months' follow-up

4.6 Tennessee Self concept
subscale follow-up values

2

1

2

3

2

1

3

2

1

2

2

1

1

2

1

1

1

1

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

223

Std. Mean Difference (IV, Random, 95% CI)

0.41 [0.12, 0.69]

246

Std. Mean Difference (IV, Random, 95% CI)

0.20 [-0.06, 0.47]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

237

223

Std. Mean Difference (IV, Random, 95% CI)

0.29 [-0.06, 0.64]

Std. Mean Difference (IV, Random, 95% CI)

0.21 [-0.07, 0.49]

260

Std. Mean Difference (IV, Random, 95% CI)

0.19 [-0.08, 0.45]

Mean Difference (IV, Random, 95% CI)

Subtotals only

223

Mean Difference (IV, Random, 95% CI)

1.30 [0.51, 2.09]

246

Mean Difference (IV, Random, 95% CI)

0.84 [-0.27, 1.95]

Mean Difference (IV, Random, 95% CI)

Subtotals only

223

223

Mean Difference (IV, Random, 95% CI)

1.05 [-0.35, 2.45]

Mean Difference (IV, Random, 95% CI)

1.41 [-0.06, 2.87]

246

Mean Difference (IV, Random, 95% CI)

0.79 [-0.56, 2.15]

Mean Difference (IV, Random, 95% CI)

Subtotals only

14

14

Mean Difference (IV, Random, 95% CI)

23.00 [-0.11, 46.11]

Mean Difference (IV, Random, 95% CI)

9.10 [-23.70, 41.90]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

237

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

4.6.1 Up to 12 weeks' fol-
low-up

4.6.2 6 months' follow-up

4.7 Tennessee physical sub-
scale follow-up vales

4.7.1 Up to 12 weeks' fol-
low-up

4.7.2 6 months' follow-up

1

1

1

1

1

14

14

14

14

Mean Difference (IV, Random, 95% CI)

7.70 [-23.85, 39.25]

Mean Difference (IV, Random, 95% CI)

5.20 [-31.26, 41.66]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

7.70 [-1.69, 17.09]

Mean Difference (IV, Random, 95% CI)

3.40 [-7.93, 14.73]

Analysis 4.1.   Comparison 4: Body image/self-esteem, Outcome 1: Overall body image/self-esteem change

Study or Subgroup

Mean

Experimental
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

4.1.1 More than 12 weeks' to less than 6 months' follow-up
Courneya 2007a
Courneya 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 2.81 (P = 0.005)

74
76
150

0.3
0.3

3.5
3.5

-1
-1

4.1.2 6 months' follow-up
Cadmus 2009
Courneya 2007a
Courneya 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.61, df = 2 (P = 0.74); I² = 0%
Test for overall effect: Z = 1.49 (P = 0.14)

22
73
68
163

-0.6
1.1
0.9

4.6
4.3
4.1

-0.6
-0.1
-0.1

2.4
2.4

3
4.2
4.2

37
36
73

50.2%
49.8%
100.0%

0.41 [0.01 , 0.80]
0.40 [0.00 , 0.80]
0.41 [0.12 , 0.69]

23
30
30
83

21.2%
39.8%
39.0%
100.0%

0.00 [-0.58 , 0.58]
0.28 [-0.15 , 0.71]
0.24 [-0.19 , 0.67]
0.20 [-0.06 , 0.47]

Test for subgroup differences: Chi² = 1.02, df = 1 (P = 0.31), I² = 1.7%

-10
Favours control

-5

0

5

10
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

238

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.2.   Comparison 4: Body image/self-esteem, Outcome 2: Overall body image/self-esteem follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

4.2.1 Up to 12 weeks' follow-up
Courneya 2007a
Courneya 2007a
Mock 1994
Subtotal (95% CI)
Heterogeneity: Tau² = 0.03; Chi² = 2.80, df = 2 (P = 0.25); I² = 29%
Test for overall effect: Z = 1.63 (P = 0.10)

73
75
9
157

34.1
33.8
79.2

32.9
32.9
56.2

5
4.8
10.4

4.2.2 More than 12 weeks' to less than 6 months' follow-up
Courneya 2007a
Courneya 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.04, df = 1 (P = 0.85); I² = 0%
Test for overall effect: Z = 1.48 (P = 0.14)

75
73
148

33.8
34.1

4.8
5

32.9
32.9

4.2.3 6 months' follow-up
Cadmus 2009
Courneya 2007a
Courneya 2007a
Mock 1994
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.78, df = 3 (P = 0.85); I² = 0%
Test for overall effect: Z = 1.40 (P = 0.16)

22
68
73
9
172

34.3
35
35.2
79.7

4.9
4.7
4.6
30

34.5
33.9
33.9
70.6

5.1
5.1
25.2

38
37
5
80

46.3%
46.1%
7.6%
100.0%

0.24 [-0.16 , 0.63]
0.18 [-0.21 , 0.58]
1.28 [0.05 , 2.51]
0.29 [-0.06 , 0.64]

5.1
5.1

3.6
5.6
5.6
30

37
38
75

49.9%
50.1%
100.0%

0.18 [-0.21 , 0.58]
0.24 [-0.16 , 0.63]
0.21 [-0.07 , 0.49]

23
30
30
5
88

20.0%
36.8%
37.5%
5.6%
100.0%

-0.05 [-0.63 , 0.54]
0.22 [-0.21 , 0.65]
0.26 [-0.16 , 0.69]
0.28 [-0.82 , 1.38]
0.19 [-0.08 , 0.45]

Test for subgroup differences: Chi² = 0.23, df = 2 (P = 0.89), I² = 0%

-10
Favours control

-5

0

5

10
Favours exercise

Analysis 4.3.   Comparison 4: Body image/self-esteem, Outcome 3: Rosenberg self-esteem change

Study or Subgroup

Mean

Exercsie
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

4.3.1 More than 12 weeks' to less than 6 months' follow-up
Courneya 2007a
Courneya 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 3.24 (P = 0.001)

76
74
150

3.5
3.5

0.3
0.3

-1
-1

4.3.2 6 months' follow-up
Cadmus 2009
Courneya 2007a
Courneya 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.71, df = 2 (P = 0.70); I² = 0%
Test for overall effect: Z = 1.48 (P = 0.14)

22
68
73
163

-0.6
0.9
1.1

4.6
4.1
4.3

-0.6
-0.1
-0.1

2.4
2.4

3
4.2
4.2

36
37
73

50.0%
50.0%
100.0%

1.30 [0.19 , 2.41]
1.30 [0.19 , 2.41]
1.30 [0.51 , 2.09]

23
30
30
83

23.6%
38.3%
38.0%
100.0%

0.00 [-2.28 , 2.28]
1.00 [-0.79 , 2.79]
1.20 [-0.60 , 3.00]
0.84 [-0.27 , 1.95]

Test for subgroup differences: Chi² = 0.44, df = 1 (P = 0.51), I² = 0%

-50
Favours control

-25

0

25

50
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

239

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.4.   Comparison 4: Body image/self-esteem, Outcome 4: Rosenberg self-esteem follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

4.4.1 Up to 12 weeks' follow-up
Courneya 2007a
Courneya 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.04, df = 1 (P = 0.83); I² = 0%
Test for overall effect: Z = 1.47 (P = 0.14)

73
75
148

34.1
33.8

5
4.8

32.9
32.9

4.4.2 More than 12 weeks' to less than 6 months' follow-up
Courneya 2007a
Courneya 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.02, df = 1 (P = 0.89); I² = 0%
Test for overall effect: Z = 1.88 (P = 0.06)

76
74
150

34.7
34.5

4.2
5.1

33.2
33.2

4.4.3 6 months' follow-up
Cadmus 2009
Courneya 2007a
Courneya 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.86, df = 2 (P = 0.65); I² = 0%
Test for overall effect: Z = 1.15 (P = 0.25)

22
73
68
163

34.3
35.2
35

4.9
4.6
4.7

34.5
33.9
33.9

5.1
5.1

5.5
5.5

3.6
5.6
5.6

38
37
75

49.6%
50.4%
100.0%

1.20 [-0.79 , 3.19]
0.90 [-1.07 , 2.87]
1.05 [-0.35 , 2.45]

37
36
73

53.2%
46.8%
100.0%

1.50 [-0.51 , 3.51]
1.30 [-0.84 , 3.44]
1.41 [-0.06 , 2.87]

23
30
30
83

29.0%
36.0%
35.0%
100.0%

-0.20 [-2.72 , 2.32]
1.30 [-0.96 , 3.56]
1.10 [-1.19 , 3.39]
0.79 [-0.56 , 2.15]

Test for subgroup differences: Chi² = 0.36, df = 2 (P = 0.83), I² = 0%

-50
Favours control

-25

0

25

50
Favours exercise

Analysis 4.5.   Comparison 4: Body image/self-esteem, Outcome 5: Body Image Visual Analog Scale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

4.5.1 Up to 12 weeks' follow-up
Mock 1994
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.95 (P = 0.05)

79.2

10.4

4.5.2 6 months' follow-up
Mock 1994
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.54 (P = 0.59)

79.7

30

9
9

9
9

56.2

25.2

5
5

100.0%
100.0%

23.00 [-0.11 , 46.11]
23.00 [-0.11 , 46.11]

70.6

30

5
5

100.0%
100.0%

9.10 [-23.70 , 41.90]
9.10 [-23.70 , 41.90]

Test for subgroup differences: Chi² = 0.46, df = 1 (P = 0.50), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

240

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.6.   Comparison 4: Body image/self-esteem, Outcome 6: Tennessee Self concept subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

4.6.1 Up to 12 weeks' follow-up
Mock 1994
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.48 (P = 0.63)

387.3

4.6.2 6 months' follow-up
Mock 1994
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.28 (P = 0.78)

386.2

31

40

9
9

9
9

379.6

27.6

5
5

100.0%
100.0%

7.70 [-23.85 , 39.25]
7.70 [-23.85 , 39.25]

381

29

5
5

100.0%
100.0%

5.20 [-31.26 , 41.66]
5.20 [-31.26 , 41.66]

Test for subgroup differences: Chi² = 0.01, df = 1 (P = 0.92), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 4.7.   Comparison 4: Body image/self-esteem, Outcome 7: Tennessee physical subscale follow-up vales

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

4.7.1 Up to 12 weeks' follow-up
Mock 1994
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.61 (P = 0.11)

73.7

4.7.2 6 months' follow-up
Mock 1994
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.59 (P = 0.56)

71.6

8

11

9
9

9
9

66

8.9

5
5

100.0%
100.0%

7.70 [-1.69 , 17.09]
7.70 [-1.69 , 17.09]

68.2

10

5
5

100.0%
100.0%

3.40 [-7.93 , 14.73]
3.40 [-7.93 , 14.73]

Test for subgroup differences: Chi² = 0.33, df = 1 (P = 0.57), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Comparison 5.   Cognitive functioning

Outcome or subgroup title

5.1 Overall cognitive functioning change

5.1.1 Up to 12 weeks' follow-up

5.1.2 6 months' follow-up

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

5

5

1

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

342

36

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.21 [-0.60, 0.19]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.23 [-0.89, 0.43]

5.2 Overall cognitive functioning follow-up val-
ues

10

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

241

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Outcome or subgroup title

5.2.1 Up to 12 weeks' follow-up

5.2.2 More than 12 weeks' to less than 6 months'
follow-up

5.2.3 6 months' follow-up

5.3 QLQ-C30 cognitive subscale change

5.3.1 Up to 12 weeks' follow-up

5.4 QLQ-C30 cognitive subscale follow-up values

5.4.1 Up to 12 weeks' follow-up

5.4.2 More than 12 weeks' to less than 6 months'
follow-up

5.4.3 6 months' follow-up

5.5 FACT-Cog change

5.5.1 Up to 12 weeks' follow-up

5.5.2 6 months' follow-up

5.6 FACT-Cog follow-up values

5.6.1 Up to 12 weeks' follow-up

5.6.2 6 months' follow-up

5.7 POMS confusion subscale change

5.7.1 Up to 12 weeks' follow-up

5.8 POMS confusion subscale follow-up values

Cochrane Database of Systematic Reviews

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

9

3

2

2

2

6

5

3

1

1

1

1

1

1

1

1

1

1

684

127

65

98

411

127

29

37

36

37

36

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.16 [-0.31, -0.01]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.26 [-0.79, 0.27]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.32 [-0.84, 0.20]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

7.71 [0.21, 15.21]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

5.08 [-0.37, 10.53]

Mean Difference (IV, Random,
95% CI)

6.04 [-7.24, 19.31]

Mean Difference (IV, Random,
95% CI)

15.80 [-3.59, 35.19]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-8.70 [-21.05, 3.65]

Mean Difference (IV, Random,
95% CI)

-4.72 [-18.12, 8.68]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-10.50 [-27.02, 6.02]

Mean Difference (IV, Random,
95% CI)

-2.80 [-23.50, 17.90]

Mean Difference (IV, Random,
95% CI)

Subtotals only

167

Mean Difference (IV, Random,
95% CI)

1.20 [-0.67, 3.07]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

242

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

5.8.1 Up to 12 weeks' follow-up

5.9 QLSI cognitive functioning subscale fol-
low-up values

5.9.1 Up to 12 weeks' follow-up

5.10 MDASI-T problem remembering subscale
change

5.10.1 Up to 12 weeks' follow-up

5.11 MDASI-T problem remembering subscale
follow-up values

5.11.1 Up to 12 weeks' follow-up

1

1

1

1

1

1

1

No. of
partici-
pants

128

68

40

40

Statistical method

Effect size

Mean Difference (IV, Random,
95% CI)

-0.43 [-1.83, 0.97]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-3.04 [-8.31, 2.23]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-0.37 [-0.72, -0.02]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-0.67 [-2.09, 0.75]

Analysis 5.1.   Comparison 5: Cognitive functioning, Outcome 1: Overall cognitive functioning change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

5.1.1 Up to 12 weeks' follow-up
Arbane 2009
Oh 2010
Rogers 2009
Targ 2002
Yang 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.13; Chi² = 11.19, df = 4 (P = 0.02); I² = 64%
Test for overall effect: Z = 1.04 (P = 0.30)

37.23
15.1
6.8
7.2
0.77

-1.59
-7.3
-4
-2
-0.32

21
23
19
79
19
161

-8.7
0.5
4.7
-3.2
0.05

32.13
14.7
25.9
4.7
0.04

23
31
18
88
21
181

18.6%
19.8%
17.1%
27.0%
17.4%
100.0%

0.20 [-0.39 , 0.79]
-0.52 [-1.07 , 0.03]
-0.46 [-1.11 , 0.20]
0.20 [-0.11 , 0.50]
-0.68 [-1.32 , -0.04]
-0.21 [-0.60 , 0.19]

5.1.2 6 months' follow-up
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.69 (P = 0.49)

-5.4

16.3

-0.68

23.6

19
19

17
17

100.0%
100.0%

-0.23 [-0.89 , 0.43]
-0.23 [-0.89 , 0.43]

Test for subgroup differences: Chi² = 0.00, df = 1 (P = 0.96), I² = 0%

-20
Favours exercise

-10

0

10

20
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

243

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.2.   Comparison 5: Cognitive functioning, Outcome 2: Overall cognitive functioning follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

5.2.1 Up to 12 weeks' follow-up
Adamsen 2009
Arbane 2009
Hacker 2011
Jarden 2009
Lanctot 2010
Moadel 2007
Rogers 2009
Wiskemann 2011
Yang 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 7.87, df = 8 (P = 0.45); I² = 0%
Test for overall effect: Z = 2.08 (P = 0.04)

16.7
32.45
7.7
25.4
6.25
3.77
30.8
26.7
2.13

-83.8
87.3
-95.8
-79.4
5.18
3.17
125
69.6
2

-81.3
92.03
-85.2
-61.8
8.22
3.6
135.5
62.1
2.67

118
21
8
17
37
84
19
40
19
363

5.2.2 More than 12 weeks' to less than 6 months' follow-up
Jarden 2009
Moros 2010
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.10; Chi² = 3.56, df = 2 (P = 0.17); I² = 44%
Test for overall effect: Z = 0.96 (P = 0.34)

-86.5
-83.3
-73.8

-64.1
-88
-71.3

20.4
17.5
22.3

17
10
40
67

5.2.3 6 months' follow-up
Jarden 2009
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 1.11, df = 1 (P = 0.29); I² = 10%
Test for overall effect: Z = 1.21 (P = 0.23)

-88.9
126.4

-73.1
129.2

15
31.8

16
19
35

19.8
25.06
21.2
24.1
13.83
3.88
19.5
28
2.44

31.8
24.9
19.6

33
31.5

117
23
9
17
31
44
18
41
21
321

35.3%
6.6%
2.4%
4.8%
10.1%
17.4%
5.4%
12.1%
5.9%
100.0%

-0.14 [-0.39 , 0.12]
-0.16 [-0.75 , 0.43]
-0.62 [-1.60 , 0.37]
-0.69 [-1.39 , 0.00]
-0.29 [-0.77 , 0.19]
-0.11 [-0.48 , 0.25]
-0.40 [-1.05 , 0.26]
0.27 [-0.17 , 0.71]
-0.29 [-0.91 , 0.34]
-0.16 [-0.31 , -0.01]

13
7
40
60

29.5%
21.3%
49.2%
100.0%

-0.84 [-1.60 , -0.08]
0.21 [-0.75 , 1.18]
-0.12 [-0.56 , 0.32]
-0.26 [-0.79 , 0.27]

13
17
30

43.8%
56.2%
100.0%

-0.62 [-1.37 , 0.13]
-0.09 [-0.74 , 0.57]
-0.32 [-0.84 , 0.20]

Test for subgroup differences: Chi² = 0.43, df = 2 (P = 0.81), I² = 0%

-10
Favours exercise

-5

0

5

10
Favours control

Analysis 5.3.   Comparison 5: Cognitive functioning, Outcome 3: QLQ-C30 cognitive subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

5.3.1 Up to 12 weeks' follow-up
Arbane 2009
Oh 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.95); I² = 0%
Test for overall effect: Z = 2.01 (P = 0.04)

37.23
15.1

-1.59
7.3

21
23
44

-8.7
-0.5

32.13
14.7

23
31
54

13.2%
86.8%
100.0%

7.11 [-13.53 , 27.75]
7.80 [-0.25 , 15.85]
7.71 [0.21 , 15.21]

Test for subgroup differences: Not applicable

-100
Favours exercise

-50

0

50

100

Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

244

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.4.   Comparison 5: Cognitive functioning, Outcome 4: QLQ-C30 cognitive subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

5.4.1 Up to 12 weeks' follow-up
Adamsen 2009
Arbane 2009
Hacker 2011
Jarden 2009
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 8.87; Chi² = 5.03, df = 4 (P = 0.28); I² = 21%
Test for overall effect: Z = 1.83 (P = 0.07)

16.7
32.45
7.7
25.4
26.7

81.3
92.03
85.2
61.8
62.1

118
21
8
17
40
204

83.8
87.3
95.8
79.4
69.6

5.4.2 More than 12 weeks' to less than 6 months' follow-up
Jarden 2009
Moros 2010
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 70.94; Chi² = 4.02, df = 2 (P = 0.13); I² = 50%
Test for overall effect: Z = 0.89 (P = 0.37)

20.4
17.5
22.3

64.1
88
71.3

86.5
83.3
73.8

17
10
40
67

19.8
25.06
21.2
24.1
28

31.8
24.9
19.6

117
23
9
17
41
207

53.0%
9.0%
11.7%
9.5%
16.9%
100.0%

2.50 [-2.19 , 7.19]
-4.73 [-21.98 , 12.52]
10.60 [-4.24 , 25.44]
17.60 [0.96 , 34.24]
7.50 [-4.41 , 19.41]
5.08 [-0.37 , 10.53]

13
7
40
60

26.5%
24.1%
49.4%
100.0%

22.40 [2.58 , 42.22]
-4.70 [-26.10 , 16.70]
2.50 [-6.70 , 11.70]
6.04 [-7.24 , 19.31]

5.4.3 6 months' follow-up
Jarden 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.60 (P = 0.11)

88.9

15

73.1

33

16
16

13
13

100.0%
100.0%

15.80 [-3.59 , 35.19]
15.80 [-3.59 , 35.19]

Test for subgroup differences: Chi² = 1.09, df = 2 (P = 0.58), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 5.5.   Comparison 5: Cognitive functioning, Outcome 5: FACT-Cog change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

5.5.1 Up to 12 weeks' follow-up
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.38 (P = 0.17)

-4

6.8

5.5.2 6 months' follow-up
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.69 (P = 0.49)

-5.4

16.3

19
19

19
19

4.7

25.9

18
18

100.0%
100.0%

-8.70 [-21.05 , 3.65]
-8.70 [-21.05 , 3.65]

-0.68

23.6

17
17

100.0%
100.0%

-4.72 [-18.12 , 8.68]
-4.72 [-18.12 , 8.68]

Test for subgroup differences: Chi² = 0.18, df = 1 (P = 0.67), I² = 0%

-100
Favours exercise

-50

0

50

100

Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

245

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.6.   Comparison 5: Cognitive functioning, Outcome 6: FACT-Cog follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

5.6.1 Up to 12 weeks' follow-up
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.25 (P = 0.21)

125

30.8

5.6.2 6 months' follow-up
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.27 (P = 0.79)

126.4

31.8

19
19

19
19

135.5

19.5

18
18

100.0%
100.0%

-10.50 [-27.02 , 6.02]
-10.50 [-27.02 , 6.02]

129.2

31.5

17
17

100.0%
100.0%

-2.80 [-23.50 , 17.90]
-2.80 [-23.50 , 17.90]

Test for subgroup differences: Chi² = 0.32, df = 1 (P = 0.57), I² = 0%

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 5.7.   Comparison 5: Cognitive functioning, Outcome 7: POMS confusion subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

5.7.1 Up to 12 weeks' follow-up
Targ 2002
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.26 (P = 0.21)

-2

7.2

Test for subgroup differences: Not applicable

-3.2

4.7

79
79

88
88

100.0%
100.0%

1.20 [-0.67 , 3.07]
1.20 [-0.67 , 3.07]

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 5.8.   Comparison 5: Cognitive functioning, Outcome 8: POMS confusion subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

5.8.1 Up to 12 weeks' follow-up
Moadel 2007
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.60 (P = 0.55)

3.17

3.77

3.6

3.88

84
84

44
44

100.0%
100.0%

-0.43 [-1.83 , 0.97]
-0.43 [-1.83 , 0.97]

Test for subgroup differences: Not applicable

-100
Favours exercise

-50

0

50

100

Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

246

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.9.   Comparison 5: Cognitive functioning, Outcome 9: QLSI cognitive functioning subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

5.9.1 Up to 12 weeks' follow-up
Lanctot 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.13 (P = 0.26)

5.18

6.25

8.22

13.83

37
37

31
31

100.0%
100.0%

-3.04 [-8.31 , 2.23]
-3.04 [-8.31 , 2.23]

Test for subgroup differences: Not applicable

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 5.10.   Comparison 5: Cognitive functioning, Outcome 10: MDASI-T problem remembering subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

5.10.1 Up to 12 weeks' follow-up
-0.32
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.09 (P = 0.04)

0.77

Test for subgroup differences: Not applicable

0.05

0.04

19
19

21
21

100.0%
100.0%

-0.37 [-0.72 , -0.02]
-0.37 [-0.72 , -0.02]

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 5.11.   Comparison 5: Cognitive functioning, Outcome
11: MDASI-T problem remembering subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

5.11.1 Up to 12 weeks' follow-up
2
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.93 (P = 0.35)

2.13

Test for subgroup differences: Not applicable

2.67

2.44

19
19

21
21

100.0%
100.0%

-0.67 [-2.09 , 0.75]
-0.67 [-2.09 , 0.75]

-50
Favours exercise

-25

0

25

50
Favours control

Comparison 6.   Depression

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

6.1 Overall depression change

6.1.1 Up to 12 weeks' fol-
low-up

6.1.2 More than 12 weeks' to
less than 6 months' follow-up

6

4

1

418

223

Statistical method

Effect size

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

-0.27 [-0.61, 0.08]

Std. Mean Difference (IV, Random, 95% CI)

-0.04 [-0.32, 0.24]

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

247

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

6.1.3 6 months' follow-up

6.2 Overall depression fol-
low-up values

6.2.1 Up to 12 weeks' fol-
low-up

2

17

15

6.2.2 More than 12 weeks' to
less than 6 months' follow-up

6.2.3 6 months' follow-up

6.3 Centers for Epidemiologi-
cal Studies Depression change

6.3.1 Up to 12 weeks' fol-
low-up

6.3.2 More than 12 weeks' to
less than 6 months' follow-up

6.3.3 6 months' follow-up

6.4 Centers for Epidemiologi-
cal Studies Depression Scale
follow-up values

6.4.1 Up to 12 weeks' fol-
low-up

6.4.2 More than 12 weeks' to
less than 6 months' follow-up

6.4.3 6 months' follow-up

6.5 Hospital Anxiety and De-
pression Scale depression sub-
scale follow-up values

6.5.1 Up to 12 weeks' fol-
low-up

6.5.2 More than 12 weeks' to
less than 6 months' follow-up

6.5.3 6 months' follow-up

6.6 Beck Depression Inventory
change

6.6.1 Up to 12 weeks' fol-
low-up

5

4

3

1

1

2

5

4

2

2

4

4

2

1

1

1

246

Std. Mean Difference (IV, Random, 95% CI)

-0.08 [-0.35, 0.19]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

1250

Std. Mean Difference (IV, Random, 95% CI)

-0.55 [-0.87, -0.22]

406

452

122

223

246

425

279

246

Std. Mean Difference (IV, Random, 95% CI)

-0.21 [-0.43, 0.01]

Std. Mean Difference (IV, Random, 95% CI)

-0.29 [-0.48, -0.09]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-2.40 [-4.05, -0.75]

Mean Difference (IV, Random, 95% CI)

-0.35 [-2.25, 1.55]

Mean Difference (IV, Random, 95% CI)

-0.78 [-2.99, 1.42]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.97 [-2.31, 0.37]

Mean Difference (IV, Random, 95% CI)

-0.74 [-3.19, 1.70]

Mean Difference (IV, Random, 95% CI)

-1.95 [-4.29, 0.40]

Mean Difference (IV, Random, 95% CI)

Totals not selected

Mean Difference (IV, Random, 95% CI)

Totals not selected

Mean Difference (IV, Random, 95% CI)

Totals not selected

Mean Difference (IV, Random, 95% CI)

Totals not selected

Mean Difference (IV, Random, 95% CI)

Subtotals only

21

Mean Difference (IV, Random, 95% CI)

-1.30 [-3.72, 1.12]

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

248

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

6.7 Beck Depression Inventory
follow-up values

6.7.1 Up to 12 weeks' fol-
low-up

6.7.2 6 months' follow-up

6.8 POMS Depression subscale
change

6.8.1 Up to 12 weeks' fol-
low-up

6.9 POMS depression subscale
follow-up values

6.9.1 Up to 12 weeks' fol-
low-up

6.9.2 More than 12 weeks' to
less than 6 months' follow-up

6.10 Symptom Checklist 90 Re-
vised Depression subscale fol-
low-up values

6.10.1 Up to 12 weeks' fol-
low-up

6.11 General Health Question-
naire Depression subscale fol-
low-up values

6.11.1 More than 12 weeks' to
less than 6 months' follow-up

5

5

1

2

2

3

3

1

1

1

1

1

Mean Difference (IV, Random, 95% CI)

Subtotals only

362

177

Mean Difference (IV, Random, 95% CI)

-3.36 [-5.87, -0.85]

Mean Difference (IV, Random, 95% CI)

-2.40 [-4.57, -0.23]

Mean Difference (IV, Random, 95% CI)

Subtotals only

275

Mean Difference (IV, Random, 95% CI)

-0.98 [-5.32, 3.35]

Mean Difference (IV, Random, 95% CI)

Subtotals only

162

Mean Difference (IV, Random, 95% CI)

-0.23 [-1.32, 0.86]

80

Mean Difference (IV, Random, 95% CI)

-6.30 [-12.62, 0.02]

Mean Difference (IV, Random, 95% CI)

Subtotals only

59

Mean Difference (IV, Random, 95% CI)

-1.10 [-3.28, 1.08]

Mean Difference (IV, Random, 95% CI)

Subtotals only

17

Mean Difference (IV, Random, 95% CI)

-0.28 [-2.65, 2.09]

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

249

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 6.1.   Comparison 6: Depression, Outcome 1: Overall depression change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

6.1.1 Up to 12 weeks' follow-up
Courneya 2009
Monga 2007
Oh 2010
Targ 2002
Subtotal (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 8.06, df = 3 (P = 0.04); I² = 63%
Test for overall effect: Z = 1.52 (P = 0.13)

4.6
2.5
5.9
25.3139

-2.2
-0.7
-1.01
-0.38

60
11
54
79
204

0.2
0.6
1.5
-2.6

6.1.2 More than 12 weeks' to less than 6 months' follow-up
Courneya 2007a
Courneya 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.97); I² = 0%
Test for overall effect: Z = 0.31 (P = 0.76)

74
76
150

-2.2
-2.3

8.6
8.8

-1.9
-1.9

6.1.3 6 months' follow-up
Cadmus 2009
Courneya 2007a
Courneya 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.25, df = 2 (P = 0.88); I² = 0%
Test for overall effect: Z = 0.61 (P = 0.54)

22
73
68
163

9.2
10.7
10.7

-2.8
-4.1
-5.6

-2.2
-4
-4

4.7
3.1
7.4
11.4216

62
10
54
88
214

28.9%
11.4%
27.9%
31.8%
100.0%

-0.51 [-0.87 , -0.15]
-0.45 [-1.31 , 0.42]
-0.37 [-0.75 , 0.01]
0.11 [-0.19 , 0.42]
-0.27 [-0.61 , 0.08]

5.7
5.6

6.4
7
7

37
36
73

50.2%
49.8%
100.0%

-0.04 [-0.43 , 0.36]
-0.05 [-0.45 , 0.35]
-0.04 [-0.32 , 0.24]

23
30
30
83

21.1%
39.9%
39.0%
100.0%

-0.07 [-0.66 , 0.51]
-0.01 [-0.44 , 0.41]
-0.16 [-0.59 , 0.27]
-0.08 [-0.35 , 0.19]

Test for subgroup differences: Chi² = 1.05, df = 2 (P = 0.59), I² = 0%

-10
Favours exercise

-5

0

5

10
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

250

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 6.2.   Comparison 6: Depression, Outcome 2: Overall depression follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

6.2.1 Up to 12 weeks' follow-up
Adamsen 2009
Banerjee 2007
Chandwani 2010
Chang 2008
Courneya 2007a
Courneya 2007a
Courneya 2009
Danhauer 2009
Dimeo 1999
Donnelly 2011
Jarden 2009
Lanctot 2010
Monga 2007
Mutrie 2007
Raghavendra 2007
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.35; Chi² = 106.64, df = 15 (P < 0.00001); I² = 86%
Test for overall effect: Z = 3.26 (P = 0.001)

2.74
3.4
7.7
1.25
12.6
12.2
5.4
8.1
6.9
11.25
3.9
10.23
2.8
8.6
6.6
15.1

3.84
9.7
8.2
1.47
13.7
13.7
6.1
17.8
6.2
13.41
6
11.8
4.2
11.5
14.2
15.8

2.43
0.5
6.6
1.22
9.4
9.8
4.5
8.9
10
8.29
3.3
4.55
5.5
6.8
4.6
2

106
35
26
11
75
73
60
13
27
16
17
39
11
82
28
40
659

3.15
1.2
7.8
1.51
10.2
10.2
5
16.9
7.8
10.1
2.5
8.03
3.4
8.6
6.6
2.1

6.2.2 More than 12 weeks' to less than 6 months' follow-up
Chandwani 2010
Courneya 2007a
Courneya 2007a
Jarden 2009
Moros 2010
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 5.53, df = 5 (P = 0.35); I² = 10%
Test for overall effect: Z = 1.91 (P = 0.06)

27
74
76
17
10
40
244

9
10.8
10.8
6.3
1.28
16.4

7.7
9.7
10.6
3.2
1
15.6

12
9.3
9.5
2.9
2.2
1.7

6.2.3 6 months' follow-up
Cadmus 2009
Courneya 2007a
Courneya 2007a
Jarden 2009
Mutrie 2007
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.67, df = 4 (P = 0.80); I² = 0%
Test for overall effect: Z = 2.91 (P = 0.004)

22
68
73
16
82
261

7.9
7.2
9.6
3.1
8.4

7.1
7.5
10
3
7.2

10
10.2
10.2
4.9
10.8

13.5
9.4
9.4
3.5
2.62
2.3

7.6
9.5
9.5
3.7
7.5

103
23
27
11
37
38
62
14
32
17
17
30
10
95
34
41
591

29
37
36
13
7
40
162

7.5%
3.0%
6.5%
5.2%
7.1%
7.1%
7.2%
5.5%
6.6%
5.9%
5.8%
6.8%
5.1%
7.4%
6.4%
6.9%
100.0%

15.5%
25.6%
25.4%
7.6%
4.9%
21.0%
100.0%

-0.39 [-0.66 , -0.12]
-7.34 [-8.82 , -5.86]
-0.07 [-0.61 , 0.47]
-0.15 [-0.99 , 0.68]
-0.11 [-0.51 , 0.28]
-0.15 [-0.54 , 0.24]
-0.15 [-0.50 , 0.21]
-0.69 [-1.47 , 0.09]
0.08 [-0.43 , 0.59]
-0.23 [-0.91 , 0.46]
-0.70 [-1.40 , -0.01]
-0.25 [-0.72 , 0.23]
-0.29 [-1.15 , 0.57]
-0.37 [-0.67 , -0.07]
-1.30 [-1.85 , -0.74]
-0.34 [-0.78 , 0.10]
-0.55 [-0.87 , -0.22]

-0.10 [-0.62 , 0.42]
-0.12 [-0.51 , 0.28]
-0.02 [-0.42 , 0.38]
-0.95 [-1.72 , -0.18]
-0.11 [-1.08 , 0.86]
-0.39 [-0.83 , 0.05]
-0.21 [-0.43 , 0.01]

23
30
30
13
95
191

10.8%
19.9%
20.6%
6.7%
42.1%
100.0%

-0.28 [-0.87 , 0.31]
-0.36 [-0.80 , 0.07]
-0.06 [-0.49 , 0.36]
-0.53 [-1.27 , 0.22]
-0.32 [-0.62 , -0.03]
-0.29 [-0.48 , -0.09]

Test for subgroup differences: Chi² = 2.81, df = 2 (P = 0.24), I² = 28.9%

-10
Favours exercise

-5

0

5

10
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

251

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 6.3.   Comparison 6: Depression, Outcome 3: Centers for Epidemiological Studies Depression change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

6.3.1 Up to 12 weeks' follow-up
Courneya 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.85 (P = 0.004)

-2.2

4.6

0.2

4.7

60
60

62
62

100.0%
100.0%

-2.40 [-4.05 , -0.75]
-2.40 [-4.05 , -0.75]

6.3.2 More than 12 weeks' to less than 6 months' follow-up
Courneya 2007a
Courneya 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.96); I² = 0%
Test for overall effect: Z = 0.36 (P = 0.72)

74
76
150

-2.2
-2.3

8.6
8.8

-1.9
-1.9

6.3.3 6 months' follow-up
Cadmus 2009
Courneya 2007a
Courneya 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.35, df = 2 (P = 0.84); I² = 0%
Test for overall effect: Z = 0.70 (P = 0.49)

22
73
68
163

9.2
10.7
10.7

-2.8
-4.1
-5.6

-2.2
-4
-4

5.7
5.6

6.4
7
7

37
36
73

50.2%
49.8%
100.0%

-0.30 [-2.99 , 2.39]
-0.40 [-3.09 , 2.29]
-0.35 [-2.25 , 1.55]

23
30
30
83

22.4%
39.5%
38.1%
100.0%

-0.60 [-5.25 , 4.05]
-0.10 [-3.61 , 3.41]
-1.60 [-5.17 , 1.97]
-0.78 [-2.99 , 1.42]

Test for subgroup differences: Chi² = 2.87, df = 2 (P = 0.24), I² = 30.3%

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 6.4.   Comparison 6: Depression, Outcome 4: Centers
for Epidemiological Studies Depression Scale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

6.4.1 Up to 12 weeks' follow-up
Chandwani 2010
Courneya 2007a
Courneya 2007a
Courneya 2009
Danhauer 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 3.10, df = 4 (P = 0.54); I² = 0%
Test for overall effect: Z = 1.42 (P = 0.15)

26
73
75
60
13
247

7.7
12.2
12.6
5.4
8.1

6.6
9.8
9.4
4.5
8.9

8.2
13.7
13.7
6.1
17.8

6.4.2 More than 12 weeks' to less than 6 months' follow-up
Chandwani 2010
Courneya 2007a
Courneya 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.14, df = 2 (P = 0.93); I² = 0%
Test for overall effect: Z = 0.59 (P = 0.55)

27
76
74
177

7.7
10.6
9.7

12
9.5
9.3

9
10.8
10.8

6.4.3 6 months' follow-up
Cadmus 2009
Courneya 2007a
Courneya 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.71, df = 2 (P = 0.70); I² = 0%
Test for overall effect: Z = 1.62 (P = 0.10)

22
68
73
163

7.1
7.5
10

7.9
7.2
9.6

10
10.2
10.2

7.8
10.2
10.2
5
16.9

13.5
9.4
9.4

7.6
9.5
9.5

27
38
37
62
14
178

11.9%
11.5%
11.7%
63.1%
1.8%
100.0%

-0.50 [-4.38 , 3.38]
-1.50 [-5.45 , 2.45]
-1.10 [-5.02 , 2.82]
-0.70 [-2.39 , 0.99]
-9.70 [-19.79 , 0.39]
-0.97 [-2.31 , 0.37]

29
36
37
102

13.4%
42.8%
43.8%
100.0%

-1.30 [-7.98 , 5.38]
-0.20 [-3.94 , 3.54]
-1.10 [-4.80 , 2.60]
-0.74 [-3.19 , 1.70]

23
30
30
83

29.9%
37.4%
32.8%
100.0%

-2.10 [-6.40 , 2.20]
-3.00 [-6.84 , 0.84]
-0.60 [-4.70 , 3.50]
-1.95 [-4.29 , 0.40]

Test for subgroup differences: Chi² = 0.61, df = 2 (P = 0.74), I² = 0%

-50
Favours exercise

-25

0

25

50
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

252

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 6.5.   Comparison 6: Depression, Outcome 5: Hospital
Anxiety and Depression Scale depression subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

6.5.1 Up to 12 weeks' follow-up
Adamsen 2009
Banerjee 2007
Jarden 2009
Wiskemann 2011

2.74
3.4
3.9
15.1

2.43
0.5
3.3
2

106
35
17
40

6.5.2 More than 12 weeks' to less than 6 months' follow-up
Jarden 2009
Wiskemann 2011

3.2
15.6

2.9
1.7

17
40

3.84
9.7
6
15.8

6.3
16.4

3.15
1.2
2.5
2.1

3.5
2.3

103
23
17
41

-1.10 [-1.86 , -0.34]
-6.30 [-6.82 , -5.78]
-2.10 [-4.07 , -0.13]
-0.70 [-1.59 , 0.19]

13
40

-3.10 [-5.45 , -0.75]
-0.80 [-1.69 , 0.09]

6.5.3 6 months' follow-up
Jarden 2009

3.1

3

16

4.9

3.7

13

-1.80 [-4.29 , 0.69]

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 6.6.   Comparison 6: Depression, Outcome 6: Beck Depression Inventory change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

6.6.1 Up to 12 weeks' follow-up
Monga 2007
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.05 (P = 0.29)

-0.7

2.5

Test for subgroup differences: Not applicable

0.6

3.1

11
11

10
10

100.0%
100.0%

-1.30 [-3.72 , 1.12]
-1.30 [-3.72 , 1.12]

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 6.7.   Comparison 6: Depression, Outcome 7: Beck Depression Inventory follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

6.7.1 Up to 12 weeks' follow-up
Donnelly 2011
Lanctot 2010
Monga 2007
Mutrie 2007
Raghavendra 2007
Subtotal (95% CI)
Heterogeneity: Tau² = 4.97; Chi² = 11.20, df = 4 (P = 0.02); I² = 64%
Test for overall effect: Z = 2.62 (P = 0.009)

13.41
11.8
4.2
11.5
14.2

11.25
10.23
2.8
8.6
6.6

16
39
11
82
28
176

8.29
4.55
5.5
6.8
4.6

10.1
8.03
3.4
8.6
6.6

17
30
10
95
34
186

10.7%
21.4%
18.5%
26.0%
23.4%
100.0%

-2.16 [-8.45 , 4.13]
-1.57 [-4.78 , 1.64]
-1.40 [-5.27 , 2.47]
-2.90 [-5.17 , -0.63]
-7.60 [-10.40 , -4.80]
-3.36 [-5.87 , -0.85]

6.7.2 6 months' follow-up
Mutrie 2007
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.17 (P = 0.03)

8.4

7.2

10.8

7.5

82
82

95
95

100.0%
100.0%

-2.40 [-4.57 , -0.23]
-2.40 [-4.57 , -0.23]

Test for subgroup differences: Chi² = 0.32, df = 1 (P = 0.57), I² = 0%

-50
Favours exercise

-25

0

25

50
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

253

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 6.8.   Comparison 6: Depression, Outcome 8: POMS Depression subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

6.8.1 Up to 12 weeks' follow-up
Oh 2010
Targ 2002
Subtotal (95% CI)
Heterogeneity: Tau² = 5.56; Chi² = 1.99, df = 1 (P = 0.16); I² = 50%
Test for overall effect: Z = 0.44 (P = 0.66)

5.9
25.3139

54
79
133

-1.01
-0.38

1.5
-2.6

7.4
11.4216

54
88
142

67.7%
32.3%
100.0%

-2.51 [-5.03 , 0.01]
2.22 [-3.85 , 8.29]
-0.98 [-5.32 , 3.35]

Test for subgroup differences: Not applicable

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 6.9.   Comparison 6: Depression, Outcome 9: POMS depression subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

6.9.1 Up to 12 weeks' follow-up
Chang 2008
Dimeo 1999
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.42, df = 2 (P = 0.81); I² = 0%
Test for overall effect: Z = 0.41 (P = 0.68)

1.22
10
12

1.25
6.9
11.4

11
27
40
78

1.47
6.2
13

1.51
7.8
12.1

11
32
41
84

90.2%
5.5%
4.3%
100.0%

-0.22 [-1.37 , 0.93]
0.70 [-3.94 , 5.34]
-1.60 [-6.85 , 3.65]
-0.23 [-1.32 , 0.86]

6.9.2 More than 12 weeks' to less than 6 months' follow-up
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.95 (P = 0.05)

40
40

13

11

17.3

15.7

40
40

100.0%
100.0%

-6.30 [-12.62 , 0.02]
-6.30 [-12.62 , 0.02]

Test for subgroup differences: Chi² = 3.45, df = 1 (P = 0.06), I² = 71.0%

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 6.10.   Comparison 6: Depression, Outcome 10: Symptom
Checklist 90 Revised Depression subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

6.10.1 Up to 12 weeks' follow-up
4.9
Dimeo 1999
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.99 (P = 0.32)

4.6

Test for subgroup differences: Not applicable

27
27

6

3.8

32
32

100.0%
100.0%

-1.10 [-3.28 , 1.08]
-1.10 [-3.28 , 1.08]

-100
Favours exercise

-50

0

50

100

Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

254

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 6.11.   Comparison 6: Depression, Outcome 11: General
Health Questionnaire Depression subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

6.11.1 More than 12 weeks' to less than 6 months' follow-up
Moros 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.23 (P = 0.82)

10
10

2.2

1

1.28

2.62

7
7

100.0%
100.0%

-0.28 [-2.65 , 2.09]
-0.28 [-2.65 , 2.09]

Test for subgroup differences: Not applicable

-100
Favours exercise

-50

0

50

100

Favours control

Comparison 7.   Emotional well-being/mental health functioning

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

7.1 Overall emotional well-
being/mental health change

7.1.1 Up to 12 weeks' fol-
low-up

7.1.2 6 months' follow-up

7.2 Overall emotional well-
being/mental health fol-
low-up values

7.2.1 Up to 12 weeks' fol-
low-up

7.2.2 More than 12 weeks' to
less than 6 months' follow-up

7.2.3 6 months' follow-up

7.3 FACT emotional subscale
change

7.3.1 Up to 12 weeks' fol-
low-up

7.3.2 6 months' follow-up

7.4 FACT emotion subscale
follow-up values

7.4.1 Up to 12 weeks' fol-
low-up

7.4.2 6 months' follow-up

7.5 QLQ-C30 change

8

6

3

23

21

5

6

4

3

2

7

6

4

1

418

202

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

0.52 [-0.04, 1.07]

Std. Mean Difference (IV, Random, 95% CI)

-0.17 [-0.46, 0.11]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

1343

Std. Mean Difference (IV, Random, 95% CI)

0.05 [-0.18, 0.28]

242

350

Std. Mean Difference (IV, Random, 95% CI)

0.59 [0.12, 1.07]

Std. Mean Difference (IV, Random, 95% CI)

0.25 [-0.08, 0.57]

Mean Difference (IV, Random, 95% CI)

Subtotals only

167

Mean Difference (IV, Random, 95% CI)

0.96 [-0.20, 2.12]

81

Mean Difference (IV, Random, 95% CI)

0.25 [-0.81, 1.30]

Mean Difference (IV, Random, 95% CI)

Subtotals only

443

307

Mean Difference (IV, Random, 95% CI)

0.23 [-0.89, 1.36]

Mean Difference (IV, Random, 95% CI)

0.43 [-0.51, 1.37]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

255

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

7.5.1 Up to 12 weeks' fol-
low-up

7.6 QLQ-C30 emotion sub-
scale follow-up values

7.6.1 Up to 12 weeks' fol-
low-up

7.6.2 More than 12 weeks' to
less than 6 months' follow-up

7.6.3 6 months' follow-up

7.7 FACIT-E subscale change

7.7.1 Up to 12 weeks' fol-
low-up

7.8 POMS total mood change

7.8.1 Up to 12 weeks' fol-
low-up

7.9 POMS total mood fol-
low-up values

7.9.1 Up to 12 weeks' fol-
low-up

7.10 POMS anger subscale
change

7.10.1 Up to 12 weeks' fol-
low-up

7.11 POMS anger subscale
follow-up values

7.11.1 Up to 12 weeks' fol-
low-up

7.11.2 More than 12 weeks' to
less than 6 months' follow-up

7.12 MOS SF-36 Mental Com-
ponent Score follow-up val-
ues

7.12.1 Up to 12 weeks' fol-
low-up

7.12.2 More than 12 weeks' to
less than 6 months' follow-up

1

6

5

3

1

1

1

3

3

2

2

2

2

3

3

1

5

5

2

44

Mean Difference (IV, Random, 95% CI)

4.73 [-19.39, 28.85]

411

127

29

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

1.74 [-2.02, 5.49]

Mean Difference (IV, Random, 95% CI)

13.33 [5.19, 21.47]

Mean Difference (IV, Random, 95% CI)

19.10 [6.39, 31.81]

Mean Difference (IV, Random, 95% CI)

Subtotals only

167

Mean Difference (IV, Random, 95% CI)

-0.69 [-3.29, 1.91]

Mean Difference (IV, Random, 95% CI)

Subtotals only

315

Mean Difference (IV, Random, 95% CI)

-8.92 [-10.81, -7.03]

Mean Difference (IV, Random, 95% CI)

Subtotals only

168

Mean Difference (IV, Random, 95% CI)

-7.16 [-12.64, -1.69]

Mean Difference (IV, Random, 95% CI)

Subtotals only

275

Mean Difference (IV, Random, 95% CI)

0.05 [-1.48, 1.57]

Mean Difference (IV, Random, 95% CI)

Subtotals only

268

Mean Difference (IV, Random, 95% CI)

-1.28 [-3.10, 0.54]

80

Mean Difference (IV, Random, 95% CI)

-3.10 [-6.46, 0.26]

Mean Difference (IV, Random, 95% CI)

Subtotals only

443

115

Mean Difference (IV, Random, 95% CI)

4.08 [1.11, 7.05]

Mean Difference (IV, Random, 95% CI)

7.43 [-5.64, 20.50]

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

256

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

7.13 MOS SF-36 mental
health subscale change

7.13.1 6 months' follow-up

7.14 MOS SF-36 mental
health subscale follow-up
values

7.14.1 Up to 12 weeks' fol-
low-up

7.14.2 More than 12 weeks' to
less than 6 months' follow-up

7.14.3 6 months' follow-up

7.15 MOS SF-36 emotional
role subscale change

7.15.1 6 months' follow-up

7.16 MOS SF-36 emotional
role subscale follow-up val-
ues

7.16.1 Up to 12 weeks' fol-
low-up

7.16.2 More than 12 weeks' to
less than 6 months' follow-up

7.16.3 6 months' follow-up

7.17 Positive and Negative Af-
fect Schedule positivity sub-
scale follow-up values

7.17.1 Up to 12 weeks' fol-
low-up

7.17.2 6 months' follow-up

7.18 Positive and Negative Af-
fect Schedule negativity sub-
scale follow-up values

7.18.1 Up to 12 weeks' fol-
low-up

7.18.2 6 months' follow-up

7.19 Satisfaction with Life
change

2

2

4

3

1

1

2

2

4

3

1

1

3

3

1

3

3

1

1

Mean Difference (IV, Random, 95% CI)

Subtotals only

166

Mean Difference (IV, Random, 95% CI)

-3.23 [-6.70, 0.24]

Mean Difference (IV, Random, 95% CI)

Subtotals only

345

Mean Difference (IV, Random, 95% CI)

2.94 [-6.31, 12.18]

56

45

Mean Difference (IV, Random, 95% CI)

0.90 [-11.86, 13.66]

Mean Difference (IV, Random, 95% CI)

2.20 [-2.11, 6.51]

Mean Difference (IV, Random, 95% CI)

Subtotals only

166

Mean Difference (IV, Random, 95% CI)

-1.88 [-8.47, 4.71]

Mean Difference (IV, Random, 95% CI)

Subtotals only

345

Mean Difference (IV, Random, 95% CI)

8.26 [-1.77, 18.30]

56

45

160

177

234

177

Mean Difference (IV, Random, 95% CI)

5.80 [-21.26, 32.86]

Mean Difference (IV, Random, 95% CI)

2.00 [-3.76, 7.76]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

3.58 [-0.11, 7.28]

Mean Difference (IV, Random, 95% CI)

3.80 [0.98, 6.62]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-2.58 [-4.42, -0.74]

Mean Difference (IV, Random, 95% CI)

-1.70 [-3.62, 0.22]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

257

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

7.19.1 Up to 12 weeks' fol-
low-up

7.20 Satisfaction with Life fol-
low-up values

7.20.1 Up to 12 weeks' fol-
low-up

7.21 Perceived Stress fol-
low-up values

7.21.1 Up to 12 weeks' fol-
low-up

7.22 Psychosocial Adjust-
ment to Illness Scale fol-
low-up values

7.22.1 Up to 12 weeks' fol-
low-up

7.22.2 6 months' follow-up

7.23 Brief Symptom Invento-
ry follow-up values

7.23.1 Up to 12 weeks' fol-
low-up

7.23.2 6 months' follow-up

7.24 Symptom Distress Scale
follow-up values

7.24.1 Up to 12 weeks' fol-
low-up

7.25 Symptom Checklist 90
R positive symptom distress
subscale follow-up values

7.25.1 Up to 12 weeks' fol-
low-up

7.26 Symptom Checklist 90
R somatization subscale fol-
low-up values

7.26.1 Up to 12 weeks' fol-
low-up

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

19

Mean Difference (IV, Random, 95% CI)

0.42 [-0.30, 1.14]

Mean Difference (IV, Random, 95% CI)

Subtotals only

96

Mean Difference (IV, Random, 95% CI)

-2.58 [-5.79, 0.63]

Mean Difference (IV, Random, 95% CI)

Subtotals only

58

Mean Difference (IV, Random, 95% CI)

-5.50 [-6.79, -4.21]

Mean Difference (IV, Random, 95% CI)

Subtotals only

14

14

14

14

Mean Difference (IV, Random, 95% CI)

-1.20 [-8.20, 5.80]

Mean Difference (IV, Random, 95% CI)

-2.90 [-9.94, 4.14]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.26 [-0.47, -0.05]

Mean Difference (IV, Random, 95% CI)

-0.19 [-0.47, 0.09]

Mean Difference (IV, Random, 95% CI)

Subtotals only

22

Mean Difference (IV, Random, 95% CI)

-0.35 [-0.72, 0.02]

Mean Difference (IV, Random, 95% CI)

Subtotals only

59

Mean Difference (IV, Random, 95% CI)

-3.00 [-9.03, 3.03]

Mean Difference (IV, Random, 95% CI)

Subtotals only

59

Mean Difference (IV, Random, 95% CI)

-2.30 [-4.37, -0.23]

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

258

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

7.27 Symptom Checklist 90
R obsessive compulsive sub-
scale follow-up values

7.27.1 Up to 12 weeks' fol-
low-up

7.28 Symptom Checklist 90 R
hostility subscale follow-up
values

7.28.1 Up to 12 weeks' fol-
low-up

7.29 Fordyce Happiness Scale
change

7.29.1 6 months' follow-up

7.30 Fordyce Happiness Scale
follow-up values

7.30.1 6 months' follow-up

7.31 National Comprehen-
sive Cancer Network Distress
thermometer follow-up val-
ues

7.31.1 Up to 12 weeks' fol-
low-up

7.31.2 More than 12 weeks' to
less than 6 months' follow-up

7.32 Cohen's Stress change

7.32.1 6 months' follow-up

7.33 Cohen's Stress follow-up
values

7.33.1 6 months' follow-up

7.34 General Health Ques-
tionnaire follow-up values

7.34.1 More than 12 weeks' to
less than 6 months' follow-up

7.35 General Health Ques-
tionnaire somatization sub-
scale follow-up values

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

Mean Difference (IV, Random, 95% CI)

Subtotals only

59

Mean Difference (IV, Random, 95% CI)

-1.00 [-2.81, 0.81]

Mean Difference (IV, Random, 95% CI)

Subtotals only

59

Mean Difference (IV, Random, 95% CI)

-0.50 [-1.42, 0.42]

Mean Difference (IV, Random, 95% CI)

Subtotals only

45

Mean Difference (IV, Random, 95% CI)

2.00 [-12.11, 16.11]

Mean Difference (IV, Random, 95% CI)

Subtotals only

45

Mean Difference (IV, Random, 95% CI)

-0.90 [-10.52, 8.72]

Mean Difference (IV, Random, 95% CI)

Subtotals only

81

80

Mean Difference (IV, Random, 95% CI)

-1.20 [-2.30, -0.10]

Mean Difference (IV, Random, 95% CI)

-0.80 [-1.86, 0.26]

Mean Difference (IV, Random, 95% CI)

Subtotals only

45

Mean Difference (IV, Random, 95% CI)

-1.60 [-5.73, 2.53]

Mean Difference (IV, Random, 95% CI)

Subtotals only

45

Mean Difference (IV, Random, 95% CI)

-3.10 [-6.81, 0.61]

Mean Difference (IV, Random, 95% CI)

Subtotals only

17

Mean Difference (IV, Random, 95% CI)

-1.47 [-9.38, 6.44]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

259

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

7.35.1 More than 12 weeks' to
less than 6 months' follow-up

7.36 WHO BREF psychologi-
cal subscale follow-up values

7.36.1 Up to 12 weeks' fol-
low-up

7.37 MDASI-T distress sub-
scale change

7.37.1 Up to 12 weeks' fol-
low-up

7.38 MDASI-T distress sub-
scale follow-up values

7.38.1 Up to 12 weeks' fol-
low-up

7.39 MDASI-T mood subscale
change

7.39.1 Up to 12 weeks' fol-
low-up

7.40 MDASI-T mood subscale
follow-up values

7.40.1 Up to 12 weeks' fol-
low-up

7.41 MDASI-T feeling sad sub-
scale change

7.41.1 Up to 12 weeks' fol-
low-up

7.42 MDASI-T feeling sad sub-
scale follow-up values

7.42.1 Up to 12 weeks' fol-
low-up

7.43 MDASI-T enjoyment of
life subscale change

7.43.1 Up to 12 weeks' fol-
low-up

7.44 MDASI-T enjoyment of
life subscale follow-up values

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

17

Mean Difference (IV, Random, 95% CI)

-0.08 [-2.27, 2.11]

Mean Difference (IV, Random, 95% CI)

Subtotals only

37

Mean Difference (IV, Random, 95% CI)

0.46 [-0.96, 1.88]

Mean Difference (IV, Random, 95% CI)

Subtotals only

40

Mean Difference (IV, Random, 95% CI)

-1.89 [-2.49, -1.29]

Mean Difference (IV, Random, 95% CI)

Subtotals only

40

Mean Difference (IV, Random, 95% CI)

-2.29 [-3.54, -1.04]

Mean Difference (IV, Random, 95% CI)

Subtotals only

40

Mean Difference (IV, Random, 95% CI)

-1.42 [-1.97, -0.87]

Mean Difference (IV, Random, 95% CI)

Subtotals only

40

Mean Difference (IV, Random, 95% CI)

-2.02 [-3.12, -0.92]

Mean Difference (IV, Random, 95% CI)

Subtotals only

40

Mean Difference (IV, Random, 95% CI)

-1.67 [-2.08, -1.26]

Mean Difference (IV, Random, 95% CI)

Subtotals only

40

Mean Difference (IV, Random, 95% CI)

-2.41 [-3.69, -1.13]

Mean Difference (IV, Random, 95% CI)

Subtotals only

40

Mean Difference (IV, Random, 95% CI)

-1.35 [-2.28, -0.42]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

260

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

7.44.1 Up to 12 weeks' fol-
low-up

7.45 QLSI affective function-
ing subscale follow-up values

7.45.1 Up to 12 weeks' fol-
low-up

1

1

1

40

Mean Difference (IV, Random, 95% CI)

-1.49 [-2.46, -0.52]

Mean Difference (IV, Random, 95% CI)

Subtotals only

67

Mean Difference (IV, Random, 95% CI)

-4.31 [-10.17, 1.55]

Analysis 7.1.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 1: Overall emotional well-being/mental health change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

7.1.1 Up to 12 weeks' follow-up
Arbane 2009
Monga 2007
Oh 2010
Rogers 2009
Targ 2002
Yang 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.38; Chi² = 32.08, df = 5 (P < 0.00001); I² = 84%
Test for overall effect: Z = 1.82 (P = 0.07)

-17.03
1
-1.91
-0.1
7.95
-1.77

-12.3
0.1
8.73
0.9
12.34
7.21

21
11
54
20
79
19
204

44.3
2
20.6
2.5
38
0.94

36.54
3.6
26.2
2.7
34.7
4.48

23
10
54
18
88
21
214

17.0%
13.9%
19.1%
16.4%
19.8%
13.8%
100.0%

0.11 [-0.48 , 0.71]
-0.30 [-1.16 , 0.56]
0.45 [0.07 , 0.83]
0.38 [-0.27 , 1.02]
0.12 [-0.18 , 0.42]
2.66 [1.78 , 3.53]
0.52 [-0.04 , 1.07]

7.1.2 6 months' follow-up
Cadmus 2009
Rogers 2009
Segal 2001
Segal 2001
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.66, df = 3 (P = 0.45); I² = 0%
Test for overall effect: Z = 1.19 (P = 0.23)

22
19
40
40
121

3.1
2.7
16.2
13.8

1.4
-0.29
7.6
7.6

1.6
0
1.6
3.4

2
1.7
8.3
8.3

23
17
20
21
81

24.0%
19.1%
27.9%
29.0%
100.0%

0.08 [-0.51 , 0.66]
0.12 [-0.53 , 0.78]
-0.42 [-0.96 , 0.12]
-0.34 [-0.87 , 0.19]
-0.17 [-0.46 , 0.11]

Test for subgroup differences: Chi² = 4.69, df = 1 (P = 0.03), I² = 78.7%

-10
Favours control

-5

0

5

10
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

261

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.2.   Comparison 7: Emotional well-being/mental health functioning,
Outcome 2: Overall emotional well-being/mental health follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

7.2.1 Up to 12 weeks' follow-up
Adamsen 2009
Arbane 2009
Banerjee 2007
Chandwani 2010
Danhauer 2009
Dimeo 1999
Donnelly 2011
Galvao 2010
Hacker 2011
Hwang 2008
Jarden 2009
Lanctot 2010
Moadel 2007
Mock 1994
Monga 2007
Mutrie 2007
Rogers 2009
Tang 2010
Wiskemann 2011
Yang 2011
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.20; Chi² = 77.53, df = 20 (P < 0.00001); I² = 74%
Test for overall effect: Z = 0.45 (P = 0.66)

80.6
90.94
20.4
50.6
18.2
-2.4
29.65
49.2
85.2
12.25
66.7
-10.22
-16.32
-17.7
22.6
18.9
21.1
44.92
59.2
-36.1
20.8

81.3
86.51
14.9
52.8
20.8
-2.7
30.43
50.2
88.5
12.71
79.4
-5.91
-17.76
-16.5
22.5
20.1
20
55.47
62.3
-25.74
19.5

17.2
34
2.4
8.7
3.2
4.8
8.81
10.4
10.9
2.02
19.8
4.66
5.06
7.5
2.6
4.2
3.1
10.07
25.3
10.1
3.1

118
21
35
26
13
27
16
29
8
17
17
37
84
9
11
82
20
36
40
19
28
693

18
22.88
2.5
8.8
6.1
4.7
9.3
11
21
2.4
23
15.84
5.6
5.7
1.6
4.4
2.9
13
22
14.74
2.7

117
23
23
27
14
32
17
28
9
20
17
30
44
5
10
92
18
35
41
21
27
650

6.4%
4.8%
4.4%
5.0%
3.9%
5.2%
4.3%
5.2%
3.2%
4.5%
4.3%
5.3%
5.9%
2.7%
3.5%
6.3%
4.5%
5.3%
5.6%
4.5%
5.1%
100.0%

0.04 [-0.22 , 0.30]
-0.15 [-0.74 , 0.44]
-2.22 [-2.90 , -1.55]
0.25 [-0.29 , 0.79]
0.51 [-0.26 , 1.28]
-0.06 [-0.57 , 0.45]
0.08 [-0.60 , 0.77]
0.09 [-0.43 , 0.61]
0.18 [-0.77 , 1.14]
0.20 [-0.45 , 0.85]
0.58 [-0.11 , 1.27]
0.38 [-0.10 , 0.87]
-0.27 [-0.64 , 0.09]
0.16 [-0.93 , 1.26]
-0.04 [-0.90 , 0.81]
0.28 [-0.02 , 0.58]
-0.36 [-1.00 , 0.28]
0.90 [0.41 , 1.39]
0.13 [-0.31 , 0.57]
0.80 [0.15 , 1.44]
-0.44 [-0.98 , 0.10]
0.05 [-0.18 , 0.28]

7.2.2 More than 12 weeks' to less than 6 months' follow-up
Chandwani 2010
Jarden 2009
Moros 2010
Tang 2010
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.18; Chi² = 11.71, df = 4 (P = 0.02); I² = 66%
Test for overall effect: Z = 2.45 (P = 0.01)

50.9
89.6
70
57.87
70

50.4
68.6
61.9
44.02
60.5

27
17
10
24
40
118

14
12.7
28.1
10.7
24.2

7.2.3 6 months' follow-up
Cadmus 2009
Jarden 2009
Mock 1994
Mutrie 2007
Rogers 2009
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 8.95, df = 5 (P = 0.11); I² = 44%
Test for overall effect: Z = 1.49 (P = 0.14)

21.1
92.8
-14.8
19.7
19.5
19.8

20.6
73.7
-17.7
18.6
20.8
19.1

22
16
9
82
19
24
172

2.4
8.8
7.6
4
3.1
2.8

15.6
23
29
12
25

3.1
22
5.7
4.5
3
3.6

29
13
7
35
40
124

22.8%
16.9%
13.6%
21.8%
24.8%
100.0%

0.03 [-0.49 , 0.56]
1.14 [0.36 , 1.93]
0.27 [-0.70 , 1.24]
1.19 [0.62 , 1.75]
0.38 [-0.06 , 0.82]
0.59 [0.12 , 1.07]

23
13
5
95
17
25
178

17.5%
11.8%
7.1%
30.2%
15.1%
18.3%
100.0%

0.18 [-0.41 , 0.76]
1.16 [0.36 , 1.95]
0.39 [-0.72 , 1.49]
0.26 [-0.04 , 0.55]
-0.42 [-1.08 , 0.25]
0.21 [-0.35 , 0.77]
0.25 [-0.08 , 0.57]

Test for subgroup differences: Chi² = 4.28, df = 2 (P = 0.12), I² = 53.2%

-10
Favours control

-5

0

5

10
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

262

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.3.   Comparison 7: Emotional well-being/mental
health functioning, Outcome 3: FACT emotional subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.3.1 Up to 12 weeks' follow-up
Monga 2007
Oh 2010
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.39; Chi² = 3.11, df = 2 (P = 0.21); I² = 36%
Test for overall effect: Z = 1.62 (P = 0.11)

1
0.05
-0.1

11
54
20
85

2
2.7
2.5

0.1
1.6
0.9

7.3.2 6 months' follow-up
Cadmus 2009
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.93); I² = 0%
Test for overall effect: Z = 0.46 (P = 0.65)

22
19
41

3.1
2.7

1.6
0

1.4
-0.29

3.6
2.9
2.7

2
1.7

10
54
18
82

17.1%
51.3%
31.6%
100.0%

-0.90 [-3.42 , 1.62]
1.55 [0.49 , 2.61]
1.00 [-0.66 , 2.66]
0.96 [-0.20 , 2.12]

23
17
40

47.6%
52.4%
100.0%

0.20 [-1.33 , 1.73]
0.29 [-1.17 , 1.75]
0.25 [-0.81 , 1.30]

Test for subgroup differences: Chi² = 0.79, df = 1 (P = 0.37), I² = 0%

-20
Favours control

-10

0

10

20
Favours exercise

Analysis 7.4.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 4: FACT emotion subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.4.1 Up to 12 weeks' follow-up
Danhauer 2009
Moadel 2007
Monga 2007
Mutrie 2007
Rogers 2009
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 1.03; Chi² = 11.09, df = 5 (P = 0.05); I² = 55%
Test for overall effect: Z = 0.41 (P = 0.68)

20.8
17.76
22.5
20.1
20
19.5

18.2
16.32
22.6
18.9
21.1
20.8

13
84
11
82
20
28
238

3.2
5.06
2.6
4.2
3.1
3.1

7.4.2 6 months' follow-up
Cadmus 2009
Mutrie 2007
Rogers 2009
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.24; Chi² = 4.06, df = 3 (P = 0.26); I² = 26%
Test for overall effect: Z = 0.89 (P = 0.37)

22
82
19
24
147

21.1
19.7
19.5
19.8

20.6
18.6
20.8
19.1

2.4
4
3.1
2.8

6.1
5.6
1.6
4.4
2.9
2.7

3.1
4.5
3
3.6

14
44
10
92
18
27
205

7.4%
16.1%
17.3%
22.6%
16.6%
20.0%
100.0%

2.60 [-1.04 , 6.24]
1.44 [-0.54 , 3.42]
-0.10 [-1.93 , 1.73]
1.20 [-0.08 , 2.48]
-1.10 [-3.01 , 0.81]
-1.30 [-2.83 , 0.23]
0.23 [-0.89 , 1.36]

23
95
17
25
160

25.1%
35.5%
18.1%
21.3%
100.0%

0.50 [-1.12 , 2.12]
1.10 [-0.15 , 2.35]
-1.30 [-3.29 , 0.69]
0.70 [-1.10 , 2.50]
0.43 [-0.51 , 1.37]

Test for subgroup differences: Chi² = 0.07, df = 1 (P = 0.79), I² = 0%

-20
Favours control

-10

0

10

20
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

263

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.5.   Comparison 7: Emotional well-being/mental health functioning, Outcome 5: QLQ-C30 change

Study or Subgroup

Mean

Experimental
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.5.1 Up to 12 weeks' follow-up
Arbane 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.38 (P = 0.70)

-12.3

44.3

-17.03

36.54

21
21

23
23

100.0%
100.0%

4.73 [-19.39 , 28.85]
4.73 [-19.39 , 28.85]

Test for subgroup differences: Not applicable

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 7.6.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 6: QLQ-C30 emotion subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.6.1 Up to 12 weeks' follow-up
Adamsen 2009
Arbane 2009
Hacker 2011
Jarden 2009
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 3.02, df = 4 (P = 0.56); I² = 0%
Test for overall effect: Z = 0.91 (P = 0.36)

81.3
86.51
88.5
79.4
62.3

118
21
8
17
40
204

17.2
34
10.9
19.8
25.3

80.6
90.94
85.2
66.7
59.2

7.6.2 More than 12 weeks' to less than 6 months' follow-up
Jarden 2009
Moros 2010
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.79, df = 2 (P = 0.41); I² = 0%
Test for overall effect: Z = 3.21 (P = 0.001)

89.6
70
70

12.7
28.1
24.2

17
10
40
67

68.6
61.9
60.5

18
22.88
21
23
22

117
23
9
17
41
207

69.6%
4.7%
5.7%
6.8%
13.2%
100.0%

0.70 [-3.80 , 5.20]
-4.43 [-21.72 , 12.86]
3.30 [-12.36 , 18.96]
12.70 [-1.73 , 27.13]
3.10 [-7.24 , 13.44]
1.74 [-2.02 , 5.49]

23
29
25

13
7
40
60

34.4%
8.7%
57.0%
100.0%

21.00 [7.12 , 34.88]
8.10 [-19.56 , 35.76]
9.50 [-1.28 , 20.28]
13.33 [5.19 , 21.47]

7.6.3 6 months' follow-up
Jarden 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.94 (P = 0.003)

92.8

8.8

73.7

22

16
16

13
13

100.0%
100.0%

19.10 [6.39 , 31.81]
19.10 [6.39 , 31.81]

Test for subgroup differences: Chi² = 11.64, df = 2 (P = 0.003), I² = 82.8%

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 7.7.   Comparison 7: Emotional well-being/mental health functioning, Outcome 7: FACIT-E subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.7.1 Up to 12 weeks' follow-up
Targ 2002
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.52 (P = 0.60)

1.68

10.7

2.37

5.2

79
79

88
88

100.0%
100.0%

-0.69 [-3.29 , 1.91]
-0.69 [-3.29 , 1.91]

Test for subgroup differences: Not applicable

-100
Favours exercise

-50

0

50

100

Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

264

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.8.   Comparison 7: Emotional well-being/mental health functioning, Outcome 8: POMS total mood change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.8.1 Up to 12 weeks' follow-up
Oh 2010
Targ 2002
Yang 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.79, df = 2 (P = 0.67); I² = 0%
Test for overall effect: Z = 9.26 (P < 0.00001)

-8.73
-12.34
-7.21

54
79
19
152

20.6
38
0.94

1.91
-7.95
1.77

26.2
34.7
4.48

54
88
21
163

4.5%
2.9%
92.6%
100.0%

-10.64 [-19.53 , -1.75]
-4.39 [-15.47 , 6.69]
-8.98 [-10.94 , -7.02]
-8.92 [-10.81 , -7.03]

Test for subgroup differences: Not applicable

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 7.9.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 9: POMS total mood follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.9.1 Up to 12 weeks' follow-up
Moadel 2007
Yang 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 2.31; Chi² = 1.17, df = 1 (P = 0.28); I² = 15%
Test for overall effect: Z = 2.56 (P = 0.01)

84
19
103

16.57
10.1

21.88
36.1

17.16
25.74

19
14.74

44
21
65

56.7%
43.3%
100.0%

-4.72 [-11.36 , 1.92]
-10.36 [-18.13 , -2.59]
-7.16 [-12.64 , -1.69]

Test for subgroup differences: Not applicable

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 7.10.   Comparison 7: Emotional well-being/mental
health functioning, Outcome 10: POMS anger subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.10.1 Up to 12 weeks' follow-up
-0.05
Oh 2010
-1.3
Targ 2002
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.11, df = 1 (P = 0.74); I² = 0%
Test for overall effect: Z = 0.06 (P = 0.95)

54
79
133

4.6
8.9

-0.3
-1.01

5.6
7.3

54
88
142

62.3%
37.7%
100.0%

0.25 [-1.68 , 2.18]
-0.29 [-2.78 , 2.20]
0.05 [-1.48 , 1.57]

Test for subgroup differences: Not applicable

-50
Favours exercise

-25

0

25

50
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

265

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.11.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 11: POMS anger subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.11.1 Up to 12 weeks' follow-up
2.7
Dimeo 1999
5.23
Moadel 2007
4.8
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.71; Chi² = 2.75, df = 2 (P = 0.25); I² = 27%
Test for overall effect: Z = 1.38 (P = 0.17)

27
84
40
151

2.4
7.07
7.7

4.8
6.07
6.4

4.7
7.2
8.5

32
44
41
117

38.3%
37.1%
24.7%
100.0%

0.30 [-2.14 , 2.74]
-1.84 [-4.33 , 0.65]
-2.90 [-6.17 , 0.37]
-1.28 [-3.10 , 0.54]

7.11.2 More than 12 weeks' to less than 6 months' follow-up
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.81 (P = 0.07)

40
40

7.1

6

9.1

8.2

40
40

100.0%
100.0%

-3.10 [-6.46 , 0.26]
-3.10 [-6.46 , 0.26]

Test for subgroup differences: Chi² = 0.87, df = 1 (P = 0.35), I² = 0%

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 7.12.   Comparison 7: Emotional well-being/mental health functioning,
Outcome 12: MOS SF-36 Mental Component Score follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.12.1 Up to 12 weeks' follow-up
50.5
Adamsen 2009
52.8
Chandwani 2010
52.2
Danhauer 2009
50.2
Galvao 2010
55.47
Tang 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 5.21; Chi² = 7.64, df = 4 (P = 0.11); I² = 48%
Test for overall effect: Z = 2.69 (P = 0.007)

47.3
50.6
47.5
49.2
44.92

9.4
8.7
6.6
10.4
10.07

118
26
13
29
36
222

7.12.2 More than 12 weeks' to less than 6 months' follow-up
Chandwani 2010
Tang 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 76.84; Chi² = 7.26, df = 1 (P = 0.007); I² = 86%
Test for overall effect: Z = 1.11 (P = 0.27)

50.9
57.87

50.4
44.02

14
10.7

27
24
51

10
8.8
14
11
13

117
27
14
28
35
221

33.7%
20.9%
10.2%
17.3%
17.9%
100.0%

3.20 [0.72 , 5.68]
2.20 [-2.51 , 6.91]
4.70 [-3.46 , 12.86]
1.00 [-4.56 , 6.56]
10.55 [5.13 , 15.97]
4.08 [1.11 , 7.05]

15.6
12

29
35
64

48.1%
51.9%
100.0%

0.50 [-7.25 , 8.25]
13.85 [8.01 , 19.69]
7.43 [-5.64 , 20.50]

Test for subgroup differences: Chi² = 0.24, df = 1 (P = 0.62), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

266

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.13.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 13: MOS SF-36 mental health subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.13.1 6 months' follow-up
Cadmus 2009
Segal 2001
Segal 2001
Subtotal (95% CI)
Heterogeneity: Tau² = 0.80; Chi² = 2.19, df = 2 (P = 0.34); I² = 9%
Test for overall effect: Z = 1.82 (P = 0.07)

22
40
40
102

11
13.8
16.2

2.3
3.4
1.6

2.3
7.6
7.6

7.6
8.3
8.3

23
21
20
64

35.6%
35.4%
29.0%
100.0%

0.00 [-5.55 , 5.55]
-4.20 [-9.76 , 1.36]
-6.00 [-12.20 , 0.20]
-3.23 [-6.70 , 0.24]

Test for subgroup differences: Not applicable

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 7.14.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 14: MOS SF-36 mental health subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.14.1 Up to 12 weeks' follow-up
69.6
Adamsen 2009
82.1
Chandwani 2010
72.4
Galvao 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 29.24; Chi² = 3.58, df = 2 (P = 0.17); I² = 44%
Test for overall effect: Z = 0.62 (P = 0.53)

118
26
29
173

40.1
14.8
39.9

58.7
83
77.7

7.14.2 More than 12 weeks' to less than 6 months' follow-up
Chandwani 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.14 (P = 0.89)

27
27

82.7

22.9

81.8

42
17.1
40

117
27
28
172

38.4%
45.9%
15.7%
100.0%

10.90 [0.40 , 21.40]
-0.90 [-9.50 , 7.70]
-5.30 [-26.05 , 15.45]
2.94 [-6.31 , 12.18]

25.8

29
29

100.0%
100.0%

0.90 [-11.86 , 13.66]
0.90 [-11.86 , 13.66]

7.14.3 6 months' follow-up
Cadmus 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.00 (P = 0.32)

52.4

6.6

50.2

8.1

22
22

23
23

100.0%
100.0%

2.20 [-2.11 , 6.51]
2.20 [-2.11 , 6.51]

Test for subgroup differences: Chi² = 0.06, df = 2 (P = 0.97), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

267

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.15.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 15: MOS SF-36 emotional role subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.15.1 6 months' follow-up
Cadmus 2009
Segal 2001
Segal 2001
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.42, df = 2 (P = 0.81); I² = 0%
Test for overall effect: Z = 0.56 (P = 0.58)

22
40
40
102

14.5
47.5
32.5

3.4
4.8
10.3

4.2
12.2
12.2

12.9
25
25

23
21
20
64

67.3%
13.1%
19.6%
100.0%

-0.80 [-8.83 , 7.23]
-7.40 [-25.59 , 10.79]
-1.90 [-16.78 , 12.98]
-1.88 [-8.47 , 4.71]

Test for subgroup differences: Not applicable

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 7.16.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 16: MOS SF-36 emotional role subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.16.1 Up to 12 weeks' follow-up
69.6
Adamsen 2009
91.3
Chandwani 2010
72.4
Galvao 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 11.80; Chi² = 2.27, df = 2 (P = 0.32); I² = 12%
Test for overall effect: Z = 1.61 (P = 0.11)

118
26
29
173

40.1
44.9
39.9

58.7
74.8
77.7

42
50.9
40

117
27
28
172

64.7%
14.1%
21.2%
100.0%

10.90 [0.40 , 21.40]
16.50 [-9.32 , 42.32]
-5.30 [-26.05 , 15.45]
8.26 [-1.77 , 18.30]

7.16.2 More than 12 weeks' to less than 6 months' follow-up
Chandwani 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.42 (P = 0.67)

27
27

88.8

49.4

83

53.9

29
29

100.0%
100.0%

5.80 [-21.26 , 32.86]
5.80 [-21.26 , 32.86]

7.16.3 6 months' follow-up
Cadmus 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.68 (P = 0.50)

51.1

8.6

49.1

11

22
22

23
23

100.0%
100.0%

2.00 [-3.76 , 7.76]
2.00 [-3.76 , 7.76]

Test for subgroup differences: Chi² = 1.15, df = 2 (P = 0.56), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

268

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.17.   Comparison 7: Emotional well-being/mental health functioning,
Outcome 17: Positive and Negative Affect Schedule positivity subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.17.1 Up to 12 weeks' follow-up
38.2
Danhauer 2009
30.43
Donnelly 2011
33.4
Mutrie 2007
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.47, df = 2 (P = 0.48); I² = 0%
Test for overall effect: Z = 1.90 (P = 0.06)

6.8
8.81
8.5

31.8
29.65
29.3

13
16
8
37

11
9.3
9.8

14
17
92
123

29.1%
35.7%
35.2%
100.0%

6.40 [-0.45 , 13.25]
0.78 [-5.40 , 6.96]
4.10 [-2.12 , 10.32]
3.58 [-0.11 , 7.28]

7.17.2 6 months' follow-up
Mutrie 2007
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.64 (P = 0.008)

33

8.1

29.2

11

82
82

95
95

100.0%
100.0%

3.80 [0.98 , 6.62]
3.80 [0.98 , 6.62]

Test for subgroup differences: Chi² = 0.01, df = 1 (P = 0.93), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 7.18.   Comparison 7: Emotional well-being/mental health functioning,
Outcome 18: Positive and Negative Affect Schedule negativity subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.18.1 Up to 12 weeks' follow-up
14
Danhauer 2009
15.44
Donnelly 2011
15.6
Mutrie 2007
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.58, df = 2 (P = 0.45); I² = 0%
Test for overall effect: Z = 2.74 (P = 0.006)

13
16
82
111

3.9
6.46
6.6

19.9
18.12
17.7

9.8
10
7.4

14
17
92
123

11.0%
10.4%
78.6%
100.0%

-5.90 [-11.45 , -0.35]
-2.68 [-8.39 , 3.03]
-2.10 [-4.18 , -0.02]
-2.58 [-4.42 , -0.74]

7.18.2 6 months' follow-up
Mutrie 2007
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.74 (P = 0.08)

15.7

6.1

17.4

6.9

82
82

95
95

100.0%
100.0%

-1.70 [-3.62 , 0.22]
-1.70 [-3.62 , 0.22]

Test for subgroup differences: Chi² = 0.42, df = 1 (P = 0.52), I² = 0%

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 7.19.   Comparison 7: Emotional well-being/mental
health functioning, Outcome 19: Satisfaction with Life change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.19.1 Up to 12 weeks' follow-up
0.4
Campbell 2005
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.14 (P = 0.25)

0.9

Test for subgroup differences: Not applicable

-0.02

0.7

10
10

9
9

100.0%
100.0%

0.42 [-0.30 , 1.14]
0.42 [-0.30 , 1.14]

-20
Favours control

-10

0

10

20
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

269

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.20.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 20: Satisfaction with Life follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.20.1 Up to 12 weeks' follow-up
30.2
Courneya 2003a
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.58 (P = 0.12)

9.01

Test for subgroup differences: Not applicable

32.78

7

51
51

45
45

100.0%
100.0%

-2.58 [-5.79 , 0.63]
-2.58 [-5.79 , 0.63]

-50
Favours control

-25

0

25

50
Favours exercise

Analysis 7.21.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 21: Perceived Stress follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.21.1 Up to 12 weeks' follow-up
14.9
Banerjee 2007
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 8.33 (P < 0.00001)

2.4

Test for subgroup differences: Not applicable

20.4

2.5

35
35

23
23

100.0%
100.0%

-5.50 [-6.79 , -4.21]
-5.50 [-6.79 , -4.21]

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 7.22.   Comparison 7: Emotional well-being/mental health functioning,
Outcome 22: Psychosocial Adjustment to Illness Scale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.22.1 Up to 12 weeks' follow-up
16.5
Mock 1994
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.34 (P = 0.74)

7.5

7.22.2 6 months' follow-up
Mock 1994
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.81 (P = 0.42)

14.8

7.6

9
9

9
9

17.7

5.7

5
5

100.0%
100.0%

-1.20 [-8.20 , 5.80]
-1.20 [-8.20 , 5.80]

17.7

5.7

5
5

100.0%
100.0%

-2.90 [-9.94 , 4.14]
-2.90 [-9.94 , 4.14]

Test for subgroup differences: Chi² = 0.11, df = 1 (P = 0.74), I² = 0%

-100
Favours exercise

-50

0

50

100

Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

270

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.23.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 23: Brief Symptom Inventory follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.23.1 Up to 12 weeks' follow-up
0.16
Mock 1994
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.37 (P = 0.02)

0.19

7.23.2 6 months' follow-up
Mock 1994
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.33 (P = 0.18)

0.16

0.15

9
9

9
9

0.42

0.2

5
5

100.0%
100.0%

-0.26 [-0.47 , -0.05]
-0.26 [-0.47 , -0.05]

0.35

0.3

5
5

100.0%
100.0%

-0.19 [-0.47 , 0.09]
-0.19 [-0.47 , 0.09]

Test for subgroup differences: Chi² = 0.15, df = 1 (P = 0.70), I² = 0%

-20
Favours exercise

-10

0

10

20
Favours control

Analysis 7.24.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 24: Symptom Distress Scale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.24.1 Up to 12 weeks' follow-up
1.56
Chang 2008
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.85 (P = 0.06)

0.38

Test for subgroup differences: Not applicable

1.91

0.5

11
11

11
11

100.0%
100.0%

-0.35 [-0.72 , 0.02]
-0.35 [-0.72 , 0.02]

-20
Favours exercise

-10

0

10

20
Favours control

Analysis 7.25.   Comparison 7: Emotional well-being/mental health functioning, Outcome
25: Symptom Checklist 90 R positive symptom distress subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.25.1 Up to 12 weeks' follow-up
17.7
Dimeo 1999
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.97 (P = 0.33)

12.4

Test for subgroup differences: Not applicable

20.7

11

27
27

32
32

100.0%
100.0%

-3.00 [-9.03 , 3.03]
-3.00 [-9.03 , 3.03]

-100
Favours exercise

-50

0

50

100

Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

271

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.26.   Comparison 7: Emotional well-being/mental health functioning,
Outcome 26: Symptom Checklist 90 R somatization subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.26.1 Up to 12 weeks' follow-up
4.3
Dimeo 1999
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.18 (P = 0.03)

3

27
27

6.6

5

32
32

100.0%
100.0%

-2.30 [-4.37 , -0.23]
-2.30 [-4.37 , -0.23]

Test for subgroup differences: Not applicable

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 7.27.   Comparison 7: Emotional well-being/mental health functioning,
Outcome 27: Symptom Checklist 90 R obsessive compulsive subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.27.1 Up to 12 weeks' follow-up
2.7
Dimeo 1999
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.08 (P = 0.28)

3.8

Test for subgroup differences: Not applicable

3.7

3.2

27
27

32
32

100.0%
100.0%

-1.00 [-2.81 , 0.81]
-1.00 [-2.81 , 0.81]

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 7.28.   Comparison 7: Emotional well-being/mental health functioning,
Outcome 28: Symptom Checklist 90 R hostility subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.28.1 Up to 12 weeks' follow-up
0.9
Dimeo 1999
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.07 (P = 0.28)

1.2

Test for subgroup differences: Not applicable

1.4

2.3

27
27

32
32

100.0%
100.0%

-0.50 [-1.42 , 0.42]
-0.50 [-1.42 , 0.42]

-20
Favours exercise

-10

0

10

20
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

272

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.29.   Comparison 7: Emotional well-being/mental
health functioning, Outcome 29: Fordyce Happiness Scale change

Study or Subgroup

Mean

Experimental
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.29.1 6 months' follow-up
Cadmus 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.28 (P = 0.78)

9.5

27.1

7.5

20.6

22
22

23
23

100.0%
100.0%

2.00 [-12.11 , 16.11]
2.00 [-12.11 , 16.11]

Test for subgroup differences: Not applicable

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 7.30.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 30: Fordyce Happiness Scale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.30.1 6 months' follow-up
Cadmus 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.18 (P = 0.85)

70.2

16.9

71.1

16

22
22

23
23

100.0%
100.0%

-0.90 [-10.52 , 8.72]
-0.90 [-10.52 , 8.72]

Test for subgroup differences: Not applicable

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 7.31.   Comparison 7: Emotional well-being/mental health functioning, Outcome
31: National Comprehensive Cancer Network Distress thermometer follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.31.1 Up to 12 weeks' follow-up
3.4
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.15 (P = 0.03)

2.2

4.6

2.8

40
40

41
41

100.0%
100.0%

-1.20 [-2.30 , -0.10]
-1.20 [-2.30 , -0.10]

7.31.2 More than 12 weeks' to less than 6 months' follow-up
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.49 (P = 0.14)

40
40

3.2

2.2

4

2.6

40
40

100.0%
100.0%

-0.80 [-1.86 , 0.26]
-0.80 [-1.86 , 0.26]

Test for subgroup differences: Chi² = 0.27, df = 1 (P = 0.61), I² = 0%

-50
Favours exercise

-25

0

25

50
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

273

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.32.   Comparison 7: Emotional well-being/mental health functioning, Outcome 32: Cohen's Stress change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.32.1 6 months' follow-up
Cadmus 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.76 (P = 0.45)

-4

8.1

Test for subgroup differences: Not applicable

-2.4

5.8

22
22

23
23

100.0%
100.0%

-1.60 [-5.73 , 2.53]
-1.60 [-5.73 , 2.53]

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 7.33.   Comparison 7: Emotional well-being/mental
health functioning, Outcome 33: Cohen's Stress follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.33.1 6 months' follow-up
Cadmus 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.64 (P = 0.10)

9.5

5.4

Test for subgroup differences: Not applicable

12.6

7.2

22
22

23
23

100.0%
100.0%

-3.10 [-6.81 , 0.61]
-3.10 [-6.81 , 0.61]

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 7.34.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 34: General Health Questionnaire follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.34.1 More than 12 weeks' to less than 6 months' follow-up
Moros 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.36 (P = 0.72)

10
10

8.39

9.1

10.57

8.05

7
7

100.0%
100.0%

-1.47 [-9.38 , 6.44]
-1.47 [-9.38 , 6.44]

Test for subgroup differences: Not applicable

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 7.35.   Comparison 7: Emotional well-being/mental health functioning,
Outcome 35: General Health Questionnaire somatization subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.35.1 More than 12 weeks' to less than 6 months' follow-up
Moros 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.07 (P = 0.94)

10
10

2.89

3.2

3.28

1.7

7
7

100.0%
100.0%

-0.08 [-2.27 , 2.11]
-0.08 [-2.27 , 2.11]

Test for subgroup differences: Not applicable

-50
Favours exercise

-25

0

25

50
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

274

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.36.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 36: WHO BREF psychological subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.36.1 Up to 12 weeks' follow-up
12.71
Hwang 2008
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.63 (P = 0.53)

2.02

Test for subgroup differences: Not applicable

12.25

2.4

17
17

20
20

100.0%
100.0%

0.46 [-0.96 , 1.88]
0.46 [-0.96 , 1.88]

-50
Favours control

-25

0

25

50
Favours exercise

Analysis 7.37.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 37: MDASI-T distress subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.37.1 Up to 12 weeks' follow-up
-1.32
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 6.15 (P < 0.00001)

1.32

Test for subgroup differences: Not applicable

0.57

0.24

19
19

21
21

100.0%
100.0%

-1.89 [-2.49 , -1.29]
-1.89 [-2.49 , -1.29]

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 7.38.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 38: MDASI-T distress subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.38.1 Up to 12 weeks' follow-up
0.95
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.58 (P = 0.0003)

1.08

Test for subgroup differences: Not applicable

3.24

2.7

19
19

21
21

100.0%
100.0%

-2.29 [-3.54 , -1.04]
-2.29 [-3.54 , -1.04]

-50
Favours exercise

-25

0

25

50
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

275

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.39.   Comparison 7: Emotional well-being/mental
health functioning, Outcome 39: MDASI-T mood subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.39.1 Up to 12 weeks' follow-up
-1.47
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 5.07 (P < 0.00001)

1.12

Test for subgroup differences: Not applicable

-0.05

0.51

19
19

21
21

100.0%
100.0%

-1.42 [-1.97 , -0.87]
-1.42 [-1.97 , -0.87]

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 7.40.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 40: MDASI-T mood subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.40.1 Up to 12 weeks' follow-up
0.84
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.59 (P = 0.0003)

1.01

Test for subgroup differences: Not applicable

2.86

2.35

19
19

21
21

100.0%
100.0%

-2.02 [-3.12 , -0.92]
-2.02 [-3.12 , -0.92]

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 7.41.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 41: MDASI-T feeling sad subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.41.1 Up to 12 weeks' follow-up
-1.05
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 8.01 (P < 0.00001)

0.7

Test for subgroup differences: Not applicable

0.62

0.61

19
19

21
21

100.0%
100.0%

-1.67 [-2.08 , -1.26]
-1.67 [-2.08 , -1.26]

-50
Favours exercise

-25

0

25

50
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

276

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.42.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 42: MDASI-T feeling sad subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.42.1 Up to 12 weeks' follow-up
1.26
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.69 (P = 0.0002)

1.56

Test for subgroup differences: Not applicable

3.67

2.5

19
19

21
21

100.0%
100.0%

-2.41 [-3.69 , -1.13]
-2.41 [-3.69 , -1.13]

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 7.43.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 43: MDASI-T enjoyment of life subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.43.1 Up to 12 weeks' follow-up
-1.11
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.85 (P = 0.004)

1.95

Test for subgroup differences: Not applicable

0.24

0.71

19
19

21
21

100.0%
100.0%

-1.35 [-2.28 , -0.42]
-1.35 [-2.28 , -0.42]

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 7.44.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 44: MDASI-T enjoyment of life subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.44.1 Up to 12 weeks' follow-up
0.89
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.00 (P = 0.003)

1.1

Test for subgroup differences: Not applicable

2.38

1.96

19
19

21
21

100.0%
100.0%

-1.49 [-2.46 , -0.52]
-1.49 [-2.46 , -0.52]

-50
Favours exercise

-25

0

25

50
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

277

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.45.   Comparison 7: Emotional well-being/mental health
functioning, Outcome 45: QLSI affective functioning subscale follow-up values

Study or Subgroup

Mean

Experimental
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

7.45.1 Up to 12 weeks' follow-up
5.91
Lanctot 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.44 (P = 0.15)

4.66

Test for subgroup differences: Not applicable

10.22

15.84

37
37

30
30

100.0%
100.0%

-4.31 [-10.17 , 1.55]
-4.31 [-10.17 , 1.55]

-50
Favours exercise

-25

0

25

50
Favours control

Comparison 8.   Fatigue

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

8.1 Overall fatigue change

8.1.1 Up to 12 weeks' fol-
low-up

8.1.2 More than 12 weeks' to
less than 6 months' follow-up

8.1.3 6 months' follow-up

8.2 Overall fatigue follow-up
values

8.2.1 Up to 12 weeks' fol-
low-up

8.2.2 More than 12 weeks' to
less than 6 months' follow-up

8.2.3 6 months' follow-up

8.3 FACT-F subscale change

8.3.1 Up to 12 weeks' fol-
low-up

8.3.2 More than 12 weeks' to
less than 6 months' follow-up

8.3.3 6 months' follow-up

8.4 FACT-F follow-up values

8.4.1 Up to 12 weeks' fol-
low-up

17

12

2

6

28

23

10

7

6

4

1

2

9

9

971

261

614

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

-0.73 [-1.14, -0.31]

Std. Mean Difference (IV, Random, 95% CI)

-0.11 [-0.37, 0.14]

Std. Mean Difference (IV, Random, 95% CI)

0.03 [-0.14, 0.19]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

1721

Std. Mean Difference (IV, Random, 95% CI)

-0.38 [-0.57, -0.18]

838

633

439

223

237

Std. Mean Difference (IV, Random, 95% CI)

-0.19 [-0.33, -0.05]

Std. Mean Difference (IV, Random, 95% CI)

-0.18 [-0.35, -0.00]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

5.35 [2.13, 8.56]

Mean Difference (IV, Random, 95% CI)

1.35 [-1.09, 3.79]

Mean Difference (IV, Random, 95% CI)

-0.13 [-2.58, 2.32]

Mean Difference (IV, Random, 95% CI)

Subtotals only

884

Mean Difference (IV, Random, 95% CI)

2.79 [0.97, 4.61]

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

278

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

8.4.2 More than 12 weeks' to
less than 6 months' follow-up

8.4.3 6 months' follow-up

8.5 FACIT-F subscale change

8.5.1 Up to 12 weeks' fol-
low-up

8.5.2 More than 12 weeks' to
less than 6 months' follow-up

8.6 FACIT-F subscale follow-up
values

8.6.1 Up to 12 weeks' fol-
low-up

8.6.2 More than 12 weeks' to
less than 6 months' follow-up

8.7 QLQ-C30 change

8.7.1 Up to 12 weeks' fol-
low-up

8.8 QLQ-C30 fatigue subscale
follow-up values

8.8.1 Up to 12 weeks' fol-
low-up

8.8.2 More than 12 weeks' to
less than 6 months' follow-up

8.8.3 6 months' follow-up

8.9 Brief Fatigue Inventory
change

8.9.1 Up to 12 weeks' fol-
low-up

8.9.2 More than 12 weeks' to
less than 6 months' follow-up

8.10 Brief Fatigue Inventory
follow-up values

8.10.1 Up to 12 weeks' fol-
low-up

3

5

1

1

1

3

3

1

1

1

6

5

3

1

1

1

1

4

3

374

471

38

38

Mean Difference (IV, Random, 95% CI)

2.40 [0.17, 4.64]

Mean Difference (IV, Random, 95% CI)

2.02 [0.10, 3.95]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

4.16 [-0.31, 8.63]

Mean Difference (IV, Random, 95% CI)

0.01 [-4.69, 4.71]

Mean Difference (IV, Random, 95% CI)

Subtotals only

143

Mean Difference (IV, Random, 95% CI)

5.68 [3.62, 7.74]

38

Mean Difference (IV, Random, 95% CI)

2.82 [-3.68, 9.32]

Mean Difference (IV, Random, 95% CI)

Subtotals only

44

Mean Difference (IV, Random, 95% CI)

-0.36 [-28.87, 28.15]

411

127

29

38

38

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-7.40 [-12.19, -2.62]

Mean Difference (IV, Random, 95% CI)

-9.07 [-18.42, 0.27]

Mean Difference (IV, Random, 95% CI)

-20.00 [-41.23, 1.23]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.07 [-0.83, 0.69]

Mean Difference (IV, Random, 95% CI)

-0.78 [-1.91, 0.35]

Mean Difference (IV, Random, 95% CI)

Totals not selected

Mean Difference (IV, Random, 95% CI)

Totals not selected

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

279

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

8.10.2 More than 12 weeks' to
less than 6 months' follow-up

8.11 POMS fatigue subscale
change

8.11.1 Up to 12 weeks' fol-
low-up

8.11.2 6 months' follow-up

8.12 POMS fatigue subscale
follow-up values

8.12.1 Up to 12 weeks' fol-
low-up

8.12.2 More than 12 weeks' to
less than 6 months' follow-up

8.13 POMS vigor subscale
change

8.13.1 Up to 12 weeks' fol-
low-up

8.13.2 6 months' follow-up

8.14 POMS vigor subscale fol-
low-up values

8.14.1 Up to 12 weeks' fol-
low-up

8.14.2 More than 12 weeks' to
less than 6 months' follow-up

8.15 Piper Fatigue Scale
change

8.15.1 Up to 12 weeks' fol-
low-up

8.15.2 More than 12 weeks' to
less than 6 months' follow-up

8.16 Piper Fatigue Scale fol-
low-up values

8.16.1 Up to 12 weeks' fol-
low-up

8.16.2 More than 12 weeks' to
less than 6 months' follow-up

3

3

3

1

2

2

1

2

2

1

2

2

1

3

2

1

2

1

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

378

103

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.96 [-2.39, 0.47]

Mean Difference (IV, Random, 95% CI)

-1.60 [-11.34, 8.14]

Mean Difference (IV, Random, 95% CI)

Subtotals only

140

Mean Difference (IV, Random, 95% CI)

-2.63 [-8.02, 2.76]

80

Mean Difference (IV, Random, 95% CI)

-6.70 [-11.05, -2.35]

270

103

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

2.80 [-3.93, 9.53]

Mean Difference (IV, Random, 95% CI)

-1.10 [-11.21, 9.01]

Mean Difference (IV, Random, 95% CI)

Subtotals only

140

Mean Difference (IV, Random, 95% CI)

3.04 [0.01, 6.08]

80

Mean Difference (IV, Random, 95% CI)

2.60 [-1.74, 6.94]

Mean Difference (IV, Random, 95% CI)

Subtotals only

40

Mean Difference (IV, Random, 95% CI)

-3.16 [-5.54, -0.77]

108

Mean Difference (IV, Random, 95% CI)

-0.60 [-1.62, 0.42]

Mean Difference (IV, Random, 95% CI)

Subtotals only

21

Mean Difference (IV, Random, 95% CI)

-2.00 [-3.73, -0.27]

108

Mean Difference (IV, Random, 95% CI)

-0.20 [-1.14, 0.74]

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

280

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

8.17 MOS SF-36 vitality sub-
scale change

8.17.1 6 months' follow-up

8.18 MOS SF-36 vitality sub-
scale follow-up values

8.18.1 Up to 12 weeks' fol-
low-up

8.18.2 More than 12 weeks' to
less than 6 months' follow-up

8.18.3 6 months' follow-up

8.19 Fatigue Severity Scale
change

8.19.1 More than 12 weeks' to
less than 6 months' follow-up

8.20 Fatigue Severity Scale fol-
low-up values

8.20.1 More than 12 weeks' to
less than 6 months' follow-up

8.21 Multidimensional Fatigue
Inventory follow-up values

8.21.1 Up to 12 weeks' fol-
low-up

8.21.2 More than 12 weeks' to
less than 6 months' follow-up

8.22 Multidimensional Fatigue
Inventory physical fatigue sub-
scale follow-up values

8.22.1 Up to 12 weeks' fol-
low-up

8.22.2 More than 12 weeks' to
less than 6 months' follow-up

8.23 Multidimensional Fatigue
Inventory reduced activation
subscale follow-up values

8.23.1 Up to 12 weeks' fol-
low-up

2

2

4

3

1

1

1

1

1

1

2

2

1

1

1

1

1

1

Mean Difference (IV, Random, 95% CI)

Subtotals only

166

Mean Difference (IV, Random, 95% CI)

-3.93 [-7.88, 0.03]

Mean Difference (IV, Random, 95% CI)

Subtotals only

345

Mean Difference (IV, Random, 95% CI)

9.64 [5.30, 13.98]

56

45

Mean Difference (IV, Random, 95% CI)

4.80 [-10.73, 20.33]

Mean Difference (IV, Random, 95% CI)

0.70 [-4.74, 6.14]

Mean Difference (IV, Random, 95% CI)

Subtotals only

100

Mean Difference (IV, Random, 95% CI)

-0.30 [-0.83, 0.23]

Mean Difference (IV, Random, 95% CI)

Subtotals only

100

Mean Difference (IV, Random, 95% CI)

-0.31 [-0.84, 0.22]

Mean Difference (IV, Random, 95% CI)

Subtotals only

114

Mean Difference (IV, Random, 95% CI)

-2.09 [-3.82, -0.35]

80

Mean Difference (IV, Random, 95% CI)

-2.50 [-4.34, -0.66]

Mean Difference (IV, Random, 95% CI)

Subtotals only

81

80

Mean Difference (IV, Random, 95% CI)

-1.70 [-3.62, 0.22]

Mean Difference (IV, Random, 95% CI)

-2.60 [-4.62, -0.58]

Mean Difference (IV, Random, 95% CI)

Subtotals only

81

Mean Difference (IV, Random, 95% CI)

-0.60 [-2.41, 1.21]

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

281

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

8.23.2 More than 12 weeks' to
less than 6 months' follow-up

8.24 Multidimensional Fatigue
Inventory reduced motivation
subscale follow-up values

8.24.1 Up to 12 weeks' fol-
low-up

8.24.2 More than 12 weeks' to
less than 6 months' follow-up

8.25 Multidimensional Fatigue
Inventory mental fatigue sub-
scale follow-up values

8.25.1 Up to 12 weeks' fol-
low-up

8.25.2 More than 12 weeks' to
less than 6 months' follow-up

8.26 Schwartz Fatigue fol-
low-up values

8.26.1 6 months' follow-up

8.27 LASA change

8.27.1 Up to 12 weeks' fol-
low-up

8.27.2 More than 12 weeks' to
less than 6 months' follow-up

8.28 MDASI-T fatigue subscale
change

8.28.1 Up to 12 weeks' fol-
low-up

8.29 MDASI-T fatigue subscale
follow-up values

8.29.1 Up to 12 weeks' fol-
low-up

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

81

Mean Difference (IV, Random, 95% CI)

-0.50 [-2.38, 1.38]

Mean Difference (IV, Random, 95% CI)

Subtotals only

81

80

81

80

Mean Difference (IV, Random, 95% CI)

-0.50 [-2.02, 1.02]

Mean Difference (IV, Random, 95% CI)

-0.40 [-1.93, 1.13]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.60 [-2.50, 1.30]

Mean Difference (IV, Random, 95% CI)

0.00 [-1.78, 1.78]

Mean Difference (IV, Random, 95% CI)

Subtotals only

17

Mean Difference (IV, Random, 95% CI)

0.50 [-4.26, 5.26]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-1.50 [-12.30, 9.30]

Mean Difference (IV, Random, 95% CI)

-3.00 [-13.33, 7.33]

103

103

Mean Difference (IV, Random, 95% CI)

Subtotals only

40

Mean Difference (IV, Random, 95% CI)

-2.11 [-2.57, -1.65]

Mean Difference (IV, Random, 95% CI)

Subtotals only

40

Mean Difference (IV, Random, 95% CI)

-1.95 [-3.03, -0.87]

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

282

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.1.   Comparison 8: Fatigue, Outcome 1: Overall fatigue change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

8.1.1 Up to 12 weeks' follow-up
Arbane 2009
Campbell 2005
Cheville 2010
Courneya 2008
Culos-Reed 2010
Monga 2007
Mustian 2009
Oh 2010
Segal 2003
Segal 2009
Segal 2009
Targ 2002
Yang 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.48; Chi² = 105.18, df = 12 (P < 0.00001); I² = 89%
Test for overall effect: Z = 3.44 (P = 0.0006)

10.15
-0.25
-11.7
-9.1
-0.04
2.7
1.05
-0.64
2.2
5.57
5.57
-0.25
0.9

42.67
2.3
13.8
12.4
1.6
2
8.69
7.2
5.8
7.3
7
7.1
0.85

9.79
-2.11
-9.3
-7.8
-0.34
-1.6
-3.11
-6.34
-8
1.46
0.93
-1.27
-1.21

21
10
49
26
53
11
19
54
82
40
40
79
19
503

53.59
2.5
25.08
12.4
1.1
2.2
4.84
5.1
5.8
4.8
4.9
8.2
0.61

23
9
54
29
47
10
19
54
73
20
21
88
21
468

7.7%
6.2%
8.5%
8.0%
8.5%
5.6%
7.5%
8.5%
8.5%
7.9%
7.9%
8.7%
6.4%
100.0%

-0.01 [-0.60 , 0.58]
-0.74 [-1.68 , 0.20]
0.12 [-0.27 , 0.50]
0.10 [-0.43 , 0.63]
-0.21 [-0.61 , 0.18]
-1.97 [-3.05 , -0.89]
-0.58 [-1.23 , 0.07]
-0.91 [-1.30 , -0.51]
-1.75 [-2.12 , -1.38]
-0.62 [-1.16 , -0.07]
-0.72 [-1.26 , -0.18]
-0.13 [-0.44 , 0.17]
-2.82 [-3.72 , -1.92]
-0.73 [-1.14 , -0.31]

8.1.2 More than 12 weeks' to less than 6 months' follow-up
Courneya 2007a
Courneya 2007a
Mustian 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.17, df = 2 (P = 0.92); I² = 0%
Test for overall effect: Z = 0.87 (P = 0.38)

-0.4
-0.9
-3.89

74
76
19
169

10.8
10.9
7.77

0.7
0.7
-3.88

8.1.3 6 months' follow-up
Cadmus 2009
Cheville 2010
Courneya 2007a
Courneya 2007a
Mock 2005
Rogers 2009
Segal 2001
Segal 2001
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 4.69, df = 7 (P = 0.70); I² = 0%
Test for overall effect: Z = 0.33 (P = 0.74)

0.1
-6.4
-6.6
-6.4
1
-0.08
-1.5
-2.1

9.1
25
11.6
11.6
2.9
7.8
23.5
16.8

22
49
68
73
54
19
40
40
365

-2.9
-4.8
-7
-7
1.6
1.2
-6.7
-6.7

7.5
7.4
7

10.1
25.4
7.8
7.8
2.5
8.6
11.3
11.6

37
36
19
92

42.1%
41.6%
16.2%
100.0%

-0.11 [-0.51 , 0.28]
-0.16 [-0.56 , 0.24]
-0.00 [-0.64 , 0.63]
-0.11 [-0.37 , 0.14]

23
54
30
30
54
17
20
21
249

7.8%
18.1%
14.7%
15.0%
19.0%
6.3%
9.4%
9.6%
100.0%

0.31 [-0.28 , 0.89]
-0.06 [-0.45 , 0.32]
0.04 [-0.39 , 0.47]
0.06 [-0.37 , 0.48]
-0.22 [-0.60 , 0.16]
-0.15 [-0.81 , 0.50]
0.25 [-0.29 , 0.79]
0.30 [-0.23 , 0.83]
0.03 [-0.14 , 0.19]

Test for subgroup differences: Chi² = 11.04, df = 2 (P = 0.004), I² = 81.9%

-10
Favours exercise

-5

0

5

10
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

283

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.2.   Comparison 8: Fatigue, Outcome 2: Overall fatigue follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

8.2.1 Up to 12 weeks' follow-up
Adamsen 2009
Arbane 2009
Bourke 2011
Chandwani 2010
Chang 2008
Courneya 2003a
Courneya 2007a
Courneya 2007a
Danhauer 2009
Dimeo 1999
Donnelly 2011
Galvao 2010
Hacker 2011
Jarden 2009
Moadel 2007
Monga 2007
Mustian 2009
Mutrie 2007
Rogers 2009
Segal 2009
Segal 2009
Wang 2010
Windsor 2004
Wiskemann 2011
Yang 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.17; Chi² = 87.41, df = 24 (P < 0.00001); I² = 73%
Test for overall effect: Z = 3.75 (P = 0.0002)

41
22.71
-42
1.4
4.8
-22.37
-32.3
-32.3
-32.6
11.5
-34
50.7
46.9
58.8
-33.82
2.8
-35.94
-36
-10.1
-39
-39
-39.91
21.6
66.4
3.48

34.6
20.11
-49
1.5
4.6
-19.67
-34
-33.1
-39.8
11.7
-36.5
62.4
23.6
50.3
-34.37
0.8
-41.79
-40.3
-12.4
-41.3
-43.1
-45.81
16
60.3
1.53

24.3
32.13
4
2.5
3
11.31
11.5
11.3
11.5
8.9
10.61
20.4
13.9
24.6
11.26
1.8
8.99
10.4
10.4
9.1
8.8
4.29
1.8
28.5
1.58

118
21
21
26
11
51
73
75
13
27
16
29
8
17
84
11
19
82
20
40
40
35
32
40
19
928

22.7
30.79
8
2.1
3.5
9.84
12.3
12.3
15.5
8.6
13.3
22.6
24.1
26
13
2.2
12.1
12.1
6.6
8.9
8.9
5.38
3.2
27.4
1.89

8.2.2 More than 12 weeks' to less than 6 months' follow-up
Chandwani 2010
Courneya 2007a
Courneya 2007a
Culos-Reed 2010
Jarden 2009
Mock 2005
Moros 2010
Mustian 2009
Segal 2009
Segal 2009
Windsor 2004
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 3.31, df = 11 (P = 0.99); I² = 0%
Test for overall effect: Z = 2.62 (P = 0.009)

2
-34.9
-34.9
4.46
57.3
3.7
30.1
-40.35
-42.1
-42.1
1.7
60.8

1.6
-36.8
-36.3
4.15
44.4
3.5
31.1
-43.17
-44.2
-45.1
1.8
49.7

3.1
10.4
9.4
1.58
25
2.4
24.4
7.74
8.9
9.1
2
28.9

27
74
76
53
17
54
10
19
40
40
32
40
482

8.2.3 6 months' follow-up
Bourke 2011
Cadmus 2009
Caldwell 2009
Courneya 2007a
Courneya 2007a
Jarden 2009
Mutrie 2007
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 6.26, df = 7 (P = 0.51); I² = 0%
Test for overall effect: Z = 2.02 (P = 0.04)

-43
51.7
10.5
-42.1
-40.8
29.6
-41.3
-13.8

7
9.6
6.41
10.5
10.5
21.3
9.7
11.7

15
22
8
68
73
16
82
19
303

-40
51
10
-41.5
-41.5
49.6
-37.6
-13.5

3.2
12.5
12.5
1.12
26
2.6
18.9
12.2
8.8
8.8
2.4
29.2

8
9
2.6
9.8
9.8
34
12
11

117
23
22
27
11
45
38
37
14
32
17
28
9
17
44
10
19
92
18
20
21
37
33
41
21
793

29
37
36
47
13
54
7
19
21
20
33
40
356

113
23
9
30
30
13
95
17
330

5.4%
3.9%
3.7%
4.1%
2.9%
4.8%
4.8%
4.8%
3.1%
4.3%
3.5%
4.2%
2.2%
3.5%
5.0%
2.6%
3.6%
5.3%
3.7%
4.1%
4.2%
4.3%
3.8%
4.6%
3.5%
100.0%

7.0%
12.4%
12.3%
12.5%
3.6%
13.6%
2.1%
4.7%
6.9%
6.6%
8.2%
9.9%
100.0%

10.1%
8.7%
3.3%
16.0%
16.4%
5.2%
33.4%
6.9%
100.0%

-0.27 [-0.53 , -0.01]
-0.08 [-0.67 , 0.51]
-1.08 [-1.72 , -0.43]
0.04 [-0.50 , 0.58]
-0.06 [-0.89 , 0.78]
0.25 [-0.15 , 0.65]
-0.14 [-0.54 , 0.25]
-0.07 [-0.46 , 0.33]
-0.51 [-1.28 , 0.26]
0.02 [-0.49 , 0.53]
-0.20 [-0.89 , 0.48]
0.54 [0.01 , 1.07]
-1.11 [-2.15 , -0.06]
-0.33 [-1.01 , 0.35]
-0.05 [-0.41 , 0.32]
-0.96 [-1.88 , -0.05]
-0.54 [-1.19 , 0.11]
-0.38 [-0.68 , -0.08]
-0.26 [-0.90 , 0.38]
-0.25 [-0.79 , 0.29]
-0.46 [-0.99 , 0.08]
-1.20 [-1.70 , -0.69]
-2.12 [-2.74 , -1.51]
-0.22 [-0.65 , 0.22]
-1.09 [-1.76 , -0.42]
-0.38 [-0.57 , -0.18]

-0.13 [-0.65 , 0.40]
-0.17 [-0.56 , 0.23]
-0.13 [-0.53 , 0.26]
-0.22 [-0.62 , 0.17]
-0.49 [-1.23 , 0.24]
-0.08 [-0.46 , 0.30]
0.04 [-0.92 , 1.01]
-0.27 [-0.91 , 0.37]
-0.23 [-0.76 , 0.30]
-0.33 [-0.87 , 0.21]
0.04 [-0.44 , 0.53]
-0.38 [-0.82 , 0.06]
-0.19 [-0.33 , -0.05]

-0.38 [-0.92 , 0.16]
0.07 [-0.51 , 0.66]
0.10 [-0.85 , 1.05]
-0.06 [-0.49 , 0.37]
0.07 [-0.36 , 0.49]
-0.70 [-1.46 , 0.05]
-0.34 [-0.63 , -0.04]
-0.03 [-0.68 , 0.63]
-0.18 [-0.35 , -0.00]

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

284

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Analysis 8.2.   (Continued)

Heterogeneity: Tau² = 0.00; Chi² = 6.26, df = 7 (P = 0.51); I² = 0%
Test for overall effect: Z = 2.02 (P = 0.04)

Test for subgroup differences: Chi² = 2.89, df = 2 (P = 0.24), I² = 30.7%

Cochrane Database of Systematic Reviews

-10
Favours exercise

-5

0

5

10
Favours control

Analysis 8.3.   Comparison 8: Fatigue, Outcome 3: FACT-F subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.3.1 Up to 12 weeks' follow-up
Courneya 2008
Oh 2010
Segal 2003
Segal 2009
Segal 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 10.51; Chi² = 24.78, df = 4 (P < 0.0001); I² = 84%
Test for overall effect: Z = 3.26 (P = 0.001)

7.8
6.34
8
-0.93
-1.46

9.1
0.64
-2.2
-5.57
-5.57

26
54
82
40
40
242

12.4
7.2
5.8
7
7.3

8.3.2 More than 12 weeks' to less than 6 months' follow-up
Courneya 2007a
Courneya 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.04, df = 1 (P = 0.84); I² = 0%
Test for overall effect: Z = 1.09 (P = 0.28)

74
76
150

10.8
10.9

0.4
0.9

-0.7
-0.7

8.3.3 6 months' follow-up
Courneya 2007a
Courneya 2007a
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.34, df = 2 (P = 0.84); I² = 0%
Test for overall effect: Z = 0.11 (P = 0.92)

73
68
19
160

6.4
6.6
0.08

11.6
11.6
7.8

7
7
-1.2

12.4
5.1
5.8
4.9
4.8

7.5
7.4

7.8
7.8
8.6

29
54
73
21
20
197

12.4%
22.5%
23.6%
20.9%
20.7%
100.0%

-1.30 [-7.86 , 5.26]
5.70 [3.35 , 8.05]
10.20 [8.37 , 12.03]
4.64 [1.62 , 7.66]
4.11 [1.02 , 7.20]
5.35 [2.13 , 8.56]

37
36
73

49.9%
50.1%
100.0%

1.10 [-2.35 , 4.55]
1.60 [-1.84 , 5.04]
1.35 [-1.09 , 3.79]

30
30
17
77

40.3%
39.0%
20.7%
100.0%

-0.60 [-4.46 , 3.26]
-0.40 [-4.32 , 3.52]
1.28 [-4.11 , 6.67]
-0.13 [-2.58 , 2.32]

Test for subgroup differences: Chi² = 7.18, df = 2 (P = 0.03), I² = 72.1%

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

285

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.4.   Comparison 8: Fatigue, Outcome 4: FACT-F follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.4.1 Up to 12 weeks' follow-up
Bourke 2011
Courneya 2003a
Courneya 2007a
Courneya 2007a
Danhauer 2009
Jarden 2009
Moadel 2007
Mutrie 2007
Rogers 2009
Segal 2009
Segal 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 3.45; Chi² = 16.05, df = 10 (P = 0.10); I² = 38%
Test for overall effect: Z = 3.00 (P = 0.003)

49
19.67
33.1
34
39.8
33.9
34.37
40.3
12.4
41.3
43.1

42
22.37
32.3
32.3
32.6
27.8
33.82
36
10.1
39
39

4
11.31
11.3
11.5
11.5
9.7
11.26
10.4
10.4
9.1
8.8

21
51
75
73
13
17
84
82
20
40
40
516

8.4.2 More than 12 weeks' to less than 6 months' follow-up
Courneya 2007a
Courneya 2007a
Jarden 2009
Segal 2009
Segal 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.09, df = 4 (P = 0.90); I² = 0%
Test for overall effect: Z = 2.11 (P = 0.04)

74
76
17
40
40
247

36.8
36.3
37.1
45.1
44.2

10.4
9.4
8.9
9.1
8.9

34.9
34.9
31.2
42.1
42.1

8.4.3 6 months' follow-up
Bourke 2011
Courneya 2007a
Courneya 2007a
Jarden 2009
Mutrie 2007
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 4.56, df = 5 (P = 0.47); I² = 0%
Test for overall effect: Z = 2.06 (P = 0.04)

15
68
73
16
82
19
273

43
42.1
40.8
40.1
41.3
13.8

7
10.5
10.5
10.6
9.7
11.7

40
41.5
41.5
33.2
37.6
13.5

8
9.84
12.3
12.3
15.5
9
13
12.1
6.6
8.9
8.9

12.5
12.5
11.9
8.8
8.8

8
9.8
9.8
13
12
11

22
45
37
38
14
17
44
92
18
20
21
368

12.1%
10.6%
9.3%
9.3%
2.8%
6.3%
9.8%
13.6%
7.6%
9.1%
9.4%
100.0%

7.00 [3.24 , 10.76]
-2.70 [-6.93 , 1.53]
0.80 [-3.92 , 5.52]
1.70 [-3.02 , 6.42]
7.20 [-3.05 , 17.45]
6.10 [-0.19 , 12.39]
0.55 [-3.98 , 5.08]
4.30 [0.96 , 7.64]
2.30 [-3.18 , 7.78]
2.30 [-2.51 , 7.11]
4.10 [-0.58 , 8.78]
2.79 [0.97 , 4.61]

37
36
13
20
21
127

22.9%
23.7%
8.4%
22.0%
23.0%
100.0%

1.90 [-2.77 , 6.57]
1.40 [-3.20 , 6.00]
5.90 [-1.83 , 13.63]
3.00 [-1.78 , 7.78]
2.10 [-2.57 , 6.77]
2.40 [0.17 , 4.64]

13
30
30
13
95
17
198

11.8%
20.0%
20.5%
4.8%
36.2%
6.7%
100.0%

3.00 [-2.61 , 8.61]
0.60 [-3.70 , 4.90]
-0.70 [-4.95 , 3.55]
6.90 [-1.87 , 15.67]
3.70 [0.50 , 6.90]
0.30 [-7.12 , 7.72]
2.02 [0.10 , 3.95]

Test for subgroup differences: Chi² = 0.32, df = 2 (P = 0.85), I² = 0%

-50
Favours control

-25

0

25

50
Favours exercise

Analysis 8.5.   Comparison 8: Fatigue, Outcome 5: FACIT-F subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.5.1 Up to 12 weeks' follow-up
Mustian 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.82 (P = 0.07)

3.11

8.69

-1.05

4.84

19
19

19
19

100.0%
100.0%

4.16 [-0.31 , 8.63]
4.16 [-0.31 , 8.63]

8.5.2 More than 12 weeks' to less than 6 months' follow-up
Mustian 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)

19
19

7.77

3.89

3.88

7

19
19

100.0%
100.0%

0.01 [-4.69 , 4.71]
0.01 [-4.69 , 4.71]

Test for subgroup differences: Chi² = 1.57, df = 1 (P = 0.21), I² = 36.3%

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

286

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.6.   Comparison 8: Fatigue, Outcome 6: FACIT-F subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.6.1 Up to 12 weeks' follow-up
Donnelly 2011
Mustian 2009
Wang 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.62, df = 2 (P = 0.73); I² = 0%
Test for overall effect: Z = 5.40 (P < 0.00001)

36.5
41.79
45.81

10.61
8.99
4.29

34
35.94
39.91

16
19
35
70

8.6.2 More than 12 weeks' to less than 6 months' follow-up
Mustian 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.85 (P = 0.39)

19
19

43.17

7.74

40.35

13.3
12.1
5.38

17
19
37
73

6.3%
9.2%
84.4%
100.0%

2.50 [-5.69 , 10.69]
5.85 [-0.93 , 12.63]
5.90 [3.66 , 8.14]
5.68 [3.62 , 7.74]

12.2

19
19

100.0%
100.0%

2.82 [-3.68 , 9.32]
2.82 [-3.68 , 9.32]

Test for subgroup differences: Chi² = 0.68, df = 1 (P = 0.41), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 8.7.   Comparison 8: Fatigue, Outcome 7: QLQ-C30 change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.7.1 Up to 12 weeks' follow-up
Arbane 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.02 (P = 0.98)

9.79

42.67

10.15

53.59

21
21

23
23

100.0%
100.0%

-0.36 [-28.87 , 28.15]
-0.36 [-28.87 , 28.15]

Test for subgroup differences: Not applicable

-100
Favours exercise

-50

0

50

100

Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

287

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.8.   Comparison 8: Fatigue, Outcome 8: QLQ-C30 fatigue subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.8.1 Up to 12 weeks' follow-up
Adamsen 2009
Arbane 2009
Hacker 2011
Jarden 2009
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 3.27, df = 4 (P = 0.51); I² = 0%
Test for overall effect: Z = 3.03 (P = 0.002)

24.3
32.13
13.9
24.6
28.5

34.6
20.11
23.6
50.3
60.3

118
21
8
17
40
204

41
22.71
46.9
58.8
66.4

8.8.2 More than 12 weeks' to less than 6 months' follow-up
Jarden 2009
Moros 2010
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.18, df = 2 (P = 0.55); I² = 0%
Test for overall effect: Z = 1.90 (P = 0.06)

25
24.4
28.9

44.4
31.1
49.7

17
10
40
67

57.3
30.1
60.8

22.7
30.79
24.1
26
27.4

26
18.9
29.2

117
23
9
17
41
207

63.3%
6.6%
6.7%
7.9%
15.4%
100.0%

-6.40 [-12.41 , -0.39]
-2.60 [-21.23 , 16.03]
-23.30 [-41.76 , -4.84]
-8.50 [-25.51 , 8.51]
-6.10 [-18.28 , 6.08]
-7.40 [-12.19 , -2.62]

13
7
40
60

25.6%
20.6%
53.8%
100.0%

-12.90 [-31.37 , 5.57]
1.00 [-19.61 , 21.61]
-11.10 [-23.83 , 1.63]
-9.07 [-18.42 , 0.27]

8.8.3 6 months' follow-up
Jarden 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.85 (P = 0.06)

29.6

21.3

49.6

34

16
16

13
13

100.0%
100.0%

-20.00 [-41.23 , 1.23]
-20.00 [-41.23 , 1.23]

Test for subgroup differences: Chi² = 1.33, df = 2 (P = 0.52), I² = 0%

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 8.9.   Comparison 8: Fatigue, Outcome 9: Brief Fatigue Inventory change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.9.1 Up to 12 weeks' follow-up
Mustian 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.18 (P = 0.86)

-0.25

1.24

-0.18

1.16

19
19

19
19

100.0%
100.0%

-0.07 [-0.83 , 0.69]
-0.07 [-0.83 , 0.69]

8.9.2 More than 12 weeks' to less than 6 months' follow-up
Mustian 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.35 (P = 0.18)

19
19

-0.66

1.52

0.12

2

19
19

100.0%
100.0%

-0.78 [-1.91 , 0.35]
-0.78 [-1.91 , 0.35]

Test for subgroup differences: Chi² = 1.04, df = 1 (P = 0.31), I² = 4.0%

-50
Favours exercise

-25

0

25

50
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

288

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.10.   Comparison 8: Fatigue, Outcome 10: Brief Fatigue Inventory follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.10.1 Up to 12 weeks' follow-up
1.5
Chandwani 2010
4.6
Chang 2008
16
Windsor 2004

2.5
3
1.8

26
11
32

1.4
4.8
21.6

8.10.2 More than 12 weeks' to less than 6 months' follow-up
Chandwani 2010
Mustian 2009
Windsor 2004

3.1
0.98
2

1.6
1.16
1.8

27
19
32

2
2.73
1.7

2.1
3.5
3.2

3.2
2.6
2.4

27
11
33

29
19
33

0.10 [-1.15 , 1.35]
-0.20 [-2.92 , 2.52]
-5.60 [-6.86 , -4.34]

-0.40 [-2.05 , 1.25]
-1.57 [-2.82 , -0.32]
0.10 [-0.97 , 1.17]

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 8.11.   Comparison 8: Fatigue, Outcome 11: POMS fatigue subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.11.1 Up to 12 weeks' follow-up
-9.3
Cheville 2010
-2.42
Oh 2010
-1.27
Targ 2002
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.76, df = 2 (P = 0.68); I² = 0%
Test for overall effect: Z = 1.32 (P = 0.19)

49
54
79
182

13.8
5
7.1

-11.7
-1.3
-0.25

25.08
4.9
8.2

54
54
88
196

3.4%
58.6%
37.9%
100.0%

2.40 [-5.33 , 10.13]
-1.12 [-2.99 , 0.75]
-1.02 [-3.34 , 1.30]
-0.96 [-2.39 , 0.47]

8.11.2 6 months' follow-up
Cheville 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.32 (P = 0.75)

-6.4

25

-4.8

25.4

49
49

54
54

100.0%
100.0%

-1.60 [-11.34 , 8.14]
-1.60 [-11.34 , 8.14]

Test for subgroup differences: Chi² = 0.02, df = 1 (P = 0.90), I² = 0%

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 8.12.   Comparison 8: Fatigue, Outcome 12: POMS fatigue subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.12.1 Up to 12 weeks' follow-up
11.7
Dimeo 1999
15
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 10.31; Chi² = 3.14, df = 1 (P = 0.08); I² = 68%
Test for overall effect: Z = 0.96 (P = 0.34)

11.5
20.3

27
40
67

8.9
8.7

8.12.2 More than 12 weeks' to less than 6 months' follow-up
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.02 (P = 0.003)

40
40

12.8

9.2

19.5

8.6
10.1

32
41
73

48.6%
51.4%
100.0%

0.20 [-4.29 , 4.69]
-5.30 [-9.40 , -1.20]
-2.63 [-8.02 , 2.76]

10.6

40
40

100.0%
100.0%

-6.70 [-11.05 , -2.35]
-6.70 [-11.05 , -2.35]

Test for subgroup differences: Chi² = 1.33, df = 1 (P = 0.25), I² = 24.7%

-100
Favours exercise

-50

0

50

100

Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

289

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.13.   Comparison 8: Fatigue, Outcome 13: POMS vigor subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.13.1 Up to 12 weeks' follow-up
-5.1
Cheville 2010
1.08
Targ 2002
Subtotal (95% CI)
Heterogeneity: Tau² = 17.09; Chi² = 3.07, df = 1 (P = 0.08); I² = 67%
Test for overall effect: Z = 0.82 (P = 0.41)

49
79
128

-12.4
0.9

16.3
7.5

22.69
8.6

54
88
142

36.8%
63.2%
100.0%

7.30 [-0.28 , 14.88]
0.18 [-2.26 , 2.62]
2.80 [-3.93 , 9.53]

8.13.2 6 months' follow-up
Cheville 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.21 (P = 0.83)

-1.8

24.6

-0.7

27.75

49
49

54
54

100.0%
100.0%

-1.10 [-11.21 , 9.01]
-1.10 [-11.21 , 9.01]

Test for subgroup differences: Chi² = 0.40, df = 1 (P = 0.53), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 8.14.   Comparison 8: Fatigue, Outcome 14: POMS vigor subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.14.1 Up to 12 weeks' follow-up
19.6
Dimeo 1999
20.83
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.31, df = 1 (P = 0.58); I² = 0%
Test for overall effect: Z = 1.96 (P = 0.05)

27
40
67

9
8.9

15.5
18.49

8.14.2 More than 12 weeks' to less than 6 months' follow-up
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.17 (P = 0.24)

40
40

22.8

9.9

20.2

9.8
9.1

9.9

32
41
73

40.0%
60.0%
100.0%

4.10 [-0.70 , 8.90]
2.34 [-1.58 , 6.26]
3.04 [0.01 , 6.08]

40
40

100.0%
100.0%

2.60 [-1.74 , 6.94]
2.60 [-1.74 , 6.94]

Test for subgroup differences: Chi² = 0.03, df = 1 (P = 0.87), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

290

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.15.   Comparison 8: Fatigue, Outcome 15: Piper Fatigue Scale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.15.1 Up to 12 weeks' follow-up
-2.11
Campbell 2005
-1.6
Monga 2007
Subtotal (95% CI)
Heterogeneity: Tau² = 1.94; Chi² = 2.87, df = 1 (P = 0.09); I² = 65%
Test for overall effect: Z = 2.59 (P = 0.010)

-0.25
2.7

10
11
21

2.3
2

2.5
2.2

9
10
19

46.8%
53.2%
100.0%

-1.86 [-4.03 , 0.31]
-4.30 [-6.10 , -2.50]
-3.16 [-5.54 , -0.77]

8.15.2 More than 12 weeks' to less than 6 months' follow-up
Mock 2005
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.15 (P = 0.25)

54
54

2.9

1

1.6

2.5

54
54

100.0%
100.0%

-0.60 [-1.62 , 0.42]
-0.60 [-1.62 , 0.42]

Test for subgroup differences: Chi² = 3.73, df = 1 (P = 0.05), I² = 73.2%

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 8.16.   Comparison 8: Fatigue, Outcome 16: Piper Fatigue Scale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.16.1 Up to 12 weeks' follow-up
0.8
Monga 2007
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.27 (P = 0.02)

1.8

2.8

2.2

11
11

10
10

100.0%
100.0%

-2.00 [-3.73 , -0.27]
-2.00 [-3.73 , -0.27]

8.16.2 More than 12 weeks' to less than 6 months' follow-up
Mock 2005
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.42 (P = 0.68)

54
54

2.4

3.5

3.7

2.6

54
54

100.0%
100.0%

-0.20 [-1.14 , 0.74]
-0.20 [-1.14 , 0.74]

Test for subgroup differences: Chi² = 3.21, df = 1 (P = 0.07), I² = 68.8%

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 8.17.   Comparison 8: Fatigue, Outcome 17: MOS SF-36 vitality subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.17.1 6 months' follow-up
Cadmus 2009
Segal 2001
Segal 2001
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.22, df = 2 (P = 0.90); I² = 0%
Test for overall effect: Z = 1.95 (P = 0.05)

22
40
40
102

9.1
16.8
23.5

-0.1
2.1
1.5

2.9
6.7
6.7

10.1
11.6
11.3

23
21
20
64

49.6%
30.2%
20.2%
100.0%

-3.00 [-8.61 , 2.61]
-4.60 [-11.79 , 2.59]
-5.20 [-14.01 , 3.61]
-3.93 [-7.88 , 0.03]

Test for subgroup differences: Not applicable

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

291

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.18.   Comparison 8: Fatigue, Outcome 18: MOS SF-36 vitality subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.18.1 Up to 12 weeks' follow-up
65.5
Adamsen 2009
65.1
Chandwani 2010
62.4
Galvao 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.55, df = 2 (P = 0.76); I² = 0%
Test for overall effect: Z = 4.35 (P < 0.0001)

118
26
29
173

18.1
21.4
20.4

55.6
59.5
50.7

8.18.2 More than 12 weeks' to less than 6 months' follow-up
Chandwani 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.61 (P = 0.54)

27
27

28.1

62

57.2

21.6
24.4
22.6

117
27
28
172

72.6%
12.4%
15.1%
100.0%

9.90 [4.80 , 15.00]
5.60 [-6.74 , 17.94]
11.70 [0.51 , 22.89]
9.64 [5.30 , 13.98]

31.2

29
29

100.0%
100.0%

4.80 [-10.73 , 20.33]
4.80 [-10.73 , 20.33]

8.18.3 6 months' follow-up
Cadmus 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.25 (P = 0.80)

51.7

9.6

22
22

51

9

23
23

100.0%
100.0%

0.70 [-4.74 , 6.14]
0.70 [-4.74 , 6.14]

Test for subgroup differences: Chi² = 6.36, df = 2 (P = 0.04), I² = 68.6%

-100

-50

0

Favours control

50

100
Favours exercie

Analysis 8.19.   Comparison 8: Fatigue, Outcome 19: Fatigue Severity Scale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.19.1 More than 12 weeks' to less than 6 months' follow-up
-0.34
Culos-Reed 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.10 (P = 0.27)

53
53

1.6

-0.04

1.1

47
47

100.0%
100.0%

-0.30 [-0.83 , 0.23]
-0.30 [-0.83 , 0.23]

Test for subgroup differences: Not applicable

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 8.20.   Comparison 8: Fatigue, Outcome 20: Fatigue Severity Scale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.20.1 More than 12 weeks' to less than 6 months' follow-up
Culos-Reed 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.14 (P = 0.25)

53
53

1.58

4.15

4.46

1.12

47
47

100.0%
100.0%

-0.31 [-0.84 , 0.22]
-0.31 [-0.84 , 0.22]

Test for subgroup differences: Not applicable

-50
Favours exercise

-25

0

25

50
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

292

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.21.   Comparison 8: Fatigue, Outcome 21: Multidimensional Fatigue Inventory follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.21.1 Up to 12 weeks' follow-up
9.06
Donnelly 2011
12.7
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.70, df = 1 (P = 0.40); I² = 0%
Test for overall effect: Z = 2.35 (P = 0.02)

17.07
3.6

16
40
56

17.52
14.7

8.21.2 More than 12 weeks' to less than 6 months' follow-up
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.66 (P = 0.008)

40
40

4.1

11

13.5

26.4
4.4

17
41
58

1.3%
98.7%
100.0%

-8.46 [-23.54 , 6.62]
-2.00 [-3.75 , -0.25]
-2.09 [-3.82 , -0.35]

4.3

40
40

100.0%
100.0%

-2.50 [-4.34 , -0.66]
-2.50 [-4.34 , -0.66]

Test for subgroup differences: Chi² = 0.10, df = 1 (P = 0.75), I² = 0%

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 8.22.   Comparison 8: Fatigue, Outcome 22: Multidimensional
Fatigue Inventory physical fatigue subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.22.1 Up to 12 weeks' follow-up
12.9
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.74 (P = 0.08)

4.1

14.6

4.7

40
40

41
41

100.0%
100.0%

-1.70 [-3.62 , 0.22]
-1.70 [-3.62 , 0.22]

8.22.2 More than 12 weeks' to less than 6 months' follow-up
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.53 (P = 0.01)

40
40

11.4

4.7

14

4.5

40
40

100.0%
100.0%

-2.60 [-4.62 , -0.58]
-2.60 [-4.62 , -0.58]

Test for subgroup differences: Chi² = 0.40, df = 1 (P = 0.53), I² = 0%

-100
Favours exercise

-50

0

50

100

Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

293

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.23.   Comparison 8: Fatigue, Outcome 23: Multidimensional
Fatigue Inventory reduced activation subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.23.1 Up to 12 weeks' follow-up
12.9
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.65 (P = 0.52)

4.1

13.5

4.2

40
40

41
41

100.0%
100.0%

-0.60 [-2.41 , 1.21]
-0.60 [-2.41 , 1.21]

8.23.2 More than 12 weeks' to less than 6 months' follow-up
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.52 (P = 0.60)

40
40

4.5

12

12.5

4.1

41
41

100.0%
100.0%

-0.50 [-2.38 , 1.38]
-0.50 [-2.38 , 1.38]

Test for subgroup differences: Chi² = 0.01, df = 1 (P = 0.94), I² = 0%

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 8.24.   Comparison 8: Fatigue, Outcome 24: Multidimensional
Fatigue Inventory reduced motivation subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.24.1 Up to 12 weeks' follow-up
8.5
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.64 (P = 0.52)

3.5

40
40

9

3.5

41
41

100.0%
100.0%

-0.50 [-2.02 , 1.02]
-0.50 [-2.02 , 1.02]

8.24.2 More than 12 weeks' to less than 6 months' follow-up
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.51 (P = 0.61)

40
40

3.5

8.2

8.6

3.5

40
40

100.0%
100.0%

-0.40 [-1.93 , 1.13]
-0.40 [-1.93 , 1.13]

Test for subgroup differences: Chi² = 0.01, df = 1 (P = 0.93), I² = 0%

-50
Favours exercise

-25

0

25

50
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

294

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.25.   Comparison 8: Fatigue, Outcome 25: Multidimensional
Fatigue Inventory mental fatigue subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.25.1 Up to 12 weeks' follow-up
10.3
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.62 (P = 0.54)

4.6

10.9

4.1

40
40

41
41

100.0%
100.0%

-0.60 [-2.50 , 1.30]
-0.60 [-2.50 , 1.30]

8.25.2 More than 12 weeks' to less than 6 months' follow-up
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)

40
40

10.2

4.2

10.2

3.9

40
40

100.0%
100.0%

0.00 [-1.78 , 1.78]
0.00 [-1.78 , 1.78]

Test for subgroup differences: Chi² = 0.20, df = 1 (P = 0.65), I² = 0%

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 8.26.   Comparison 8: Fatigue, Outcome 26: Schwartz Fatigue follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.26.1 6 months' follow-up
Caldwell 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.21 (P = 0.84)

10.5

6.41

10

2.6

8
8

9
9

100.0%
100.0%

0.50 [-4.26 , 5.26]
0.50 [-4.26 , 5.26]

Test for subgroup differences: Not applicable

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 8.27.   Comparison 8: Fatigue, Outcome 27: LASA change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.27.1 Up to 12 weeks' follow-up
-6.6
Cheville 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.27 (P = 0.79)

27.1

-5.1

28.8

49
49

54
54

100.0%
100.0%

-1.50 [-12.30 , 9.30]
-1.50 [-12.30 , 9.30]

8.27.2 More than 12 weeks' to less than 6 months' follow-up
Cheville 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.57 (P = 0.57)

49
49

27.1

-9.5

-6.5

26.27

54
54

100.0%
100.0%

-3.00 [-13.33 , 7.33]
-3.00 [-13.33 , 7.33]

Test for subgroup differences: Chi² = 0.04, df = 1 (P = 0.84), I² = 0%

-100
Favours exercise

-50

0

50

100

Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

295

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.28.   Comparison 8: Fatigue, Outcome 28: MDASI-T fatigue subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.28.1 Up to 12 weeks' follow-up
-1.21
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 8.94 (P < 0.00001)

0.85

Test for subgroup differences: Not applicable

0.9

0.61

19
19

21
21

100.0%
100.0%

-2.11 [-2.57 , -1.65]
-2.11 [-2.57 , -1.65]

-20
Favours exercise

-10

0

10

20
Favours control

Analysis 8.29.   Comparison 8: Fatigue, Outcome 29: MDASI-T fatigue subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

8.29.1 Up to 12 weeks' follow-up
1.53
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.55 (P = 0.0004)

1.58

Test for subgroup differences: Not applicable

3.48

1.89

19
19

21
21

100.0%
100.0%

-1.95 [-3.03 , -0.87]
-1.95 [-3.03 , -0.87]

-50
Favours exercise

-25

0

25

50
Favours control

Comparison 9.   General health perspective

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

9.1 Overall general health change

9.1.1 Up to 12 weeks' follow-up

9.1.2 6 months' follow-up

9.2 Overall general health perspective follow-up
values

9.2.1 Up to 12 weeks' follow-up

9.2.2 More than 12 weeks' to less than 6 months'
follow-up

9.2.3 6 months' follow-up

9.3 MOS SF-36 general health change

4

2

3

7

6

1

2

2

78

202

242

56

81

Std. Mean Difference (IV,
Random, 95% CI)

Subtotals only

Std. Mean Difference (IV,
Random, 95% CI)

1.03 [-1.16, 3.21]

Std. Mean Difference (IV,
Random, 95% CI)

0.09 [-0.20, 0.37]

Std. Mean Difference (IV,
Random, 95% CI)

Subtotals only

Std. Mean Difference (IV,
Random, 95% CI)

0.33 [0.01, 0.64]

Std. Mean Difference (IV,
Random, 95% CI)

0.20 [-0.32, 0.73]

Std. Mean Difference (IV,
Random, 95% CI)

0.05 [-0.43, 0.54]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

296

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Outcome or subgroup title

No. of
studies

9.3.1 6 months' follow-up

9.4 MOS SF-36 general health subscale follow-up
values

9.4.1 Up to 12 weeks' follow-up

9.4.2 More than 12 weeks' to less than 6 months'
follow-up

9.4.3 6 months' follow-up

9.5 WHO BREF follow-up values

9.5.1 Up to 12 weeks' follow-up

9.6 Ferrans and Powers health and functioning
subscale follow-up values

9.6.1 Up to 12 weeks' follow-up

9.7 Single question change

9.7.1 Up to 12 weeks' follow-up

9.7.2 6 months' follow-up

9.8 Single question follow-up values

9.8.1 Up to 12 weeks' follow-up

9.8.2 6 months' follow-up

9.9 MDASI-T general activity subscale change

9.9.1 Up to 12 weeks' follow-up

9.10 MDASI-T general activity subscale follow-up
values

2

3

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

No. of
partici-
pants

166

57

56

45

37

17

38

36

38

36

40

Cochrane Database of Systematic Reviews

Statistical method

Effect size

Mean Difference (IV, Ran-
dom, 95% CI)

0.83 [-1.85, 3.52]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

11.20 [-0.66, 23.06]

Mean Difference (IV, Ran-
dom, 95% CI)

4.60 [-7.06, 16.26]

Mean Difference (IV, Ran-
dom, 95% CI)

2.40 [-2.48, 7.28]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

0.28 [-0.23, 0.79]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

2.30 [-4.03, 8.63]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

-0.05 [-0.47, 0.37]

Mean Difference (IV, Ran-
dom, 95% CI)

0.04 [-0.35, 0.43]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

-0.30 [-0.76, 0.16]

Mean Difference (IV, Ran-
dom, 95% CI)

-0.20 [-0.79, 0.39]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

-1.72 [-2.23, -1.21]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

297

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

9.10.1 Up to 12 weeks' follow-up

1

40

Mean Difference (IV, Ran-
dom, 95% CI)

-1.57 [-2.74, -0.40]

Analysis 9.1.   Comparison 9: General health perspective, Outcome 1: Overall general health change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

9.1.1 Up to 12 weeks' follow-up
Rogers 2009
Yang 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 2.35; Chi² = 18.38, df = 1 (P < 0.0001); I² = 95%
Test for overall effect: Z = 0.92 (P = 0.36)

0.2
-0.14

0.15
1.58

0.6
1.12

20
19
39

9.1.2 6 months' follow-up
Cadmus 2009
Rogers 2009
Segal 2001
Segal 2001
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.34, df = 3 (P = 0.95); I² = 0%
Test for overall effect: Z = 0.59 (P = 0.55)

22
19
40
40
121

1.5
0.16
-0.6
-2.4

6.4
0.6
10.8
15.6

1.4
0.12
-2.8
-2.8

0.7
0.19

18
21
39

50.6%
49.4%
100.0%

-0.08 [-0.71 , 0.56]
2.15 [1.36 , 2.95]
1.03 [-1.16 , 3.21]

7
0.6
7.7
7.9

23
17
20
21
81

23.8%
19.0%
28.1%
29.1%
100.0%

0.01 [-0.57 , 0.60]
0.07 [-0.59 , 0.72]
0.22 [-0.32 , 0.76]
0.03 [-0.50 , 0.56]
0.09 [-0.20 , 0.37]

Test for subgroup differences: Chi² = 0.70, df = 1 (P = 0.40), I² = 0%

-10
Favours control

-5

0

5

10
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

298

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 9.2.   Comparison 9: General health perspective,
Outcome 2: Overall general health perspective follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

9.2.1 Up to 12 weeks' follow-up
Chandwani 2010
Galvao 2010
Hacker 2011
Hwang 2008
Rogers 2009
Yang 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.05; Chi² = 7.25, df = 5 (P = 0.20); I² = 31%
Test for overall effect: Z = 2.05 (P = 0.04)

71.6
71.4
22.6
2.88
3.5
-1.05

64.3
60.2
20.3
2.6
3.8
-2.62

26
29
8
17
20
19
119

18.4
18
6
0.7
0.9
1.27

21.3
26.7
7.3
0.88
0.5
2.38

27
28
9
20
18
21
123

20.6%
21.4%
8.9%
16.2%
16.5%
16.4%
100.0%

0.36 [-0.18 , 0.90]
0.49 [-0.04 , 1.01]
0.32 [-0.64 , 1.29]
0.34 [-0.31 , 0.99]
-0.40 [-1.04 , 0.25]
0.80 [0.15 , 1.44]
0.33 [0.01 , 0.64]

9.2.2 More than 12 weeks' to less than 6 months' follow-up
Chandwani 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.76 (P = 0.45)

27
27

69.1

20.8

64.5

23.7

29
29

100.0%
100.0%

0.20 [-0.32 , 0.73]
0.20 [-0.32 , 0.73]

9.2.3 6 months' follow-up
Cadmus 2009
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 1.24, df = 1 (P = 0.27); I² = 19%
Test for overall effect: Z = 0.22 (P = 0.83)

51.4
3.5

22
19
41

49
3.7

8.5
0.9

8.2
0.9

23
17
40

54.5%
45.5%
100.0%

0.28 [-0.31 , 0.87]
-0.22 [-0.87 , 0.44]
0.05 [-0.43 , 0.54]

Test for subgroup differences: Chi² = 0.87, df = 2 (P = 0.65), I² = 0%

-10
Favours control

-5

0

5

10
Favours exercise

Analysis 9.3.   Comparison 9: General health perspective, Outcome 3: MOS SF-36 general health change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

9.3.1 6 months' follow-up
Cadmus 2009
Segal 2001
Segal 2001
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.47, df = 2 (P = 0.79); I² = 0%
Test for overall effect: Z = 0.61 (P = 0.54)

22
40
40
102

6.4
15.6
10.8

1.5
-2.4
-0.6

1.4
-2.8
-2.8

7
7.9
7.7

23
21
20
64

47.2%
20.8%
32.0%
100.0%

0.10 [-3.82 , 4.02]
0.40 [-5.50 , 6.30]
2.20 [-2.55 , 6.95]
0.83 [-1.85 , 3.52]

Test for subgroup differences: Not applicable

-50
Favours control

-25

0

25

50
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

299

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 9.4.   Comparison 9: General health perspective,
Outcome 4: MOS SF-36 general health subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

9.4.1 Up to 12 weeks' follow-up
Galvao 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.85 (P = 0.06)

71.4

18

60.2

26.7

29
29

28
28

100.0%
100.0%

11.20 [-0.66 , 23.06]
11.20 [-0.66 , 23.06]

9.4.2 More than 12 weeks' to less than 6 months' follow-up
Chandwani 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.77 (P = 0.44)

27
27

69.1

20.8

64.5

23.7

29
29

100.0%
100.0%

4.60 [-7.06 , 16.26]
4.60 [-7.06 , 16.26]

9.4.3 6 months' follow-up
Cadmus 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.96 (P = 0.34)

51.4

8.5

22
22

49

8.2

23
23

100.0%
100.0%

2.40 [-2.48 , 7.28]
2.40 [-2.48 , 7.28]

Test for subgroup differences: Chi² = 1.83, df = 2 (P = 0.40), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 9.5.   Comparison 9: General health perspective, Outcome 5: WHO BREF follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

9.5.1 Up to 12 weeks' follow-up
Hwang 2008
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.08 (P = 0.28)

2.88

0.7

Test for subgroup differences: Not applicable

2.6

0.88

17
17

20
20

100.0%
100.0%

0.28 [-0.23 , 0.79]
0.28 [-0.23 , 0.79]

-20
Favours control

-10

0

10

20
Favours exercise

Analysis 9.6.   Comparison 9: General health perspective, Outcome 6:
Ferrans and Powers health and functioning subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

9.6.1 Up to 12 weeks' follow-up
Hacker 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.71 (P = 0.48)

22.6

6

Test for subgroup differences: Not applicable

20.3

7.3

8
8

9
9

100.0%
100.0%

2.30 [-4.03 , 8.63]
2.30 [-4.03 , 8.63]

-100
Favours exercise

-50

0

50

100

Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

300

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 9.7.   Comparison 9: General health perspective, Outcome 7: Single question change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

9.7.1 Up to 12 weeks' follow-up
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.24 (P = 0.81)

0.15

0.6

9.7.2 6 months' follow-up
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.20 (P = 0.84)

0.16

0.6

20
20

19
19

0.2

0.7

18
18

100.0%
100.0%

-0.05 [-0.47 , 0.37]
-0.05 [-0.47 , 0.37]

0.12

0.6

17
17

100.0%
100.0%

0.04 [-0.35 , 0.43]
0.04 [-0.35 , 0.43]

Test for subgroup differences: Chi² = 0.09, df = 1 (P = 0.76), I² = 0%

-20
Favours control

-10

0

10

20
Favours exercise

Analysis 9.8.   Comparison 9: General health perspective, Outcome 8: Single question follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

9.8.1 Up to 12 weeks' follow-up
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.29 (P = 0.20)

3.5

0.9

9.8.2 6 months' follow-up
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.67 (P = 0.51)

3.5

0.9

20
20

19
19

3.8

0.5

18
18

100.0%
100.0%

-0.30 [-0.76 , 0.16]
-0.30 [-0.76 , 0.16]

3.7

0.9

17
17

100.0%
100.0%

-0.20 [-0.79 , 0.39]
-0.20 [-0.79 , 0.39]

Test for subgroup differences: Chi² = 0.07, df = 1 (P = 0.79), I² = 0%

-20
Favours control

-10

0

10

20
Favours exercise

Analysis 9.9.   Comparison 9: General health perspective, Outcome 9: MDASI-T general activity subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

9.9.1 Up to 12 weeks' follow-up
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 6.61 (P < 0.00001)

-1.58

1.12

0.14

0.19

19
19

21
21

100.0%
100.0%

-1.72 [-2.23 , -1.21]
-1.72 [-2.23 , -1.21]

Test for subgroup differences: Not applicable

-50
Favours exercise

-25

0

25

50
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

301

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 9.10.   Comparison 9: General health perspective,
Outcome 10: MDASI-T general activity subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

9.10.1 Up to 12 weeks' follow-up
1.05
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.64 (P = 0.008)

1.27

Test for subgroup differences: Not applicable

Comparison 10.   Pain

Outcome or subgroup title

2.62

2.38

19
19

21
21

100.0%
100.0%

-1.57 [-2.74 , -0.40]
-1.57 [-2.74 , -0.40]

-50
Favours exercise

-25

0

25

50
Favours control

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

10.1 Overall pain change

10.1.1 Up to 12 weeks' follow-up

10.1.2 More than 12 weeks' to less
than 6 months' follow-up

10.1.3 6 months' follow-up

5

2

1

2

10.2 Overall pain follow-up values

11

10.2.1 Up to 12 weeks' follow-up

10.2.2 More than 12 weeks' to less
than 6 months' follow-up

10.2.3 6 months' follow-up

10.3 QLQ-C30 change

10.3.1 Up to 12 weeks' follow-up

10.4 QLQ-C30 pain follow-up values

10.4.1 Up to 12 weeks' follow-up

10.4.2 More than 12 weeks' to less
than 6 months' follow-up

10.4.3 6 months' follow-up

9

5

1

1

1

6

5

3

1

Std. Mean Difference (IV, Random,
95% CI)

Totals not selected

Std. Mean Difference (IV, Random,
95% CI)

Totals not selected

Std. Mean Difference (IV, Random,
95% CI)

Totals not selected

Std. Mean Difference (IV, Random,
95% CI)

Totals not selected

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.20 [-0.41, 0.00]

Std. Mean Difference (IV, Random,
95% CI)

-0.17 [-0.39, 0.06]

Std. Mean Difference (IV, Random,
95% CI)

-1.05 [-1.83, -0.26]

Mean Difference (IV, Random, 95% CI)

Subtotals only

598

309

29

44

Mean Difference (IV, Random, 95% CI)

3.11 [-15.93, 22.15]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-3.31 [-7.54, 0.92]

Mean Difference (IV, Random, 95% CI)

-7.26 [-15.82, 1.29]

Mean Difference (IV, Random, 95% CI)

-21.20 [-36.86, -5.54]

411

127

29

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

302

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

10.5 MOS SF-36 bodily pain subscale
change

10.5.1 More than 12 weeks' to less
than 6 months' follow-up

10.5.2 6 months' follow-up

10.6 MOS SF-36 bodily pain follow-up
values

10.6.1 Up to 12 weeks' follow-up

10.6.2 More than 12 weeks' to less
than 6 months' follow-up

10.6.3 6 months' follow-up

10.7 Visual Analog Scale follow-up val-
ues

10.7.1 Up to 12 weeks' follow-up

10.8 MDASI-T pain subscale change

10.8.1 Up to 12 weeks' follow-up

10.9 MDASI-T pain subscale follow-up
values

10.9.1 Up to 12 weeks' follow-up

3

1

2

4

3

2

0

1

1

1

1

1

1

126

166

345

182

0

37

40

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-2.41 [-11.29, 6.47]

Mean Difference (IV, Random, 95% CI)

1.43 [-3.53, 6.40]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

2.46 [-2.24, 7.16]

Mean Difference (IV, Random, 95% CI)

-3.13 [-10.11, 3.86]

Mean Difference (IV, Random, 95% CI)

Not estimable

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-4.60 [-18.52, 9.32]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-2.66 [-3.17, -2.15]

Mean Difference (IV, Random, 95% CI)

Subtotals only

40

Mean Difference (IV, Random, 95% CI)

-2.22 [-3.51, -0.93]

Analysis 10.1.   Comparison 10: Pain, Outcome 1: Overall pain change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

10.1.1 Up to 12 weeks' follow-up
2.38
Arbane 2009
1.42
Yang 2011

29
1.14

21
19

-0.73
-1.24

35.35
0.04

23
21

0.09 [-0.50 , 0.69]
3.32 [2.33 , 4.31]

10.1.2 More than 12 weeks' to less than 6 months' follow-up
-2.79
Griffith 2009

27.31

68

-0.38

23.56

58

-0.09 [-0.44 , 0.26]

10.1.3 6 months' follow-up
Cadmus 2009
Segal 2001
Segal 2001

4.9
2.3
0.7

12.1
20.6
22.2

22
40
40

2.9
0.5
0.5

14.2
14.5
14.9

23
20
21

0.15 [-0.44 , 0.73]
0.09 [-0.44 , 0.63]
0.01 [-0.52 , 0.54]

-10
Favours control

-5

0

5

10
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

303

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 10.2.   Comparison 10: Pain, Outcome 2: Overall pain follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

10.2.1 Up to 12 weeks' follow-up
14.6
Adamsen 2009
18.25
Arbane 2009
-75.3
Chandwani 2010
-79.8
Galvao 2010
18.8
Hacker 2011
-25.4
Hwang 2008
23.5
Jarden 2009
32.1
Wiskemann 2011
1.21
Yang 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.03; Chi² = 10.96, df = 8 (P = 0.20); I² = 27%
Test for overall effect: Z = 1.93 (P = 0.05)

16.8
22.46
-80.2
-71.4
35.2
-30
36.3
35.4
3.43

17.1
25.22
28
21.6
20.8
22.3
27
32.8
1.32

118
21
26
29
8
17
17
40
19
295

10.2.2 More than 12 weeks' to less than 6 months' follow-up
-69.9
Chandwani 2010
75
Griffith 2009
11.5
Jarden 2009
21.6
Moros 2010
25
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 3.03, df = 4 (P = 0.55); I² = 0%
Test for overall effect: Z = 1.47 (P = 0.14)

32.7
21.86
13.2
26.1
31.8

27
68
17
10
40
162

-73.2
78.1
20.5
16.6
35.8

20.6
30.41
31.7
21.6
36.8
20.6
28.4
29.3
2.69

36.6
21.38
21.7
16.6
28.9

117
23
27
28
9
20
17
41
21
303

25.9%
9.4%
10.9%
11.4%
4.1%
8.2%
7.5%
14.7%
7.9%
100.0%

-0.12 [-0.37 , 0.14]
-0.15 [-0.74 , 0.45]
0.16 [-0.38 , 0.70]
-0.38 [-0.91 , 0.14]
-0.51 [-1.48 , 0.46]
0.21 [-0.44 , 0.86]
-0.45 [-1.13 , 0.23]
-0.11 [-0.54 , 0.33]
-1.01 [-1.67 , -0.35]
-0.20 [-0.41 , 0.00]

29
58
13
7
40
147

18.4%
41.0%
9.3%
5.4%
25.9%
100.0%

0.09 [-0.43 , 0.62]
-0.14 [-0.49 , 0.21]
-0.50 [-1.24 , 0.23]
0.21 [-0.76 , 1.18]
-0.35 [-0.79 , 0.09]
-0.17 [-0.39 , 0.06]

10.2.3 6 months' follow-up
Jarden 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.60 (P = 0.009)

4.4

9.9

25.6

27.4

16
16

13
13

100.0%
100.0%

-1.05 [-1.83 , -0.26]
-1.05 [-1.83 , -0.26]

Test for subgroup differences: Chi² = 4.46, df = 2 (P = 0.11), I² = 55.2%

-10
Favours exercise

-5

0

5

10
Favours control

Analysis 10.3.   Comparison 10: Pain, Outcome 3: QLQ-C30 change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

10.3.1 Up to 12 weeks' follow-up
2.38
Arbane 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.32 (P = 0.75)

29

Test for subgroup differences: Not applicable

-0.73

35.35

21
21

23
23

100.0%
100.0%

3.11 [-15.93 , 22.15]
3.11 [-15.93 , 22.15]

-100
Favours exercise

-50

0

50

100

Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

304

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 10.4.   Comparison 10: Pain, Outcome 4: QLQ-C30 pain follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

10.4.1 Up to 12 weeks' follow-up
14.6
Adamsen 2009
18.25
Arbane 2009
18.8
Hacker 2011
23.5
Jarden 2009
32.1
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.05, df = 4 (P = 0.73); I² = 0%
Test for overall effect: Z = 1.53 (P = 0.13)

17.1
25.22
20.8
27
32.8

118
21
8
17
40
204

16.8
22.46
35.2
36.3
35.4

10.4.2 More than 12 weeks' to less than 6 months' follow-up
Jarden 2009
Moros 2010
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.74, df = 2 (P = 0.42); I² = 0%
Test for overall effect: Z = 1.66 (P = 0.10)

11.5
21.6
25

13.2
26.1
31.8

17
10
40
67

20.5
16.6
35.8

20.6
30.41
36.8
28.4
29.3

21.7
16.6
28.9

117
23
9
17
41
207

76.2%
6.6%
2.3%
5.2%
9.7%
100.0%

-2.20 [-7.04 , 2.64]
-4.21 [-20.67 , 12.25]
-16.40 [-44.43 , 11.63]
-12.80 [-31.43 , 5.83]
-3.30 [-16.86 , 10.26]
-3.31 [-7.54 , 0.92]

13
7
40
60

41.0%
17.7%
41.3%
100.0%

-9.00 [-22.36 , 4.36]
5.00 [-15.32 , 25.32]
-10.80 [-24.12 , 2.52]
-7.26 [-15.82 , 1.29]

10.4.3 6 months' follow-up
Jarden 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.65 (P = 0.008)

4.4

9.9

25.6

27.4

16
16

13
13

100.0%
100.0%

-21.20 [-36.86 , -5.54]
-21.20 [-36.86 , -5.54]

Test for subgroup differences: Chi² = 4.99, df = 2 (P = 0.08), I² = 59.9%

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 10.5.   Comparison 10: Pain, Outcome 5: MOS SF-36 bodily pain subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

10.5.1 More than 12 weeks' to less than 6 months' follow-up
-2.79
Griffith 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.53 (P = 0.59)

68
68

27.31

-0.38

10.5.2 6 months' follow-up
Cadmus 2009
Segal 2001
Segal 2001
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.09, df = 2 (P = 0.95); I² = 0%
Test for overall effect: Z = 0.57 (P = 0.57)

22
40
40
102

12.1
22.2
20.6

4.9
0.7
2.3

2.9
0.5
0.5

23.56

58
58

100.0%
100.0%

-2.41 [-11.29 , 6.47]
-2.41 [-11.29 , 6.47]

14.2
14.9
14.5

23
21
20
64

41.6%
28.0%
30.4%
100.0%

2.00 [-5.70 , 9.70]
0.20 [-9.18 , 9.58]
1.80 [-7.21 , 10.81]
1.43 [-3.53 , 6.40]

Test for subgroup differences: Chi² = 0.55, df = 1 (P = 0.46), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

305

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 10.6.   Comparison 10: Pain, Outcome 6: MOS SF-36 bodily pain follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

10.6.1 Up to 12 weeks' follow-up
77.6
Adamsen 2009
75.3
Chandwani 2010
79.8
Galvao 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.92, df = 2 (P = 0.38); I² = 0%
Test for overall effect: Z = 1.03 (P = 0.30)

118
26
29
173

20
28
21.6

75.7
80.2
71.4

10.6.2 More than 12 weeks' to less than 6 months' follow-up
Chandwani 2010
Griffith 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.98); I² = 0%
Test for overall effect: Z = 0.88 (P = 0.38)

32.7
21.86

69.9
75

27
68
95

73.2
78.1

22.7
31.7
21.6

117
27
28
172

73.9%
8.5%
17.6%
100.0%

1.90 [-3.57 , 7.37]
-4.90 [-20.99 , 11.19]
8.40 [-2.82 , 19.62]
2.46 [-2.24 , 7.16]

36.6
21.38

29
58
87

14.8%
85.2%
100.0%

-3.30 [-21.45 , 14.85]
-3.10 [-10.67 , 4.47]
-3.13 [-10.11 , 3.86]

10.6.3 6 months' follow-up
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable

0

0

Not estimable

Test for subgroup differences: Chi² = 1.69, df = 1 (P = 0.19), I² = 41.0%

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 10.7.   Comparison 10: Pain, Outcome 7: Visual Analog Scale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

10.7.1 Up to 12 weeks' follow-up
25.4
Hwang 2008
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.65 (P = 0.52)

22.3

Test for subgroup differences: Not applicable

17
17

30

20.6

20
20

100.0%
100.0%

-4.60 [-18.52 , 9.32]
-4.60 [-18.52 , 9.32]

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 10.8.   Comparison 10: Pain, Outcome 8: MDASI-T pain subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

10.8.1 Up to 12 weeks' follow-up
-1.42
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 10.17 (P < 0.00001)

1.14

Test for subgroup differences: Not applicable

1.24

0.04

19
19

21
21

100.0%
100.0%

-2.66 [-3.17 , -2.15]
-2.66 [-3.17 , -2.15]

-50
Favours exercise

-25

0

25

50
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

306

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 10.9.   Comparison 10: Pain, Outcome 9: MDASI-T pain subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

10.9.1 Up to 12 weeks' follow-up
1.21
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.36 (P = 0.0008)

1.32

Test for subgroup differences: Not applicable

3.43

2.69

19
19

21
21

100.0%
100.0%

-2.22 [-3.51 , -0.93]
-2.22 [-3.51 , -0.93]

-50
Favours exercise

-25

0

25

50
Favours control

Comparison 11.   Physical functioning

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

11.1 Overall physical function
change

11

Statistical method

Effect size

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

0.69 [0.16, 1.22]

Std. Mean Difference (IV, Random, 95% CI)

-0.18 [-0.53, 0.17]

Std. Mean Difference (IV, Random, 95% CI)

0.28 [-0.00, 0.55]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

540

126

305

1272

Std. Mean Difference (IV, Random, 95% CI)

0.28 [0.11, 0.45]

368

336

Std. Mean Difference (IV, Random, 95% CI)

0.33 [-0.17, 0.82]

Std. Mean Difference (IV, Random, 95% CI)

0.29 [0.07, 0.50]

Mean Difference (IV, Random, 95% CI)

Subtotals only

167

Mean Difference (IV, Random, 95% CI)

2.31 [0.65, 3.98]

81

Mean Difference (IV, Random, 95% CI)

1.01 [-1.24, 3.25]

Mean Difference (IV, Random, 95% CI)

Subtotals only

539

307

Mean Difference (IV, Random, 95% CI)

0.34 [-0.67, 1.35]

Mean Difference (IV, Random, 95% CI)

1.17 [0.14, 2.19]

Mean Difference (IV, Random, 95% CI)

Subtotals only

11.1.1 Up to 12 weeks' fol-
low-up

11.1.2 More than 12 weeks' to
less than 6 months' follow-up

11.1.3 6 months' follow-up

11.2 Overall physical function
follow-up values

11.2.1 Up to 12 weeks' fol-
low-up

11.2.2 More than 12 weeks' to
less than 6 months' follow-up

11.2.3 6 months' follow-up

11.3 FACT-P subscale change

11.3.1 Up to 12 weeks' fol-
low-up

11.3.2 6 months' follow-up

11.4 FACT-P subscale fol-
low-up values

11.4.1 Up to 12 weeks' fol-
low-up

11.4.2 6 months' follow-up

11.5 FACIT-F change

8

1

4

21

18

6

5

4

3

2

8

7

4

1

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

307

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

11.5.1 Up to 12 weeks' fol-
low-up

11.6 QLQ-C30 Physical sub-
scale change

11.6.1 Up to 12 weeks' fol-
low-up

11.7 QLQ-C30 Physical sub-
scale follow-up values

11.7.1 Up to 12 weeks' fol-
low-up

11.7.2 More than 12 weeks' to
less than 6 months' follow-up

11.7.3 6 months' follow-up

11.8 MOS SF-36 Physical
component score follow-up
values

11.8.1 Up to 12 weeks' fol-
low-up

11.8.2 More than 12 weeks' to
less than 6 months' follow-up

11.8.3 6 months' follow-up

11.9 MOS SF-36 Physical
Functioning subscale change

11.9.1 More than 12 weeks' to
less than 6 months' follow-up

11.9.2 6 months' follow-up

11.10 MOS SF-36 Physical
Functioning subscale fol-
low-up values

11.10.1 Up to 12 weeks' fol-
low-up

11.10.2 More than 12 weeks'
to less than 6 months' fol-
low-up

11.10.3 6 months' follow-up

1

2

2

6

5

3

1

5

5

2

0

3

1

2

5

3

2

1

167

Mean Difference (IV, Random, 95% CI)

-0.40 [-9.67, 8.87]

Mean Difference (IV, Random, 95% CI)

Subtotals only

63

Mean Difference (IV, Random, 95% CI)

5.32 [-0.16, 10.80]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

3.72 [0.61, 6.84]

Mean Difference (IV, Random, 95% CI)

8.01 [0.89, 15.12]

Mean Difference (IV, Random, 95% CI)

12.70 [-1.38, 26.78]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

3.96 [0.99, 6.94]

Mean Difference (IV, Random, 95% CI)

8.60 [-3.38, 20.58]

Mean Difference (IV, Random, 95% CI)

Not estimable

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.40 [-6.43, 5.63]

Mean Difference (IV, Random, 95% CI)

3.60 [-5.64, 12.83]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

4.04 [0.63, 7.46]

Mean Difference (IV, Random, 95% CI)

-0.69 [-8.84, 7.46]

411

127

29

443

115

0

126

166

345

182

45

Mean Difference (IV, Random, 95% CI)

-0.90 [-5.19, 3.39]

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

308

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

11.11 MOS SF-36 role physi-
cal change

11.11.1 More than 12 weeks'
to less than 6 months' fol-
low-up

11.11.2 6 months' follow-up

11.12 MOS SF-36 role physi-
cal follow-up values

11.12.1 Up to 12 weeks' fol-
low-up

11.12.2 More than 12 weeks'
to less than 6 months' fol-
low-up

11.12.3 6 months' follow-up

11.13 LASA change

11.13.1 Up to 12 weeks' fol-
low-up

11.13.2 6 months' follow-up

11.14 WHO BREF physical
subscale follow-up values

11.14.1 Up to 12 weeks' fol-
low-up

11.15 MDASI-T Symptom
Severity change

11.15.1 Up to 12 weeks' fol-
low-up

11.16 MDASI-T Symptom
Severity follow-up values

11.16.1 Up to 12 weeks' fol-
low-up

11.17 QLSI physical health
subscale follow-up values

11.17.1 Up to 12 months' fol-
low-up

3

1

2

5

3

2

1

1

1

1

1

1

1

1

1

1

1

1

Mean Difference (IV, Random, 95% CI)

Subtotals only

126

Mean Difference (IV, Random, 95% CI)

-8.71 [-25.74, 8.32]

166

Mean Difference (IV, Random, 95% CI)

-0.37 [-7.26, 6.52]

Mean Difference (IV, Random, 95% CI)

Subtotals only

345

182

Mean Difference (IV, Random, 95% CI)

11.24 [3.10, 19.39]

Mean Difference (IV, Random, 95% CI)

-6.92 [-28.18, 14.34]

45

Mean Difference (IV, Random, 95% CI)

2.20 [-5.02, 9.42]

103

103

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

3.80 [-5.75, 13.35]

Mean Difference (IV, Random, 95% CI)

-0.60 [-10.19, 8.99]

Mean Difference (IV, Random, 95% CI)

Subtotals only

37

Mean Difference (IV, Random, 95% CI)

2.90 [1.44, 4.36]

Mean Difference (IV, Random, 95% CI)

Subtotals only

40

Mean Difference (IV, Random, 95% CI)

-1.47 [-1.76, -1.18]

Mean Difference (IV, Random, 95% CI)

Subtotals only

40

Mean Difference (IV, Random, 95% CI)

-1.61 [-2.50, -0.72]

Mean Difference (IV, Random, 95% CI)

Subtotals only

64

Mean Difference (IV, Random, 95% CI)

-0.31 [-4.42, 3.80]

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

309

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 11.1.   Comparison 11: Physical functioning, Outcome 1: Overall physical function change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

11.1.1 Up to 12 weeks' follow-up
-16.19
Arbane 2009
4.33
Campbell 2005
2.8
Cheville 2010
2.3
Monga 2007
3.06
Oh 2010
2.3
Rogers 2009
0.88
Targ 2002
0.68
Yang 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.47; Chi² = 53.20, df = 7 (P < 0.00001); I² = 87%
Test for overall effect: Z = 2.55 (P = 0.01)

-14.78
-1.2
-1
-1.3
0.98
2.6
1.28
-0.79

53.52
4.03
25.7
1.8
4
5.1
41.5
0.64

21
10
49
11
54
20
79
19
263

53.33
7.61
23.56
2.1
3.4
6.4
7.1
0.03

23
9
54
10
54
18
88
21
277

13.1%
10.4%
14.4%
9.7%
14.5%
12.8%
14.9%
10.2%
100.0%

-0.03 [-0.62 , 0.57]
0.88 [-0.07 , 1.84]
0.15 [-0.23 , 0.54]
1.77 [0.73 , 2.82]
0.56 [0.17 , 0.94]
-0.05 [-0.69 , 0.59]
-0.01 [-0.32 , 0.29]
3.27 [2.29 , 4.24]
0.69 [0.16 , 1.22]

11.1.2 More than 12 weeks' to less than 6 months' follow-up
-19.49
Griffith 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.99 (P = 0.32)

68
68

51.6

-10.78

11.1.3 6 months' follow-up
Cadmus 2009
Cheville 2010
Rogers 2009
Segal 2001
Segal 2001
Subtotal (95% CI)
Heterogeneity: Tau² = 0.03; Chi² = 5.49, df = 4 (P = 0.24); I² = 27%
Test for overall effect: Z = 1.95 (P = 0.05)

22
49
19
40
40
170

5.6
23.4
5.4
14.1
11.3

1.2
0.9
0.9
-4.1
-4.1

2.3
0.3
1.8
2.2
5.7

45.9

58
58

100.0%
100.0%

-0.18 [-0.53 , 0.17]
-0.18 [-0.53 , 0.17]

4.9
26.26
4.6
15.6
16

23
54
17
20
21
135

17.1%
30.2%
14.4%
19.2%
19.1%
100.0%

0.21 [-0.38 , 0.79]
-0.02 [-0.41 , 0.36]
0.17 [-0.48 , 0.83]
0.43 [-0.12 , 0.97]
0.74 [0.19 , 1.28]
0.28 [-0.00 , 0.55]

Test for subgroup differences: Chi² = 7.96, df = 2 (P = 0.02), I² = 74.9%

-10
Favours control

-5

0

5

10
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

310

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 11.2.   Comparison 11: Physical functioning, Outcome 2: Overall physical function follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

11.2.1 Up to 12 weeks' follow-up
89
Adamsen 2009
96.19
Arbane 2009
44.9
Chandwani 2010
20.3
Courneya 2003a
22.5
Danhauer 2009
49.2
Galvao 2010
85.8
Hacker 2011
15
Hwang 2008
75.3
Jarden 2009
-8.32
Lanctot 2010
19.6
Moadel 2007
26.1
Monga 2007
23.1
Mutrie 2007
23.3
Rogers 2009
47.26
Tang 2010
63.3
Wiskemann 2011
-1.39
Yang 2011
23.2
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.06; Chi² = 33.70, df = 17 (P = 0.009); I² = 50%
Test for overall effect: Z = 3.26 (P = 0.001)

86.4
93.04
44.4
19.36
21.1
44.8
83.7
12.1
63.5
-8.63
19.26
24.2
21.9
25.4
37.43
53.5
-3
23.8

12.4
46.74
14.8
5.14
7.6
7.9
13.1
2.24
17.4
7.47
6.65
3
4.9
4.5
9.78
22.5
0.98
3.3

118
21
26
51
13
29
8
17
17
35
84
11
82
20
36
40
19
28
655

11.2.2 More than 12 weeks' to less than 6 months' follow-up
Chandwani 2010
Griffith 2009
Jarden 2009
Moros 2010
Tang 2010
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.29; Chi² = 24.60, df = 5 (P = 0.0002); I² = 80%
Test for overall effect: Z = 1.29 (P = 0.20)

46.9
39.7
77.1
86.6
50.28
73.7

44.8
53.45
67.7
87.6
35.93
63.5

27
68
17
10
24
40
186

15.1
42.8
18.1
14.7
10.6
19.6

11.2.3 6 months' follow-up
Cadmus 2009
Jarden 2009
Mutrie 2007
Rogers 2009
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.59, df = 4 (P = 0.63); I² = 0%
Test for overall effect: Z = 2.61 (P = 0.009)

22
16
82
19
24
163

23.9
87.1
23.9
23.2
23.6

4.2
13.2
4.3
4.5
3.9

23.5
74.4
22.3
23.5
22

14.5
46.95
16.1
5.11
5.7
9.5
23.1
2.27
22.6
9.02
6.36
2.6
5.1
2.3
13.39
25.1
1.82
3.1

16.2
41.2
23.12
19
11.3
22.2

3.3
23
5.3
5.7
5

117
23
27
45
14
28
9
20
17
29
44
10
92
18
35
41
21
27
617

29
58
13
7
35
40
182

9.7%
4.9%
5.5%
7.3%
3.6%
5.6%
2.5%
3.9%
4.1%
6.1%
7.9%
2.8%
9.0%
4.4%
6.1%
6.8%
4.2%
5.6%
100.0%

17.6%
19.8%
14.9%
12.0%
17.0%
18.7%
100.0%

0.19 [-0.06 , 0.45]
0.07 [-0.53 , 0.66]
0.03 [-0.51 , 0.57]
0.18 [-0.22 , 0.58]
0.20 [-0.55 , 0.96]
0.50 [-0.03 , 1.03]
0.10 [-0.85 , 1.06]
1.26 [0.54 , 1.97]
0.57 [-0.12 , 1.26]
0.04 [-0.45 , 0.53]
0.05 [-0.31 , 0.42]
0.65 [-0.24 , 1.53]
0.24 [-0.06 , 0.54]
-0.57 [-1.22 , 0.08]
0.83 [0.35 , 1.32]
0.41 [-0.03 , 0.85]
1.06 [0.40 , 1.73]
-0.18 [-0.71 , 0.35]
0.28 [0.11 , 0.45]

0.13 [-0.39 , 0.66]
-0.32 [-0.68 , 0.03]
0.45 [-0.28 , 1.18]
-0.06 [-1.02 , 0.91]
1.28 [0.71 , 1.86]
0.48 [0.04 , 0.93]
0.33 [-0.17 , 0.82]

23
13
95
17
25
173

13.6%
8.2%
52.7%
10.9%
14.6%
100.0%

0.10 [-0.48 , 0.69]
0.68 [-0.08 , 1.43]
0.33 [0.03 , 0.63]
-0.06 [-0.71 , 0.60]
0.35 [-0.21 , 0.91]
0.29 [0.07 , 0.50]

Test for subgroup differences: Chi² = 0.03, df = 2 (P = 0.99), I² = 0%

-10
Favours control

-5

0

5

10
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

311

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 11.3.   Comparison 11: Physical functioning, Outcome 3: FACT-P subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

11.3.1 Up to 12 weeks' follow-up
2.3
Monga 2007
3.06
Oh 2010
2.3
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 1.09; Chi² = 4.18, df = 2 (P = 0.12); I² = 52%
Test for overall effect: Z = 2.72 (P = 0.006)

-1.3
0.98
2.6

11
54
20
85

1.8
4
5.1

11.3.2 6 months' follow-up
Cadmus 2009
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.93); I² = 0%
Test for overall effect: Z = 0.88 (P = 0.38)

22
19
41

5.6
5.4

2.3
1.8

1.2
0.9

2.1
3.4
6.4

4.9
4.6

10
54
18
82

39.5%
45.0%
15.5%
100.0%

3.60 [1.92 , 5.28]
2.08 [0.68 , 3.48]
-0.30 [-4.01 , 3.41]
2.31 [0.65 , 3.98]

23
17
40

53.0%
47.0%
100.0%

1.10 [-1.98 , 4.18]
0.90 [-2.37 , 4.17]
1.01 [-1.24 , 3.25]

Test for subgroup differences: Chi² = 0.84, df = 1 (P = 0.36), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 11.4.   Comparison 11: Physical functioning, Outcome 4: FACT-P subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

11.4.1 Up to 12 weeks' follow-up
20.3
Courneya 2003a
22.5
Danhauer 2009
19.6
Moadel 2007
26.1
Monga 2007
23.1
Mutrie 2007
23.3
Rogers 2009
23.2
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.62; Chi² = 9.15, df = 6 (P = 0.17); I² = 34%
Test for overall effect: Z = 0.66 (P = 0.51)

19.36
21.1
19.26
24.2
21.9
25.4
23.8

5.14
7.6
6.65
3
4.9
4.5
3.3

51
13
84
11
82
20
28
289

11.4.2 6 months' follow-up
Cadmus 2009
Mutrie 2007
Rogers 2009
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.66, df = 3 (P = 0.65); I² = 0%
Test for overall effect: Z = 2.23 (P = 0.03)

22
82
19
24
147

23.9
23.9
23.2
23.6

4.2
4.3
4.5
3.9

23.5
22.3
23.5
22

5.11
5.7
6.36
2.6
5.1
2.3
3.1

3.3
5.3
5.7
5

45
14
44
10
92
18
27
250

15.5%
3.6%
12.9%
12.6%
22.3%
13.8%
19.5%
100.0%

0.94 [-1.11 , 2.99]
1.40 [-3.70 , 6.50]
0.34 [-2.02 , 2.70]
1.90 [-0.50 , 4.30]
1.20 [-0.29 , 2.69]
-2.10 [-4.34 , 0.14]
-0.60 [-2.29 , 1.09]
0.34 [-0.67 , 1.35]

23
95
17
25
160

21.5%
52.6%
9.2%
16.8%
100.0%

0.40 [-1.81 , 2.61]
1.60 [0.19 , 3.01]
-0.30 [-3.68 , 3.08]
1.60 [-0.91 , 4.11]
1.17 [0.14 , 2.19]

Test for subgroup differences: Chi² = 1.27, df = 1 (P = 0.26), I² = 21.6%

-50
Favours control

-25

0

25

50
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

312

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 11.5.   Comparison 11: Physical functioning, Outcome 5: FACIT-F change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

11.5.1 Up to 12 weeks' follow-up
0.88
Targ 2002
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.08 (P = 0.93)

41.5

Test for subgroup differences: Not applicable

1.28

7.1

79
79

88
88

100.0%
100.0%

-0.40 [-9.67 , 8.87]
-0.40 [-9.67 , 8.87]

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 11.6.   Comparison 11: Physical functioning, Outcome 6: QLQ-C30 Physical subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

11.6.1 Up to 12 weeks' follow-up
-16.19
Arbane 2009
4.33
Campbell 2005
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.18, df = 1 (P = 0.67); I² = 0%
Test for overall effect: Z = 1.90 (P = 0.06)

53.52
4.03

21
10
31

-14.78
-1.2

53.33
7.61

23
9
32

3.0%
97.0%
100.0%

-1.41 [-33.02 , 30.20]
5.53 [-0.03 , 11.09]
5.32 [-0.16 , 10.80]

Test for subgroup differences: Not applicable

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 11.7.   Comparison 11: Physical functioning, Outcome 7: QLQ-C30 Physical subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

11.7.1 Up to 12 weeks' follow-up
89
Adamsen 2009
96.19
Arbane 2009
85.8
Hacker 2011
75.3
Jarden 2009
63.3
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 3.12, df = 4 (P = 0.54); I² = 0%
Test for overall effect: Z = 2.35 (P = 0.02)

12.4
46.74
13.1
17.4
22.5

118
21
8
17
40
204

86.4
93.04
83.7
63.5
53.5

11.7.2 More than 12 weeks' to less than 6 months' follow-up
Jarden 2009
Moros 2010
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.36, df = 2 (P = 0.51); I² = 0%
Test for overall effect: Z = 2.21 (P = 0.03)

18.1
14.7
19.6

77.1
86.6
73.7

17
10
40
67

67.7
87.6
63.5

14.5
46.95
23.1
22.6
25.1

23.12
19
22.2

117
23
9
17
41
207

81.3%
1.3%
3.1%
5.3%
9.0%
100.0%

2.60 [-0.85 , 6.05]
3.15 [-24.56 , 30.86]
2.10 [-15.51 , 19.71]
11.80 [-1.76 , 25.36]
9.80 [-0.58 , 20.18]
3.72 [0.61 , 6.84]

13
7
40
60

21.8%
18.0%
60.1%
100.0%

9.40 [-5.83 , 24.63]
-1.00 [-17.77 , 15.77]
10.20 [1.02 , 19.38]
8.01 [0.89 , 15.12]

11.7.3 6 months' follow-up
Jarden 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.77 (P = 0.08)

87.1

13.2

74.4

23

16
16

13
13

100.0%
100.0%

12.70 [-1.38 , 26.78]
12.70 [-1.38 , 26.78]

Test for subgroup differences: Chi² = 2.45, df = 2 (P = 0.29), I² = 18.3%

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

313

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 11.8.   Comparison 11: Physical functioning, Outcome
8: MOS SF-36 Physical component score follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

11.8.1 Up to 12 weeks' follow-up
47.4
Adamsen 2009
44.9
Chandwani 2010
44.8
Danhauer 2009
49.2
Galvao 2010
47.26
Tang 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 4.76; Chi² = 7.19, df = 4 (P = 0.13); I² = 44%
Test for overall effect: Z = 2.61 (P = 0.009)

45.1
44.4
42.7
44.8
37.43

118
26
13
29
36
222

6.7
14.8
12.4
7.9
9.78

11.8.2 More than 12 weeks' to less than 6 months' follow-up
Chandwani 2010
Tang 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 62.12; Chi² = 5.81, df = 1 (P = 0.02); I² = 83%
Test for overall effect: Z = 1.41 (P = 0.16)

44.8
35.93

46.9
50.28

15.1
10.6

27
24
51

8.5
16.1
11.8
9.5
13.39

117
27
14
28
35
221

40.1%
10.1%
8.7%
22.8%
18.4%
100.0%

2.30 [0.34 , 4.26]
0.50 [-7.82 , 8.82]
2.10 [-7.05 , 11.25]
4.40 [-0.14 , 8.94]
9.83 [4.36 , 15.30]
3.96 [0.99 , 6.94]

16.2
11.3

29
35
64

46.9%
53.1%
100.0%

2.10 [-6.10 , 10.30]
14.35 [8.69 , 20.01]
8.60 [-3.38 , 20.58]

11.8.3 6 months' follow-up
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable

0

0

Not estimable

Test for subgroup differences: Chi² = 0.54, df = 1 (P = 0.46), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 11.9.   Comparison 11: Physical functioning, Outcome 9: MOS SF-36 Physical Functioning subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

11.9.1 More than 12 weeks' to less than 6 months' follow-up
-7.11
Griffith 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.13 (P = 0.90)

68
68

19.33

-6.71

11.9.2 6 months' follow-up
Cadmus 2009
Segal 2001
Segal 2001
Subtotal (95% CI)
Heterogeneity: Tau² = 54.99; Chi² = 12.26, df = 2 (P = 0.002); I² = 84%
Test for overall effect: Z = 0.76 (P = 0.45)

22
40
40
102

7.4
14.1
11.3

-1.5
2.2
5.7

2.3
-4.1
-4.1

15.19

58
58

100.0%
100.0%

-0.40 [-6.43 , 5.63]
-0.40 [-6.43 , 5.63]

5.7
15.6
16

23
20
21
64

37.7%
30.8%
31.5%
100.0%

-3.80 [-7.67 , 0.07]
6.30 [-1.81 , 14.41]
9.80 [2.11 , 17.49]
3.60 [-5.64 , 12.83]

Test for subgroup differences: Chi² = 0.50, df = 1 (P = 0.48), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

314

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 11.10.   Comparison 11: Physical functioning, Outcome
10: MOS SF-36 Physical Functioning subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

11.10.1 Up to 12 weeks' follow-up
88.2
Adamsen 2009
81.7
Chandwani 2010
82.9
Galvao 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.11, df = 2 (P = 0.95); I² = 0%
Test for overall effect: Z = 2.32 (P = 0.02)

118
26
29
173

13.2
26.5
17.3

84.3
78.9
77.5

11.10.2 More than 12 weeks' to less than 6 months' follow-up
86.2
Chandwani 2010
77.2
Griffith 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 9.58; Chi² = 1.28, df = 1 (P = 0.26); I² = 22%
Test for overall effect: Z = 0.17 (P = 0.87)

26.5
21.87

80
80.4

27
68
95

16.2
29.1
18.7

29.1
20.1

117
27
28
172

81.5%
5.2%
13.3%
100.0%

3.90 [0.12 , 7.68]
2.80 [-12.17 , 17.77]
5.40 [-3.96 , 14.76]
4.04 [0.63 , 7.46]

29
58
87

26.7%
73.3%
100.0%

6.20 [-8.36 , 20.76]
-3.20 [-10.53 , 4.13]
-0.69 [-8.84 , 7.46]

11.10.3 6 months' follow-up
Cadmus 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.41 (P = 0.68)

49.5

8.8

50.4

5.4

22
22

23
23

100.0%
100.0%

-0.90 [-5.19 , 3.39]
-0.90 [-5.19 , 3.39]

Test for subgroup differences: Chi² = 3.54, df = 2 (P = 0.17), I² = 43.5%

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 11.11.   Comparison 11: Physical functioning, Outcome 11: MOS SF-36 role physical change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

11.11.1 More than 12 weeks' to less than 6 months' follow-up
-19.49
Griffith 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.00 (P = 0.32)

68
68

51.6

-10.78

11.11.2 6 months' follow-up
Cadmus 2009
Segal 2001
Segal 2001
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.03, df = 2 (P = 0.60); I² = 0%
Test for overall effect: Z = 0.11 (P = 0.92)

22
40
40
102

5.4
25
11.9

14
45.7
44.7

5.7
18.9
18.9

45.9

58
58

100.0%
100.0%

-8.71 [-25.74 , 8.32]
-8.71 [-25.74 , 8.32]

14.1
26.1
25.4

23
21
20
64

70.4%
14.6%
15.0%
100.0%

-0.30 [-8.51 , 7.91]
6.10 [-11.93 , 24.13]
-7.00 [-24.77 , 10.77]
-0.37 [-7.26 , 6.52]

Test for subgroup differences: Chi² = 0.79, df = 1 (P = 0.37), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

315

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 11.12.   Comparison 11: Physical functioning, Outcome 12: MOS SF-36 role physical follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

11.12.1 Up to 12 weeks' follow-up
46.1
Adamsen 2009
50.8
Chandwani 2010
82.9
Galvao 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.12, df = 2 (P = 0.57); I² = 0%
Test for overall effect: Z = 2.71 (P = 0.007)

118
26
29
173

40.2
56.6
24.6

31.8
48
77.3

11.12.2 More than 12 weeks' to less than 6 months' follow-up
76.8
Chandwani 2010
39.7
Griffith 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 108.16; Chi² = 1.60, df = 1 (P = 0.21); I² = 37%
Test for overall effect: Z = 0.64 (P = 0.52)

66.5
53.45

60.8
42.8

27
68
95

37.6
61.8
35.2

70
41.2

117
27
28
172

67.0%
6.5%
26.5%
100.0%

14.30 [4.35 , 24.25]
2.80 [-29.09 , 34.69]
5.60 [-10.22 , 21.42]
11.24 [3.10 , 19.39]

29
58
87

28.4%
71.6%
100.0%

10.30 [-23.98 , 44.58]
-13.75 [-28.44 , 0.94]
-6.92 [-28.18 , 14.34]

11.12.3 6 months' follow-up
Cadmus 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.60 (P = 0.55)

44.9

11.7

42.7

13

22
22

23
23

100.0%
100.0%

2.20 [-5.02 , 9.42]
2.20 [-5.02 , 9.42]

Test for subgroup differences: Chi² = 4.02, df = 2 (P = 0.13), I² = 50.3%

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 11.13.   Comparison 11: Physical functioning, Outcome 13: LASA change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

11.13.1 Up to 12 weeks' follow-up
2.8
Cheville 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.78 (P = 0.44)

25.7

11.13.2 6 months' follow-up
Cheville 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.12 (P = 0.90)

0.3

23.4

49
49

49
49

-1

23.56

54
54

100.0%
100.0%

3.80 [-5.75 , 13.35]
3.80 [-5.75 , 13.35]

0.9

26.26

54
54

100.0%
100.0%

-0.60 [-10.19 , 8.99]
-0.60 [-10.19 , 8.99]

Test for subgroup differences: Chi² = 0.41, df = 1 (P = 0.52), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 11.14.   Comparison 11: Physical functioning, Outcome 14: WHO BREF physical subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

11.14.1 Up to 12 weeks' follow-up
15
Hwang 2008
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.90 (P < 0.0001)

2.24

Test for subgroup differences: Not applicable

12.1

2.27

17
17

20
20

100.0%
100.0%

2.90 [1.44 , 4.36]
2.90 [1.44 , 4.36]

-100
Favours exercise

-50

0

50

100

Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

316

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 11.15.   Comparison 11: Physical functioning, Outcome 15: MDASI-T Symptom Severity change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

11.15.1 Up to 12 weeks' follow-up
-0.68
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 10.00 (P < 0.00001)

0.64

Test for subgroup differences: Not applicable

0.79

0.03

19
19

21
21

100.0%
100.0%

-1.47 [-1.76 , -1.18]
-1.47 [-1.76 , -1.18]

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 11.16.   Comparison 11: Physical functioning, Outcome 16: MDASI-T Symptom Severity follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

11.16.1 Up to 12 weeks' follow-up
1.39
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.53 (P = 0.0004)

0.98

Test for subgroup differences: Not applicable

19
19

3

1.82

21
21

100.0%
100.0%

-1.61 [-2.50 , -0.72]
-1.61 [-2.50 , -0.72]

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 11.17.   Comparison 11: Physical functioning, Outcome 17: QLSI physical health subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

11.17.1 Up to 12 months' follow-up
Lanctot 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.15 (P = 0.88)

8.32

7.47

8.63

9.02

35
35

29
29

100.0%
100.0%

-0.31 [-4.42 , 3.80]
-0.31 [-4.42 , 3.80]

Test for subgroup differences: Not applicable

-50
Favours exercise

-25

0

25

50
Favours control

Comparison 12.   Role function

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

12.1 Overall role function
change

12.1.1 Up to 12 weeks' fol-
low-up

12.1.2 6 months' follow-up

8

7

2

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

439

Std. Mean Difference (IV, Random, 95% CI)

0.48 [0.07, 0.90]

81

Std. Mean Difference (IV, Random, 95% CI)

0.07 [-0.46, 0.60]

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

317

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

12.2 Overall role function fol-
low-up values

12.2.1 Up to 12 weeks' fol-
low-up

17

15

12.2.2 More than 12 weeks' to
less than 6 months' follow-up

12.2.3 6 months' follow-up

12.3 FACT role function sub-
scale change

12.3.1 Up to 12 weeks' fol-
low-up

12.3.2 6 months' follow-up

12.4 FACT role function sub-
scale follow-up values

12.4.1 Up to 12 weeks' fol-
low-up

12.4.2 More than 12 weeks' to
less than 6 months' follow-up

12.4.3 6 months' follow-up

12.5 QLQ-C30 change

12.5.1 Up to 12 weeks' fol-
low-up

12.6 QLQ-C30 function sub-
scale follow-up values

12.6.1 Up to 12 weeks' fol-
low-up

12.6.2 More than 12 weeks' to
less than 6 months' follow-up

12.6.3 6 months' follow-up

12.7 FACIT function subscale
change

12.7.1 Up to 12 weeks' fol-
low-up

12.8 WHO BREF environmental
subscale follow-up values

3

5

5

4

2

9

8

1

5

1

1

5

4

3

1

1

1

1

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

1100

Std. Mean Difference (IV, Random, 95% CI)

0.17 [0.00, 0.34]

127

336

Std. Mean Difference (IV, Random, 95% CI)

0.32 [-0.37, 1.00]

Std. Mean Difference (IV, Random, 95% CI)

0.32 [0.03, 0.61]

Mean Difference (IV, Random, 95% CI)

Subtotals only

188

Mean Difference (IV, Random, 95% CI)

2.25 [-0.16, 4.66]

81

Mean Difference (IV, Random, 95% CI)

0.43 [-1.76, 2.62]

Mean Difference (IV, Random, 95% CI)

Subtotals only

573

Mean Difference (IV, Random, 95% CI)

1.41 [-0.03, 2.86]

30

Mean Difference (IV, Random, 95% CI)

6.00 [1.96, 10.04]

336

Mean Difference (IV, Random, 95% CI)

1.53 [0.15, 2.91]

Mean Difference (IV, Random, 95% CI)

Subtotals only

44

Mean Difference (IV, Random, 95% CI)

2.03 [-20.58, 24.64]

367

127

29

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

4.90 [-0.88, 10.67]

Mean Difference (IV, Random, 95% CI)

12.82 [-12.71, 38.36]

Mean Difference (IV, Random, 95% CI)

26.70 [4.32, 49.08]

Mean Difference (IV, Random, 95% CI)

Subtotals only

167

Mean Difference (IV, Random, 95% CI)

0.34 [-1.44, 2.12]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

318

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

12.8.1 Up to 12 weeks' fol-
low-up

12.9 Ferrans and Power family
subscale follow-up values

12.9.1 Up to 12 weeks' fol-
low-up

12.10 Symptom Checklist 90 R
interpersonal sensitivity sub-
scale follow-up values

12.10.1 Up to 12 weeks' fol-
low-up

12.11 MDASI-T relations with
other people subscale change

12.11.1 Up to 12 weeks' fol-
low-up

12.12 MDASI-T relations with
other people subscale fol-
low-up values

12.12.1 Up to 12 weeks' fol-
low-up

12.13 MDASI-T work subscale
change

12.13.1 Up to 12 weeks' fol-
low-up

12.14 MDASI-T work subscale
follow-up values

12.14.1 Up to 12 weeks' fol-
low-up

12.15 QLSI marital life subscale
follow-up values

12.15.1 Up to 12 weeks' fol-
low-up

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

37

Mean Difference (IV, Random, 95% CI)

-0.18 [-2.07, 1.71]

Mean Difference (IV, Random, 95% CI)

Subtotals only

17

Mean Difference (IV, Random, 95% CI)

-0.40 [-2.45, 1.65]

Mean Difference (IV, Random, 95% CI)

Subtotals only

59

Mean Difference (IV, Random, 95% CI)

-0.20 [-1.07, 0.67]

Mean Difference (IV, Random, 95% CI)

Subtotals only

40

Mean Difference (IV, Random, 95% CI)

-2.01 [-3.02, -1.00]

Mean Difference (IV, Random, 95% CI)

Subtotals only

40

Mean Difference (IV, Random, 95% CI)

-1.52 [-2.63, -0.41]

Mean Difference (IV, Random, 95% CI)

Subtotals only

40

Mean Difference (IV, Random, 95% CI)

-2.28 [-2.87, -1.69]

Mean Difference (IV, Random, 95% CI)

Subtotals only

40

Mean Difference (IV, Random, 95% CI)

-1.54 [-2.58, -0.50]

Mean Difference (IV, Random, 95% CI)

Subtotals only

58

Mean Difference (IV, Random, 95% CI)

3.64 [-1.41, 8.69]

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

319

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.1.   Comparison 12: Role function, Outcome 1: Overall role function change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

12.1.1 Up to 12 weeks' follow-up
-1.59
Arbane 2009
3.67
Campbell 2005
1.8
Monga 2007
2.46
Oh 2010
0.4
Rogers 2009
2.17
Targ 2002
1.63
Yang 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.22; Chi² = 23.07, df = 6 (P = 0.0008); I² = 74%
Test for overall effect: Z = 2.26 (P = 0.02)

35.71
5.24
4.2
3.5
3.3
5.1
2.25

-3.62
-1.5
-2.3
-0.13
1.4
1.83
-0.38

21
10
11
54
20
79
19
214

12.1.2 6 months' follow-up
Cadmus 2009
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.05; Chi² = 1.46, df = 1 (P = 0.23); I² = 31%
Test for overall effect: Z = 0.25 (P = 0.80)

6.9
2.99

22
19
41

1.6
-0.2

0.6
1.1

40.81
6
4.2
2.8
4.3
6.6
0.18

23
9
10
54
20
88
21
225

14.8%
10.1%
10.5%
17.8%
14.4%
19.0%
13.5%
100.0%

0.05 [-0.54 , 0.64]
0.88 [-0.07 , 1.83]
0.94 [0.02 , 1.85]
0.81 [0.42 , 1.20]
-0.26 [-0.88 , 0.37]
0.06 [-0.25 , 0.36]
1.27 [0.58 , 1.95]
0.48 [0.07 , 0.90]

3.5
4

23
17
40

54.1%
45.9%
100.0%

-0.18 [-0.77 , 0.40]
0.36 [-0.30 , 1.02]
0.07 [-0.46 , 0.60]

Test for subgroup differences: Chi² = 1.45, df = 1 (P = 0.23), I² = 30.9%

-20
Favours control

-10

0

10

20
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

320

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.2.   Comparison 12: Role function, Outcome 2: Overall role function follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

12.2.1 Up to 12 weeks' follow-up
74.8
Adamsen 2009
16.58
Courneya 2003a
21.9
Danhauer 2009
1.3
Dimeo 1999
75
Hacker 2011
11.82
Hwang 2008
16.8
Jarden 2009
-8.62
Lanctot 2010
17.45
Moadel 2007
24.8
Monga 2007
14.6
Mutrie 2007
21.4
Rogers 2009
31.7
Wiskemann 2011
-0.53
Yang 2011
19.2
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.04; Chi² = 23.72, df = 14 (P = 0.05); I² = 41%
Test for overall effect: Z = 1.97 (P = 0.05)

68.9
16.39
17.4
1.5
70.4
12
11.3
-4.98
15.68
22.4
13.1
23.8
33.3
-2.05
18

26.3
5.3
4.7
1.5
17.8
3.38
6.5
11.95
6.86
6
4.6
4.8
29.4
1.12
4.5

118
51
13
27
8
17
17
36
84
11
82
20
40
19
28
571

12.2.2 More than 12 weeks' to less than 6 months' follow-up
Jarden 2009
Moros 2010
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.23; Chi² = 5.58, df = 2 (P = 0.06); I² = 64%
Test for overall effect: Z = 0.91 (P = 0.36)

5.3
19.3
28.5

12.8
80.9
43.8

18.8
78.3
45

17
10
40
67

12.2.3 6 months' follow-up
Cadmus 2009
Jarden 2009
Mutrie 2007
Rogers 2009
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.03; Chi² = 5.86, df = 4 (P = 0.21); I² = 32%
Test for overall effect: Z = 2.18 (P = 0.03)

22
16
82
19
24
163

21.9
16
13.6
22.4
17.2

21.4
19.8
15.8
21.9
19.6

5.4
5.4
4.2
4.7
3.5

26.5
5.45
7.5
1.9
35.1
2.29
4
7.67
6.56
4.3
5
3.2
34.8
2.31
5.2

5.8
24
33

3.4
6
5.1
5.4
4.8

117
45
14
32
9
20
17
22
44
10
92
18
41
21
27
529

12.8%
9.0%
3.7%
6.8%
2.7%
5.0%
4.3%
6.5%
9.8%
3.1%
11.6%
4.9%
8.2%
5.0%
6.5%
100.0%

0.22 [-0.03 , 0.48]
0.04 [-0.37 , 0.44]
0.69 [-0.09 , 1.47]
-0.11 [-0.63 , 0.40]
0.15 [-0.80 , 1.11]
-0.06 [-0.71 , 0.58]
1.00 [0.28 , 1.71]
-0.34 [-0.87 , 0.19]
0.26 [-0.11 , 0.63]
0.44 [-0.43 , 1.31]
0.31 [0.01 , 0.61]
-0.57 [-1.22 , 0.08]
-0.05 [-0.48 , 0.39]
0.81 [0.16 , 1.46]
0.24 [-0.29 , 0.77]
0.17 [0.00 , 0.34]

13
7
40
60

31.3%
25.6%
43.2%
100.0%

1.06 [0.28 , 1.83]
-0.12 [-1.08 , 0.85]
0.04 [-0.40 , 0.48]
0.32 [-0.37 , 1.00]

23
13
95
17
25
173

17.6%
11.9%
37.6%
14.8%
18.1%
100.0%

-0.11 [-0.69 , 0.48]
0.65 [-0.10 , 1.40]
0.47 [0.17 , 0.77]
-0.10 [-0.75 , 0.56]
0.56 [-0.01 , 1.13]
0.32 [0.03 , 0.61]

Test for subgroup differences: Chi² = 0.87, df = 2 (P = 0.65), I² = 0%

-20
Favours control

-10

0

10

20
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

321

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.3.   Comparison 12: Role function, Outcome 3: FACT role function subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

12.3.1 Up to 12 weeks' follow-up
3.67
Campbell 2005
1.8
Monga 2007
2.46
Oh 2010
0.4
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 3.82; Chi² = 9.76, df = 3 (P = 0.02); I² = 69%
Test for overall effect: Z = 1.83 (P = 0.07)

-1.5
-2.3
-0.13
1.4

5.24
4.2
3.5
3.3

10
11
54
20
95

12.3.2 6 months' follow-up
Cadmus 2009
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.59; Chi² = 1.29, df = 1 (P = 0.26); I² = 22%
Test for overall effect: Z = 0.38 (P = 0.70)

6.9
2.99

22
19
41

1.6
-0.2

0.6
1.1

6
4.2
2.8
4.3

3.5
4

9
10
54
20
93

14.3%
21.0%
36.1%
28.6%
100.0%

5.17 [0.08 , 10.26]
4.10 [0.50 , 7.70]
2.59 [1.39 , 3.79]
-1.00 [-3.38 , 1.38]
2.25 [-0.16 , 4.66]

23
17
40

37.9%
62.1%
100.0%

-1.00 [-4.22 , 2.22]
1.30 [-1.03 , 3.63]
0.43 [-1.76 , 2.62]

Test for subgroup differences: Chi² = 1.20, df = 1 (P = 0.27), I² = 16.9%

-50
Favours control

-25

0

25

50
Favours exercise

Analysis 12.4.   Comparison 12: Role function, Outcome 4: FACT role function subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

12.4.1 Up to 12 weeks' follow-up
16.58
Courneya 2003a
21.9
Danhauer 2009
16.8
Jarden 2009
17.45
Moadel 2007
24.8
Monga 2007
14.6
Mutrie 2007
21.4
Rogers 2009
19.2
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 2.26; Chi² = 16.34, df = 7 (P = 0.02); I² = 57%
Test for overall effect: Z = 1.92 (P = 0.05)

16.39
17.4
11.3
15.68
22.4
13.1
23.8
18

5.3
4.7
6.5
6.86
6
4.6
4.8
4.5

51
13
17
84
11
82
20
28
306

12.4.2 More than 12 weeks' to less than 6 months' follow-up
Jarden 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.91 (P = 0.004)

17
17

18.8

5.3

12.8

12.4.3 6 months' follow-up
Cadmus 2009
Jarden 2009
Mutrie 2007
Rogers 2009
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.85; Chi² = 6.14, df = 4 (P = 0.19); I² = 35%
Test for overall effect: Z = 2.17 (P = 0.03)

22
16
82
19
24
163

21.4
19.8
15.8
21.9
19.6

21.9
16
13.6
22.4
17.2

5.4
5.4
4.2
4.7
3.5

5.45
7.5
4
6.56
4.3
5
3.2
5.2

5.8

3.4
6
5.1
5.4
4.8

45
14
17
44
10
92
18
27
267

15.6%
6.8%
9.5%
14.2%
7.3%
19.4%
13.6%
13.6%
100.0%

0.19 [-1.97 , 2.35]
4.50 [-0.19 , 9.19]
5.50 [1.87 , 9.13]
1.77 [-0.66 , 4.20]
2.40 [-2.04 , 6.84]
1.50 [0.07 , 2.93]
-2.40 [-4.97 , 0.17]
1.20 [-1.37 , 3.77]
1.41 [-0.03 , 2.86]

13
13

100.0%
100.0%

6.00 [1.96 , 10.04]
6.00 [1.96 , 10.04]

23
13
95
17
25
173

18.6%
9.1%
37.2%
13.3%
21.8%
100.0%

-0.50 [-3.15 , 2.15]
3.80 [-0.40 , 8.00]
2.20 [0.83 , 3.57]
-0.50 [-3.82 , 2.82]
2.40 [0.05 , 4.75]
1.53 [0.15 , 2.91]

Test for subgroup differences: Chi² = 4.57, df = 2 (P = 0.10), I² = 56.2%

-50
Favours control

-25

0

25

50
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

322

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.5.   Comparison 12: Role function, Outcome 5: QLQ-C30 change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

12.5.1 Up to 12 weeks' follow-up
-1.59
Arbane 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.18 (P = 0.86)

35.71

Test for subgroup differences: Not applicable

-3.62

40.81

21
21

23
23

100.0%
100.0%

2.03 [-20.58 , 24.64]
2.03 [-20.58 , 24.64]

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 12.6.   Comparison 12: Role function, Outcome 6: QLQ-C30 function subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

12.6.1 Up to 12 weeks' follow-up
74.8
Adamsen 2009
75
Hacker 2011
52
Jarden 2009
31.7
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.26, df = 3 (P = 0.74); I² = 0%
Test for overall effect: Z = 1.66 (P = 0.10)

118
8
17
40
183

26.3
17.8
35.3
29.4

68.9
70.4
39.2
33.3

12.6.2 More than 12 weeks' to less than 6 months' follow-up
Jarden 2009
Moros 2010
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 414.89; Chi² = 11.16, df = 2 (P = 0.004); I² = 82%
Test for overall effect: Z = 0.98 (P = 0.33)

24.3
19.3
28.5

74
78.3
45

32.1
80.9
43.8

17
10
40
67

26.5
35.1
42.5
34.8

34
24
33

117
9
17
41
184

73.2%
4.9%
4.8%
17.0%
100.0%

5.90 [-0.85 , 12.65]
4.60 [-21.44 , 30.64]
12.80 [-13.46 , 39.06]
-1.60 [-15.62 , 12.42]
4.90 [-0.88 , 10.67]

13
7
40
60

31.5%
31.8%
36.7%
100.0%

41.90 [20.10 , 63.70]
-2.60 [-24.03 , 18.83]
1.20 [-12.31 , 14.71]
12.82 [-12.71 , 38.36]

12.6.3 6 months' follow-up
Jarden 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.34 (P = 0.02)

76.7

27.3

16
16

50

33

13
13

100.0%
100.0%

26.70 [4.32 , 49.08]
26.70 [4.32 , 49.08]

Test for subgroup differences: Chi² = 3.66, df = 2 (P = 0.16), I² = 45.4%

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 12.7.   Comparison 12: Role function, Outcome 7: FACIT function subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

12.7.1 Up to 12 weeks' follow-up
2.17
Targ 2002
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.37 (P = 0.71)

5.1

Test for subgroup differences: Not applicable

1.83

6.6

79
79

88
88

100.0%
100.0%

0.34 [-1.44 , 2.12]
0.34 [-1.44 , 2.12]

-100
Favours exercise

-50

0

50

100

Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

323

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.8.   Comparison 12: Role function, Outcome 8: WHO BREF environmental subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

12.8.1 Up to 12 weeks' follow-up
11.82
Hwang 2008
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.19 (P = 0.85)

3.38

Test for subgroup differences: Not applicable

17
17

12

2.29

20
20

100.0%
100.0%

-0.18 [-2.07 , 1.71]
-0.18 [-2.07 , 1.71]

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 12.9.   Comparison 12: Role function, Outcome 9: Ferrans and Power family subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

12.9.1 Up to 12 weeks' follow-up
26.4
Hacker 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.38 (P = 0.70)

2.1

Test for subgroup differences: Not applicable

26.8

2.2

8
8

9
9

100.0%
100.0%

-0.40 [-2.45 , 1.65]
-0.40 [-2.45 , 1.65]

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 12.10.   Comparison 12: Role function, Outcome 10: Symptom
Checklist 90 R interpersonal sensitivity subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

12.10.1 Up to 12 weeks' follow-up
1.3
Dimeo 1999
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.45 (P = 0.65)

1.5

Test for subgroup differences: Not applicable

1.5

1.9

27
27

32
32

100.0%
100.0%

-0.20 [-1.07 , 0.67]
-0.20 [-1.07 , 0.67]

-50
Favours control

-25

0

25

50
Favours exercise

Analysis 12.11.   Comparison 12: Role function, Outcome 11: MDASI-T relations with other people subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

12.11.1 Up to 12 weeks' follow-up
-1.63
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.88 (P = 0.0001)

2.25

Test for subgroup differences: Not applicable

0.38

0.18

19
19

21
21

100.0%
100.0%

-2.01 [-3.02 , -1.00]
-2.01 [-3.02 , -1.00]

-50
Favours exercise

-25

0

25

50
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

324

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.12.   Comparison 12: Role function, Outcome 12:
MDASI-T relations with other people subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

12.12.1 Up to 12 weeks' follow-up
0.53
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.69 (P = 0.007)

1.12

Test for subgroup differences: Not applicable

2.05

2.31

19
19

21
21

100.0%
100.0%

-1.52 [-2.63 , -0.41]
-1.52 [-2.63 , -0.41]

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 12.13.   Comparison 12: Role function, Outcome 13: MDASI-T work subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

12.13.1 Up to 12 weeks' follow-up
-1.95
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 7.63 (P < 0.00001)

1.24

Test for subgroup differences: Not applicable

0.33

0.42

19
19

21
21

100.0%
100.0%

-2.28 [-2.87 , -1.69]
-2.28 [-2.87 , -1.69]

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 12.14.   Comparison 12: Role function, Outcome 14: MDASI-T work subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

12.14.1 Up to 12 weeks' follow-up
0.89
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.89 (P = 0.004)

1.24

Test for subgroup differences: Not applicable

2.43

2.06

19
19

21
21

100.0%
100.0%

-1.54 [-2.58 , -0.50]
-1.54 [-2.58 , -0.50]

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 12.15.   Comparison 12: Role function, Outcome 15: QLSI marital life subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

12.15.1 Up to 12 weeks' follow-up
8.62
Lanctot 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.41 (P = 0.16)

11.95

Test for subgroup differences: Not applicable

4.98

7.67

36
36

22
22

100.0%
100.0%

3.64 [-1.41 , 8.69]
3.64 [-1.41 , 8.69]

-50
Favours exercise

-25

0

25

50
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

325

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 13.   Sleep

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

13.1 Overall sleep change

13.1.1 Up to 12 weeks' follow-up

13.1.2 6 months' follow-up

13.2 Overall sleep follow-up values

13.2.1 Up to 12 weeks' follow-up

13.2.2 More than 12 weeks' to less than
6 months' follow-up

13.2.3 6 months' follow-up

13.3 Pittsburgh Sleep Quality Index
change

13.3.1 Up to 12 weeks' follow-up

13.3.2 6 months' follow-up

13.4 Pittsburgh Sleep Quality Index fol-
low-up values

13.4.1 Up to 12 weeks' follow-up

13.4.2 More than 12 weeks' to less than
6 months' follow-up

13.5 QLQ-C30 insomnia subscale
change

13.5.1 Up to 12 weeks' follow-up

13.6 QLQ-C30 insomnia subscale fol-
low-up values

13.6.1 Up to 12 weeks' follow-up

13.6.2 More than 12 weeks' to less than
6 months' follow-up

13.6.3 6 months' follow-up

3

3

1

12

12

4

1

1

1

1

7

7

2

1

1

4

4

2

1

122

36

650

225

29

38

36

434

115

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.55 [-1.95, 0.85]

Std. Mean Difference (IV, Random, 95%
CI)

-0.11 [-0.76, 0.55]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.40 [-0.67, -0.14]

Std. Mean Difference (IV, Random, 95%
CI)

-0.36 [-0.86, 0.14]

Std. Mean Difference (IV, Random, 95%
CI)

-0.69 [-1.45, 0.07]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

0.15 [-2.21, 2.51]

Mean Difference (IV, Random, 95% CI)

-0.26 [-1.75, 1.23]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-1.67 [-2.88, -0.46]

Mean Difference (IV, Random, 95% CI)

-1.73 [-5.18, 1.71]

Mean Difference (IV, Random, 95% CI)

Subtotals only

44

Mean Difference (IV, Random, 95% CI)

11.52 [-6.51, 29.55]

Mean Difference (IV, Random, 95% CI)

Subtotals only

176

110

29

Mean Difference (IV, Random, 95% CI)

-5.68 [-15.99, 4.63]

Mean Difference (IV, Random, 95% CI)

-5.48 [-16.82, 5.86]

Mean Difference (IV, Random, 95% CI)

-17.50 [-36.67, 1.67]

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

326

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

13.7 MDASI-T disturbed sleep subscale
change

13.7.1 Up to 12 weeks' follow-up

13.8 MDASI-T disturbed sleep subscale
follow-up values

13.8.1 Up to 12 weeks' follow-up

1

1

1

1

Mean Difference (IV, Random, 95% CI)

Subtotals only

40

Mean Difference (IV, Random, 95% CI)

-0.83 [-1.06, -0.60]

Mean Difference (IV, Random, 95% CI)

Subtotals only

40

Mean Difference (IV, Random, 95% CI)

-2.14 [-3.85, -0.43]

Analysis 13.1.   Comparison 13: Sleep, Outcome 1: Overall sleep change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

13.1.1 Up to 12 weeks' follow-up
15.87
Arbane 2009
0.45
Rogers 2009
-0.26
Yang 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 1.41; Chi² = 26.17, df = 2 (P < 0.00001); I² = 92%
Test for overall effect: Z = 0.77 (P = 0.44)

27.12
2.1
0.02

4.35
0.3
0.57

21
20
19
60

33.79
4.7
0.53

23
18
21
62

33.9%
33.6%
32.4%
100.0%

0.37 [-0.23 , 0.96]
0.04 [-0.60 , 0.68]
-2.11 [-2.90 , -1.32]
-0.55 [-1.95 , 0.85]

13.1.2 6 months' follow-up
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.33 (P = 0.74)

-0.2

2.7

0.06

1.8

19
19

17
17

100.0%
100.0%

-0.11 [-0.76 , 0.55]
-0.11 [-0.76 , 0.55]

Test for subgroup differences: Chi² = 0.31, df = 1 (P = 0.58), I² = 0%

-20
Favours exercise

-10

0

10

20
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

327

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 13.2.   Comparison 13: Sleep, Outcome 2: Overall sleep follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

13.2.1 Up to 12 weeks' follow-up
19.05
Arbane 2009
8.1
Chandwani 2010
5.8
Cohen 2004
6.1
Danhauer 2009
6.88
Donnelly 2011
25
Hacker 2011
21.6
Jarden 2009
6.7
Rogers 2009
10.67
Tang 2010
7.5
Wang 2010
51.7
Wiskemann 2011
2
Yang 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.12; Chi² = 25.89, df = 11 (P = 0.007); I² = 58%
Test for overall effect: Z = 2.97 (P = 0.003)

27.02
4.1
2.3
4.3
3.96
23.6
26.2
4.2
3.23
3.2
36.9
2.03

29
7.6
8.1
7
10.06
18.5
41.2
5.5
13.09
10.94
52.5
4.14

21
26
16
123
16
8
17
20
36
35
40
19
377

13.2.2 More than 12 weeks' to less than 6 months' follow-up
Chandwani 2010
Jarden 2009
Tang 2010
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.18; Chi² = 10.05, df = 3 (P = 0.02); I² = 70%
Test for overall effect: Z = 1.40 (P = 0.16)

7.1
23.1
13.11
35.8

27
17
24
40
108

4.7
24.3
3.06
32.4

7.3
16.7
9.78
30.8

32.26
4.7
2.4
4.2
4.75
17.6
32.3
4
2.74
3.62
33.7
3.37

5.4
28.5
2.89
31.5

23
27
14
14
17
9
17
18
35
37
41
21
273

8.5%
9.3%
6.7%
9.1%
7.3%
5.1%
7.4%
8.0%
10.0%
9.9%
10.7%
8.0%
100.0%

-0.33 [-0.92 , 0.27]
0.11 [-0.43 , 0.65]
-0.95 [-1.72 , -0.19]
-0.21 [-0.76 , 0.34]
-0.71 [-1.41 , -0.00]
0.30 [-0.66 , 1.26]
-0.65 [-1.34 , 0.04]
0.29 [-0.35 , 0.93]
-0.80 [-1.28 , -0.31]
-0.99 [-1.49 , -0.50]
-0.02 [-0.46 , 0.41]
-0.74 [-1.39 , -0.10]
-0.40 [-0.67 , -0.14]

29
13
35
40
117

26.0%
20.7%
25.0%
28.4%
100.0%

0.04 [-0.49 , 0.56]
-0.24 [-0.96 , 0.49]
-1.11 [-1.67 , -0.55]
-0.15 [-0.59 , 0.28]
-0.36 [-0.86 , 0.14]

13.2.3 6 months' follow-up
Jarden 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.79 (P = 0.07)

13.3

16.9

30.8

31.8

16
16

13
13

100.0%
100.0%

-0.69 [-1.45 , 0.07]
-0.69 [-1.45 , 0.07]

Test for subgroup differences: Chi² = 0.56, df = 2 (P = 0.76), I² = 0%

-20
Favours exercise

-10

0

10

20
Favours control

Analysis 13.3.   Comparison 13: Sleep, Outcome 3: Pittsburgh Sleep Quality Index change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

13.3.1 Up to 12 weeks' follow-up
0.45
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.12 (P = 0.90)

2.1

13.3.2 6 months' follow-up
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.34 (P = 0.73)

-0.2

2.7

20
20

19
19

0.3

4.7

18
18

100.0%
100.0%

0.15 [-2.21 , 2.51]
0.15 [-2.21 , 2.51]

0.06

1.8

17
17

100.0%
100.0%

-0.26 [-1.75 , 1.23]
-0.26 [-1.75 , 1.23]

Test for subgroup differences: Chi² = 0.08, df = 1 (P = 0.77), I² = 0%

-100
Favours exercise

-50

0

50

100

Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

328

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 13.4.   Comparison 13: Sleep, Outcome 4: Pittsburgh Sleep Quality Index follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

13.4.1 Up to 12 weeks' follow-up
8.1
Chandwani 2010
5.8
Cohen 2004
6.1
Danhauer 2009
6.88
Donnelly 2011
6.7
Rogers 2009
10.67
Tang 2010
7.5
Wang 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 1.54; Chi² = 15.17, df = 6 (P = 0.02); I² = 60%
Test for overall effect: Z = 2.70 (P = 0.007)

7.6
8.1
7
10.06
5.5
13.09
10.94

4.1
2.3
4.3
3.96
4.2
3.23
3.2

26
16
123
16
20
36
35
272

13.4.2 More than 12 weeks' to less than 6 months' follow-up
Chandwani 2010
Tang 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 5.00; Chi² = 5.08, df = 1 (P = 0.02); I² = 80%
Test for overall effect: Z = 0.99 (P = 0.32)

7.1
13.11

7.3
9.78

4.7
3.06

27
24
51

4.7
2.4
4.2
4.75
4
2.74
3.62

5.4
2.89

27
14
14
17
18
35
37
162

12.7%
16.7%
12.9%
9.9%
11.5%
18.7%
17.5%
100.0%

0.50 [-1.87 , 2.87]
-2.30 [-3.99 , -0.61]
-0.90 [-3.23 , 1.43]
-3.18 [-6.16 , -0.20]
1.20 [-1.41 , 3.81]
-2.42 [-3.81 , -1.03]
-3.44 [-5.02 , -1.86]
-1.67 [-2.88 , -0.46]

29
35
64

45.2%
54.8%
100.0%

0.20 [-2.45 , 2.85]
-3.33 [-4.88 , -1.78]
-1.73 [-5.18 , 1.71]

Test for subgroup differences: Chi² = 0.00, df = 1 (P = 0.97), I² = 0%

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 13.5.   Comparison 13: Sleep, Outcome 5: QLQ-C30 insomnia subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

13.5.1 Up to 12 weeks' follow-up
15.87
Arbane 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.25 (P = 0.21)

27.12

Test for subgroup differences: Not applicable

4.35

33.79

21
21

23
23

100.0%
100.0%

11.52 [-6.51 , 29.55]
11.52 [-6.51 , 29.55]

-100
Favours exercise

-50

0

50

100

Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

329

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 13.6.   Comparison 13: Sleep, Outcome 6: QLQ-C30 insomnia subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

13.6.1 Up to 12 weeks' follow-up
19.05
Arbane 2009
25
Hacker 2011
21.6
Jarden 2009
51.7
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 26.56; Chi² = 3.94, df = 3 (P = 0.27); I² = 24%
Test for overall effect: Z = 1.08 (P = 0.28)

27.02
23.6
26.2
36.9

29
18.5
41.2
52.5

21
8
17
40
86

13.6.2 More than 12 weeks' to less than 6 months' follow-up
Jarden 2009
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.91); I² = 0%
Test for overall effect: Z = 0.95 (P = 0.34)

16.7
30.8

24.3
32.4

17
40
57

23.1
35.8

32.26
17.6
32.3
33.7

23
9
17
41
90

25.9%
21.2%
21.6%
31.3%
100.0%

-9.95 [-27.48 , 7.58]
6.50 [-13.49 , 26.49]
-19.60 [-39.37 , 0.17]
-0.80 [-16.20 , 14.60]
-5.68 [-15.99 , 4.63]

28.5
31.5

13
40
53

34.4%
65.6%
100.0%

-6.40 [-25.72 , 12.92]
-5.00 [-19.00 , 9.00]
-5.48 [-16.82 , 5.86]

13.6.3 6 months' follow-up
Jarden 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.79 (P = 0.07)

13.3

16.9

30.8

31.8

16
16

13
13

100.0%
100.0%

-17.50 [-36.67 , 1.67]
-17.50 [-36.67 , 1.67]

Test for subgroup differences: Chi² = 1.28, df = 2 (P = 0.53), I² = 0%

-100
Favours exercise

-50

0

50

100

Favours control

Analysis 13.7.   Comparison 13: Sleep, Outcome 7: MDASI-T disturbed sleep subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

13.7.1 Up to 12 weeks' follow-up
-0.26
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 7.17 (P < 0.00001)

0.02

Test for subgroup differences: Not applicable

0.57

0.53

19
19

21
21

100.0%
100.0%

-0.83 [-1.06 , -0.60]
-0.83 [-1.06 , -0.60]

-50
Favours exercise

-25

0

25

50
Favours control

Analysis 13.8.   Comparison 13: Sleep, Outcome 8: MDASI-T disturbed sleep subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

13.8.1 Up to 12 weeks' follow-up
2
Yang 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.46 (P = 0.01)

2.03

Test for subgroup differences: Not applicable

4.14

3.37

19
19

21
21

100.0%
100.0%

-2.14 [-3.85 , -0.43]
-2.14 [-3.85 , -0.43]

-50
Favours exercise

-25

0

25

50
Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

330

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Comparison 14.   Social functioning

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Cochrane Database of Systematic Reviews

Statistical method

Effect size

14.1 Overall social functioning
change

14.1.1 Up to 12 weeks' fol-
low-up

14.1.2 6 months' follow-up

14.2 Overall social functioning
follow-up values

14.2.1 Up to 12 weeks' fol-
low-up

14.2.2 More than 12 weeks' to
less than 6 months' follow-up

14.2.3 6 months' follow-up

14.3 FACT social subscale
change

14.3.1 Up to 12 weeks' fol-
low-up

14.3.2 6 months' follow-up

14.4 FACT social subscale fol-
low-up values

14.4.1 Up to 12 weeks' fol-
low-up

14.4.2 6 months' follow-up

14.5 QLQ-C30 change

14.5.1 Up to 12 weeks' fol-
low-up

14.6 QLQ-C30 social subscale
follow-up values

14.6.1 Up to 12 weeks' fol-
low-up

14.6.2 More than 12 weeks' to
less than 6 months' follow-up

14.6.3 6 months' follow-up

7

5

3

18

16

4

5

4

3

2

8

7

4

1

1

6

5

3

1

378

247

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

0.54 [0.03, 1.05]

Std. Mean Difference (IV, Random, 95% CI)

-0.07 [-0.42, 0.29]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

1164

Std. Mean Difference (IV, Random, 95% CI)

0.16 [0.04, 0.27]

183

381

Std. Mean Difference (IV, Random, 95% CI)

0.09 [-0.26, 0.44]

Std. Mean Difference (IV, Random, 95% CI)

0.24 [0.03, 0.44]

Mean Difference (IV, Random, 95% CI)

Subtotals only

167

Mean Difference (IV, Random, 95% CI)

2.88 [1.94, 3.83]

81

Mean Difference (IV, Random, 95% CI)

1.25 [-3.28, 5.79]

Mean Difference (IV, Random, 95% CI)

Subtotals only

539

307

Mean Difference (IV, Random, 95% CI)

0.79 [-0.06, 1.63]

Mean Difference (IV, Random, 95% CI)

1.15 [0.04, 2.25]

Mean Difference (IV, Random, 95% CI)

Subtotals only

44

Mean Difference (IV, Random, 95% CI)

3.34 [-22.39, 29.07]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

3.67 [-0.87, 8.20]

Mean Difference (IV, Random, 95% CI)

3.58 [-11.78, 18.94]

Mean Difference (IV, Random, 95% CI)

18.30 [-7.41, 44.01]

411

127

29

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

331

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

14.7 FACIT social subscale
change

14.7.1 Up to 12 weeks' fol-
low-up

14.8 MOS SF-36 social function
subscale change

14.8.1 6 months' follow-up

14.9 MOS SF-36 social function
subscale follow-up values

14.9.1 Up to 12 weeks' fol-
low-up

14.9.2 More than 12 weeks' to
less than 6 months' follow-up

14.9.3 6 months' follow-up

14.10 WHO BREF social func-
tion subscale follow-up values

14.10.1 Up to 12 weeks' fol-
low-up

14.11 Ferrans and Power social
economic subscale follow-up
values

14.11.1 Up to 12 weeks' fol-
low-up

14.12 General Health Ques-
tionnaire social dysfunction
subscale follow-up values

14.12.1 More than 12 weeks' to
less than 6 months' follow-up

14.13 QLSI social and familial
functioning subscale follow-up
values

14.13.1 Up to 12 weeks' fol-
low-up

1

1

2

2

4

3

1

1

1

1

1

1

1

1

1

1

Mean Difference (IV, Random, 95% CI)

Subtotals only

167

Mean Difference (IV, Random, 95% CI)

-0.15 [-1.60, 1.30]

Mean Difference (IV, Random, 95% CI)

Subtotals only

166

Mean Difference (IV, Random, 95% CI)

-2.49 [-7.40, 2.42]

Mean Difference (IV, Random, 95% CI)

Subtotals only

345

Mean Difference (IV, Random, 95% CI)

2.98 [-1.76, 7.72]

56

45

Mean Difference (IV, Random, 95% CI)

-1.00 [-18.60, 16.60]

Mean Difference (IV, Random, 95% CI)

1.30 [-4.66, 7.26]

Mean Difference (IV, Random, 95% CI)

Subtotals only

37

Mean Difference (IV, Random, 95% CI)

0.96 [-0.28, 2.20]

Mean Difference (IV, Random, 95% CI)

Subtotals only

17

Mean Difference (IV, Random, 95% CI)

-3.00 [-7.48, 1.48]

Mean Difference (IV, Random, 95% CI)

Subtotals only

17

Mean Difference (IV, Random, 95% CI)

0.60 [-1.41, 2.61]

Mean Difference (IV, Random, 95% CI)

Subtotals only

67

Mean Difference (IV, Random, 95% CI)

-0.18 [-2.37, 2.01]

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

332

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.1.   Comparison 14: Social functioning, Outcome 1: Overall social functioning change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

14.1.1 Up to 12 weeks' follow-up
-3.18
Arbane 2009
1.5
Monga 2007
2.29
Oh 2010
0.9
Rogers 2009
0.43
Targ 2002
Subtotal (95% CI)
Heterogeneity: Tau² = 0.25; Chi² = 19.27, df = 4 (P = 0.0007); I² = 79%
Test for overall effect: Z = 2.09 (P = 0.04)

46.13
1.9
3.8
2.6
4

-6.52
-1.7
-0.97
-1.2
0.58

21
11
54
20
79
185

14.1.2 6 months' follow-up
Cadmus 2009
Cadmus 2009
Rogers 2009
Segal 2001
Segal 2001
Subtotal (95% CI)
Heterogeneity: Tau² = 0.08; Chi² = 7.62, df = 4 (P = 0.11); I² = 48%
Test for overall effect: Z = 0.36 (P = 0.72)

6.3
-1.3
-0.04
2.1
1.5

22
22
19
40
40
143

13.5
3.3
4.3
20.6
4.1

5.4
-0.5
-3.9
6.7
6.7

40.43
2.4
3.8
2.7
5.5

12.3
3.3
6.6
19.1
18.6

23
10
54
18
88
193

19.8%
13.5%
23.3%
18.6%
24.7%
100.0%

0.08 [-0.52 , 0.67]
1.43 [0.45 , 2.41]
0.85 [0.46 , 1.25]
0.78 [0.11 , 1.44]
-0.03 [-0.33 , 0.27]
0.54 [0.03 , 1.05]

23
23
17
21
20
104

19.9%
19.8%
16.9%
22.0%
21.4%
100.0%

0.07 [-0.52 , 0.65]
-0.24 [-0.82 , 0.35]
0.69 [0.01 , 1.36]
-0.23 [-0.76 , 0.30]
-0.46 [-1.00 , 0.08]
-0.07 [-0.42 , 0.29]

Test for subgroup differences: Chi² = 3.68, df = 1 (P = 0.06), I² = 72.8%

-100
Favours exercise

-50

0

50

100

Favours control

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

333

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.2.   Comparison 14: Social functioning, Outcome 2: Overall social functioning follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

14.2.1 Up to 12 weeks' follow-up
82.6
Adamsen 2009
86.51
Arbane 2009
85.2
Chandwani 2010
17.85
Courneya 2003a
23.1
Danhauer 2009
87
Galvao 2010
81.3
Hacker 2011
13.71
Hwang 2008
71.6
Jarden 2009
-2.14
Lanctot 2010
20.38
Moadel 2007
25.2
Monga 2007
24.2
Mutrie 2007
22.6
Rogers 2009
43.8
Wiskemann 2011
19.6
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 8.27, df = 15 (P = 0.91); I² = 0%
Test for overall effect: Z = 2.66 (P = 0.008)

79.4
86.96
84.8
18.59
20.4
83.3
77.8
12.75
54.9
-2.32
18.37
23.2
23.4
21.8
42.1
18.8

20.5
34.41
24.5
4.13
5
18.4
22.6
1.65
30.5
2.78
5.57
4.1
4.6
4.1
31.3
4.9

118
21
26
51
13
29
8
17
17
37
84
11
82
20
40
28
602

14.2.2 More than 12 weeks' to less than 6 months' follow-up
Chandwani 2010
Jarden 2009
Moros 2010
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.03; Chi² = 4.01, df = 3 (P = 0.26); I² = 25%
Test for overall effect: Z = 0.50 (P = 0.62)

86.2
52.6
88
46.7

85.2
71.9
76.6
49.2

31.7
27.7
22.4
32.5

27
17
10
40
94

14.2.3 6 months' follow-up
Cadmus 2009
Cadmus 2009
Jarden 2009
Mutrie 2007
Rogers 2009
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 3.29, df = 5 (P = 0.66); I² = 0%
Test for overall effect: Z = 2.29 (P = 0.02)

22
22
16
82
19
24
185

3.8
10.2
33.9
4.8
4.7
3.6

22.7
48.7
81.1
23.9
21.4
20.9

23.1
47.4
62.8
22.9
18.8
18.6

20.8
31.37
28.1
4.62
6.8
23.5
34.4
2.2
23.4
5.6
6.28
2.9
5
5.7
29.2
5.6

35.5
27.1
20.8
29.3

5
10.2
36.1
5.5
8.4
4.5

117
23
27
45
14
28
9
20
17
30
44
10
92
18
41
27
562

20.5%
3.8%
4.6%
8.4%
2.3%
5.0%
1.5%
3.1%
2.8%
5.8%
10.0%
1.8%
15.1%
3.3%
7.1%
4.8%
100.0%

0.15 [-0.10 , 0.41]
-0.01 [-0.61 , 0.58]
0.01 [-0.52 , 0.55]
-0.17 [-0.57 , 0.23]
0.44 [-0.33 , 1.20]
0.17 [-0.35 , 0.69]
0.11 [-0.84 , 1.07]
0.48 [-0.18 , 1.13]
0.60 [-0.09 , 1.29]
0.04 [-0.44 , 0.52]
0.34 [-0.02 , 0.71]
0.54 [-0.34 , 1.41]
0.17 [-0.13 , 0.46]
0.16 [-0.48 , 0.80]
0.06 [-0.38 , 0.49]
0.15 [-0.38 , 0.68]
0.16 [0.04 , 0.27]

29
13
7
40
89

31.1%
18.3%
11.4%
39.1%
100.0%

-0.03 [-0.55 , 0.49]
0.68 [-0.06 , 1.43]
-0.50 [-1.48 , 0.49]
0.08 [-0.36 , 0.52]
0.09 [-0.26 , 0.44]

23
23
13
95
17
25
196

12.0%
12.0%
7.4%
46.7%
9.4%
12.5%
100.0%

-0.09 [-0.67 , 0.50]
0.13 [-0.46 , 0.71]
0.51 [-0.24 , 1.26]
0.19 [-0.10 , 0.49]
0.38 [-0.28 , 1.04]
0.55 [-0.02 , 1.13]
0.24 [0.03 , 0.44]

Test for subgroup differences: Chi² = 0.65, df = 2 (P = 0.72), I² = 0%

-10
Favours control

-5

0

5

10
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

334

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.3.   Comparison 14: Social functioning, Outcome 3: FACT social subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

14.3.1 Up to 12 weeks' follow-up
1.5
Monga 2007
2.29
Oh 2010
0.9
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.20, df = 2 (P = 0.55); I² = 0%
Test for overall effect: Z = 5.99 (P < 0.00001)

11
54
20
85

-1.7
-0.97
-1.2

1.9
3.8
2.6

14.3.2 6 months' follow-up
Cadmus 2009
Rogers 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 8.61; Chi² = 4.82, df = 1 (P = 0.03); I² = 79%
Test for overall effect: Z = 0.54 (P = 0.59)

-1.3
-0.04

22
19
41

-0.5
-3.9

3.3
4.3

2.4
3.8
2.7

3.3
6.6

10
54
18
82

25.6%
43.3%
31.1%
100.0%

3.20 [1.34 , 5.06]
3.26 [1.83 , 4.69]
2.10 [0.41 , 3.79]
2.88 [1.94 , 3.83]

23
17
40

55.9%
44.1%
100.0%

-0.80 [-2.73 , 1.13]
3.86 [0.17 , 7.55]
1.25 [-3.28 , 5.79]

Test for subgroup differences: Chi² = 0.48, df = 1 (P = 0.49), I² = 0%

-50
Favours control

-25

0

25

50
Favours exercise

Analysis 14.4.   Comparison 14: Social functioning, Outcome 4: FACT social subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

14.4.1 Up to 12 weeks' follow-up
17.85
Courneya 2003a
23.1
Danhauer 2009
20.38
Moadel 2007
25.2
Monga 2007
24.2
Mutrie 2007
22.6
Rogers 2009
19.6
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 5.39, df = 6 (P = 0.50); I² = 0%
Test for overall effect: Z = 1.83 (P = 0.07)

4.13
5
5.57
4.1
4.6
4.1
4.9

51
13
84
11
82
20
28
289

18.59
20.4
18.37
23.2
23.4
21.8
18.8

14.4.2 6 months' follow-up
Cadmus 2009
Mutrie 2007
Rogers 2009
de Oliveira 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.79, df = 3 (P = 0.42); I² = 0%
Test for overall effect: Z = 2.04 (P = 0.04)

22
82
19
24
147

22.7
23.9
21.4
20.9

3.8
4.8
4.7
3.6

23.1
22.9
18.8
18.6

4.62
6.8
6.28
2.9
5
5.7
5.6

5
5.5
8.4
4.5

45
14
44
10
92
18
27
250

22.9%
3.5%
14.6%
7.8%
34.9%
7.0%
9.2%
100.0%

-0.74 [-2.50 , 1.02]
2.70 [-1.78 , 7.18]
2.01 [-0.19 , 4.21]
2.00 [-1.02 , 5.02]
0.80 [-0.63 , 2.23]
0.80 [-2.39 , 3.99]
0.80 [-1.98 , 3.58]
0.79 [-0.06 , 1.63]

23
95
17
25
160

18.1%
52.6%
5.9%
23.4%
100.0%

-0.40 [-2.99 , 2.19]
1.00 [-0.52 , 2.52]
2.60 [-1.92 , 7.12]
2.30 [0.02 , 4.58]
1.15 [0.04 , 2.25]

Test for subgroup differences: Chi² = 0.26, df = 1 (P = 0.61), I² = 0%

-50
Favours control

-25

0

25

50
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

335

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.5.   Comparison 14: Social functioning, Outcome 5: QLQ-C30 change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

14.5.1 Up to 12 weeks' follow-up
-3.18
Arbane 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.25 (P = 0.80)

46.13

Test for subgroup differences: Not applicable

-6.52

40.43

21
21

23
23

100.0%
100.0%

3.34 [-22.39 , 29.07]
3.34 [-22.39 , 29.07]

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 14.6.   Comparison 14: Social functioning, Outcome 6: QLQ-C30 social subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

14.6.1 Up to 12 weeks' follow-up
82.6
Adamsen 2009
86.51
Arbane 2009
81.3
Hacker 2011
71.6
Jarden 2009
43.8
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.24, df = 4 (P = 0.69); I² = 0%
Test for overall effect: Z = 1.58 (P = 0.11)

20.5
34.41
22.6
30.5
31.3

118
21
8
17
40
204

79.4
86.96
77.8
54.9
42.1

14.6.2 More than 12 weeks' to less than 6 months' follow-up
Jarden 2009
Moros 2010
Wiskemann 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 101.63; Chi² = 4.46, df = 2 (P = 0.11); I² = 55%
Test for overall effect: Z = 0.46 (P = 0.65)

52.6
88
46.7

27.7
22.4
32.5

71.9
76.6
49.2

17
10
40
67

20.8
31.37
34.4
23.4
29.2

27.1
20.8
29.3

117
23
9
17
41
207

73.8%
5.4%
2.7%
6.2%
11.8%
100.0%

3.20 [-2.08 , 8.48]
-0.45 [-19.97 , 19.07]
3.50 [-23.89 , 30.89]
16.70 [-1.57 , 34.97]
1.70 [-11.49 , 14.89]
3.67 [-0.87 , 8.20]

13
7
40
60

30.2%
28.7%
41.1%
100.0%

19.30 [-0.46 , 39.06]
-11.40 [-32.14 , 9.34]
2.50 [-11.06 , 16.06]
3.58 [-11.78 , 18.94]

14.6.3 6 months' follow-up
Jarden 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.40 (P = 0.16)

81.1

33.9

62.8

36.1

16
16

13
13

100.0%
100.0%

18.30 [-7.41 , 44.01]
18.30 [-7.41 , 44.01]

Test for subgroup differences: Chi² = 1.21, df = 2 (P = 0.55), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 14.7.   Comparison 14: Social functioning, Outcome 7: FACIT social subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

14.7.1 Up to 12 weeks' follow-up
0.43
Targ 2002
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.20 (P = 0.84)

4

79
79

0.58

5.5

88
88

100.0%
100.0%

-0.15 [-1.60 , 1.30]
-0.15 [-1.60 , 1.30]

Test for subgroup differences: Not applicable

-100

-50

0

Favours control

50

100
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

336

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.8.   Comparison 14: Social functioning, Outcome 8: MOS SF-36 social function subscale change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

14.8.1 6 months' follow-up
Cadmus 2009
Segal 2001
Segal 2001
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.35, df = 2 (P = 0.51); I² = 0%
Test for overall effect: Z = 0.99 (P = 0.32)

22
40
40
102

13.5
4.1
20.6

6.3
1.5
2.1

5.4
6.7
6.7

12.3
18.6
19.1

23
20
21
64

42.2%
35.4%
22.4%
100.0%

0.90 [-6.66 , 8.46]
-5.20 [-13.45 , 3.05]
-4.60 [-14.97 , 5.77]
-2.49 [-7.40 , 2.42]

Test for subgroup differences: Not applicable

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 14.9.   Comparison 14: Social functioning, Outcome 9: MOS SF-36 social function subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

14.9.1 Up to 12 weeks' follow-up
79.7
Adamsen 2009
85.2
Chandwani 2010
87
Galvao 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.15, df = 2 (P = 0.93); I² = 0%
Test for overall effect: Z = 1.23 (P = 0.22)

118
26
29
173

22.2
24.5
18.4

76.5
84.8
83.3

14.9.2 More than 12 weeks' to less than 6 months' follow-up
Chandwani 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.11 (P = 0.91)

27
27

85.2

31.7

86.2

22
28.1
23.5

117
27
28
172

70.2%
11.2%
18.6%
100.0%

3.20 [-2.45 , 8.85]
0.40 [-13.78 , 14.58]
3.70 [-7.28 , 14.68]
2.98 [-1.76 , 7.72]

35.5

29
29

100.0%
100.0%

-1.00 [-18.60 , 16.60]
-1.00 [-18.60 , 16.60]

14.9.3 6 months' follow-up
Cadmus 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.43 (P = 0.67)

48.7

10.2

47.4

10.2

22
22

23
23

100.0%
100.0%

1.30 [-4.66 , 7.26]
1.30 [-4.66 , 7.26]

Test for subgroup differences: Chi² = 0.32, df = 2 (P = 0.85), I² = 0%

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 14.10.   Comparison 14: Social functioning, Outcome
10: WHO BREF social function subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

14.10.1 Up to 12 weeks' follow-up
13.71
Hwang 2008
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.51 (P = 0.13)

1.65

Test for subgroup differences: Not applicable

12.75

2.2

17
17

20
20

100.0%
100.0%

0.96 [-0.28 , 2.20]
0.96 [-0.28 , 2.20]

-50
Favours control

-25

0

25

50
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

337

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.11.   Comparison 14: Social functioning, Outcome 11:
Ferrans and Power social economic subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

14.11.1 Up to 12 weeks' follow-up
19.6
Hacker 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.31 (P = 0.19)

4.7

Test for subgroup differences: Not applicable

22.6

4.7

8
8

9
9

100.0%
100.0%

-3.00 [-7.48 , 1.48]
-3.00 [-7.48 , 1.48]

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 14.12.   Comparison 14: Social functioning, Outcome 12: General
Health Questionnaire social dysfunction subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

14.12.1 More than 12 weeks' to less than 6 months' follow-up
Moros 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.58 (P = 0.56)

10
10

2.31

2.6

2

1.91

7
7

100.0%
100.0%

0.60 [-1.41 , 2.61]
0.60 [-1.41 , 2.61]

Test for subgroup differences: Not applicable

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 14.13.   Comparison 14: Social functioning, Outcome 13:
QLSI social and familial functioning subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

14.13.1 Up to 12 weeks' follow-up
2.14
Lanctot 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.16 (P = 0.87)

2.78

Test for subgroup differences: Not applicable

Comparison 15.   Spiritual functioning

Outcome or subgroup title

2.32

5.6

37
37

30
30

100.0%
100.0%

-0.18 [-2.37 , 2.01]
-0.18 [-2.37 , 2.01]

-50
Favours exercise

-25

0

25

50
Favours control

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

15.1 Overall spiritual function change

15.1.1 Up to 12 weeks' follow-up

1

1

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

167

Std. Mean Difference (IV, Random, 95%
CI)

0.01 [-0.30, 0.31]

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

338

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

15.2 Overall spiritual function follow-up
values

15.2.1 Up to 12 weeks' follow-up

15.3 FACT -Sp change

15.3.1 Up to 12 weeks' follow-up

15.4 FACIT-Sp follow-up values

15.4.1 Up to 12 weeks' follow-up

15.5 Ferrans and Power psychologi-
cal/spiritual subscale follow-up values

15.5.1 Up to 12 weeks' follow-up

3

3

1

1

2

2

1

1

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

172

Std. Mean Difference (IV, Random, 95%
CI)

0.46 [0.14, 0.77]

Mean Difference (IV, Random, 95% CI)

Subtotals only

167

Mean Difference (IV, Random, 95% CI)

0.05 [-2.89, 2.99]

Mean Difference (IV, Random, 95% CI)

Subtotals only

155

Mean Difference (IV, Random, 95% CI)

4.03 [0.81, 7.25]

Mean Difference (IV, Random, 95% CI)

Subtotals only

17

Mean Difference (IV, Random, 95% CI)

3.80 [-0.26, 7.86]

Analysis 15.1.   Comparison 15: Spiritual functioning, Outcome 1: Overall spiritual function change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

15.1.1 Up to 12 weeks' follow-up
3.4
Targ 2002
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.03 (P = 0.97)

9.3

Test for subgroup differences: Not applicable

3.35

10.1

79
79

88
88

100.0%
100.0%

0.01 [-0.30 , 0.31]
0.01 [-0.30 , 0.31]

-20
Favours control

-10

0

10

20
Favours exercise

Analysis 15.2.   Comparison 15: Spiritual functioning, Outcome 2: Overall spiritual function follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

15.2.1 Up to 12 weeks' follow-up
26
Danhauer 2009
26.4
Hacker 2011
37.4
Moadel 2007
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.67, df = 2 (P = 0.71); I² = 0%
Test for overall effect: Z = 2.84 (P = 0.004)

13
8
84
105

21.5
22.6
33.55

6.7
3.2
9.1

9.4
5.2
11

14
9
44
67

16.7%
9.9%
73.4%
100.0%

0.53 [-0.24 , 1.30]
0.82 [-0.18 , 1.83]
0.39 [0.02 , 0.76]
0.46 [0.14 , 0.77]

Test for subgroup differences: Not applicable

-20
Favours control

-10

0

10

20
Favours exercise

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

339

 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 15.3.   Comparison 15: Spiritual functioning, Outcome 3: FACT -Sp change

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

15.3.1 Up to 12 weeks' follow-up
3.4
Targ 2002
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.03 (P = 0.97)

9.3

Test for subgroup differences: Not applicable

3.35

10.1

79
79

88
88

100.0%
100.0%

0.05 [-2.89 , 2.99]
0.05 [-2.89 , 2.99]

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 15.4.   Comparison 15: Spiritual functioning, Outcome 4: FACIT-Sp follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

15.4.1 Up to 12 weeks' follow-up
26
Danhauer 2009
37.4
Moadel 2007
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.03, df = 1 (P = 0.86); I² = 0%
Test for overall effect: Z = 2.45 (P = 0.01)

13
84
97

6.7
9.1

21.5
33.55

9.4
11

14
44
58

27.7%
72.3%
100.0%

4.50 [-1.62 , 10.62]
3.85 [0.06 , 7.64]
4.03 [0.81 , 7.25]

Test for subgroup differences: Not applicable

-100

-50

0

Favours control

50

100
Favours exercise

Analysis 15.5.   Comparison 15: Spiritual functioning, Outcome 5:
Ferrans and Power psychological/spiritual subscale follow-up values

Study or Subgroup

Mean

Exercise
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

15.5.1 Up to 12 weeks' follow-up
26.4
Hacker 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.84 (P = 0.07)

3.2

Test for subgroup differences: Not applicable

22.6

5.2

8
8

9
9

100.0%
100.0%

3.80 [-0.26 , 7.86]
3.80 [-0.26 , 7.86]

-100

-50

0

Favours control

50

100
Favours exercise

A D D I T I O N A L   T A B L E S

Table 1.   HRQoL instruments used by investigators 

Instrument name

Abbrevia-
tion

Overall
domain
or sub-
scale

Health-related quality of life

Direction of response

Trials using this scale

European Organization for Re-
search and Treatment of Can-

QLQ-C30

HRQoL

Higher score  indicates better sta-
tus

Adamsen 2009; Arbane 2009;
Culos-Reed 2010; Gomes 2011;

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

340

 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Table 1.   HRQoL instruments used by investigators  (Continued)

cer Quality of Life Question-
naire-C30

European Organization for Re-
search and Treatment of Can-
cer Quality of Life Question-
naire-RB23

QLQ-B23

HRQoL

Higher score  indicates better sta-
tus

Gomes 2011

Cochrane Database of Systematic Reviews

Hacker 2011; Jarden 2009; Moros
2010; Wiskemann 2011

Functional Assessment of Can-
cer Therapy - Anemia

FACT-An

HRQoL

Higher score  indicates better sta-
tus

Courneya 2007a; Courneya 2008;
Courneya 2009; Jarden 2009

Functional Assessment of Can-
cer Therapy - Breast

FACT-B

HRQoL

Higher score  indicates better sta-
tus

Functional Assessment of Can-
cer Therapy - General

FACT-G

HRQoL

Higher score  indicates better sta-
tus

Campbell 2005; Courneya 2003a;
Danhauer 2009; de Oliveira 2010;
DiSipio 2009; Rogers 2009; Segal
2001

Bourke 2011; Cadmus 2009;
Campbell 2005; Courneya 2003a;
de Oliveira 2010; Donnelly 2011;
Jarden 2009; Moadel 2007; Mutrie
2007; Oh 2010; Rogers 2009; Se-
gal 2001; Segal 2009; Wang 2010

Functional Assessment of Can-
cer Therapy - Prostate

FACT-P

HRQoL

Higher score  indicates better sta-
tus

Bourke 2011; Monga 2007; Segal
2003

Medical Outcomes Study Short
Form-36

MOS
SF-36

HRQoL

Higher score  indicates better sta-
tus

Griffith 2009; Haddad 2011

Functional Assessment of
Chronic Illness Therapy-Fatigue

FACIT-F

HRQoL

Higher score  indicates better sta-
tus

Headley 2004; Mustian 2009; Targ
2002

World Health Organization
Quality of Life (mean score)

WHO QOL-
BREF

HRQoL

Higher score  indicates better sta-
tus

Hwang 2008

World Health Organization
Quality of Life (single item)

WHO QOL-
BREF

HRQoL

Higher score  indicates better sta-
tus

Hwang 2008

Medical Outcomes Study Short
Form-36

MOS
SF-36

HRQoL

Higher score  indicates better sta-
tus

Griffith 2009; Mock 2001

Ferrans and Powers Quality of
Life Instrument

FPQLI

HRQoL

Higher score  indicates better sta-
tus

Hacker 2011

Functional Living Index for Can-
cer

FLIC

HRQoL

Higher score  indicates better sta-
tus

Raghavendra 2007

Spitzer QOL Uniscale

HRQoL

Higher score  indicates better sta-
tus

Cheville 2010

Linear Analog Scales of Assess-
ment

LASA

HRQoL

Higher score  indicates better sta-
tus

Cheville 2010

Quality of Life Systematic Inven-
tory

HRQoL

Unclear

Lanctot 2010

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

341

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 1.   HRQoL instruments used by investigators  (Continued)

Condition-specific HRQoL

Functional Assessment of Can-
cer Therapy - Breast

FACT-B

Functional Assessment of Can-
cer Therapy 

FACT

Functional Assessment of Can-
cer Therapy - Prostate

FACT-P

Functional Assessment of 
Chronic Illness Therapy-Fatigue

FACIT-F

Expanded Prostate Cancer In-
dex Composite

EPIC

Addition-
al breast
cancer
concerns

Lym-
phoma
cancer
concerns

Prostate
cancer
concerns

General
cancer
concerns

Prostate
cancer
concerns

Anxiety

Higher score indicates better sta-
tus

Cadmus 2009; Campbell 2005;
Courneya 2003a; Courneya
2007a; Danhauer 2009; de
Oliveira 2010; Mutrie 2007; Rogers
2009

Higher score indicates better sta-
tus

Courneya 2009

Higher score indicates better sta-
tus

Monga 2007; Segal 2009

Higher score  indicates better sta-
tus

Targ 2002

Higher score  indicates worse sta-
tus

Culos-Reed 2010

Hospital Anxiety and Depres-
sion Scale

HADS

Anxiety 

Higher score  indicates worse sta-
tus

Adamsen 2009; Banerjee 2007;
Jarden 2009; Wiskemann 2011

State-Trait Anxiety Scale

STAI

State anx-
iety

Higher score  indicates worse sta-
tus

Cadmus 2009; Chandwani 2010;
Cohen 2004; Courneya 2003a;
Courneya 2007a; Courneya 2009;
Raghavendra 2007

Profile of Mood Scale

POMS

Ten-
sion-anxi-
ety

Higher score  indicates worse sta-
tus

Chang 2008; Moadel 2007; Oh
2010; Targ 2002

Symptom Checklist 90 Revised

SCL-90-R

Anxiety

Higher score  indicates better sta-
tus

Dimeo 1999

Symptom Checklist 90 Revised

SCL-90-R

Phobic
anxiety

Higher score  indicates better sta-
tus

Dimeo 1999

General Health Questionnaire

GHQ

Anxiety

Symptom Assessment Scale

SAS

Anxiety

Higher score  indicates worse sta-
tus

Moros 2010

Higher score  indicates worse sta-
tus

Mock 1997

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

342

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 1.   HRQoL instruments used by investigators  (Continued)

Body Image/self-esteem

Tennessee Self-Concept Scale

TSCS

Self-con-
cept

Higher score  indicates better sta-
tus

Mock 1994

Body Image Visual Analogue
Scale

BIVAS

Body im-
age

Higher score  indicates better sta-
tus

Mock 1994

Rosenberg Self-Esteem

Self-es-
teem

Higher score  indicates better sta-
tus

Cadmus 2009; Courneya 2007a

Symptom Assessment Scale

SAS

Cognitive function

European Organization for Re-
search and Treatment of Can-
cer Quality of Life Question-
naire-C30

QLQ-C30

Functional Assessment of Can-
cer Therapy-Cognitive

FACT-Cog

Profile of Mood Scale

POMS

Body dis-
satisfac-
tion

Cognitive
function-
ing

Cognitive
function-
ing

Confu-
sion-be-
wilder-
ment

Higher score  indicates worse sta-
tus

Mock 1997

Higher score  indicates better sta-
tus

Adamsen 2009; Hacker 2011; Jar-
den 2009; Moros 2010; Wiske-
mann 2011

Higher score  indicates worse sta-
tus

Oh 2010; Rogers 2009

Higher score  indicates worse sta-
tus

Moadel 2007; Oh 2010; Targ 2002

Linear Analog Scales of Assess-
ment

LASA

Cognitive

Higher score  indicates better sta-
tus

Cheville 2010

Attentional Functional Index

AFI

Cognitive
function-
ing

Higher score  indicates better sta-
tus

Crowley 2003

Depression

Centers for Epidemiological
Studies - Depression Scale

CES-D

Depres-
sion

Higher score indicates worse sta-
tus

Cadmus 2009; Chandwani 2010;
Cohen 2004; Courneya 2003a;
Courneya 2007a; Courneya 2009;
Culos-Reed 2010; Danhauer 2009;
Haddad 2011

Hospital Anxiety and Depres-
sion Scale

HADS

Beck Depression Inventory-II

BDI

Depres-
sion

Depres-
sion

Higher score  indicates worse sta-
tus

Adamsen 2009; Banerjee 2007;
Jarden 2009; Wiskemann 2011

Higher score indicates worse sta-
tus

Donnelly 2011; Lanctot 2010;
Monga 2007; Mutrie 2007;
Raghavendra 2007

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

343

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 1.   HRQoL instruments used by investigators  (Continued)

Profile of Mood Scale

POMS

Symptom Checklist 90 Revised

SCL-90-R

General Health Questionnaire

GHQ

Symptom Assessment Scale

SAS

Depres-
sion-de-
jection

Depres-
sion

Depres-
sion

Depres-
sion

Emotional function/mental
health

Higher score  indicates worse sta-
tus

Chang 2008; Dimeo 1999; Oh
2010; Targ 2002; Wiskemann 2011

Higher score  indicates better sta-
tus

Dimeo 1999

Higher score  indicates worse sta-
tus

Moros 2010

Higher score  indicates worse sta-
tus

Mock 1997

Functional Assessment of Can-
cer Therapy - Breast

FACT-B

Emotional
well-being

Higher score  indicates better sta-
tus

Danhauer 2009; de Oliveira 2010;
Rogers 2009

Functional Assessment of Can-
cer Therapy - General

FACT-G

Emotional
well-being

Higher score  indicates better sta-
tus

Cadmus 2009; Moadel 2007; Mon-
ga 2007; Mutrie 2007; Oh 2010

Functional Assessment
of Chronic Illness - Fatigue

FACIT-F

Emotional
well-being

Higher score  indicates better sta-
tus

Targ 2002

European Organization for Re-
search and Treatment of Can-
cer Quality of Life Question-
naire-C30

QLQ-C30

Emotional
function-
ing

Higher score  indicates better sta-
tus

Adamsen 2009; Hacker 2011; Jar-
den 2009; Moros 2010; Wiske-
mann 2011

Profile of Mood Scale

POMS

Mood 

Higher score  indicates worse sta-
tus

Griffith 2009; Moadel 2007; Mock
2001; Oh 2010; Targ 2002; Yang
2011

Profile of Mood Scale

POMS

Anger-
hostility

Higher score  indicates worse sta-
tus

Dimeo 1999; Oh 2010; Targ 2002;
Wiskemann 2011

Profile of Mood Scale

POMS

Higher score  indicates worse sta-
tus

Moadel 2007; Oh 2010

Irritability 

Fordyce Happiness Measure

FORDYCE

Happiness Higher score  indicates better sta-

Cadmus 2009

tus

Happiness Measure

HM

Happiness Higher score  indicates better sta-

Courneya 2009

Medical Outcomes Study Short
Form-12

MOS
SF-12

Mental
health
compo-
nent

tus

Higher score  indicates better sta-
tus

Danhauer 2009 

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

344

 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 1.   HRQoL instruments used by investigators  (Continued)

Medical Outcomes Study Short
Form-36

MOS
SF-36

Medical Outcomes Study Short
Form-36

MOS
SF-36

Mental
health
compo-
nent

Mental
health

Higher score  indicates better sta-
tus

Adamsen 2009; Cadmus 2009;
Chandwani 2010; Galvao 2010;
Tang 2010

Higher score  indicates better sta-
tus

Adamsen 2009; Chandwani 2010;
Crowley 2003; Galvao 2010; Mock
2001; Segal 2001

Medical Outcomes Study Short
Form-36

MOS
SF-36

Role emo-
tional

Higher score  indicates better sta-
tus

Cadmus 2009; Chandwani 2010;
Crowley 2003; Galvao 2010; Mock
2001; Segal 2001

Positive and Negative Affect
Scale

PANAS

Positivity

Higher score  indicates better sta-
tus

Danhauer 2009; Donnelly 2011;
Mutrie 2007

Functional Assessment of Can-
cer Therapy - Breast

FACT-B

Psycho-
logical
function-
ing

Higher score  indicates better sta-
tus

Danhauer 2009; Rogers 2009

Satisfaction with Life Scale

SWLS

Satisfac-
tion

Higher score  indicates better sta-
tus

Campbell 2005; Courneya 2003a

Psychosocial Adjustment to Ill-
ness Scale

PAIS

WHO QOL-BREF subscale

WHO QOL-
BREF 

Psychoso-
cial re-
sponse to
illness

Psycho-
logical
function-
ing

Higher score  indicates worse sta-
tus

Mock 1994

Higher score  indicates better sta-
tus

Hwang 2008

Perceived Stress Scale

PSS

Stress

Higher score  indicates worse sta-
tus

Banerjee 2007

Brief Symptom Inventory (sub-
set of SCL-90-R)

BSI

Psycho-
logical
distress

Higher score  indicates better sta-
tus

Mock 1994

National Comprehensive Cancer
Network Distress Thermometer

NCCN

Distress 

Higher score  indicates worse sta-
tus

Wiskemann 2011

Cohen's Perceived Stress Scale

Stress

Higher score  indicates worse sta-
tus

Cadmus 2009

Linear Analog Scales of Assess-
ment

LASA

Emotional

Higher score  indicates better sta-
tus

Cheville 2010

Symptom Distress Scale (mod-
ification of Symptom Checklist
90)

SDS

Stress

Higher score  indicates worse sta-
tus

Cheville 2010; Griffith 2009

Symptom Checklist 90 Revised

SCL-90-R

Psycho-
logical
distress

Higher score  indicates better sta-
tus

Dimeo 1999

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

345

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 1.   HRQoL instruments used by investigators  (Continued)

Symptom Checklist 90 Revised

SCL-90-R

Obsessive
compul-
sive

Higher score  indicates better sta-
tus

Dimeo 1999

Symptom Checklist 90 Revised

SCL-90-R

Hostility

Higher score  indicates better sta-
tus

Dimeo 1999

Symptom Checklist 90 Revised

SCL-90-R

Somatiza-
tion

Higher score  indicates better sta-
tus

Dimeo 1999

General Health Questionnaire

GHQ

Psycho-
logical
status

Higher score  indicates worse sta-
tus

Moros 2010

General Health Questionnaire

GHQ

Somatiza-
tion

Higher score  indicates worse sta-
tus

Moros 2010

Fatigue

European Organization for Re-
search and Treatment of Can-
cer Quality of Life Question-
naire-C30

QLQ-C30

Fatigue

Higher score  indicates worse sta-
tus

Adamsen 2009; Hacker 2011; Jar-
den 2009; Wiskemann 2011

Functional Assessment of Can-
cer Therapy - Anemia

FACT-An

Fatigue

Higher score  indicates better sta-
tus

Courneya 2007a; Courneya 2008;
Courneya 2009; Jarden 2009

Functional Assessment of Can-
cer Therapy 

FACT

Fatigue

Higher score  indicates worse sta-
tus

Courneya 2003a

Functional Assessment of Can-
cer Therapy - Fatigue

FACT-F

Fatigue

Higher score  indicates worse sta-
tus

Profile of Mood Scale

POMS

Fa-
tigue-iner-
tia

Higher score  indicates worse sta-
tus

Profile of Mood Scale

POMS

Vigor-ac-
tivity

Higher score  indicates better sta-
tus

Bourke 2011; Danhauer 2009;
Mutrie 2007; Segal 2003; Segal
2009

Brown 2006; Cheville 2010;
Dimeo 1999; Oh 2010; Targ 2002;
Wiskemann 2011

 Brown 2006; Cheville 2010;
Dimeo 1999; Oh 2010; Targ 2002;
Wiskemann 2011

Linear Analog Self-Assessment

LASA

Fatigue

Higher score  indicates worse sta-
tus

Brown 2006

Schwartz Cancer Fatigue Scale

SCFS

Fatigue

Higher score  indicates worse sta-
tus

Caldwell 2009

Multidimensional Fatigue Inven-
tory

MFI

Fatigue

Higher score  indicates worse sta-
tus

Donnelly 2011; Wiskemann 2011

Piper Fatigue Scale

PFS

Fatigue

Higher score  indicates worse sta-
tus

Battaglini 2008; Campbell 2005;
Crowley 2003; Griffith 2009; Mock
1997; Mock 2001; Mock 2005;
Monga 2007

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

346

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 1.   HRQoL instruments used by investigators  (Continued)

Functional Assessment of
Chronic Illness Therapy - Fa-
tigue

FACIT-F

Fatigue

Higher score  indicates better sta-
tus

Donnelly 2011; Headley 2004;
Moadel 2007; Mustian 2009; Oh
2010; Wang 2010

Linear Analog Scales of Assess-
ment

LASA

Fatigue

Higher score  indicates better sta-
tus

Cheville 2010

Medical Outcomes Study Short
Form-36

MOS
SF-36

Vitality

Higher score  indicates better sta-
tus

Brief Fatigue Inventory

BFI

Fatigue

Higher score  indicates worse sta-
tus

Adamsen 2009; Cadmus 2009;
Chandwani 2010; Crowley 2003;
Galvao 2010; Mock 2001; Segal
2001

Chandwani 2010; Chang 2008;
Cohen 2004; Haddad 2011;
Hwang 2008; Mustian 2009; Wind-
sor 2004

Daily diary

Fatigue

Higher score  indicates worse sta-
tus

Mock 2001

State-Trait Anxiety Scale

STAI

Fatigue

Higher score  indicates worse sta-
tus

Brown 2006

Symptom Distress Scale (mod-
ification of Symptom Checklist
90)

SDS

Fatigue

Higher score  indicates worse sta-
tus

Brown 2006; Chang 2008

Attentional Functional Index

AFI

Attention-
al fatigue

Higher score  indicates better sta-
tus

Crowley 2003

Fatigue Severity Score

FSS

Fatigue

Higher score  indicates worse sta-
tus

Culos-Reed 2010

Symptom Assessment Scale

SAS

Fatigue

Higher score  indicates worse sta-
tus

Mock 1997

Chalder Fatigue Questionnaire

Fatigue

Unclear

Gomes 2011

General health perspective

Medical Outcomes Study Short
Form-12

MOS
SF-12

Item on
health

Higher score  indicates better sta-
tus

Cadmus 2009; Chandwani 2010;
Courneya 2009; Crowley 2003;
Galvao 2010; Mock 2001; Segal
2001

Single question on health

WHO QOL-BREF single item

Perceived
health

Higher score  indicates better sta-
tus

Rogers 2009

WHO QOL-
BREF

Gener-
al health
score

Higher score  indicates better sta-
tus

Hwang 2008

Ferrans and Powers Quality of
Life Instrument

FPQLI

Health
and func-

Higher score  indicates better sta-
tus

Hacker 2011

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

347

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 1.   HRQoL instruments used by investigators  (Continued)

tioning
subscale

Pain

European Organization for Re-
search and Treatment of Can-
cer Quality of Life Question-
naire-C30

QLQ-C30

Pain

Higher score  indicates worse sta-
tus

Adamsen 2009; Hacker 2011; Jar-
den 2009; Wiskemann 2011

Medical Outcomes Study Short
Form-36

MOS
SF-36

Bodily
pain

Higher score  indicates better sta-
tus

Adamsen 2009; Cadmus 2009;
Chandwani 2010; Crowley 2003;
Galvao 2010; Griffith 2009; Mock
2001; Segal 2001

Visual Analog Scale

VAS

Pain

Higher score  indicates worse sta-
tus

Hwang 2008

Linear Analog Scales of Assess-
ment

Linear Analog Scales of Assess-
ment

LASA

LASA

Pain fre-
quency

Higher score  indicates better sta-
tus

Cheville 2010

Pain
severity

Higher score  indicates better sta-
tus

Cheville 2010

Physical well-being

European Organization for Re-
search and Treatment of Can-
cer Quality of Life Question-
naire-C30

QLQ-C30

Physical
function

Higher score  indicates better sta-
tus

Adamsen 2009; Hacker 2011; Jar-
den 2009; Moros 2010; Wiske-
mann 2011

Functional Assessment of Can-
cer Therapy - Anemia

FACT-An
TOI

Physical
well-being

Higher score  indicates better sta-
tus

Courneya 2009

Functional Assessment of Can-
cer Therapy - Breast

FACT-B

Physical
well-being

Higher score  indicates better sta-
tus

Campbell 2005; Courneya 2003a;
Danhauer 2009; de Oliveira 2010;
Rogers 2009

Functional Assessment of Can-
cer Therapy - General

FACT-G

Physical
well-being

Higher score  indicates better sta-
tus

Cadmus 2009; Moadel 2007; Mon-
ga 2007; Mutrie 2007; Oh 2010

Functional Assessment of 
Chronic Illness  Fatigue

FACIT-F

Physical
well-being

Higher score  indicates better sta-
tus

Targ 2002

Medical Outcomes Study Short
Form-12

MOS
SF-12

Physical
function

Higher score  indicates better sta-
tus

Cadmus 2009; Chandwani 2010;
Danhauer 2009; Mock 2001; Segal
2001

Medical Outcomes Study Short
Form-36

MOS
SF-36

Physical
compo-
nent

Higher score  indicates better sta-
tus

Adamsen 2009; Chandwani 2010;
Galvao 2010; Tang 2010

Medical Outcomes Study Short
Form-36

MOS
SF-36

Role phys-
ical

Higher score  indicates better sta-
tus

Adamsen 2009; Cadmus 2009;
Chandwani 2010; Galvao 2010;

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

348

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Table 1.   HRQoL instruments used by investigators  (Continued)

Cochrane Database of Systematic Reviews

Griffith 2009; Mock 2001; Segal
2001

Medical Outcomes Study Short
Form-36

MOS
SF-36

WHO QOL-BREF subscale

WHO QOL-
BREF 

Physical
function-
ing

Physical 
function-
ing

Higher score  indicates better sta-
tus

Adamsen 2009; Crowley 2003;
Galvao 2010; Griffith 2009; Mock
2001; Mock 2005; Segal 2001

Higher score  indicates better sta-
tus

Hwang 2008

Linear Analog Scales of Assess-
ment

LASA

Physical

Higher score  indicates better sta-
tus

Cheville 2010

Role function

Functional Assessment of Can-
cer Therapy - Anemia

FACT-An

Functional Assessment of Can-
cer Therapy - Breast

FACT-B

Functional Assessment of Can-
cer Therapy - General

FACT-G

Functional Assessment
of Chronic Illness Fatigue

FACIT-F

European Organization for Re-
search and Treatment of Can-
cer Quality of Life Question-
naire-C30

WHO QOL-BREF subscale

QLQ-C30

WHO QOL-
BREF 

Function-
al well-be-
ing

Function-
al well-be-
ing

Function-
al well-be-
ing

Function-
al well-be-
ing

Function-
al well-be-
ing

Environ-
mental 
function-
ing

Higher score  indicates better sta-
tus

Jarden 2009

Higher score  indicates better sta-
tus

Campbell 2005; Courneya 2003a;
Danhauer 2009; de Oliveira 2010;
Rogers 2009

Higher score  indicates better sta-
tus

Cadmus 2009; Moadel 2007; Mon-
ga 2007; Mutrie 2007; Oh 2010

Higher score  indicates better sta-
tus

Targ 2002

Higher score  indicates better sta-
tus

Adamsen 2009; Hacker 2011; Jar-
den 2009; Moros 2010; Wiske-
mann 2011

higher score  indicates better sta-
tus

Hwang 2008

Ferrans and Powers Quality of
Life Instrument

FPQLI

Family

Higher score  indicates better sta-
tus

Hacker 2011

Symptom Checklist 90 Revised

SCL-90-R

Interper-
sonal sen-
sitivity

Higher score  indicates better sta-
tus

Dimeo 1999

Sleep

European Organization for Re-
search and Treatment of Can-

QLQ-C30

Insomnia

Higher score  indicates worse sta-
tus

Hacker 2011; Jarden 2009; Wiske-
mann 2011

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

349

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 1.   HRQoL instruments used by investigators  (Continued)

cer Quality of Life Question-
naire-C30

Pittsburgh Sleep Quality Index

PSQI

Sleep dis-
turbance

Higher score  indicates worse sta-
tus

Chandwani 2010; Cohen 2004;
Danhauer 2009; Donnelly 2011;
Rogers 2009; Wang 2010

Taiwanese Pittsburgh Sleep
Quality Index

PSQI

Sleep dis-
turbance

Higher score  indicates worse sta-
tus

Tang 2010

Social functioning

European Organization for Re-
search and Treatment of Can-
cer Quality of Life Question-
naire-C30

QLQ-C30

Functional Assessment of Can-
cer Therapy - Breast

FACT-B

Functional Assessment of Can-
cer Therapy - General

FACT-G

Functional Assessment of 
Chronic Illness Therapy-Fatigue

FACIT-F

Medical Outcomes Study Short
Form-36

MOS
SF-36

WHO QoL-BREF subscale

WHO QoL-
BREF 

Ferrans and Powers Quality of
Life Instrument

FPQLI

Linear Analog Scales of Assess-
ment

Linear Analog Scales of Assess-
ment

LASA

LASA

General Health Questionnaire

GHQ

Social
function-
ing

So-
cial/fami-
ly well-be-
ing 

So-
cial/fami-
ly well-be-
ing 

So-
cial/fami-
ly well-be-
ing 

So-
cial/fami-
ly well-be-
ing 

Social
function-
ing

So-
cial/eco-
nomic

Higher score  indicates better sta-
tus

Adamsen 2009; Hacker 2011; Jar-
den 2009; Moros 2010; Wiske-
mann 2011

Higher score  indicates better sta-
tus

Courneya 2003a; Danhauer 2009;
de Oliveira 2010; Rogers 2009

Higher score  indicates better sta-
tus

Cadmus 2009; Moadel 2007; Mon-
ga 2007; Mutrie 2007; Oh 2010

Higher score  indicates better sta-
tus

Targ 2002

Higher score  indicates better sta-
tus

Adamsen 2009; Cadmus 2009;
Chandwani 2010; Crowley 2003;
Galvao 2010; Mock 2001; Segal
2001

Higher score  indicates better sta-
tus

Hwang 2008

Higher score  indicates better sta-
tus

Hacker 2011

Social
well-being

Higher score  indicates better sta-
tus

Cheville 2010

Social
support

Higher score  indicates better sta-
tus

Cheville 2010

Social
dysfunc-
tion

Higher score  indicates worse sta-
tus

Moros 2010

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

350

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 1.   HRQoL instruments used by investigators  (Continued)

Spiritual function

Functional Assessment of Can-
cer Therapy - Breast

FACT-B

Spiritual 

Higher score  indicates better sta-
tus

Courneya 2003a; Haddad 2011;
Rogers 2009; Targ 2002

Functional Assessment of
Chronic Illness Therapy-Spiritu-
ality

FACIT-SP

Peace

Higher score  indicates better sta-
tus

Cheville 2010; Danhauer 2009;
Moadel 2007

Principles of Living Survey

PLS

Spiritual 

Higher score  indicates better sta-
tus

Targ 2002

Ferrans and Powers Quality of
Life Instrument

FPQLI

Psycho-
logi-
cal/spiri-
tual

Higher score  indicates better sta-
tus

Hacker 2011

Linear Analog Scales of Assess-
ment

LASA

Spiritual
well-being

Higher score  indicates better sta-
tus

Cheville 2010

A P P E N D I C E S

Appendix 1. MEDLINE search strategy

[inception to May 2010; 430 hits] [January 2010 to November 2011; 190 hits]

1. exp exercise/
2. exercise tolerance/
3. exp exertion/
4. Pliability/
5. physical fitness/
6. "Physical Education and Training"/
7. exp physical endurance/
8. exercise therapy/
9. exercising.mp.
10.physical condition$.mp.
11.stamina.mp.
12.motor activity/
13.exercise test/
14.exp Sports/
15.tai chi.mp. or tai ji/
16.yoga/
17.muscle stretching exercises/
18.exp "range of motion, articular"/
19.pilates.mp.
20.qigong.mp.
21.chi kung.mp.
22.resistance training.mp.
23.mind body therap$.mp.
24.exp complementary therapies/
25.Bad Ragaz.mp.
26.Ai Chi.mp.

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

351

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

27.Halliwick.mp.
28.hippotherapy.mp.
29.Hydrotherapy/
30.balance exercise$.mp.
31.aquatic exercise$.mp.
32.1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26

or 27 or 28 or 29 or 30 or 31

33."quality of life"/
34.exp health status/
35."activities of daily living"/
36.life qualit$.mp.
37.exp self concept/
38.health level.mp.
39.level of health.mp.
40.wellness.mp.
41.well being.mp.
42.(activities of daily life or daily living activities).mp. [mp=protocol supplementary concept, rare disease supplementary concept, title,

original title, abstract, name of substance word, subject heading word, unique identifier]

43.functional ability.mp.
44.good health.mp.
45.healthiness.mp.
46.patient reported outcomes.mp.
47.social adjustment/
48.physical limitations.mp.
49.psychiatric status.mp.
50.pain measurement/
51.functional assessment.mp.
52.fact questionnaire.mp.
53.fact survey.mp.
54.qlc-c30.mp.
55.facit.mp.
56.toi.mp.
57.(flic or sf-36 or ces-d or bdi or sta1 or bfi or hads or lasa or poms or qli or rsci or pais or bpi or msas or mos or ptgi or panas).mp.
58.sense of coherence.mp.
59.randomized.ab.
60.placebo.ab.
61.randomly.ab.
62.trial.ab.
63.randomized controlled trial.pt.
64.controlled clinical trial.pt.
65.random$.ab
66.exp neoplasms/
67.cancer.mp.
68.(neoplasm$ or tumor$ or tumour or malignan$).mp.
69.active treatment.mp.
70.35 or 33 or 53 or 48 or 42 or 46 or 44 or 55 or 50 or 39 or 57 or 36 or 40 or 51 or 58 or 41 or 47 or 52 or 38 or 34 or 56 or 49 or 37 or 45 or 43 or 54
71.59 or 60 or 63 or 64 or 61 or 62 or 65
72.66 or 67 or 68 or 69
73.32 and 70 and 71 and 72
74.Survivors/
75.survivor.mp.
76.74 or 75

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

352

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

77.73 not 76

Appendix 2. CENTRAL search strategy

[inception to May 2010; 423 hits] [January 2010 to November 2011; 219 hits]

Searched via Ovid EBM Reviews

[mp=ti, ot, ab, tx, kw, ct, sh, hw]

Cochrane Database of Systematic Reviews

1. exercise.mp.
2. physical fitness.mp. 
3. physical endurance.mp.
4. exercising.mp. 
5. physical conditioning.mp.
6. stamina.mp.
7. sports.mp.
8. tai chi.mp.
9. yoga.mp.
10.pilates.mp.
11.qigong.mp.
12.chi kung.mp.
13.resistance training.mp.  
14.mind body therap$.mp.
15.complementary therap$.mp.  
16.bad ragaz.mp.  
17.ai chi.mp. 
18.halliwick.mp.  
19.hippotherapy.mp.  
20.hydrotherapy.mp.  
21.balance exercise$.mp.  
22.aquatic exercise$.mp.  
23.exercise tolerance.mp.  
24.pliability.mp.  
25.exertion.mp.  
26.exercise therapy.mp.  
27.motor activit$.mp.  
28.exercise test$.mp.  
29.muscle stretching exercise$.mp.  
30.range of motion.mp.  
31.1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26

or 27 or 28 or 29 or 30

32.quality of life.mp.  
33.health status.mp.  
34.activities of daily living.mp.  
35.life qualit$.mp.  
36.self concept.mp.  
37.health level.mp.  
38.level of health.mp.  
39.wellness.mp.  
40.well being.mp.  
41.(activities of daily life or daily living activities).mp.  
42.functional ability.mp. 
43.good health.mp.  
44.healthiness.mp.  

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

353

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

45.patient reported outcomes.mp. 
46.social adjustment.mp.  
47.physical limitation$.mp.  
48.psychiatric status.mp.  
49.pain measurement.mp.  
50.functional assessment.mp.  
51.fact questionnaire.mp.  
52.fact survey.mp.  
53.qlc-c30.mp.  
54.facit.mp.  
55.toi.mp.  
56.(flic or sf-36 or ces-d or bdi or sta1 or bfi or hads or lasa or poms or qli or rsci or pais or bpi or msas or mos or ptgi).mp.  
57.sense of coherence.mp.  
58.32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57
59.randomized.ab.
60.placebo.ab.
61.randomly.ab.
62.trial.ab.
63.random$.ab.
64.59 or 60 or 61 or 62 or 63
65.cancer.mp.  
66.(neoplasm$ or tumor$ or tumour$ or malignan$).mp.  
67.active treatment.mp.  
68.65 or 66 or 67
69.31 and 58 and 64 and 68
70.survivor$.mp.  
71.69 not 70

Appendix 3. EMBASE search strategy

[inception to May 2010; 713 hits] [January 2010 to November 2011; 349 hits]

1. exp exercise/
2. exertion.mp.
3. pliability/
4. fitness/
5. (physical  education  and  training).mp.  [mp=title,  abstract,  subject  headings,  heading  word,  drug  trade  name,  original  title,  device

manufacturer, drug manufacturer name]

6. physical endurance.mp. or endurance/
7. kinesiotherapy/
8. exercising.mp.
9. "physical condition$".mp.
10.stamina.mp.
11.exp motor activity/
12.exp sports/
13.exercise test/
14.tai chi.mp.
15.tai ji.mp.
16.yoga/
17.stretching exercise/
18."range of motion"/
19.pilates.mp.
20.qigong.mp.
21.chi kung.mp.

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

354

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

22.muscle strength/ or muscle training/ or resistance training.mp.
23.mind body therapy.mp.
24.alternative medicine/
25.bad ragaz.mp.
26.ai chi.mp.
27.halliwick.mp.
28.hippotherapy.mp.
29.hydrotherapy/
30.balance exercises.mp.
31.aquatic exercise/
32.1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26

or 27 or 28 or 29 or 30 or 31

33."quality of life"/
34.exp health status/
35.daily life activity/
36.life qualit$.mp.
37.exp self concept/
38.health level.mp.
39."level of health".mp.
40.wellbeing/
41.wellness.mp.
42.good health.mp.
43.functional ability.mp.
44.healthiness.mp.
45."patient reported outcomes".mp.
46.social adaptation/
47.physical limitation$.mp.
48.psychiatric status.mp.
49.pain assessment/
50.functional assessment/
51.questionnaire/ or fact questionnaire.mp.
52.fact survey.mp.
53.health survey/
54.qlc-c30.mp.
55.facit.mp.
56.toi.mp.
57.sense of coherence.mp.
58.(flic or sf-36 or ces-d or bdi or stal or bfi or hads or lasa or poms or qli or rsci or pais or bpi or msas or mos or ptgi or panas).mp. [mp=title,

abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]

59.randomized.ab.
60.placebo.ab.
61.randomly.ab.
62.trial.ab.
63.random$.ab.
64.randomized controlled trial.pt
65.59 or 60 or 61 or 62 or 63 or 64
66.35 or 33 or 53 or 48 or 42 or 46 or 44 or 55 or 50 or 39 or 57 or 36 or 40 or 51 or 58 or 41 or 47 or 52 or 38 or 34 or 56 or 49 or 37 or 45 or 43 or 54
67.exp neoplasm/
68.cancer.mp.
69.(neoplasm$ or tumor$ or tumour or malignan$).mp3   
70.active treatment
71.(67 or 68 or 69 or 70)

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

355

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

72.Survivors/
73.survivor$.mp.
74.72 or 73
75.32 and 65 and 66 and 71
76.75 not 74

Appendix 4. CINAHL search strategy

[inception to May 2010; 92 hits] [January 2010 to November 2011; 36 hits]

Search ID#

S73

S72

S71

S70

S69

S68

S67

S66

S65

S64

S63

S62

S61

S60

S59

S58

S57

S56

S55

S54

S53

Search Terms

s72 NOT s70

S32 and S59 and S65 and S71

S66 or S67

S68 or S69

survivor*

(MH "Cancer Survivors")

cancer

(MH "Neoplasms+")

S60 or S61 or S62 or S63 or S64

AB randomized controlled trial

PT clinical trial

AB randomly or trial

AB placebo

AB randomized

S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41 or S42 or S43 or S44 or S45 or S46 or S47
or S48 or S49 or S50 or S51 or S52 or S55 or S56 or S57 or S58

sense of coherence

(flic or sf-36 or ces-d or bdi or sta1 or bfi or hads or lasa or poms or qli or rsci or pais or bpi or msas
or mos or ptgi or panas)

toi

facit

qlc-c30

fact survey

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

356

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

Cochrane Database of Systematic Reviews

S52

S51

S50

S49

S48

S47

S46

S45

S44

S43

S42

S41

S40

S39

S38

S37

S36

S35

S34

S33

S32

S31

S30

S29

S28

S27

S26

S25

"fact questionnaire"

(MH "Functional Assessment")

(MH "Pain Measurement")

"psychiatric status"

physical limitations

(MH "Social Adjustment")

"patient reported outcomes"

healthiness

good health

(MH "Functional Status")

activities of daily life or daily living activities

(MH "Psychological Well-Being")

(MH "Wellness")

level of health

health level

(MH "Self Concept+")

life qualit*

(MH "Activities of Daily Living")

(MH "Health Status+")

(MH "Quality of Life+")

S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or
S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or S30 or S31

aquatic exercise*

balance exercise*

hydrotherapy

hippotherapy

halliwick

bad ragaz

(MH "Alternative Therapies")

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

357

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

Cochrane Database of Systematic Reviews

S24

S23

S22

S21

S20

S19

S18

S17

S16

S15

S14

S13

S12

S11

S10

S9

S8

S7

S6

S5

S4

S3

S2

S1

mind body therap*

("resistance training") or (MH "Muscle Strengthening")

chi kung

qigong

pilates

(MH "Range of Motion")

"muscle stretching exercises"

(MH "Yoga")

tai chi

(MH "Sports+")

(MH "Exercise Test")

(MH "Motor Activity")

stamina

physical condition*

exercising

(MH "Therapeutic Exercise")

(MH "Physical Endurance")

(MH "Physical Therapy")

(MH "Physical Education and Training")

(MH "Physical Fitness")

(MH "Pliability")

(MH "Exertion")

(MH "Exercise Tolerance")

(MH "Exercise")

Appendix 5. PsycINFO search strategy

[inception to May 2010; 18 hits] [January 2010 to November 2011; 4 hits]

1. exp exercise/
2. physical fitness/
3. exp physical endurance/

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

358

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

4. exercising.mp.
5. physical condition$.mp.
6. stamina.mp.
7. exp Sports/
8. tai chi.mp. or tai ji/
9. yoga/
10.pilates.mp.
11.qigong.mp.
12.chi kung.mp.
13.resistance training.mp.
14.mind body therap$.mp.
15.exp complementary therapies/
16.Bad Ragaz.mp.
17.Ai Chi.mp.
18.Halliwick.mp.
19.hippotherapy.mp.
20.balance exercise$.mp.
21.aquatic exercise$.mp.
22."quality of life"/
23.exp health status/
24."activities of daily living"/
25.life qualit$.mp.
26.exp self concept/
27.health level.mp.
28.level of health.mp.
29.wellness.mp.
30.well being.mp.
31.(activities of daily life or daily living activities).mp.
32.functional ability.mp.
33.good health.mp.
34.healthiness.mp.
35.patient reported outcomes.mp.
36.social adjustment/
37.physical limitations.mp.
38.psychiatric status.mp.
39.pain measurement/
40.functional assessment.mp.
41.fact questionnaire.mp.
42.fact survey.mp.
43.qlc-c30.mp.
44.facit.mp.
45.toi.mp.
46.(flic or sf-36 or ces-d or bdi or sta1 or bfi or hads or lasa or poms or qli or rsci or pais or bpi or msas or mos or ptgi or panas).mp.
47.sense of coherence.mp.
48.randomized.ab.
49.placebo.ab.
50.randomly.ab.
51.trial.ab.
52.exp neoplasms/
53.cancer.mp.
54.24 or 22 or 42 or 37 or 31 or 35 or 33 or 44 or 39 or 28 or 46 or 25 or 29 or 40 or 47 or 30 or 36 or 41 or 27 or 23 or 45 or 38 or 26 or 34 or 32 or 43
55.random$.ab.

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

359

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

56.(neoplasm$ or tumor$ or tumour or malignan$).mp.
57.active treatment.mp.
58.52 or 53 or 56 or 57
59.Survivors/
60.59 or survivor.mp.
61.exercise tolerance.mp.
62.Physical Education/
63.exertion.mp.
64.pliability.mp.
65.exercise therapy.mp.
66.Motor Processes/ or motor activity.mp.
67.exercise test.mp.
68.muscle stretching exercise*.mp.
69."Range of Motion"/
70.hydrotherapy.mp.
71.1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 61 or 62 or 63 or 64 or 65

or 66 or 67 or 68 or 69 or 70

72.54 and 58 and 71
73.48 or 49 or 50 or 51 or 55
74.72 and 73
75.74 not 60

Appendix 6. Other search strategies

LILACS search strategy [inception to May 2010; 3 hits] [January 2010 to November 2011; 12 hits]

Neoplasms and exercise and treatment

OT Seeker search strategy [inception to May 2010; 26 hits] [January 2010 to November 2011; 20 hits]

Database Note returned with search: A precise search did not find any articles. A less precise search has been done and the results are
shown below.

(exercise  OR exertion OR pliability OR "physical fitness" OR "physical endurance" OR "exercise therapy" OR "motor activity" OR sports)
AND cancer AND "quality of life" AND "active treatment"

Limits: Method: clinical trial and Diagnosis/Subdiscipline: Oncology/palliative care

PEDro search strategy [inception to May 2010; 71 hits] [January 2010 to November 2011; 33 hits]

exercise AND cancer  AND "quality of life" AND  treatment

SIGLE search strategy (now OpenGrey) [inception to July 2010; 0 hits] [January 2010 to November 2011; 0 hits]

exercise AND (cancer OR neoplasms) AND "quality of life AND treatment

Sociological Abstracts (SocINDEX) search strategy [inception to May 2010; 16 hits] [January 2010 to November 2011; 1 hit]

Search ID#

Search Terms

S74

S73

S72

S71

s73 NOT survivor*

S32 and S58 and S71 and S72

S66 or S67 or S68 or S69 or S70

S59 or S60 or S61 or S62 or S63 or S64 or S65

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

360

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

Cochrane Database of Systematic Reviews

S70

S69

S68

S67

S66

S65

S64

S63

S62

S61

S60

S59

S58

S57

S56

S55

S54

S53

S52

S51

S50

S49

S48

S47

S46

S45

S44

active treatment

malignan*

tumor or tumour

neoplasm*

DE Cancer

AB random*

controlled clinical trial

randomized controlled trial

AB trial

AB randomly

AB placebo

AB randomized

S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41 or S42 or S43 or S44 or S45 or S46 or S47
or S48 or S49 or S50 or S51 or S52 or S54 or S55 or S56 or S57

sense of coherence

flic or sf-36 or ces-d or bdi or sta1 or bfi or hads or lasa or pms or qli or rsci or pais or bpi or msas or
mos or ptgi or panas

facit

toi

qlc-c30

fact survey

fact questionnaire

functional assessment

pain measurement

psychiatric status

physical limitations

DE "SOCIAL adjustment"

patient reported outcomes

healthiness

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

361

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

Cochrane Database of Systematic Reviews

S43

S42

S41

S40

S39

S38

S37

S36

S35

S34

S33

S32

S31

S30

S29

S28

S27

S26

S25

S24

S23

S22

S21

S20

S19

S18

S17

S16

good health

functional ability

activities of daily life OR daily living activities

wellness

level of health

health level

self concept

life qualit*

DE "ACTIVITIES of daily living"

health status

DE "QUALITY of life"

S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or
S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25 or S28 or S29 or S30 or S31

aquatic exercise*

balance exercise*

hydrotherapy

hippotherapy

halliwick

ai chi

bad ragaz

complementary therap*

mind body therap*

resistance training

chi kung

qigong

pilates

range of motion

muscle strengthening exercise*

yoga

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

362

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

Cochrane Database of Systematic Reviews

S15

S14

S13

S12

S11

S10

S9

S8

S7

S6

S5

S4

S3

S2

S1

tai chi

sports

exercise test

motor activity

stamina

physical condition*

exercising

exercise therapy

physical endurance

physical education

DE "PHYSICAL fitness"

pliability

exertion

exercise tolerance

DE "EXERCISE"

SportDiscus search strategy [inception to May 2010; 21 hits] [January 2010 to November 2011; 10 hits]

Search ID#

S76

S75

S74

S73

S72

S71

S70

S69

Search Terms

S74 NOT S75

survivor*

S34 and S70 and S71 and S73

S66 or S67 or S68 or S72

active treatment

S60 or S61 or S62 or S63 or S64 or S65 or S69

S35 or S36 or S37 or S38 or S39 or S40 or S41 or S42 or S43 or S44 or S45 or S46 or S47 or S48 or S49
or S50 or S51 or S52 or S53 or S54 or S55 or S56 or S57 or S58 or S59

random*

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

363

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

Cochrane Database of Systematic Reviews

S68

S67

S66

S65

S64

S63

S62

S61

S60

S59

S58

S57

S56

S55

S54

S53

S52

S51

S50

S49

S48

S47

S46

S45

S44

S43

S42

cancer

neoplasms

DE "CANCER" OR DE "BREAST -- Cancer" OR DE "LEUKEMIA" OR DE "LUNGS -- Cancer" OR DE
"MELANOMA"

controlled clinical trial

randomized controlled trial

trial

randomly

placebo

randomized

sense of coherence

(flic OR sf-36 OR ces-d OR bdi OR sta1 OR bfi OR hads OR lasa OR poms OR qli OR rsci OR pais OR bpi
OR msas OR mos OR ptgi OR panas)

toi

facit

qlc-c30

fact survey

fact questionnaire

functional assessment

pain measurement

psychiatric status

physical limitations

social adjustment

patient reported outcomes

healthiness

good health

functional ability

activities of daily living OR daily living activities

well being

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

364

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

Cochrane Database of Systematic Reviews

S41

S40

S39

S38

S37

S36

S35

S34

S33

S32

S31

S30

S29

S28

S27

S26

S25

S24

S23

S22

S21

S20

S19

S18

S17

S16

S15

wellness

level of health

health level

self concept

life qualit*

DE "ACTIVITIES of daily living"

DE "QUALITY of life" OR DE "HEALTH status indicators" OR DE "LIFESTYLES" OR DE "WELL-being"

S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or
S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or S30 or S31
or S32 or S33

DE "AQUATIC exercises"

balance exercise*

DE hydrotherapy

hippotherapy

halliwick

ai chi

bad ragaz

complementary therap*

mind body therap*

resistance training

DE "WEIGHT training" OR DE "BENCH press" OR DE "DEAD lift (Weight lifting)" OR DE "POWER-
LIFTING" OR DE "SQUAT (Weight lifting)" OR DE "STONE lifting" OR DE "WEIGHT lifting"

chi kung

qigong

DE pilates

DE pilates

DE "JOINTS -- Range of motion"

muscle stretching exercise*

DE yoga

DE tai chi

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

365

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

Cochrane Database of Systematic Reviews

S14

S13

S12

S11

S10

S9

S8

S7

S6

S5

S4

S3

S2

S1

DE sports

exercise test

motor activity

stamina

physical condition*

exercising

DE "EXERCISE therapy"

physical endurance

DE "PHYSICAL education & training"

DE "PHYSICAL fitness"

pliability

exertion

exercise tolerance

DE "EXERCISE"

W H A T ' S   N E W

Date

Event

Description

12 May 2020

Amended

The Editors are looking for contributors to update and maintain
this Cochrane Review. Contact ruh-tr.gnoc-cochrane@nhs.net
for further information. The searches have been updated to
May 2019 and potentially relevant studies added to ‘Other refer-
ences; Classification pending’.

H I S T O R Y

Protocol first published: Issue 4, 2010
Review first published: Issue 8, 2012

C O N T R I B U T I O N S   O F   A U T H O R S

Shiraz I. Mishra: content expert; contributed by conceptualization of the project, identifying trials eligible for the review, extracting data
for trials meeting the eligibility criteria, preparing data tables, analyzing the data, and writing the review.

Roberta W. Scherer: methodologic expert; contributed by identifying trials eligible for the review, extracting data for trials meeting the
eligibility criteria, preparing data tables, analyzing the data, and writing the review.

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

366

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Claire Snyder: content expert; contributed by identifying trials eligible for the review, extracting data for studies meeting the inclusion
criteria, interpreting the HRQoL measures, and providing editorial input.

Paula M. Geigle: content expert; contributed by extracting data for trials meeting the inclusion criteria and providing editorial input.

Debra R. Berlanstein: information specialist, contributed to development of the search strategy, conducting all the electronic database
searches, and retrieving potentially eligible trials.

Ozlem Topaloglu: contributed by extracting data for trials meeting the inclusion criteria.

D E C L A R A T I O N S   O F   I N T E R E S T

The authors declare no conflict of interest.

S O U R C E S   O F   S U P P O R T

Internal sources

• None, Other

External sources

• National Institute for Health Research (NIHR) Health Technology Assessment programme, UK

HTA Project: 10/81/01 - Exercise interventions for the management of health related quality of life and fatigue in cancer survivors during
and after treatment

D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W

This review included trials that included both participants who were undergoing active cancer treatment for their primary or recurrent
cancer and those who had completed active treatment for their cancer. This revised inclusion criteria was applied to studies that did not
have the majority of participants who had completed active treatment for their primary or recurrent cancer.

We have included a Summary of findings 1 instead of calculating number needed to treat for an additional beneficial outcome (NNTB) for
the review findings.

I N D E X   T E R M S

Medical Subject Headings (MeSH)

Anxiety  [therapy];  Bicycling  [psychology];  Breathing Exercises;  Depression  [therapy];  Exercise Therapy  [*methods]  [psychology];
  Fatigue  [therapy];  *Health Status;  Neoplasms  [psychology]  [*therapy];  *Quality of Life;  Randomized Controlled Trials as Topic; 
Resistance Training  [methods];  Survivors  [psychology];  Walking  [psychology];  Yoga  [psychology]

MeSH check words

Adult; Female; Humans; Male

Exercise interventions on health-related quality of life for people with cancer during active treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

367
